0001437749-24-03393110-Q OPKO HEALTH, INC. 20241107202411071616281616291616291616291

092024-01-09 0000944809opk:The2029ConvertibleNotes1Memberopk:ScenarioEventofDefaultMember2024-01-092024-01-09 0000944809opk:The2029Convertible144ANotesMember2023-12-31 0000944809opk:The2029Convertible144ANotesMember2024-09-30 0000944809opk:The2029Convertible144ANotesMember2024-01-012024-09-30 0000944809opk:The2029ConvertibleNotes1Member2024-09-30 0000944809opk:The2029ConvertibleNotes1Member2024-07-012024-09-30 0000944809opk:The2025NotesMemberus-gaap:ConvertibleDebtMemberopk:ScenarioEventofDefaultMember2019-02-28 0000944809opk:ConversionOfThe2025NotesIntoCommonStockMember2021-05-012021-05-31 0000944809opk:The2025NotesMemberus-gaap:ConvertibleDebtMember2024-01-09 0000944809opk:The2029ConvertibleNotes1Memberus-gaap:ConvertibleDebtMember2024-01-092024-01-09 0000944809opk:The2025NotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:ConvertibleDebtMember2019-02-012019-02-01 0000944809opk:The2023ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2018-02-28 0000944809opk:The2023ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2018-02-012018-02-28 0000944809opk:The2023ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2023-02-102023-02-10 0000944809opk:The2029ConvertibleAffiliateNotesMemberus-gaap:ConvertibleDebtMember2024-01-09 0000944809opk:The2033SeniorNotesMemberus-gaap:SeniorNotesMember2023-01-31 0000944809opk:The2033SeniorNotesMemberus-gaap:SeniorNotesMember2013-01-31 0000944809opk:The2033SeniorNotesMemberus-gaap:ConvertibleDebtMember2013-02-012016-12-31 0000944809opk:The2033SeniorNotesMemberus-gaap:ConvertibleDebtMember2019-02-01 0000944809opk:The2033SeniorNotesMemberus-gaap:ConvertibleDebtMember2024-01-012024-03-31 0000944809opk:The2033SeniorNotesMemberus-gaap:ConvertibleDebtMember2024-03-31 0000944809us-gaap:RevolvingCreditFacilityMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember2015-11-30 0000944809us-gaap:BridgeLoanMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember2015-11-30 0000944809us-gaap:LetterOfCreditMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember2015-11-30 0000944809us-gaap:RevolvingCreditFacilityMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember2024-09-162024-09-16 0000944809us-gaap:RevolvingCreditFacilityMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember2023-12-31 0000944809opk:JPMorganChaseMember2024-09-30 0000944809opk:JPMorganChaseMember2023-12-31 0000944809opk:ItauBankMember2024-09-30 0000944809opk:ItauBankMember2023-12-31 0000944809opk:BankOfChileMember2024-09-30 0000944809opk:BankOfChileMember2023-12-31 0000944809opk:BiceBankMember2024-09-30 0000944809opk:BiceBankMember2023-12-31 0000944809opk:ScotiabankMember2024-09-30 0000944809opk:ScotiabankMember2023-12-31 0000944809opk:SantanderBankMember2024-09-30 0000944809opk:SantanderBankMember2023-12-31 0000944809opk:SecurityBankMember2024-09-30 0000944809opk:SecurityBankMember2023-12-31 0000944809opk:EstadoBankMember2024-09-30 0000944809opk:EstadoBankMember2023-12-31 0000944809opk:BciBankMember2024-09-30 0000944809opk:BciBankMember2023-12-31 0000944809opk:InternacionalBankMember2024-09-30 0000944809opk:InternacionalBankMember2023-12-31 0000944809opk:ConsorcioBankMember2024-09-30 0000944809opk:ConsorcioBankMember2023-12-31 0000944809opk:BancoDeSabadellMember2024-09-30 0000944809opk:BancoDeSabadellMember2023-12-31 0000944809opk:SantanderBank2Member2024-09-30 0000944809opk:SantanderBank2Member2023-12-31 0000944809us-gaap:LineOfCreditMember2024-09-30 0000944809us-gaap:LineOfCreditMember2023-12-31 0000944809opk:NotesPayableAndOtherLongTermLiabilitiesMember2024-09-30 0000944809opk:NotesPayableAndOtherLongTermLiabilitiesMember2023-12-31 0000944809opk:NotesAndOtherDebtMember2024-09-30 0000944809opk:NotesAndOtherDebtMember2023-12-31 0000944809us-gaap:AccumulatedTranslationAdjustmentMember2023-12-31 0000944809us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-30 0000944809us-gaap:AccumulatedTranslationAdjustmentMember2024-09-30 0000944809us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0000944809us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0000944809us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-30 0000944809us-gaap:FairValueMeasurementsRecurringMember2024-09-30 0000944809us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000944809us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000944809us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000944809us-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000944809opk:The2029ConvertibleNotes1Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-09-30 0000944809opk:The2029ConvertibleNotes1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-09-30 0000944809opk:The2029ConvertibleNotes1Memberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-09-30 0000944809opk:The2029ConvertibleNotes1Memberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-09-30 0000944809opk:The2029ConvertibleNotes1Memberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-09-30 0000944809opk:The2025ConvertibleNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-09-30 0000944809opk:The2025ConvertibleNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-09-30 0000944809opk:The2025ConvertibleNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-09-30 0000944809opk:The2025ConvertibleNotesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-09-30 0000944809opk:The2025ConvertibleNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-09-30 0000944809us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-12-31 0000944809us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2024-01-012024-09-30 0000944809us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2024-09-30 0000944809opk:InvestmentNetMemberopk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember2024-09-30 0000944809opk:InvestmentNetMemberopk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember2023-12-31 0000944809opk:AccruedExpensesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-09-30 0000944809opk:AccruedExpensesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-12-31 0000944809opk:The2029ConvertibleNotes1Memberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NondesignatedMember2024-07-012024-09-30 0000944809opk:The2029ConvertibleNotes1Memberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NondesignatedMember2023-07-012023-09-30 0000944809opk:The2029ConvertibleNotes1Memberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NondesignatedMember2024-01-012024-09-30 0000944809opk:The2029ConvertibleNotes1Memberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NondesignatedMember2023-01-012023-09-30 0000944809opk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember2024-07-012024-09-30 0000944809opk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember2023-07-012023-09-30 0000944809opk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember2024-01-012024-09-30 0000944809opk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember2023-01-012023-09-30 0000944809us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-07-012024-09-30 0000944809us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-07-012023-09-30 0000944809us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-01-012024-09-30 0000944809us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-01-012023-09-30 0000944809us-gaap:NondesignatedMember2024-07-012024-09-30 0000944809us-gaap:NondesignatedMember2023-07-012023-09-30 0000944809us-gaap:NondesignatedMember2024-01-012024-09-30 0000944809us-gaap:NondesignatedMember2023-01-012023-09-30 utr:acre 0000944809opk:FrostRealEstateHoldingsLlcMember2024-07-31 utr:sqft 0000944809opk:FrostRealEstateHoldingsLlcMember2024-08-01 0000944809opk:The2023ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2024-01-09 0000944809opk:RuenhuiBiopharmaceuticalsIncMember2023-05-04 0000944809opk:LicenseAgreementMemberopk:RuenhuiBiopharmaceuticalsIncMember2023-05-042023-05-04 0000944809opk:LicenseAgreementMemberopk:RuenhuiBiopharmaceuticalsIncMember2023-05-04 0000944809opk:TransitionServicesAgreementMemberopk:GeneDxMember2024-01-012024-03-31 0000944809opk:ServicesRenderedMemberopk:TransitionServicesAgreementMemberopk:GeneDxMember2024-07-012024-09-30 0000944809opk:ServicesRenderedMemberopk:TransitionServicesAgreementMemberopk:GeneDxMember2024-01-012024-09-30 0000944809opk:TransitionServicesAgreementMemberopk:GeneDxMember2024-09-30 0000944809srt:DirectorMemberopk:PharmsynthezMember2024-09-30 0000944809srt:DirectorMemberopk:XeneticMember2024-09-30 0000944809opk:NeovascMember2023-10-012023-12-31 0000944809opk:BeckmanCoulterMember2024-01-012024-09-30 0000944809opk:IntegratedDNATechnologiesIncMember2024-01-012024-09-30 0000944809opk:LeicaMicrosystemsIncMember2024-01-012024-09-30 0000944809opk:ReimbursementOfTravelExpensesMembersrt:ExecutiveOfficerMember2024-07-012024-09-30 0000944809opk:ReimbursementOfTravelExpensesMembersrt:ExecutiveOfficerMember2024-01-012024-09-30 0000944809opk:ReimbursementOfTravelExpensesMembersrt:ExecutiveOfficerMember2023-07-012023-09-30 0000944809opk:ReimbursementOfTravelExpensesMembersrt:ExecutiveOfficerMember2023-01-012023-09-30 0000944809us-gaap:ForeignCountryMemberus-gaap:IsraelTaxAuthorityMemberopk:TaxYear2014ThroughTaxYear2020Member2022-12-292022-12-29 0000944809us-gaap:SettledLitigationMember2022-07-142022-07-14 0000944809us-gaap:SettledLitigationMember2022-07-14 0000944809us-gaap:SettledLitigationMembercountry:US2022-07-142022-07-14 0000944809us-gaap:SettledLitigationMemberopk:CommonwealthMember2022-07-142022-07-14 0000944809us-gaap:SettledLitigationMemberstpr:CT2022-07-142022-07-14 0000944809opk:HealthcareInsurersMemberus-gaap:ServiceMember2024-07-012024-09-30 0000944809opk:HealthcareInsurersMemberus-gaap:ServiceMember2023-07-012023-09-30 0000944809opk:HealthcareInsurersMemberus-gaap:ServiceMember2024-01-012024-09-30 0000944809opk:HealthcareInsurersMemberus-gaap:ServiceMember2023-01-012023-09-30 0000944809opk:GovernmentPayersMemberus-gaap:ServiceMember2024-07-012024-09-30 0000944809opk:GovernmentPayersMemberus-gaap:ServiceMember2023-07-012023-09-30 0000944809opk:GovernmentPayersMemberus-gaap:ServiceMember2024-01-012024-09-30 0000944809opk:GovernmentPayersMemberus-gaap:ServiceMember2023-01-012023-09-30 0000944809opk:ClientPayersMemberus-gaap:ServiceMember2024-07-012024-09-30 0000944809opk:ClientPayersMemberus-gaap:ServiceMember2023-07-012023-09-30 0000944809opk:ClientPayersMemberus-gaap:ServiceMember2024-01-012024-09-30 0000944809opk:ClientPayersMemberus-gaap:ServiceMember2023-01-012023-09-30 0000944809us-gaap:SelfPayMemberus-gaap:ServiceMember2024-07-012024-09-30 0000944809us-gaap:SelfPayMemberus-gaap:ServiceMember2023-07-012023-09-30 0000944809us-gaap:SelfPayMemberus-gaap:ServiceMember2024-01-012024-09-30 0000944809us-gaap:SelfPayMemberus-gaap:ServiceMember2023-01-012023-09-30 0000944809opk:RayaldeeMember2024-07-012024-09-30 0000944809opk:RayaldeeMember2024-01-012024-09-30 0000944809opk:RayaldeeMember2023-07-012023-09-30 0000944809opk:RayaldeeMember2023-01-012023-09-30 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2024-06-30 0000944809opk:RayaldeeMemberopk:GovernmentalMember2024-06-30 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2024-06-30 0000944809opk:RayaldeeMember2024-06-30 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2024-07-012024-09-30 0000944809opk:RayaldeeMemberopk:GovernmentalMember2024-07-012024-09-30 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2024-07-012024-09-30 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2024-09-30 0000944809opk:RayaldeeMemberopk:GovernmentalMember2024-09-30 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2024-09-30 0000944809opk:RayaldeeMember2024-09-30 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2023-12-31 0000944809opk:RayaldeeMemberopk:GovernmentalMember2023-12-31 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2023-12-31 0000944809opk:RayaldeeMember2023-12-31 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2024-01-012024-09-30 0000944809opk:RayaldeeMemberopk:GovernmentalMember2024-01-012024-09-30 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2024-01-012024-09-30 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2023-06-30 0000944809opk:RayaldeeMemberopk:GovernmentalMember2023-06-30 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2023-06-30 0000944809opk:RayaldeeMember2023-06-30 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2023-07-012023-09-30 0000944809opk:RayaldeeMemberopk:GovernmentalMember2023-07-012023-09-30 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2023-07-012023-09-30 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2023-09-30 0000944809opk:RayaldeeMemberopk:GovernmentalMember2023-09-30 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2023-09-30 0000944809opk:RayaldeeMember2023-09-30 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2022-12-31 0000944809opk:RayaldeeMemberopk:GovernmentalMember2022-12-31 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2022-12-31 0000944809opk:RayaldeeMember2022-12-31 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2023-01-012023-09-30 0000944809opk:RayaldeeMemberopk:GovernmentalMember2023-01-012023-09-30 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2023-01-012023-09-30 0000944809opk:BardaAgreementMember2024-07-012024-09-30 0000944809opk:PfizerIncMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:MilestonePaymentsMember2024-07-012024-09-30 0000944809opk:PfizerIncMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:MilestonePaymentsMember2023-07-012023-09-30 0000944809opk:MerckSharpDohmeLLCMemberopk:MerckAgreementMember2023-09-282023-09-28 0000944809opk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DevelopmentAndLicenseAgreementMember2023-01-012023-12-31 0000944809opk:NicoyaMacauLimitedMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DevelopmentAndLicenseAgreementMember2023-01-012023-12-31 0000944809opk:PfizerIncMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:MilestonePaymentsMember2024-01-012024-09-30 0000944809opk:PfizerIncMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:MilestonePaymentsMember2023-01-012023-09-30 0000944809opk:BardaAgreementMember2024-01-012024-09-30 0000944809opk:BardaAgreementMember2024-09-30 0000944809opk:BardaAgreementMember2024-09-012024-09-30 0000944809opk:BardaAgreementMember2024-06-30 0000944809opk:MerckSharpDohmeLLCMemberopk:MerckAgreementMember2023-03-082023-03-08 0000944809opk:MerckSharpDohmeLLCMemberopk:MerckAgreementMember2023-03-08 0000944809opk:MerckSharpDohmeLLCMemberopk:MerckAgreementMember2023-12-31 0000944809opk:MerckSharpDohmeLLCMemberopk:MerckAgreementMember2023-03-092024-09-30 0000944809opk:LeaderMedJointVentureMemberus-gaap:CorporateJointVentureMember2021-09-14 0000944809opk:LeaderMedJointVentureMemberus-gaap:CorporateJointVentureMember2021-09-142021-09-14 0000944809opk:LeaderMedMemberopk:LeaderMedJointVentureMemberus-gaap:CorporateJointVentureMember2021-09-142021-09-14 0000944809opk:LeaderMedMemberopk:LeaderMedJointVentureMemberus-gaap:CorporateJointVentureMember2021-09-14 0000944809opk:Camp4Member2021-07-062021-07-06 0000944809opk:Camp4Member2021-07-06 0000944809opk:Camp4Memberopk:DravetSyndromeProductsMember2021-07-06 0000944809opk:Camp4Memberopk:NondravetSyndromeProductsMember2021-07-06 0000944809opk:Camp4Memberopk:DravetSyndromeProductsMember2021-07-062021-07-06 0000944809opk:Camp4Memberopk:NondravetSyndromeProductsMember2021-07-062021-07-06 0000944809opk:EirgenMemberopk:NicoyaMacauLimitedMemberopk:DevelopmentAndLicenseAgreementMember2021-06-182021-06-18 0000944809opk:EirgenMemberopk:NicoyaMacauLimitedMemberopk:DevelopmentAndLicenseAgreementMember2021-06-18 0000944809opk:EirgenMemberopk:NicoyaMacauLimitedMemberopk:DevelopmentAndLicenseAgreementMember2023-03-31 0000944809opk:EirgenMemberopk:NicoyaMacauLimitedMemberopk:DevelopmentAndLicenseAgreementMember2023-01-012023-03-31 0000944809opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:DevelopmentAndLicenseAgreementMember2023-01-012023-12-31 0000944809opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:TransferOfIntellectualPropertyAndOtherMember2022-01-012022-12-31

0000944809opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:FirstMarketingApprovalOfRayaldeeInEuropeMemberopk:DevelopmentAndLicenseAgreementMember2020-05-05 0000944809opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:GermanyPriceApprovalByLocalSickFundAssociationMemberopk:DevelopmentAndLicenseAgreementMember2020-05-05 0000944809opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:DevelopmentAndLicenseAgreementMember2020-05-05 0000944809opk:PfizerIncMemberopk:PfizerAgreementMember2023-01-012023-12-31 0000944809opk:PfizerIncMemberopk:PfizerAgreementMember2022-01-012022-12-31 0000944809opk:PfizerIncMemberopk:PfizerAgreementMember2019-10-01 0000944809opk:PfizerIncMemberopk:PfizerAgreementMember2024-09-30 0000944809opk:PfizerIncMemberopk:PfizerAgreementMember2023-12-31 0000944809opk:PfizerIncMembersrt:MinimumMemberopk:PfizerAgreementMember2019-10-01 0000944809opk:PfizerIncMembersrt:MaximumMemberopk:PfizerAgreementMember2019-10-01 0000944809opk:PfizerIncMemberopk:PfizerAgreementMember2023-07-012024-09-30 0000944809us-gaap:IntersegmentEliminationMember2024-01-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:PharmaceuticalMember2024-07-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:PharmaceuticalMember2023-07-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:PharmaceuticalMember2024-01-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:PharmaceuticalMember2023-01-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:DiagnosticsMember2024-07-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:DiagnosticsMember2023-07-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:DiagnosticsMember2024-01-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:DiagnosticsMember2023-01-012023-09-30 0000944809us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2024-07-012024-09-30 0000944809us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2023-07-012023-09-30 0000944809us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2024-01-012024-09-30 0000944809us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2023-01-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:PharmaceuticalMember2024-07-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:PharmaceuticalMember2023-07-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:PharmaceuticalMember2024-01-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:PharmaceuticalMember2023-01-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:DiagnosticsMember2024-07-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:DiagnosticsMember2023-07-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:DiagnosticsMember2024-01-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:DiagnosticsMember2023-01-012023-09-30 0000944809us-gaap:CorporateNonSegmentMemberus-gaap:ProductMember2024-07-012024-09-30 0000944809us-gaap:CorporateNonSegmentMemberus-gaap:ProductMember2023-07-012023-09-30 0000944809us-gaap:CorporateNonSegmentMemberus-gaap:ProductMember2024-01-012024-09-30 0000944809us-gaap:CorporateNonSegmentMemberus-gaap:ProductMember2023-01-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:PharmaceuticalMember2024-07-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:PharmaceuticalMember2023-07-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:PharmaceuticalMember2024-01-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:PharmaceuticalMember2023-01-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DiagnosticsMember2024-07-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DiagnosticsMember2023-07-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DiagnosticsMember2024-01-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DiagnosticsMember2023-01-012023-09-30 0000944809us-gaap:CorporateNonSegmentMemberopk:TransferOfIntellectualPropertyAndOtherMember2024-07-012024-09-30 0000944809us-gaap:CorporateNonSegmentMemberopk:TransferOfIntellectualPropertyAndOtherMember2023-07-012023-09-30 0000944809us-gaap:CorporateNonSegmentMemberopk:TransferOfIntellectualPropertyAndOtherMember2024-01-012024-09-30 0000944809us-gaap:CorporateNonSegmentMemberopk:TransferOfIntellectualPropertyAndOtherMember2023-01-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember2024-07-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember2023-07-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember2024-01-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember2023-01-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember2024-07-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember2023-07-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember2024-01-012024-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember2023-01-012023-09-30 0000944809us-gaap:CorporateNonSegmentMember2024-07-012024-09-30 0000944809us-gaap:CorporateNonSegmentMember2023-07-012023-09-30 0000944809us-gaap:CorporateNonSegmentMember2024-01-012024-09-30 0000944809us-gaap:CorporateNonSegmentMember2023-01-012023-09-30 0000944809country:US2024-07-012024-09-30 0000944809country:US2023-07-012023-09-30 0000944809country:US2024-01-012024-09-30 0000944809country:US2023-01-012023-09-30 0000944809country:IE2024-07-012024-09-30 0000944809country:IE2023-07-012023-09-30 0000944809country:IE2024-01-012024-09-30 0000944809country:IE2023-01-012023-09-30 0000944809country:CL2024-07-012024-09-30 0000944809country:CL2023-07-012023-09-30 0000944809country:CL2024-01-012024-09-30 0000944809country:CL2023-01-012023-09-30 0000944809country:ES2024-07-012024-09-30 0000944809country:ES2023-07-012023-09-30 0000944809country:ES2024-01-012024-09-30 0000944809country:ES2023-01-012023-09-30 0000944809country:IL2024-07-012024-09-30 0000944809country:IL2023-07-012023-09-30 0000944809country:IL2024-01-012024-09-30 0000944809country:IL2023-01-012023-09-30 0000944809country:MX2024-07-012024-09-30 0000944809country:MX2023-07-012023-09-30 0000944809country:MX2024-01-012024-09-30 0000944809country:MX2023-01-012023-09-30 0000944809opk:OtherCountriesMember2024-07-012024-09-30 0000944809opk:OtherCountriesMember2023-07-012023-09-30 0000944809opk:OtherCountriesMember2024-01-012024-09-30 0000944809opk:OtherCountriesMember2023-01-012023-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember2024-09-30 0000944809us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember2023-12-31 0000944809us-gaap:CorporateNonSegmentMember2024-09-30 0000944809us-gaap:CorporateNonSegmentMember2023-12-31 0000944809us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-30 0000944809us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-30 0000944809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-30 0000944809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-31 0000944809opk:OfficeSpaceMemberopk:ModexTherapeuticsIncMember2023-01-02

WASHINGTON, DC 20549 FORM 10-Q (Mark One) â˜ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Â to Â . Commission file number 001-33528 OPKO Health, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 75-2402409 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) Â 4400 Biscayne Blvd. MiamiÂ Â Â FLÂ Â Â 33137 Â (Address of Principal Executive Offices) (Zip Code) Â (305)Â 575-4100 Â (Registrantâ€™s Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.01 per share OPK NASDAQ Global Select Market Â Indicate by check mark whether the registrant: (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days.Â Â Â Â â˜’Â Â YesÂ Â Â Â â˜Â Â No Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-TÂ (Â§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Â Â Â Â Â â˜’Â Â YesÂ Â Â Â Â â˜Â Â No Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12b-2 of the Exchange Act: Â Large accelerated filer â˜’ AcceleratedÂ filer â˜ Non-accelerated filer â˜ SmallerÂ reportingÂ company â˜ Â Â Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act):Â Â Â Â â˜Â Â YesÂ Â Â Â Â â˜’Â Â No Â As of November 1, 2024, the registrant had 682,483,029 shares of Common Stock outstanding. Â Â Table of Contents Â Â TABLE OF CONTENTS Â PART I. FINANCIAL INFORMATION Page ItemÂ 1. Financial Statements Â Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 (unaudited) 6 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (unaudited) 7 Condensed Consolidated Statements of Comprehensive lossÂ for the three and nine months endedSeptember 30, 2024 and 2023 (unaudited) 8 Condensed Consolidated Statements of EquityÂ for the three and nine months endedSeptember 30, 2024 and 2023 (unaudited) 9 Condensed Consolidated Statements of Cash FlowsÂ for the nine months ended September 30, 2024 and 2023 (unaudited) 11 Notes to Condensed Consolidated Financial Statements (unaudited) 12 ItemÂ 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 49 ItemÂ 3. Quantitative and Qualitative Disclosures About Market Risk 65 ItemÂ 4. Controls and Procedures 66 PART II. OTHER INFORMATION Â ItemÂ 1. Legal Proceedings 67 ItemÂ 1A. Risk Factors 67 ItemÂ 2. Unregistered Sales of Equity Securities and Use of Proceeds 67 ItemÂ 3. Defaults Upon Senior Securities 67 ItemÂ 4. Mine Safety Disclosures 68 ItemÂ 5. Other Information 68 ItemÂ 6. Exhibits 68 Signatures 69 Â Â 3 Table of Contents Â Â CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Â This Quarterly Report on Form 10-Q contains â€œforward-looking statements,â€ as that term is defined under the Private Securities Litigation Reform Act of 1995 (â€œPSLRAâ€), SectionÂ 27A of the Securities Act of 1933, as amended (the â€œSecurities Actâ€), and SectionÂ 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). Forward-looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or prospects, operating results, cash flows and/or financial condition. You can identify forward-looking statements by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described below and in â€œItem 1A-Risk Factorsâ€ of our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023, and described from time to time in our other filings with the Securities and Exchange Commission (the â€œSECâ€). We do not undertake any obligation to update forward-looking statements, except to the extent required by applicable law. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Â Risks and uncertainties, the occurrence of which could adversely affect our business, include the following: Â Â â€¢ we have had a history of losses and may not generate sustained positive cash flow sufficient to fund our operations and research and development programs; Â â€¢ our need for, and ability to obtain, additional financing when needed on favorable terms, or at all; Â â€¢ adverse results in material litigation matters or governmental inquiries; Â â€¢ the risks inherent in developing, obtaining regulatory approvals for and commercializing new, commercially viable and competitive products and treatments; Â â€¢ our research and development activities may not result in commercially viable products; Â â€¢ that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results; Â â€¢ that we may not generate or sustain profits or cash flow from our laboratory operations or substantial revenue from NGENLA,Â Rayaldee and our other pharmaceutical and diagnostic products; Â â€¢ our ability to manage our growth and our expanded operations; Â â€¢ that our acquisition of ModeX Therapeutics, Inc. will be successful and the products in the R&D pipeline will ultimately be commercialized; Â â€¢ that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied; Â â€¢ our ability and our distribution and marketing partnersâ€™ ability to comply with regulatory requirements regarding the sales, marketing and manufacturing of our products and product candidates and the operation of our laboratories; Â â€¢ the performance of our third-party distribution partners, licensees and manufacturers over which we have limited control; Â â€¢ changes in regulation and policies in the U.S. and other countries, including increasing downward pressure on healthcare reimbursement; Â â€¢ increased competition, including price competition; Â â€¢ our success is dependent on the involvement and continued efforts of our Chairman and Chief Executive Officer; Â â€¢ integration challenges for acquired businesses; Â 4 Table of Contents Â Â â€¢ changing relationships with payors, including the various state and multi-state programs, suppliers and strategic partners; Â â€¢ efforts by third-party payors to reduce utilization and reimbursement for clinical testing services; Â â€¢ our ability to maintain reimbursement coverage for our products and services, including Rayaldee and the 4Kscore test; Â â€¢ failure to timely or accurately bill and collect for our services; Â â€¢ the information technology systems that we rely on may be subject to unauthorized tampering, cyberattack or other data security or privacy incidents that could impact our billing processes or disrupt our operations; Â â€¢ failure to obtain and retain new clients and business partners, or a reduction in tests ordered or specimens submitted by existing clients; Â â€¢ failure to establish, and perform to, appropriate quality standards to assure that the highest level of quality is observed in the performance of our testing services; Â â€¢ failure to maintain the security of patient-related information; Â â€¢ our ability to obtain and maintain intellectual property protection for our products; Â â€¢ our ability to defend our intellectual property rights with respect to our products; Â â€¢ our ability to operate our business without infringing the intellectual property rights of others; Â â€¢ our ability to attract and retain key scientific and management personnel; Â â€¢ the risk that the carrying value of certain assets may exceed the fair value of the assets causing us to impair goodwill or other intangible assets; Â â€¢ our ability to comply with the terms of our 2022 Corporate Integrity Agreement with the U.S. Office of Inspector General of the Department of Health and Human Services; Â â€¢ failure to obtain and maintain regulatory approval for our products and services outside the U.S.;Â Â â€¢ legal, economic, political, regulatory, currency exchange, and other risks associated with international operations; and Â â€¢ disruptions to operations, including impact on employees, and business continuity, including physical damage or impaired access to company facilities, office of technology from the current conflicts in the Middle East Â PART I. FINANCIAL INFORMATION Â Unless the context otherwise requires, all references in this Quarterly Report on Form 10-Q to the â€œCompanyâ€, â€œOPKOâ€, â€œweâ€, â€œourâ€, â€œoursâ€, and â€œusâ€ refer to OPKO Health, Inc., a Delaware corporation, including our consolidated subsidiaries. Â Item 1. Financial Statements Â The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements. Â 5 Table of Contents Â Â OPKO Health, Inc. and Subsidiaries CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (In thousands, except share and per share data) Â Â Â September 30, 2024 Â Â December 31, 2023 Â ASSETS Â Â Â Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Â Â Â Cash, cash equivalents and current restricted cash Â $406,400Â Â $95,881Â Accounts receivable, net Â Â 106,579Â Â Â 123,379Â Inventory, net Â Â 59,408Â Â Â 65,697Â Other current assets and prepaid expenses Â Â 57,249Â Â Â 24,519Â Total current assets Â Â 629,636Â Â Â 309,476Â Property, plant and equipment, net Â Â 72,271Â Â Â 75,429Â Intangible assets, net Â Â 641,396Â Â Â 740,283Â In-process research and development Â Â 195,000Â Â Â 195,000Â Goodwill Â Â 535,868Â Â Â 598,260Â Investments Â Â 100,609Â Â Â 16,082Â Operating lease right-of-use assets

Â Â 62,812Â Â Â 68,088Â Other assets Â Â 18,511Â Â Â 9,080Â Total assets Â $2,256,103Â Â $2,011,698Â LIABILITIES AND EQUITY Â Â Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Â Â Accounts payable Â $62,721Â Â $69,677Â Accrued expenses Â Â 122,806Â Â Â 90,086Â Current maturities of operating leases Â Â 12,741Â Â Â 12,996Â Current portion of convertible notes Â Â 170Â Â Â â€”Â Current portion of lines of credit and notes payable Â Â 13,222Â Â Â 27,293Â Total current liabilities Â Â 211,660Â Â Â 200,052Â Operating lease liabilities Â Â 52,057Â Â Â 54,140Â Long term portion of convertible notes Â Â 178,695Â Â Â 214,325Â Senior secured notes Â Â 245,358Â Â Â â€”Â Deferred tax liabilities Â Â 128,412Â Â Â 126,773Â Other long-term liabilities, principally contract liabilities, contingent consideration and lines of credit Â Â 36,504Â Â Â 27,189Â Total long-term liabilities Â Â 641,026Â Â Â 422,427Â Total liabilities Â Â 852,686Â Â Â 622,479Â Equity: Â Â Â Â Â Â Â Â Common Stock - $0.01 par value, 1,250,000,000 shares authorized; 712,283,206 and 781,936,885 shares issued at September 30, 2024 and December 31, 2023, respectively Â Â 7,124Â Â Â 7,820Â Treasury Stock - 29,800,177, and 8,655,082 shares at September 30, 2024 and December 31, 2023, respectively Â Â (1,791)Â Â (1,791) Additional paid-in capital Â Â 3,516,735Â Â Â 3,433,006Â Accumulated other comprehensive loss Â Â (39,614)Â Â (38,030) Accumulated deficit Â Â (2,079,037)Â Â (2,011,786) Total shareholdersâ€™ equity Â Â 1,403,417Â Â Â 1,389,219Â Total liabilities and equity Â $2,256,103Â Â $2,011,698Â Â Â The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements. Â 6 Table of Contents Â Â OPKO Health, Inc. and Subsidiaries CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except share and per share data) Â Â Â For the three months ended September 30, Â Â For the nine months ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenues: Â Â Â Â Â Â Â Â

generally accepted in the U.S. (â€œGAAPâ€) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Companyâ€™s results of operations, financial position and cash flows have been made. The results of operations and cash flows for the nine months ended September 30, 2024 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2024 or any other future periods. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. Â Principles of consolidation. The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and our wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Â Use of estimates. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates. Â Cash, cash equivalents and restricted cash. Cash, cash equivalents and restricted cash include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase. We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities. Â The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheet to the sum ofÂ such amountsÂ in the Condensed Consolidated Statements of Cash Flows: Â Â Â September 30, 2024 Â Â December 31, 2023 Â Cash and cash equivalents Â $400,079Â Â $95,881Â Restricted cash, current Â Â 6,321Â Â Â â€”Â Restricted cash, long-term Â Â 13,665Â Â Â â€”Â Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows Â $420,065Â Â $95,881Â Â 13 Table of Contents Â The Company classifies cash deposits related to letters of credit securing insurance and lease obligations as restricted cash, which is included in other assets, non-current, within the Consolidated Balance Sheet. Â Inventories. Inventories are valued at the lower of cost and net realizable value. Cost is determined by the first-in, first-out method. We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value. Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which are used in our testing laboratories. Â Inventory obsolescence expense for the three and nine months ended September 30, 2024 wasÂ $0.6 million and $1.6 million, respectively. Inventory obsolescence expense for the three and nine months ended September 30, 2023 wasÂ $2.6 million and $4.0 million, respectively. Â Goodwill and intangible assets. Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting. Refer to Note 5. Goodwill, in-process research and development (â€œIPR&Dâ€) and other intangible assets acquired in business combinations, licensing and other transactions was $1.4 billion and $1.5 billion at September 30, 2024 and December 31, 2023, respectively. Â Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. At acquisition, we generally determine the fair value of intangible assets, including IPR&D, using the â€œincome method.â€ Â Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable. Â Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment. We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing. Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value. Goodwill was $535.9 million and $598.3 million, respectively, at September 30, 2024 and December 31, 2023. Â Net intangible assets other than goodwill were $836.4 million on each of September 30, 2024, and December 31, 2023, with IPR&D accounting for $195.0 million on each date. Considering the high risk nature of research and development and the industryâ€™s success rate of bringing developmental compounds to market, IPR&D impairment charges may occur in future periods. Estimating the fair value of IPR&D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment. Â Upon regulatory approval, IPR&D assets are classified as finite-lived intangible assets. These assets are then amortized on a straight-line basis over their estimated useful lives. If a project is abandoned, the associated IPR&D costs are immediately expensed. We also regularly assess finite-lived intangible assets for impairment. This assessment involves comparing the carrying amount of an asset, which is its cost minus accumulated amortization, to its estimated future undiscounted cash flows. If the carrying amount exceeds the estimated future cash flows, an impairment charge is recognized to reflect the difference between the asset's carrying amount and its fair value.Â Â 14 Table of Contents Â While we believe our estimates and assumptions used in impairment testing (including for goodwill and IPR&D) are reasonable and reflect those used by market participants, there is a potential risk of material impairment charges. Based on the current financial performance of our diagnostics segment and our Ireland reporting unit (which includes Eirgen and Rayaldee), we could be subject to such charges if their future performance deviates from our current estimates and assumptions. For reference, the combined goodwill of these units totaled $304.9 million and $367.3 million at September 30, 2024 and December 31, 2023, respectively. Â We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years. We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up. Amortization expense wasÂ $20.4 million andÂ $62.3 million for the three and nine months ended September 30, 2024, respectively. Amortization expense wasÂ $21.5 million andÂ $64.5 million for the three and nine months ended September 30, 2023, respectively. Â Fair value measurements. The carrying amounts of our cash, cash equivalents, restricted cash, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments. Investments that are considered equity securities as of September 30, 2024 and December 31, 2023 are predominately carried at fair value. Our debt under the Credit Agreement (as defined below) approximates fair value due to the variable rate of interest applicable to such debt. Â In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts. Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange. Refer to Note 9. Â Contingent consideration. Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense. Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability. Contingent considerationÂ mayÂ change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value whichÂ mayÂ have a material impact on our results from operations and financial position. Â Derivative financial instruments. We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges. For a derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At September 30, 2024 and December 31, 2023, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges. Accordingly, we recognized all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations. Refer to Note 10. In addition, we have determined the value of the embedded derivative liability within the 2029 Convertible 144A Notes (as defined in Note 7) and recorded it at fair value. Refer to Note 7. The changes in the fair value of the embedded derivatives are recognized in the fair value changes of derivatives instruments, net. Refer to Note 9. Â Property, plant and equipment. Property, plant and equipment are recorded at cost or fair value if acquired in a business combination. Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases. The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, and automobiles - 3-5 years. Expenditures for repairs and maintenance are charged to expense as incurred. Assets held under finance leases are included within Property, plant and equipment, net in our Condensed Consolidated Balance Sheets and are amortized over the shorter of their useful lives or the expected term of their related leases. Depreciation expense was $3.7 million andÂ $11.9 million for the three and nine months ended September 30, 2024, respectively. Depreciation expense wasÂ $4.8 million andÂ $14.8 million for the three and nine months ended September 30, 2023, respectively. Â 15 Table of Contents Â Impairment of long-lived assets. Long-lived assets, such as property and equipment and assets held for sale, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. Â Income taxes. Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment. Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold. Â We operate in various countries and tax jurisdictions globally.Â For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results.Â For the nine months ended September 30, 2024, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit. Â Included in Other long-term liabilities is an accrual of $9.9 million related to uncertain tax positions involving income recognition. In connection with an examination of foreign tax returns for the 2015 through 2021 tax years, a foreign taxing authority has issued an income tax assessment of approximately $246Â million (including interest). We are appealing this assessment, as we believe, other than for uncertain tax positions for which we have reserved, the issues are without technical merit. We intend to exhaust all judicial remedies necessary to resolve the matter as necessary,Â which could be a lengthy process. There can be no assurance that this matter will be resolved in our favor, and an adverse outcome, or any future tax examinations involving similar assertions, could have a material adverse effect on our financial condition, results of operations and cash flows. Â Revenue recognition. We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (â€œTopic 606â€). The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. Â We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. For a complete discussion of accounting for Revenues from services, Revenues from products and Revenue from transfer of intellectual property and other, refer to Note 13. Â Concentration of credit risk and allowance for credit losses. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions. Â While we have receivables due from federal and state governmental agencies, such receivables are not a credit risk because federal and state governments fund the related healthcare programs. Payment is primarily dependent upon submitting appropriate documentation. On September 30, 2024 and December 31, 2023, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were 6.5% and 6.7%, respectively, of our consolidated Accounts receivable, net. The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk. At September 30, 2024 and December 31, 2023, receivables due from patients represented approximately 2.2% and 2.0%, respectively, of our consolidated Accounts receivable, net. Â 16 Table of Contents Â We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customerâ€™s ability to pay. Actual results could differ from those estimates. The allowance for credit losses was $2.0 million on each ofÂ September 30, 2024 and December 31, 2023. The credit loss expense for the three and nine months ended September 30, 2024, was a reversal expense of $75.2 thousand and $67.5 thousand of expense, respectively. The credit loss expense for the three and nine months ended September 30, 2023, wasÂ $98.3 thousand and $183.4 thousand, respectively. Â As of September 30, 2024, accounts receivable included $1.6 million of revenue earned under the BARDA Contract (as defined in Note 14). As of December 31, 2023, accounts receivable included $0.6 million under this contract. Refer to Note 13, Government Contract Revenue for further information on government contracts and to Note 14, Strategic Alliances for further information on the BARDA Contract. Â Stock Repurchase Program. On July 18, 2024, the Company announced that its Board of Directors authorized the repurchase of up to $100 millionÂ shares of Common Stock. Under this program, OPKO may repurchase shares through various methods, including open market purchases, block trades, privately negotiated transactions, and accelerated share repurchases, as well as pursuant to pre-set trading plans meeting the requirements of Rule 10b5-1(c) of the Exchange Act, and otherwise in compliance with applicable laws. The timing and volume of repurchases will depend on market conditions, the Company's capital management, investment opportunities, and other factors. The program does not obligate the Company to repurchase any specific number of shares, has no set expiration date, and may be modified, suspended, or discontinued at the Company's discretion. The Company repurchased 14,893,026 shares for approximately $23.8 million during the three months ended September 30, 2024. Â Equity-based compensation. We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award. We record excess tax benefits realized from the exercise of stock options as cash flows from operations. For the three and nine months ended September 30, 2024, we recordedÂ $2.8 million and $8.0 million, respectively, of equity-based compensation expense. For the three and nine months ended September 30, 2023, we recorded $3.2 million and $8.7 million, respectively, of equity-based compensation expense. Â Research and development expenses. Research and development expenses include external and internal expenses. External expenses include clinical and nonclinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs. Research and development employee-related expenses include salaries, benefits and equity-based compensation expense. Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities. We expense these costs in the period in which they are incurred. We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance

with the specific third party contract. Â Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility, and which have no alternative future use. For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining estimated useful life. Â Segment reporting. Our chief operating decision-maker (â€œCODMâ€) is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Dr. Frost reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis. We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense or income taxes. Refer to Note 15. Â Shipping and handling costs. We do not charge customers for shipping and handling costs. Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations. Â 17 Table of Contents Â Foreign currency translation. The financial statements of certain of our foreign operations are measured using the local currency as the functional currency. The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date. The local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods. Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss). During the three and nine months ended September 30, 2024, we recorded foreign currency transaction income of $4.1 million and $0.1 million, respectively. During the three and nine months ended September 30, 2023, we recorded foreign currency transaction loss ofÂ $3.8 million and $1.9 million, respectively. Â Variable interest entities. The consolidation of a variable interest entity (â€œVIEâ€) is required when an enterprise has a controlling financial interest. A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIEâ€™s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE. Refer to Note 6. Â Investments. We have made strategic investments in development stage and emerging companies. We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees. For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations. Refer to Note 6. For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value. Refer to Note 6. Â Accounting standards yet to be adopted. Â In December 2023, the FASB issued ASU No. 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€ (â€œASU 2023-09â€), which modifies the rules on income tax disclosures to require entities to disclose (i) specific categories in the rate reconciliation, (ii) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (iii) income tax expense or benefit from continuing operations (separated by federal, state and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state, and local jurisdictions, among other changes. The guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. ASU 2023-09 should be applied on a prospective basis, but retrospective application is permitted. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures. Â In November 2023, the FASB issued ASU No 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€). ASU 2023-07 enhances disclosures for significant segment expenses for all public entities required to report segment information in accordance with ASC 280. ASC 280 requires a public entity to report for each reportable segment a measure of segment profit or loss that its CODM uses to assess segment performance and to make decisions about resource allocations. The ASU is effective for fiscal years beginning after December 15, 2024 with updates to be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures. Â Recently adopted accounting standards. Â In 2021, the Organization for Economic Co-operation and Development (â€œOECDâ€) established an inclusive framework on base erosion and profit shifting and agreed on a two-pillar solution (â€œPillar Twoâ€) to global taxation, focusing on global profit allocation and a 15% global minimum effective tax rate. On December 15, 2022, the EU member states agreed to implement the OECDâ€™s global minimum tax rate of 15%. The OECD issued Pillar Two model rules and continues to release guidance on these rules. The inclusive framework calls for tax law changes by participating countries to take effect in 2024 and 2025. Various countries have enacted or have announced plans to enact new tax laws to implement the global minimum tax. We considered the applicable tax law changes on Pillar Two implementation in the relevant countries, and there is no material impact to our tax results for the period. We anticipate further legislative activity and administrative guidance in 2024, and will continue to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in the non-US tax jurisdictions we operate in. Â 18 Table of Contents Â Â NOTE 4 EARNINGS (LOSS) PER SHARE Â Basic income (loss) per share is computed by dividing our net income (loss) by the weighted average number of shares of our Common Stock outstanding during the period. Shares of Common Stock outstanding under theÂ share lendingÂ arrangement entered into in conjunction with the 2025 Notes (as defined in Note 7) have been excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent. We terminated the share lending agreement on January 22, 2024.Â Refer to Note 7. For diluted earnings per share, the dilutive impact of stock options and warrants is determined by applying the â€œtreasury stockâ€ method. The dilutive impact of the 2029 Convertible Notes, 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes (each, as defined and discussed in Note 7) has been considered using the â€œif convertedâ€ method. For periods in which their effect would have been antidilutive, no effect is given in the dilutive computation to Common Stock issuable under outstanding options or warrants or the potentially dilutive shares issuable pursuant to the 2029 Convertible Notes, 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes. The following table sets forth the computation of basic and diluted income (loss) per share: Â Â Â For the three months ended September 30, Â Â For the nine months ended September 30, Â (In thousands, except per share data) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Numerator Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss), basic Â $24,890Â Â $(84,473)Â Â $(67,251)Â Â $(122,380) Add: Interest on 2025 Notes Â Â 1Â Â Â -Â Â Â -Â Â Â -Â Add: Interest on 2029 Convertible Notes Â Â 6,858Â Â Â -Â Â Â -Â Â Â -Â Add: Loss on buy back of 2029 Convertible Notes Â Â 32Â Â Â -Â Â Â -Â Â Â -Â Net income (loss), diluted Â $31,781Â Â $(84,473)Â Â $(67,251)Â Â $(122,380) Â Denominator Â (Shares in thousands) Â Weighted average common shares outstanding, basic Â Â 694,622,466Â Â Â 751,525,007Â Â Â 699,675,944Â Â Â 751,716,692Â Effect of dilutive securities: Â Stock options Â Â 76,922Â Â Â -Â Â Â -Â Â Â -Â Warrants Â Â -Â Â Â -Â Â Â -Â Â Â -Â 2025 Notes Â Â 48,295Â Â Â -Â Â Â -Â Â Â -Â 2023 Convertible Notes Â Â -Â Â Â -Â Â Â -Â Â Â -Â 2033 Senior Notes Â Â 8,489Â Â Â -Â Â Â -Â Â Â -Â 2029 Convertible Notes Â Â 303,607,464Â Â Â Â Â Â Â Â Â Â Â Dilutive potential shares Â Â 303,741,170Â Â Â -Â Â Â -Â Â Â -Â Weighted average common shares outstanding, diluted Â Â 998,363,636Â Â Â 751,525,007Â Â Â 699,675,944Â Â Â 751,716,692Â Loss per share, basic Â $0.04Â Â $(0.11)Â $(0.10)Â $(0.16) Loss per share, diluted Â $0.03Â Â $(0.11)Â $(0.10)Â $(0.16) Â A total of 0 and 83,074,689 potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the three months ended September 30, 2024 and 2023, respectively, because their inclusion would have been antidilutive.Â A total of 286,281,585 and 82,368,398 potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the nine months ended September 30, 2024 and 2023, respectively, because their inclusion would have been antidilutive. Â During the three months ended September 30, 2024, no options were exercised and no restricted stock units vested, resulting in the issuance of no shares of Common Stock. Â During the nine months ended September 30, 2024, no options were exercised and 549,687 restricted stock units vested, resulting in the issuance of 384,378 shares of Common Stock. Â During the three months ended September 30, 2023, 18,750 options were exercised and no restricted stock units vested, resulting in the issuance of 18,750 shares of Common Stock. Â During the nine months ended September 30, 2023, 18,750 options were exercised and 549,680 restricted stock units vested, resulting in the issuance of 405,721 shares of Common Stock. Â 19 Table of Contents Â Â NOTE 5 COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS Â Â Â September 30, Â Â December 31, Â (In thousands) Â 2024 Â Â 2023 Â Accounts receivable, net: Â Â Â Â Â Â Â Â Accounts receivable Â $108,583Â Â $125,379Â Less: allowance for credit losses Â Â (2,004)Â Â (2,000) Â Â $106,579Â Â $123,379Â Inventories, net: Â Â Â Â Â Â Â Â Consumable supplies Â $16,218Â Â $25,864Â Finished products Â Â 34,206Â Â Â 35,582Â Work-in-process Â Â 2,265Â Â Â 1,731Â Raw materials Â Â 10,491Â Â Â 8,981Â Less: inventory reserve Â Â (3,772)Â Â (6,461) Â Â $59,408Â Â $65,697Â Other current assets and prepaid expenses: Â Â Â Â Â Â Â Â Escrow receivable Â $23,750Â Â $â€”Â Taxes recoverable Â Â 6,767Â Â Â 4,211Â Prepaid expenses Â Â 9,572Â Â Â 6,177Â Prepaid insurance Â Â 6,302Â Â Â 3,848Â Other receivables Â Â 1,563Â Â Â 2,610Â Other Â Â 9,295Â Â Â 7,673Â Â Â $57,249Â Â $24,519Â Intangible assets, net: Â Â Â Â Â Â Â Â Customer relationships Â $258,048Â Â $315,799Â Technologies Â Â 818,971Â Â Â 831,509Â Trade names Â Â 49,759Â Â Â 49,758Â Covenants not to compete Â Â 12,917Â Â Â 12,916Â Licenses Â Â 6,311Â Â Â 6,205Â Product registrations Â Â 6,738Â Â Â 6,790Â Other Â Â 6,052Â Â Â 6,000Â Less: accumulated amortization Â Â (517,400)Â Â (488,694) Â Â $641,396Â Â $740,283Â Accrued expenses: Â Â Â Â Â Â Â Â Employee benefits and severance Â $38,474Â Â $28,952Â Clinical trials Â Â 3,725Â Â Â 7,624Â Commitments and contingencies Â Â 11,141Â Â Â 8,088Â Accrued interest Â Â 6,021Â Â Â 2,601Â Gross to net provision Â Â 6,033Â Â Â 9,420Â Inventory received but not invoiced Â Â 2,306Â Â Â 1,653Â Finance leases short-term Â Â 1,855Â Â Â 2,827Â Professional fees Â Â 4,375Â Â Â 3,470Â Taxes payable Â Â 15,334Â Â Â 1,384Â Royalties Â Â 767Â Â Â 1,544Â Commissions Â Â 1,521Â Â Â 1,822Â Other Â Â 31,254Â Â Â 20,701Â Â Â $122,806Â Â $90,086Â Other long-term liabilities: Â Â Â Â Â Â Â Â Employee severance Â $16,284Â Â $â€”Â Mortgages and other debts payable Â Â 3,529Â Â Â 7,709Â Finance leases long-term Â Â 4,689Â Â Â 7,274Â Contract liabilities Â Â 7Â Â Â 7Â Other Â Â 11,995Â Â Â 12,199Â Â Â $36,504Â Â $27,189Â Â 20 Table of Contents Â Our intangible assets and goodwill relate principally to our completed acquisitions of OPKO Renal, OPKO Biologics, EirGen, BioReference and ModeX. We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives. The estimated useful lives by asset class are as follows: technologies - 7-17 years, customer relationships - 5-20 years, product registrations - 7-10 years, covenants not to compete - 5 years, trade names - 5-10 years, other 9-13 years. We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred. Our goodwill is not tax deductible for income tax purposes in any jurisdiction in which we operate. Â Changes in value of the intangible assets and goodwill during theÂ nine months ended September 30, 2024 and 2023 were primarily due to foreign currency fluctuations between the Euro, and the Chilean Peso against the U.S. dollar. Â The following table summarizes the changes in Goodwill by reporting unit during the nine months ended September 30, 2024. Â Â Â 2024 Â (In thousands) Â Gross goodwill at January 1, 2024 Â Â Cumulative impairment at January 1 Â Â Acquisitions, dispositions and other Â Â Foreign exchange and other Â Â Balance at September 30, 2024 Â Pharmaceuticals Â CURNA Â $4,827Â Â $(4,827)Â $â€”Â Â $â€”Â Â $â€”Â Rayaldee Â Â 84,273Â Â Â Â â€”Â Â Â Â â€”Â Â Â 925Â Â Â 85,198Â FineTech Â Â 11,698Â Â Â (11,698)Â Â â€”Â Â Â â€”Â Â Â â€”Â ModeX Â Â 80,260Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 80,260Â OPKO Biologics Â Â 139,784Â Â Â â€”Â Â Â â€”Â Â Â (0)Â Â 139,784Â OPKO Chile Â Â 3,642Â Â Â Â â€”Â Â Â â€”Â Â Â (81)Â Â 3,561Â OPKO Health Europe Â Â 7,276Â Â Â Â â€”Â Â Â Â â€”Â Â Â 82Â Â Â 7,358Â OPKO Mexico Â Â 100Â Â Â (100)Â Â â€”Â Â Â â€”Â Â Â â€”Â Transition Therapeutics Â Â 3,421Â Â Â (3,421)Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Diagnostics Â BioReference Â Â 283,025Â Â Â â€”Â Â Â (63,318)Â Â â€”Â Â Â 219,707Â OPKO Diagnostics Â Â 17,977Â Â Â (17,977)Â Â â€”Â Â Â â€”Â Â Â $636,283Â Â $(38,023)Â $(63,318)Â $926Â Â $535,868Â Â 21 Table of Contents Â Â NOTE 6 INVESTMENTS Â Investments Â The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of September 30, 2024 and December 31, 2023: Â (in thousands) Â As of September 30, 2024 Â Â As of December 31, 2023 Â Investment type Â Investment Carrying Value Â Â Underlying Equity in Net Assets Â Â Investment Carrying Value Â Â Underlying Equity in Net Assets Â Equity method investments Â $(0)Â $1,782Â Â $(0)Â $2,942Â Variable interest entity, equity method Â Â 790Â Â Â â€”Â Â Â 796Â Â Â 420Â Equity method investments - FV option Â Â 92,166Â Â Â Â Â Â Â 9,786Â Â Â Â Â Â Equity securities Â Â 130Â Â Â Â Â Â Â 116Â Â Â Â Â Â Equity securities with no readily determinable fair value Â Â 7,521Â Â Â Â Â Â Â 5,382Â Â Â Â Â Â Warrants and options Â Â 2Â Â Â Â Â Â Â 2Â Â Â Â Â Â Total carrying value of investments Â $100,609Â Â Â Â Â Â $16,082Â Â Â Â Â Â Â Equity method investments Â Our equity method investments, other than in GeneDx Holdings, as describedÂ below, consist of investments in Pharmsynthez (ownership 6%), Cocrystal Pharma, Inc. (â€œCOCPâ€) (2%), Non-Invasive Monitoring Systems, Inc. (â€œNIMSâ€) (1%), BioCardia, Inc. (â€œBioCardiaâ€) (1%), Xenetic Biosciences, Inc. (â€œXeneticâ€) (3%),Â Zebra Biologics, Inc. (â€œZebraâ€) (29%), and LeaderMed Health Group Limited (â€œLeaderMedâ€) (47%). Neovasc, Inc., in which we owned a 0.5% interest, was acquired by Shockwave Medical, Inc. in April 2023. As a result, we received $363 thousand in merger consideration in exchange for our shares. The aggregate amount of assets, liabilities, and net losses of these equity method investees as of and for theÂ nine months ended September 30, 2024 were $66.1 million, $23.3 million, and $27.7 million, respectively. The aggregate amount of assets, liabilities, and net losses of our equity method investees as of and for the year ended December 31, 2023 were $85.5 million, $20.8 million, and $37.7 million, respectively. We have determined that we or our related parties have the ability to exercise significant influence over our equity method investments through our board representation or voting power. Accordingly, we account for our investment in these entities under the equity method and record our proportionate share of their losses in Loss from investments in investees in our Consolidated Statement of Operations. The aggregate value of our equity method investments based on the quoted market prices of their respective shares of common stock and the number of shares held by us as of September 30, 2024 and December 31, 2023 was $0.6 million and $0.7 million, respectively. Â Equity method investments - Fair value option Â On January 14, 2022, the Company entered into an Agreement and Plan of Merger and Reorganization (the â€œGeneDx Merger Agreementâ€) with GeneDx Holdings Corp. (f/k/a Sema4 Holdings Corp.), a Delaware corporation (â€œGeneDx Holdingsâ€), pursuant to which GeneDx Holdings acquired our former subsidiary, GeneDx LLC (formerly GeneDx, Inc. â€œGeneDxâ€), on April 28, 2022. During the third quarter of 2024, the Company sold 1,386,929 shares of GeneDx common stock at various prices per share for an aggregate of $46.7 million. As a result of the sale, the Company's total ownership in GeneDx Holdings decreased from 13.61% to 8.1% as of September 30, 2024. Â Pursuant to the GeneDx Merger Agreement, the Company designated, and GeneDx Holdings nominated for election an individual to serve on the board of directors of GeneDx Holdings.Â This individual was subsequently elected by GeneDx Holdings stockholders and has continued to serve on the board following his re-election in 2024. His term will extend until the GeneDx Holdings annual meeting of stockholders in 2027. We have a shareholder agreement with GeneDx Holdings, pursuant to which we have agreed to vote our shares of GeneDx Holdings common stock in accordance with the recommendation of GeneDx Holdings' board of directors for so long as we continue to hold at least 5% of the outstanding shares of GeneDx Holdings common stock. Other than through our position as a shareholder, we are unable to influence GeneDx Holdings' policy-making process.Â Â 22 Table of Contents Â We account for our investment in GeneDx Holdings under the equity method fair value option and record gains and losses from changes in fair value in other income (expense), net in our Condensed Consolidated Statements of Operations. For the three and nine months ended September 30, 2024, we recognizedÂ $35.4 million andÂ $118.6 million in net income related to the change in fair value of our GeneDx Holdings investment, respectively.Â For the three and nine months ended September 30, 2023, we recognizedÂ $8.3 million andÂ $19.9 million in net loss related to the change in fair value of our GeneDx Holdings investment, respectively. As of September 30, 2024,Â the aggregate value of our GeneDx Holdings investment wasÂ $92.2 million based on the quoted market price of the GeneDx Holdings common stock. Â Investments in equity securities Â Our equity securities consist of investments in VBI Vaccines Inc.Â (0.00%), ChromaDex Corporation (â€œChromaDexâ€) (0.05%), and Eloxx Pharmaceuticals, Inc. (â€œEloxxâ€) (1%).Â During the third quarter of 2024, we recorded a $30 thousand loss from our investment in VBI Vaccines Inc. due to the company filing for bankruptcy. Our equity securities without readily determinable fair value consists of CAMP4 Therapeutics Corporation (â€œCAMP4â€) (2%) and HealthSnap, Inc. (4%). We have determined that our ownership, along with that of our related parties, does not provide us with significant influence over the operations of these investments. Accordingly, we account for our investment in these entities as equity securities, and we record changes in the fair value of these investments in Other income (expense) each reporting period when they have a readily determinable fair

value. Equity securities without a readily determinable fair value are adjusted to fair value when there is an observable price change. Net gains and losses on our equity securities for theÂ nine months ended September 30, 2024 and 2023 were as follows: Â Â Â For the nine months ended September 30, Â (in thousands) Â 2024 Â Â 2023 Â Equity Securities: Â Â Â Â Â Â Â Â Net gains and losses recognized during the period on equity securities Â $43Â Â $(411) Less: Net gains and losses realized during the period on equity securities Â Â (30)Â Â â€”Â Unrealized net losses recognized during the period on equity securities still held at the reporting date Â $13Â Â $(411) Â Sales of investments Â Gains (losses) included in earnings from sales of our investments are recorded in Other income (expense), net in our Condensed Consolidated Statement of Operations. The cost of securities sold is based on the specific identification method. Â Warrants and options Â In addition to our equity method investments and equity securities, we hold options to purchase 47 thousand additional shares of BioCardia, all of which were vested as of September 30, 2024 and December 31, 2023, and warrants to purchase 0.7 million additional shares of InCellDx Inc. We recorded the changes in the fair value of the options and warrants in fair value changes of derivative instruments, net in our Condensed Consolidated Statement of Operations. We also recorded the fair value of the options and warrants in Investments, net in our Condensed Consolidated Balance Sheet. See further discussion of the Companyâ€™s options and warrants in Note 9 and Note 10. Â 23 Table of Contents Â Investments in variable interest entities Â We have determined that we hold variable interests in LeaderMed and Zebra. We made this determination as a result of our assessment that they do not have sufficient resources to carry out their principal activities without additional financial support. Â In September 2021, we and LeaderMed, a pharmaceutical development company with operations based in Asia, formed a joint venture to develop, manufacture and commercialize two of OPKOâ€™s clinical stage, long-acting drug products in Greater China and eight other Asian territories. Under the terms of the agreements, we granted the joint venture exclusive rights to develop, manufacture and commercialize (a) OPK88003, an oxyntomodulin analog being developed for the treatment of obesity and diabetes, and (b) Factor VIIa-CTP, a novel long acting coagulation factor being developed to treat hemophilia, in exchange for 4,703 shares 47% ownership interest in the joint venture. In addition, we received an upfront payment of $1.0Â million and will be reimbursed for clinical trial material and technical support we provide the joint venture. Â In order to determine the primary beneficiary of the joint venture, we evaluated our investment and our related partiesâ€™ investment, as well as our investment combined with the related partiesâ€™ investment to identify if we had the power to direct the activities that most significantly impact the economic performance of the joint venture. Based on the capital structure, governing documents and overall business operations of the joint venture, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact the joint ventureâ€™s economic performance and do not have an obligation to fund expected losses. We did determine that we can significantly influence control of the joint venture through our board representation and voting power. Therefore, we have the ability to exercise significant influence over the joint ventureâ€™s operations and account for our investment in the joint venture under the equity method. Â We own 1,260,000 shares of Zebraâ€™s Series A-2 Preferred Stock and 900,000 shares of Zebra restricted common stock (ownership 29%) at September 30, 2024 and December 31, 2023. Zebra is a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drugs. Dr. Richard Lerner, M.D., a former member of our Board of Directors, was a founder of Zebra.Â Dr. FrostÂ serves as a member of Zebraâ€™s Board of Directors. Â In order to determine the primary beneficiary of Zebra, we evaluated our investment and our related partiesâ€™ investment, as well as our investment combined with the related partiesâ€™ investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Zebra. Based on the capital structure, governing documents and overall business operations of Zebra, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Zebraâ€™s economic performance and have no obligation to fund expected losses. We determined, however, that we can significantly influence control of Zebra through our board representation and voting power. Therefore, we have the ability to exercise significant influence over Zebraâ€™s operations and account for our investment in Zebra under the equity method. Â 24 Table of Contents Â Â Â NOTE 7 DEBT Â As of September 30, 2024 and December 31, 2023, our debt consisted of the following: Â Â Â September 30, Â Â December 31, Â (In thousands) Â 2024 Â Â 2023 Â 2029 Convertible Notes Â $ 178,645 Â Â $ â€” Â 2025 Notes Â Â 170 Â Â Â 143,250 Â 2033 Senior Notes Â Â 50 Â Â Â 50 Â 2023 Convertible Notes Â Â â€” Â Â Â 71,025 Â 2044 Notes Â Â 245,358 Â Â Â â€” Â JPMorgan Chase Bank line of credit Â Â â€” Â Â Â 12,671 Â Chilean and Spanish lines of credit Â Â Â 11,713 Â Â Â Â 12,629 Â Current portion of notes payable Â Â 1,509 Â Â Â 1,993 Â Long term portion of notes payable Â Â 3,529 Â Â Â 7,727 Â Total Â $ 440,974 Â Â $ 249,345 Â Â Â Â Â Â Â Â Â Â Balance sheet captions Â Â Â Â Â Â Â Â Current portion of convertible notes Â $ 170 Â Â $ â€” Â Long term portion of convertible notes Â Â 178,695 Â Â Â 214,325 Â Current portion of lines of credit and notes payable Â Â 13,222 Â Â Â 27,293 Â Long Term notes payable included in long-term liabilities Â Â 248,887 Â Â Â 7,727 Â Total Â $ 440,974 Â Â $ 249,345 Â Â 2044 Note Purchase Agreement Â On July 17, 2024, the Company completed a private offering of $250 million aggregate principal amount of senior secured notes (the â€œ2044 Notesâ€), pursuant to a note purchase agreement dated July 17, 2024 (the â€œ2044 Note Purchase Agreement), by and among the Company, certain purchasers from time to time party thereto, the Companyâ€™s wholly owned subsidiaries OPKO Biologics (â€œOBLâ€) and EirGen as guarantors (OBL and EirGen collectively, the â€œ2044 Note Guarantorsâ€), and HCR Injection SPV, LLC, as agent. Â The 2044 Notes mature on July 17, 2044 and bear interest at the 3-month Secured Overnight Financing Rate (SOFR) subject to a 4.0% per annum floor, plus 7.5% per annum. Interest is payable on the 2044 Notes on a quarterly basis determined by profit share payments received by EirGen pursuant to the profit share arrangement with Pfizer, Inc. (the â€œRoyalty Paymentsâ€) set forth in the Restated Pfizer Agreement (as defined and described in Note 14). In the event that the aggregate amount of the Royalty Payments received by EirGen during the quarter preceding any quarterly interest payment date are less than the accrued and unpaid interest payable on such date, the excess interest payable on such date shall be paid-in-kind and added to the outstanding principal amount of the 2044 Notes.Â The Company will be required to pay the noteholders a 3% exit fee in connection with any repayment in full of the 2044 Notes, whether at maturity or otherwise.Â In addition, in the event that the Company repays the 2044 Notes in full prior to the maturity date, the Company will be required to pay the noteholders a make whole payment in an amount necessary such that the noteholders shall have received aggregate payments of principal, interest and fees in respect of the 2044 Notes equal to at least 150% of the initial principal amount of the 2044 Notes, in the event that such prepayment shall occur on or prior to July 17, 2029, or 200% of the initial principal amount of the 2044 Notes, in the event that such prepayment shall occur following July 17, 2029.Â If the 2044 Notes have not been fully repaid by the maturity date, the Company may elect to either repay the unpaid balance of the principal amount in full, together with any accrued and unpaid interest thereon and the 3% exit fee, or elect to transfer 80% of all future Royalty Payments to the agent and the noteholders in satisfaction of the outstanding 2044 Notes. The Company may authorize up to an additional $50,000,000 in additional 2044 Notes to the purchasers on the same terms and conditions of the initial 2044 Notes. The 2044 Notes are secured by the Royalty Payments, and the 2044 Note Guarantors have guaranteed the obligations under the 2044 Notes by granting a security interest in certain assets of the 2044 Note Guarantors. The 2044 Note Purchase Agreement contains customary terms and covenants, including negative covenants, such as limitations on indebtedness, liens, amendments to certain material contracts and disposition of assets. Â 25 Table of Contents Â 2029 Convertible 144A Notes Â InÂ January 2024,Â we completed a private offering of $230.0Â million aggregate principal amount of ourÂ 3.75% Convertible Senior Notes dueÂ 2029Â (theÂ â€œ2029Â Convertible 144A Notesâ€) in accordance with the terms of a note purchase agreement (theÂ â€œ144AÂ Note Purchase Agreementâ€) entered into by and between the Company and J.P. Morgan Securities LLC (the â€œInitial Purchaserâ€). Â Net proceeds from the 2029 Convertible 144A Notes issuance totaled approximately $222.0 million after deducting fees and estimated offering expenses payable by us. We allocated approximately $50.0 million of these net proceeds to repurchase shares of our Common Stock. These repurchases were from purchasers of the 2029 Convertible 144A Notes in privately negotiated transactions effected with or through the Initial Purchaser or its affiliate. The purchase price per share of the Common Stock in these transactions equaled the closing sale price of $0.9067 per share of Common Stock on January 4, 2024. Â Contemporaneously with the closing of the offering of the 2029 Convertible 144A Notes on January 9, 2024, we issued and sold approximately $71.1 million aggregate principal amount of our 3.75% Convertible Senior Notes due 2029 (the â€œ2029 Convertible Affiliate Notesâ€ and, together with the 2029 Convertible 144A Notes, the â€œ2029 Convertible Notesâ€) pursuant to the terms of a note purchase agreement entered into on January 4, 2024 (the â€œAffiliate Note Purchase Agreementâ€) by and among the Company and certain investors, Frost Gamma Investments Trust, a trust controlled by Dr. Phillip Frost, and Dr. Jane H. HsiaoÂ (collectively, the â€œAffiliate Purchasersâ€). Pursuant to the Affiliate Note Purchase Agreement, we issued and sold the 2029 Convertible Affiliate Notes to the Affiliate Purchasers in exchange for the entirety of the $55.0 million aggregate principal amount of our outstanding 2023 Convertible Notes held by the Affiliate Purchasers, together with approximately $16.1 million of accrued but unpaid interest thereon. Â On January 9th, 2024, we recorded the $125.6 million value of the embedded derivative liability within the 2029 Convertible Notes as a debt discount. To determine the fair value of this derivative, we employed the Binomial Lattice model. Key inputs and assumptions for this valuation included our common stock price, the derivative's exercise price, risk-free interest rate, volatility, annual coupon rate, and remaining contractual term. We are amortizing the debt discount as non-cash interest expense over the term of the Notes. Â From the date the Notes were issued through March 31, 2024, we observed an increase in the market price of our Common Stock which resulted in a $26.25 million increase in the estimated fair value of our embedded derivatives recorded in Fair value changes of derivative instruments, net in our Condensed Consolidated Statements of Operations. Effective April 1, 2024, the conversion option contained in the 2029 Convertible Notes met the classification of an equity component. As a result, we reclassified $151.9 million of the embedded derivative liability from debt, non-current, to additional paid-in capital section of stockholders' equity on our Condensed Consolidated Balance Sheet. Â As of September 30, 2024 the 2029 Convertible 144A Notes are currently convertible. HoldersÂ mayÂ convert theirÂ 2029Â Convertible Notes at their option prior to the close of business on the business day immediately precedingÂ September 15, 2028Â only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending onÂ March 31, 2024 (and only during such calendar quarter), if the last reported sale price of our Common Stock for at leastÂ 20Â trading days (whether orÂ notÂ consecutive) during the period ofÂ 30Â consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal toÂ 130% of the applicable conversion price on each applicable trading day; (2) during theÂ fiveÂ consecutive business day period after anyÂ tenÂ consecutive trading day period (the â€œconvertible note measurement periodâ€) in which the trading price perÂ $1,000Â principal amount of notes for each trading day of the convertible note measurement period was less thanÂ 98% of the product of the last reported sale price of our Common Stock and the applicable conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events specified in the indenture governing theÂ 2029Â Convertible Notes. On or afterÂ September 15, 2028Â until the close of business on the business day immediately preceding the maturity date, holdersÂ mayÂ convert their notes at any time, regardless of the foregoing conditions. Upon conversion of a note, we will pay or deliver, as the caseÂ mayÂ be, cash, shares of our Common Stock or a combination of cash and shares of our Common Stock, at our election. Â 26 Table of Contents Â The conversion rate is initially equal toÂ 869.5652Â shares of Common Stock perÂ $1,000Â principal amount of notes (equivalent to an initial conversion price of approximately $1.15Â per share of Common Stock). The conversion rate for theÂ 2029Â Convertible Notes will be subject to adjustment upon the occurrence of certain events but willÂ notÂ be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date of the notes,Â in certain circumstances we will increase the conversion rate of theÂ 2029Â Convertible NotesÂ for a holder who elects to convert its notes in connection with such a corporate event. Â WeÂ mayÂ notÂ redeem the notes prior to the maturity date, andÂ noÂ sinking fund is provided for the notes. If we undergo a fundamental change, holdersÂ mayÂ require us to purchase the notes in whole or in part for cash at a fundamental change purchase price equal toÂ 100% of the principal amount of the notes to be purchased,Â plusÂ accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date. TheÂ 2029Â Convertible Notes areÂ our senior unsecured obligations andÂ rank senior in right of payment to any indebtedness that is expressly subordinated in right of payment to the notes, and equal in right of payment with all of our existing and future unsecured indebtedness that isÂ notÂ so subordinated. The notes are effectively subordinated to all of our existing and future secured indebtedness to the extent of the value of the assets securing such indebtedness and structurally subordinated to all existing and future liabilities of our subsidiaries. Â The indenture governing the notes provides for customary events of default which include (subject in certain cases to customary grace and cure periods), among others, the following: nonpayment of principal or interest; breach of covenants or other agreements in the indenture; defaults in failure to pay certain other indebtedness; judgment defaults; and certain events of bankruptcy or insolvency. Generally, if an event of default occurs and is continuing under the indenture, the trustee thereunder or the holders of at leastÂ 25%Â in aggregate principal amount of the notes then outstandingÂ mayÂ declareÂ 100%Â of the principal of and accrued and unpaid interest, if any on all then-outstanding notes to be immediately due and payable.Â In certain circumstances, weÂ may,Â for a period of time, elect to pay additional interest on the notes as the sole remedy to holders of the notes in the case of an event of default related to certain failures by us to comply with certain reporting covenants in the indenture. Â The following table sets forth information related to theÂ 2029Â Convertible Notes which is included in our Condensed Consolidated Balance Sheet as of September 30, 2024: Â (In thousands) Â 2029 convertible notes Â Â Embedded conversion option Â Â Discount Â Â Debt Issuance costs Â Â Total Â Balance at December 31, 2023 Â $â€”Â Â $â€”Â Â $â€”Â Â $â€”Â Â $â€”Â Issuance of 3.75% 2029 Convertible Notes Â Â 301,054Â Â Â 125,620Â Â Â (125,620)Â Â (8,562)Â Â 292,492Â Amortization of debt discount and debt issuance costs Â Â â€”Â Â Â â€”Â Â 12,585Â Â Â 1,236Â Â Â 13,821Â Change in fair value of embedded derivative Â Â â€”Â Â 26,250Â Â Â â€”Â Â Â â€”Â Â 26,250Â Reclassification of embedded derivative to equity Â Â â€”Â Â Â (151,870)Â Â â€”Â Â Â â€”Â Â Â (151,870) Repurchase Â Â (3,500)Â Â â€”Â Â Â 1,338Â Â Â 114Â Â Â (2,048) Balance at September 30, 2024 Â $297,554Â Â $â€”Â Â $(111,697)Â $(7,212)Â $178,645Â Â Â Â During the third quarter of 2024, the Company repurchasedÂ $3.5Â millionÂ in aggregate principal amount of the 2029 Convertible 144A Notes forÂ $4.8Â millionÂ in cash. Such convertible debt repurchaseÂ resulted in a gain ofÂ $32 thousand, which included unamortized discount ofÂ $1.3 million and debt issuance costs ofÂ $0.1 million. Â Â 27 Table of Contents Â 2025 Convertible Notes Â In February 2019, we issued $200.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the â€œ2025 Notesâ€) in an underwritten public offering. The 2025 Notes bear interest at a rate of 4.50% per year, payable semiannually in arrears on FebruaryÂ 15 and AugustÂ 15 of each year. The 2025 Notes mature on FebruaryÂ 15, 2025, unless earlier repurchased, redeemed or converted. Â InÂ May 2021,Â we entered into an agreement with certain holders of theÂ 2025Â Notes pursuant to which the holders exchanged $55.4Â million in aggregate principal amount of the outstandingÂ 2025Â Notes forÂ 19,051,270Â shares of our Common Stock (the â€œExchangeâ€). Â Contemporaneously with the closing of our offering of theÂ 2029Â Convertible Notes,Â we repurchased approximately $144.4Â million aggregate principal amount of theÂ 2025Â Notes for cash, using $146.3Â million of the net proceeds from our issuance and sale of theÂ 2029Â Convertible Notes, following which only $170Â thousand aggregate principal amount of theÂ 2025Â Notes remained outstanding. Â On January 22, 2024, we terminated our share lending agreement, dated February 4, 2019, with Jefferies Capital Services, LLC (â€œShare Borrowerâ€). Through this agreement, we had lent the Share Borrower approximately 30 million shares of our Common Stock related to our 2019 issuance of the 2025 Notes. With the termination of this agreement, all remaining borrowed shares of Common Stock have been returned to us and are now held as treasury shares. Â 2023 Convertible Notes Â In February 2018, we issued a series of 5% Convertible Promissory Notes (the â€œ2023 Convertible Notesâ€) in the aggregate principal amount of $55.0 million. The original maturity of the 2023 Convertible Notes was five years following the date of issuance. Each holder of a 2023 Convertible Note originally had the option, from time to time, to convert all or any portion of the outstanding principal balance of such 2023 Convertible Note, together with accrued and unpaid interest thereon, into shares of our Common Stock at a conversion price of $5.00 per share. Â On February 10, 2023, we amended the 2023 Convertible Notes to extendÂ the maturity to January 31, 2025 and reset the conversion price to the 10 day volume weighted average price immediately preceding the date of the amended note, plus a 25% conversion premium, or $1.66 per share. Purchasers of the 2023 Convertible Notes included an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer. Â In connection with the closing of the 2029 Convertible Notes offering, the Company issued approximately $71.1 million aggregate principal amount of its 2029 Convertible Affiliate Notes in exchange for all issued and outstanding 2023 Convertible notes, following which exchange, no 2023 Convertible Notes remained outstanding. Â 2033 Senior Notes Â InÂ January 2013,Â we issued an aggregate of $175.0Â million of ourÂ 3.0% Senior Notes dueÂ 2033Â (theÂ â€œ2033Â Senior Notesâ€) in a private placement. TheÂ 2033Â Senior Notes bearÂ interest at the rate ofÂ 3.0% per year, payable semiannually onÂ February 1Â andÂ August 1Â of each year and matureÂ onÂ February 1, 2033,Â unless earlier repurchased, redeemed or converted. FromÂ 2013Â toÂ 2016,Â holders of theÂ 2033Â Senior Notes converted $143.2Â million in aggregate principal amount into Common Stock, and, onÂ February 1, 2019,Â approximately $28.8Â million aggregate principal amount ofÂ 2033Â Senior Notes were tendered by holders pursuant to such holdersâ€™ option to require us to repurchase theÂ 2033Â Senior Notes. During the first quarter of 2023, we paid approximately $3.0Â million to purchaseÂ 2033Â Senior Notes in accordance with the indenture governing theÂ 2033Â Senior Notes, following which

$50.6Â thousandÂ 2033Â Senior Notes remained outstanding. Â 28 Table of Contents Â JPMorgan Chase Credit Agreement Â In November 2015, BioReference and certain subsidiaries established a credit agreement with JPMorgan Chase Bank, N.A. ("CB") as lender and administrative agent (the "Credit Agreement"). As amended, the Credit Agreement provided for a $50.0 million secured revolving credit facility, including a $20.0 million sub-facility for swingline loans and a $20.0 million sub-facility for letters of credit. Â On September 16, 2024, BioReference fully repaid its obligations and terminated theÂ Credit Agreement. BioReference paid approximately $9.7 million to settle its obligations, incurring no prepayment premium or penalty. Â The Credit Agreement had been guaranteed by all of BioReferenceâ€™s domestic subsidiaries and secured by substantially all assets of BioReference and its domestic subsidiaries, as well as a non-recourse pledge by us of our equity interest in BioReference. All guarantees and security interests were released together with the termination of the Credit Agreement. Â As of December 31, 2023, $12.7 million was outstanding under the Credit Agreement. Â International Line of Credit Agreements Â The Company hasÂ line of credit agreements with twelve other financial institutions as of September 30, 2024, and December 31, 2023, in the U.S., Chile and Spain. These lines of credit are used primarily as sources of working capital for inventory purchases. Â The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit: Â (Dollars in thousands) Â Â Â

not apply to any of the Companyâ€™s subsidiaries other than BioReference, and its scope is generally limited to â€œfocus arrangementsâ€, which are those â€œarrangementsâ€ (as defined in the CIA) (i) between BioReference and any actual source or recipient of health care business or referrals and involves, directly or indirectly, the offer, payment, or provision of anything of value, or (ii) is between BioReference and any physician (or a physicianâ€™s immediate family member). Most of these measures have already been implemented at BioReference. Following its acquisition of BioReference, the Company and BioReference implemented robust compliance measures that substantially align with those actions required under the CIA. Â 35 Table of Contents Â On March 1, 2019, the Company received a Civil Investigative Demand (â€œCIDâ€) from the U.S. Department of Justice (â€œDOJâ€), Washington, DC. The CID sets forth document requests and interrogatories in connection with allegations that the Company and certain of its affiliates violated the False Claims Act and/or the Anti-Kickback Statute. On January 13, 2022, the Federal Government notified the U.S.D.C., Middle District Florida, Jacksonville Division, that it is declining to intervene in the matter but retains the right, via the Attorney General, to consent to any proposed dismissal of the action by the Court. On February 9, 2022, the States of Florida, Georgia, and Commonwealth of Massachusetts notified the U.S.D.C., Middle District Florida, Jacksonville Division, that they are declining to intervene in the matter. Notwithstanding the above declinations, on February 17, 2022, the Company was served with the Relatorâ€™s Summons and Complaint (â€œComplaintâ€), which had been previously sealed. The Complaint alleges violations of the False Claims Act, the California Fraud Preventions Act, the Florida False Claims Act, the Massachusetts False Claims Act, the Georgia False Medicaid Claims Act, and illegal kickbacks. A motion to dismiss the Complaint was filed on April 25, 2022 and the case was dismissed in March 2023. However, the Relator filed an amended complaint in April 2023 and a second amended complaint, both of which were dismissed. Relator then filed an appeal in the U.S. Eleventh Circuit Court of Appeals which is pending before the court following a failed mediation in April 2024.Â While management cannot predict the outcome of these matters at this time, the ultimate outcome could be material to our business, financial condition, results of operations, and cash flows. Â From time to time, we may receive inquiries, document requests, CIDs or subpoenas from the Department of Justice, OCR, CMS, various payors and fiscal intermediaries, and other state and federal regulators regarding investigations, audits and reviews. In addition to the matters discussed in this note, we are currently responding to CIDs, subpoenas, payor audits, and document requests for various matters relating to our laboratory operations. Some pending or threatened proceedings against us may involve potentially substantial amounts as well as the possibility of civil, criminal, or administrative fines, penalties, or other sanctions, which could be material. Settlements of suits involving the types of issues that we routinely confront may require monetary payments as well as corporate integrity agreements. Additionally, qui tam or â€œwhistleblowerâ€ actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Actâ€™s requirements for filing such suits. Also, from time to time, we may detect issues of non-compliance with federal healthcare laws pertaining to claims submission and reimbursement practices and/or financial relationships with physicians, among other things. We may avail ourselves of various mechanisms to address these issues, including participation in voluntary disclosure protocols. Participating in voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action. The Company generally has cooperated, and intends to continue to cooperate, with appropriate regulatory authorities as and when investigations, audits and inquiries arise. Â We are a party to other litigation in the ordinary course of business. While we cannot predict the ultimate outcome of legal matters, we accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss. Itâ€™s reasonably possible the ultimate liability could exceed amounts currently estimated and we review established accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. Because of the high degree of judgment involved in establishing loss estimates, the ultimate outcome of such matters will differ from our estimates and such differences may be material to our business, financial condition, results of operations, and cash flows. Â At September 30, 2024, we were committed to make future purchases for inventory and other items in 2024 that occur in the ordinary course of business under various purchase arrangements with fixed purchase provisions aggregating approximately $44.0 million Â Â NOTE 13 REVENUE RECOGNITION Â We generate revenues from services, products and intellectual property as follows: Â Revenue from services Â Revenue for laboratory services is recognized at the time test results are reported, which approximates when services are provided and the performance obligations are satisfied. Services are provided to patients covered by various third-party payor programs including various managed care organizations, as well as the Medicare and Medicaid programs. Billings for services are included in revenue net of allowances for contractual discounts, allowances for differences between the amounts billed and estimated program payment amounts, and implicit price concessions provided to uninsured patients which are all elements of variable consideration. Â 36 Table of Contents Â The following are descriptions of our payors for laboratory services: Â Healthcare Insurers. Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules. Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements. Adjustments to the allowances, based on actual receipts from the third-party payors, are recorded upon settlement. Â Government Payors. Reimbursements from government payors are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid. Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements. Adjustments to the allowances, based on actual receipts from the government payors, are recorded upon settlement. Â Client Payors. Client payors include physicians, hospitals, employers, and other institutions for which services are performed on a wholesale basis, and are billed and recognized as revenue based on negotiated fee schedules. Â Patients. Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients. Insured patients (including amounts for coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers. Collection of billings from patients is subject to credit risk and ability of the patients to pay. Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with our policies and implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration that we expect to receive from patients, which considers historical collection experience and other factors including current market conditions. Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement. Â The complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, require us to estimate the potential for retroactive adjustments as an element of variable consideration in the recognition of revenue in the period the related services are rendered. Actual amounts are adjusted in the period those adjustments become known. For the nine months ended September 30, 2024 and 2023, we recorded $2.2 million and $19.8 million of negative revenue adjustments primarily due to the composition of patient pay mix. Â Third-party payors, including government programs, may decide to deny payment or recoup payments for testing they contend were improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. Our revenues may be subject to retroactive adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payors in interpretations, requirements, and â€œconditions of participationâ€ in various programs. We have processed requests for recoupment from third-party payors in the ordinary course of our business, and it is likely that we will continue to do so in the future. If a third-party payor denies payment for testing or recoups money from us in a later period, reimbursement for our testing could decline. Â As an integral part of our billing compliance program, we periodically assess our billing and coding practices, respond to payor audits on a routine basis, and investigate reported failures or suspected failures to comply with federal and state healthcare reimbursement requirements, as well as overpayment claims which may arise from time to time without fault on the part of the Company. We may have an obligation to reimburse Medicare, Medicaid,Â and third-party payors for overpaymentsÂ regardless of fault. We have periodically identified and reportedÂ overpayments, reimbursed payors forÂ overpaymentsÂ and taken appropriate corrective action. Â Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are also considered variable consideration and are included in the determination of the estimated transaction price for providing services. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and our historical settlement activity, including an assessment of the probability a significant reversal of cumulative revenue recognized will occur when the uncertainty is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. As of September 30, 2024 and December 31, 2023, we had liabilities of approximately $4.9 million and $3.1 million, respectively, within Accrued expenses and Other long-term liabilities related to reimbursements for payor overpayments. Â 37 Table of Contents Â The composition of revenue from services by payor for theÂ three and nine months ended September 30, 2024 and 2023 was as follows: Â Â Â Three months ended September 30, Â Â Nine months ended September 30, Â (In thousands) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Healthcare insurers Â $76,184Â Â $81,469Â Â $229,600Â Â $238,934Â Government payers Â Â 20,368Â Â Â 19,909Â Â Â 63,561Â Â Â 61,250Â Client payers Â Â 20,773Â Â Â 25,906Â Â Â 71,521Â Â Â 77,973Â Patients Â Â 3,946Â Â Â 4,395Â Â Â 12,875Â Â Â 12,943Â Total Â $121,271Â Â $131,679Â Â $377,557Â Â $391,100Â Â Revenue from products Â We recognize revenue from product sales when a customer obtains control of promised goods or services. The amount of revenueÂ recorded reflects the consideration that we expect to receive in exchange for those goods or services. Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and our evaluation of specific factors that may increase or decrease the risk of product returns. Product revenues are recorded net of estimated rebates, chargebacks, discounts, co-pay assistance and other deductions (collectively, â€œSales Deductionsâ€) as well as estimated product returns which are all elements of variable consideration. Allowances are recorded as a reduction of revenue at the time product revenues are recognized. The actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect revenue from products in the period such variances become known. Â Rayaldee is distributed in the U.S. principally through the retail pharmacy channel, which initiates with the largest wholesalers in the U.S. (collectively, â€œRayaldee Customersâ€). In addition to distribution agreements with Rayaldee Customers, we have entered into arrangements with many healthcare providers and payors that provide for government-mandated or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of Rayaldee.Â Â We recognize revenue for shipments of Rayaldee at the time of delivery to customers after estimating Sales Deductions and product returns as elements of variable consideration utilizing historical information and market research projections. For the three and nine months ended September 30, 2024, we recognizedÂ $5.8 million and $19.9 million, respectively, in net product revenue from sales of Rayaldee. For the three and nine months ended September 30, 2023, we recognizedÂ $7.3 million and $21.7 million, respectively, in net product revenue from sales of Rayaldee. Â The following table presents an analysis of Rayaldee product sales allowances and accruals for the three and nine months ended September 30, 2024 and 2023: Â (In thousands) Â Chargebacks, discounts, rebates and fees Â Â Governmental Â Â Returns Â Â Total Â Balance at June 30, 2024 Â $2,743Â Â $5,991Â Â $2,194Â Â $10,928Â Provision related to current period sales Â Â 4,005Â Â Â 5,776Â Â Â 317Â Â Â 10,098Â Credits or payments made Â Â (5,058)Â Â (7,013)Â Â (278)Â Â (12,349) Balance at September 30, 2024 Â $1,690Â Â $4,754Â Â $2,233Â Â $8,677Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $15,865Â Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales Â 64% Â 38 Table of Contents Â Â (In thousands) Â Chargebacks, discounts, rebates and fees Â Â Governmental Â Â Returns Â Â Total Â Balance at December 31, 2023 Â $2,578Â Â $6,150Â Â $2,192Â Â $10,920Â Provision related to current period sales Â Â 12,224Â Â Â Â 16,325Â Â Â Â 989Â Â Â Â 29,538Â Credits or payments made Â Â (13,112)Â Â (17,721)Â Â (948)Â Â (31,781) Balance at September 30, 2024 Â $1,690Â Â $4,754Â Â $2,233Â Â $8,677Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $49,447Â Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 60% Â Â (In thousands) Â Chargebacks, discounts, rebates and fees Â Â Governmental Â Â Returns Â Â Total Â Balance at June 30, 2023 Â $2,330Â Â $5,954Â Â $1,634Â Â $9,918Â Provision related to current period sales Â Â 3,446Â Â Â 4,998Â Â Â 322Â Â Â 8,766Â Credits or payments made Â Â (4,125)Â Â (4,207)Â Â (15)Â Â (8,347) Balance at September 30, 2023 Â $1,651Â Â $6,745Â Â $1,941Â Â $10,337Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $16,090Â Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 54% Â Â (In thousands) Â Chargebacks, discounts, rebates and fees Â Â Governmental Â Â Returns Â Â Total Â Balance at December 31, 2022 Â $1,532Â Â $5,063Â Â $1,683Â Â $8,278Â Provision related to current period sales Â Â 10,702Â Â Â Â 14,604Â Â Â Â 959Â Â Â Â 26,265Â Credits or payments made Â Â (10,583)Â Â (12,922)Â Â (701)Â Â (24,206) Balance at September 30, 2023 Â $1,651Â Â $6,745Â Â $1,941Â Â $10,337Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $47,940Â Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 55% Â Taxes collected from customers related to revenues from services and revenues from products are excluded from revenues. Â Revenue from intellectual property and other Â We recognize revenues from the transfer of intellectual property generated through license, development, collaboration and/or commercialization agreements. The terms of these agreements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development and commercialization milestone payments; funding of research and/or development activities; and royalties on sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer. Â 39 Table of Contents Â For research, development and/or commercialization agreements that result in revenues, we identify all material performance obligations, which may include a license to intellectual property and know-how, and research and development activities. In order to determine the transaction price, in addition to any upfront payment, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. We constrain (reduce) our estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, we consider whether there are factors outside of our control that could result in a significant reversal of revenue. In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. Â Upfront License Fees: If a license to our intellectual property is determined to be functional intellectual property distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Â Research and Development Activities: If we are entitled to reimbursement from our customers for specified research and development expenses, we account for them as separate performance obligations if distinct. We also determine whether the research and development funding would result in revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The corresponding revenues or offset to research and development expenses are recognized as the related performance obligations are satisfied. Â BARDA Contract:Â Revenue from the BARDA Contract is generated under terms that are cost plus fee. We recognize revenue using the incurred costs output method to measure progress. Revenue will only be recognized when research and development services are performed to the extent of actual costs incurred. Â Sales-based Milestone and Royalty Payments: Our customers may be required to pay us sales-based milestone payments or royalties on future sales of commercial products. We recognize revenues related to sales-based milestone and royalty payments upon the later to occur of (i) achievement of the customerâ€™s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to our intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate. Â Other Potential Products and Services: Arrangements may include an option for license rights, future supply of drug substance or drug product for either clinical development or commercial supply at the licenseeâ€™s election. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the inception of the contract and revenue is recognized only if the option is exercised and products or services are subsequently

delivered or when the rights expire. If the promise is based on market terms and not considered a material right, the option is accounted for if and when exercised. If we are entitled to additional payments when the licensee exercises these options, any additional payments are generally recorded in license or other revenues when the licensee obtains control of the goods, which is upon delivery. Â For the three months ended September 30, 2024, revenue from the transfer of intellectual property and other was $13.2 million, an increase fromÂ $6.2 million for the three months ended September 30, 2023. This increase was primarily attributable to $5.5 million from the BARDA Contract (as defined and described in Note 14). Gross profit share and royalty payments for NGENLA (Somatrogon) and Pfizer's GenotropinÂ® (Somatropin) also increased to $7.0 million, compared with $4.9 million for the same period in 2023. Â 40 Table of Contents Â For the nine months ended September 30, 2024, revenue from the transfer of intellectual property and other decreased toÂ $34.3 million fromÂ $165.9 million for the nine months ended September 30, 2023. This decrease was primarily due to one-time milestone payments received in 2023, including a $90.0 million payment related to NGENLA, a $50.0 million payment from Merck for rights granted under the Merck Agreement, a $7.0 million payment from VFMCRP triggered by the German price approval for Rayaldee, and a $2.5 million payment from Nicoya upon submission of an investigational new drug application to China's Center for Drug Evaluation. See Note 14 for a description of the arrangements pursuant to which such milestone payments were received. Revenue for the nine months ended September 30, 2024, included $18.9 million in gross profit share and royalty payments for NGENLA (Somatrogon) and Pfizer's GenotropinÂ® (Somatropin), compared to $11.8 million in the same period in 2023, as well as $12.8 million from the BARDA Contract during the 2024 period. Â Â NOTE 14 STRATEGIC ALLIANCES Â Biomedical Advanced Research and Development Authority Â On September 28, 2023, ModeX was awarded a contract (as amended as decribed below, the â€œBARDA Contractâ€) by the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services. This contract aims to advance a platform and product candidates addressing various public health threats, specifically in viral infectious diseases. The funding enables the research, development, and clinical evaluation of multispecific antibodies based on ModeX's proprietary MSTAR technology. MSTAR is a flexible, plug-and-play platform capable of incorporating multiple independent antibody binding sites into a single molecule, expanding its therapeutic potential and enabling rapid responses to emerging infections, including viral variants like COVID-19, influenza, and other pathogens. Â In September 2024, ModeX entered into two amendments (the â€œBARDA Amendmentsâ€) to modify the scope and funding of the BARDA Contract. The BARDA Amendments structuredÂ the funding thereunder as cost-plus-fixed-fee, which includes a $26.9 millionÂ supplement to further advance the development of COVID-19 multispecific antibodies. This increased funding supports the ongoing development, manufacturing, and execution of a Phase 1 clinical trial for a next-generation MSTAR multispecific antibody with broad neutralizing activity against known SARS-CoV-2 variants. The BARDA Amendments also provided for BARDA's exercise of the option for the development of a multispecific protein antibody for influenza or another pathogen, with $24.1 million allocated to cover the expanded work under this exercised option. These modifications increased the total value of the BARDA Contract from $59.0 million to $110.0 million, with the potential value if BARDA exercises all options thereunder to expand ModeX's services, increasing from $168.6 million to $205 million. Â As part of the research program, gene-based delivery methods for the multispecific antibodies will be developed using mRNA or DNA vectors to leverage the body's natural protein production processes. BARDA will make periodic progress assessments, and the continuation of the BARDA Contract depends on ModeXâ€™s performance, the timeliness and quality of deliverables, and other factors. The BARDA Contract contains customary government contract provisions, including BARDA's right to terminate the contract inÂ its discretion. Â The Company evaluated the BARDA Contract under ASC Topic 606, Revenue from Contracts with Customers (â€œASC 606â€), and determined that the U.S. government meets the definition of a customer. The scope of the BARDA Contract includes preclinical, clinical, and manufacturing activities, as well as regulatory, quality assurance, management, and administrative activities. The research and development effort will progress in stages covering base and option segments, with ModeX completing specific tasks in each segment. Â The Company identified three potential material promises under the BARDA Contract: (i) development of a tetravalent trispecific antibody for COVID-19; (ii) development of a multispecific protein antibody for influenza or another pathogen; and (iii) nucleic acid delivery of a multispecific antibody for influenza or another pathogen. The Company determined the promise to develop a tetravalent trispecific antibody for COVID-19 is a separate performance obligation, as it is distinct within the contract and provides standalone value. Similarly, the exercised option to develop a multispecific protein antibody for influenza or another pathogen is also a separate performance obligation. However, the Company determined that the nucleic acid delivery option does not offer incremental discounts beyond those typically provided for such goods and services, and therefore does not represent a material right. As such, the options in (iii) were not considered performance obligations at the outset of the BARDA Contract. Â 41 Table of Contents Â The Company concluded that research and development services performed under the BARDA Contract would be recognized as revenue when research and development services are performed to the extent of actual costs incurred including a fixed fee and will be reimbursed by BARDA. Costs incurred represent work performed, which corresponds with, and thereby best depicts, the transfer of control of the research and development to BARDA. Types of contract costs include labor, material, and third-party services. As such, the related BARDA revenue is recognized as revenue from transfer of intellectual property and other within the Companyâ€™s Consolidated Statements of Operations. For the three and nine months ended September 30, 2024, we recorded $5.5 million and $12.8 million in revenue under the BARDA Contract. As of September 30, 2024, the aggregate amount of transaction price allocated to remaining performance obligations, excluding unexercised contract options, was $96.0 million. We expect to recognize this amount as revenue through February 2028. Â Merck Â On March 8, 2023, ModeX, the Company (with respect to certain sections), and Merck Sharp & Dohme LLC (â€œMerckâ€) entered into a License and Research Collaboration Agreement (the â€œMerck Agreementâ€) pursuant to which ModeX granted to Merck a license to certain patent rights and know-how in connection with the development of ModeXâ€™s preclinical nanoparticle vaccine candidate targeting the Epstein-Barr Virus. Â Under the terms of the Merck Agreement, ModeX granted to Merck an exclusive, sublicensable, royalty-bearing license to certain intellectual property to develop, manufacture, use and commercialize (i) a multivalent or monovalent vaccine assembled usingÂ our platform for Epstein-Barr Virus (â€œVaccineâ€), and (ii) any pharmaceutical or biological preparation in final form containing a Vaccine for sale or for administration to human patients in a clinical trial for all uses (â€œProductâ€). We received an initial payment of $50.0Â million and are eligible to receive up to an additional $872.5Â million upon the achievement of certain commercial and development milestones under several indications. We are also eligible to receive tiered royalty payments ranging from high single digits to low double digits upon achievement of certain sales targets of the Product. Certain of the rights subject to the license provided by us under the Merck Agreement were obtained by us from Sanofi pursuant to that certain License Agreement entered into as of July 1, 2021 (â€œSanofi In-License Agreementâ€) between us and Sanofi, a French corporation (â€œSanofiâ€), and a portion of the upfront payment, milestones and royalties received by us under the Merck Agreement may be payable to Sanofi under the terms of the Sanofi In-License Agreement. As a result of such obligations under the Sanofi In-License Agreement, we paid $12.5 million to Sanofi during the three months ended September 30, 2023. Â As part of their strategic collaboration, ModeX and Merck have put in place a research plan to manage research and other development activities related to the development of a Vaccine or Product including a joint steering committee to facilitate the research program. As part of the research plan, they will use a third-party contract development and manufacturing organizationÂ to carry out such activities unless otherwise agreed. Development costs incurred by ModeX in furtherance of these development activities will be reimbursed by Merck. To date, we have spent $24.5 million of development costs related to the Epstein -Barr Virus, for which Merck has provided reimbursement. Â The Merck Agreement will remain in effect until one or more Products receive marketing authorization, and, thereafter, until the expiration of all royalty obligations unless earlier terminated as permitted under the Merck Agreement. In addition to termination rights for material breach and bankruptcy, Merck is permitted to terminate the Merck Agreement in its entirety without cause after a specified notice period. If Merck terminates the Merck Agreement for convenience or by us for Merckâ€™s uncured material breach, we may elect to receive a reversion license such that we can continue its work with Vaccines and Products which have not been terminated due to a material safety issue. Â LeaderMed Â On September 14, 2021, we and LeaderMed announced the formation of a joint venture to develop, manufacture and commercialize two of OPKOâ€™s clinical stage, long-acting drug products in Greater China and eight other Asian territories. Â Under the terms of the agreements, we have granted the joint venture exclusive rights to develop, manufacture and commercialize (a) OPK88003, an oxyntomodulin analog being developed for the treatment of obesity and diabetes, and (b) Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia, in exchange for a 47% ownership interest in the joint venture. In addition, during 2021 we received an upfront payment of $1Â million and will be reimbursed for clinical trial material and technical support we provide the joint venture. Â 42 Table of Contents Â LeaderMed is responsible for funding the joint ventureâ€™s operations, development and commercialization efforts and, together with its syndicate partners, initially invested $11Â million in exchange for a 53% ownership interest. We retain full rights to oxyntomodulin and Factor VIIa-CTP in all other geographies. Â CAMP4 Therapeutics Â On July 6, 2021, we entered into an exclusive license agreement (the â€œCAMP4 Agreementâ€) with CAMP4, pursuant to which we granted to CAMP4 an exclusive license to develop, manufacture, commercialize or improve therapeutics utilizing the AntagoNAT technology, an oligonucleotide platform developed under OPKO CURNA, which includes the molecule for the treatment of Dravet syndrome, together with any derivative or modification thereof (the â€œLicensed Compoundâ€) and any pharmaceutical product that comprises or contains the Licensed Compound, alone or in combination with one or more other active ingredients (â€œLicensed Productâ€), worldwide. The CAMP4 Agreement grant covers human pharmaceutical, prophylactic, and therapeutic and certain diagnostic uses. Â We received an initial upfront payment of $1.5Â million and 3,373,008 shares of CAMP4â€™s Series A Prime Preferred Stock (â€œPreferred Stockâ€), which then equated to approximately 9% of the outstanding shares of CAMP4, and we are eligible to receive up to $3.5Â million in development milestone payments for Dravet syndrome products, and $4Â million for non-Dravet syndrome products, as well as sales milestones of up to $90Â million for Dravet syndrome products and up to $90Â million for non-Dravet syndrome products. We may also receive double digit royalty payments on the net sales of royalty bearing products, subject to adjustment. In addition, upon achievement of certain development milestones, we will be eligible to receive equity consideration of up to 5,782,299 shares of Preferred Stock in connection with Dravet syndrome products and up to 1,082,248 shares of Preferred Stock in connection with non-Dravet syndrome products. In connection with our acquisition of CURNA, we agreed to pay future consideration to the sellers upon the achievement of certain events. As a result of our execution of the CAMP4 Agreement, we will have to pay a percentage of any payments received under the CAMP4 Agreement to the former CURNA stockholders. Â The Company was notified that the FDAÂ placed the Dravet clinical trials on hold and CAMP4 subsequently ceased development efforts. Â NICOYA Macau Limited Â On June 18, 2021, EirGen, our wholly owned subsidiary, and NICOYA Macau Limited (â€œNicoyaâ€), a Macau corporation and an affiliate of NICOYA Therapeutics, entered into a Development and License Agreement (the â€œNicoya Agreementâ€) granting Nicoya the exclusive rights for the development and commercialization of extended release calcifediol (the â€œNicoya Productâ€) in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan (collectively, the â€œNicoya Territoryâ€). Extended release calcifediol is marketed in the U.S. by OPKO under the tradename Rayaldee. The license grant to Nicoya covers the therapeutic and preventative use of the Nicoya Product for SHPT in non-dialysis and hemodialysis chronic kidney disease patients (the â€œNicoya Fieldâ€). Â EirGen received an initial upfront payment of $5Â million and was eligible to receive an additional $5Â million tied to the first anniversary of the effective date of the Nicoya Agreement, as amended, of which EirGen has received $2.5Â million plus accrued interest for the delayed payment. Furthermore, EirGen received the additional $2.5Â million upon Nicoyaâ€™s submission of an investigational new drug (IND) application to the Center for Drug Evaluation of China in March 2023. EirGen is also eligible to receive up to an additional aggregate amount of $115Â million upon the achievement of certain development, regulatory and sales-based milestones by Nicoya for the Nicoya Product in the Nicoya Territory. EirGen is eligible to receive tiered, double digit royalty payments at rates in the low double digits on net product sales within the Nicoya Territory and in the Nicoya Field. Â Nicoya is, at its sole cost and expense,Â responsible for performing all development activities necessary to obtain all regulatory approvals for the Nicoya Product in the Nicoya Territory and will be responsible for all commercial activities pertaining to the Nicoya Product in the Nicoya Territory. Â 43 Table of Contents Â Unless earlier terminated, the Nicoya Agreement will remain in effect until such time as all royalty payment terms and extended payment terms have expired, and Nicoya shall have no further payment obligations to EirGen under the terms of the Nicoya Agreement. Nicoyaâ€™s royalty obligations expire on the later of (i) expiration of the last to expire valid patent claim covering the Nicoya Product sold in the Nicoya Territory, (ii) expiration of all regulatory and data exclusivity applicable to the Nicoya Product in the Nicoya Territory, and (iii) on a product-by-product basis, ten (10) years after such Nicoya Productâ€™s first commercial sale in the Nicoya Territory. In addition to termination rights for material breach and bankruptcy, Nicoya is permitted to terminate the Nicoya Agreement after a specified notice period. Â VFMCRP Â In May 2016, EirGen and Vifor Fresenius Medical Care Renal Pharma Ltd. (â€œVFMCRP â€) entered into a Development and License Agreement (the â€œVFMCRP Agreementâ€) for the development and commercialization of Rayaldee (the â€œProductâ€) worldwide, except for (i) the United States and Canada, (ii) any country in Central America or South America (including Mexico), (iii) Russia, (iv) China, (v) South Korea, (vi) Ukraine, (vii) Belorussia, (viii) Azerbaijan, (ix) Kazakhstan, (x) Taiwan (xi) the Middle East, and (xii) all countries of Africa (the â€œVFMCRP Territoryâ€), as amended. The license toÂ VFMCRP potentially covers all therapeutic and prophylactic uses of the Product in human patients (the â€œVFMCRP Fieldâ€), provided that initially the license is for the use of the Product for the treatment or prevention of SHPT related to patients with CKD and vitamin D insufficiency/deficiency (the â€œVFMCRP Initial Indicationâ€). Â In January 2023, the German Association of Statutory Health Insurance funds (GKV-SV) granted price approval for Rayaldee. This triggered a milestone payment of $7.0 million. In 2022, we recognized a separate milestone payment of $3.0 million in revenue from the transfer of intellectual property and other for the first sale of Rayaldee in Europe. Â Effective May 23, 2021, we entered into an amendment to theÂ VFMCRP Agreement pursuant to which the parties thereto agreed to include Japan as part of theÂ VFMCRP Territory. Â Effective May 5, 2020, we entered into an amendment to the VFMCRP Agreement pursuant to which the parties agreed to exclude Mexico, South Korea, the Middle East and all of the countries of Africa from the VFMCRP Territory. In addition, the parties agreed to certain amendments to the milestone structure and to reduce minimum royalties payable. As revised, the Company has received a $3 million payment triggered by the first marketing approval of Rayaldee in Europe, $7.0 million payment triggered by the Germany price approval by the local sick fund association, and is eligible to receive up to an additional $15 million in regulatory milestones and $200 million in milestone payments tied to launch, pricing and sales of Rayaldee, and tiered, double-digit royalties. Â We plan to share responsibility withÂ VFMCRP for the conduct of trials specified within an agreed-upon development plan, with each company leading certain activities within the plan. EirGen will lead the manufacturing activities within and outside theÂ VFMCRP Territory and the commercialization activities outside theÂ VFMCRP Territory and outside theÂ VFMCRP Field in theÂ VFMCRP Territory andÂ VFMCRP will lead the commercialization activities in theÂ VFMCRP Territory and theÂ VFMCRP Field. For the initial development plan, the companies have agreed to certain cost sharing arrangements.Â VFMCRP will be responsible for all other development costs thatÂ VFMCRP considers necessary to develop the Product for the use of the Product for the VFMCRP Initial Indication in theÂ VFMCRP Territory in theÂ VFMCRP Field except as otherwise provided in theÂ VFMCRP Agreement. The first of the clinical studies provided for in the development activities commenced in September 2018. Â In connection with the VFMCRP Agreement, the parties entered into a letter agreement pursuant to which EirGen granted toÂ VFMCRP an exclusive option (the â€œOptionâ€) to acquire an exclusive license under certain EirGen patents and technology to use, import, offer for sale, sell, distribute and commercialize the Product in the U.S. solely for the treatment of SHPT in dialysis patients with CKD and vitamin D insufficiency (the â€œDialysis Indicationâ€). Upon exercise of the Option, VFMCRP has agreed to reimburse EirGen for all of the development costs incurred by EirGen with respect to the Product for the Dialysis Indication in the U.S. VFMCRP would also pay EirGen up to an additional aggregate amount of $555Â million of sales-based milestones upon the achievement of certain milestones and would be obligated to pay royalties at percentage rates that range from the mid-teens to the mid-twenties on sales of the Product in the U.S. for the Dialysis Indication. To date,Â VFMCRP has not exercised the Option. Â 44 Table of Contents Â Payments received for regulatory milestones and sales milestones are non-refundable. The regulatory milestones are payable if and whenÂ VFMCRP obtains approval from certain regulatory authorities and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. We account for the sales milestones as royalties and sales milestones payments will be recognized as revenue in the period in which the associated milestone is achieved or sales occur, assuming all other revenue recognition criteria are met. Â Pfizer Inc. Â In December 2014, we entered into an exclusive worldwide agreement with Pfizer for the development and commercialization of our long-acting Somatrogon (hGH-CTP) for the treatment of growth hormone deficiency (â€œGHDâ€) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (the â€œPfizer Transactionâ€).Â In May 2020, we entered into an amended and restated development and commercialization license with Pfizer, effective January 1, 2020 (the â€œRestated Pfizer Agreementâ€), pursuant to which the parties agreed, among other things, to share all costs for Manufacturing Activities, as defined in the Restated Pfizer Agreement, for developing a licensed product for the three indications included in the Restated

Pfizer Agreement. Â In June 2023, the FDA approved NGENLA (Somatrogon (hGH-CTP)) a once-weekly injection to treat pediatric growth hormone deficiency in the United States. In early 2022, the European Commission and Ministry of Health, Labour and Welfare in Japan approved NGENLA (Somatrogon). We have also received pricing approvals in Germany and Japan. NGENLA (Somatrogon (hGH-CTP)) is approved for the treatment of pediatric GHD in more than 50 markets, including Canada, Australia, Japan, and EU Member States. With the achievement of these milestones, in 2023 we recorded revenue of $90 million, and in 2022 we recorded $85.0Â million, in each case under the Restated Pfizer Agreement. Â On October 21, 2019, we and Pfizer announced that the global phase 3 trial evaluating Somatrogon dosed once-weekly in prepubertal children with GHD met its primary endpoint of non-inferiority to daily GenotropinÂ® (somatropin) for injection, as measured by annual height velocity at 12 months. Â Under the terms of the Restated Pfizer Agreement we received non-refundable and non-creditable upfront payments of $295.0 million and are eligible to receive up to an additional $275.0 million upon the achievement of certain regulatory milestones. Pfizer received the exclusive license to commercialize Somatrogon worldwide. In addition, we are eligible to receiveÂ regional, tiered gross profit sharing for both Somatrogon and Pfizerâ€™s GenotropinÂ® (somatropin) in all global markets, with the U.S. region commencing gross profit sharing in August 2023. Â The Restated Pfizer Agreement will remain in effect until the last sale of the licensed product, unless earlier terminated in accordance with its terms. In addition to termination rights for material breach and bankruptcy, Pfizer is permitted to terminate the Restated Pfizer Agreement in its entirety, or with respect to one or more world regions, without cause after a specified notice period. If the Restated Pfizer Agreement is terminated by us for Pfizerâ€™s uncured material breach, or by Pfizer without cause, provision has been made for transition of product and product responsibilities to us for the terminated regions, as well as continued supply of product by Pfizer or transfer of supply to us in order to support the terminated regions. Â We recognized the non-refundable $295.0 million upfront payments as revenue as the research and development services were completed. As of September 30, 2024 and December 31, 2023, we had no contract liabilities related to the Pfizer Transaction. Â TheÂ Restated Pfizer Agreement includes milestone payments of $275.0 million upon the achievement of certain milestones. The milestones range from $20.0 million to $90.0 million each and are based on achievement of regulatory approval in the U.S. and regulatory approval and price approval in other major markets. The milestone payments will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. To date, $175.0 million of revenue has been recognized related to the achievement of the milestones. Â Other Â We have completed strategic deals with numerous institutions and commercial partners. In connection with these agreements, upon the achievement of certain milestones we are obligated to make certain payments and have royalty obligations upon sales of products developed under the license agreements. At this time, we are unable to estimate the timing and amounts of payments as the obligations are based on future development of the licensed products. Â 45 Table of Contents Â Â Â NOTE 15 SEGMENTS Â We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinicalÂ laboratory operations through BioReference. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes. Â Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows: Â Â Â For the three months ended September 30, Â Â For the nine months ended September 30, Â (In thousands) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue from services: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Pharmaceutical Â $â€”Â Â $â€”Â Â $â€”Â Â $â€”Â Diagnostics Â Â 121,271Â Â Â Â 131,679Â Â Â Â 377,557Â Â Â Â 391,100Â Corporate Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â $121,271Â Â $131,679Â Â $377,557Â Â $391,100Â Revenue from products: Â Pharmaceutical Â $39,143Â Â $40,670Â Â $117,675Â Â $124,553Â Diagnostics Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Corporate Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â $39,143Â Â $40,670Â Â $117,675Â Â $124,553Â Revenue from transfer of intellectual property and other: Â Pharmaceutical Â $13,218Â Â $6,246Â Â $34,272Â Â $165,938Â Diagnostics Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Corporate Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â $13,218Â Â $6,246Â Â $34,272Â Â $165,938Â Operating income (loss): Â Pharmaceutical Â $(32,196)Â $(25,375)Â $(84,697)Â $57,210Â Diagnostics Â Â 58,541Â Â Â Â (29,081)Â Â Â Â (2,443)Â Â Â Â (113,344) Corporate Â Â (12,129)Â Â Â Â (9,951)Â Â Â Â (31,786)Â Â Â Â (31,841) Â Â $14,216Â Â $(64,407)Â $(118,926)Â $(87,975) Depreciation and amortization: Â Pharmaceutical Â $18,043Â Â $17,807Â Â $53,899Â Â $53,649Â Diagnostics Â Â 6,120Â Â Â Â 8,376Â Â Â Â 20,238Â Â Â Â 25,666Â Corporate Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â $24,163Â Â $26,183Â Â $74,137Â Â $79,315Â Loss from investment in investees: Â Pharmaceutical Â $(3)Â $(20)Â $(7)Â $(99) Diagnostics Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Corporate Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â $(3)Â $(20)Â $(7)Â $(99) Revenues: Â United States Â $132,663Â Â $139,043Â Â $410,422Â Â $462,987Â Ireland Â Â 11,514Â Â Â Â 8,654Â Â Â Â 30,579Â Â Â Â 121,249Â Chile Â Â 16,576Â Â Â Â 16,932Â Â Â Â 49,067Â Â Â Â 52,427Â Spain Â Â 6,297Â Â Â Â 4,349Â Â Â Â 17,828Â Â Â Â 16,427Â Israel Â Â 196Â Â Â Â 3,155Â Â Â Â 797Â Â Â Â 9,388Â Mexico Â Â 5,630Â Â Â Â 5,897Â Â Â Â 18,621Â Â Â Â 17,447Â Other Â Â 756Â Â Â Â 565Â Â Â Â 2,190Â Â Â Â 1,666Â Â Â $173,632Â Â $178,595Â Â $529,504Â Â $681,591Â Â 46 Table of Contents Â Â Â September 30, Â Â December 31, Â (In thousands) Â 2024 Â Â 2023 Â Assets: Â Â Â Â Â Â Â Â Â Pharmaceutical Â $1,271,781Â Â $1,331,764Â Diagnostics Â Â 517,871Â Â Â Â 630,753Â Corporate Â Â 466,451Â Â Â Â 49,181Â Â Â $2,256,103Â Â $2,011,698Â Goodwill: Â Â Â Â Â Â Â Â Â Pharmaceutical Â $316,161Â Â $315,235Â Diagnostics Â Â 219,707Â Â Â Â 283,025Â Â Â Â $535,868Â Â $598,260Â Â No customer represented more than 10% of our total consolidated revenue for the nine months ended September 30, 2024 and 2023. As of September 30, 2024 and December 31, 2023, no customer represented more than 10% of our accounts receivable balance. Â Â NOTE 16 LEASES Â We have operating leases for office space, laboratory operations, research and development facilities, manufacturing locations, warehouses and certain equipment. We determine if a contract contains a lease at inception or modification of a contract. Our leases generally do not provide an implicit interest rate, and we therefore use our incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. We used the incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date. Many of our leases contain rental escalation, renewal options and/or termination options that are factored into our determination of lease payments as appropriate. Variable lease payment amounts that cannot be determined at the commencement of the lease are not included in the right-to-use assets or liabilities. Â We elected the use of permitted practical expedients of not recording leases on our Condensed Consolidated Balance Sheet when the leases have terms of 12 months or less, and we elected not to separate nonlease components from lease components and instead account for each separate lease component and the nonlease components associated with that lease component as a single lease component. Â On January 2, 2023, ModeX entered into a 10-year office lease agreement that commenced in October 2023. ModeX was previously located in Natick, Massachusetts and relocated to Weston, Massachusetts, upon lease commencement. The new location is approximately 33,056 square feet of office space. ModeX has two options to extend the lease term for an additional five years per extension, which would commence upon the expiration of the term in October 2033. Straight-line monthly expense for the lease is $243.5 thousand. Â 47 Table of Contents Â The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of September 30, 2024 and December 31, 2023: Â (in thousands) Classification on the Balance Sheet Â September 30, 2024 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Â Â Â Operating lease assets Operating lease right-of-use assets Â $62,812Â Â $68,088Â Finance lease assets Property, plant and equipment, net Â Â 6,544Â Â Â Â 10,101Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Current Â Â Â Â Â Â Â Â Â Operating lease liabilities Current maturities of operating leases Â Â 12,741Â Â Â Â 12,996Â Accrued expenses Current maturities of finance leases Â Â 1,855Â Â Â Â 2,827Â Long-term Â Â Â Â Â Â Â Â Â Operating lease liabilities Operating lease liabilities Â Â 52,057Â Â Â Â 54,140Â Other long-term liabilities Finance lease liabilities Â $4,689Â Â $7,274Â Â Â Â Â Â Â Â Â Â Â Â Weighted average remaining lease term Â Â Â Â Â Â Â Â Â Operating leases (in years) Â Â 6.3Â Â Â Â 7.1Â Finance leases (in years) Â Â 7.1Â Â Â Â 6.2Â Weighted average discount rate Â Â Â Â Â Â Â Â Â Operating leases Â Â 5.3%Â Â 5.4% Finance leases Â Â 3.7%Â Â 3.8% Â The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of September 30, 2024: Â (in thousands) Â Operating Â Â Finance Â October 1, 2024 through December 31, 2024 Â $3,043Â Â $673Â 2025 Â Â 11,772Â Â Â Â 1,813Â 2026 Â Â 10,937Â Â Â Â 1,334Â 2027 Â Â 10,775Â Â Â Â 806Â 2028 Â Â 10,785Â Â Â Â 203Â Thereafter Â Â 26,534Â Â Â Â 1,959Â Total undiscounted future minimum lease payments Â Â 73,846Â Â Â Â 6,788Â Less: Difference between lease payments and discounted lease liabilities Â Â 9,048Â Â Â Â 244Â Total lease liabilities Â $64,798Â Â $6,544Â Â Expense under operating leases and finance leases was $15.2 million and $2.5 million, respectively, for the nine months ended September 30, 2024, which included $1.5 million of variable lease costs. Expense under operating leases and finance leases wasÂ $12.0 million and $2.2 million, respectively, for the nine months ended September 30, 2023, which included $0.9 million of variable lease costs. Operating lease costs and finance lease costs are included within Operating loss in the Condensed Consolidated Statement of Operations. Short-term lease costs were not material. Â Supplemental cash flow information is as follows: Â Â Â For the nine months ended September 30, Â (in thousands) Â 2024 Â Â 2023 Â Operating cash out flows from operating leases Â $15,101Â Â $11,704Â Operating cash out flows from finance leases Â Â 354Â Â Â Â 327Â Financing cash out flows from finance leases Â Â 2,118Â Â Â Â 1,919Â Total Â $17,573Â Â $13,950Â Â 48 Table of Contents Â Â Â ITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. Â OVERVIEW Â You should read this discussion together with the unaudited Condensed Consolidated Financial Statements, related notes, and other financial information included elsewhere in this Quarterly Report on Form 10-Q together with our audited consolidated financial statements, related notes, and other information contained in our Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 (the â€œForm 10-Kâ€). The following discussion contains assumptions, estimates and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under â€œRisk Factors,â€ in Part I, ItemÂ 1A of the Form 10-K and as described from time to time in our other filings with the Securities and Exchange Commission. These risks could cause our actual results to differ materially from those anticipated in these forward-looking statements. Â We are a diversified healthcare company that seeks to establish industry leading positions in large and rapidly growing medical markets. Our pharmaceutical business features Rayaldee, a U.S. Food and Drug Administration (â€œFDAâ€) approved treatment for secondary hyperparathyroidism (â€œSHPTâ€) in adults with stage 3 or 4 chronic kidney disease (â€œCKDâ€) and vitamin D insufficiency, andÂ Somatrogon (hGH-CTP),Â a once-weekly human growth hormone injection.Â We have partnered with Pfizer Inc. (â€œPfizerâ€) for the development and commercialization of Somatrogon (hGH-CTP). Regulatory approvals for Somatrogon (hGH-CTP) for the treatment of growth hormone deficiency in children and adolescents have been secured in all major markets, including the United States, European Union (â€œEU") Member States, Japan, Canada, and Australia, where it is marketed under the brand name NGENLAÂ®. Our 2022 acquisition of ModeX Therapeutics, Inc. (â€œModeXâ€) has expanded our pharmaceutical pipeline with early-stage immune therapies targeting cancer and infectious diseases. Â Our diagnostics business, BioReference Health, LLC (â€œBioReferenceâ€), is a highly specialized laboratory in the United States, with a sales and marketing team focused on growth and new product integration, including the 4KscoreÂ® prostate cancer test. BioReferenceÂ® offers a broad spectrum of diagnostic testing services for oncology, urology (4Kscore), and corrections nationwide, setting new standards with our industry-leading turnaround times. BioReference also provides comprehensive clinical and womenâ€™s health testing in New York and New Jersey. Our test offerings are backed by a team of board-certified medical professionals and driven by the latest healthcare guidelines and standards- marketed directly to physicians, geneticists, hospitals, clinics, correctional facilities, and other healthcare providers.Â Â On September 16, 2024 we completed an agreement to sell select assets of BioReference to Laboratory Corporation of America Holdings ("Labcorp"), as described below. Â The Company maintains established, revenue-generating pharmaceutical platforms in Spain, Ireland, Chile, and Mexico, contributing to positive cash flow and facilitating market entry for our development pipeline. In addition to these platforms, we operate a global pharmaceutical development and commercial supply company, a global supply chain operation, and manufacture specialty active pharmaceutical ingredients (API) in Israel through our subsidiary, FineTech. Â 49 Table of Contents Â RECENT DEVELOPMENTS Â ModeX Expands BARDA Collaboration Â In September 2024, ModeX entered into two amendments (the "BARDA Amendments") to modify the scope and funding with our existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services. The BARDA AmendmentÂ increased the total contract value to $110.0 million, with a potential value of $205 million if BARDA exercises all options thereunder to expand ModeX's services. The BARDA AmendmentÂ includes a $26.9 million supplement to accelerate the development of our COVID-19 program, including a Phase 1 clinical trial for a next-generation multispecific antibody with broad neutralizing activity against SARS-CoV-2 variants. Additionally, BARDA exercised a $24.1 million option to initiate the development of a multispecific antibody for influenza or another pathogen. Â Completion of Disposition of Select BioReference Assets Â On September 16, 2024, the Company completed the sale of certain assets of BioReference (the â€œBioReference Transactionâ€)Â to Labcorp. Labcorp paid to the Company aggregate consideration of $237.5 million in cash, which is subject to certain adjustments as set forth in the Labcorp Asset Purchase Agreement (as defined in Note 1 to our condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q (our "Quarterly Financial Statements")). The assets acquired by Labcorp include BioReference's laboratory testing businesses focused on clinical diagnostics, reproductive health, and women's health across the United States, excluding New York and New Jersey operations. We retained our oncology and urology diagnostic services nationwide. The BioReference assets were formerly part of our diagnostics segment. We recognized a gain of $121.5 million from theÂ BioReference Transaction for the three and nine months ended September 30, 2024. Â Stock Repurchase Program Â On July 18, 2024, our Board of Directors authorized the repurchase of up to $100 million of our Common Stock. Under this program, we may repurchase shares through various methods, including open market purchases, block trades, privately negotiated transactions and accelerated share repurchases, as well as pursuant to pre-set trading plans meeting the requirements of Rule 10b5-1(c) of the Exchange Act, and otherwise in compliance with applicable laws. The timing and volume of repurchases will depend on market conditions, our capital management, investment opportunities, and other factors. The program does not obligate us to repurchase any specific number of shares, has no set expiration date, and may be modified, suspended, or discontinued at our discretion. The Company repurchased 14,893,026 shares for approximately $23.8 million during the three months ended September 30, 2024. Â $250 Million Note Purchase Agreement Secured by NGENLAâ€™s Profit Share Payments Â On July 17, 2024, the Company completed a private offering of $250 million aggregate principal amount of senior secured notes (the â€œ2044 Notesâ€), pursuant to a note purchase agreement dated July 17, 2024 (the â€œ2044 Note Purchase Agreement), by and among the Company, certain purchasers party thereto, the Companyâ€™s wholly-owned subsidiaries OPKO Biologics Limited (â€œOPKO Biologicsâ€) and EirGen Pharma Ltd. (â€œEirGenâ€) as guarantors (OPKO Biologics and EirGen collectively, the â€œ2044 Note Guarantorsâ€), and HCR Injection SPV, LLC, as agent (â€œAgentâ€). The 2044 Notes mature on July 17, 2044 and bear interest at the 3-month Secured Overnight Financing Rate (â€œSOFRâ€) subject to a 4.0% per annum floor, plus 7.5% per annum. Interest is payable on the 2044 Notes on a quarterly basis determined by profit share payments received by EirGen pursuant to the profit share arrangement with Pfizer, Inc. (the â€œRoyalty Paymentsâ€) set forth in the Restated Pfizer Agreement (as described in Note 4 to our Quarterly Financials). In the event that the aggregate amount of the Royalty Payments received by EirGen during the quarter preceding any quarterly interest payment date are less than the accrued and unpaid interest payable on such date, the excess interest payable on such date shall be paid-in-kind and added to the outstanding principal amount of the 2044 Notes.Â The Company will be required to pay the noteholders a 3% exit fee in connection with any repayment in full of the 2044 Notes, whether at maturity or otherwise.Â In addition, in the event that the Company repays the 2044 Notes in full prior to the maturity date, the Company will be required to pay the noteholders a make whole payment in an amount necessary such that the noteholders shall have received aggregate payments of principal, interest and fees in respect of the 2044 Notes equal to at least 150% of the initial principal amount of the 2044 Notes, in the event that such prepayment shall occur on or prior to July 17, 2029, or 200% of the initial principal amount of the 2044 Notes, in the event that such prepayment shall occur following July 17, 2029. The Company may authorize up to an additional $50,000,000 in additional 2044 Notes to the purchasers on the same terms and conditions of the initial 2044 Notes. Â 50 Table of Contents Â Offering of 3.75% Convertible Senior Notes due 2029 Â InÂ January 2024,Â we completed a private offering of $230.0Â million aggregate principal amount ofÂ 3.75% Convertible Senior Notes dueÂ 2029Â (theÂ â€œ2029Â ConvertibleÂ 144AÂ Notesâ€) in accordance with the terms of a note purchase agreement (theÂ â€œ144AÂ Note Purchase Agreementâ€) entered into by and between the Company and J.P. Morgan Securities LLC (the â€œInitial Purchaserâ€). The $230.0Â million aggregate principal amount ofÂ 2029Â ConvertibleÂ 144AÂ Notes includedÂ $30.0Â million aggregate principal amount ofÂ 2029Â ConvertibleÂ 144AÂ Notes purchased on the Closing Date by the Initial Purchaser in accordance with its overallotment option. Â Net proceeds from the 2029 Convertible 144A Notes

issuance totaled approximately $222.0 million after deducting fees and estimated offering expenses payable by us. We allocated approximately $50.0 million of these net proceeds to repurchase shares of our Common Stock. These repurchases were from purchasers of the 2029 Convertible 144A Notes in privately negotiated transactions effected with or through the Initial Purchaser or its affiliate. The purchase price per share of the Common Stock in these transactions equaled the closing sale price of $0.9067 per share of Common Stock on January 4, 2024. Â Contemporaneously with the closing of the offering of the 2029 Convertible Notes on January 9, 2024, we issued and sold approximately $71.1 million aggregate principal amount of our 3.75% Convertible Senior Notes due 2029 (the â€œ2029 Convertible Affiliate Notesâ€ and, together with the 2029 Convertible 144A Notes, the â€œ2029 Convertible Notesâ€) pursuant to the terms of a note purchase agreement entered into on January 4, 2024 (the â€œAffiliate Note Purchase Agreementâ€) by and among the Company and certain investors including, Frost Gamma Investments Trust, a trust controlled by Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer (collectively, the â€œAffiliate Purchasersâ€). Pursuant to the Affiliate Note Purchase Agreement, we issued and sold the 2029 Convertible Affiliate Notes to the Affiliate Purchasers in exchange for the entirety of the $55.0 million aggregate principal amount of our outstanding 2023 Convertible Notes held by the affiliate Purchasers, together with approximately $16.1 million of accrued but unpaid interest thereon. Â Furthermore, in connection with the closing of our offering of theÂ 2029Â Convertible Notes,Â we repurchased approximately $144.4Â million aggregate principal amount of theÂ 2025Â Notes for cash, using $146.3Â million of the net proceeds from our issuance and sale of theÂ 2029Â ConvertibleÂ 144AÂ Notes. Â Termination of Share Lending Agreement Â On January 22, 2024, we terminated our share lending agreement, dated February 4, 2019, with Jefferies Capital Services, LLC (â€œShare Borrowerâ€). Through this agreement, we had lent the Share Borrower approximately 30 million shares of our common stock related to our 2019 issuance of the $200.0 million in 2025 Notes. We had since reduced the number of outstanding borrowed shares by approximately 8.313 million. With the termination of this agreement, all remaining shares have been returned to us and are now held as treasury shares. Â 51 Table of Contents Â RESULTS OF OPERATIONS Â Foreign Currency Exchange Rates Â Approximately 22.3% of our revenue for the nine months ended September 30, 2024, was denominated in currencies other than the U.S. Dollar (USD). This compares to 30.7% for the same period in 2023. Our financial statements are reported in USD; therefore, fluctuations in exchange rates affect the translation of foreign-denominated revenue and expenses. During the second quarter of 2024 and the year ended December 31, 2023, our most significant currency exchange rate exposures were to the Euro and the Chilean Peso. Gross accumulated currency translation adjustments, recorded as a separate component of shareholdersâ€™ equity, totaled $36.2 million and $34.6 million at September 30, 2024 and December 31, 2023, respectively. Â We are subject to foreign currency transaction risk due to fluctuations in exchange rates between the time a transaction is initiated and settled. To mitigate this risk, we use foreign currency forward contracts. These contracts fix an exchange rate, allowing us to offset potential losses (or gains) caused by exchange rate changes at the settlement date. As of September 30, 2024, we held no open foreign exchange forward contracts related to inventory purchases on letters of credit. As of December 31, 2023, we held 52 open foreign exchange forward contracts related to inventory purchases on letters of credit. These contracts matured monthly through January 2024 with a total notional value of approximately $2.9 million. Â Â FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 Â Our consolidated (loss) income from operations for the three months ended September 30, 2024 and 2023 was as follows: Â Â Â For the three months ended September 30, Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (In thousands) Â 2024 Â Â 2023 Â Â Change Â Â Â % Change Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revenue from services Â $ 121,271 Â Â $ 131,679 Â Â $ (10,408) Â Â (8)% Revenue from products Â Â 39,143 Â Â Â 40,670 Â Â Â (1,527) Â Â (4)% Revenue from transfer of intellectual property and other Â Â 13,218 Â Â Â 6,246 Â Â Â 6,972 Â Â Â 112 % Total revenues Â Â 173,632 Â Â Â 178,595 Â Â Â (4,963) Â Â (3)% Costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cost of revenue Â Â 133,503 Â Â Â 130,918 Â Â Â 2,585 Â Â Â 2 % Selling, general and administrative Â Â 98,203 Â Â Â 72,240 Â Â Â 25,963 Â Â Â 36 % Research and development Â Â 28,770 Â Â Â 19,435 Â Â Â 9,335 Â Â Â 48 % Contingent consideration Â Â â€” Â Â Â (1,125) Â Â 1,125 Â Â Â 100 % Amortization of intangible assets Â Â 20,433 Â Â Â 21,534 Â Â Â (1,101) Â Â (5)% Gain on sale of assets Â Â (121,493) Â Â â€” Â Â Â (121,493) Â Â (100)% Total costs and expenses Â Â 159,416 Â Â Â 243,002 Â Â Â (83,586) Â Â (34)% Income (loss) from operations Â $ 14,216 Â Â $ (64,407) Â $ 78,623 Â Â Â 122 % Â 52 Table of Contents Â Diagnostics Â Â Â For the three months ended September 30, Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (In thousands) Â 2024 Â Â 2023 Â Â Change Â Â % Change Â Revenues Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revenue from services Â $ 121,271 Â Â $ 131,679 Â Â $ (10,408) Â Â (8)% Total revenues Â Â 121,271 Â Â Â 131,679 Â Â Â (10,408) Â Â (8)% Costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cost of revenue Â Â 108,846 Â Â Â 106,375 Â Â Â 2,471 Â Â Â 2 % Selling, general and administrative Â Â 70,946 Â Â Â 48,799 Â Â Â 22,147 Â Â Â 45 % Research and development Â Â 493 Â Â Â 537 Â Â Â (44) Â Â (8)% Amortization of intangible assets Â Â 3,938 Â Â Â 5,049 Â Â Â (1,111) Â Â (22)% Gain on sale of assets Â Â (121,493) Â Â â€” Â Â Â (121,493) Â Â (100)% Total costs and expenses Â Â 62,730 Â Â Â 160,760 Â Â Â (98,030) Â Â (61)% Income (loss) from operations Â $ 58,541 Â Â $ (29,081) Â $ 87,622 Â Â Â 301 % Â Revenue. Revenue from services for the three months ended September 30, 2024 decreased by approximately $10.4 million,Â a decrease ofÂ 7.9% compared to the same period in 2023. This decrease was primarily due to a $2.0 million reduction in clinical test reimbursement rates and an $8.4 million decrease in clinical test volume, of which $3.3 million was attributable to the BioReference Transaction. Â Estimated collection amounts are subject to the complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, and require us to consider the potential for retroactive adjustments when estimating variable consideration in the recognition of revenue in the period the related services are rendered. For the three months ended September 30, 2024 and 2023, we recorded $0.7 million and $1.5 million, respectively. These adjustments reflect changes in estimated implicit price concessions for services provided in prior periods, primarily due to shifts in the composition of our client mix Â The composition of revenue from services by payor for theÂ three months ended September 30, 2024 and 2023 was as follows: Â Â Â Â Three months ended September 30, Â (In thousands) Â 2024 Â Â 2023 Â Healthcare insurers Â $ 76,184 Â Â $ 81,469 Â Government payers Â Â 20,368 Â Â Â 19,909 Â Client payers Â Â 20,773 Â Â Â 25,906 Â Patients Â Â 3,946 Â Â Â 4,395 Â Total Â $ 121,271 Â Â $ 131,679 Â Â Cost of revenue. Cost of revenue for the three months ended September 30, 2024 increased $2.5 million,Â an increase ofÂ 2.3% compared to the three months ended September 30, 2023. The increase is primarily due to $4.2 million in accruals set aside to cover volume shortfalls on contracts as a result of the Labcorp transaction. Â Selling, general and administrative expenses. Selling, general and administrative expenses for the three months ended September 30, 2024 and 2023 wereÂ $71.0 million and $48.8 million, respectively, representing anÂ increase ofÂ 45.4% from the prior period. The increase in selling, general and administrative expenses was primarily due to severance expense of $26.3 million, offset by a decrease in employee-related expenses, reflecting continued cost-reduction initiatives. Â 53 Table of Contents Â Research and development expenses. The following table summarizes the components of our research and development expenses: Â Research and Development Expenses Â Three months ended September 30, Â (In thousands) Â Â 2024 Â Â Â 2023 Â Research and development employee-related expenses Â $ 161 Â Â $ 446 Â Other internal research and development expenses Â Â 332 Â Â Â 91 Â Total research and development expenses Â $ 493 Â Â $ 537 Â Â The decrease in research and development expenses for the three months endedÂ September 30, 2024 as compared to 2023 was primarily due to a decrease in employee-related expenses as a result of the continued cost-reduction initiatives implemented at BioReference. Â Amortization of intangible assets. Amortization of intangible assets wasÂ $3.9 million and $5.1 million, respectively, for the three months ended September 30, 2024 and 2023. The decrease is primarily attributable to the BioReference Transaction, which impacted the amount of amortizable intangible assets. Â Gain on sale of assets. Gain on sale of assets for the three months ended September 30, 2024, was $121.5 million which reflects the gain on sale from the BioReference Transaction. Â Â Pharmaceuticals Â Â Â For the three months ended September 30, Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (In thousands) Â 2024 Â Â 2023 Â Â Change Â Â % Change Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revenue from products Â $ 39,143 Â Â $ 40,670 Â Â $ (1,527) Â Â (4)% Revenue from transfer of intellectual property and other Â Â 13,218 Â Â Â 6,246 Â Â Â 6,972 Â Â Â 112 % Total revenues Â Â 52,361 Â Â Â 46,916 Â Â Â 5,445 Â Â Â 12 % Costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cost of revenue Â Â 24,657 Â Â Â 24,543 Â Â Â 114 Â Â Â 0 % Selling, general and administrative Â Â 15,161 Â Â Â 13,503 Â Â Â 1,658 Â Â Â 12 % Research and development Â Â 28,244 Â Â Â 18,885 Â Â Â 9,359 Â Â Â 50 % Contingent consideration Â Â â€” Â Â Â (1,125) Â Â 1,125 Â Â Â 100 % Amortization of intangible assets Â Â 16,495 Â Â Â 16,485 Â Â Â 10 Â Â Â 0 % Total costs and expenses Â Â 84,557 Â Â Â 72,291 Â Â Â 12,266 Â Â Â 17 % Loss from operations Â $ (32,196) Â $ (25,375) Â $ (6,821) Â Â (27)% Â Revenue from products. Revenue from products for the three months ended September 30, 2024 decreasedÂ $1.5 million or 3.8%, compared to the three months ended September 30, 2023.Â This decrease was largely attributable to lower Rayaldee sales, which generated $5.8 million of revenue for the three months ended September 30, 2024, compared to $7.3 millionÂ forÂ the same period in 2023. In addition, demand for our products in international operations increased, foreign currency fluctuations also negatively impacted revenue. Â Revenue from transfer of intellectual property and other.Â For the three months ended September 30, 2024, revenue from the transfer of intellectual property and other wasÂ $13.2 million compared toÂ $6.3 million for the prior year period.Â This increase was primarily attributable to $5.5 million from the BARDA Contract (as defined and described in Note 14 to our Quarterly Financials). Gross profit share and royalty payments for NGENLA (Somatrogon) and Pfizer's GenotropinÂ® (Somatropin) also increased to $7.0 million, compared with $4.9 million for the same period in 2023. Â Cost of revenue. Cost of revenueÂ for the three months ended September 30, 2024 increased $0.1 million, an increase ofÂ 0.5%, compared to the three months ended September 30, 2023. Cost of revenue increased primarily due to a shift in product mix offset by favorable foreign currency exchange, which had a positive impact on cost of revenue, reducing it by $1.5 million. Â 54 Table of Contents Â Selling, general and administrative expenses. Selling, general and administrative expenses for the three months endedÂ September 30, 2024 and 2023 wereÂ $15.2 million and $13.5 million, respectively, an increase ofÂ 12.3% from the prior year period. This increase was primarily driven by higher professional fees. Additionally, employee-related expenses also contributed to the increase in SG&A in our international operations. Â Research and development expenses. Research and development expensesÂ for the three months ended September 30, 2024 and 2023 wereÂ $28.2 million and $18.9 million, respectively, an increase ofÂ 49.6% from the prior year period. Research and development expenses include external and internal expenses, partially offset by third-party grants and funding arising from collaboration agreements. External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs. We track external research and development expenses by individual program for phase 3 clinical trials for drug approval and premarket approval for diagnostics tests, if any. Internal expenses include employee-related expenses such as salaries, benefits and equity-based compensation expense. Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities. Â The following table summarizes the components of our research and development expenses: Â Â Research and Development Expenses Â Three months ended September 30, Â (In thousands) Â Â 2024 Â Â Â 2023 Â External expenses: Â Â Â Â Â Â Â Â Manufacturing expense for biological products Â $ 9,355 Â Â $ 4,060 Â Phase 3 studies Â Â 684 Â Â Â 744 Â Post-marketing studies Â Â 226 Â Â Â 184 Â Earlier-stage programs Â Â 7,481 Â Â Â 7,122 Â Research and development employee-related expenses Â Â 10,276 Â Â Â 8,822 Â Other internal research and development expenses Â Â 2,031 Â Â Â 1,034 Â Third-party grants and funding from collaboration agreements Â Â (1,809) Â Â (3,081) Total research and development expenses Â $ 28,244 Â Â $ 18,885 Â Â Research and development expenses for the three months ended September 30, 2024 increased primarily due to higher expenses at ModeX. This increase was driven by a combination of factors, including growth in our BARDA collaboration, advancements and expansion in our early-stage programs, and higher employee-related expenses. Â Contingent consideration. Contingent considerationÂ for the three months endedÂ September 30, 2024 was zero, as compared to $1.1 million reversal of expense for the three months ended September 30, 2023. Contingent considerationÂ for the three months endedÂ September 30, 2023 was primarily attributable to changes in assumptions regarding the timing of achievement of future milestones for OPKO Renal, and potential amounts payable to former stockholders of OPKO Renal in connection therewith, pursuant to our acquisition agreement in 2013. Â Amortization of intangible assets. Amortization of intangible assets wasÂ $16.5 million and $16.5 million, respectively, for the three months ended September 30, 2024 and 2023. Amortization expense reflects the amortization of acquired intangible assets with defined useful lives. Our indefinite lived IPR&D assets will not be amortized until the underlying development programs are completed. Upon obtaining regulatory approval by the FDA, the IPR&D assets will be accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life. The assets will be amortized on a straight-line basis over their estimated useful life of approximately 12 years. Â 55 Table of Contents Â Corporate Â Â Â Â For the three months ended September 30, Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (In thousands) Â 2024 Â Â 2023 Â Â Change Â Â % Change Â Costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Selling, general and administrative Â $ 12,096 Â Â $ 9,938 Â Â $ 2,158 Â Â Â 22 % Research and development Â Â 33 Â Â Â 13 Â Â Â 20 Â Â Â 154 % Total costs and expenses Â Â 12,129 Â Â Â 9,951 Â Â Â 2,178 Â Â Â 22 % Loss from operations Â $ (12,129) Â $ (9,951) Â $ (2,178) Â Â (22)% Â Operating loss for our unallocated corporate operationsÂ for the three months ended September 30, 2024 and 2023 wasÂ $12.1 million and $10.0 million, respectively, and principally reflect general and administrative expenses incurred in connection with our corporate operations. The increase in operating loss for our unallocated corporate operations was primarily due to an increase in employee-related expenses. Â Other Â Interest income. Interest income for the three months ended September 30, 2024 and 2023 wasÂ $2.9 million andÂ $1.0 million, respectively. The increase in interest income is driven by the yield obtained in our larger cash investment. Â Interest expense. Interest expense increased toÂ $17.4 million for the three months ended September 30, 2024, compared toÂ $3.4 million in the same period of 2023. The increase in interest expense was primarily driven by $14.6 million interest incurred on the 2029 Convertible Notes and the 2044 Notes, including amortization of deferred financing and debt issuance costs. This increase was partially offset by the extinguishment of our outstanding 2023 Convertible Notes and the repurchase of the 2025 Convertible Notes. Â Fair value changes of derivative instruments, net. Fair value changes of derivative instruments, net for the three months ended September 30, 2024 and 2023, wasÂ $1.0 thousand andÂ $88.0 thousand of expense, respectively. Derivative expense was principally related to foreign currency forward exchange contracts at OPKO Chile. Â Other income (expense), net.Â Other income (expense), net for the three months ended September 30, 2024, resulted inÂ $48.6 million of income compared to $11.7 million of expense for the 2023 period. This was primarily driven by changes in the fair value of our investment in GeneDx Holdings (as defined in Note 6 to our Quarterly Financials). During the three months ended September 30, 2024, we recorded income of $35.4 million related to this investment, compared to an expense of $8.3 million in the prior-year period. Additionally, we realized a gain of $10.5 million from the sale of 1,386,929 shares of GeneDx during the three months ended September 30, 2024. Foreign currency income of $4.1 million was recorded for the 2024 period, compared with aÂ $3.8 million expense in the 2023 period. Â Income tax provision. Our income tax provisionÂ for the three months ended September 30, 2024 and 2023 was $23.5 million and $6.1 million, respectively. This significant increase was primarily driven by a discrete expense related to the BioReference Transaction. While the U.S. federal statutory rate is 21%, our effective tax rate for the three months ended September 30, 2024 and 2023 differed from this rate primarily due to the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions and operating results in tax jurisdictions which do not result in a tax benefit. Â Loss from investments in investees. We have invested in certain early-stage companies that we perceive to have valuable proprietary technology and significant potential to create value for us as an equity holder. We account for these investments under the equity method of accounting, resulting in the recording of our proportionate share of their losses until our share of their loss exceeds our investment. Until the investeesâ€™ technologies are commercialized, if ever, we anticipate they will report net losses Loss from investments in investees was $3.0 thousand and $20.0 thousand for the three months ended September 30, 2024 and 2023, respectively. Â 56 Table of Contents Â FOR THE nine months ended September 30, 2024 and 2023 Â Our consolidated loss from operations for theÂ nine months ended September 30, 2024 and 2023 was as follows: Â Â Â For the nine months ended September 30, Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (In thousands) Â 2024 Â Â 2023 Â Â Change Â Â % Change Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revenue from services Â $ 377,557 Â Â $ 391,100 Â Â $ (13,543) Â Â (3)% Revenue from products Â Â 117,675 Â Â Â 124,553 Â Â Â (6,878) Â Â (6)% Revenue from transfer of intellectual property and other Â Â 34,272 Â Â Â 165,938 Â Â Â (131,666) Â Â (79)% Total revenues Â Â 529,504 Â Â Â 681,591 Â Â Â (152,087) Â Â (22)% Costs and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cost of revenue Â Â 395,653 Â Â Â 408,171 Â Â Â (12,518) Â Â (3)% Selling, general and administrative Â Â 237,191 Â Â Â 227,676 Â Â Â 9,515 Â Â Â 4 % Research and development Â Â 74,789 Â Â Â 70,199 Â Â Â 4,590 Â Â Â 7 % Contingent consideration Â Â â€” Â Â Â (1,023) Â Â 1,023 Â Â Â 100 % Amortization of intangible assets Â Â 62,290 Â Â Â 64,543 Â Â Â (2,253) Â Â (3)% Gain on sale of assets Â Â (121,493) Â Â â€” Â Â Â (121,493) Â Â (100)% Total costs and expenses Â Â 648,430 Â Â Â 769,566 Â Â Â (121,136) Â Â (16)% Loss from operations Â $ (118,926) Â $ (87,975) Â $ (30,951) Â Â (35)% Â Diagnostics Â Â Â For the nine months ended September 30, Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (In thousands) Â 2024 Â Â 2023 Â Â Change Â Â % Change Â Revenues Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revenue from services Â $

377,557 Â Â $ 391,100 Â Â $ (13,543) Â Â (3)% Total revenues Â Â 377,557 Â Â Â 391,100 Â Â Â (13,543) Â Â (3)% Costs and expenses: Â Cost of revenue Â Â 325,797 Â Â Â 333,463 Â Â Â (7,666) Â Â (2)% Selling, general and administrative Â Â 161,208 Â Â Â 153,992 Â Â Â 7,216 Â Â Â 5 % Research and development Â Â 1,545 Â Â Â 1,843 Â Â Â (298) Â Â (16)% Amortization of intangible assets Â Â 12,943 Â Â Â 15,146 Â Â Â (2,203) Â Â (15)% Gain on sale of assets Â Â (121,493) Â Â â€” Â Â Â (121,493) Â Â (100)% Total costs and expenses Â Â 380,000 Â Â Â 504,444 Â Â Â (124,444) Â Â (25)% Loss from operations Â $ (2,443) Â $ (113,344) Â $ 110,901 Â Â Â 98 % Â Revenue. Revenue from services for theÂ nine months ended September 30, 2024 decreased by approximatelyÂ $13.5 million,Â a decrease of 3.5% compared to the nine months ended September 30, 2023. This decrease was primarily due to a $6.5 million reduction in clinical test reimbursement rates and an $7.0 million decrease in clinical test volume, of which $3.3 million was attributable to the BioReference Transaction. Â Estimated collection amounts are subject to the complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, and require us to consider the potential for retroactive adjustments when estimating variable consideration in the recognition of revenue in the period the related services are rendered. For the nine months ended September 30, 2024 and 2023, we recorded $2.2 million and $19.8 million, respectively, of negative revenue adjustments due to changes in estimates of implicit price concessions for performance obligations satisfied in prior periods mainly due to the composition of patient pay mix. Â 57 Table of Contents Â The composition of revenue from services by payor for theÂ nine months ended September 30, 2024 and 2023 was as follows: Â Â Â Nine months ended September 30, Â (In thousands) Â 2024 Â Â 2023 Â Healthcare insurers Â $ 229,600 Â Â $ 238,934 Â Government payers Â Â 63,561 Â Â Â 61,250 Â Client payers Â Â 71,521 Â Â Â 77,973 Â Patients Â Â 12,875 Â Â Â 12,943 Â Total Â $ 377,557 Â Â $ 391,100 Â Â Cost of revenue. Cost of revenue for the nine months ended September 30, 2024 decreasedÂ $7.7 million,Â a decrease of 2.3% compared to the nine months ended September 30, 2023. Cost of revenue decreased primarily due to lower employee headcount, reflecting our continued cost-reduction initiatives implemented at BioReference, changes in the mix of testing ordered during the period, and by a decrease in consumption reflecting theÂ timing of the BioReference Transaction. Â Selling, general and administrative expenses. Selling, general and administrative expenses for the nine months ended September 30, 2024 and 2023 wereÂ $161.2 million and $154.0 million, respectively, representing a decrease of 4.7% from the prior period. The increase in selling, general and administrative expenses was primarily due to severance expense of $26.3 million, offset by a decrease in employee-related expenses, reflecting continued cost-reduction initiatives. Â Research and development expenses. The following table summarizes the components of our research and development expenses: Â Research and Development Expenses Â Nine months ended September 30, Â Â Â 2024 Â Â 2023 Â Research and development employee-related expenses Â $ 1,006 Â Â $ 1,292 Â Other internal research and development expenses Â Â 539 Â Â Â 551 Â Total research and development expenses Â $ 1,545 Â Â $ 1,843 Â Â The decrease in research and development expenses for the nine months ended September 30, 2024 was primarily due to a decrease in employee-related expenses as a result of the continued cost-reduction initiatives implemented at BioReference. Â Amortization of intangible assets. Amortization of intangible assets wasÂ $12.9 million and $15.2 million, respectively, for the nine months ended September 30, 2024 and 2023. The decrease is primarily attributable to the BioReference Transaction, which impacted the amount of amortizable intangible assets. Â Gain on sale of assets. Gain on sale of assets for the nine months ended September 30, 2024, was $121.5 million due to the BioReference Transaction that closed during the third quarter of 2024. Â Pharmaceuticals Â Â Â For the nine months ended September 30, Â Â Â Â Â Â Â Â Â (In thousands) Â 2024 Â Â 2023 Â Â Change Â Â % Change Â Revenues: Â Revenue from products Â $ 117,675 Â Â $ 124,553 Â Â $ (6,878) Â Â (6)% Revenue from transfer of intellectual property and other Â Â 34,272 Â Â Â 165,938 Â Â Â (131,666) Â Â (79)% Total revenues Â Â 151,947 Â Â Â 290,491 Â Â Â (138,544) Â Â (48)% Costs and expenses: Â Cost of revenue Â Â 69,856 Â Â Â 74,708 Â Â Â (4,852) Â Â (6)% Selling, general and administrative Â Â 44,264 Â Â Â 41,895 Â Â Â 2,369 Â Â Â 6 % Research and development Â Â 73,177 Â Â Â 68,304 Â Â Â 4,873 Â Â Â 7 % Contingent consideration Â Â â€” Â Â Â (1,023) Â Â 1,023 Â Â Â 100 % Amortization of intangible assets Â Â 49,347 Â Â Â 49,397 Â Â Â (50) Â Â (0)% Total costs and expenses Â Â 236,644 Â Â Â 233,281 Â Â Â 3,363 Â Â Â 1 % (Loss) income from operations Â $ (84,697) Â $ 57,210 Â Â $ (141,907) Â Â (248)% Â 58 Table of Contents Â Revenue from products. Revenue from products for nine months ended September 30, 2024 decreased $6.9 million or 5.5%, compared to theÂ nine months ended September 30, 2023. While we experienced higher sales volumes in 2024 compared to 2023, this increase was more than offset by unfavorable foreign exchange fluctuations of approximately $6.7 million from our international operations, resulting in an overall decrease in revenue. Additionally, revenue from sales of Rayaldee for the nine months ended September 30, 2024, wasÂ $19.9 million compared to $21.7 million recorded in the same period in 2023. Â Revenue from transfer of intellectual property and other.Â For the nine months ended September 30, 2024, revenue from the transfer of intellectual property and other wasÂ $34.3 million compared toÂ $165.9 million for the prior period. This decrease was primarily due to one-time milestone payments received in 2023, including a $90.0 million payment triggered by the FDA approval of NGENLA (Somatrogon), a $50.0 million payment from Merck for rights granted under the Merck AgreementÂ (as defined and described in Note 14 to our Quarterly Financials), a $7.0 million payment from VFMCRP triggered by the German price approval for Rayaldee (as described in Note 14 to our Quarterly Financials) and a $2.5 million payment from Nicoya due to Nicoyaâ€™s submission of the investigational new drug application to China's Center for Drug Evaluation pursuant to the Nicoya Agreement (as described in Note 14 to our Quarterly Financials). For the nine months ended September 30, 2024, revenue from the transfer of intellectual property and other reflects $18.9 million in gross profit share and royalty payments for NGENLA (Somatrogon) and Pfizer's GenotropinÂ® (Somatropin), compared with $11.8 million received in the same period in 2023.Â Furthermore, revenue for theÂ nine months ended September 30, 2024 included $12.8 million from the BARDA Contract (as defined and described in Note 14 to our Quarterly Financials). Â Cost of revenue. Cost of revenue for the nine months ended September 30, 2024 decreased $4.9 million, a decrease ofÂ 6.5% compared to the nine months ended September 30, 2023 which was primarily driven by favorable foreign exchange fluctuations. Despite increased sales volumes during the period, which typically increases cost of revenue, we were able to achieve this decrease due to a combination of factors. Favorable foreign currency fluctuations positively impacted cost of revenue, and we also realized a $2.6 million reduction in Rayaldee cost of revenue resulting from a lower standard cost per bottle. Â Selling, general and administrative expenses. Selling, general and administrative expenses for the nine months ended September 30, 2024 and 2023 were $44.3 million and $41.9 million, respectively, an increase of 5.7% from the prior year period. The increase in selling, general and administrative expenses was due to higher employee-related and professional expenses related to our international operations. Â Research and development expenses. Research and development expenses for the nine months ended September 30, 2024 and 2023 were $73.2 million and $68.3 million, respectively, an increase of 7.1% from the prior year period. Research and development expenses include external and internal expenses, partially offset by third-party grants and funding arising from collaboration agreements. External expenses include clinical and non-clinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs. We track external research and development expenses by individual program for phase 3 clinical trials for drug approval and premarket approval for diagnostics tests, if any. Internal expenses include employee-related expenses such as salaries, benefits and equity-based compensation expense. Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities. Â The following table summarizes the components of our research and development expenses: Â Research and Development Expenses Â Nine months ended September 30, Â (In thousands) Â Â 2024 Â Â Â 2023 Â External expenses: Â Â Â Â Â Â Â Â Manufacturing expense for biological products Â $ 22,590 Â Â $ 10,039 Â Phase III studies Â Â 1,332 Â Â Â 3,871 Â Post-marketing studies Â Â 514 Â Â Â 342 Â Earlier-stage programs Â Â 25,505 Â Â Â 37,197 Â Research and development employee-related expenses Â Â 28,132 Â Â Â 25,584 Â Other internal research and development expenses Â Â 5,969 Â Â Â 3,037 Â Third-party grants and funding from collaboration agreements Â Â (10,865) Â Â (11,766) Total research and development expenses Â $ 73,177 Â Â $ 68,304 Â Â 59 Table of Contents Â Research and development expenses for the nine months ended September 30, 2024, increased primarily to growth in our BARDA collaboration and higher employee-related expenses. These increases were partially offset by a one-time payment to Sanofi of $12.5 million made in 2023 pursuant to the Sanofi In-License Agreement, which was triggered as a result of the Merck Agreement, and lower costs related to Somatrogon (hGH-CTP) following the closure of open-label extension studies in countries where it has received marketing authorization. Â Contingent consideration. Contingent consideration for the nine months ended September 30, 2024 was zero, as compared to aÂ $1.0 million reversal of expense for the nine months ended September 30, 2023. Contingent consideration for theÂ nine months ended September 30, 2023 was primarily attributable to changes in assumptions regarding the timing of achievement of future milestones for OPKO Renal, and potential amounts payable to former stockholders of OPKO Renal in connection therewith, pursuant to our acquisition agreement in 2013. Â Amortization of intangible assets. Amortization of intangible assets wasÂ $49.4 million for both for the nine months ended September 30, 2024 and 2023. Amortization expense reflects the amortization of acquired intangible assets with defined useful lives. Our indefinite lived IPR&D assets will not be amortized until the underlying development programs are completed. Upon obtaining regulatory approval by the FDA, the IPR&D assets will be accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life. The assets will be amortized on a straight-line basis over their estimated useful life of approximately 12 years. Â Corporate Â Â Â For the nine months ended September 30, Â Â Â Â Â Â Â Â Â (In thousands) Â 2024 Â Â 2023 Â Â Change Â Â % Change Â Costs and expenses: Â Selling, general and administrative Â $ 31,719 Â Â $ 31,789 Â Â $ (70) Â Â (0)% Research and development Â Â 67 Â Â Â 52 Â Â Â 15 Â Â Â 29 % Total costs and expenses Â Â 31,786 Â Â Â 31,841 Â Â Â (55) Â Â (0)% Loss from operations Â $ (31,786) Â $ (31,841) Â $ 55 Â Â Â 0 % Â Operating loss for our unallocated corporate operations for the nine months ended September 30, 2024 and 2023 wasÂ $31.8 million and $31.8 million, respectively, and principally reflect general and administrative expenses incurred in connection with our corporate operations. Â Other Â Interest income. Interest income for the nine months ended September 30, 2024 and 2023 wasÂ $4.1 million andÂ $3.1 million, respectively. The increase is driven byÂ higher average cash and investment balances as a result of the cash received from the BioReference Transaction and the issuance of the 2044 Notes. Â Interest expense. Interest expense increased to $33.2 million for the nine months ended September 30, 2024, compared to $10.1 million in the same period of 2023. The increase was primarily driven by interest incurred on the 2029 Convertible Notes and the 2044 Senior Secured Notes, including amortization of deferred financing and debt issuance costs. This increase was partially offset by the extinguishment of our outstanding 2023 Convertible Notes in connection with their exchange for 2029 Convertible Notes and the repurchase of a portion of the 2025 Convertible Notes. Â Fair value changes of derivative instruments, net. Fair value changes of derivative instruments, net for the nine months ended September 30, 2024 and 2023, was $26.2 million andÂ $0.8 million of expense, respectively. Derivative expense was principally related to the change in fair value on the 2029 Convertible Notes and on foreign currency forward exchange contracts at OPKO Chile. Â Other income (expense), net.Â Other income (expense), net for the nine months ended September 30, 2024, wasÂ $128.8 million of income, compared toÂ $16.1 million of expense for the 2023 period. Other income (expense), net for the nine months ended September 30, 2024 and 2023, includedÂ $118.6 million of income and $19.9 million of expense, respectively, as a result of the change in the fair value of our investment in GeneDx Holdings (as defined in Note 6 to our Quarterly Financials). Furthermore, the nine months ended September 30, 2023, reflected $8.5 million of income due to GeneDx Holdings reaching specific revenue targets for the fiscal year ending December 31, 2022. Finally, a foreign currency gain of $0.1 million was recorded for the 2024 period, compared with a $1.8 million loss in the 2023 period. Â 60 Table of Contents Â Income tax provision. Our income tax provision for the nine months ended September 30, 2024 and 2023 was a $21.9 million and $10.5 million, respectively. For the nine months ended September 30, 2024 and 2023, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, a discrete expense impact related to the BioReference Transaction, the impact of the payments under Merck Agreement, and operating results in tax jurisdictions which do not result in a tax benefit. Â Loss from investments in investees. We have invested in certain early stage companies that we perceive to have valuable proprietary technology and significant potential to create value for us as an equityholder. We account for these investments under the equity method of accounting, resulting in the recording of our proportionate share of their losses until our share of their loss exceeds our investment. Until the investeesâ€™ technologies are commercialized, if ever, we anticipate they will report net losses. Loss from investments in investees wasÂ $7.0 thousand andÂ $99.0 thousand for the nine months ended September 30, 2024 and 2023, respectively. Â Â LIQUIDITY AND CAPITAL RESOURCES Â On September 30, 2024, we had cash, cash equivalents and restricted cash of approximately $420.1 million. Cash used in operations of $139.1 million for theÂ nine months ended September 30, 2024 was primarily driven by a $121.5 million gain on the sale of assets related to the BioReference Transaction and $94.6 million change in fair value from equity securities. We also incurred general and administrative expenses related to our corporate operations and research and development activities. Cash from investing activities was $236.2 million for theÂ nine months ended September 30, 2024 primarily reflected both the proceeds from the BioReference Transaction and the sale of equity securities, offset by capital expenditures. Cash provided by financing activities for theÂ nine months ended September 30, 2024 of $224.6 million primarily reflected net borrowings on our lines of credit, the issuance of our 2029Â Convertible Notes, the issuance of the 2044 Notes, the redemption of the 2025 Notes, and repurchase of shares of our Common Stock. We have historically not generated sustained positive cash flow sufficient to offset our operating and other expenses, and our primary sources of cash have been from the public and private placement of equity and debt, as well as credit facilities available to us. Â In September 2024, ModeX entered into the BARDA Amendment which increased funding by $26.9 million,Â for the ongoing development, manufacturing, and execution of a Phase 1 clinical trial for a next-generation MSTAR multispecific antibody with broad neutralizing activity against known variants of SARS-CoV-2. The BARDA AmendmentÂ also included BARDA's exercise ofÂ an option for the development of a multispecific protein antibody for influenza or another pathogen, with the additional funding allocated to cover the expanded work. These modifications increased the total value of the BARDA Contract to $110.0 million, with a potential value, of $205.0 million if BARDA exercises all options thereunder thereunder to expand MOdeX's services. The BARDA Contract covers a five-year period through February 2028. We expect this funding will support the development of a second novel multispecific antibody to SARS-CoV-2, from preclinical through Phase 1 trials, as well as preclinical work on gene-based expression of multispecific antibodies to SARS-CoV-2, including mRNA and/or DNA vectors. In addition, ModeX will begin development of influenza multispecifics with gene and/or protein delivery modalities. As of September 30, 2024, the aggregate amount remaining to be funded by BARDA, which is subject to performance obligations and excluding unexercised contract options, is $96.0 million. Â On September 16, 2024, the Company consummated the BioReference Transaction, pursuant to which Labcorp acquired select assets of the Company's subsidiary, BioReference. Labcorp paid to the Company aggregate consideration of $237.5 million in cash, subject to certain adjustments as set forth in the Labcorp Asset Purchase Agreement. The assets acquired by Labcorp include BioReference's laboratory testing businesses focused on clinical diagnostics, reproductive health, and women's health across the United States, excluding New York and New Jersey operations. Â During the third quarter of 2024, the Company sold 1,386,929 shares of GeneDx Holdings common stock at various prices per share for approximately $46.7 million in aggregate proceeds. This sale reduced the Company's total ownership in GeneDx Holdings from 13.61% to 8.1% as of September 30, 2024. As of September 30, 2024, the aggregate value of our GeneDx Holdings investment was $92.2 million based on the closing market price of the GeneDx Holdings common stock. Â On July 18, 2024, our Board of Directors authorized the repurchase of up to $100 million of our Common Stock. Under this program, we may repurchase shares through various methods, including open market purchases, block trades, privately negotiated transactions and accelerated share repurchases, as well as pursuant to pre-set trading plans meeting the requirements of Rule 10b5-1(c) of the Exchange Act, and otherwise in compliance with applicable laws. The timing and volume of repurchases will depend on market conditions, our capital management, investment opportunities, and other factors. The program does not obligate us to repurchase any specific number of shares, has no set expiration date, and may be modified, suspended, or discontinued at our discretion.Â In connection with this new authorization, the Company repurchased 14,893,026 shares for $23.8 million during the three months ended September 30, 2024. Â 61 Table of Contents Â On July 17, 2024, we completed a private offering of $250 million aggregate principal amount of the 2044 Notes in accordance with the terms of the 2044 Note Purchase Agreement. The 2044 Notes are secured by the Companyâ€™s profit share payments from Pfizer, received under the Restated Pfizer Agreement. The 2044 Notes bear interest at the 3-month SOFR plus 7.5%, subject to a minimum interest rate of 4.0% per annum. The 2044 Notes mature in July 2044, with interest-only payments required for the first four years. Â In January 2024, we completed a private offering of $230.0 million aggregate principal amount of our 2029 Convertible 144A Notes in accordance with the terms of theÂ 144AÂ Note Purchase Agreement entered into by and between the Company and the Initial Purchaser. Â The Company received approximately $220.0 million of net proceeds from the issuance of the 2029 Convertible 144A Notes, after deducting fees and estimated offering expenses. The Company used approximately $50.0 million of the net proceeds to repurchase shares of our Common Stock from purchasers of the 2029 Convertible 144A Notes in privately negotiated transactions at a

purchase price equal to the closing sale price per share of Common Stock on January 4, 2024, which was $0.9067. Contemporaneously with the pricing of the 2029 Convertible 144A Notes, the Company entered into separate, privately negotiated transactions with certain holders of the Companyâ€™s outstanding 4.50% Convertible Senior Notes due 2025 to repurchase, on the closing date, approximately $144.4 million aggregate principal amount of such notes. The Company effected such repurchases for cash, using $146.3 million of the net proceeds from the offering of the 2029 Convertible 144A Notes, following which only $170Â thousand aggregate principal amount of theÂ 2025Â Notes remained outstanding. Â Additionally, the Company issued and sold approximately $71.1 million aggregate principal amount of the 2029 Convertible Affiliate NotesÂ pursuant to the terms of the Affiliate Note Purchase AgreementÂ by and among the Company and the Affiliate Purchasers. Pursuant to the Affiliate Note Purchase Agreement, the Company issued and sold the 2029 Convertible Affiliate Notes to the Affiliate Purchasers in exchange for $55.0 million aggregate principal amount of 2023 Convertible Notes, held by the Affiliate Purchasers, together with approximately $16.1 million of accrued but unpaid interest thereon. Following such exchange, no 2023 Convertible Notes remained outstanding. Â HoldersÂ mayÂ convert theirÂ 2029Â Convertible Notes at their option prior to the close of business on the business day immediately precedingÂ September 15, 2028Â only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending onÂ March 31, 2024 (and only during such calendar quarter), if the last reported sale price of our Common Stock for at leastÂ 20Â trading days (whether orÂ notÂ consecutive) during the period ofÂ 30Â consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal toÂ 130% of the applicable conversion price on each applicable trading day; (2) during theÂ fiveÂ consecutive business day period after anyÂ tenÂ consecutive trading day period (the â€œconvertible note measurement periodâ€) in which the trading priceÂ perÂ $1,000Â principal amount of notes for each trading day of the convertible note measurement period was less thanÂ 98% of the product of the last reported sale price of our Common Stock and the applicable conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events specified in the indenture governing theÂ 2029Â Convertible Notes. On or afterÂ September 15, 2028Â until the close of business on the business day immediately preceding the maturity date, holdersÂ mayÂ convert their notes at any time, regardless of the foregoing conditions. Upon conversion of a note, we will pay or deliver, as the caseÂ mayÂ be, cash, shares of our Common Stock or a combination of cash and shares of our Common Stock, at our election. Â The conversion rate is initially equal toÂ 869.5652Â shares of Common Stock perÂ $1,000Â principal amount of notes (equivalent to an initial conversion price of approximately $1.15Â per share of Common Stock). The conversion rate for theÂ 2029Â Convertible Notes is subject to adjustment upon the occurrence of certain events but willÂ notÂ be adjusted for any accrued and unpaid interest. Â On March 8, 2023, ModeX, the Company (with respect to certain sections), and Merck entered into the Merck AgreementÂ pursuant to which Merck obtained a license to certain patent rights and know-how in connection with the development of ModeXâ€™s preclinical nanoparticle vaccine candidate targeting the Epstein -Barr Virus. Â 62 Table of Contents Â ModeX and Merck have established a strategic collaboration with a detailed research plan to guide the development of such a vaccine or related product. This plan includes the creation of a joint steering committee and the potential use of third-party contract development and manufacturing organization carry out such activities unless otherwise agreed. Merck will reimburse ModeX for development costs incurred as part of this research plan. To date, we have incurred $24.5 million of development costs related to the Epstein -Barr Virus, for which Merck has provided reimbursement in full. Â As of September 30, 2024, the total commitments under our lines of credit with financial institutions in Chile and Spain were $30.0 million, of which $11.7 million was drawn as of September 30, 2024. On September 30, 2024, the weighted average interest rate on these lines of credit was approximately 5.4%. These lines of credit are short-term and are used primarily as a source of working capital. The highest aggregate principal balance at any time outstanding during theÂ nine months ended September 30, 2024 was $23.6 million. We intend to continue to draw under these lines of credit as needed. There is no assurance that these lines of credit or other funding sources will be available to us on acceptable terms, or at all, in the future. Â Separately, on September 16, 2024, BioReference fully repaid its obligations and terminated theÂ Credit Agreement as amended and restated. BioReference paid approximately $9.7 million to settle its obligations, incurring no prepayment premium or penalty. Â In connection with our agreements with Merck, Pfizer, VFMCRP, Nicoya and CAMP4, we are eligible to receive various milestone payments and royalty considerations. Under the terms of the Merck Agreement, we received an initial payment of $50.0 million and are also eligible to receive up to an additional $872.5 million upon the achievement of certain commercial and development milestones under several indications. We are also eligible to receive tiered royalty payments ranging from high single digits to low double digits upon achievement of certain sales targets of the Product (as defined in the Merck Agreement). Under the terms of the Restated Pfizer Agreement, we have received or are eligible to receive up to an additional $275.0 million upon the achievement of certain regulatory milestones, including $90 million triggered by the FDA approval in the United States and $85 million due to the commencement of sales of NGENLA (Somatrogon) in Europe and Japan, which we received in 2022. In addition, we are eligible to receive regional, tiered gross profit sharing for both Somatrogon (hGH-CTP) and Pfizerâ€™s GenotropinÂ®. Under the terms of the VFMCRP Agreement, we are entitled to receive up to an additional $15 million in regulatory milestones and $200 million in milestone payments tied to the launch, pricing and sales of Rayaldee, including a $7 million regulatory milestone payment we recorded in the first quarter of 2023 triggered by the German price approval for Rayaldee and $3 million regulatory milestone payment we recognized in 2022 following the first sale of Rayaldee in Europe. In addition, we are eligible to receive tiered, double-digit royalty payments. Under the terms of the Nicoya Agreement, we received an initial upfront payment of $5 million and are eligible to receive an aggregate of $5Â million tied to the first anniversary of the effective date of the Nicoya Agreement, of which we have received $2.5 million. Furthermore, we received the additional $2.5 million upon Nicoyaâ€™s submission of the investigational new drug application to the Center for Drug Evaluation of China in March 2023. We are also eligible to receive up to an additional aggregate amount of $115 million upon the achievement of certain development, regulatory and sales-based milestones by Nicoya for the Nicoya Product in the Nicoya Territory. We are also eligible to receive tiered, double digit royalty payments at rates in the low double digits on net product sales within the Nicoya Territory and in the Nicoya Field. Under the terms of the CAMP4 Agreement, we received an initial upfront payment of $1.5 million. Â We believe that the cash, cash equivalents and restricted cash on hand at September 30, 2024, which includes the amounts received from the sale of the 2044 Notes and the BioReference Transaction, are sufficient to meet our anticipated cash requirements for operations and debt service beyond the next 12 months. We based this estimate on assumptions that may prove to be wrong or are subject to change, and we may be required to use our available cash resources sooner than we currently expect. If we acquire additional assets or companies, accelerate our product development programs or initiate additional clinical trials, we will need additional funds. Our future cash requirements, and the timing of those requirements, will depend on a number of factors, includingÂ the approval and success of our products and products in development, particularly our long acting Somatrogon (hGH-CTP) for which we have received approval in over 50 markets, including the United States, Europe, Japan, Australia and Canada, the commercial success of Rayaldee, BioReferenceâ€™s financial performance, possible acquisitions and dispositions, the continued progress of research and development of our product candidates, the timing and outcome of clinical trials and regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims and other intellectual property rights, the status of competitive products, the availability of financing, our success in developing markets for our product candidates and results of government investigations, payor claims, existing legal proceedings (including the ITA litigation) and those that may arise in the future. We have historically not generated sustained positive cash flow and if we are not able to secure additional funding when needed, we may have to delay, reduce the scope of, or eliminate one or more of our clinical trials or research and development programs or possible acquisitions or reduce our marketing or sales efforts or cease operations. Â 63 Table of Contents Â The following table provides information as of September 30, 2024, with respect to the amounts and timing of our known contractual obligation payments due by period. Â Contractual obligations Â Remaining three months ending Â Â Â

reports that it files or submits under the Exchange Act is accumulated and communicated to the companyâ€™s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on managementâ€™s evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2024. Â Changes to the Companyâ€™s Internal Control Over Financial Reporting Â There have been no changes to the Companyâ€™s internal control over financial reporting that occurred during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, the Companyâ€™s internal control over financial reporting. Â 66 Table of Contents Â Â PART II. OTHER INFORMATION Â ItemÂ 1. Legal Proceedings Â We are, from time to time, party to various legal proceedings arising out of our business. During the reporting period covered by this Quarterly Report on Form 10-Q, there have been no material changes to the description of legal proceedings set forth in our Annual Report on Form 10-K for the year ended December 31, 2023, or previously reported on Quarterly Reports on Form 10-Q. Â ItemÂ 1A. Risk Factors Â There have been no material changes to our risk factors as previously disclosed in our Form 10-K. Â Â Â ItemÂ 2. Unregistered Sales of Equity Securities and Use of Proceeds Â The following table presents our share repurchase activity for the quarter ended SeptemberÂ 30, 2024 [(dollars in thousands, except per share amounts)] Â Period Â Total Number of Shares Purchased Â Â Average Price Paid per Share Â Â Total number of Shares Purchased as Part of Publicly Announced Plans or Programs Â Â Maximum Dollar Value that May Yet be Purchased Under the Plans or Programs Â July 1, 2024 to July 31, 2024 Â Â â€” Â Â $ - Â Â Â â€” Â Â Â â€” Â August 1, 2024 to August 31, 2024 Â Â 7,121,936 Â Â Â 1.58 Â Â Â 7,121,936 Â Â Â 92,878,064 Â September 1, 2024 to September 30, 2024 Â Â 7,771,090 Â Â Â 1.61 Â Â Â 7,771,090 Â Â Â 85,106,974 Â Total Â Â 14,893,026 Â Â $ 1.60 Â Â Â 14,893,026 Â Â Â 85,106,974 Â Â Â 1. All of the above repurchases were made on the open market at prevailing market rates plus related expenses under our stock repurchase program, which authorizes the repurchase of up to $100 million of our common stock. We publicly announced this program on July 18, 2024. Â Â ItemÂ 3. Defaults Upon Senior Securities Â None. Â 67 Table of Contents Â ItemÂ 4. Mine Safety Disclosures Â Not Applicable. Â Â ItemÂ 5. Other Information Â During the quarter ended September 30, 2024, none of our officers or directors adopted or terminated any contract, instruction or written plan for the purchase or sale of securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any â€œnon-Rule 10b5-1 trading arrangementâ€, as defined in Item 408 of Regulation S-K.Â Â Â ItemÂ 6. Exhibits Â Exhibit 10.1+ Note Purchase Agreement dated July 17, 2024 by and among the Company, certain purchasers party thereto, OPKO Biologics Limited, Eirgen Pharma Ltd. and HCR Injection SPV, LLC as agent, filed with the Companyâ€™s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024, and incorporated herein by reference. Exhibit 10.2 Form of Note, dated July 17, 2024, filed with the Companyâ€™s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024, and incorporated herein by reference. ExhibitÂ 31.1* Certification by Phillip Frost, Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 ofÂ the Sarbanes-Oxley Act of 2002 for the quarterly period ended September 30, 2024. ExhibitÂ 31.2* Certification by Adam Logal, Chief Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended September 30, 2024. ExhibitÂ 32.1* Certification by Phillip Frost, Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended September 30, 2024. ExhibitÂ 32.2* Certification by Adam Logal, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for the quarterly period ended September 30, 2024. Exhibit 101.INS Inline XBRL Instance Document Exhibit 101.SCH Inline XBRL Taxonomy Extension Schema Document Exhibit 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document Exhibit 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document Exhibit 101.LAB inline XBRL Taxonomy Extension Label Linkbase Document Exhibit 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document Exhibit 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) Â * Furnished herewith. + Pursuant to Item 601(b)(10)(iv) of Regulation S-K, portions of this exhibit have been omitted because the Company customarily and actually treats the omitted portions as private or confidential, and such portions are not material. The Company will supplementally provide a copy of an unredacted copy of this exhibit to the U.S. Securities and Exchange Commission or its staff upon request. Â Â 68 Table of Contents Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Date: November 7, 2024 Â OPKO Health, Inc. Â Â Â Â Â /s/Â Adam Logal Â Â Adam Logal Â Â Senior Vice President and Chief Financial Â Â Officer Â Â 69 EX-31.1 2 ex_716426.htm EXHIBIT 31.1 ex_716426.htm Exhibit 31.1 CERTIFICATIONS Â I, Phillip Frost, certify that: Â Â (1) I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.; Â Â (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â (4) The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â c. Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â d. Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â Â (5) The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 7, 2024 /s/ Phillip Frost, M.D. Â Phillip Frost, M.D. Â Chief Executive Officer Â Â Â Â EX-31.2 3 ex_716427.htm EXHIBIT 31.2 ex_716427.htm Exhibit 31.2 CERTIFICATIONS Â I, Adam Logal, certify that: Â Â (1) I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.; Â Â (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â Â (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â Â (4) The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â c. Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â Â d. Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â Â (5) The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â Â b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 7, 2024 /s/ Adam Logal Â Adam Logal Â Senior Vice President and Chief Financial Officer Â Â EX-32.1 4 ex_716428.htm EXHIBIT 32.1 ex_716428.htm Exhibit 32.1 Â Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) Â Pursuant to 18 U.S.C. Section 1350, as adopted pursuant Section 906 of the Sarbanes-Oxley Act of 2002, I, Phillip Frost, Chief Executive Officer of OPKO Health, Inc. (the â€œCompanyâ€), hereby certify that: Â The Quarterly Report on Form 10-Q for the quarterly period endedÂ September 30, 2024 (the â€œForm 10-Qâ€) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: November 7, 2024 /s/ Phillip Frost, M.D. Â Phillip Frost, M.D. Â Chief Executive Officer Â Â Â EX-32.2 5 ex_716429.htm EXHIBIT 32.2 ex_716429.htm Exhibit 32.2 Â Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Â (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) Â Pursuant to 18 U.S.C. Section 1350, as adopted pursuant Section 906 of the Sarbanes-Oxley Act of 2002, I, Adam Logal, Chief Financial Officer of OPKO Health, Inc. (the â€œCompanyâ€), hereby certify that: Â The Quarterly Report on Form 10-Q for the quarterly period endedÂ September 30, 2024 (the â€œForm 10-Qâ€) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: November 7, 2024 /s/ Adam Logal Â Adam Logal Â Senior Vice President and Chief Financial Officer Â Â Â EX-101.SCH 6 opk-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Business and Organization link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Foreign Exchange Rates link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Earnings (Loss) Per Share link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Composition of Certain Financial Statement Captions link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Investments link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Debt link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Accumulated Other Comprehensive Loss link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Derivative Contracts link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 13 - Revenue Recognition link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 14 - Strategic Alliances link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 15 - Segments link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 16 - Leases link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 4 - Earnings (Loss) Per Share (Tables) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 5 - Composition of Certain Financial Statement Captions (Tables) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 6 - Investments (Tables) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 7 - Debt (Tables) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 8 - Accumulated Other Comprehensive Loss (Tables) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 9 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 10 - Derivative Contracts (Tables) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 13 - Revenue Recognition (Tables) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 15 - Segments (Tables) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 16 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 1 - Business and Organization (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 2 - Foreign Exchange Rates (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Reconciliation of Cash (Details) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 4 - Earnings (Loss) Per Share (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 4 - Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 5 - Composition of Certain Financial Statement Captions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 5 - Composition of Certain Financial Statement Captions - Schedule of Financial Statement Information (Details) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 5 - Composition of Certain Financial Statement Captions - Schedule of Goodwill (Details) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note 6 - Investments (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 6 - Investments - Schedule of Investments (Details) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note 6 - Investments - Gains and Losses on Equity Securities (Details) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note 7 - Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note 7 - Debt - Schedule of Debt (Details) link:calculationLink link:definitionLink link:presentationLink 995495 - Disclosure - Note 7 - Debt - Schedule of Long-term Debt (Details) link:calculationLink link:definitionLink link:presentationLink 995496 - Disclosure - Note 7 - Debt - Schedule of Long-term Debt (Details) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 995497 - Disclosure - Note 7 - Debt - Schedule of Line of Credit Facilities (Details) link:calculationLink link:definitionLink link:presentationLink 995498 - Disclosure - Note 7 - Debt - Schedule of Debt Instruments (Details) link:calculationLink link:definitionLink link:presentationLink 995499 - Disclosure - Note 8 - Accumulated Other Comprehensive Loss - Changed in Accumulated Other Comprehensive Loss (Details) link:calculationLink link:definitionLink link:presentationLink 995500 - Disclosure - Note 9 - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 995501 - Disclosure - Note 9 - Fair Value Measurements - Carrying Value and Estimated Fair Value of Notes (Details) link:calculationLink link:definitionLink link:presentationLink 995502 - Disclosure - Note 9 - Fair Value Measurements - Reconciliation of Level 3 Instruments (Details) link:calculationLink link:definitionLink link:presentationLink 995503 - Disclosure - Note 10 - Derivative Contracts - Summary of Fair Values and Presentation of Derivatives

Financial Instruments (Details) link:calculationLink link:definitionLink link:presentationLink 995504 - Disclosure - Note 10 - Derivative Contracts - Summary of Gains and Losses Recorded (Details) link:calculationLink link:definitionLink link:presentationLink 995505 - Disclosure - Note 11 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995506 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995507 - Disclosure - Note 13 - Revenue Recognition (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995508 - Disclosure - Note 13 - Revenue Recognition - Composition of Revenue From Services (Details) link:calculationLink link:definitionLink link:presentationLink 995509 - Disclosure - Note 13 - Revenue Recognition - Analysis of Product Sales Allowances and Accruals (Details) link:calculationLink link:definitionLink link:presentationLink 995510 - Disclosure - Note 14 - Strategic Alliances (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995511 - Disclosure - Note 15 - Segments (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995512 - Disclosure - Note 15 - Segments - Operations by Segment (Details) link:calculationLink link:definitionLink link:presentationLink 995513 - Disclosure - Note 15 - Segments - Assets by Segment (Details) link:calculationLink link:definitionLink link:presentationLink 995514 - Disclosure - Note 16 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995515 - Disclosure - Note 16 - Leases - Lease Balances (Details) link:calculationLink link:definitionLink link:presentationLink 995516 - Disclosure - Note 16 - Leases - Undiscounted Future Minimum Lease Payments (Details) link:calculationLink link:definitionLink link:presentationLink 995517 - Disclosure - Note 16 - Leases - Supplemental Cash Flow Information (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 opk-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 opk-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 opk-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual us-gaap_DerivativeGainLossOnDerivativeNet Derivative gain (loss) Significant Accounting Policies Note 3 - Summary of Significant Accounting Policies Note 4 - Earnings (Loss) Per Share Note 5 - Composition of Certain Financial Statement Captions Note 6 - Investments Note 7 - Debt Note 8 - Accumulated Other Comprehensive Loss Note 9 - Fair Value Measurements Note 10 - Derivative Contracts us-gaap_LongTermLineOfCredit Long-Term Line of Credit, Noncurrent Note 13 - Revenue Recognition Note 15 - Segments Note 16 - Leases Note 3 - Summary of Significant Accounting Policies - Reconciliation of Cash (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 4 - Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details) Note 5 - Composition of Certain Financial Statement Captions - Schedule of Financial Statement Information (Details) Note 5 - Composition of Certain Financial Statement Captions - Schedule of Goodwill (Details) Note 6 - Investments - Schedule of Investments (Details) Note 6 - Investments - Gains and Losses on Equity Securities (Details) Note 7 - Debt - Schedule of Debt (Details) Note 7 - Debt - Schedule of Long-term Debt (Details) Note 7 - Debt - Schedule of Long-term Debt (Details) (Parentheticals) Note 7 - Debt - Schedule of Line of Credit Facilities (Details) Note 7 - Debt - Schedule of Debt Instruments (Details) Note 8 - Accumulated Other Comprehensive Loss - Changed in Accumulated Other Comprehensive Loss (Details) Note 9 - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details) Note 9 - Fair Value Measurements - Carrying Value and Estimated Fair Value of Notes (Details) Note 9 - Fair Value Measurements - Reconciliation of Level 3 Instruments (Details) us-gaap_LitigationSettlementAmountAwardedToOtherParty Litigation Settlement, Amount Awarded to Other Party Note 10 - Derivative Contracts - Summary of Fair Values and Presentation of Derivatives Financial Instruments (Details) Note 10 - Derivative Contracts - Summary of Gains and Losses Recorded (Details) Note 13 - Revenue Recognition - Composition of Revenue From Services (Details) Note 13 - Revenue Recognition - Analysis of Product Sales Allowances and Accruals (Details) Change in foreign currency translation and other comprehensive income (loss) us-gaap_DerivativeNumberOfInstrumentsHeld Derivative, Number of Instruments Held Note 15 - Segments - Operations by Segment (Details) Note 15 - Segments - Assets by Segment (Details) Note 16 - Leases - Lease Balances (Details) Note 16 - Leases - Undiscounted Future Minimum Lease Payments (Details) Note 16 - Leases - Supplemental Cash Flow Information (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Current portion of notes payable Current portion of notes payable Other comprehensive income (loss), net of tax: Current portion of lines of credit and notes payable Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Current portion of convertible notes Taxes payable Accrued expenses Accrued Liabilities, Current Accrued interest Accounts payable Employee benefits and severance us-gaap_OtherAccruedLiabilitiesCurrent Other us-gaap_PolicyTextBlockAbstract Accounting Policies Commissions Professional fees Unusual or Infrequent Items, or Both, Disclosure [Text Block] Royalties Current liabilities: Supplemental Balance Sheet Disclosures [Text Block] Product [Member] us-gaap_Assets Assets Total assets Other Currency [Member] Escrow receivable Escrow Deposit us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Less: accumulated amortization us-gaap_FiniteLivedIntangibleAssetsNet Finite-Lived Intangible Assets, Net Intangible assets, net Finite lived intangible assets, gross Settled Litigation [Member] us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Indefinite-Lived Intangible Assets (Excluding Goodwill) Litigation Status [Axis] Litigation Status [Domain] Commitments and Contingencies Disclosure [Text Block] Goodwill Goodwill Goodwill us-gaap_ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest us-gaap_DerivativeAssets Common stock options/warrants Embedded Derivative Financial Instruments [Member] Derivative Instrument [Axis] Derivative Contract [Domain] Equity securities with no readily determinable fair value Bridge Loan [Member] us-gaap_EquitySecuritiesFvNi Equity securities Convertible Debt [Member] Loss from investments in investees Income (Loss) from Equity Method Investments Losses from investments in investees Letter of Credit [Member] Equity method investments us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income (loss) before income taxes and investment losses Line of Credit [Member] us-gaap_IncomeTaxExpenseBenefit Income tax provision Consolidation, Variable Interest Entity, Policy [Policy Text Block] Variable Interest Entity, Not Primary Beneficiary [Member] us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Gain on sale of assets Fair value changes of derivative instruments, net us-gaap_GainLossOnInvestments Loss from investment in investees us-gaap_OperatingExpenses Operating Expenses Total costs and expenses Restricted cash, long-term All Currencies [Domain] Restricted cash, current Cash and cash equivalents us-gaap_GainLossOnRepurchaseOfDebtInstrument Gain (Loss) on Repurchase of Debt Instrument Amendment Flag City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Less: Net gains and losses realized during the period on equity securities Document Period End Date Entity File Number Entity Emerging Growth Company us-gaap_WriteOffOfDeferredDebtIssuanceCost Deferred Debt Issuance Cost, Writeoff Document Type Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] Service [Member] us-gaap_AreaOfRealEstateProperty Area of Real Estate Property (Acre) Entity Filer Category us-gaap_InvestmentOwnedBalanceShares Investment Owned, Balance, Shares (in shares) Entity Current Reporting Status us-gaap_AccountsReceivableNet Accounts Receivable, after Allowance for Credit Loss us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage Statement of Comprehensive Income [Abstract] Entity Tax Identification Number Entity Central Index Key Entity Registrant Name Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] Entity Address, Address Line One Amortization of intangible assets Amortization of Intangible Assets ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code SUPPLEMENTAL INFORMATION: Entity Address, State or Province Concentration Risk Type [Axis] ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Concentration Risk Type [Domain] Material Terms of Trading Arrangement [Text Block] Entity Common Stock, Shares Outstanding Revenue Benchmark [Member] Accounts Receivable [Member] Revenue from Contract with Customer Benchmark [Member] Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Local Phone Number us-gaap_TableTextBlock Notes Tables us-gaap_GainLossOnDispositionOfAssets1 Realized loss (gain) on disposal of fixed assets and sales of equity securities The 2025 Convertible Notes [Member] The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities. The 2029 Convertible Notes [Member] The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities. Selling, general and administrative us-gaap_ProvisionForDoubtfulAccounts Accounts Receivable, Credit Loss Expense (Reversal) The 2029 Convertible 144A Notes [Member] Information pertaining to the debt. The 2029 Convertible Affiliate Notes [Member] Information pertaining to the debt. us-gaap_DebtInstrumentIssuedPrincipal Debt Instrument, Issued, Principal opk_GainLossOnConversionOfDebt Loss on conversion convertible senior notes Amount of gain or loss on conversion of debt. Scenario, Event of Default [Member] Pertains to the event of default. opk_DebtInstrumentOwnershipInterest Debt Instrument, Ownership Interest Pertains to ownership interest in the aggregate principal amount. Related Party Transaction [Axis] Related Party Transaction [Domain] Research and development Proceeds from the exercise of common stock options The net cash inflow or outflow resulting from exercise of stock options and warrants. us-gaap_InterestExpense Interest Expense Derivative Instruments, Gain (Loss) [Table Text Block] Amortization of debt issuance cost Issuance of 3.75% 2029 Convertible Notes Cash inflow from convertible debt. us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Derivative Instruments and Hedging Activities Disclosure [Text Block] Issuance of 3.75% 2029 convertible notes, embedded conversion option Pertains to proceeds from embedded derivative instrument. opk_RecognitionOfDebtDiscount Issuance of 3.75% 2029 convertible notes, discount Pertains to debt discount. Government Contract, BARDA [Member] Represents government contract, BARDA. Labcorp [Member] Represents Labcorp. Select Assets of BioReference [Member] Represents select assets of BioReference. Gross to net provision Represents the amount of net provision costs gross included in accrued liabilities. opk_AdjustmentsToAdditionalPaidInCapitalRepurchaseOfConvertibleDebt Repurchase of 2029 Convertible Notes Amount of decrease in additional paid in capital (APIC) resulting from repurchase of convertible debt. Fair Value Measurement, Policy [Policy Text Block] The 2029 Convertible Notes 1 [Member] Represents the 2029 Convertible Notes. opk_InvestmentOwnedSharesSold Investment Owned, Shares Sold (in shares) The number of shares sold of investment. Segment Reporting, Policy [Policy Text Block] us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] opk_WriteoffOfUnamortizedDiscount Write-off of Unamortized Discount Amount of write-off of unamortized discount Foreign Currency Transactions and Translations Policy [Policy Text Block] Other assets SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Frost Real Estate Holdings, LLC [Member] Represents Frost Real Estate Holdings, LLC. Business Combinations Policy [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life (Year) opk_DebtConversionDebtIssuanceCosts Repurchase The amount of the debt issuance costs on original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. opk_DebtConversionUnamortizedDiscount Repurchase The amount of the unamortized discount on debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. opk_DebtConversionOriginalDebtNetAmount Repurchase The amount of the original debt, less discounts and costs, being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. us-gaap_Revenues Revenues opk_CollaborativeArrangementValueIncludingMilestones Collaborative Arrangement, Value, Including Milestones Value of collaborative arrangement including milestones. Costs and expenses: Income Tax, Policy [Policy Text Block] opk_CollaborativeArrangementSupplementForAdvanceOfDevelopment Collaborative Arrangement, Supplement for Advance of Development Amount of supplement for advance of development under the arrangement. opk_CollaborativeArrangementValue Collaborative Arrangement, Value Value of collaborative arrangement. us-gaap_LesseeOperatingLeaseTermOfContract Lessee, Operating Lease, Term of Contract (Year) us-gaap_LesseeOperatingLeaseRenewalTerm Lessee, Operating Lease, Renewal Term (Year) Research and Development Expense, Policy [Policy Text Block] Investments Cash, cash equivalents and current restricted cash Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. us-gaap_AssetsCurrent Total current assets Compensation Related Costs, Policy [Policy Text Block] Stockholders' Equity, Policy [Policy Text Block] Revenue from Contract with Customer [Policy Text Block] us-gaap_OtherAssetsCurrent Other Taxes recoverable us-gaap_OtherPrepaidExpenseCurrent Prepaid expenses Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Goodwill and Intangible Assets, Policy [Policy Text Block] Inventory, net Inventory, Net CONNECTICUT Prepaid insurance Work in-process us-gaap_InventoryValuationReserves Less: inventory reserve us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Gain (Loss), Foreign Currency Transaction, before Tax Finished products The 2044 Notes [Member] Related to the 2044 notes. Repurchase of Common Stock [Member] Related to repurchase of common stock. Reconciliation of Assets from Segment to Consolidated [Table Text Block] opk_CollaborativeArrangementDevelopmentCosts Collaborative Arrangement, Development Costs Represents the development costs related to collaborative arrangements. opk_DebtInstrumentEarlyExtinguishmentPercentOfPrincipalAmount Debt Instrument, Early Extinguishment, Percent of Principal Amount The percent of principal amount required to be paid for early extinguishment of debt instrument. opk_DebtInstrumentRepaymentFeePercent Debt Instrument, Repayment Fee, Percent The repayment fee percent for a debt instrument. Raw materials opk_AggregateTransactionPriceAllocatedToRemainingPerformanceObligationsExcludingUnexercisedContractOptionsAmount Aggregate Transaction Price Allocated to Remaining Performance Obligations, Excluding Unexercised Contract Options, Amount Represents the amount of aggregate transaction price allocated to remaining performance obligations, excluding unexercised contract options. opk_DebtInstrumentAdditionalAuthorizedAmount Debt Instrument, Additional Authorized Amount The additional authorized amount for debt instrument. Consumable supplies Software and Software Development Costs [Member] us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) Other receivables Schedule of Segment Reporting Information, by Segment [Table Text Block] Accounts receivable us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Accounts Receivable, Allowance for Credit Loss, Current Less: allowance for credit losses Furniture and Fixtures [Member] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current us-gaap_NumberOfReportableSegments Number of Reportable Segments Building and Building Improvements [Member] Revenues: Property, Plant and Equipment, Policy [Policy Text Block] Other income (expense), net Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Other income (expense), net Long-Lived Tangible Asset [Domain] Segment Reporting Disclosure [Text Block] Current assets: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Inventory, Policy [Policy Text Block] Interest income Effect of exchange rate changes on cash, cash equivalents and restricted cash us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease in cash, cash equivalents and restricted cash us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by (used in) financing activities Director [Member] Executive Officer [Member] us-gaap_OperatingIncomeLoss Operating income (loss) Operating income (loss) Other income and (expense), net: us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash provided by (used in) investing activities Services Rendered [Member] Related to services rendered. Cost of Goods and Services Sold Derivatives, Policy [Policy Text Block] us-gaap_InventoryWriteDown Inventory Write-down Investment, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] us-gaap_PaymentsForRepurchaseOfCommonStock Share repurchase Scenario [Domain] Forecast [Member] Total gross Rayaldee sales Revenues Revenue from Contract with Customer, Excluding Assessed Tax Common stock options, warrants, and restricted stock units surrendered in net exercise Monetary amount of common stock options and warrants surrendered in net exercise. Fair value of shares received related to milestone achieved from GeneDx Holdings Represents the cash flow impact of shares included in business divesture. Scenario [Axis] Consorcio Bank [Member] Represents Consorcio Bank. us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss Income Tax Examination, Estimate of Possible Loss us-gaap_RevenueRemainingPerformanceObligation Revenue, Remaining Performance Obligation, Amount Israel Tax Authority [Member] License Agreement [Member] Relating to license agreement. Ruen-Hui Biopharmaceuticals, Inc. [Member] Relating to Ruen-Hui Biopharmaceuticals, Inc. Comprehensive Income (Loss) Note [Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] us-gaap_PaymentsOfDebtIssuanceCosts Issuance of 3.75% 2029 convertible notes, debt issuance cost Milestone Payments [Member] Relating to milestone payments. Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Domain] Disaggregation of Revenue

[Table Text Block] Foreign Tax Jurisdiction [Member] Revenue from Contract with Customer [Text Block] us-gaap_RepaymentsOfConvertibleDebt Repayments of Convertible Debt Repurchase of 2029 Convertible Notes Cash and Cash Equivalents, Policy [Policy Text Block] opk_DebtInstrumentRepaymentFeeRoyaltyPercentage Debt Instrument, Repayment Fee, Royalty Percentage Represents the percentage of future royalties payments that would be considered a fee for repayment of a debt instrument. Accounting Policies [Abstract] Significant Accounting Policies [Text Block] us-gaap_OpenTaxYear Open Tax Year Basis of Accounting, Policy [Policy Text Block] us-gaap_RepaymentsOfSeniorDebt Redemption of 2025 Notes and 2033 Senior Notes Equity Method Investment, Nonconsolidated Investee [Axis] Issuance of 2044 Notes Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] Equity Method Investment, Nonconsolidated Investee [Domain] Issuance of 3.00% convertible senior notes, net (including related parties) Proceeds from Convertible Debt Tax Period [Domain] Tax Period [Axis] us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Dilutive potential shares (in shares) us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Commonwealth [Member] Represents Commonwealth. us-gaap_RepaymentsOfLinesOfCredit Repayments of Lines of Credit Repayments of lines of credit opk_LitigationSettlementInterestRate Litigation Settlement, Interest Rate Interest rate under litigation settlement. Weighted average common shares outstanding, diluted (in shares) Weighted average common shares outstanding, diluted (in shares) Borrowings on lines of credit Statement of Financial Position [Abstract] Income (loss) per share, diluted (in dollars per share) Loss per share, diluted (in dollars per share) Weighted average common shares outstanding, basic (in shares) Income (loss) per share, basic (in dollars per share) Loss per share, basic (in dollars per share) Statement of Cash Flows [Abstract] Lease Contractual Term [Domain] Statement of Stockholders' Equity [Abstract] Lease Contractual Term [Axis] us-gaap_ProceedsFromIssuanceOfDebt Proceeds from Issuance of Debt us-gaap_RepaymentsOfDebt Repayments of Debt us-gaap_FinanceLeaseInterestExpense Finance Lease, Interest Expense us-gaap_FinanceLeaseLiabilityPaymentsDue Total undiscounted future minimum lease payments, finance us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount Less: Difference between lease payments and discounted lease liabilities, finance us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths 2025, finance us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo 2026, finance Unrealized Gain (Loss) on Investments [Table Text Block] us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree 2027, finance us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour 2028, finance srt_StockRepurchaseProgramAuthorizedAmount1 Share Repurchase Program, Authorized, Amount Finance leases us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent Share Repurchase Program [Domain] Share Repurchase Program [Axis] us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear April 1, 2024 through December 31, 2024, finance Finance leases (in years) (Year) us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Cash flows from financing activities: opk_OperatingLeaseMonthlyRentExpense Operating Lease, Monthly Rent Expense Amount of monthly rent expense under operating lease. us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Office Space [Member] Represents office space. Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] us-gaap_ProceedsFromSaleOfEquityMethodInvestments Proceeds from Sale of Equity Method Investments Proceeds from LabCorp Sale us-gaap_PaymentsToAcquireInterestInJointVenture Payments to Acquire Interest in Joint Venture us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates Investments in investees Property, plant and equipment, net us-gaap_PaymentsToAcquireEquityMethodInvestments Payments to Acquire Equity Method Investments Class of Stock [Axis] Class of Stock [Domain] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] us-gaap_DerivativeNotionalAmount Derivative, Notional Amount Not Designated as Hedging Instrument [Member] Hedging Designation [Axis] Hedging Designation [Domain] Schedule of Debt [Table Text Block] Equity securities us-gaap_PaymentsToAcquireMarketableSecurities Purchase of marketable securities us-gaap_GoodwillGross Goodwill, gross us-gaap_GoodwillImpairedAccumulatedImpairmentLoss Goodwill, impairment Schedule of Goodwill [Table Text Block] Revolving Credit Facility [Member] Credit Facility [Axis] Proceeds from the sale of property, plant and equipment Credit Facility [Domain] Trade Names [Member] us-gaap_PaymentsToAcquireProductiveAssets Capital expenditures Licensing Agreements [Member] Other Intangible Assets [Member] us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants Warrants (in shares) Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets, Major Class Name [Domain] us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Stock options (in shares) us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities Notes (in shares) Non-cash financing: Noncompete Agreements [Member] Income taxes paid, net of refunds Unrealized net losses recognized during the period on equity securities still held at the reporting date Developed Technology Rights [Member] Net gains and losses recognized during the period on equity securities Technology-Based Intangible Assets [Member] In Process Research and Development [Member] Net income (loss), basic Customer Relationships [Member] Investment [Text Block] Investment [Table Text Block] us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Net income (loss), diluted us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Add: Loss on buy back of 2029 Convertible Notes Add: Interest on Notes Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Net loss Net income (loss) Restricted Stock [Member] Goodwill, foreign exchange effect Proceeds from sale of equity securities Proceeds from Sale of Equity Securities, FV-NI Long-Term Debt, Type [Axis] Long-Term Debt, Type [Domain] us-gaap_EquityMethodInvestmentOwnershipPercentage Equity Method Investment, Ownership Percentage Cash flows from investing activities: Income (loss) per share: Earnings Per Share [Text Block] us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction Intersegment Eliminations [Member] us-gaap_LongTermDebtPercentageBearingVariableInterestRate Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate Related Party Transactions Disclosure [Text Block] CHILE Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable us-gaap_DebtInstrumentRedemptionPricePercentage Debt Instrument, Redemption Price, Percentage Debt Instrument, Redemption, Period One [Member] Debt Instrument, Redemption, Period Two [Member] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] us-gaap_DebtInstrumentTerm Debt Instrument, Term (Year) SPAIN us-gaap_DebtInstrumentSinkingFundPayment Debt Instrument, Sinking Fund Payment Issuance of 3.75% 2029 convertible notes, total us-gaap_DebtInstrumentConvertibleThresholdTradingDays Debt Instrument, Convertible, Threshold Trading Days us-gaap_InterestExpenseNonoperating Interest expense us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 Debt Instrument, Convertible, Threshold Consecutive Trading Days us-gaap_DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price (in dollars per share) us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger us-gaap_DebtInstrumentConvertibleConversionRatio1 Debt Instrument, Convertible, Conversion Ratio opk_DebtInstrumentConvertibleConversionPremiumPerShare Debt Instrument, Convertible, Conversion Premium, Per Share (in dollars per share) The per share amount of conversion premium for convertible debt instrument. Included in results of operations opk_DebtInstrumentConvertibleConversionPremiumPercent Debt Instrument, Convertible, Conversion Premium, Percent The percent conversion premium of convertible debt instrument. us-gaap_ComprehensiveIncomeNetOfTax Comprehensive income (loss) IRELAND us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Net cash (used in) provided by operating activities ISRAEL Accrued expenses and other liabilities us-gaap_CommonStockSharesOutstanding Balance (in shares) Balance (in shares) us-gaap_DebtWeightedAverageInterestRate Debt, Weighted Average Interest Rate us-gaap_IncreaseDecreaseInOtherOperatingAssets Other assets us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate Interest rate, convertible notes us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_VariableLeaseCost Variable Lease, Cost us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Other current assets and prepaid expenses Operating leases us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent us-gaap_OperatingLeaseCost Operating Lease, Cost Assets acquired by finance leases Operating lease right-of-use assets in exchange for lease obligations Operating leases (in years) (Year) us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount us-gaap_DebtInstrumentRepurchaseAmount Debt Instrument, Repurchase Amount Interim Period, Costs Not Allocable [Domain] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 Reclassification of embedded derivatives to equity Nature of Expense [Axis] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Balance at December 31, 2023 Balance at September 30, 2024 Debt Instrument [Axis] Debt Instrument, Name [Domain] SIFMA Municipal Swap Rate [Member] Additions Variable Rate [Domain] Schedule of Long-Term Debt Instruments [Table Text Block] us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable, net Equity-based compensation expense Liability Class [Axis] Fair Value by Liability Class [Domain] MEXICO Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] us-gaap_TreasuryStockCommonValue Treasury Stock - 29,800,177, and 8,655,082 shares at September 30, 2024 and December 31, 2023, respectively us-gaap_StockRepurchasedDuringPeriodShares Stock Repurchased During Period, Shares (in shares) Share repurchase (in shares) us-gaap_StockRepurchasedDuringPeriodValue Stock Repurchased During Period, Value Share repurchase Long-Term Debt [Text Block] us-gaap_IncreaseDecreaseInInventories Inventory, net 2025 Notes Corporate Joint Venture [Member] Interest rate Exercise of common stock options and warrants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares) Credit line capacity Line of Credit Facility, Maximum Borrowing Capacity Exercise of common stock options and warrants Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Domain] us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares) Secured Overnight Financing Rate (SOFR) [Member] Line of Credit Facility, Lender [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Schedule of Line of Credit Facilities [Table Text Block] Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and equity Balance, embedded conversion option us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet Balance, embedded conversion option Reported Value Measurement [Member] UNITED STATES us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability Embedded Derivative, Fair Value of Embedded Derivative Liability Accumulated deficit Accumulated other comprehensive loss Debt Disclosure [Text Block] Changes in assets and liabilities: us-gaap_NotesPayableFairValueDisclosure Notes Schedule of Cash and Cash Equivalents [Table Text Block] Operating lease liabilities Operating lease liabilities Total lease liabilities, operating us-gaap_OperatingLeaseLiability Non-cash interest Operating lease liabilities Current maturities of operating leases Accrued expenses Finance leases short-term Other long-term liabilities Finance leases long-term Operating lease assets Operating lease right-of-use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total undiscounted future minimum lease payments, operating us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: Difference between lease payments and discounted lease liabilities, operating Total lease liabilities, finance us-gaap_FinanceLeaseLiability Financing cash out flows from finance leases us-gaap_FinanceLeasePrincipalPayments Deferred income tax (benefit) provision us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2027, operating us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2028, operating Finance lease assets us-gaap_FinanceLeaseRightOfUseAsset us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2025, operating us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2026, operating us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Equity-based compensation â€“ employees and non-employees Share-Based Payment Arrangement, Noncash Expense us-gaap_DebtConversionConvertedInstrumentAmount1 Debt Conversion, Converted Instrument, Amount us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued (in shares) us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear April 1, 2024 through December 31, 2024, operating Amortization of debt discount and debt issuance costs, total us-gaap_DebtConversionOriginalDebtAmount1 Debt Conversion, Original Debt, Amount Repurchase Debt Conversion Description [Axis] Debt Conversion, Name [Domain] Amortization of debt discount us-gaap_AssetsFairValueDisclosure Total assets us-gaap_Depreciation Depreciation Lessee, Lease Liability, Maturity [Table Text Block] Tabular disclosure of undiscounted cash flows of operating and finance lease liability. opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour Thereafter, operating Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Depreciation and amortization Depreciation and amortization us-gaap_LiabilitiesFairValueDisclosure Total liabilities Schedule of Supplemental Cash Flow Information of Leases [Table Text Block] Tabular disclosure of supplemental cash information related to leases. opk_PaymentsForLeases Total Amount of cash outflow for leases. 2025 Notes (in shares) Lessee, Leases [Text Block] The entire disclosure for finance and operating leases of lessee. Includes, but is not limited to, description of lessee's finance and operating lease and maturity analysis of finance and operating lease liability. opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour Thereafter, finance Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). us-gaap_CashAndCashEquivalentsFairValueDisclosure Money market funds Accrued Expenses [Member] Represents accrued expenses. Assets and Liabilities, Lessee [Table Text Block] Tabular disclosure of lessee's assets and liabilities. Other Countries [Member] Represents other countries. Transfer of Intellectual Property and Other [Member] Represents transfer of intellectual property and other. Diagnostics [Member] Represents Diagnostics. Pharmaceutical [Member] Represents Pharmaceutical. Treasury Stock, Common, Shares (in shares) Merck Agreement [Member] Represents the Merck Agreement. Contingent consideration opk_CollaborativeArrangementDevelopmentMilestonePayment Collaborative Arrangement, Development Milestone Payment Amount of development milestone payment from collaborative arrangement. opk_NumberOfMajorCustomers Number of Major Customers The number of major customers. Common Stock - $0.01 par value, 1,250,000,000 shares authorized; 712,283,206 and 781,936,885 shares issued at September 30, 2024 and December 31, 2023, respectively Senior Notes [Member] In-process research and development Represents the capitalized costs for research and development in process. Measurement Frequency [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, authorized (in shares) LeaderMed Joint Venture [Member] Represents LeaderMed joint venture. Merck Sharp & Dohme LLC [Member] Represents Merck Sharp & Dohme LLC. Common stock, issued (in shares) opk_CollaborativeArrangementUpfrontPaymentShares Collaborative Arrangement, Upfront Payment, Shares (in shares) The number of shares issued as upfront payment for collaborative arrangement. LeaderMed [Member] Represents LeaderMed. Common stock, par value (in dollars per share) opk_CollaborativeArrangementDevelopmentMilestonePaymentShares Collaborative Arrangement, Development Milestone Payment, Shares (in shares) The number of shares for development milestone payment in collaborative arrangement. opk_CollaborativeArrangementSalesMilestonePayment Collaborative Arrangement, Sales Milestone Payment Amount of sales milestone payment in collaborative arrangement. opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale Collaborative Arrangement, Period Following First Commercial Sale (Year) Period following from first commercial sale for collaborative arrangement. CAMP4 [Member] Represents CAMP4. Non-Dravet Syndrome Products [Member] Represents non-Dravet syndrome products. Dravet Syndrome Products [Member] Represents Dravet syndrome products. Statistical Measurement [Domain] Operating cash out flows from operating leases Maximum [Member] Minimum [Member] Ownership [Domain] Product and Service [Axis] Product and Service [Domain] Statistical Measurement [Axis] Operating cash out flows from finance leases Investment, Name [Domain] Ownership [Axis] opk_IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal Net income (loss) before investment losses Amount after tax of income (loss) from continuing operations, after deduction of income tax expense (benefit), but before income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. Interest paid Investment, Name [Axis] Development and License Agreement [Member] Represents Development and License Agreement. Geographical [Axis] opk_CollaborativeAgreementDelayedPaymentReceivedCumulative Collaborative Agreement, Delayed Payment Received, Cumulative Amount of cumulative delayed payment received under collaborative agreement. Geographical [Domain] opk_CollaborativeArrangementMaximumRegulatoryMilestonePayments Collaborative Arrangement, Maximum Regulatory Milestone Payments Represents maximum regulatory milestone payments under collaborative agreement. Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] Represents Vifor Fresenius Medical Care Renal Pharma Ltd. EirGen [Member] Represents EirGen. Portion at Fair Value Measurement [Member] opk_CollaborativeAgreementDelayedPayment Collaborative Agreement, Delayed Payment Amount of delayed payment under collaborative agreement. NICOYA Macau Limited [Member] Represents NICOYA Macau Limited. Estimate of Fair Value Measurement

[Member] Pfizer Agreement [Member] Represents the Pfizer Agreement. Pfizer Inc. [Member] Represents Pfizer Inc. opk_CollaborativeAgreementsEachMilestonePayment Collaborative Agreements, Each Milestone Payment Amount of each milestone payment under collaborative agreements. Measurement Basis [Axis] opk_CollaborativeAgreementOptionSalesMilestonePayments Collaborative Agreement, Option, Sales Milestone Payments Amount of sales milestone payment of option in collaborative arrangement. Fair Value, Inputs, Level 3 [Member] Germany Price Approval by Local Sick Fund Association [Member] Represent the Germany price approval by the local sick fund association. First Marketing Approval of Rayaldee in Europe [Member] Represents the first marketing approval of Rayaldee in Europe. Currency [Axis] Fair Value Hierarchy and NAV [Domain] Customer [Axis] Customer [Domain] Government Payers [Member] Represents government payers. Fair Value, Inputs, Level 1 [Member] Healthcare Insurers [Member] Represents Healthcare insurers. Fair Value, Inputs, Level 2 [Member] Rayaldee [Member] Represent Rayaldee. opk_AccruedExpensePayorOverpaymentReimbursementLiability Accrued Expense, Payor Overpayment Reimbursement, Liability Amount of liability related to reimbursements for payor overpayments. Fair Value Hierarchy and NAV [Axis] Sales Returns [Member] Represents sales returns. Governmental [Member] Represents governmental. ModeX Therapeutics, Inc [Member] Information by business combination or series of individually immaterial business combinations. Schedule of Product Sales Allowances and Accruals [Table Text Block] Tabular disclosure of product sales allowances and accruals. Client Payers [Member] Represents client payers. opk_ChangesInFairValueGainLossInEquitySecuritiesFvniAndDerivativeInstruments Change in fair value of equity securities and derivative instruments Amount of unrealized gain (loss) on investment in equity securities and derivative instruments measured at fair value with change in fair value recognized in net income. Chargebacks, Discounts, Rebates and Fees [Member] Represents Chargebacks, discounts, rebates and fees. Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales opk_ProvisionForSalesAllowanceAsPercentOfGrossSales Percentage of gross sales for provision for sales allowance. Transition Services Agreement [Member] Represents Transition Services Agreement. Pharmsynthez [Member] Represents Pharmsynthez. GeneDx [Member] Represents GeneDx. Tax Year 2014 Through Tax Year 2020 [Member] Represents tax year 2014 through tax year 2020. Cash flows from operating activities: COCP [Member] Represents COCP. ChromaDex Corporation [Member] Represents ChromaDex Corporation. NIMS [Member] Represents NIMS. Statement [Line Items] Xenetic [Member] Represents Xenetic. Neovasc [Member] Represents Neovasc. Zebra [Member] Represents Zebra. Additional paid-in capital Accumulated Foreign Currency Adjustment Attributable to Parent [Member] BioCardia [Member] Represents BioCardia. AOCI Attributable to Parent [Member] Equity: Equity method investments - FV option Equity Method - Fair value option GeneDx Holdings [Member] Represents GeneDx Holdings. opk_OperatingLeasesMonthlyPaymentsYearFive Operating Leases, Monthly Payments, Year Five Amount of monthly payments in year five for operating lease. opk_OperatingLeasesMonthlyPaymentsYearOne Operating Leases, Monthly Payments, Year One Amount of monthly payments in first year for operating lease. Fair Value Disclosures [Text Block] Fair Value, by Balance Sheet Grouping [Table Text Block] InCellDx [Member] Represents InCellDx. Reimbursement of Travel Expenses [Member] Represents reimbursement of travel expenses. Beckman Coulter [Member] Represents Beckman Coulter. Leica Microsystems Inc. [Member] Represents Leica Microsystems Inc. Integrated DNA Technologies Inc. [Member] Represents Integrated DNA Technologies Inc. us-gaap_Liabilities Liabilities Total liabilities Investment, Net [Member] Represents Investments, net. Common Stock Options/ Warrants [Member] Represents Common Stock options/warrants. us-gaap_ContractWithCustomerLiabilityRevenueRecognized Contract with Customer, Liability, Revenue Recognized Other current assets and prepaid expenses Prepaid Expense and Other Assets, Current us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod Contract with Customer, Performance Obligation Satisfied in Previous Period Counterparty Name [Axis] Counterparty Name [Domain] Consolidation Items [Domain] Deferred tax liabilities us-gaap_ContractWithCustomerLiability Contract with Customer, Liability us-gaap_DerivativeLiabilities Forward contracts Consolidation Items [Axis] us-gaap_InterestPayableCurrentAndNoncurrent Interest Payable Equity method investments, underlying value us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued us-gaap_EquityMethodInvestmentQuotedMarketValue Equity Method Investment, Quoted Market Value Consolidated Entities [Axis] Consolidated Entities [Domain] Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member] Disposal Group Classification [Axis] Disposal Group Classification [Domain] us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent Other Condensed Balance Sheet [Table Text Block] Retained Earnings [Member] opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets Represents the amount of goodwill and intangible assets acquired as part of a business combination. us-gaap_TreasuryStockAcquiredAverageCostPerShare Shares Acquired, Average Cost Per Share (in dollars per share) Treasury Stock, Common [Member] Additional Paid-in Capital [Member] Common Stock [Member] Equity Components [Axis] Equity Component [Domain] Medicare and Medicaid [Member] Relating to medicare and medicaid. Long-term debt us-gaap_LongTermDebt Long-Term Debt Total Balance, total Balance, total Individual Patients [Member] Relating to individual patients. The 2025 Notes [Member] Represents the 2025 notes. Other Noncurrent Liabilities [Member] us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Conversion of the 2025 Notes into Common Stock [Member] Represents the conversion of the 2025 notes into common stock. Line of credit us-gaap_ConvertibleDebt Convertible Debt Vehicles [Member] Balance, debt issuance cost us-gaap_DeferredFinanceCostsNet Balance, debt issuance cost The 2023 Convertible Notes [Member] Represents the 2023 Convertible Notes. Machinery and Equipment [Member] Self-Pay [Member] Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Domain] Balance, discount Balance, discount us-gaap_DebtInstrumentUnamortizedDiscount Health Care Organization, Revenue Sources [Axis] Document Quarterly Report Health Care Organization, Revenue Sources [Domain] Entity Incorporation, State or Country Code us-gaap_DebtInstrumentCarryingAmount Balance Balance Document Transition Report Entity Interactive Data Current Inventory received but not invoiced Amount of inventory not yet billed included in accrued liabilities. Project Registration [Member] Relating to project registration. Clinical trials Represents the amount of clinical trial costs included in accrued liabilities. Commitments and contingencies Represents the amount of commitments and contingencies included in current accrued commitments. Security Exchange Name BARDA Agreement [Member] Relating to BARDA Agreement. Title of 12(b) Security OPKO Health Europe [Member] Relating to OPKO Health Europe. OPKO Chile [Member] Relating to OPKO Chile. Transition Therapeutics [Member] Relating to Transition Therapeutics. OPKO Mexico [Member] Relating to OPKO Mexico. CURNA [Member] Relating to CURNA. Goodwill, acquired (disposed of) Represents the amount of goodwill acquired (disposed of) during the period. OPKO Biologics [Member] Relating to OPKO Biologics. FineTech [Member] Relating to FineTech. opk_BusinessAcquisitionOutstandingSharesHeldPercentage Business Acquisition, Outstanding Shares Held, Percentage Represents the percentage of outstanding shares held for business acquisition. VBI Vaccines Inc. [Member] Relating to VBI Vaccines. us-gaap_ValuationAllowancesAndReservesBalance Balance at beginning Balance at end OPKO Diagnostics [Member] Relating to OPKO diagnostics. Provision related to current period sales BioReference [Member] Relating to BioReference. us-gaap_ValuationAllowancesAndReservesDeductions Credits or payments made Warrants and options Represents the carrying value of equity instruments held as part of equity investments. Series A-2 Preferred Stock [Member] Relating to Series A-2 Preferred Stock. Collaborative Arrangement and Arrangement Other than Collaborative [Axis] opk_EquityMethodInvestmentVariableInterestEntity Variable interest entity, equity method Amount of variable interest entities included equity method investments. Eloxx Pharmaceuticals, Inc. [Member] Relating to Eloxx Pharmaceuticals, Inc. opk_MinorityInterestSharesIssued Minority Interest, Shares Issued (in shares) Represents the amount of minority interest shares acquired. Collaborative Arrangement Disclosure [Text Block] HealthSnap, Inc. [Member] Relating to HealthSnap, Inc. us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners Subsidiary, Ownership Percentage, Noncontrolling Owner The 2033 Senior Notes [Member] Relating to the 2033 Senior Notes. Variable interest entity, equity method This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity for a variable interest entities. Subsegments [Axis] Subsegments [Domain] Credit Agreement [Member] Relating to a credit agreement. Segments [Axis] BICE Bank [Member] Relating to BICE Bank. Segments [Domain] Bank of Chile [Member] Relating to Bank of Chile. Santander Bank [Member] Relating to Santander Bank. Scotiabank [Member] Relating to Scotiabank. Line Of Credit And Notes And Loans Payable Current Member Relating to current line of credit and notes and loans payable . Convertible Notes [Member] Relating to Convertible Notes. Itau Bank [Member] Relating to Itau Bank. J P Morgan Chase [Member] Relating to J P Morgan Chase. Banco De Sabadell [Member] Relating to Banco De Sabadell. Notes Payable And Other Long Term Liabilities [Member] Relating to notes payable and other long term liabilities. Santander Bank 2 [Member] Relating to Santander Bank 2. Estado Bank [Member] Relating to Estado Bank. us-gaap_PurchaseObligation Purchase Obligation Security Bank [Member] Relating to Security Bank. Internacional Bank [Member] Relating to Internacional Bank. BCI Bank [Member] Relating to BCI Bank. Shipping and Handling Costs [Policy Text Block] Disclosure of the company's policy regarding shipping and handling costs. Chilean and Spanish Lines of Credit [Member] Relating to Chilean and Spanish Lines of Credit. Statement [Table] us-gaap_MinorityInterestOwnershipPercentageByParent Subsidiary, Ownership Percentage, Parent Notes and Other Debt [Member] Relating to notes and other debt. us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Disposal Group, Including Discontinued Operation, Consideration Income Statement [Abstract] Other comprehensive loss Disposal Group Name [Axis] Disposal Group Name [Domain] us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity Reclassification of embedded derivative to equity Change in fair value of embedded derivative, total Change in fair value of embedded derivative Embedded Derivative, Gain (Loss) on Embedded Derivative, Net us-gaap_LiabilitiesNoncurrent Total long-term liabilities Other long-term liabilities, principally contract liabilities, contingent consideration and lines of credit Other long-term liabilities Other Liabilities, Noncurrent us-gaap_DerivativeFairValueOfDerivativeNet Derivative financial instruments Employee severance Currency Concentration Risk [Member] Represents currency concentration risk. Foreign currency measurement Amount of increase (decrease) in foreign currency measurement. Foreign Exchange Forward [Member] us-gaap_StockholdersEquity Total shareholdersâ€™ equity Balance at December 31, 2023 Balance at September 30, 2024 us-gaap_ContractWithCustomerLiabilityNoncurrent Contract liabilities Mortgages and other debts payable Long term portion of notes payable Operating Segments [Member] Derivative Financial Instruments, Liabilities [Member] Senior secured notes Long term portion of convertible notes EX-101.PRE 10 opk-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Document Information [Line Items] Â Â Entity Central Index Key 0000944809 Â Entity Registrant Name OPKO HEALTH, INC. Â Amendment Flag false Â Current Fiscal Year End Date --12-31 Â Document Fiscal Period Focus Q3 Â Document Fiscal Year Focus 2024 Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-33528 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 75-2402409 Â Entity Address, Address Line One 4400 Biscayne Blvd. Â Entity Address, City or Town Miami Â Entity Address, State or Province FL Â Entity Address, Postal Zip Code 33137 Â City Area Code 305 Â Local Phone Number 575-4100 Â Title of 12(b) Security Common Stock, par value $0.01 per share Â Trading Symbol OPK Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 682,483,029 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1:

http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash, cash equivalents and current restricted cash $ 406,400 $ 95,881 Accounts receivable, net 106,579 123,379 Inventory, net 59,408 65,697 Other current assets and prepaid expenses 57,249 24,519 Total current assets 629,636 309,476 Property, plant and equipment, net 72,271 75,429 Intangible assets, net 641,396 740,283 In-process research and development 195,000 195,000 Goodwill 535,868 598,260 Investments 100,609 16,082 Operating lease right-of-use assets 62,812 68,088 Other assets 18,511 9,080 Total assets 2,256,103 2,011,698 Current liabilities: Â Â Accounts payable 62,721 69,677 Accrued expenses 122,806 90,086 Current maturities of operating leases 12,741 12,996 Current portion of convertible notes 170 0 Current portion of lines of credit and notes payable 13,222 27,293 Total current liabilities 211,660 200,052 Operating lease liabilities 52,057 54,140 Long term portion of convertible notes 178,695 214,325 Senior secured notes 245,358 0 Deferred tax liabilities 128,412 126,773 Other long-term liabilities, principally contract liabilities, contingent consideration and lines of credit 36,504 27,189 Total long-term liabilities 641,026 422,427 Total liabilities 852,686 622,479 Equity: Â Â Common Stock - $0.01 par value, 1,250,000,000 shares authorized; 712,283,206 and 781,936,885 shares issued at September 30, 2024 and December 31, 2023, respectively 7,124 7,820 Treasury Stock - 29,800,177, and 8,655,082 shares at September 30, 2024 and December 31, 2023, respectively (1,791) (1,791) Additional paid-in capital 3,516,735 3,433,006 Accumulated other comprehensive loss (39,614) (38,030) Accumulated deficit (2,079,037) (2,011,786) Total shareholdersâ€™ equity 1,403,417 1,389,219 Total liabilities and equity $ 2,256,103 $ 2,011,698 X - DefinitionRepresents the capitalized costs for research and development in process. + ReferencesNo definition available. + Details Name: opk_CapitalizedResearchAndDevelopmentInProcess Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesNo definition available. + Details Name: opk_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsCurrent Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6:

http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleLongTermNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleNotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_LoansPayableToBankCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_SeniorLongTermNotes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit

Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Common stock, par value (in dollars per share) $ 0.01 $ 0.01 Common stock, authorized (in shares) 1,250,000,000 1,250,000,000 Common stock, issued (in shares) 712,283,206 781,936,885 Treasury Stock, Common, Shares (in shares) 29,800,177 8,655,082 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues: Â Â Â Â Revenues $ 173,632 $ 178,595 $ 529,504 $ 681,591 Costs and expenses: Â Â Â Â Selling, general and administrative 98,203 72,240 237,191 227,676 Research and development 28,770 19,435 74,789 70,199 Contingent consideration 0 (1,125) 0 (1,023) Amortization of intangible assets 20,433 21,534 62,290 64,543 Gain on sale of assets (121,493) 0 (121,493) 0 Total costs and expenses 159,416 243,002 648,430 769,566 Operating income (loss) 14,216 (64,407) (118,926) (87,975) Other income and (expense), net: Â Â Â Â Interest income 2,928 970 4,132 3,077 Interest expense (17,359) (3,384) (33,225) (10,053) Fair value changes of derivative instruments, net (1) 88 (26,161) (829) Other income (expense), net 48,636 (11,645) 128,834 (16,045) Other income (expense), net 34,204 (13,971) 73,580 (23,850) Income (loss) before income taxes and investment losses 48,420 (78,378) (45,346) (111,825) Income tax provision (23,527) (6,075) (21,898) (10,456) Net income (loss) before investment losses 24,893 (84,453) (67,244) (122,281) Loss from investments in investees (3) (20) (7) (99) Net income (loss) $ 24,890 $ (84,473) $ (67,251) $ (122,380) Income (loss) per share: Â Â Â Â Income (loss) per share, basic (in dollars per share) $ 0.04 $ (0.11) $ (0.1) $ (0.16) Income (loss) per share, diluted (in dollars per share) $ 0.03 $ (0.11) $ (0.1) $ (0.16) Weighted average common shares outstanding, basic (in shares) 694,622,466 751,525,007 699,675,944 751,716,692 Weighted average common shares outstanding, diluted (in shares) 998,363,636 751,525,007 699,675,944 751,716,692 Service [Member] Â Â Â Â Revenues: Â Â Â Â Revenues $ 121,271 $ 131,679 $ 377,557 $ 391,100 Costs and expenses: Â Â Â Â Cost of Goods and Services Sold 108,847 106,375 325,798 333,460 Product [Member] Â Â Â Â Revenues: Â Â Â Â Revenues 39,143 40,670 117,675 124,553 Costs and expenses: Â Â Â Â Cost of Goods and Services Sold 24,656 24,543 69,855 74,711 Transfer of Intellectual Property and Other [Member] Â Â Â Â Revenues: Â Â Â Â Revenues $ 13,218 $ 6,246 $ 34,272 $ 165,938 X - DefinitionAmount after tax of income (loss) from continuing operations, after deduction of income tax expense (benefit), but before income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + ReferencesNo definition available. + Details Name: opk_IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482090/360-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5 + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting

Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Net loss $ 24,890 $ (84,473) $ (67,251) $ (122,380) Other comprehensive income (loss), net of tax: Â Â Â Â Change in foreign currency translation and other comprehensive income (loss) 7,038 (9,554) (1,585) (3,173) Comprehensive income (loss) $ 31,928 $ (94,027) $ (68,836) $ (125,553) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Equity (Unaudited) - USD ($) $ in Thousands The 2025 Convertible Notes [Member] Common Stock [Member] The 2025 Convertible Notes [Member] Treasury Stock, Common [Member] The 2025 Convertible Notes [Member] Additional Paid-in Capital [Member] The 2025 Convertible Notes [Member] AOCI Attributable to Parent [Member] The 2025 Convertible Notes [Member] Retained Earnings [Member] The 2025 Convertible Notes [Member] The 2029 Convertible Notes 1 [Member] Common Stock [Member] The 2029 Convertible Notes 1 [Member] Treasury Stock, Common [Member] The 2029 Convertible Notes 1 [Member] Additional Paid-in Capital [Member] The 2029 Convertible Notes 1 [Member] AOCI Attributable to Parent [Member] The 2029 Convertible Notes 1 [Member] Retained Earnings [Member] The 2029 Convertible Notes 1 [Member] Common Stock [Member] Treasury Stock, Common [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Total Balance (in shares) at Dec. 31, 2022 Â Â Â

Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net loss $ (67,251) $ (122,380) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation and amortization 74,137 79,315 Non-cash interest 12,753 2,057 Amortization of debt issuance cost 1,328 908 Losses from investments in investees 7 99 Equity-based compensation â€“ employees and non-employees 7,983 8,746 Realized loss (gain) on disposal of fixed assets and sales of equity securities (9,489) 1,444 Change in fair value of equity securities and derivative instruments (94,626) 14,406 Loss on conversion convertible senior notes 725 0 Contingent consideration 0 (1,023) Deferred income tax (benefit) provision 7,695 7,307 Gain on sale of assets (121,493) 0 Changes in assets and liabilities: Â Â Accounts receivable, net 15,680 8,741 Inventory, net 6,452 4,082 Other current assets and prepaid expenses (8,395) 10,220 Other assets 564 (2,666) Accounts payable (6,527) 191 Foreign currency measurement (3,575) 24 Accrued expenses and other liabilities 44,952 (1,374) Net cash (used in) provided by operating activities (139,080) 10,097 Cash flows from investing activities: Â Â Investments in investees 0 (5,000) Proceeds from sale of equity securities 46,731 364 Purchase of marketable securities (1,454) 0 Proceeds from the sale of property, plant and equipment 169 1,109 Capital expenditures (19,597) (13,253) Proceeds from LabCorp Sale 210,378 0 Net cash provided by (used in) investing activities 236,227 (16,780) Cash flows from financing activities: Â Â Issuance of 3.00% convertible senior notes, net (including related parties) 230,000 0 Issuance of 2044 Notes 250,000 0 Issuance of 3.75% 2029 convertible notes, debt issuance cost (13,385) 0 Share repurchase (73,759) 0 Proceeds from the exercise of common stock options (208) (273) Repurchase of 2029 Convertible Notes (4,881) 0 Borrowings on lines of credit 448,459 515,318 Repayments of lines of credit (465,301) (519,597) Redemption of 2025 Notes and

2033 Senior Notes (146,287) (3,000) Net cash provided by (used in) financing activities 224,638 (7,552) Effect of exchange rate changes on cash, cash equivalents and restricted cash 2,399 (335) Net decrease in cash, cash equivalents and restricted cash 324,184 (14,570) Cash, cash equivalents and restricted cash at beginning of period 95,881 153,191 Cash, cash equivalents and restricted cash at end of period 420,065 138,621 SUPPLEMENTAL INFORMATION: Â Â Interest paid 12,982 10,748 Income taxes paid, net of refunds 3,801 (823) Assets acquired by finance leases 0 713 Operating lease right-of-use assets in exchange for lease obligations 0 5,966 Non-cash financing: Â Â Common stock options, warrants, and restricted stock units surrendered in net exercise 208 301 Fair value of shares received related to milestone achieved from GeneDx Holdings $ 0 $ 6,689 X - DefinitionAmount of unrealized gain (loss) on investment in equity securities and derivative instruments measured at fair value with change in fair value recognized in net income. + ReferencesNo definition available. + Details Name: opk_ChangesInFairValueGainLossInEquitySecuritiesFvniAndDerivativeInstruments Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMonetary amount of common stock options and warrants surrendered in net exercise. + ReferencesNo definition available. + Details Name: opk_CommonStockOptionsAndWarrantsNetExercised Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain or loss on conversion of debt. + ReferencesNo definition available. + Details Name: opk_GainLossOnConversionOfDebt Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in foreign currency measurement. + ReferencesNo definition available. + Details Name: opk_IncreaseDecreaseInForeignCurrencyMeasurement Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net cash inflow or outflow resulting from exercise of stock options and warrants. + ReferencesNo definition available. + Details Name: opk_ProceedsFromRepurchaseOfStockOptionsAndWarrantsExercised Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the cash flow impact of shares included in business divesture. + ReferencesNo definition available. + Details Name: opk_SharesIncludedInBusinessDivestureCashFlowImpact Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5 + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -

Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionInterest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_PaidInKindInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinesses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details Name: us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment Namespace Prefix:

us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfSeniorDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Business and Organization 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] NOTE 1 BUSINESS AND ORGANIZATION Â

OPKOÂ Health,Â Inc.,Â aÂ DelawareÂ corporationÂ (â€œOPKOâ€,Â the â€œCompanyâ€, â€œweâ€, â€œusâ€,Â or â€œourâ€)Â is a diversified healthcare company that seeks to establish industry leading positions in large and rapidly growing medical markets. Our pharmaceutical business features Rayaldee, a U.S. Food and Drug Administration (â€œFDAâ€) approved treatment for secondary hyperparathyroidism (â€œSHPTâ€) in adults with stage 3 or 4 chronic kidney disease (â€œCKDâ€) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. We have partnered with Pfizer Inc. (â€œPfizerâ€) for the development and commercialization of Somatrogon (hGH-CTP). Regulatory approvals for Somatrogon (hGH-CTP) for the treatment of growth hormone deficiency in children and adolescents have been secured in more than 50 markets, including the United States, European Union (â€œEUâ€) Member States, Japan, Canada, and Australia, where it is marketed under the brand name NGENLAÂ®. Through our 2022 acquisition of ModeX Therapeutics, Inc. (â€œModeXâ€), we haveÂ expanded our pharmaceutical pipeline with early-stage immune therapies targeting cancer and infectious diseases. Â Our diagnostics business, BioReference Health, LLC (â€œBioReferenceâ€), is a highly specialized laboratory in the United States, with a sales and marketing team focused on growth and new product integration, including the 4KscoreÂ® prostate cancer test. BioReferenceÂ® offers a broad spectrum of diagnostic testing services for oncology, urology (4Kscore), and corrections nationwide, setting new standards with our industry-leading turnaround times. BioReference also provides comprehensive clinical and womenâ€™s health testing in New York and New Jersey. Our test offerings are backed by a team of board-certified medical professionals and driven by the latest healthcare guidelines and standards- marketed directly to physicians, geneticists, hospitals, clinics, correctional facilities, and other healthcare providers. On September 16, 2024 we consummated the sale of certain assets of BioReference to Laboratory Corporation of America Holdings ("Labcorp"), as described below. Â The Company maintains established, revenue-generating pharmaceutical platforms in Spain, Ireland, Chile, and Mexico, contributing to positive cash flow and facilitating market entry for our development pipeline. In addition to these platforms, we operate a global pharmaceutical development and commercial supply company, a global supply chain operation, and manufacture specialty active pharmaceutical ingredients (API) in Israel through our subsidiary, FineTech. Â Our management team possesses extensive industry experience in development, regulatory affairs, and commercialization. Their industry relationships support the identification and pursuit of commercial opportunities. Research and development activities are primarily conducted in facilities located in Weston, Massachusetts, Waterford, Ireland, Kiryat Gat, Israel, and Barcelona, Spain. Â On March 27, 2024, the Company and BioReference entered into a definitive agreement with Labcorp (the â€œLabcorp Asset Purchase Agreementâ€), pursuant to which Labcorp acquired select assets ofÂ BioReference (the â€œBioReference Transactionâ€). The BioReference Transaction closed on September 16, 2024, and upon closing,Â Labcorp paid to the Company aggregate consideration of $237.5 million in cash, which is subject to certain adjustments as set forth in the Labcorp Asset Purchase Agreement.Â These assets were part of our diagnostics segment and include BioReference's laboratory testing businesses focused on clinical diagnostics, reproductive health, and women's health across the United States, excluding BioReference's New York and New Jersey operations.Â Â Pursuant to the Labcorp Asset Purchase Agreement, a total of approximately $23.7 million was withheld at closing and deposited by Labcorp into an escrow account with an escrow account to satisfy potential indemnity claims. The escrow will be released to the Company on the twelve-month anniversary of the closing date, subject to anyÂ outstanding or liquidated indemnity claims. The Company recorded the escrow within other current assets on the Condensed Consolidated Balance Sheet. Â We recognized a gain of $121.5 million from the BioReference Transaction for the three and nine months ended September 30, 2024. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Foreign Exchange Rates 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Unusual or Infrequent Items, or Both, Disclosure [Text Block] NOTE 2 FOREIGN EXCHANGE RATES Â Foreign Currency Exchange Rates Â Approximately 22.3% of our revenue for the nine months ended September 30, 2024, was denominated in currencies other than the U.S. Dollar (USD). This compares to 30.7% for the same period in 2023. Our financial statements are reported in USD; therefore, fluctuations in exchange rates affect the translation of foreign-denominated revenue and expenses. During theÂ nine months ended September 30, 2024 and the year ended December 31, 2023, our most significant currency exchange rate exposures were to the Euro and the Chilean Peso. Gross accumulated currency translation adjustments, recorded as a separate component of shareholdersâ€™ equity, totaled $36.2 million and $34.6 million at September 30, 2024 and December 31, 2023, respectively. Â We are subject to foreign currency transaction risk due to fluctuations in exchange rates between the time a transaction is initiated and settled. To mitigate this risk, we use foreign currency forward contracts. These contracts fix an exchange rate, allowing us to offset potential losses (or gains) caused by exchange rate changes at the settlement date. As of September 30, 2024, we held no open foreign exchange forward contracts related to inventory purchases on letters of credit. As of December 31, 2023, we held 52 open foreign exchange forward contracts related to inventory purchases on letters of credit. These contracts matured monthly through January 2024 with a total notional value of approximately $2.9 million. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/220-20/tableOfContent + Details Name: us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Significant Accounting Policies [Text Block] Â NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Basis of presentation. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. (â€œGAAPâ€) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Companyâ€™s results of operations, financial position and cash flows have been made. The results of operations and cash flows for the nine months ended September 30, 2024 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2024 or any other future periods. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. Â Principles of consolidation. The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and our wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Â Use of estimates. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates. Â Cash, cash equivalents and restricted cash. Cash, cash equivalents and restricted cash include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase. We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities. Â The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheet to the sum ofÂ such amountsÂ in the Condensed Consolidated Statements of Cash Flows: Â Â Â September 30, 2024 Â Â December 31, 2023 Â Cash and cash equivalents Â $400,079Â Â $95,881Â Restricted cash, current Â Â 6,321Â Â Â Â â€”Â Restricted cash, long-term Â Â 13,665Â Â Â Â â€”Â Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows Â $420,065Â Â $95,881Â Â The Company classifies cash deposits related to letters of credit securing insurance and lease obligations as restricted cash, which is included in other assets, non-current, within the Consolidated Balance Sheet. Â Inventories. Inventories are valued at the lower of cost and net realizable value. Cost is determined by the first-in, first-out method. We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value. Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which are used in our testing laboratories. Â Inventory obsolescence expense for the three and nine months ended September 30, 2024 wasÂ $0.6 million and $1.6 million, respectively. Inventory obsolescence expense for the three and nine months ended September 30, 2023 wasÂ $2.6 million and $4.0 million, respectively. Â Goodwill and intangible assets. Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting. Refer to Note 5. Goodwill, in-process research and development (â€œIPR&Dâ€) and other intangible assets acquired in business combinations, licensing and other transactions was $1.4 billion and $1.5 billion at September 30, 2024 and December 31, 2023, respectively. Â Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. At acquisition, we generally determine the fair value of intangible assets, including IPR&D, using the â€œincome method.â€ Â Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable. Â Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment. We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing. Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value. Goodwill was $535.9 million and $598.3 million, respectively, at September 30, 2024 and December 31, 2023. Â Net intangible assets other than goodwill were $836.4 million on each of September 30, 2024, and December 31, 2023, with IPR&D accounting for $195.0 million on each date. Considering the high risk nature of research and development and the industryâ€™s success rate of bringing developmental compounds to market, IPR&D impairment charges may occur in future periods. Estimating the fair value of IPR&D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment. Â Upon regulatory approval, IPR&D assets are classified as finite-lived intangible assets. These assets are then amortized on a straight-line basis over their estimated useful lives. If a project is abandoned, the associated IPR&D costs are immediately expensed. We also regularly assess finite-lived intangible assets for impairment. This assessment involves comparing the carrying amount of an asset, which is its cost minus accumulated amortization, to its estimated future undiscounted cash flows. If the carrying amount exceeds the estimated future cash flows, an impairment charge is recognized to reflect the difference between the asset's carrying amount and its fair value.Â Â While we believe our estimates and assumptions used in impairment testing (including for goodwill and IPR&D) are reasonable and reflect those used by market participants, there is a potential risk of material impairment charges. Based on the current financial performance of our diagnostics segment and our Ireland reporting unit (which includes Eirgen and Rayaldee), we could be subject to such charges if their future performance deviates from our current estimates and assumptions. For reference, the combined goodwill of these units totaled $304.9 million and $367.3 million at September 30, 2024 and December 31, 2023, respectively. Â We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years. We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up. Amortization expense wasÂ $20.4 million andÂ $62.3 million for the three and nine months ended September 30, 2024, respectively. Amortization expense wasÂ $21.5 million andÂ $64.5 million for the three and nine months ended September 30, 2023, respectively. Â Fair value measurements. The carrying amounts of our cash, cash equivalents, restricted cash, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments. Investments that are considered equity securities as of September 30, 2024 and December 31, 2023 are predominately carried at fair value. Our debt under the Credit Agreement (as defined below) approximates fair value due to the variable rate of interest applicable to such debt. Â In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts. Accordingly,

the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange. Refer to Note 9. Â Contingent consideration. Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense. Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability. Contingent considerationÂ mayÂ change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value whichÂ mayÂ have a material impact on our results from operations and financial position. Â Derivative financial instruments. We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges. For a derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At September 30, 2024 and December 31, 2023, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges. Accordingly, we recognized all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations. Refer to Note 10. In addition, we have determined the value of the embedded derivative liability within the 2029 Convertible 144A Notes (as defined in Note 7) and recorded it at fair value. Refer to Note 7. The changes in the fair value of the embedded derivatives are recognized in the fair value changes of derivatives instruments, net. Refer to Note 9. Â Property, plant and equipment. Property, plant and equipment are recorded at cost or fair value if acquired in a business combination. Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases. The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, and automobiles - 3-5 years. Expenditures for repairs and maintenance are charged to expense as incurred. Assets held under finance leases are included within Property, plant and equipment, net in our Condensed Consolidated Balance Sheets and are amortized over the shorter of their useful lives or the expected term of their related leases. Depreciation expense was $3.7 million andÂ $11.9 million for the three and nine months ended September 30, 2024, respectively. Depreciation expense wasÂ $4.8 million andÂ $14.8 million for the three and nine months ended September 30, 2023, respectively. Â Impairment of long-lived assets. Long-lived assets, such as property and equipment and assets held for sale, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. Â Income taxes. Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment. Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold. Â We operate in various countries and tax jurisdictions globally.Â For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results.Â For the nine months ended September 30, 2024, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit. Â Included in Other long-term liabilities is an accrual of $9.9 million related to uncertain tax positions involving income recognition. In connection with an examination of foreign tax returns for the 2015 through 2021 tax years, a foreign taxing authority has issued an income tax assessment of approximately $246Â million (including interest). We are appealing this assessment, as we believe, other than for uncertain tax positions for which we have reserved, the issues are without technical merit. We intend to exhaust all judicial remedies necessary to resolve the matter as necessary,Â which could be a lengthy process. There can be no assurance that this matter will be resolved in our favor, and an adverse outcome, or any future tax examinations involving similar assertions, could have a material adverse effect on our financial condition, results of operations and cash flows. Â Revenue recognition. We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (â€œTopic 606â€). The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. Â We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. For a complete discussion of accounting for Revenues from services, Revenues from products and Revenue from transfer of intellectual property and other, refer to Note 13. Â Concentration of credit risk and allowance for credit losses. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions. Â While we have receivables due from federal and state governmental agencies, such receivables are not a credit risk because federal and state governments fund the related healthcare programs. Payment is primarily dependent upon submitting appropriate documentation. On September 30, 2024 and December 31, 2023, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were 6.5% and 6.7%, respectively, of our consolidated Accounts receivable, net. The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk. At September 30, 2024 and December 31, 2023, receivables due from patients represented approximately 2.2% and 2.0%, respectively, of our consolidated Accounts receivable, net. Â We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customerâ€™s ability to pay. Actual results could differ from those estimates. The allowance for credit losses was $2.0 million on each ofÂ September 30, 2024 and December 31, 2023. The credit loss expense for the three and nine months ended September 30, 2024, was a reversal expense of $75.2 thousand and $67.5 thousand of expense, respectively. The credit loss expense for the three and nine months ended September 30, 2023, wasÂ $98.3 thousand and $183.4 thousand, respectively. Â As of September 30, 2024, accounts receivable included $1.6 million of revenue earned under the BARDA Contract (as defined in Note 14). As of December 31, 2023, accounts receivable included $0.6 million under this contract. Refer to Note 13, Government Contract Revenue for further information on government contracts and to Note 14, Strategic Alliances for further information on the BARDA Contract. Â Stock Repurchase Program. On July 18, 2024, the Company announced that its Board of Directors authorized the repurchase of up to $100 millionÂ shares of Common Stock. Under this program, OPKO may repurchase shares through various methods, including open market purchases, block trades, privately negotiated transactions, and accelerated share repurchases, as well as pursuant to pre-set trading plans meeting the requirements of Rule 10b5-1(c) of the Exchange Act, and otherwise in compliance with applicable laws. The timing and volume of repurchases will depend on market conditions, the Company's capital management, investment opportunities, and other factors. The program does not obligate the Company to repurchase any specific number of shares, has no set expiration date, and may be modified, suspended, or discontinued at the Company's discretion. The Company repurchased 14,893,026 shares for approximately $23.8 million during the three months ended September 30, 2024. Â Equity-based compensation. We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award. We record excess tax benefits realized from the exercise of stock options as cash flows from operations. For the three and nine months ended September 30, 2024, we recordedÂ $2.8 million and $8.0 million, respectively, of equity-based compensation expense. For the three and nine months ended September 30, 2023, we recorded $3.2 million and $8.7 million, respectively, of equity-based compensation expense. Â Research and development expenses. Research and development expenses include external and internal expenses. External expenses include clinical and nonclinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs. Research and development employee-related expenses include salaries, benefits and equity-based compensation expense. Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities. We expense these costs in the period in which they are incurred. We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract. Â Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility, and which have no alternative future use. For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining estimated useful life. Â Segment reporting. Our chief operating decision-maker (â€œCODMâ€) is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Dr. Frost reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis. We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense or income taxes. Refer to Note 15. Â Shipping and handling costs. We do not charge customers for shipping and handling costs. Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations. Â Foreign currency translation. The financial statements of certain of our foreign operations are measured using the local currency as the functional currency. The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date. The local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods. Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss). During the three and nine months ended September 30, 2024, we recorded foreign currency transaction income of $4.1 million and $0.1 million, respectively. During the three and nine months ended September 30, 2023, we recorded foreign currency transaction loss ofÂ $3.8 million and $1.9 million, respectively. Â Variable interest entities. The consolidation of a variable interest entity (â€œVIEâ€) is required when an enterprise has a controlling financial interest. A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIEâ€™s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE. Refer to Note 6. Â Investments. We have made strategic investments in development stage and emerging companies. We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees. For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations. Refer to Note 6. For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value. Refer to Note 6. Â Accounting standards yet to be adopted. Â In December 2023, the FASB issued ASU No. 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€ (â€œASU 2023-09â€), which modifies the rules on income tax disclosures to require entities to disclose (i) specific categories in the rate reconciliation, (ii) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (iii) income tax expense or benefit from continuing operations (separated by federal, state and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state, and local jurisdictions, among other changes. The guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. ASU 2023-09 should be applied on a prospective basis, but retrospective application is permitted. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures. Â In November 2023, the FASB issued ASU No 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€). ASU 2023-07 enhances disclosures for significant segment expenses for all public entities required to report segment information in accordance with ASC 280. ASC 280 requires a public entity to report for each reportable segment a measure of segment profit or loss that its CODM uses to assess segment performance and to make decisions about resource allocations. The ASU is effective for fiscal years beginning after December 15, 2024 with updates to be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures. Â Recently adopted accounting standards. Â In 2021, the Organization for Economic Co-operation and Development (â€œOECDâ€) established an inclusive framework on base erosion and profit shifting and agreed on a two-pillar solution (â€œPillar Twoâ€) to global taxation, focusing on global profit allocation and a 15% global minimum effective tax rate. On December 15, 2022, the EU member states agreed to implement the OECDâ€™s global minimum tax rate of 15%. The OECD issued Pillar Two model rules and continues to release guidance on these rules. The inclusive framework calls for tax law changes by participating countries to take effect in 2024 and 2025. Various countries have enacted or have announced plans to enact new tax laws to implement the global minimum tax. We considered the applicable tax law changes on Pillar Two implementation in the relevant countries, and there is no material impact to our tax results for the period. We anticipate further legislative activity and administrative guidance in 2024, and will continue to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in the non-US tax jurisdictions we operate in. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Earnings (Loss) Per Share 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Earnings Per Share [Text Block] NOTE 4 EARNINGS (LOSS) PER SHARE Â Basic income (loss) per share is computed by dividing our net income (loss) by the weighted average number of shares of our Common Stock outstanding during the period. Shares of Common Stock outstanding under theÂ share lendingÂ arrangement entered into in conjunction with the 2025 Notes (as defined in Note 7) have been excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends

paid on the shares lent. We terminated the share lending agreement on January 22, 2024.Â Refer to Note 7. For diluted earnings per share, the dilutive impact of stock options and warrants is determined by applying the â€œtreasury stockâ€ method. The dilutive impact of the 2029 Convertible Notes, 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes (each, as defined and discussed in Note 7) has been considered using the â€œif convertedâ€ method. For periods in which their effect would have been antidilutive, no effect is given in the dilutive computation to Common Stock issuable under outstanding options or warrants or the potentially dilutive shares issuable pursuant to the 2029 Convertible Notes, 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes. The following table sets forth the computation of basic and diluted income (loss) per share: Â Â Â For the three months ended September 30, Â Â For the nine months ended September 30, Â (In thousands, except per share data) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Numerator Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss), basic Â $24,890Â Â $(84,473)Â $(67,251)Â $(122,380) Add: Interest on 2025 Notes Â Â 1Â Â Â -Â Â Â -Â Â Â -Â Add: Interest on 2029 Convertible Notes Â Â 6,858Â Â Â -Â Â Â -Â Â Â -Â Add: Loss on buy back of 2029 Convertible Notes Â Â 32Â Â Â -Â Â Â -Â Â Â -Â Net income (loss), diluted Â $31,781Â Â $(84,473)Â $(67,251)Â $(122,380) Â Denominator Â (Shares in thousands) Â Weighted average common shares outstanding, basic Â Â 694,622,466Â Â Â 751,525,007Â Â Â 699,675,944Â Â Â 751,716,692Â Effect of dilutive securities: Â Stock options Â Â 76,922Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Warrants Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â 2025 Notes Â Â 48,295Â Â Â -Â Â Â -Â Â Â -Â 2023 Convertible Notes Â Â -Â Â Â -Â Â Â -Â Â Â -Â 2033 Senior Notes Â Â 8,489Â Â Â -Â Â Â -Â Â Â -Â 2029 Convertible Notes Â Â 303,607,464Â Dilutive potential shares Â Â 303,741,170Â Â Â -Â Â Â -Â Â Â -Â Weighted average common shares outstanding, diluted Â Â 998,363,636Â Â Â 751,525,007Â Â Â 699,675,944Â Â Â 751,716,692Â Â Loss per share, basic Â $0.04Â Â $(0.11)Â $(0.10)Â $(0.16) Loss per share, diluted Â $0.03Â Â $(0.11)Â $(0.10)Â $(0.16) Â A total of 0 and 83,074,689 potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the three months ended September 30, 2024 and 2023, respectively, because their inclusion would have been antidilutive.Â A total of 286,281,585 and 82,368,398 potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the nine months ended September 30, 2024 and 2023, respectively, because their inclusion would have been antidilutive. Â During the three months ended September 30, 2024, no options were exercised and no restricted stock units vested, resulting in the issuance of no shares of Common Stock. Â During the nine months ended September 30, 2024, no options were exercised and 549,687 restricted stock units vested, resulting in the issuance of 384,378 shares of Common Stock. Â During the three months ended September 30, 2023, 18,750 options were exercised and no restricted stock units vested, resulting in the issuance of 18,750 shares of Common Stock. Â During the nine months ended September 30, 2023, 18,750 options were exercised and 549,680 restricted stock units vested, resulting in the issuance of 405,721 shares of Common Stock. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Composition of Certain Financial Statement Captions 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Supplemental Balance Sheet Disclosures [Text Block] NOTE 5 COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS Â Â Â September 30, Â Â December 31, Â (In thousands) Â 2024 Â Â 2023 Â Accounts receivable, net: Â Â Â Â Â Â Â Â Accounts receivable Â $108,583Â Â $125,379Â Less: allowance for credit losses Â Â (2,004)Â Â (2,000) Â Â $106,579Â Â $123,379Â Inventories, net: Â Â Â Â Â Â Â Â Consumable supplies Â $16,218Â Â $25,864Â Finished products Â Â 34,206Â Â Â 35,582Â Work in-process Â Â 2,265Â Â Â 1,731Â Raw materials Â Â 10,491Â Â Â 8,981Â Less: inventory reserve Â Â (3,772)Â Â (6,461) Â Â $59,408Â Â $65,697Â Other current assets and prepaid expenses: Â Â Â Â Â Â Â Â Escrow receivable Â $23,750Â Â $â€”Â Taxes recoverable Â Â 6,767Â Â Â 4,211Â Prepaid expenses Â Â 9,572Â Â Â 6,177Â Prepaid insurance Â Â 6,302Â Â Â 3,848Â Other receivables Â Â 1,563Â Â Â 2,610Â Other Â Â 9,295Â Â Â 7,673Â Â Â $57,249Â Â $24,519Â Intangible assets, net: Â Â Â Â Â Â Â Â Customer relationships Â $258,048Â Â $315,799Â Technologies Â Â 818,971Â Â Â 831,509Â Trade names Â Â 49,759Â Â Â 49,758Â Covenants not to compete Â Â 12,917Â Â Â 12,916Â Licenses Â Â 6,311Â Â Â 6,205Â Product registrations Â Â 6,738Â Â Â 6,790Â Other Â Â 6,052Â Â Â 6,000Â Less: accumulated amortization Â Â (517,400)Â Â (488,694) Â Â $641,396Â Â $740,283Â Accrued expenses: Â Â Â Â Â Â Â Â Employee benefits and severance Â $38,474Â Â $28,952Â Clinical trials Â Â 3,725Â Â Â 7,624Â Commitments and contingencies Â Â 11,141Â Â Â 8,088Â Accrued interest Â Â 6,021Â Â Â 2,601Â Gross to net provision Â Â 6,033Â Â Â 9,420Â Inventory received but not invoiced Â Â 2,306Â Â Â 1,653Â Finance leases short-term Â Â 1,855Â Â Â 2,827Â Professional fees Â Â 4,375Â Â Â 3,470Â Taxes payable Â Â 15,334Â Â Â 1,384Â Royalties Â Â 767Â Â Â 1,544Â Commissions Â Â 1,521Â Â Â 1,822Â Other Â Â 31,254Â Â Â 20,701Â Â Â $122,806Â Â $90,086Â Other long-term liabilities: Â Â Â Â Â Â Â Â Employee severance Â $16,284Â Â $â€”Â Mortgages and other debts payable Â Â 3,529Â Â Â 7,709Â Finance leases long-term Â Â 4,689Â Â Â 7,274Â Contract liabilities Â Â 7Â Â Â 7Â Other Â Â 11,995Â Â Â 12,199Â Â Â $36,504Â Â $27,189Â Â Our intangible assets and goodwill relate principally to our completed acquisitions of OPKO Renal, OPKO Biologics, EirGen, BioReference and ModeX. We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives. The estimated useful lives by asset class are as follows: technologies - 7-17 years, customer relationships - 5-20 years, product registrations - 7-10 years, covenants not to compete - 5 years, trade names - 5-10 years, other 9-13 years. We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred. Our goodwill is not tax deductible for income tax purposes in any jurisdiction in which we operate. Â Changes in value of the intangible assets and goodwill during theÂ nine months ended September 30, 2024 and 2023 were primarily due to foreign currency fluctuations between the Euro, and the Chilean Peso against the U.S. dollar. Â The following table summarizes the changes in Goodwill by reporting unit during the nine months ended September 30, 2024. Â Â Â 2024 Â (In thousands) Â Gross goodwill at January 1, 2024 Â Â Cumulative impairment at January 1 Â Â Acquisitions, dispositions and other Â Â Foreign exchange and other Â Â Balance at September 30, 2024 Â Pharmaceuticals Â CURNA Â $4,827Â Â $(4,827)Â $â€”Â Â $â€”Â Â $â€”Â Rayaldee Â Â 84,273Â Â Â â€”Â Â Â â€”Â Â Â 925Â Â Â 85,198Â FineTech Â Â 11,698Â Â Â (11,698)Â Â â€”Â Â Â â€”Â Â Â â€”Â ModeX Â Â 80,260Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 80,260Â OPKO Biologics Â Â 139,784Â Â Â â€”Â Â Â â€”Â Â Â (0)Â Â 139,784Â OPKO Chile Â Â 3,642Â Â Â â€”Â Â Â â€”Â Â Â (81)Â Â 3,561Â OPKO Health Europe Â Â 7,276Â Â Â â€”Â Â Â â€”Â Â Â 82Â Â Â 7,358Â OPKO Mexico Â Â 100Â Â Â (100)Â Â â€”Â Â Â â€”Â Â Â â€”Â Transition Therapeutics Â Â 3,421Â Â Â (3,421)Â Â â€”Â Â Â â€”Â Â Â â€”Â Diagnostics Â BioReference Â Â 283,025Â Â Â â€”Â Â Â (63,318)Â Â â€”Â Â Â 219,707Â OPKO Diagnostics Â Â 17,977Â Â Â (17,977)Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â $636,283Â Â $(38,023)Â $(63,318)Â $926Â Â $535,868Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Investments 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Investment [Text Block] NOTE 6 INVESTMENTS Â Investments Â The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of September 30, 2024 and December 31, 2023: Â (in thousands) Â As of September 30, 2024 Â Â As of December 31, 2023 Â Investment type Â Investment Carrying Value Â Â Underlying Equity in Net Assets Â Â Investment Carrying Value Â Â Underlying Equity in Net Assets Â Equity method investments Â $(0)Â $1,782Â Â $(0)Â $2,942Â Variable interest entity, equity method Â Â 790Â Â Â â€”Â Â Â 796Â Â Â 420Â Equity method investments - FV option Â Â 92,166Â Â Â Â Â Â Â 9,786Â Â Â Â Â Â Equity securities Â Â 130Â Â Â Â Â Â Â 116Â Â Â Â Â Â Equity securities with no readily determinable fair value Â Â 7,521Â Â Â Â Â Â Â 5,382Â Â Â Â Â Â Warrants and options Â Â 2Â Â Â Â Â Â Â 2Â Â Â Â Â Â Total carrying value of investments Â $100,609Â Â Â Â Â Â $16,082Â Â Â Â Â Â Â Equity method investments Â Our equity method investments, other than in GeneDx Holdings, as describedÂ below, consist of investments in Pharmsynthez (ownership 6%), Cocrystal Pharma, Inc. (â€œCOCPâ€) (2%), Non-Invasive Monitoring Systems, Inc. (â€œNIMSâ€) (1%), BioCardia, Inc. (â€œBioCardiaâ€) (1%), Xenetic Biosciences, Inc. (â€œXeneticâ€) (3%),Â Zebra Biologics, Inc. (â€œZebraâ€) (29%), and LeaderMed Health Group Limited (â€œLeaderMedâ€) (47%). Neovasc, Inc., in which we owned a 0.5% interest, was acquired by Shockwave Medical, Inc. in April 2023. As a result, we received $363 thousand in merger consideration in exchange for our shares. The aggregate amount of assets, liabilities, and net losses of these equity method investees as of and for theÂ nine months ended September 30, 2024 were $66.1 million, $23.3 million, and $27.7 million, respectively. The aggregate amount of assets, liabilities, and net losses of our equity method investees as of and for the year ended December 31, 2023 were $85.5 million, $20.8 million, and $37.7 million, respectively. We have determined that we or our related parties have the ability to exercise significant influence over our equity method investments through our board representation or voting power. Accordingly, we account for our investment in these entities under the equity method and record our proportionate share of their losses in Loss from investments in investees in our Consolidated Statement of Operations. The aggregate value of our equity method investments based on the quoted market prices of their respective shares of common stock and the number of shares held by us as of September 30, 2024 and December 31, 2023 was $0.6 million and $0.7 million, respectively. Â Equity method investments - Fair value option Â On January 14, 2022, the Company entered into an Agreement and Plan of Merger and Reorganization (the â€œGeneDx Merger Agreementâ€) with GeneDx Holdings Corp. (f/k/a Sema4 Holdings Corp.), a Delaware corporation (â€œGeneDx Holdingsâ€), pursuant to which GeneDx Holdings acquired our former subsidiary, GeneDx LLC (formerly GeneDx, Inc. â€œGeneDxâ€), on April 28, 2022. During the third quarter of 2024, the Company sold 1,386,929 shares of GeneDx common stock at various prices per share for an aggregate of $46.7 million. As a result of the sale, the Company's total ownership in GeneDx Holdings decreased from 13.61% to 8.1% as of September 30, 2024. Â Pursuant to the GeneDx Merger Agreement, the Company designated, and GeneDx Holdings nominated for election an individual to serve on the board of directors of GeneDx Holdings.Â This individual was subsequently elected by GeneDx Holdings stockholders and has continued to serve on the board following his re-election in 2024. His term will extend until the GeneDx Holdings annual meeting of stockholders in 2027. We have a shareholder agreement with GeneDx Holdings, pursuant to which we have agreed to vote our shares of GeneDx Holdings common stock in accordance with the recommendation of GeneDx Holdings' board of directors for so long as we continue to hold at least 5% of the outstanding shares of GeneDx Holdings common stock. Other than through our position as a shareholder, we are unable to influence GeneDx Holdings' policy-making process.Â Â We account for our investment in GeneDx Holdings under the equity method fair value option and record gains and losses from changes in fair value in other income (expense), net in our Condensed Consolidated Statements of Operations. For the three and nine months ended September 30, 2024, we recognizedÂ $35.4 million andÂ $118.6 million in net income related to the change in fair value of our GeneDx Holdings investment, respectively.Â For the three and nine months ended September 30, 2023, we recognizedÂ $8.3 million andÂ $19.9 million in net loss related to the change in fair value of our GeneDx Holdings investment, respectively. As of September 30, 2024,Â the aggregate value of our GeneDx Holdings investment wasÂ $92.2 million based on the quoted market price of the GeneDx Holdings common stock. Â Investments in equity securities Â Our equity securities consist of investments in VBI Vaccines Inc.Â (0.00%), ChromaDex Corporation (â€œChromaDexâ€) (0.05%), and Eloxx Pharmaceuticals, Inc. (â€œEloxxâ€) (1%).Â During the third quarter of 2024, we recorded a $30 thousand loss from our investment in VBI Vaccines Inc. due to the company filing for bankruptcy. Our equity securities without readily determinable fair value consists of CAMP4 Therapeutics Corporation (â€œCAMP4â€) (2%) and HealthSnap, Inc. (4%). We have determined that our ownership, along with that of our related parties, does not provide us with significant influence over the operations of these investments. Accordingly, we account for our investment in these entities as equity securities, and we record changes in the fair value of these investments in Other income (expense) each reporting period when they have a readily determinable fair value. Equity securities without a readily determinable fair value are adjusted to fair value when there is an observable price change. Net gains and losses on our equity securities for theÂ nine months ended September 30, 2024 and 2023 were as follows: Â Â Â For the nine months ended September 30, Â (in thousands) Â 2024 Â Â 2023 Â Equity Securities: Â Â Â Â Â Â Â Â Net gains and losses recognized during the period on equity securities Â $43Â Â $(411) Less: Net gains and losses realized during the period on equity securities Â Â (30)Â Â â€”Â Unrealized net losses recognized during the period on equity securities still held at the reporting date Â $13Â Â $(411) Â Sales of investments Â Gains (losses) included in earnings from sales of our investments are recorded in Other income (expense), net in our Condensed Consolidated Statement of Operations. The cost of securities sold is based on the specific identification method. Â Warrants and options Â In addition to our equity method investments and equity securities, we hold options to purchase 47 thousand additional shares of BioCardia, all of which were vested as of September 30, 2024 and December 31, 2023, and warrants to purchase 0.7 million additional shares of InCellDx Inc. We recorded the changes in the fair value of the options and warrants in fair value changes of derivative instruments, net in our Condensed Consolidated Statement of Operations. We also recorded the fair value of the options and warrants in Investments, net in our Condensed Consolidated Balance Sheet. See further discussion of the Companyâ€™s options and warrants in Note 9 and Note 10. Â Investments in variable interest entities Â We have determined that we hold variable interests in LeaderMed and Zebra. We made this determination as a result of our assessment that they do not have sufficient resources to carry out their principal activities without additional financial support. Â In September 2021, we and LeaderMed, a pharmaceutical development company with operations based in Asia, formed a joint venture to develop, manufacture and commercialize two of OPKOâ€™s clinical stage, long-acting drug products in Greater China and eight other Asian territories. Under the terms of the agreements, we granted the joint venture exclusive rights to develop, manufacture and commercialize (a) OPK88003, an oxyntomodulin analog being developed for the treatment of obesity and diabetes, and (b) Factor VIIa-CTP, a novel long acting coagulation factor being developed to treat hemophilia, in exchange for 4,703 shares 47% ownership interest in the joint venture. In addition, we received an upfront payment of $1.0Â million and will be reimbursed for clinical trial material and technical support we provide the joint venture. Â In order to determine the primary beneficiary of the joint venture, we evaluated our investment and our related partiesâ€™ investment, as well as our investment combined with the related partiesâ€™ investment to identify if we had the power to direct the activities that most significantly impact the economic performance of the joint venture. Based on the capital structure, governing documents and overall business operations of the joint venture, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact the joint ventureâ€™s economic performance and do not have an obligation to fund expected losses. We did determine that we can significantly influence control of the joint venture through our board representation and voting power. Therefore, we have the ability to exercise significant influence over the joint ventureâ€™s operations and account for our investment in the joint venture under the equity method. Â We own 1,260,000 shares of Zebraâ€™s Series A-2 Preferred Stock and 900,000 shares of Zebra restricted common stock (ownership 29%) at September 30, 2024 and December 31, 2023. Zebra is a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drugs. Dr. Richard Lerner, M.D., a former member of our Board of Directors, was a founder of Zebra.Â Dr. FrostÂ serves as a member of Zebraâ€™s Board of Directors. Â In order to determine the primary beneficiary of Zebra, we evaluated our investment and our related partiesâ€™ investment, as well as our investment combined with the related partiesâ€™ investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Zebra. Based on the capital structure, governing documents and overall business operations of Zebra, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Zebraâ€™s economic performance and have no obligation to fund expected losses. We determined, however, that we can significantly influence control of Zebra through our board representation and voting power. Therefore, we have the ability to exercise significant influence over Zebraâ€™s operations and account for our investment in Zebra under the equity method. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investment. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name

Accounting Standards Codification -Topic 321 -Publisher FASB -URI https://asc.fasb.org/321/tableOfContentReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 325 -Publisher FASB -URI https://asc.fasb.org/325/tableOfContent + Details Name: us-gaap_InvestmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Debt 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Debt Disclosure [Text Block] NOTE 7 DEBT Â As of September 30, 2024 and December 31, 2023, our debt consisted of the following: Â Â Â September 30, Â Â December 31, Â (In thousands) Â 2024 Â Â 2023 Â 2029 Convertible Notes Â $ 178,645 Â Â $ â€” Â 2025 Notes Â Â 170 Â Â Â 143,250 Â 2033 Senior Notes Â Â 50 Â Â Â 50 Â 2023 Convertible Notes Â Â â€” Â Â Â 71,025 Â 2044 Notes Â Â 245,358 Â Â Â â€” Â JPMorgan Chase Bank line of credit Â Â â€” Â Â Â 12,671 Â Chilean and Spanish lines of credit Â Â 11,713 Â Â Â 12,629 Â Current portion of notes payable Â Â 1,509 Â Â Â 1,993 Â Long term portion of notes payable Â Â 3,529 Â Â Â 7,727 Â Total Â $ 440,974 Â Â $ 249,345 Â Â Â Â Â Â Â Â Â Â Balance sheet captions Â Â Â Â Â Â Â Â Â Current portion of convertible notes Â $ 170 Â Â $ â€” Â Long term portion of convertible notes Â Â 178,695 Â Â Â 214,325 Â Current portion of lines of credit and notes payable Â Â 13,222 Â Â Â 27,293 Â Long Term notes payable included in long-term liabilities Â Â 248,887 Â Â Â 7,727 Â Total Â $ 440,974 Â Â $ 249,345 Â Â 2044 Note Purchase Agreement Â On July 17, 2024, the Company completed a private offering of $250 million aggregate principal amount of senior secured notes (the â€œ2044 Notesâ€), pursuant to a note purchase agreement dated July 17, 2024 (the â€œ2044 Note Purchase Agreement), by and among the Company, certain purchasers from time to time party thereto, the Companyâ€™s wholly owned subsidiaries OPKO Biologics (â€œOBLâ€) and EirGen as guarantors (OBL and EirGen collectively, the â€œ2044 Note Guarantorsâ€), and HCR Injection SPV, LLC, as agent. Â The 2044 Notes mature on July 17, 2044 and bear interest at the 3-month Secured Overnight Financing Rate (SOFR) subject to a 4.0% per annum floor, plus 7.5% per annum. Interest is payable on the 2044 Notes on a quarterly basis determined by profit share payments received by EirGen pursuant to the profit share arrangement with Pfizer, Inc. (the â€œRoyalty Paymentsâ€) set forth in the Restated Pfizer Agreement (as defined and described in Note 14). In the event that the aggregate amount of the Royalty Payments received by EirGen during the quarter preceding any quarterly interest payment date are less than the accrued and unpaid interest payable on such date, the excess interest payable on such date shall be paid-in-kind and added to the outstanding principal amount of the 2044 Notes.Â The Company will be required to pay the noteholders a 3% exit fee in connection with any repayment in full of the 2044 Notes, whether at maturity or otherwise.Â In addition, in the event that the Company repays the 2044 Notes in full prior to the maturity date, the Company will be required to pay the noteholders a make whole payment in an amount necessary such that the noteholders shall have received aggregate payments of principal, interest and fees in respect of the 2044 Notes equal to at least 150% of the initial principal amount of the 2044 Notes, in the event that such prepayment shall occur on or prior to July 17, 2029, or 200% of the initial principal amount of the 2044 Notes, in the event that such prepayment shall occur following July 17, 2029.Â If the 2044 Notes have not been fully repaid by the maturity date, the Company may elect to either repay the unpaid balance of the principal amount in full, together with any accrued and unpaid interest thereon and the 3% exit fee, or elect to transfer 80% of all future Royalty Payments to the agent and the noteholders in satisfaction of the outstanding 2044 Notes. The Company may authorize up to an additional $50,000,000 in additional 2044 Notes to the purchasers on the same terms and conditions of the initial 2044 Notes. The 2044 Notes are secured by the Royalty Payments, and the 2044 Note Guarantors have guaranteed the obligations under the 2044 Notes by granting a security interest in certain assets of the 2044 Note Guarantors. The 2044 Note Purchase Agreement contains customary terms and covenants, including negative covenants, such as limitations on indebtedness, liens, amendments to certain material contracts and disposition of assets. Â 2029 Convertible 144A Notes Â InÂ January 2024,Â we completed a private offering of $230.0Â million aggregate principal amount of ourÂ 3.75% Convertible Senior Notes dueÂ 2029Â (theÂ â€œ2029Â Convertible 144A Notesâ€) in accordance with the terms of a note purchase agreement (theÂ â€œ144AÂ Note Purchase Agreementâ€) entered into by and between the Company and J.P. Morgan Securities LLC (the â€œInitial Purchaserâ€). Â Net proceeds from the 2029 Convertible 144A Notes issuance totaled approximately $222.0 million after deducting fees and estimated offering expenses payable by us. We allocated approximately $50.0 million of these net proceeds to repurchase shares of our Common Stock. These repurchases were from purchasers of the 2029 Convertible 144A Notes in privately negotiated transactions effected with or through the Initial Purchaser or its affiliate. The purchase price per share of the Common Stock in these transactions equaled the closing sale price of $0.9067 per share of Common Stock on January 4, 2024. Â Contemporaneously with the closing of the offering of the 2029 Convertible 144A Notes on January 9, 2024, we issued and sold approximately $71.1 million aggregate principal amount of our 3.75% Convertible Senior Notes due 2029 (the â€œ2029 Convertible Affiliate Notesâ€ and, together with the 2029 Convertible 144A Notes, the â€œ2029 Convertible Notesâ€) pursuant to the terms of a note purchase agreement entered into on January 4, 2024 (the â€œAffiliate Note Purchase Agreementâ€) by and among the Company and certain investors, Frost Gamma Investments Trust, a trust controlled by Dr. Phillip Frost, and Dr. Jane H. HsiaoÂ (collectively, the â€œAffiliate Purchasersâ€). Pursuant to the Affiliate Note Purchase Agreement, we issued and sold the 2029 Convertible Affiliate Notes to the Affiliate Purchasers in exchange for the entirety of the $55.0 million aggregate principal amount of our outstanding 2023 Convertible Notes held by the Affiliate Purchasers, together with approximately $16.1 million of accrued but unpaid interest thereon. Â On January 9th, 2024, we recorded the $125.6 million value of the embedded derivative liability within the 2029 Convertible Notes as a debt discount. To determine the fair value of this derivative, we employed the Binomial Lattice model. Key inputs and assumptions for this valuation included our common stock price, the derivative's exercise price, risk-free interest rate, volatility, annual coupon rate, and remaining contractual term. We are amortizing the debt discount as non-cash interest expense over the term of the Notes. Â From the date the Notes were issued through March 31, 2024, we observed an increase in the market price of our Common Stock which resulted in a $26.25 million increase in the estimated fair value of our embedded derivatives recorded in Fair value changes of derivative instruments, net in our Condensed Consolidated Statements of Operations. Effective April 1, 2024, the conversion option contained in the 2029 Convertible Notes met the classification of an equity component. As a result, we reclassified $151.9 million of the embedded derivative liability from debt, non-current, to additional paid-in capital section of stockholders' equity on our Condensed Consolidated Balance Sheet. Â As of September 30, 2024 the 2029 Convertible 144A Notes are currently convertible. HoldersÂ mayÂ convert theirÂ 2029Â Convertible Notes at their option prior to the close of business on the business day immediately precedingÂ September 15, 2028Â only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending onÂ March 31, 2024 (and only during such calendar quarter), if the last reported sale price of our Common Stock for at leastÂ 20Â trading days (whether orÂ notÂ consecutive) during the period ofÂ 30Â consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal toÂ 130% of the applicable conversion price on each applicable trading day; (2) during theÂ fiveÂ consecutive business day period after anyÂ tenÂ consecutive trading day period (the â€œconvertible note measurement periodâ€) in which the trading price perÂ $1,000Â principal amount of notes for each trading day of the convertible note measurement period was less thanÂ 98% of the product of the last reported sale price of our Common Stock and the applicable conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events specified in the indenture governing theÂ 2029Â Convertible Notes. On or afterÂ September 15, 2028Â until the close of business on the business day immediately preceding the maturity date, holdersÂ mayÂ convert their notes at any time, regardless of the foregoing conditions. Upon conversion of a note, we will pay or deliver, as the caseÂ mayÂ be, cash, shares of our Common Stock or a combination of cash and shares of our Common Stock, at our election. Â The conversion rate is initially equal toÂ 869.5652Â shares of Common Stock perÂ $1,000Â principal amount of notes (equivalent to an initial conversion price of approximately $1.15Â per share of Common Stock). The conversion rate for theÂ 2029Â Convertible Notes will be subject to adjustment upon the occurrence of certain events but willÂ notÂ be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date of the notes,Â in certain circumstances we will increase the conversion rate of theÂ 2029Â Convertible NotesÂ for a holder who elects to convert its notes in connection with such a corporate event. Â WeÂ mayÂ notÂ redeem the notes prior to the maturity date, andÂ noÂ sinking fund is provided for the notes. If we undergo a fundamental change, holdersÂ mayÂ require us to purchase the notes in whole or in part for cash at a fundamental change purchase price equal toÂ 100% of the principal amount of the notes to be purchased,Â plusÂ accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date. TheÂ 2029Â Convertible Notes areÂ our senior unsecured obligations andÂ rank senior in right of payment to any indebtedness that is expressly subordinated in right of payment to the notes, and equal in right of payment with all of our existing and future unsecured indebtedness that isÂ notÂ so subordinated. The notes are effectively subordinated to all of our existing and future secured indebtedness to the extent of the value of the assets securing such indebtedness and structurally subordinated to all existing and future liabilities of our subsidiaries. Â The indenture governing the notes provides for customary events of default which include (subject in certain cases to customary grace and cure periods), among others, the following: nonpayment of principal or interest; breach of covenants or other agreements in the indenture; defaults in failure to pay certain other indebtedness; judgment defaults; and certain events of bankruptcy or insolvency. Generally, if an event of default occurs and is continuing under the indenture, the trustee thereunder or the holders of at leastÂ 25%Â in aggregate principal amount of the notes then outstandingÂ mayÂ declareÂ 100%Â of the principal of and accrued and unpaid interest, if any on all then-outstanding notes to be immediately due and payable.Â In certain circumstances, weÂ may,Â for a period of time, elect to pay additional interest on the notes as the sole remedy to holders of the notes in the case of an event of default related to certain failures by us to comply with certain reporting covenants in the indenture. Â The following table sets forth information related to theÂ 2029Â Convertible Notes which is included in our Condensed Consolidated Balance Sheet as of September 30, 2024: Â (In thousands) Â 2029 convertible notes Â Â Embedded conversion option Â Â Discount Â Â Debt Issuance costs Â Â Total Â Balance at December 31, 2023 Â $â€”Â Â $â€”Â Â $â€”Â Â $â€”Â Â $â€”Â Â Issuance of 3.75% 2029 Convertible Notes Â Â 301,054Â Â Â 125,620Â Â Â (125,620)Â Â Â (8,562)Â Â Â 292,492Â Â Amortization of debt discount and debt issuance costs Â Â â€”Â Â Â â€”Â Â Â 12,585Â Â Â 1,236Â Â Â Â 13,821Â Â Change in fair value of embedded derivative Â Â â€”Â Â Â 26,250Â Â Â â€”Â Â Â â€”Â Â Â 26,250Â Â Reclassification of embedded derivative to equity Â Â â€”Â Â Â (151,870)Â Â â€”Â Â Â â€”Â Â Â (151,870) Repurchase Â Â (3,500)Â Â â€”Â Â Â 1,338Â Â Â 114Â Â Â (2,048) Balance at September 30, 2024 Â $297,554Â Â $â€”Â Â $(111,697)Â $(7,212)Â $178,645Â Â Â Â Â During the third quarter of 2024, the Company repurchasedÂ $3.5Â millionÂ in aggregate principal amount of the 2029 Convertible 144A Notes forÂ $4.8Â millionÂ in cash. Such convertible debt repurchaseÂ resulted in a gain ofÂ $32 thousand, which included unamortized discount ofÂ $1.3 million and debt issuance costs ofÂ $0.1 million. Â Â 2025 Convertible Notes Â In February 2019, we issued $200.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the â€œ2025 Notesâ€) in an underwritten public offering. The 2025 Notes bear interest at a rate of 4.50% per year, payable semiannually in arrears on FebruaryÂ 15 and AugustÂ 15 of each year. The 2025 Notes mature on FebruaryÂ 15, 2025, unless earlier repurchased, redeemed or converted. Â InÂ May 2021,Â we entered into an agreement with certain holders of theÂ 2025Â Notes pursuant to which the holders exchanged $55.4Â million in aggregate principal amount of the outstandingÂ 2025Â Notes forÂ 19,051,270Â shares of our Common Stock (the â€œExchangeâ€). Â Contemporaneously with the closing of our offering of theÂ 2029Â Convertible Notes,Â we repurchased approximately $144.4Â million aggregate principal amount of theÂ 2025Â Notes for cash, using $146.3Â million of the net proceeds from our issuance and sale of theÂ 2029Â Convertible Notes, following which only $170Â thousand aggregate principal amount of theÂ 2025Â Notes remained outstanding. Â On January 22, 2024, we terminated our share lending agreement, dated February 4, 2019, with Jefferies Capital Services, LLC (â€œShare Borrowerâ€). Through this agreement, we had lent the Share Borrower approximately 30 million shares of our Common Stock related to our 2019 issuance of the 2025 Notes. With the termination of this agreement, all remaining borrowed shares of Common Stock have been returned to us and are now held as treasury shares. Â 2023 Convertible Notes Â In February 2018, we issued a series of 5% Convertible Promissory Notes (the â€œ2023 Convertible Notesâ€) in the aggregate principal amount of $55.0 million. The original maturity of the 2023 Convertible Notes was five years following the date of issuance. Each holder of a 2023 Convertible Note originally had the option, from time to time, to convert all or any portion of the outstanding principal balance of such 2023 Convertible Note, together with accrued and unpaid interest thereon, into shares of our Common Stock at a conversion price of $5.00 per share. Â On February 10, 2023, we amended the 2023 Convertible Notes to extendÂ the maturity to January 31, 2025 and reset the conversion price to the 10 day volume weighted average price immediately preceding the date of the amended note, plus a 25% conversion premium, or $1.66 per share. Purchasers of the 2023 Convertible Notes included an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer. Â In connection with the closing of the 2029 Convertible Notes offering, the Company issued approximately $71.1 million aggregate principal amount of its 2029 Convertible Affiliate Notes in exchange for all issued and outstanding 2023 Convertible notes, following which exchange, no 2023 Convertible Notes remained outstanding. Â 2033 Senior Notes Â InÂ January 2013,Â we issued an aggregate of $175.0Â million of ourÂ 3.0% Senior Notes dueÂ 2033Â (theÂ â€œ2033Â Senior Notesâ€) in a private placement. TheÂ 2033Â Senior Notes bearÂ interest at the rate ofÂ 3.0% per year, payable semiannually onÂ February 1Â andÂ August 1Â of each year and matureÂ onÂ February 1, 2033,Â unless earlier repurchased, redeemed or converted. FromÂ 2013Â toÂ 2016,Â holders of theÂ 2033Â Senior Notes converted $143.2Â million in aggregate principal amount into Common Stock, and,Â onÂ February 1, 2019,Â approximately $28.8Â million aggregate principal amount ofÂ 2033Â Senior Notes were tendered by holders pursuant to such holdersâ€™ option to require us to repurchase theÂ 2033Â Senior Notes. During the first quarter of 2023, we paid approximately $3.0Â million to purchaseÂ 2033Â Senior Notes in accordance with the indenture governing theÂ 2033Â Senior Notes, following which $50.6Â thousandÂ 2033Â Senior Notes remained outstanding. Â JPMorgan Chase Credit Agreement Â In November 2015, BioReference and certain subsidiaries established a credit agreement with JPMorgan Chase Bank, N.A. ("CB") as lender and administrative agent (the "Credit Agreement"). As amended, the Credit Agreement provided for a $50.0 million secured revolving credit facility, including a $20.0 million sub-facility for swingline loans and a $20.0 million sub-facility for letters of credit. Â On September 16, 2024, BioReference fully repaid its obligations and terminated theÂ Credit Agreement. BioReference paid approximately $9.7 million to settle its obligations, incurring no prepayment premium or penalty. Â The Credit Agreement had been guaranteed by all of BioReferenceâ€™s domestic subsidiaries and secured by substantially all assets of BioReference and its domestic subsidiaries, as well as a non-recourse pledge by us of our equity interest in BioReference. All guarantees and security interests were released together with the termination of the Credit Agreement. Â As of December 31, 2023, $12.7 million was outstanding under the Credit Agreement. Â International Line of Credit Agreements Â The Company hasÂ line of credit agreements with twelve other financial institutions as of September 30, 2024, and December 31, 2023, in the U.S., Chile and Spain. These lines of credit are used primarily as sources of working capital for inventory purchases. Â The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit: Â (Dollars in thousands) Â Â Â Â Â Â Â Â Â Balance Outstanding Â Â Â Interest rate on borrowings at Â Â Credit line Â Â September 30, Â Â December 31, Â Lender Â September 30, 2024 Â Â capacity Â Â 2024 Â Â 2023 Â JPMorgan Chase Â Â 0.00 % Â $ â€” Â Â $ â€” Â Â $ 12,671 Â Itau Bank Â Â 5.50 % Â Â 1,900 Â Â Â 469 Â Â Â 1,264 Â Bank of Chile Â Â 6.60 % Â Â 2,500 Â Â Â 711 Â Â Â 1,728 Â BICE Bank Â Â 5.50 % Â Â 2,500 Â Â Â 2,433 Â Â Â 1,734 Â Scotiabank Â Â 5.00 % Â Â 5,500 Â Â Â 3,060 Â Â Â 981 Â Santander Bank Â Â 5.50 % Â Â 5,000 Â Â Â 1,742 Â Â Â 450 Â Security Bank Â Â 5.50 % Â Â 1,400 Â Â Â â€” Â Â Â â€” Â Estado Bank Â Â 5.50 % Â Â 4,000 Â Â Â 1,355 Â Â Â 3,303 Â BCI Bank Â Â 5.00 % Â Â 2,500 Â Â Â 346 Â Â Â 1,626 Â Internacional Bank Â Â 5.50 % Â Â 1,597 Â Â Â 1,597 Â Â Â 1,197 Â Consorcio Bank Â Â 5.00 % Â Â 2,000 Â Â Â â€” Â Â Â 346 Â Banco De Sabadell Â Â 1.75 % Â Â 558 Â Â Â â€” Â Â Â â€” Â Santander Bank Â Â 5.36 % Â Â 558 Â Â Â â€” Â Â Â â€” Â Total Â Â Â Â $ 30,013 Â Â $ 11,713 Â Â $ 25,300 Â Â At September 30, 2024 and December 31, 2023, the weighted average interest rate on our lines of credit was approximately 5.4% and 7.5%, respectively. Â At September 30, 2024 and December 31, 2023, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the 2025 Notes, the Credit Agreement and amounts outstanding under lines of credit described above) as follows: Â Â Â September 30, Â Â December 31, Â (In thousands) Â 2024 Â Â 2023 Â Current portion of notes payable Â $ 1,509 Â Â $ 1,993 Â Other long-term liabilities Â Â 3,529 Â Â Â 7,727 Â Total Â $ 5,038 Â Â $ 9,720 Â Â The notes and other debt mature at various dates ranging from 2024 through 2032, bearing variable interest rates from 0.7% up to 4.5%. The weighted average interest rate on the notes and other debt was 1.8% on September 30, 2024 and 2.9% on December 31, 2023. The notes are partially secured by our office space in Barcelona. Â X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Accumulated Other Comprehensive Loss 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Comprehensive Income (Loss) Note [Text Block] NOTE 8 ACCUMULATED OTHER COMPREHENSIVE LOSS Â For the nine months ended September 30, 2024, changes in Accumulated other comprehensive loss, net of tax, were as follows: Â Â Â Foreign Â Â Â currency Â (In thousands) Â translation Â Balance at December 31, 2023 Â $ (38,030) Other comprehensive loss Â Â (1,585) Balance at September 30, 2024 Â $ (39,615) Â X - DefinitionThe entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/220/tableOfContent + Details Name: us-gaap_ComprehensiveIncomeNoteTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Fair Value Measurements 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Fair Value Disclosures [Text Block] NOTE 9 FAIR VALUE MEASUREMENTS Â We record fair values at an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Â As of September 30, 2024, we had equity securities and an equity method fair value option (refer to Note 6), forward foreign currency exchange contracts for inventory purchases (refer to Note 10). In addition, in connection with our investment and our consulting agreement with BioCardia, we record the related BioCardia options at fair value as well as warrants from COCP.Â In addition, restricted cash collateralized by money market funds is a financial asset measured at fair value as a Level 1 financial instrument under the fair value hierarchy.Â Â Our financial assets and liabilities measured at fair value on a recurring basis are as follows: Â Â Â Fair value measurements as of September 30, 2024 Â Â Â Quoted Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â prices in Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â active Â Â Significant Â Â Â Â Â Â Â Â Â Â markets for Â Â other Â Â Significant Â Â Â Â Â Â identical Â Â observable Â Â unobservable Â Â Â Â Â Â Â assets Â Â inputs Â Â inputs Â Â Â Â Â (In thousands) Â (Level 1) Â Â (Level 2) Â Â (Level 3) Â Â Total Â Assets: Â Â Â Â Â Â Â Â Â Money market funds Â $ 354,537 Â Â $ â€” Â Â $ â€” Â Â $ 354,537 Â Equity securities Â Â 130 Â Â Â â€” Â Â Â â€” Â Â Â 130 Â Equity Method - Fair value option Â Â 92,166 Â Â Â â€” Â Â Â â€” Â Â Â 92,166 Â Common stock options Â Â â€” Â Â Â 2 Â Â Â â€” Â Â Â 2 Â Total assets Â $ 446,833 Â Â $ 2 Â Â $ â€” Â Â $ 446,835 Â Â Â Â Fair value measurements as of December 31, 2023 Â Â Â Quoted Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â prices in Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â active Â Â Significant Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â markets for Â Â other Â Â Significant Â Â Â Â Â Â identical Â Â observable Â Â unobservable Â Â Â Â Â Â Â assets Â Â inputs Â Â inputs Â Â Â Â Â (In thousands) Â (Level 1) Â Â (Level 2) Â Â (Level 3) Â Â Total Â Assets: Â Â Â Â Â Â Â Â Â Money market funds Â $ 32,404 Â Â $ â€” Â Â $ â€” Â Â $ 32,404 Â Equity securities Â Â 116 Â Â Â â€” Â Â Â â€” Â Â Â 116 Â Equity Method - fair value option Â Â 9,786 Â Â Â â€” Â Â Â â€” Â Â Â 9,786 Â Common stock options/warrants Â Â â€” Â Â Â 2 Â Â Â â€” Â Â Â 2 Â Total assets Â $ 42,306 Â Â $ 2 Â Â $ â€” Â Â $ 42,308 Â Liabilities: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Forward contracts Â Â â€” Â Â Â 29 Â Â Â â€” Â Â Â 29 Â Total liabilities Â $ â€” Â Â $ 29 Â Â $ â€” Â Â $ 29 Â Â The carrying amount and estimated fair value of our 2029 Convertible Notes and 2025 Notes, as well as the applicable fair value hierarchy tiers, are contained in the table below. Additionally, the fair value of the 2029 Convertible Notes and 2025 Notes is determined using inputs other than quoted prices in active markets that are directly observable. Â Â Â September 30, 2024 Â Â Â Carrying Â Â Total Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â (In thousands) Â Value Â Â Fair Value Â Â Level 1 Â Â Level 2 Â Â Level 3 Â 2029 Convertible Notes Â $ 178,645 Â Â $ 396,652 Â Â $ â€” Â Â $ 396,652 Â Â $ â€” Â 2025 Notes Â $ 170 Â Â $ 170 Â Â $ â€” Â Â $ 170 Â Â $ â€” Â There have been no transfers between Level 1 and Level 2 and no transfers to Level 3 of the fair value hierarchy. . Â Â The following table reconcile the beginning and ending balances of our Level 3 assets and liabilities as of September 30, 2024. Â Â Â September 30, 2024 Â Â Â Embedded conversion Â (In thousands) Â option Â Balance at December 31, 2023 Â $ â€” Â Additions Â Â 125,620 Â Change in fair value: Â Â Â Â Included in results of operations Â Â 26,250 Â Reclassification of embedded derivatives to equity Â Â (151,870) Balance at September 30, 2024 Â $ â€” Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Note 10 - Derivative Contracts 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Derivative Instruments and Hedging Activities Disclosure [Text Block] NOTE 10 DERIVATIVE CONTRACTS Â The following table summarizes the fair values and the presentation of our derivative financial instruments in the Condensed Consolidated Balance Sheets: Â Â Balance Sheet Â September 30, Â Â December 31, Â (In thousands) Component Â 2024 Â Â 2023 Â Derivative financial instruments: Â Â Â Â Â Â Â Â Common Stock options/warrants Investments, net Â $ 2 Â Â $ 2 Â Forward contracts Unrealized losses on forward contracts are recorded in Accrued expenses. Â $ â€” Â Â $ (29) Â We enter into foreign currency forward exchange contracts with respect to the risk of exposure to exchange rate differences arising from inventory purchases on letters of credit. Under these forward contracts, for any rate above or below the fixed rate, we receive or pay the difference between the spot rate and the fixed rate for the given amount at the settlement date. Â To qualify the derivative instrument as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At September 30, 2024 and December 31, 2023, our derivative financial instruments did not meet the documentation requirements to be designated as hedges. Accordingly, we recognize the changes in fair value of derivative instruments, net in our Condensed Consolidated Statement of Operations. The following table summarizes the losses and gains recorded for the three and nine months ended September 30, 2024 and 2023: Â Â Â Three months ended September 30, Â Â Nine months ended September 30, Â (In thousands) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Derivative gain (loss): Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Notes Â $ â€” Â Â $ â€” Â Â $ (26,250) Â $ â€” Â Common Stock options/warrants Â Â (1) Â Â (37) Â Â 1 Â Â Â (27) Forward contracts Â Â â€” Â Â Â 125 Â Â Â 88 Â Â Â (802) Total Â $ (1) Â $ 88 Â Â $ (26,161) Â $ (829) Â X - DefinitionThe entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815/tableOfContent + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Related Party Transactions 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Related Party Transactions Disclosure [Text Block] NOTE 11 RELATED PARTY TRANSACTIONS Â We lease office space from Frost Real Estate Holdings, LLC (â€œFrost Holdingsâ€) in Miami, Florida, where our principal executive offices are located. Effective August 1, 2024, we entered into an amendment to our lease agreement with Frost Holdings to decrease the lease space from approximately 29,500 square feet to approximately 26,328 square feet of space. The amended lease provides for payments of approximately $91 thousand per month in the first year increasing annually to $103 thousand per month in the fifth year, plus applicable sales tax. The rent is inclusive of operating expenses, property taxes and parking. Â In January 2024, in connection with the closing of the offering of the 2029 Convertible Notes, we issued and sold approximately $71.1 million aggregate principal amount of the 2029 Convertible

Affiliate Notes to the Affiliate Purchasers, in exchange for $55.0 million aggregate principal amount of the 2023 Convertible Notes, together with approximately $16.1 million accrued but unpaid interest thereon, held by such Affiliate Purchasers. See Note 7 for additional information. Â On October 12, 2023, the Company entered into an E-Commerce Distribution Agreement with NextPlat Corp (â€œNextPlatâ€), a global e-commerce provider, in which Dr. Frost owns more than a 20% interest. Under the terms of the agreement, NextPlat has agreed toÂ launch an OPKO Health-branded online storefront on the Alibaba Group Holding Limited Tmall Global e-commerce platform in China, featuring an assortment of nutraceutical and veterinary products sold and distributed by OPKO Health Europe SLU, our wholly-owned subsidiary. The Company and NextPlat amended the agreementÂ in October 2024 to extend the term of the agreement to 2026, and permit NextPlat to launch an online storefront on additional e-commerce platforms throughout Asia. Â On May 4, 2023, the Company entered into an Assignment and Assumption Agreement (the â€œAssignment Agreementâ€) with Ruen-Hui Biopharmaceuticals, Inc., a Taiwanese entity (â€œRuen-Huiâ€) in which Dr. Hsiao owns more than a 10% interest. Ruen-Hui assumed the Company's obligations under an exclusive license agreement with Academia Sinica in exchange for an upfront payment of $150,000, a number of potential milestone payments up to $1 million, commercial milestones ranging from low to double digit millions, and royalty payments.Â Ruen Hui is alsoÂ responsible for any outstanding payment obligations under such license agreement, including patent maintenance costs, and any payments due to Academia Sinica. Â On April 29, 2022, upon consummation of our sale ofÂ GeneDx, the Company entered into a Transition Services Agreement (the â€œTransition Services Agreementâ€) with GeneDx, pursuant to which the Company agreed to provide, at cost, certain customary support services in respect of GeneDxâ€™s business through August 31, 2023, including human resources, information technology support, and finance and accounting. As of September 30, 2024, the Company had incurred aggregate expenses of $1.2 million for services rendered under the Transition Services Agreement. For the three and nine months ended September 30, 2024, the company did not incur expenses for services rendered under the Transaction Services Agreement. As of September 30, 2024, the Company does not have a receivable balance payable to the Company by GeneDx in accordance with the terms of the Transition Services Agreement. Â The Company owns approximately 6% of Pharmsynthez and Pharmsynthez is the largest and controlling shareholder of Xenetic, in which the Company has a 3% ownership interest. Adam Logal, our Senior Vice President and Chief Financial Officer, is a director of Xenetic. Â We hold investments in Zebra (ownership 29%),Â ChromaDexÂ (0.05%), COCP (2%), NIMS (1%), Eloxx (1%), BioCardia (1%) and LeaderMedÂ (47%). Neovasc, Inc., in which we owned a 0.5% interest,Â was acquired by Shockwave Medical, Inc. in April 2023, and during the third quarter of 2023, we received $363 thousand in merger consideration in exchange for our shares. These investments were considered related party transactions as a result of our executive managementâ€™s ownership interests and/or board representation in these entities. We also hold an investment in GeneDx Holdings (Nasdaq: WGS) representing a 8.1% ownership interest as a result of our sale of GeneDx, Inc. and subsequent participation in an underwritten offering by GeneDx Holdings. Richard Pfenniger who sits on our Board also sits on the GeneDx Board. See further discussion of our investments in Note 6. Â Dr. Elias Zerhouni, our Vice Chairman and President, sits on the board of directors of Danaher Corporation (â€œDanaherâ€). Our subsidiary, BioReference, routinely procures products and services from several subsidiaries of Danaher, including Beckman Coulter, Integrated DNA Technologies Inc., and Leica Microsystems Inc., to which BioReference has paid $2.6 million, $3.3 million, and $0.3 million, respectively, during theÂ nine months ended September 30, 2024. Â BioReference purchases and uses certain products acquired from InCellDx, a company in which we hold a 29% minority interest. Â We reimburse Dr.Â Frost for Company-related use by Dr.Â Frost and our other executives of an airplane owned by a company that is beneficially owned by Dr.Â Frost. We reimburse Dr. Frost for out-of-pocket operating costs for the use of the airplane by Dr. Frost or Company executives for Company-related business. We do not reimburse Dr.Â Frost for personal use of the airplane by Dr.Â Frost or any other executive. For the three and nine months ended September 30, 2024, we reimbursed and accrued approximately $0.0 thousand and $23.9 thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives. For the three and nine months ended September 30, 2023, we reimbursed and accrued approximately $49.5 thousand and $78.8 thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives. Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Commitments and Contingencies Disclosure [Text Block] NOTE 12 COMMITMENTS AND CONTINGENCIES Â In February 2023, the Office of the Attorney General for the State of Texas (â€œTX OAGâ€) informed BioReference that it believes that, from 2005 to the present, BioReference may have violated the Texas Medicaid Fraud Prevention Act with respect to claims it presented to Texas Medicaid for reimbursement. BioReference and the TX OAG have reached an agreement in principle to settle this matter and are currently negotiating the settlement agreement. Â On December 29, 2022, the Israel Tax Authority (the â€œITAâ€) issued an assessment against our subsidiary, OPKO Biologics in the amount of approximately $246Â million (including interest) related to uncertain tax positions involving income recognition in connection with an examination of foreign tax returns for the 2014 through 2020 tax years. We recognize that local tax law is inherently complex and the local taxing authorities may not agree with certain tax positions taken. We are appealing this assessment, as we believe, other than for uncertain tax positions for which we have reserved, the issues are without technical merit. We intend to exhaust all judicial remedies necessary to resolve the matter, as necessary, which could be a lengthy process. There can be no assurance that this matter will be resolved in our favor, and an adverse outcome, or any future tax examinations involving similar assertions, could have a material effect on our financial condition, results of operations and cash flows. Â The Company and BioReference entered into (i) a settlement agreement (the â€œSettlement Agreementâ€), effective July 14, 2022, with the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General of the Department of Health and Human Services (â€œOIG-HHSâ€), and the Defense Health Agency, acting on behalf of the TRICARE Program (collectively, the â€œUnited Statesâ€), the Commonwealth of Massachusetts , the State of Connecticut, and the relator identified therein (â€œRelatorâ€), and (ii) a Corporate Integrity Agreement, effective July 14, 2022 (the â€œCIAâ€), with the OIG-HHS, to resolve the investigation and related civil action concerning alleged fee-for-service claims for payment to the Medicare Program, the Medicaid Program, and the TRICARE Program (collectively, the â€œFederal Health Care Programsâ€). Â Under the Settlement Agreement, the Company and BioReference admitted only to having made payments to certain physicians and physiciansâ€™ groups for office space rentals for amounts that exceeded fair market value, and that it did not report or return any such overpayments to the Federal Health Care Programs (the â€œCovered Conductâ€). The Covered Conduct had commenced prior to the Companyâ€™s acquisition of BioReference in 2015. With the exception of the Covered Conduct, the Company and BioReference expressly deny the allegations of the Relator as set forth in her civil action. The Company has paid a total of $10,000,000Â plus accrued interest from September 24, 2021 at a rate ofÂ 1.5% per annum (the â€œSettlement Amountâ€). The Settlement Amount consists of $9,853,958Â payable to the United States, $141,041Â payable to the Commonwealth and $5,001Â payable to Connecticut, in each case plus interest and was paid on July 18, 2022. Conditioned upon payment of the Settlement Amount, the United States, Massachusetts and Connecticut agreed to release the Company and BioReference from any civil or administrative monetarily liability arising from the Covered Conduct. Upon payment of the Settlement Amount and the amount due under a separate agreement with the Relator, the RelatorÂ released the Company and BioReference from any and all claims and potential claims. Further, in consideration of the obligations of the Company and BioReference in the Settlement Agreement and the CIA, the OIG-HHSÂ released and refrained from instituting any administrative action seeking to exclude the Company or BioReference from participating in Medicare, Medicaid or other Federal health care programs as a result of the Covered Conduct. Â Under the CIA, which has a term ofÂ 5Â years, BioReference is required to, among other things: (i) maintain a Compliance Officer, a Compliance Committee, board review and oversight of certain federal healthcare compliance matters, compliance programs, and disclosure programs; (ii) provide management certifications and compliance training and education; (iii) establish written compliance policies and procedures to meet federal health care program requirements; (iv) create procedures designed to ensure compliance with the Anti-Kickback Statute and/or Stark Law; (v) engage an independent review organization to conduct a thorough review of BioReferenceâ€™ s systems, policies, processes and procedures related to certain arrangements; (vi) implement a risk assessment and internal review process; (vii) establish a disclosure program for whistleblowers; and (viii) report or disclose certain events and physician payments. The Companyâ€™s or BioReferenceâ€™s failure to comply with its obligations under the CIA could result in monetary penalties and the exclusion from participation in Federal Health Care Programs. The CIA does not apply to any of the Companyâ€™s subsidiaries other than BioReference, and its scope is generally limited to â€œfocus arrangementsâ€, which are those â€œarrangementsâ€ (as defined in the CIA) (i) between BioReference and any actual source or recipient of health care business or referrals and involves, directly or indirectly, the offer, payment, or provision of anything of value, or (ii) is between BioReference and any physician (or a physicianâ€™s immediate family member). Most of these measures have already been implemented at BioReference. Following its acquisition of BioReference, the Company and BioReference implemented robust compliance measures that substantially align with those actions required under the CIA. Â On March 1, 2019, the Company received a Civil Investigative Demand (â€œCIDâ€) from the U.S. Department of Justice (â€œDOJâ€), Washington, DC. The CID sets forth document requests and interrogatories in connection with allegations that the Company and certain of its affiliates violated the False Claims Act and/or the Anti-Kickback Statute. On January 13, 2022, the Federal Government notified the U.S.D.C., Middle District Florida, Jacksonville Division, that it is declining to intervene in the matter but retains the right, via the Attorney General, to consent to any proposed dismissal of the action by the Court. On February 9, 2022, the States of Florida, Georgia, and Commonwealth of Massachusetts notified the U.S.D.C., Middle District Florida, Jacksonville Division, that they are declining to intervene in the matter. Notwithstanding the above declinations, on February 17, 2022, the Company was served with the Relatorâ€™s Summons and Complaint (â€œComplaintâ€), which had been previously sealed. The Complaint alleges violations of the False Claims Act, the California Fraud Preventions Act, the Florida False Claims Act, the Massachusetts False Claims Act, the Georgia False Medicaid Claims Act, and illegal kickbacks. A motion to dismiss the Complaint was filed on April 25, 2022 and the case was dismissed in March 2023. However, the Relator filed an amended complaint in April 2023 and a second amended complaint, both of which were dismissed. Relator then filed an appeal in the U.S. Eleventh Circuit Court of Appeals which is pending before the court following a failed mediation in April 2024.Â While management cannot predict the outcome of these matters at this time, the ultimate outcome could be material to our business, financial condition, results of operations, and cash flows. Â From time to time, we may receive inquiries, document requests, CIDs or subpoenas from the Department of Justice, OCR, CMS, various payors and fiscal intermediaries, and other state and federal regulators regarding investigations, audits and reviews. In addition to the matters discussed in this note, we are currently responding to CIDs, subpoenas, payor audits, and document requests for various matters relating to our laboratory operations. Some pending or threatened proceedings against us may involve potentially substantial amounts as well as the possibility of civil, criminal, or administrative fines, penalties, or other sanctions, which could be material. Settlements of suits involving the types of issues that we routinely confront may require monetary payments as well as corporate integrity agreements. Additionally, qui tam or â€œwhistleblowerâ€ actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Actâ€™s requirements for filing such suits. Also, from time to time, we may detect issues of non-compliance with federal healthcare laws pertaining to claims submission and reimbursement practices and/or financial relationships with physicians, among other things. We may avail ourselves of various mechanisms to address these issues, including participation in voluntary disclosure protocols. Participating in voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action. The Company generally has cooperated, and intends to continue to cooperate, with appropriate regulatory authorities as and when investigations, audits and inquiries arise. Â We are a party to other litigation in the ordinary course of business. While we cannot predict the ultimate outcome of legal matters, we accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss. Itâ€™s reasonably possible the ultimate liability could exceed amounts currently estimated and we review established accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. Because of the high degree of judgment involved in establishing loss estimates, the ultimate outcome of such matters will differ from our estimates and such differences may be material to our business, financial condition, results of operations, and cash flows. Â At September 30, 2024, we were committed to make future purchases for inventory and other items in 2024 that occur in the ordinary course of business under various purchase arrangements with fixed purchase provisions aggregating approximately $44.0 million X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Note 13 - Revenue Recognition 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Revenue from Contract with Customer [Text Block] NOTE 13 REVENUE RECOGNITION Â We generate revenues from services, products and intellectual property as follows: Â Revenue from services Â Revenue for laboratory services is recognized at the time test results are reported, which approximates when services are provided and the performance

obligations are satisfied. Services are provided to patients covered by various third-party payor programs including various managed care organizations, as well as the Medicare and Medicaid programs. Billings for services are included in revenue net of allowances for contractual discounts, allowances for differences between the amounts billed and estimated program payment amounts, and implicit price concessions provided to uninsured patients which are all elements of variable consideration. Â The following are descriptions of our payors for laboratory services: Â Healthcare Insurers. Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules. Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements. Adjustments to the allowances, based on actual receipts from the third-party payors, are recorded upon settlement. Â Government Payors. Reimbursements from government payors are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid. Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements. Adjustments to the allowances, based on actual receipts from the government payors, are recorded upon settlement. Â Client Payors. Client payors include physicians, hospitals, employers, and other institutions for which services are performed on a wholesale basis, and are billed and recognized as revenue based on negotiated fee schedules. Â Patients. Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients. Insured patients (including amounts for coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers. Collection of billings from patients is subject to credit risk and ability of the patients to pay. Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with our policies and implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration that we expect to receive from patients, which considers historical collection experience and other factors including current market conditions. Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement. Â The complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, require us to estimate the potential for retroactive adjustments as an element of variable consideration in the recognition of revenue in the period the related services are rendered. Actual amounts are adjusted in the period those adjustments become known. For the nine months ended September 30, 2024 and 2023, we recorded $2.2 million and $19.8 million of negative revenue adjustments primarily due to the composition of patient pay mix. Â Third-party payors, including government programs, may decide to deny payment or recoup payments for testing they contend were improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. Our revenues may be subject to retroactive adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payors in interpretations, requirements, and â€œconditions of participationâ€ in various programs. We have processed requests for recoupment from third-party payors in the ordinary course of our business, and it is likely that we will continue to do so in the future. If a third-party payor denies payment for testing or recoups money from us in a later period, reimbursement for our testing could decline. Â As an integral part of our billing compliance program, we periodically assess our billing and coding practices, respond to payor audits on a routine basis, and investigate reported failures or suspected failures to comply with federal and state healthcare reimbursement requirements, as well as overpayment claims which may arise from time to time without fault on the part of the Company. We may have an obligation to reimburse Medicare, Medicaid,Â and third-party payors for overpaymentsÂ regardless of fault. We have periodically identified and reportedÂ overpayments, reimbursed payors forÂ overpaymentsÂ and taken appropriate corrective action. Â Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are also considered variable consideration and are included in the determination of the estimated transaction price for providing services. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and our historical settlement activity, including an assessment of the probability a significant reversal of cumulative revenue recognized will occur when the uncertainty is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. As of September 30, 2024 and December 31, 2023, we had liabilities of approximately $4.9 million and $3.1 million, respectively, within Accrued expenses and Other long-term liabilities related to reimbursements for payor overpayments. Â The composition of revenue from services by payor for theÂ three and nine months ended September 30, 2024 and 2023 was as follows: Â Â Â Three months ended September 30, Â Â Nine months ended September 30, Â (In thousands) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Healthcare insurers Â $76,184Â Â $81,469Â Â $229,600Â Â $238,934Â Government payers Â Â 20,368Â Â Â 19,909Â Â Â 63,561Â Â Â 61,250Â Client payers Â Â 20,773Â Â Â 25,906Â Â Â 71,521Â Â Â 77,973Â Patients Â Â 3,946Â Â Â 4,395Â Â Â 12,875Â Â Â 12,943Â Total Â $121,271Â Â $131,679Â Â $377,557Â Â $391,100Â Â Revenue from products Â We recognize revenue from product sales when a customer obtains control of promised goods or services. The amount of revenueÂ recorded reflects the consideration that we expect to receive in exchange for those goods or services. Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and our evaluation of specific factors that may increase or decrease the risk of product returns. Product revenues are recorded net of estimated rebates, chargebacks, discounts, co-pay assistance and other deductions (collectively, â€œSales Deductionsâ€) as well as estimated product returns which are all elements of variable consideration. Allowances are recorded as a reduction of revenue at the time product revenues are recognized. The actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect revenue from products in the period such variances become known. Â Rayaldee is distributed in the U.S. principally through the retail pharmacy channel, which initiates with the largest wholesalers in the U.S. (collectively, â€œRayaldee Customersâ€). In addition to distribution agreements with Rayaldee Customers, we have entered into arrangements with many healthcare providers and payors that provide for government-mandated or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of Rayaldee.Â Â We recognize revenue for shipments of Rayaldee at the time of delivery to customers after estimating Sales Deductions and product returns as elements of variable consideration utilizing historical information and market research projections. For the three and nine months ended September 30, 2024, we recognizedÂ $5.8 million and $19.9 million, respectively, in net product revenue from sales of Rayaldee. For the three and nine months ended September 30, 2023, we recognizedÂ $7.3 million and $21.7 million, respectively, in net product revenue from sales of Rayaldee. Â The following table presents an analysis of Rayaldee product sales allowances and accruals for the three and nine months ended September 30, 2024 and 2023: Â (In thousands) Â Chargebacks, discounts, rebates and fees Â Â Governmental Â Â Returns Â Â Total Â Balance at June 30, 2024 Â $2,743Â Â $5,991Â Â $2,194Â Â $10,928Â Provision related to current period sales Â Â 4,005Â Â Â 5,776Â Â Â 317Â Â Â 10,098Â Credits or payments made Â Â (5,058)Â Â (7,013)Â Â (278)Â Â (12,349) Balance at September 30, 2024 Â $1,690Â Â $4,754Â Â $2,233Â Â $8,677Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $15,865Â Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 64% Â (In thousands) Â Chargebacks, discounts, rebates and fees Â Â Governmental Â Â Returns Â Â Total Â Balance at December 31, 2023 Â $2,578Â Â $6,150Â Â $2,192Â Â $10,920Â Provision related to current period sales Â Â 12,224Â Â Â 16,325Â Â Â 989Â Â Â 29,538Â Credits or payments made Â Â (13,112)Â Â (17,721)Â Â (948)Â Â (31,781) Balance at September 30, 2024 Â $1,690Â Â $4,754Â Â $2,233Â Â $8,677Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $49,447Â Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 60% Â Â (In thousands) Â Chargebacks, discounts, rebates and fees Â Â Governmental Â Â Returns Â Â Total Â Balance at June 30, 2023 Â $2,330Â Â $5,954Â Â $1,634Â Â $9,918Â Provision related to current period sales Â Â 3,446Â Â Â 4,998Â Â Â 322Â Â Â 8,766Â Credits or payments made Â Â (4,125)Â Â (4,207)Â Â (15)Â Â (8,347) Balance at September 30, 2023 Â $1,651Â Â $6,745Â Â $1,941Â Â $10,337Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $16,090Â Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 54% Â Â (In thousands) Â Chargebacks, discounts, rebates and fees Â Â Governmental Â Â Returns Â Â Total Â Balance at December 31, 2022 Â $1,532Â Â $5,063Â Â $1,683Â Â $8,278Â Provision related to current period sales Â Â 10,702Â Â Â 14,604Â Â Â 959Â Â Â 26,265Â Credits or payments made Â Â (10,583)Â Â (12,922)Â Â (701)Â Â (24,206) Balance at September 30, 2023 Â $1,651Â Â $6,745Â Â $1,941Â Â $10,337Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Total gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $47,940Â Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 55% Â Taxes collected from customers related to revenues from services and revenues from products are excluded from revenues. Â Revenue from intellectual property and other Â We recognize revenues from the transfer of intellectual property generated through license, development, collaboration and/or commercialization agreements. The terms of these agreements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development and commercialization milestone payments; funding of research and/or development activities; and royalties on sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer. Â For research, development and/or commercialization agreements that result in revenues, we identify all material performance obligations, which may include a license to intellectual property and know-how, and research and development activities. In order to determine the transaction price, in addition to any upfront payment, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. We constrain (reduce) our estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, we consider whether there are factors outside of our control that could result in a significant reversal of revenue. In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. Â Upfront License Fees: If a license to our intellectual property is determined to be functional intellectual property distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. Â Research and Development Activities: If we are entitled to reimbursement from our customers for specified research and development expenses, we account for them as separate performance obligations if distinct. We also determine whether the research and development funding would result in revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The corresponding revenues or offset to research and development expenses are recognized as the related performance obligations are satisfied. Â BARDA Contract:Â Revenue from the BARDA Contract is generated under terms that are cost plus fee. We recognize revenue using the incurred costs output method to measure progress. Revenue will only be recognized when research and development services are performed to the extent of actual costs incurred. Â Sales-based Milestone and Royalty Payments: Our customers may be required to pay us sales-based milestone payments or royalties on future sales of commercial products. We recognize revenues related to sales-based milestone and royalty payments upon the later to occur of (i) achievement of the customerâ€™s underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to our intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate. Â Other Potential Products and Services: Arrangements may include an option for license rights, future supply of drug substance or drug product for either clinical development or commercial supply at the licenseeâ€™s election. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the inception of the contract and revenue is recognized only if the option is exercised and products or services are subsequently delivered or when the rights expire. If the promise is based on market terms and not considered a material right, the option is accounted for if and when exercised. If we are entitled to additional payments when the licensee exercises these options, any additional payments are generally recorded in license or other revenues when the licensee obtains control of the goods, which is upon delivery. Â For the three months ended September 30, 2024, revenue from the transfer of intellectual property and other was $13.2 million, an increase fromÂ $6.2 million for the three months ended September 30, 2023. This increase was primarily attributable to $5.5 million from the BARDA Contract (as defined and described in Note 14). Gross profit share and royalty payments for NGENLA (Somatrogon) and Pfizer's GenotropinÂ® (Somatropin) also increased to $7.0 million, compared with $4.9 million for the same period in 2023. Â For the nine months ended September 30, 2024, revenue from the transfer of intellectual property and other decreased toÂ $34.3 million fromÂ $165.9 million for the nine months ended September 30, 2023. This decrease was primarily due to one-time milestone payments received in 2023, including a $90.0 million payment related to NGENLA, a $50.0 million payment from Merck for rights granted under the Merck Agreement, a $7.0 million payment from VFMCRP triggered by the German price approval for Rayaldee, and a $2.5 million payment from Nicoya upon submission of an investigational new drug application to China's Center for Drug Evaluation. See Note 14 for a description of the arrangements pursuant to which such milestone payments were received. Revenue for the nine months ended September 30, 2024, included $18.9 million in gross profit share and royalty payments for NGENLA (Somatrogon) and Pfizer's GenotropinÂ® (Somatropin), compared to $11.8 million in the same period in 2023, as well as $12.8 million from the BARDA Contract during the 2024 period. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Note 14 - Strategic Alliances 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Collaborative Arrangement Disclosure [Text Block] NOTE 14 STRATEGIC ALLIANCES Â Biomedical Advanced Research and Development Authority Â On September 28, 2023, ModeX was awarded a contract (as amended as decribed below, the â€œBARDA Contractâ€) by the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services. This contract aims to advance a platform and product candidates addressing various public health threats, specifically in viral infectious diseases. The funding enables the research, development, and clinical evaluation of multispecific antibodies

based on ModeX's proprietary MSTAR technology. MSTAR is a flexible, plug-and-play platform capable of incorporating multiple independent antibody binding sites into a single molecule, expanding its therapeutic potential and enabling rapid responses to emerging infections, including viral variants like COVID-19, influenza, and other pathogens. Â In September 2024, ModeX entered into two amendments (the â€œBARDA Amendmentsâ€) to modify the scope and funding of the BARDA Contract. The BARDA Amendments structuredÂ the funding thereunder as cost-plus-fixed-fee, which includes a $26.9 millionÂ supplement to further advance the development of COVID-19 multispecific antibodies. This increased funding supports the ongoing development, manufacturing, and execution of a Phase 1 clinical trial for a next-generation MSTAR multispecific antibody with broad neutralizing activity against known SARS-CoV-2 variants. The BARDA Amendments also provided for BARDA's exercise of the option for the development of a multispecific protein antibody for influenza or another pathogen, with $24.1 million allocated to cover the expanded work under this exercised option. These modifications increased the total value of the BARDA Contract from $59.0 million to $110.0 million, with the potential value if BARDA exercises all options thereunder to expand ModeX's services, increasing from $168.6 million to $205 million. Â As part of the research program, gene-based delivery methods for the multispecific antibodies will be developed using mRNA or DNA vectors to leverage the body's natural protein production processes. BARDA will make periodic progress assessments, and the continuation of the BARDA Contract depends on ModeXâ€™s performance, the timeliness and quality of deliverables, and other factors. The BARDA Contract contains customary government contract provisions, including BARDA's right to terminate the contract inÂ its discretion. Â The Company evaluated the BARDA Contract under ASC Topic 606, Revenue from Contracts with Customers (â€œASC 606â€), and determined that the U.S. government meets the definition of a customer. The scope of the BARDA Contract includes preclinical, clinical, and manufacturing activities, as well as regulatory, quality assurance, management, and administrative activities. The research and development effort will progress in stages covering base and option segments, with ModeX completing specific tasks in each segment. Â The Company identified three potential material promises under the BARDA Contract: (i) development of a tetravalent trispecific antibody for COVID-19; (ii) development of a multispecific protein antibody for influenza or another pathogen; and (iii) nucleic acid delivery of a multispecific antibody for influenza or another pathogen. The Company determined the promise to develop a tetravalent trispecific antibody for COVID-19 is a separate performance obligation, as it is distinct within the contract and provides standalone value. Similarly, the exercised option to develop a multispecific protein antibody for influenza or another pathogen is also a separate performance obligation. However, the Company determined that the nucleic acid delivery option does not offer incremental discounts beyond those typically provided for such goods and services, and therefore does not represent a material right. As such, the options in (iii) were not considered performance obligations at the outset of the BARDA Contract. Â The Company concluded that research and development services performed under the BARDA Contract would be recognized as revenue when research and development services are performed to the extent of actual costs incurred including a fixed fee and will be reimbursed by BARDA. Costs incurred represent work performed, which corresponds with, and thereby best depicts, the transfer of control of the research and development to BARDA. Types of contract costs include labor, material, and third-party services. As such, the related BARDA revenue is recognized as revenue from transfer of intellectual property and other within the Companyâ€™s Consolidated Statements of Operations. For the three and nine months ended September 30, 2024, we recorded $5.5 million and $12.8 million in revenue under the BARDA Contract. As of September 30, 2024, the aggregate amount of transaction price allocated to remaining performance obligations, excluding unexercised contract options, was $96.0 million. We expect to recognize this amount as revenue through February 2028. Â Merck Â On March 8, 2023, ModeX, the Company (with respect to certain sections), and Merck Sharp & Dohme LLC (â€œMerckâ€) entered into a License and Research Collaboration Agreement (the â€œMerck Agreementâ€) pursuant to which ModeX granted to Merck a license to certain patent rights and know-how in connection with the development of ModeXâ€™s preclinical nanoparticle vaccine candidate targeting the Epstein-Barr Virus. Â Under the terms of the Merck Agreement, ModeX granted to Merck an exclusive, sublicensable, royalty-bearing license to certain intellectual property to develop, manufacture, use and commercialize (i) a multivalent or monovalent vaccine assembled usingÂ our platform for Epstein-Barr Virus (â€œVaccineâ€), and (ii) any pharmaceutical or biological preparation in final form containing a Vaccine for sale or for administration to human patients in a clinical trial for all uses (â€œProductâ€). We received an initial payment of $50.0Â million and are eligible to receive up to an additional $872.5Â million upon the achievement of certain commercial and development milestones under several indications. We are also eligible to receive tiered royalty payments ranging from high single digits to low double digits upon achievement of certain sales targets of the Product. Certain of the rights subject to the license provided by us under the Merck Agreement were obtained by us from Sanofi pursuant to that certain License Agreement entered into as of July 1, 2021 (â€œSanofi In-License Agreementâ€) between us and Sanofi, a French corporation (â€œSanofiâ€), and a portion of the upfront payment, milestones and royalties received by us under the Merck Agreement may be payable to Sanofi under the terms of the Sanofi In-License Agreement. As a result of such obligations under the Sanofi In-License Agreement, we paid $12.5 million to Sanofi during the three months ended September 30, 2023. Â As part of their strategic collaboration, ModeX and Merck have put in place a research plan to manage research and other development activities related to the development of a Vaccine or Product including a joint steering committee to facilitate the research program. As part of the research plan, they will use a third-party contract development and manufacturing organizationÂ to carry out such activities unless otherwise agreed. Development costs incurred by ModeX in furtherance of these development activities will be reimbursed by Merck. To date, we have spent $24.5 million of development costs related to the Epstein -Barr Virus, for which Merck has provided reimbursement. Â The Merck Agreement will remain in effect until one or more Products receive marketing authorization, and, thereafter, until the expiration of all royalty obligations unless earlier terminated as permitted under the Merck Agreement. In addition to termination rights for material breach and bankruptcy, Merck is permitted to terminate the Merck Agreement in its entirety without cause after a specified notice period. If Merck terminates the Merck Agreement for convenience or by us for Merckâ€™s uncured material breach, we may elect to receive a reversion license such that we can continue its work with Vaccines and Products which have not been terminated due to a material safety issue. Â LeaderMed Â On September 14, 2021, we and LeaderMed announced the formation of a joint venture to develop, manufacture and commercialize two of OPKOâ€™s clinical stage, long-acting drug products in Greater China and eight other Asian territories. Â Under the terms of the agreements, we have granted the joint venture exclusive rights to develop, manufacture and commercialize (a) OPK88003, an oxyntomodulin analog being developed for the treatment of obesity and diabetes, and (b) Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia, in exchange for a 47% ownership interest in the joint venture. In addition, during 2021 we received an upfront payment of $1Â million and will be reimbursed for clinical trial material and technical support we provide the joint venture. Â LeaderMed is responsible for funding the joint venturâ€™s operations, development and commercialization efforts and, together with its syndicate partners, initially invested $11Â million in exchange for a 53% ownership interest. We retain full rights to oxyntomodulin and Factor VIIa-CTP in all other geographies. Â CAMP4 Therapeutics Â On July 6, 2021, we entered into an exclusive license agreement (the â€œCAMP4 Agreementâ€) with CAMP4, pursuant to which we granted to CAMP4 an exclusive license to develop, manufacture, commercialize or improve therapeutics utilizing the AntagoNAT technology, an oligonucleotide platform developed under OPKO CURNA, which includes the molecule for the treatment of Dravet syndrome, together with any derivative or modification thereof (the â€œLicensed Compoundâ€) and any pharmaceutical product that comprises or contains the Licensed Compound, alone or in combination with one or more other active ingredients (â€œLicensed Productâ€), worldwide. The CAMP4 Agreement grant covers human pharmaceutical, prophylactic, and therapeutic and certain diagnostic uses. Â We received an initial upfront payment of $1.5Â million and 3,373,008 shares of CAMP4â€™s Series A Prime Preferred Stock (â€œPreferred Stockâ€), which then equated to approximately 9% of the outstanding shares of CAMP4, and we are eligible to receive up to $3.5Â million in development milestone payments for Dravet syndrome products, and $4Â million for non-Dravet syndrome products, as well as sales milestones of up to $90Â million for Dravet syndrome products and up to $90Â million for non-Dravet syndrome products. We may also receive double digit royalty payments on the net sales of royalty bearing products, subject to adjustment. In addition, upon achievement of certain development milestones, we will be eligible to receive equity consideration of up to 5,782,299 shares of Preferred Stock in connection with Dravet syndrome products and up to 1,082,248 shares of Preferred Stock in connection with non-Dravet syndrome products. In connection with our acquisition of CURNA, we agreed to pay future consideration to the sellers upon the achievement of certain events. As a result of our execution of the CAMP4 Agreement, we will have to pay a percentage of any payments received under the CAMP4 Agreement to the former CURNA stockholders. Â The Company was notified that the FDAÂ placed the Dravet clinical trials on hold and CAMP4 subsequently ceased development efforts. Â NICOYA Macau Limited Â On June 18, 2021, EirGen, our wholly owned subsidiary, and NICOYA Macau Limited (â€œNicoyaâ€), a Macau corporation and an affiliate of NICOYA Therapeutics, entered into a Development and License Agreement (the â€œNicoya Agreementâ€) granting Nicoya the exclusive rights for the development and commercialization of extended release calcifediol (the â€œNicoya Productâ€) in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan (collectively, the â€œNicoya Territoryâ€). Extended release calcifediol is marketed in the U.S. by OPKO under the tradename Rayaldee. The license grant to Nicoya covers the therapeutic and preventative use of the Nicoya Product for SHPT in non-dialysis and hemodialysis chronic kidney disease patients (the â€œNicoya Fieldâ€). Â EirGen received an initial upfront payment of $5Â million and was eligible to receive an additional $5Â million tied to the first anniversary of the effective date of the Nicoya Agreement, as amended, of which EirGen has received $2.5Â million plus accrued interest for the delayed payment. Furthermore, EirGen received the additional $2.5Â million upon Nicoyaâ€™s submission of an investigational new drug (IND) application to the Center for Drug Evaluation of China in March 2023. EirGen is also eligible to receive up to an additional aggregate amount of $115Â million upon the achievement of certain development, regulatory and sales-based milestones by Nicoya for the Nicoya Product in the Nicoya Territory. EirGen is eligible to receive tiered, double digit royalty payments at rates in the low double digits on net product sales within the Nicoya Territory and in the Nicoya Field. Â Nicoya is, at its sole cost and expense,Â responsible for performing all development activities necessary to obtain all regulatory approvals for the Nicoya Product in the Nicoya Territory and will be responsible for all commercial activities pertaining to the Nicoya Product in the Nicoya Territory. Â Unless earlier terminated, the Nicoya Agreement will remain in effect until such time as all royalty payment terms and extended payment terms have expired, and Nicoya shall have no further payment obligations to EirGen under the terms of the Nicoya Agreement. Nicoyaâ€™s royalty obligations expire on the later of (i) expiration of the last to expire valid patent claim covering the Nicoya Product sold in the Nicoya Territory, (ii) expiration of all regulatory and data exclusivity applicable to the Nicoya Product in the Nicoya Territory, and (iii) on a product-by-product basis, ten (10) years after such Nicoya Productâ€™s first commercial sale in the Nicoya Territory. In addition to termination rights for material breach and bankruptcy, Nicoya is permitted to terminate the Nicoya Agreement after a specified notice period. Â VFMCRP Â In May 2016, EirGen and Vifor Fresenius Medical Care Renal Pharma Ltd. (â€œVFMCRP â€) entered into a Development and License Agreement (the â€œVFMCRP Agreementâ€) for the development and commercialization of Rayaldee (the â€œProductâ€) worldwide, except for (i) the United States and Canada, (ii) any country in Central America or South America (including Mexico), (iii) Russia, (iv) China, (v) South Korea, (vi) Ukraine, (vii) Belorussia, (viii) Azerbaijan, (ix) Kazakhstan, (x) Taiwan (xi) the Middle East, and (xii) all countries of Africa (the â€œVFMCRP Territoryâ€), as amended. The license toÂ VFMCRP potentially covers all therapeutic and prophylactic uses of the Product in human patients (the â€œVFMCRP Fieldâ€), provided that initially the license is for the use of the Product for the treatment or prevention of SHPT related to patients with CKD and vitamin D insufficiency/deficiency (the â€œVFMCRP Initial Indicationâ€). Â In January 2023, the German Association of Statutory Health Insurance funds (GKV-SV) granted price approval for Rayaldee. This triggered a milestone payment of $7.0 million. In 2022, we recognized a separate milestone payment of $3.0 million in revenue from the transfer of intellectual property and other for the first sale of Rayaldee in Europe. Â Effective May 23, 2021, we entered into an amendment to theÂ VFMCRP Agreement pursuant to which the parties thereto agreed to include Japan as part of theÂ VFMCRP Territory. Â Effective May 5, 2020, we entered into an amendment to the VFMCRP Agreement pursuant to which the parties agreed to exclude Mexico, South Korea, the Middle East and all of the countries of Africa from the VFMCRP Territory. In addition, the parties agreed to certain amendments to the milestone structure and to reduce minimum royalties payable. As revised, the Company has received a $3 million payment triggered by the first marketing approval of Rayaldee in Europe, $7.0 million payment triggered by the Germany price approval by the local sick fund association, and is eligible to receive up to an additional $15 million in regulatory milestones and $200 million in milestone payments tied to launch, pricing and sales of Rayaldee, and tiered, double-digit royalties. Â We plan to share responsibility withÂ VFMCRP for the conduct of trials specified within an agreed-upon development plan, with each company leading certain activities within the plan. EirGen will lead the manufacturing activities within and outside theÂ VFMCRP Territory and the commercialization activities outside theÂ VFMCRP Territory and outside theÂ VFMCRP Field in theÂ VFMCRP Territory andÂ VFMCRP will lead the commercialization activities in theÂ VFMCRP Territory and theÂ VFMCRP Field. For the initial development plan, the companies have agreed to certain cost sharing arrangements.Â VFMCRP will be responsible for all other development costs thatÂ VFMCRP considers necessary to develop the Product for the use of the Product for the VFMCRP Initial Indication in theÂ VFMCRP Territory in theÂ VFMCRP Field except as otherwise provided in theÂ VFMCRP Agreement. The first of the clinical studies provided for in the development activities commenced in September 2018. Â In connection with the VFMCRP Agreement, the parties entered into a letter agreement pursuant to which EirGen granted toÂ VFMCRP an exclusive option (the â€œOptionâ€) to acquire an exclusive license under certain EirGen patents and technology to use, import, offer for sale, sell, distribute and commercialize the Product in the U.S. solely for the treatment of SHPT in dialysis patients with CKD and vitamin D insufficiency (the â€œDialysis Indicationâ€). Upon exercise of the Option, VFMCRP has agreed to reimburse EirGen for all of the development costs incurred by EirGen with respect to the Product for the Dialysis Indication in the U.S. VFMCRP would also pay EirGen up to an additional aggregate amount of $555Â million of sales-based milestones upon the achievement of certain milestones and would be obligated to pay royalties at percentage rates that range from the mid-teens to the mid-twenties on sales of the Product in the U.S. for the Dialysis Indication. To date,Â VFMCRP has not exercised the Option. Â Payments received for regulatory milestones and sales milestones are non-refundable. The regulatory milestones are payable if and whenÂ VFMCRP obtains approval from certain regulatory authorities and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. We account for the sales milestones as royalties and sales milestones payments will be recognized as revenue in the period in which the associated milestone is achieved or sales occur, assuming all other revenue recognition criteria are met. Â Pfizer Inc. Â In December 2014, we entered into an exclusive worldwide agreement with Pfizer for the development and commercialization of our long-acting Somatrogon (hGH-CTP) for the treatment of growth hormone deficiency (â€œGHDâ€) in adults and children, as well as for the treatment of growth failure in children born small for gestational age (the â€œPfizer Transactionâ€).Â In May 2020, we entered into an amended and restated development and commercialization license with Pfizer, effective January 1, 2020 (the â€œRestated Pfizer Agreementâ€), pursuant to which the parties agreed, among other things, to share all costs for Manufacturing Activities, as defined in the Restated Pfizer Agreement, for developing a licensed product for the three indications included in the Restated Pfizer Agreement. Â In June 2023, the FDA approved NGENLA (Somatrogon (hGH-CTP)) a once-weekly injection to treat pediatric growth hormone deficiency in the United States. In early 2022, the European Commission and Ministry of Health, Labour and Welfare in Japan approved NGENLA (Somatrogon). We have also received pricing approvals in Germany and Japan. NGENLA (Somatrogon (hGH-CTP)) is approved for the treatment of pediatric GHD in more than 50 markets, including Canada, Australia, Japan, and EU Member States. With the achievement of these milestones, in 2023 we recorded revenue of $90 million, and in 2022 we recorded $85.0Â million, in each case under the Restated Pfizer Agreement. Â On October 21, 2019, we and Pfizer announced that the global phase 3 trial evaluating Somatrogon dosed once-weekly in prepubertal children with GHD met its primary endpoint of non-inferiority to daily GenotropinÂ® (somatropin) for injection, as measured by annual height velocity at 12 months. Â Under the terms of the Restated Pfizer Agreement we received non-refundable and non-creditable upfront payments of $295.0 million and are eligible to receive up to an additional $275.0 million upon the achievement of certain regulatory milestones. Pfizer received the exclusive license to commercialize Somatrogon worldwide. In addition, we are eligible to receiveÂ regional, tiered gross profit sharing for both Somatrogon and Pfizerâ€™s GenotropinÂ® (somatropin) in all global markets, with the U.S. region commencing gross profit sharing in August 2023. Â The Restated Pfizer Agreement will remain in effect until the last sale of the licensed product, unless earlier terminated in accordance with its terms. In addition to termination rights for material breach and bankruptcy, Pfizer is permitted to terminate the Restated Pfizer Agreement in its entirety, or with respect to one or more world regions, without cause after a specified notice period. If the Restated Pfizer Agreement is terminated by us for Pfizerâ€™s uncured material breach, or by Pfizer without cause, provision has been made for transition of product and product responsibilities to us for the terminated regions, as well as continued supply of product by Pfizer or transfer of supply to us in order to support the terminated regions. Â We recognized the non-refundable $295.0 million upfront payments as revenue as the research and development services were completed. As of September 30, 2024 and December 31, 2023, we had no contract liabilities related to the Pfizer Transaction. Â TheÂ Restated Pfizer Agreement includes milestone payments of $275.0 million upon the achievement of certain milestones. The milestones range from $20.0 million to $90.0 million each and are based on achievement of regulatory approval in the U.S.

and regulatory approval and price approval in other major markets. The milestone payments will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. To date, $175.0 million of revenue has been recognized related to the achievement of the milestones. Â Other Â We have completed strategic deals with numerous institutions and commercial partners. In connection with these agreements, upon the achievement of certain milestones we are obligated to make certain payments and have royalty obligations upon sales of products developed under the license agreements. At this time, we are unable to estimate the timing and amounts of payments as the obligations are based on future development of the licensed products. Â X - DefinitionThe entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 808 -Publisher FASB -URI https://asc.fasb.org/808/tableOfContent + Details Name: us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Note 15 - Segments 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Segment Reporting Disclosure [Text Block] NOTE 15 SEGMENTS Â We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinicalÂ laboratory operations through BioReference. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes. Â Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows: Â Â Â For the three months ended September 30, Â Â For the nine months ended September 30, Â (In thousands) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue from services: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Pharmaceutical Â $â€”Â Â $â€”Â Â $â€”Â Â $â€”Â Diagnostics Â Â 121,271Â Â Â 131,679Â Â Â 377,557Â Â Â 391,100Â Corporate Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â $121,271Â Â $131,679Â Â $377,557Â Â $391,100Â Revenue from products: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Pharmaceutical Â $39,143Â Â $40,670Â Â $117,675Â Â $124,553Â Diagnostics Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Corporate Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â $39,143Â Â $40,670Â Â $117,675Â Â $124,553Â Revenue from transfer of intellectual property and other: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Pharmaceutical Â $13,218Â Â $6,246Â Â $34,272Â Â $165,938Â Diagnostics Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Corporate Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â $13,218Â Â $6,246Â Â $34,272Â Â $165,938Â Operating income (loss): Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Pharmaceutical Â $(32,196)Â $(25,375)Â $(84,697)Â $57,210Â Diagnostics Â Â 58,541Â Â Â (29,081)Â Â (2,443)Â Â (113,344) Corporate Â Â (12,129)Â Â (9,951)Â Â (31,786)Â Â (31,841) Â Â $14,216Â Â $(64,407)Â $(118,926)Â $(87,975) Depreciation and amortization: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Pharmaceutical Â $18,043Â Â $17,807Â Â $53,899Â Â $53,649Â Diagnostics Â Â 6,120Â Â Â 8,376Â Â Â 20,238Â Â Â 25,666Â Corporate Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â $24,163Â Â $26,183Â Â $74,137Â Â $79,315Â Loss from investment in investees: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Pharmaceutical Â $(3)Â $(20)Â $(7)Â $(99) Diagnostics Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Corporate Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â $(3)Â $(20)Â $(7)Â $(99) Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â United States Â $132,663Â Â $139,043Â Â $410,422Â Â $462,987Â Ireland Â Â 11,514Â Â Â 8,654Â Â Â 30,579Â Â Â 121,249Â Chile Â Â 16,576Â Â Â 16,932Â Â Â 49,067Â Â Â 52,427Â Spain Â Â 6,297Â Â Â 4,349Â Â Â 17,828Â Â Â 16,427Â Israel Â Â 196Â Â Â 3,155Â Â Â 797Â Â Â 9,388Â Mexico Â Â 5,630Â Â Â 5,897Â Â Â 18,621Â Â Â 17,447Â Other Â Â 756Â Â Â 565Â Â Â 2,190Â Â Â 1,666Â Â Â $173,632Â Â $178,595Â Â $529,504Â Â $681,591Â Â Â Â September 30, Â Â December 31, Â (In thousands) Â 2024 Â Â 2023 Â Assets: Â Â Â Â Â Â Â Â Pharmaceutical Â $1,271,781Â Â $1,331,764Â Diagnostics Â Â 517,871Â Â Â 630,753Â Corporate Â Â 466,451Â Â Â 49,181Â Â Â $2,256,103Â Â $2,011,698Â Goodwill: Â Â Â Â Â Â Â Â Pharmaceutical Â $316,161Â Â $315,235Â Diagnostics Â Â 219,707Â Â Â 283,025Â Â Â $535,868Â Â $598,260Â Â No customer represented more than 10% of our total consolidated revenue for the nine months ended September 30, 2024 and 2023. As of September 30, 2024 and December 31, 2023, no customer represented more than 10% of our accounts receivable balance. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Note 16 - Leases 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Lessee, Leases [Text Block] NOTE 16 LEASES Â We have operating leases for office space, laboratory operations, research and development facilities, manufacturing locations, warehouses and certain equipment. We determine if a contract contains a lease at inception or modification of a contract. Our leases generally do not provide an implicit interest rate, and we therefore use our incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. We used the incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date. Many of our leases contain rental escalation, renewal options and/or termination options that are factored into our determination of lease payments as appropriate. Variable lease payment amounts that cannot be determined at the commencement of the lease are not included in the right-to-use assets or liabilities. Â We elected the use of permitted practical expedients of not recording leases on our Condensed Consolidated Balance Sheet when the leases have terms of 12 months or less, and we elected not to separate nonlease components from lease components and instead account for each separate lease component and the nonlease components associated with that lease component as a single lease component. Â On January 2, 2023, ModeX entered into a 10-year office lease agreement that commenced in October 2023. ModeX was previously located in Natick, Massachusetts and relocated to Weston, Massachusetts, upon lease commencement. The new location is approximately 33,056 square feet of office space. ModeX has two options to extend the lease term for an additional five years per extension, which would commence upon the expiration of the term in October 2033. Straight-line monthly expense for the lease is $243.5 thousand. Â The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of September 30, 2024 and December 31, 2023: Â (in thousands) Classification on the Balance Sheet Â September 30, 2024 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Â Â Â Â Â Operating lease assets Operating lease right-of-use assets Â $62,812Â Â $68,088Â Finance lease assets Property, plant and equipment, net Â Â 6,544Â Â Â 10,101Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Â Â Â Current Â Â Â Â Â Â Â Â Â Â Operating lease liabilities Current maturities of operating leases Â Â 12,741Â Â Â 12,996Â Accrued expenses Current maturities of finance leases Â Â 1,855Â Â Â 2,827Â Long-term Â Â Â Â Â Â Â Â Â Â Operating lease liabilities Operating lease liabilities Â Â 52,057Â Â Â 54,140Â Other long-term liabilities Finance lease liabilities Â $4,689Â Â $7,274Â Â Â Â Â Â Â Â Â Â Â Â Weighted average remaining lease term Â Â Â Â Â Â Â Â Â Operating leases (in years) Â Â 6.3Â Â Â 7.1Â Finance leases (in years) Â Â 7.1Â Â Â 6.2Â Weighted average discount rate Â Â Â Â Â Â Â Â Â Operating leases Â Â 5.3%Â Â 5.4% Finance leases Â Â 3.7%Â Â 3.8% Â The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of September 30, 2024: Â (in thousands) Â Operating Â Â Finance Â October 1, 2024 through December 31, 2024 Â $3,043Â Â $673Â 2025 Â Â 11,772Â Â Â 1,813Â 2026 Â Â 10,937Â Â Â 1,334Â 2027 Â Â 10,775Â Â Â 806Â 2028 Â Â 10,785Â Â Â 203Â Thereafter Â Â 26,534Â Â Â 1,959Â Total undiscounted future minimum lease payments Â Â 73,846Â Â Â 6,788Â Less: Difference between lease payments and discounted lease liabilities Â Â 9,048Â Â Â 244Â Total lease liabilities Â $64,798Â Â $6,544Â Â Expense under operating leases and finance leases was $15.2 million and $2.5 million, respectively, for the nine months ended September 30, 2024, which included $1.5 million of variable lease costs. Expense under operating leases and finance leases wasÂ $12.0 million and $2.2 million, respectively, for the nine months ended September 30, 2023, which included $0.9 million of variable lease costs. Operating lease costs and finance lease costs are included within Operating loss in the Condensed Consolidated Statement of Operations. Short-term lease costs were not material. Â Supplemental cash flow information is as follows: Â Â Â For the nine months ended September 30, Â (in thousands) Â 2024 Â Â 2023 Â Operating cash out flows from operating leases Â $15,101Â Â $11,704Â Operating cash out flows from finance leases Â Â 354Â Â Â 327Â Financing cash out flows from finance leases Â Â 2,118Â Â Â 1,919Â Total Â $17,573Â Â $13,950Â Â X - DefinitionThe entire disclosure for finance and operating leases of lessee. Includes, but is not limited to, description of lessee's finance and operating lease and maturity analysis of finance and operating lease liability. + ReferencesNo definition available. + Details Name: opk_LesseeLeasesTextBlock Namespace Prefix: opk_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Insider Trading Arr Line Items Â Â Material Terms of Trading Arrangement [Text Block] Â ItemÂ 5. Other Information Â During the quarter ended September 30, 2024, none of our officers or directors adopted or terminated any contract, instruction or written plan for the purchase or sale of securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any â€œnon-Rule 10b5-1 trading arrangementâ€, as defined in Item 408 of Regulation S-K.Â Â Rule 10b5-1 Arrangement Adopted [Flag] false Â Non-Rule 10b5-1 Arrangement Adopted [Flag] false Â Rule 10b5-1 Arrangement Terminated [Flag] false Â Non-Rule 10b5-1 Arrangement Terminated [Flag] false Â X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Accounting, Policy [Policy Text Block] Basis of

presentation. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. (â€œGAAPâ€) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Companyâ€™s results of operations, financial position and cash flows have been made. The results of operations and cash flows for the nine months ended September 30, 2024 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2024 or any other future periods. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. Â Consolidation, Policy [Policy Text Block] Principles of consolidation. The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and our wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Â Use of Estimates, Policy [Policy Text Block] Use of estimates. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates. Â Cash and Cash Equivalents, Policy [Policy Text Block] Cash, cash equivalents and restricted cash. Cash, cash equivalents and restricted cash include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase. We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities. Â The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheet to the sum ofÂ such amountsÂ in the Condensed Consolidated Statements of Cash Flows: Â Â Â September 30, 2024 Â Â December 31, 2023 Â Cash and cash equivalents Â $400,079Â Â $95,881Â Restricted cash, current Â Â 6,321Â Â Â Â â€”Â Restricted cash, long-term Â Â 13,665Â Â Â Â â€”Â Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows Â $420,065Â Â $95,881Â Â The Company classifies cash deposits related to letters of credit securing insurance and lease obligations as restricted cash, which is included in other assets, non-current, within the Consolidated Balance Sheet. Â Inventory, Policy [Policy Text Block] Inventories. Inventories are valued at the lower of cost and net realizable value. Cost is determined by the first-in, first-out method. We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value. Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which are used in our testing laboratories. Â Inventory obsolescence expense for the three and nine months ended September 30, 2024 wasÂ $0.6 million and $1.6 million, respectively. Inventory obsolescence expense for the three and nine months ended September 30, 2023 wasÂ $2.6 million and $4.0 million, respectively. Â Goodwill and Intangible Assets, Policy [Policy Text Block] Goodwill and intangible assets. Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting. Refer to Note 5. Goodwill, in-process research and development (â€œIPR&Dâ€) and other intangible assets acquired in business combinations, licensing and other transactions was $1.4 billion and $1.5 billion at September 30, 2024 and December 31, 2023, respectively. Â Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. At acquisition, we generally determine the fair value of intangible assets, including IPR&D, using the â€œincome method.â€ Â Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable. Â Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment. We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing. Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value. Goodwill was $535.9 million and $598.3 million, respectively, at September 30, 2024 and December 31, 2023. Â Net intangible assets other than goodwill were $836.4 million on each of September 30, 2024, and December 31, 2023, with IPR&D accounting for $195.0 million on each date. Considering the high risk nature of research and development and the industryâ€™s success rate of bringing developmental compounds to market, IPR&D impairment charges may occur in future periods. Estimating the fair value of IPR&D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment. Â Upon regulatory approval, IPR&D assets are classified as finite-lived intangible assets. These assets are then amortized on a straight-line basis over their estimated useful lives. If a project is abandoned, the associated IPR&D costs are immediately expensed. We also regularly assess finite-lived intangible assets for impairment. This assessment involves comparing the carrying amount of an asset, which is its cost minus accumulated amortization, to its estimated future undiscounted cash flows. If the carrying amount exceeds the estimated future cash flows, an impairment charge is recognized to reflect the difference between the asset's carrying amount and its fair value.Â Â While we believe our estimates and assumptions used in impairment testing (including for goodwill and IPR&D) are reasonable and reflect those used by market participants, there is a potential risk of material impairment charges. Based on the current financial performance of our diagnostics segment and our Ireland reporting unit (which includes Eirgen and Rayaldee), we could be subject to such charges if their future performance deviates from our current estimates and assumptions. For reference, the combined goodwill of these units totaled $304.9 million and $367.3 million at September 30, 2024 and December 31, 2023, respectively. Â We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years. We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up. Amortization expense wasÂ $20.4 million andÂ $62.3 million for the three and nine months ended September 30, 2024, respectively. Amortization expense wasÂ $21.5 million andÂ $64.5 million for the three and nine months ended September 30, 2023, respectively. Â Fair Value Measurement, Policy [Policy Text Block] Fair value measurements. The carrying amounts of our cash, cash equivalents, restricted cash, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments. Investments that are considered equity securities as of September 30, 2024 and December 31, 2023 are predominately carried at fair value. Our debt under the Credit Agreement (as defined below) approximates fair value due to the variable rate of interest applicable to such debt. Â In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts. Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange. Refer to Note 9. Â Business Combinations Policy [Policy Text Block] Contingent consideration. Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense. Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability. Contingent considerationÂ mayÂ change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value whichÂ mayÂ have a material impact on our results from operations and financial position. Â Derivatives, Policy [Policy Text Block] Derivative financial instruments. We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges. For a derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At September 30, 2024 and December 31, 2023, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges. Accordingly, we recognized all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations. Refer to Note 10. In addition, we have determined the value of the embedded derivative liability within the 2029 Convertible 144A Notes (as defined in Note 7) and recorded it at fair value. Refer to Note 7. The changes in the fair value of the embedded derivatives are recognized in the fair value changes of derivatives instruments, net. Refer to Note 9. Â Property, Plant and Equipment, Policy [Policy Text Block] Property, plant and equipment. Property, plant and equipment are recorded at cost or fair value if acquired in a business combination. Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases. The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, and automobiles - 3-5 years. Expenditures for repairs and maintenance are charged to expense as incurred. Assets held under finance leases are included within Property, plant and equipment, net in our Condensed Consolidated Balance Sheets and are amortized over the shorter of their useful lives or the expected term of their related leases. Depreciation expense was $3.7 million andÂ $11.9 million for the three and nine months ended September 30, 2024, respectively. Depreciation expense wasÂ $4.8 million andÂ $14.8 million for the three and nine months ended September 30, 2023, respectively. Â Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Impairment of long-lived assets. Long-lived assets, such as property and equipment and assets held for sale, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. Â Income Tax, Policy [Policy Text Block] Income taxes. Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment. Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold. Â We operate in various countries and tax jurisdictions globally.Â For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results.Â For the nine months ended September 30, 2024, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit. Â Included in Other long-term liabilities is an accrual of $9.9 million related to uncertain tax positions involving income recognition. In connection with an examination of foreign tax returns for the 2015 through 2021 tax years, a foreign taxing authority has issued an income tax assessment of approximately $246Â million (including interest). We are appealing this assessment, as we believe, other than for uncertain tax positions for which we have reserved, the issues are without technical merit. We intend to exhaust all judicial remedies necessary to resolve the matter as necessary,Â which could be a lengthy process. There can be no assurance that this matter will be resolved in our favor, and an adverse outcome, or any future tax examinations involving similar assertions, could have a material adverse effect on our financial condition, results of operations and cash flows. Â Revenue from Contract with Customer [Policy Text Block] Revenue recognition. We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (â€œTopic 606â€). The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. Â We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. For a complete discussion of accounting for Revenues from services, Revenues from products and Revenue from transfer of intellectual property and other, refer to Note 13. Â Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of credit risk and allowance for credit losses. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions. Â While we have receivables due from federal and state governmental agencies, such receivables are not a credit risk because federal and state governments fund the related healthcare programs. Payment is primarily dependent upon submitting appropriate documentation. On September 30, 2024 and December 31, 2023, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were 6.5% and 6.7%, respectively, of our consolidated Accounts receivable, net. The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk. At September 30, 2024 and December 31, 2023, receivables due from patients represented approximately 2.2% and 2.0%, respectively, of our consolidated Accounts receivable, net. Â We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customerâ€™s ability to pay. Actual results could differ from those estimates. The allowance for credit losses was $2.0 million on each ofÂ September 30, 2024 and December 31, 2023. The credit loss expense for the three and nine months ended September 30, 2024, was a reversal expense of $75.2 thousand and $67.5 thousand of expense, respectively. The credit loss expense for the three and nine months ended September 30, 2023, wasÂ $98.3 thousand and $183.4 thousand, respectively. Â As of September 30, 2024, accounts receivable included $1.6 million of revenue earned under the BARDA Contract (as defined in Note 14). As of December 31, 2023, accounts receivable included $0.6 million under this contract. Refer to Note 13, Government Contract Revenue for further information on government contracts and to Note 14, Strategic Alliances for further information on the BARDA Contract. Â Stockholders' Equity, Policy [Policy Text Block] Stock Repurchase Program. On July 18, 2024, the Company announced that its Board of Directors authorized the repurchase of up to $100 millionÂ shares of Common Stock. Under this program, OPKO may repurchase shares through various methods, including open market purchases, block trades, privately negotiated transactions, and accelerated share repurchases, as well as pursuant to pre-set trading plans meeting the requirements of Rule 10b5-1(c) of the Exchange Act, and otherwise in compliance with applicable laws. The timing and volume of repurchases will depend on market conditions, the Company's capital management, investment opportunities, and other factors. The program does not obligate the Company to repurchase any specific number of shares, has no set expiration date, and may be modified, suspended, or discontinued at the Company's discretion. The Company repurchased 14,893,026 shares for approximately $23.8 million during the three months ended September 30, 2024. Â Compensation Related Costs, Policy [Policy Text Block] Equity-based compensation. We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award. We record excess tax benefits realized from the exercise of stock options as cash flows from operations. For the three and nine months ended September 30, 2024, we recordedÂ $2.8 million and $8.0 million, respectively, of equity-based compensation expense. For the three and nine months ended September 30, 2023, we recorded $3.2 million and $8.7 million, respectively, of equity-based compensation expense. Â Research and Development Expense, Policy [Policy Text Block] Research and development expenses. Research and development expenses include external and internal expenses. External

expenses include clinical and nonclinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs. Research and development employee-related expenses include salaries, benefits and equity-based compensation expense. Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities. We expense these costs in the period in which they are incurred. We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract. Â Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility, and which have no alternative future use. For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining estimated useful life. Â Segment Reporting, Policy [Policy Text Block] Segment reporting. Our chief operating decision-maker (â€œCODMâ€) is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Dr. Frost reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis. We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense or income taxes. Refer to Note 15. Â Shipping and Handling Costs [Policy Text Block] Shipping and handling costs. We do not charge customers for shipping and handling costs. Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations. Â Foreign Currency Transactions and Translations Policy [Policy Text Block] Foreign currency translation. The financial statements of certain of our foreign operations are measured using the local currency as the functional currency. The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date. The local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods. Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss). During the three and nine months ended September 30, 2024, we recorded foreign currency transaction income of $4.1 million and $0.1 million, respectively. During the three and nine months ended September 30, 2023, we recorded foreign currency transaction loss ofÂ $3.8 million and $1.9 million, respectively. Â Consolidation, Variable Interest Entity, Policy [Policy Text Block] Variable interest entities. The consolidation of a variable interest entity (â€œVIEâ€) is required when an enterprise has a controlling financial interest. A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIEâ€™s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE. Refer to Note 6. Â Investment, Policy [Policy Text Block] Investments. We have made strategic investments in development stage and emerging companies. We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees. For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations. Refer to Note 6. For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value. Refer to Note 6. Â New Accounting Pronouncements, Policy [Policy Text Block] Accounting standards yet to be adopted. Â In December 2023, the FASB issued ASU No. 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosuresâ€ (â€œASU 2023-09â€), which modifies the rules on income tax disclosures to require entities to disclose (i) specific categories in the rate reconciliation, (ii) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (iii) income tax expense or benefit from continuing operations (separated by federal, state and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state, and local jurisdictions, among other changes. The guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. ASU 2023-09 should be applied on a prospective basis, but retrospective application is permitted. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures. Â In November 2023, the FASB issued ASU No 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (â€œASU 2023-07â€). ASU 2023-07 enhances disclosures for significant segment expenses for all public entities required to report segment information in accordance with ASC 280. ASC 280 requires a public entity to report for each reportable segment a measure of segment profit or loss that its CODM uses to assess segment performance and to make decisions about resource allocations. The ASU is effective for fiscal years beginning after December 15, 2024 with updates to be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures. Â Recently adopted accounting standards. Â In 2021, the Organization for Economic Co-operation and Development (â€œOECDâ€) established an inclusive framework on base erosion and profit shifting and agreed on a two-pillar solution (â€œPillar Twoâ€) to global taxation, focusing on global profit allocation and a 15% global minimum effective tax rate. On December 15, 2022, the EU member states agreed to implement the OECDâ€™s global minimum tax rate of 15%. The OECD issued Pillar Two model rules and continues to release guidance on these rules. The inclusive framework calls for tax law changes by participating countries to take effect in 2024 and 2025. Various countries have enacted or have announced plans to enact new tax laws to implement the global minimum tax. We considered the applicable tax law changes on Pillar Two implementation in the relevant countries, and there is no material impact to our tax results for the period. We anticipate further legislative activity and administrative guidance in 2024, and will continue to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in the non-US tax jurisdictions we operate in. Â X - DefinitionDisclosure of the company's policy regarding shipping and handling costs. + ReferencesNo definition available. + Details Name: opk_ShippingAndHandlingCostsPolicyTextBlock Namespace Prefix: opk_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4 + Details Name: us-gaap_BusinessCombinationsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_CompensationRelatedCostsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Paragraph 2AA -Subparagraph (a) -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-2AAReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A + Details Name: us-gaap_ConsolidationVariableInterestEntityPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for its derivative instruments and hedging activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(n)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7 + Details Name: us-gaap_DerivativesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent + Details Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X -

DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContentReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6 + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment in financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap_InvestmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1 + Details Name: us-gaap_StockholdersEquityPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Cash and Cash Equivalents [Table Text Block] Â Â September 30, 2024 Â Â December 31, 2023 Â Cash and cash equivalents Â $400,079Â Â $95,881Â Restricted cash, current Â Â 6,321Â Â Â Â â€”Â Restricted cash, long-term Â Â 13,665Â Â Â Â â€”Â Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows Â $420,065Â Â $95,881Â X - DefinitionTabular disclosure of the components of cash and cash equivalents. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Earnings (Loss) Per Share (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Â Â For the three months ended September 30, Â Â For the nine months ended September 30, Â (In thousands, except per share data) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Numerator Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income (loss), basic Â $24,890Â Â $(84,473)Â $(67,251)Â $(122,380) Add: Interest on 2025 Notes Â Â 1Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Add: Interest on 2029 Convertible Notes Â Â 6,858Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Add: Loss on buy back of 2029 Convertible Notes Â Â 32Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Net income (loss), diluted Â $31,781Â Â $(84,473)Â $(67,251)Â $(122,380) Â Denominator Â (Shares in thousands) Â Weighted average common shares outstanding, basic Â Â 694,622,466Â Â Â 751,525,007Â Â Â 699,675,944Â Â Â 751,716,692Â Effect of dilutive securities: Â Stock options Â Â 76,922Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Warrants Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â 2025 Notes Â Â 48,295Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â 2023 Convertible Notes Â Â -Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â 2033 Senior Notes Â Â 8,489Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â 2029 Convertible Notes Â Â 303,607,464Â Dilutive potential shares Â Â 303,741,170Â Â Â -Â Â Â -Â Â Â -Â Â Â -Â Weighted average common shares outstanding, diluted Â Â 998,363,636Â Â Â 751,525,007Â Â Â 699,675,944Â Â Â 751,716,692Â Â Loss per share, basic Â $0.04Â Â $(0.11)Â $(0.10)Â $(0.16) Loss per share, diluted Â $0.03Â Â $(0.11)Â $(0.10)Â $(0.16) X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type:

xbrli:stringItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Composition of Certain Financial Statement Captions (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Condensed Balance Sheet [Table Text Block] Â Â September 30, Â Â December 31, Â (In thousands) Â 2024 Â Â 2023 Â Accounts receivable, net: Â Â Â Â Â Â Â Â Accounts receivable Â $108,583Â Â $125,379Â Less: allowance for credit losses Â Â (2,004)Â Â (2,000) Â Â $106,579Â Â $123,379Â Inventories, net: Â Â Â Â Â Â Â Â Consumable supplies Â $16,218Â Â $25,864Â Finished products Â Â 34,206Â Â Â 35,582Â Work in-process Â Â 2,265Â Â Â 1,731Â Raw materials Â Â 10,491Â Â Â 8,981Â Less: inventory reserve Â Â (3,772)Â Â (6,461) Â Â $59,408Â Â $65,697Â Other current assets and prepaid expenses: Â Â Â Â Â Â Â Â Escrow receivable Â $23,750Â Â $â€”Â Taxes recoverable Â Â 6,767Â Â Â 4,211Â Prepaid expenses Â Â 9,572Â Â Â 6,177Â Prepaid insurance Â Â 6,302Â Â Â 3,848Â Other receivables Â Â 1,563Â Â Â 2,610Â Other Â Â 9,295Â Â Â 7,673Â Â Â $57,249Â Â $24,519Â Intangible assets, net: Â Â Â Â Â Â Â Â Customer relationships Â $258,048Â Â $315,799Â Technologies Â Â 818,971Â Â Â 831,509Â Trade names Â Â 49,759Â Â Â 49,758Â Covenants not to compete Â Â 12,917Â Â Â 12,916Â Licenses Â Â 6,311Â Â Â 6,205Â Product registrations Â Â 6,738Â Â Â 6,790Â Other Â Â 6,052Â Â Â 6,000Â Less: accumulated amortization Â Â (517,400)Â Â (488,694) Â Â $641,396Â Â $740,283Â Accrued expenses: Â Â Â Â Â Â Â Â Employee benefits and severance Â $38,474Â Â $28,952Â Clinical trials Â Â 3,725Â Â Â 7,624Â Commitments and contingencies Â Â 11,141Â Â Â 8,088Â Accrued interest Â Â 6,021Â Â Â 2,601Â Gross to net provision Â Â 6,033Â Â Â 9,420Â Inventory received but not invoiced Â Â 2,306Â Â Â 1,653Â Finance leases short-term Â Â 1,855Â Â Â 2,827Â Professional fees Â Â 4,375Â Â Â 3,470Â Taxes payable Â Â 15,334Â Â Â 1,384Â Royalties Â Â 767Â Â Â 1,544Â Commissions Â Â 1,521Â Â Â 1,822Â Other Â Â 31,254Â Â Â 20,701Â Â Â $122,806Â Â $90,086Â Other long-term liabilities: Â Â Â Â Â Â Â Â Employee severance Â $16,284Â Â $â€”Â Mortgages and other debts payable Â Â 3,529Â Â Â 7,709Â Finance leases long-term Â Â 4,689Â Â Â 7,274Â Contract liabilities Â Â 7Â Â Â 7Â Other Â Â 11,995Â Â Â 12,199Â Â Â $36,504Â Â $27,189Â Schedule of Goodwill [Table Text Block] Â Â 2024 Â (In thousands) Â Gross goodwill at January 1, 2024 Â Â Cumulative impairment at January 1 Â Â Acquisitions, dispositions and other Â Â Foreign exchange and other Â Â Balance at September 30, 2024 Â Pharmaceuticals Â Â Â Â Â Â Â Â

Total Â Assets: Â Money market funds Â $ 32,404 Â Â $ â€” Â Â $ â€” Â Â $ 32,404 Â Equity securities Â Â 116 Â Â Â â€” Â Â Â â€” Â Â $ 116 Â Equity Method - fair value option Â Â 9,786 Â Â Â â€” Â Â Â â€” Â Â Â 9,786 Â Common stock options/warrants Â Â â€” Â Â Â 2 Â Â Â â€” Â Â Â 2 Â Total assets Â $ 42,306 Â Â $ 2 Â Â $ â€” Â Â $ 42,308 Â Liabilities: Â Forward contracts Â Â â€” Â Â Â 29 Â Â Â â€” Â Â Â 29 Â Total liabilities Â $ â€” Â Â $ 29 Â Â $ â€” Â Â $ 29 Â Fair Value, by Balance Sheet Grouping [Table Text Block] Â Â September 30, 2024 Â Â Â Carrying Â Â Total Â (In thousands) Â Value Â Â Fair Value Â Â Level 1 Â Â Level 2 Â Â Level 3 Â 2029 Convertible Notes Â $ 178,645 Â Â $ 396,652 Â Â $ â€” Â Â $ 396,652 Â Â $ â€” Â 2025 Notes Â $ 170 Â Â $ 170 Â Â $ â€” Â Â $ 170 Â Â $ â€” Â Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Â Â September 30, 2024 Â Â Â Embedded conversion Â (In thousands) Â option Â Balance at December 31, 2023 Â $ â€” Â Additions Â Â 125,620 Â Change in fair value: Â Â Â Â Included in results of operations Â Â 26,250 Â Reclassification of embedded derivatives to equity Â Â (151,870) Balance at September 30, 2024 Â $ â€” Â X - DefinitionTabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 + Details Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Note 10 - Derivative Contracts (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Â Balance Sheet Â September 30, Â Â December 31, Â (In thousands) Component Â 2024 Â Â 2023 Â Derivative financial instruments: Â Â Â Â Â Â Â Â Common Stock options/warrants Investments, net Â $ 2 Â Â $ 2 Â Forward contracts Unrealized losses on forward contracts are recorded in Accrued expenses. Â $ â€” Â Â $ (29) Derivative Instruments, Gain (Loss) [Table Text Block] Â Â Three months ended September 30, Â Â Nine months ended September 30, Â (In thousands) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Derivative gain (loss): Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Notes Â $ â€” Â Â $ â€” Â Â $ (26,250) Â $ â€” Â Common Stock options/warrants Â Â (1) Â Â (37) Â Â 1 Â Â Â (27) Forward contracts Â Â â€” Â Â Â 125 Â Â Â 88 Â Â Â (802) Total Â $ (1) Â $ 88 Â Â $ (26,161) Â $ (829) X - DefinitionTabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Note 13 - Revenue Recognition (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Disaggregation of Revenue [Table Text Block] Â Â Three months ended September 30, Â Â Nine months ended September 30, Â (In thousands) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Healthcare insurers Â $76,184Â Â $81,469Â Â $229,600Â Â $238,934Â Government payers Â Â 20,368Â Â Â 19,909Â Â Â 63,561Â Â Â 61,250Â Client payers Â Â 20,773Â Â Â 25,906Â Â Â 71,521Â Â Â 77,973Â Patients Â Â 3,946Â Â Â 4,395Â Â Â 12,875Â Â Â 12,943Â Total Â $121,271Â Â $131,679Â Â $377,557Â Â $391,100Â Schedule of Product Sales Allowances and Accruals [Table Text Block] (In thousands) Â Chargebacks, discounts, rebates and fees Â Â Governmental Â Â Returns Â Â Total Â Balance at June 30, 2024 Â $2,743Â Â $5,991Â Â $2,194Â Â $10,928Â Provision related to current period sales Â Â 4,005Â Â Â 5,776Â Â Â 317Â Â Â 10,098Â Credits or payments made Â Â (5,058)Â Â (7,013)Â Â (278)Â Â (12,349) Balance at September 30, 2024 Â $1,690Â Â $4,754Â Â $2,233Â Â $8,677Â Total gross Rayaldee sales Â $15,865Â Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales Â 64% (In thousands) Â Chargebacks, discounts, rebates and fees Â Â Governmental Â Â Returns Â Â Total Â Balance at December 31, 2023 Â $2,578Â Â $6,150Â Â $2,192Â Â $10,920Â Provision related to current period sales Â Â 12,224Â Â Â 16,325Â Â Â 989Â Â Â 29,538Â Credits or payments made Â Â (13,112)Â Â (17,721)Â Â (948)Â Â (31,781) Balance at September 30, 2024 Â $1,690Â Â $4,754Â Â $2,233Â Â $8,677Â Total gross Rayaldee sales Â $49,447Â Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales Â 60% (In thousands) Â Chargebacks, discounts, rebates and fees Â Â Governmental Â Â Returns Â Â Total Â Balance at June 30, 2023 Â $2,330Â Â $5,954Â Â $1,634Â Â $9,918Â Provision related to current period sales Â Â 3,446Â Â Â 4,998Â Â Â 322Â Â Â 8,766Â Credits or payments made Â Â (4,125)Â Â (4,207)Â Â (15)Â Â (8,347) Balance at September 30, 2023 Â $1,651Â Â $6,745Â Â $1,941Â Â $10,337Â Total gross Rayaldee sales Â $16,090Â Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales Â 54% (In thousands) Â Chargebacks, discounts, rebates and fees Â Â Governmental Â Â Returns Â Â Total Â Balance at December 31, 2022 Â $1,532Â Â $5,063Â Â $1,683Â Â $8,278Â Provision related to current period sales Â Â 10,702Â Â Â 14,604Â Â Â 959Â Â Â 26,265Â Credits or payments made Â Â (10,583)Â Â (12,922)Â Â (701)Â Â (24,206) Balance at September 30, 2023 Â $1,651Â Â $6,745Â Â $1,941Â Â $10,337Â Total gross Rayaldee sales Â $47,940Â Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales Â 55% X - DefinitionTabular disclosure of product sales allowances and accruals. + ReferencesNo definition available. + Details Name: opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock Namespace Prefix: opk_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Note 15 - Segments (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Segment Reporting Information, by Segment [Table Text Block] Â Â For the three months ended September 30, Â Â For the nine months ended September 30, Â (In thousands) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue from services: Â Pharmaceutical Â $â€”Â Â $â€”Â Â $â€”Â Â $â€”Â Diagnostics Â Â 121,271Â Â Â 131,679Â Â Â 377,557Â Â Â 391,100Â Corporate Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â Â $121,271Â Â $131,679Â Â $377,557Â Â $391,100Â Revenue from products: Â Pharmaceutical Â $39,143Â Â $40,670Â Â $117,675Â Â $124,553Â Diagnostics Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Corporate Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â Â $39,143Â Â $40,670Â Â $117,675Â Â $124,553Â Revenue from transfer of intellectual property and other: Â Pharmaceutical Â $13,218Â Â $6,246Â Â $34,272Â Â $165,938Â Diagnostics Â Â â€”Â Â Â â€”Â Â Â â€”Â Corporate Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â Â $13,218Â Â $6,246Â Â $34,272Â Â $165,938Â Operating income (loss): Â Pharmaceutical Â $(32,196)Â $(25,375)Â $(84,697)Â $57,210Â Diagnostics Â Â 58,541Â Â Â 29,081)Â Â (2,443)Â Â (113,344) Corporate Â Â (12,129)Â Â (9,951)Â Â (31,786)Â Â (31,841) Â Â $14,216Â Â $(64,407)Â $(118,926)Â $(87,975) Depreciation and amortization: Â Pharmaceutical Â $18,043Â Â $17,807Â Â $53,899Â Â $53,649Â Diagnostics Â Â 6,120Â Â Â 8,376Â Â Â 20,238Â Â Â 25,666Â Corporate Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â Â $24,163Â Â $26,183Â Â $74,137Â Â $79,315Â Loss from investment in investees: Â Pharmaceutical Â $(3)Â $(20)Â $(7)Â $(99) Diagnostics Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Corporate Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â Â $(3)Â $(20)Â $(7)Â $(99) Revenues: Â United States Â $132,663Â Â $139,043Â Â $410,422Â Â $462,987Â Ireland Â Â 11,514Â Â Â 8,654Â Â Â 30,579Â Â Â 121,249Â Chile Â Â 16,576Â Â Â 16,932Â Â Â 49,067Â Â Â 52,427Â Spain Â Â 6,297Â Â Â 4,349Â Â Â 17,828Â Â Â 16,427Â Israel Â Â 196Â Â Â 3,155Â Â Â 797Â Â Â 9,388Â Mexico Â Â 5,630Â Â Â 5,897Â Â Â 18,621Â Â Â 17,447Â Other Â Â 756Â Â Â 565Â Â Â 2,190Â Â Â 1,666Â Â Â $173,632Â Â $178,595Â Â $529,504Â Â $681,591Â Reconciliation of Assets from Segment to Consolidated [Table Text Block] Â Â September 30, Â Â December 31, Â (In thousands) Â 2024 Â Â 2023 Â Assets: Â Â Â Â Â Â Â Â Pharmaceutical Â $1,271,781Â Â $1,331,764Â Diagnostics Â Â 517,871Â Â Â 630,753Â Corporate Â Â 466,451Â Â Â 49,181Â Â Â $2,256,103Â Â $2,011,698Â Goodwill: Â Â Â Â Â Â Â Â Pharmaceutical Â $316,161Â Â $315,235Â Diagnostics Â Â 219,707Â Â Â 283,025Â Â Â $535,868Â Â $598,260Â X - DefinitionTabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Note 16 - Leases (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Assets and Liabilities, Lessee [Table Text Block] (in thousands) Classification on the Balance Sheet Â September 30, 2024 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Â Â Operating lease assets Operating lease right-of-use assets Â $62,812Â Â $68,088Â Finance lease assets Property, plant and equipment, net Â Â 6,544Â Â Â 10,101Â Â Â Â Â Â Â Â Â Â Â Â Liabilities Â Â Â Â Â Â Â Â Current Â Â Â Â Â Â Â Â Operating lease liabilities Current maturities of operating leases Â Â 12,741Â Â Â 12,996Â Accrued expenses Current maturities of finance leases Â Â 1,855Â Â Â 2,827Â Long-term Â Â Â Â Â Â Â Â Operating lease liabilities Operating lease liabilities Â Â 52,057Â Â Â 54,140Â Other long-term liabilities Finance lease liabilities Â $4,689Â Â $7,274Â Â Â Â Â Â Â Â Â Â Â Â Weighted average remaining lease term Â Â Â Â Â Â Â Â Operating leases (in years) Â Â 6.3Â Â Â 7.1Â Finance leases (in years) Â Â 7.1Â Â Â 6.2Â Weighted average discount rate Â Â Â Â Â Â Â Â Operating leases Â Â 5.3%Â Â 5.4% Finance leases Â Â 3.7%Â Â 3.8% Lessee, Lease Liability, Maturity [Table Text Block] (in thousands) Â Operating Â Â Finance Â October 1, 2024 through December 31, 2024 Â $3,043Â Â $673Â 2025 Â Â 11,772Â Â Â 1,813Â 2026 Â Â 10,937Â Â Â 1,334Â 2027 Â Â 10,775Â Â Â 806Â 2028 Â Â 10,785Â Â Â 203Â Thereafter Â Â 26,534Â Â Â 1,959Â Total undiscounted future minimum lease payments Â Â 73,846Â Â Â 6,788Â Less: Difference between lease payments and discounted lease liabilities Â Â 9,048Â Â Â 244Â Total lease liabilities Â $64,798Â Â $6,544Â Schedule of Supplemental Cash Flow Information of Leases [Table Text Block] Â Â For the nine months ended September 30, Â (in thousands) Â 2024 Â Â 2023 Â Operating cash out flows from operating leases Â $15,101Â Â $11,704Â Operating cash out flows from finance leases Â Â 354Â Â Â 327Â Financing cash out flows from finance leases Â Â 2,118Â Â Â 1,919Â Total Â $17,573Â Â $13,950Â X - DefinitionTabular disclosure of lessee's assets and liabilities. + ReferencesNo definition available. + Details Name: opk_AssetsAndLiabilitiesLesseeTableTextBlock Namespace Prefix: opk_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of operating and finance lease liability. + ReferencesNo definition available. + Details Name: opk_LesseeLeaseLiabilityMaturityTableTextBlock Namespace Prefix: opk_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of supplemental cash information related to leases. + ReferencesNo definition available. + Details Name: opk_ScheduleOfSupplementalCashFlowInformationOfLeasesTableTextBlock Namespace Prefix: opk_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Business and Organization (Details Textual) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Mar. 28, 2024 Dec. 31, 2023 Escrow Deposit $ 23,750 Â $ 23,750 Â Â $ 0 Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal 121,493 $ (0) 121,493 $ (0) Â Â Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member] | Select Assets of BioReference [Member] |

Labcorp [Member] Â Â Â Â Â Â Disposal Group, Including Discontinued Operation, Consideration Â Â Â Â $ 237,500 Â Escrow Deposit Â Â Â Â $ 23,700 Â Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal $ 121,500 Â $ 121,500 Â Â Â X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5 + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1 + Details Name: us-gaap_EscrowDeposit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=opk_SelectAssetsOfBioreferenceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=opk_LabcorpMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Foreign Exchange Rates (Details Textual) $ in Millions 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 Dec. 31, 2023 USD ($) Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax $ 36.2 Â $ 34.6 Foreign Exchange Forward [Member] Â Â Â Derivative, Number of Instruments Held 0 Â 52 Derivative, Notional Amount Â Â $ 2.9 Currency Concentration Risk [Member] | Revenue Benchmark [Member] | Other Currency [Member] Â Â Â Concentration Risk, Percentage 22.30% 30.70% Â X - DefinitionAccumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-5AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNominal or face amount used to calculate payment on derivative. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionThe number of derivative instruments of a particular group held by the entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column C)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNumberOfInstrumentsHeld Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=opk_CurrencyConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CurrencyAxis=srt_OtherCurrencyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Jan. 09, 2024 USD ($) Sep. 30, 2024 USD ($) shares Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Jul. 18, 2024 USD ($) Inventory Write-down Â $ 600 $ 2,600 $ 1,600 $ 4,000 Â Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets Â 1,400,000 Â 1,400,000 Â $ 1,500,000 Â Goodwill Â 535,868 Â 535,868 Â 598,260 Â Indefinite-Lived Intangible Assets (Excluding Goodwill) Â 836,400 Â 836,400 Â 836,400 Â Amortization of Intangible Assets Â 20,433 21,534 62,290 64,543 Â Â Depreciation Â 3,700 4,800 $ 11,900 14,800 Â Â Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Â Â Â 21.00% Â Â Â Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Â 9,900 Â $ 9,900 Â Â Â Open Tax Year Â Â Â 2015 2016 2017 2018 2019 2020 2021 Â Â Â Accounts Receivable, Allowance for Credit Loss, Current Â 2,004 Â $ 2,004 Â 2,000 Â Accounts Receivable, Credit Loss Expense (Reversal) Â (75,200) 98,300 67,500 183,400 Â Â Stock Repurchased During Period, Value $ 50,000 23,759 Â 73,759 Â Â Â Share-Based Payment Arrangement, Noncash Expense Â 2,800 3,200 $ 7,983 8,746 Â Â Number of Reportable Segments Â Â Â 2 Â Â Â Gain (Loss), Foreign Currency Transaction, before Tax Â $ 4,100 $ (3,800) $ 100 $ (1,900) Â Â Repurchase of Common Stock [Member] Â Â Â Â Â Â Â Share Repurchase Program, Authorized, Amount Â Â Â Â Â Â $ 100,000 Stock Repurchased During Period, Shares (in shares) | shares Â 14,893,026 Â Â Â Â Â Stock Repurchased During Period, Value Â $ 23,800 Â Â Â Â Â Government Contract, BARDA [Member] Â Â Â Â Â Â Â Accounts Receivable, after Allowance for Credit Loss Â $ 1,600 Â $ 1,600 Â $ 600 Â Customer Concentration Risk [Member] | Accounts Receivable [Member] | Medicare and Medicaid [Member] Â Â Â Â Â Â Â Concentration Risk, Percentage Â Â Â 6.50% Â 6.70% Â Customer Concentration Risk [Member] | Accounts Receivable [Member] | Individual Patients [Member] Â Â Â Â Â Â Â Â Concentration Risk, Percentage Â Â Â 2.20% Â 2.00% Â Israel Tax Authority [Member] Â Â Â Â Â Â Â Income Tax Examination, Estimate of Possible Loss Â Â Â $ 246,000 Â Â Â Â Software and Software Development Costs [Member] Â Â Â Â Â Â Â Property, Plant and Equipment, Useful Life (Year) Â 3 years Â 3 years Â Â Â Minimum [Member] Â Â Â Â Â Â Â Â Finite-Lived Intangible Asset, Useful Life (Year) Â 3 years Â 3 years Â Â Â Minimum [Member] | Machinery and Equipment [Member] Â Â Â Â Â Â Â Property, Plant and Equipment, Useful Life (Year) Â 5 years Â 5 years Â Â Â Minimum [Member] | Furniture and Fixtures [Member] Â Â Â Â Â Â Â Property, Plant and Equipment, Useful Life (Year) Â 5 years Â 5 years Â Â Â Minimum [Member] | Building and Building Improvements [Member] Â Â Â Â Â Â Â Property, Plant and Equipment, Useful Life (Year) Â 10 years Â 10 years Â Â Â Minimum [Member] | Vehicles [Member] Â Â Â Â Â Â Â Property, Plant and Equipment, Useful Life (Year) Â 3 years Â 3 years Â Â Â Maximum [Member] Â Â Â Â Â Â Â Finite-Lived Intangible Asset, Useful Life (Year) Â 20 years Â 20 years Â Â Â Maximum [Member] | Machinery and Equipment [Member] Â Â Â Â Â Â Â Property, Plant and Equipment, Useful Life (Year) Â 8 years Â 8 years Â Â Â Maximum [Member] | Furniture and Fixtures [Member] Â Â Â Â Â Â Â Property, Plant and Equipment, Useful Life (Year) Â 12 years Â 12 years Â Â Â Maximum [Member] | Building and Building Improvements [Member] Â Â Â Â Â Â Â Property, Plant and Equipment, Useful Life (Year) Â 40 years Â 40 years Â Â Â Maximum [Member] | Vehicles [Member] Â Â Â Â Â Â Â Property, Plant and Equipment, Useful Life (Year) Â 5 years Â 5 years Â Â Â IRELAND Â Â Â Â Â Â Â Goodwill Â $ 304,900 Â $ 304,900 Â $ 367,300 Â In Process Research and Development [Member] Â Â Â Â Â Â Â Indefinite-Lived Intangible Assets (Excluding Goodwill) Â $ 195,000 Â $ 195,000 Â $ 195,000 Â X - DefinitionRepresents the amount of goodwill and intangible assets acquired as part of a business combination. + ReferencesNo definition available. + Details Name: opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4 + Details Name: srt_StockRepurchaseProgramAuthorizedAmount1 Namespace Prefix: srt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_AccountsReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -

Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of domestic federal statutory tax rate applicable to pretax income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.1.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionEstimated amount of loss resulting from an adverse tax position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15 + Details Name: us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2 + Details Name: us-gaap_InventoryWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionTax year that remains open to examination under enacted tax laws, in YYYY format. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15 + Details Name: us-gaap_OpenTaxYear Namespace Prefix: us-gaap_ Data Type: dtr-types:gYearListItemType Balance Type: na Period Type: duration X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15 + Details Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_ShareRepurchaseProgramAxis=opk_RepurchaseOfCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=opk_GovernmentContractBardaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=opk_MedicareAndMedicaidMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=opk_IndividualPatientsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_IE Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Summary of Significant Accounting Policies - Reconciliation of Cash (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Cash and cash equivalents $ 400,079 $ 95,881 Restricted cash, current 6,321 0 Restricted cash, long-term 13,665 0 Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows $ 420,065 $ 95,881 X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X -

DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5 + Details Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Earnings (Loss) Per Share (Details Textual) - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 0 83,074,689 286,281,585 82,368,398 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares) 0 18,750 0 18,750 Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares) 0 0 549,687 549,680 Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares) 0 18,750 384,378 405,721 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Net income (loss), basic $ 24,890 $ (84,473) $ (67,251) $ (122,380) Add: Loss on buy back of 2029 Convertible Notes 32 0 0 0 Net income (loss), diluted $ 31,781 $ (84,473) $ (67,251) $ (122,380) Weighted average common shares outstanding, basic (in shares) 694,622,466 751,525,007 699,675,944 751,716,692 Stock options (in shares) 76,922 0 0 0 Warrants (in shares) 0 0 0 0 Dilutive potential shares (in shares) 303,741,170 0 0 0 Weighted average common shares outstanding, diluted (in shares) 998,363,636 751,525,007 699,675,944 751,716,692 Loss per share, basic (in dollars per share) $ 0.04 $ (0.11) $ (0.1) $ (0.16) Loss per share, diluted (in dollars per share) $ 0.03 $ (0.11) $ (0.1) $ (0.16) The 2025 Notes [Member] Â Â Â Â Add: Interest on Notes $ 1 $ 0 $ 0 $ 0 Notes (in shares) 48,295 0 0 0 The 2029 Convertible Notes [Member] Â Â Â Â Add: Interest on Notes $ 6,858 $ 0 $ 0 $ 0 Notes (in shares) 303,607,464 The 2023 Convertible Notes [Member] Â Â Â Â Notes (in shares) 0 0 0 0 The 2033 Senior Notes [Member] Â Â Â Â Notes (in shares) 8,489 0 0 0 X - DefinitionAmount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units. + ReferencesNo definition available. + Details Name: us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting

Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-26 + Details Name: us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_InterestOnConvertibleDebtNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2025NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2029ConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2023ConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2033SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Composition of Certain Financial Statement Captions (Details Textual) Sep. 30, 2024 Minimum [Member] Â Finite-Lived Intangible Asset, Useful Life (Year) 3 years Maximum [Member] Â Finite-Lived Intangible Asset, Useful Life (Year) 20 years Developed Technology Rights [Member] | Minimum [Member] Â Finite-Lived Intangible Asset, Useful Life (Year) 7 years Developed Technology Rights [Member] | Maximum [Member] Â Finite-Lived Intangible Asset, Useful Life (Year) 17 years Customer Relationships [Member] | Minimum [Member] Â Finite-Lived Intangible Asset, Useful Life (Year) 5 years Customer Relationships [Member] | Maximum [Member] Â Finite-Lived Intangible Asset, Useful Life (Year) 20 years Project Registration [Member] | Minimum [Member] Â Finite-Lived Intangible Asset, Useful Life (Year) 7 years Project Registration [Member] | Maximum [Member] Â Finite-Lived Intangible Asset, Useful Life (Year) 10 years Noncompete Agreements [Member] Â Finite-Lived Intangible Asset, Useful Life (Year) 5 years Trade Names [Member] | Minimum [Member] Â Finite-Lived Intangible Asset, Useful Life (Year) 5 years Trade Names [Member] | Maximum [Member] Â Finite-Lived Intangible Asset, Useful Life (Year) 10 years Other Intangible Assets [Member] | Minimum [Member] Â Finite-Lived Intangible Asset, Useful Life (Year) 9 years Other Intangible Assets [Member] | Maximum [Member] Â Finite-Lived Intangible Asset, Useful Life (Year) 13 years X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=opk_ProjectRegistrationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Composition of Certain Financial Statement Captions - Schedule of Financial Statement Information (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accounts receivable $ 108,583 $ 125,379 Less: allowance for credit losses (2,004) (2,000) Accounts Receivable, after Allowance for Credit Loss, Current 106,579 123,379 Consumable supplies 16,218 25,864 Finished products 34,206 35,582 Work in-process 2,265 1,731 Raw materials 10,491 8,981 Less: inventory reserve (3,772) (6,461) Inventory, Net 59,408 65,697 Escrow receivable 23,750 0 Taxes recoverable 6,767 4,211 Prepaid expenses 9,572 6,177 Prepaid insurance 6,302 3,848 Other receivables 1,563 2,610 Other 9,295 7,673 Prepaid Expense and Other Assets, Current 57,249 24,519 Less: accumulated amortization (517,400) (488,694) Finite-Lived Intangible Assets, Net 641,396 740,283 Employee benefits and severance 38,474 28,952 Clinical trials 3,725 7,624 Commitments and contingencies 11,141 8,088 Accrued interest 6,021 2,601 Gross to net provision 6,033 9,420 Inventory received but not invoiced 2,306 1,653 Finance leases short-term 1,855 2,827 Professional fees 4,375 3,470 Taxes payable 15,334 1,384 Royalties 767 1,544 Commissions 1,521 1,822 Other 31,254 20,701 Accrued Liabilities, Current 122,806 90,086 Employee severance 16,284 0 Mortgages and other debts payable 3,529 7,709 Finance leases long-term 4,689 7,274 Contract liabilities 7 7 Other 11,995 12,199 Other Liabilities, Noncurrent 36,504 27,189 Customer Relationships [Member] Â Â Finite lived intangible assets, gross 258,048 315,799 Technology-Based Intangible Assets [Member] Â Â Finite lived intangible assets, gross 818,971 831,509 Trade Names [Member] Â Â Finite lived intangible assets, gross 49,759 49,758 Noncompete Agreements [Member] Â Â Finite lived intangible assets, gross 12,917 12,916 Licensing Agreements [Member] Â Â Finite lived intangible assets, gross 6,311 6,205 Project Registration [Member] Â Â Finite lived intangible assets, gross 6,738 6,790 Other Intangible Assets [Member] Â Â Finite lived intangible assets, gross $ 6,052 $ 6,000 X - DefinitionRepresents the amount of clinical trial costs included in accrued liabilities. + ReferencesNo definition available. + Details Name: opk_AccruedClinicalTrials Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the amount of commitments and contingencies included in current accrued commitments. + ReferencesNo definition available. + Details Name: opk_AccruedCommitmentsAndContingenciesCurrent Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the amount of net provision costs gross included in accrued liabilities. + ReferencesNo definition available. + Details Name: opk_AccruedGrossToNetProvision Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of inventory not yet billed included in accrued liabilities. + ReferencesNo definition available. + Details Name: opk_AccruedInventoryNotYetBilled Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsAndOtherReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1 + Details Name: us-gaap_AccountsReceivableGrossCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedEmployeeBenefitsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedRoyaltiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedSalesCommissionCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1 + Details Name: us-gaap_EscrowDeposit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InterestPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterials Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of valuation reserve for inventory. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryValuationReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherInventorySupplies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate carrying amount, as of the balance sheet date, of noncurrent obligations and noncurrent portion of deferred revenue not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer). Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. + ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt classified as other, payable after one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(13)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_OtherLongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFor a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 712 -SubTopic 10 -Name Accounting Standards Codification -Section 25 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481179/712-10-25-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 712 -SubTopic 10 -Name Accounting Standards Codification -Section 25 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481179/712-10-25-5 + Details Name: us-

gaap_PostemploymentBenefitsLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidTaxes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TaxesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=opk_ProjectRegistrationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Composition of Certain Financial Statement Captions - Schedule of Goodwill (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Goodwill, gross $ 636,283 Goodwill, impairment (38,023) Goodwill, acquired (disposed of) (63,318) Goodwill, foreign exchange effect 926 Goodwill 535,868 Pharmaceutical [Member] | CURNA [Member] Â Goodwill, gross 4,827 Goodwill, impairment (4,827) Goodwill, acquired (disposed of) 0 Goodwill, foreign exchange effect 0 Goodwill 0 Pharmaceutical [Member] | Rayaldee [Member] Â Goodwill, gross 84,273 Goodwill, impairment 0 Goodwill, acquired (disposed of) 0 Goodwill, foreign exchange effect 925 Goodwill 85,198 Pharmaceutical [Member] | FineTech [Member] Â Goodwill, gross 11,698 Goodwill, impairment (11,698) Goodwill, acquired (disposed of) 0 Goodwill, foreign exchange effect 0 Goodwill 0 Pharmaceutical [Member] | ModeX Therapeutics, Inc [Member] Â Goodwill, gross 80,260 Goodwill, impairment 0 Goodwill, acquired (disposed of) 0 Goodwill, foreign exchange effect 0 Goodwill 80,260 Pharmaceutical [Member] | OPKO Biologics [Member] Â Goodwill, gross 139,784 Goodwill, impairment 0 Goodwill, acquired (disposed of) 0 Goodwill, foreign exchange effect (0) Goodwill 139,784 Pharmaceutical [Member] | OPKO Chile [Member] Â Goodwill, gross 3,642 Goodwill, impairment 0 Goodwill, acquired (disposed of) 0 Goodwill, foreign exchange effect (81) Goodwill 3,561 Pharmaceutical [Member] | OPKO Health Europe [Member] Â Goodwill, gross 7,276 Goodwill, impairment 0 Goodwill, acquired (disposed of) 0 Goodwill, foreign exchange effect 82 Goodwill 7,358 Pharmaceutical [Member] | OPKO Mexico [Member] Â Goodwill, gross 100 Goodwill, impairment (100) Goodwill, acquired (disposed of) 0 Goodwill, foreign exchange effect 0 Goodwill 0 Pharmaceutical [Member] | Transition Therapeutics [Member] Â Goodwill, gross 3,421 Goodwill, impairment (3,421) Goodwill, acquired (disposed of) 0 Goodwill, foreign exchange effect 0 Goodwill 0 Diagnostics [Member] | BioReference [Member] Â Goodwill, gross 283,025 Goodwill, impairment 0 Goodwill, acquired (disposed of) (63,318) Goodwill, foreign exchange effect 0 Goodwill 219,707 Diagnostics [Member] | OPKO Diagnostics [Member] Â Goodwill, gross 17,977 Goodwill, impairment (17,977) Goodwill, acquired (disposed of) 0 Goodwill, foreign exchange effect 0 Goodwill $ 0 X - DefinitionRepresents the amount of goodwill acquired (disposed of) during the period. + ReferencesNo definition available. + Details Name: opk_GoodwillAcquiredDisposedOfDuringPeriod Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillForeignCurrencyTranslationGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillImpairedAccumulatedImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=opk_CurnaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=opk_RayaldeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=opk_FinetechMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=opk_ModexTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=opk_OpkoBiologicsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=opk_OpkoChileMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=opk_OpkoHealthEuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=opk_OpkoMexicoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=opk_TransitionTherapeuticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=opk_BioreferenceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=opk_OpkoDiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Investments (Details Textual) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2021 Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Jun. 30, 2024 Assets Â $ 2,256,103 $ 2,011,698 Â $ 2,256,103 Â $ 2,011,698 Â Liabilities Â $ 852,686 622,479 Â 852,686 Â 622,479 Â Equity Method Investment, Quoted Market Value Â 600 700 Â 600 Â 700 Â Proceeds from Sale of Equity Securities, FV-NI Â Â Â Â 46,731 $ 364 Â Â Income (Loss) from Equity Method Investments Â (3) Â $ (20) (7) (99) Â Â Revenue from Contract with Customer, Excluding Assessed Tax Â 173,632 Â 178,595 529,504 681,591 Â Â LeaderMed [Member] | LeaderMed Joint Venture [Member] Â Â Â Â Â Â Â Â Minority Interest, Shares Issued (in shares) 4,703 Â Â Â Â Â Â Â Â Subsidiary, Ownership Percentage, Parent 47.00% Â Â Â Â Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax $ 1,000 Â Â Â Â Â Â Â Â Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] Â Â Â Â Â Â Â Â Assets Â 66,100 85,500 Â 66,100 Â 85,500 Â Liabilities Â $ 23,300 $ 20,800 Â 23,300 Â 20,800 Â Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Â Â Â Â $ (27,700) Â $ (37,700) Â Pharmsynthez [Member] Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â 6.00% Â Â 6.00% Â Â Â COCP [Member] Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â 2.00% Â Â 2.00% Â Â Â NIMS [Member] Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â 1.00% Â Â 1.00% Â Â Â BioCardia [Member] Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â 1.00% Â Â 1.00% Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â 47,000 Â Â 47,000 Â Â Â Xenetic [Member] Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â 3.00% Â Â 3.00% Â Â Â Zebra [Member] Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â 29.00% Â Â 29.00% Â Â Â Zebra [Member] | Variable Interest Entity, Not Primary Beneficiary [Member] Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â 29.00% 29.00% Â 29.00% Â 29.00% Â Zebra [Member] | Variable Interest Entity, Not Primary Beneficiary [Member] | Series A-2 Preferred Stock [Member] Â Â Â Â Â Â Â Â Investment Owned, Balance, Shares (in shares) Â 1,260,000 1,260,000 Â 1,260,000 Â 1,260,000 Â Zebra [Member] | Variable Interest Entity, Not Primary Beneficiary [Member] | Restricted Stock [Member] Â Â Â Â Â Â Â Â Investment Owned, Balance, Shares (in shares) Â 900,000 900,000 Â 900,000 Â 900,000 Â LeaderMed [Member] Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â 47.00% Â Â 47.00% Â Â Â Neovasc [Member] Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â 0.50% Â Â 0.50% Â Â Â Proceeds from Sale of Equity Method Investments Â Â $ 363 Â Â Â $ 363 Â GeneDx Holdings [Member] Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â 8.10% Â Â 8.10% Â Â 13.61% Equity Method Investment, Quoted Market Value Â $ 92,200 Â Â $ 92,200 Â Â Â Investment Owned, Shares Sold (in shares) Â 1,386,929 Â Â Â Â Â Â Proceeds from Sale of Equity Securities, FV-NI Â $ 46,700 Â Â Â Â Â Â Business Acquisition, Outstanding Shares Held, Percentage Â 5.00% Â Â 5.00% Â Â Â Income (Loss) from Equity Method Investments Â $ 35,400 Â $ (8,300) $ 118,600 $ (19,900) Â Â VBI Vaccines Inc. [Member] Â Â Â Â Â Â Â Â Income (Loss) from Equity Method Investments Â $ (30) Â Â Â Â Â Â Â Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage Â 0.00% Â Â 0.00% Â Â Â ChromaDex Corporation [Member] Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â 0.05% Â Â 0.05% Â Â Â Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage Â 0.05% Â Â 0.05% Â Â Â Eloxx Pharmaceuticals, Inc. [Member] Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â 1.00% Â Â 1.00% Â Â Â Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage Â 1.00% Â Â 1.00% Â Â Â CAMP4 [Member] Â Â Â Â Â Â Â Â Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage Â 2.00% Â Â 2.00% Â Â Â HealthSnap, Inc. [Member] Â Â Â Â Â Â Â Â Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage Â 4.00% Â Â 4.00% Â Â Â InCellDx [Member] Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â Â 29.00% Â Â Â 29.00% Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â 700,000 Â Â Â 700,000 Â X - DefinitionRepresents the percentage of outstanding shares held for business acquisition. + ReferencesNo definition available. + Details Name: opk_BusinessAcquisitionOutstandingSharesHeldPercentage Namespace Prefix: opk_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe number of shares sold of investment. + ReferencesNo definition available. + Details Name: opk_InvestmentOwnedSharesSold Namespace Prefix: opk_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents the amount of minority interest shares acquired. + ReferencesNo definition available. + Details Name: opk_MinorityInterestSharesIssued Namespace Prefix: opk_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThis item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentQuotedMarketValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPercentage of ownership of equity interest excluding interest in entity that is consolidated and equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-1 + Details Name: us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of investment owned. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_InvestmentOwnedBalanceShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe parent entity's interest in net assets of the subsidiary, expressed as a percentage. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestOwnershipPercentageByParent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest

normally of 20 to 50 percent and exercises significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details Name: us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_CounterpartyNameAxis=opk_LeaderMedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=opk_LeaderMedJointVentureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocpMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NimsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_BiocardiaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_XeneticMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=opk_SeriesA2PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_LeaderMedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_GeneDxHoldingsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_VbiVaccinesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ChromadexCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_EloxxPharmaceuticalsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_Camp4Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_HealthsnapIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_InCellDxMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Investments - Schedule of Investments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Equity method investments $ (0) $ (0) Equity method investments, underlying value 1,782 2,942 Variable interest entity, equity method 790 796 Variable interest entity, equity method 0 420 Equity method investments - FV option 92,166 9,786 Equity securities 130 116 Equity securities with no readily determinable fair value 7,521 5,382 Warrants and options 2 2 Investments $ 100,609 $ 16,082 X - DefinitionRepresents the carrying value of equity instruments held as part of equity investments. + ReferencesNo definition available. + Details Name: opk_EquityInvestmentsCarryingValueOfEquityIntruments Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of variable interest entities included equity method investments. + ReferencesNo definition available. + Details Name: opk_EquityMethodInvestmentVariableInterestEntity Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThis item represents the entity's ownership percentage in the investee multiplied by the investee's total equity for a variable interest entities. + ReferencesNo definition available. + Details Name: opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThis item represents the entity's ownership percentage in the investee multiplied by the investee's total equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name

Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 + Details Name: us-gaap_EquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of investments accounted under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EquityMethodInvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Investments - Gains and Losses on Equity Securities (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Net gains and losses recognized during the period on equity securities $ 43 $ (411) Less: Net gains and losses realized during the period on equity securities (30) 0 Unrealized net losses recognized during the period on equity securities still held at the reporting date $ 13 $ (411) X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiRealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Debt (Details Textual) 1 Months Ended 3 Months Ended 9 Months Ended 47 Months Ended Sep. 16, 2024 USD ($) Jul. 17, 2024 USD ($) Apr. 01, 2024 USD ($) Jan. 09, 2024 USD ($) $ / shares Feb. 10, 2023 $ / shares Feb. 01, 2019 USD ($) May 31, 2021 USD ($) shares Feb. 28, 2018 USD ($) $ / shares Sep. 30, 2024 USD ($) Mar. 31, 2024 USD ($) Mar. 28, 2024 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2016 USD ($) Jul. 17, 2029 Dec. 31, 2023 USD ($) Jan. 31, 2023 USD ($) Feb. 28, 2019 USD ($) Nov. 30, 2015 USD ($) Jan. 31, 2013 Proceeds from Convertible Debt Â Â Â Â Â Â Â Â Â Â Â $ 230,000,000 $ 0 Â Â Â Â Â Â Â Â Stock Repurchased During Period, Value Â Â Â $ 50,000,000 Â Â Â Â $ 23,759,000 Â Â 73,759,000 Â Â Â Â Â Â Â Â Shares Acquired, Average Cost Per Share (in dollars per share) | $ / shares Â Â Â $ 0.9067 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Repayments of Convertible Debt Â Â Â Â Â Â Â Â Â Â Â Â 4,881,000 (0) Â Â Â Â Â Â Â Long-Term Debt Â Â Â Â Â Â Â Â Â 440,974,000 Â Â 440,974,000 Â Â Â $ 249,345,000 Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â Â Â Â Â Â Â $ 30,013,000 Â Â 30,013,000 Â Â Â Â Â Â Â Â Repayments of Lines of Credit Â Â Â Â Â Â Â Â Â Â Â $ 465,301,000 $ 519,597,000 Â Â Â Â Â Â Â Conversion of the 2025 Notes into Common Stock [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Conversion, Original Debt, Amount Â Â Â Â Â Â $ 55,400,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares Â Â Â Â Â Â 19,051,270 Â Â Â Â Â Â Â Â Â Â Â Line of Credit [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt, Weighted Average Interest Rate Â Â Â Â Â Â Â Â 5.40% Â Â 5.40% Â Â Â 7.50% Â Â Â Â Minimum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate Â Â Â Â Â Â Â Â 0.70% Â 0.70% Â Â Â Â Â Â Â Â Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate Â Â Â Â Â Â Â Â 4.50% Â Â 4.50% Â Â Â Â Â Â Â The 2044 Notes [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â $ 250,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Basis Spread on Variable Rate Â 7.50% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Repayment Fee, Percent Â 3.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Early Extinguishment, Percent of Principal Amount Â 150.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Repayment Fee, Royalty Percentage Â 80.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Additional Authorized Amount Â $ 50,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Long-Term Debt Â Â Â Â Â Â Â Â Â Â Â Â Â $ 245,358,000 Â Â Â $ 245,358,000 Â Â Â $ 0 Â Â Â Â The 2044 Notes [Member] | Forecast [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Early Extinguishment, Percent of Principal Amount Â Â Â Â Â Â Â Â Â Â Â Â Â 200.00% Â Â Â Â Â The 2044 Notes [Member] | Minimum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Basis Spread on Variable Rate Â 4.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The 2029 Convertible Notes 1 [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â $ 230,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Interest Rate, Stated Percentage Â Â Â 3.75% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from Convertible Debt Â Â Â $ 222,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Repurchase Amount Â Â Â Â Â Â Â 3,500,000 Â Â 3,500,000 Â Â Â Â Â Â Â Â Embedded Derivative, Fair Value of Embedded Derivative Liability Â Â Â $ 125,600,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Â Â Â Â Â Â Â Â Â Â Â $ 26,250,000 Â Â Â Â Â Â Â Â Â Â Â Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity Â Â $ 151,900,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Conversion Ratio Â Â Â 869.5652 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â Â $ 1.15 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Sinking Fund Payment Â Â Â $ 0 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Redemption Price, Percentage Â Â Â 100.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Repayments of Convertible Debt Â Â Â Â Â Â Â Â 4,800,000 Â Â Â Â Â Â Â Â Â Â Â Gain (Loss) on Repurchase of Debt Instrument Â Â Â Â Â Â Â 32,000 Â Â Â Â Â Â Â Â Â Â Â Write-off of Unamortized Discount Â Â Â Â Â Â Â 1,300,000 Â Â Â Â Â Â Â Â Â Â Deferred Debt Issuance Cost, Writeoff Â Â Â Â Â Â Â 100,000 Â Â Â Â Â Â Â Â Â Â The 2029 Convertible Notes 1 [Member] | Convertible Debt [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from Issuance of Debt Â Â Â $ 146,300,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The 2029 Convertible Notes 1 [Member] | Debt Instrument, Redemption, Period One [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Threshold Trading Days Â Â Â 20 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Threshold Consecutive Trading Days Â Â Â 30 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Â Â Â 130.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The 2029 Convertible Notes 1 [Member] | Debt Instrument, Redemption, Period Two [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Threshold Trading Days Â Â Â 5 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Threshold Consecutive Trading Days Â Â Â 10 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Â Â Â 98.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The 2029 Convertible Notes 1 [Member] | Scenario, Event of Default [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Redemption Price, Percentage Â Â Â 100.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Ownership Interest Â Â Â 25.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The 2029 Convertible Affiliate Notes [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â $ 71,100,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Interest Rate, Stated Percentage Â Â Â 3.75% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The 2029 Convertible Affiliate Notes [Member] | Convertible Debt [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â $ 71,100,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The 2023 Convertible Notes [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Repurchase Amount Â Â Â 55,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest Payable Â Â 16,100,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Convertible Debt Â Â Â 0 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Long-Term Debt Â Â Â Â Â Â Â 0 Â Â 0 Â Â Â 71,025,000 Â Â Â Â The 2023 Convertible Notes [Member] | Convertible Debt [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â 55,000,000 Â Â Â $ 55,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Interest Rate, Stated Percentage Â Â Â Â Â Â Â 5.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Interest Payable Â Â Â 16,100,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares Â Â Â Â Â Â Â $ 5 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Term (Year) Â Â Â Â Â Â Â Â 5 years Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Conversion Premium, Percent Â Â Â Â 25.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Conversion Premium, Per Share (in dollars per share) | $ / shares Â Â Â Â $ 1.66 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The 2025 Notes [Member] | Convertible Debt [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â 170,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Repurchase Amount Â Â Â $ 144,400,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The 2025 Notes [Member] | Debt Instrument, Redemption, Period One [Member] | Convertible Debt [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Convertible, Threshold Consecutive Trading Days Â Â Â Â Â 30 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The 2025 Notes [Member] | Scenario, Event of Default [Member] | Convertible Debt [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â Â Â Â Â Â Â Â Â $ 200,000,000 Â Â Debt Instrument, Interest Rate, Stated Percentage Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.50% Â Â The 2033 Senior Notes [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Long-Term Debt Â Â Â Â Â Â Â Â $ 50,000 Â Â $ 50,000 Â Â Â 50,000 Â Â Â Â The 2033 Senior Notes [Member] | Convertible Debt [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Repurchase Amount Â Â Â Â Â Â $ 28,800,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Conversion, Converted Instrument, Amount Â Â Â Â Â Â Â Â Â Â Â $ 143,200,000 Â Â Â Â Â Â Repayments of Debt Â Â Â Â Â Â Â Â Â $ 3,000,000 Â Â Â Â Â Â Â Â Â Â Â Long-Term Debt Â Â Â Â Â Â Â Â Â $ 50,600 Â Â Â Â Â Â Â Â Â Â Â The 2033 Senior Notes [Member] | Senior Notes [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 175,000,000 Â Â Â Debt Instrument, Interest Rate, Stated Percentage Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 3.00% Credit Agreement [Member] | Line of Credit [Member] | Revolving Credit Facility [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 50,000,000 Â Repayments of Lines of Credit $ 9,700,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Long-Term Line of Credit, Noncurrent Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 12,700,000 Â Â Â Â Credit Agreement [Member] | Line of Credit [Member] | Bridge Loan [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 20,000,000 Â Credit Agreement [Member] | Line of Credit [Member] | Letter of Credit [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 20,000,000 Â Notes and Other Debt [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt, Weighted Average Interest Rate Â Â Â Â Â Â Â Â 1.80% Â Â 1.80% Â Â Â 2.90% Â Â Â Â X - DefinitionThe additional authorized amount for debt instrument. + ReferencesNo definition available. + Details Name: opk_DebtInstrumentAdditionalAuthorizedAmount Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe per share amount of conversion premium for convertible debt instrument. + ReferencesNo definition available. + Details Name: opk_DebtInstrumentConvertibleConversionPremiumPerShare Namespace Prefix: opk_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe percent conversion premium of convertible debt instrument. + ReferencesNo definition available. + Details Name: opk_DebtInstrumentConvertibleConversionPremiumPercent Namespace Prefix: opk_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe percent of principal amount required to be paid for early extinguishment of debt instrument. + ReferencesNo definition available. + Details Name: opk_DebtInstrumentEarlyExtinguishmentPercentOfPrincipalAmount Namespace Prefix: opk_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPertains

to ownership interest in the aggregate principal amount. + ReferencesNo definition available. + Details Name: opk_DebtInstrumentOwnershipInterest Namespace Prefix: opk_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe repayment fee percent for a debt instrument. + ReferencesNo definition available. + Details Name: opk_DebtInstrumentRepaymentFeePercent Namespace Prefix: opk_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents the percentage of future royalties payments that would be considered a fee for repayment of a debt instrument. + ReferencesNo definition available. + Details Name: opk_DebtInstrumentRepaymentFeeRoyaltyPercentage Namespace Prefix: opk_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of write-off of unamortized discount + ReferencesNo definition available. + Details Name: opk_WriteoffOfUnamortizedDiscount Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncluding the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_ConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionOriginalDebtAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionRatio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionThreshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionMinimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThreshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdTradingDays Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage price of original principal amount of debt at which debt can be redeemed by the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentRedemptionPricePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFair value amount of debt instrument that was repurchased. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentRepurchaseAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount paid into a fund, which is used to retire the debt instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_DebtInstrumentSinkingFundPayment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average interest rate of debt outstanding. + ReferencesNo definition available. + Details Name: us-gaap_DebtWeightedAverageInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionFair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNet Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 15 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815-15/tableOfContent + Details Name: us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of the liability for the conversion option reclassified to stockholders' equity when the embedded option no longer required separation from the host instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 15 -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480960/815-15-50-3 + Details Name: us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) from the difference between the repurchase price of a debt instrument initially issued by the entity and the net carrying amount of the debt at the time of its repurchase. + ReferencesNo definition available. + Details Name: us-gaap_GainLossOnRepurchaseOfDebtInstrument Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtPercentageBearingVariableInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or

(b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481573/470-10-45-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481573/470-10-45-14 + Details Name: us-gaap_LongTermLineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal cost of shares repurchased divided by the total number of shares repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockAcquiredAverageCostPerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWrite-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_WriteOffOfDeferredDebtIssuanceCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DebtConversionByUniqueDescriptionAxis=opk_ConversionOfThe2025NotesIntoCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2044NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2029ConvertibleNotes1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=opk_ScenarioEventofDefaultMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2029ConvertibleAffiliateNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2023ConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2025NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2033SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_CreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_NotesAndOtherDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Debt - Schedule of Debt (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Long-term debt $ 440,974 $ 249,345 Current portion of notes payable 1,509 1,993 Long term portion of notes payable 3,529 7,727 Convertible Notes [Member] Â Â Current portion of notes payable 170 0 Long term portion of notes payable 178,695 214,325 Line Of Credit And Notes And Loans Payable Current Member Â Â Long-term debt 13,222 27,293 Other Noncurrent Liabilities [Member] Â Â Long-term debt 248,887 7,727 The 2029 Convertible Notes [Member] Â Â Long-term debt 178,645 0 The 2025 Convertible Notes [Member] Â Â Long-term debt 170 143,250 The 2033 Senior Notes [Member] Â Â Long-term debt 50 50 The 2023 Convertible Notes [Member] Â Â Long-term debt 0 71,025 The 2044 Notes [Member] Â Â Long-term debt 245,358 0 J P Morgan Chase [Member] Â Â Long-term debt 0 12,671 Chilean and Spanish Lines of Credit [Member] Â Â Long-term debt $ 11,713 $ 12,629 X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_BalanceSheetLocationAxis=opk_ConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=opk_LineOfCreditAndNotesAndLoansPayableCurrentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2029ConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2025ConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2033SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2023ConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2044NotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_JPMorganChaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_ChileanAndSpanishLinesOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Balance, total $ 249,345 Â Issuance of 3.75% 2029 convertible notes, debt issuance cost (13,385) $ 0 Amortization of debt issuance cost 1,328 $ 908 Balance, total 440,974 Â The 2029 Convertible 144A Notes [Member] Â Â Balance 0 Â Balance, embedded conversion option 0 Â Balance, discount 0 Â Balance, debt issuance cost 0 Â Balance, total 0 Â Issuance of 3.75% 2029 Convertible Notes 301,054 Â Issuance of 3.75% 2029 convertible notes, embedded conversion option 125,620 Â Issuance of 3.75% 2029 convertible notes, discount (125,620) Â Issuance of 3.75% 2029 convertible notes, debt issuance cost (8,562) Â Issuance of 3.75% 2029 convertible notes, total 292,492 Â Amortization of debt discount 12,585 Â Amortization of debt issuance cost 1,236 Â Amortization of debt discount and debt issuance costs, total 13,821 Â Change in fair value of embedded derivative 26,250 Â Change in fair value of embedded derivative, total 26,250 Â Reclassification of embedded derivative to equity (151,870) Â Repurchase (3,500) Â Repurchase 1,338 Â Repurchase 114 Â Repurchase (2,048) Â Balance 297,554 Â Balance, embedded conversion option 0 Â Balance, discount (111,697) Â Balance, debt issuance cost (7,212) Â Balance, total $ 178,645 Â X - DefinitionThe amount of the debt issuance costs on original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesNo definition available. + Details Name: opk_DebtConversionDebtIssuanceCosts Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of the original debt, less discounts and costs, being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesNo definition available. + Details Name: opk_DebtConversionOriginalDebtNetAmount Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of the unamortized discount on debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesNo definition available. + Details Name: opk_DebtConversionUnamortizedDiscount Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash inflow from convertible debt. + ReferencesNo definition available. + Details Name: opk_ProceedsFromConvertibleDebtGross Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPertains to proceeds from embedded derivative instrument. + ReferencesNo definition available. + Details Name: opk_ProceedsFromEmbeddedDerivativeDebt Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPertains to debt discount. + ReferencesNo definition available. + Details Name: opk_RecognitionOfDebtDiscount Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionOriginalDebtAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNet increase or decrease in the carrying amount of the debt instrument for the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt discount. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DebtInstrumentUnamortizedDiscount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNet fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as assets, net of those classified as liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480463/815-10-45-5Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNet Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 15 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815-15/tableOfContent + Details Name: us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of the liability for the conversion option reclassified to stockholders' equity when the embedded option no longer required separation from the host instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 15 -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480960/815-15-50-3 + Details Name: us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2029Convertible144ANotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Debt - Schedule of Long-term Debt (Details) (Parentheticals) Sep. 30, 2024 The 2029 Convertible 144A Notes [Member] Â Interest rate, convertible notes 3.75% X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2029Convertible144ANotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Debt - Schedule of Line of Credit Facilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Interest rate Â Credit line capacity $ 30,013 Â Line of credit $ 11,713 $ 25,300 J P Morgan Chase [Member] Â Â Interest rate 0.00% Â Credit line capacity $ 0 Â Line of credit $ 0 12,671 Itau Bank [Member] Â Â Interest rate 5.50% Â Credit line capacity $ 1,900 Â Line of credit $ 469 1,264 Bank of Chile [Member] Â Â Interest rate 6.60% Â Credit line capacity $ 2,500 Â Line of credit $ 711 1,728 BICE Bank [Member] Â Â Interest rate 5.50% Â Credit line capacity $ 2,500 Â Line of credit $ 2,433 1,734 Scotiabank [Member] Â Â Interest rate 5.00% Â Credit line capacity $ 5,500 Â Line of credit $ 3,060 981 Santander Bank [Member] Â Â Interest rate 5.50% Â Credit line capacity $ 5,000 Â Line of credit $ 1,742 450 Security Bank [Member] Â Â Interest rate 5.50% Â Credit line capacity $ 1,400 Â Line of credit $ 0 0 Estado Bank [Member] Â Â Interest rate 5.50% Â Credit line capacity $ 4,000 Â Line of credit $ 1,355 3,303 BCI Bank [Member] Â Â Interest rate 5.00% Â Credit line capacity $ 2,500 Â Line of credit $ 346 1,626 Internacional Bank [Member] Â Â Interest rate 5.50% Â Credit line capacity $ 1,597 Â Line of credit $ 1,597 1,197 Consorcio Bank [Member] Â Â Interest rate 5.00% Â Credit line capacity $ 2,000 Â Line of credit $ 0 346 Banco De Sabadell [Member] Â Â Interest rate 1.75% Â Credit line capacity $ 558 Â Line of credit $ 0 0 Santander Bank 2 [Member] Â Â Interest rate 5.36% Â Credit line capacity $ 558 Â Line of credit $ 0 $ 0 X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe effective interest rate at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LineOfCreditFacilityAxis=opk_JPMorganChaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=opk_ItauBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=opk_BankOfChileMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=opk_BiceBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=opk_ScotiabankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=opk_SantanderBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_LineOfCreditFacilityAxis=opk_SecurityBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=opk_EstadoBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=opk_BciBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=opk_InternacionalBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=opk_ConsorcioBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=opk_BancoDeSabadellMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=opk_SantanderBank2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Debt - Schedule of Debt Instruments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current portion of notes payable $ 1,509 $ 1,993 Other long-term liabilities 36,504 27,189 Total 440,974 249,345 Notes Payable And Other Long Term Liabilities [Member] Â Â Current portion of notes payable 1,509 1,993 Other long-term liabilities 3,529 7,727 Total $ 5,038 $ 9,720 X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_BalanceSheetLocationAxis=opk_NotesPayableAndOtherLongTermLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8 - Accumulated Other Comprehensive Loss - Changed in Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Balance at December 31, 2023 $ 1,395,317 $ 1,535,348 $ 1,389,219 $ 1,561,648 Other comprehensive loss 7,038 (9,553) (1,584) (3,172) Balance at September 30, 2024 1,403,417 $ 1,444,568 1,403,417 $ 1,444,568 Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Â Â Â Â Balance at December 31, 2023 Â Â (38,030) Â Other comprehensive loss Â Â (1,585) Â Balance at September 30, 2024 $ (39,615) Â $ (39,615) Â X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Equity Method - Fair value option $ 92,166 $ 9,786 Fair Value, Recurring [Member] Â Â Money market funds 354,537 32,404 Equity securities 130 116 Equity Method - Fair value option 92,166 9,786 Common stock options/warrants 2 2 Total assets 446,835 42,308 Forward contracts Â 29 Total liabilities Â 29 Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] Â Â Money market funds 354,537 32,404 Equity securities 130 116 Equity Method - Fair value option 92,166 9,786 Common stock options/warrants 0 0 Total assets 446,833 42,306 Forward contracts Â 0 Total liabilities Â 0 Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] Â Â Money market funds 0 0 Equity securities 0 0 Equity Method - Fair value option 0 0 Common stock options/warrants 2 2 Total assets 2 2 Forward contracts Â 29 Total liabilities Â 29 Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Money market funds 0 0 Equity securities 0 0 Equity Method - Fair value option 0 0 Common stock options/warrants 0 0 Total assets $ 0 0 Forward contracts Â 0 Total liabilities Â $ 0 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name

Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 30: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column G)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column G)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 28: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of investments accounted under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EquityMethodInvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Fair Value Measurements - Carrying Value and Estimated Fair Value of Notes (Details) - Convertible Debt [Member] $ in Thousands Sep. 30, 2024 USD ($) The 2029 Convertible Notes 1 [Member] | Reported Value Measurement [Member] Â Notes $ 178,645 The 2029 Convertible Notes 1 [Member] | Estimate of Fair Value Measurement [Member] Â Notes 396,652 The 2029 Convertible Notes 1 [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] Â Notes 0 The 2029 Convertible Notes 1 [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] Â Notes 396,652 The 2029 Convertible Notes 1 [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] Â Notes 0 The 2025 Convertible Notes [Member] | Reported Value Measurement [Member] Â Notes 170 The 2025 Convertible Notes [Member] | Estimate of Fair Value Measurement [Member] Â Notes 170 The 2025 Convertible Notes [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] Â Notes 0 The 2025 Convertible Notes [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] Â Notes 170 The 2025 Convertible Notes [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] Â Notes $ 0 X - DefinitionFair value portion of notes payable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_NotesPayableFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2029ConvertibleNotes1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2025ConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Fair Value Measurements - Reconciliation of Level 3 Instruments (Details) - Derivative Financial Instruments, Liabilities [Member] - Fair Value, Inputs, Level 3 [Member] $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Balance at December 31, 2023 $ 0 Additions 125,620 Included in results of operations 26,250 Reclassification of embedded derivatives to equity (151,870) Balance at September 30, 2024 $ 0 X - DefinitionAmount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByLiabilityClassAxis=us-

gaap_DerivativeFinancialInstrumentsLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Note 10 - Derivative Contracts - Summary of Fair Values and Presentation of Derivatives Financial Instruments (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Common Stock Options/ Warrants [Member] | Investment, Net [Member] Â Â Derivative financial instruments $ 2 $ 2 Foreign Exchange Forward [Member] | Accrued Expenses [Member] Â Â Derivative financial instruments $ 0 $ (29) X - DefinitionFair value of the assets less the liabilities of a derivative or group of derivatives. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeFairValueOfDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=opk_CommonStockOptionsWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=opk_InvestmentNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=opk_AccruedExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Note 10 - Derivative Contracts - Summary of Gains and Losses Recorded (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Derivative gain (loss) $ (1) $ 88 $ (26,161) $ (829) Embedded Derivative Financial Instruments [Member] | The 2029 Convertible Notes 1 [Member] Â Â Â Derivative gain (loss) 0 0 (26,250) 0 Common Stock Options/ Warrants [Member] Â Â Â Derivative gain (loss) (1) (37) 1 (27) Foreign Exchange Forward [Member] Â Â Â Derivative gain (loss) $ 0 $ 125 $ 88 $ (802) X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2029ConvertibleNotes1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=opk_CommonStockOptionsWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Related Party Transactions (Details Textual) 3 Months Ended 9 Months Ended 12 Months Ended Jan. 09, 2024 USD ($) May 04, 2023 USD ($) Sep. 30, 2024 USD ($) shares Mar. 31, 2024 USD ($) Dec. 31, 2023 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) shares Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Aug. 01, 2024 USD ($) ftÂ² Jul. 31, 2024 a Jun. 30, 2024 Feb. 28, 2018 USD ($) Operating Expenses Â Â $ 159,416,000 Â Â $ 243,002,000 $ 648,430,000 $ 769,566,000 Â Â Â Â Â Ruen-Hui Biopharmaceuticals, Inc. [Member] Â Â Â Â Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â 10.00% Â Â Â Â Â Â Â Â Â Â Ruen-Hui Biopharmaceuticals, Inc. [Member] | License Agreement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Payments to Acquire Equity Method Investments Â $ 150,000 Â Â Â Â Â Â Â Â Â Â Â Collaborative Arrangement, Maximum Regulatory Milestone Payments Â $ 1,000,000 Â Â Â Â Â Â Â Â Â Â Pharmsynthez [Member] Â Â Â Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â Â 6.00% Â Â Â 6.00% Â Â Â Â Â Â Â Xenetic [Member] Â Â Â Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â Â 3.00% Â Â Â 3.00% Â Â Â Â Â Â Zebra [Member] Â Â Â Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â Â 29.00% Â Â Â 29.00% Â Â Â Â Â Â ChromaDex Corporation [Member] Â Â Â Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â Â 0.05% Â Â Â 0.05% Â Â Â Â Â Â COCP [Member] Â Â Â Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â Â 2.00% Â Â Â 2.00% Â Â Â Â Â Â NIMS [Member] Â Â Â Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â Â 1.00% Â Â Â 1.00% Â Â Â Â Â Â Eloxx Pharmaceuticals, Inc. [Member] Â Â Â Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â Â 1.00% Â Â Â 1.00% Â Â Â Â Â Â BioCardia [Member] Â Â Â Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â Â 1.00% Â Â Â 1.00% Â Â Â Â Â Â LeaderMed [Member] Â Â Â Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â Â 47.00% Â Â Â 47.00% Â Â Â Â Â Â Neovasc [Member] Â Â Â Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â Â 0.50% Â Â Â 0.50% Â Â Â Â Â Â Proceeds from Sale of Equity Method Investments Â Â Â Â $ 363,000 Â Â Â $ 363,000 Â Â Â Â GeneDx Holdings [Member] Â Â Â Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â Â 8.10% Â Â Â 8.10% Â Â Â Â 13.61% Â InCellDx [Member] Â Â Â Â Â Â Â Â Â Â Â Equity Method Investment, Ownership Percentage Â Â Â 29.00% Â Â Â 29.00% Â Â Â Â The 2029 Convertible Notes 1 [Member] Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount $ 230,000,000 Â Â Â Â Â Â Â Â Â Â The 2029 Convertible Notes 1 [Member] | Convertible Debt [Member] Â Â Â Â Â Â Â Â Â Â Debt Instrument, Issued, Principal 71,100,000 Â Â Â Â Â Â Â Â Â Â The 2023 Convertible Notes [Member] Â Â Â Â Â Â Â Â Â Â Interest Payable $ 16,100,000 Â Â Â Â Â Â Â Â Â Â The 2023 Convertible Notes [Member] | Convertible Debt [Member] Â Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount 55,000,000 Â Â Â Â Â Â Â Â Â Â $ 55,000,000 Interest Payable $ 16,100,000 Â Â Â Â Â Â Â Â Â Â Frost Real Estate Holdings, LLC [Member] Â Â Â Â Â Â Â Â Â Â Area of Real Estate Property (Acre) Â Â Â Â Â Â Â Â 26,328 29,500 Â Â Operating Leases, Monthly Payments, Year One Â Â Â Â Â Â Â Â Â Â $ 91,000 Â Â Â Operating Leases, Monthly Payments, Year Five Â Â Â Â Â Â Â Â Â Â $ 103,000 Â Â Â GeneDx [Member] | Transition Services Agreement [Member] Â Â Â Â Â Â Â Â Â Â Operating Expenses Â Â Â $ 1,200,000 Â Â Â Â Â Â Â Â Â Accounts Receivable, after Allowance for Credit Loss Â Â $ 0 Â Â Â $ 0 Â Â Â Â Â Â GeneDx [Member] | Transition Services Agreement [Member] | Services Rendered [Member] Â Â Â Â Â Â Â Â Â Â Operating Expenses Â Â $ 0 Â Â Â $ 0 Â Â Â Â Â Director [Member] | Pharmsynthez [Member] Â Â Â Â Â Â Â Â Â Â Investment Owned, Balance, Shares (in shares) | shares Â Â 6 Â Â Â 6 Â Â Â Â Â Director [Member] | Xenetic [Member] Â Â Â Â Â Â Â Â Â Â Investment Owned, Balance, Shares (in shares) | shares Â Â 3 Â Â Â 3 Â Â Â Â Â Beckman Coulter [Member] Â Â Â Â Â Â Â Â Â Â Related Party Transaction, Amounts of Transaction Â Â Â Â Â $ 2,600,000 Â Â Â Â Â Integrated DNA Technologies Inc. [Member] Â Â Â Â Â Â Â Â Â Â Related Party Transaction, Amounts of Transaction Â Â Â Â Â 3,300,000 Â Â Â Â Â Leica Microsystems Inc. [Member] Â Â Â Â Â Â Â Â Â Â Related Party Transaction, Amounts of Transaction Â Â Â Â Â 300,000 Â Â Â Â Â Executive Officer [Member] | Reimbursement of Travel Expenses [Member] Â Â Â Â Â Â Â Â Â Â Related Party Transaction, Amounts of Transaction Â Â $ 0 Â Â $ 49,500 $ 23,900 $ 78,800 Â Â Â Â Â X - DefinitionRepresents maximum regulatory milestone payments under collaborative agreement. + ReferencesNo definition available. + Details Name: opk_CollaborativeArrangementMaximumRegulatoryMilestonePayments Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of monthly payments in year five for operating lease. + ReferencesNo definition available. + Details Name: opk_OperatingLeasesMonthlyPaymentsYearFive Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of monthly payments in first year for operating lease. + ReferencesNo definition available. + Details Name: opk_OperatingLeasesMonthlyPaymentsYearOne Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_AccountsReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionArea of a real estate property. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfRealEstateProperty Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of principal of debt issued. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_DebtInstrumentIssuedPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares of investment owned. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_InvestmentOwnedBalanceShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of transactions with related party during the financial reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_RuenhuiBiopharmaceuticalsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=opk_LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_PharmsynthezMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_XeneticMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ZebraMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ChromadexCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocpMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NimsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_EloxxPharmaceuticalsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_BiocardiaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:

srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_LeaderMedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_GeneDxHoldingsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_InCellDxMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2029ConvertibleNotes1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=opk_The2023ConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_FrostRealEstateHoldingsLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_GeneDxMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=opk_TransitionServicesAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_NatureOfExpenseAxis=opk_ServicesRenderedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_BeckmanCoulterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_IntegratedDNATechnologiesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=opk_LeicaMicrosystemsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=opk_ReimbursementOfTravelExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Note 12 - Commitments and Contingencies (Details Textual) - USD ($) 9 Months Ended Dec. 29, 2022 Jul. 14, 2022 Sep. 30, 2024 Purchase Obligation Â Â $ 44,000,000 Settled Litigation [Member] Â Â Â Litigation Settlement, Amount Awarded to Other Party Â $ 10,000,000 Â Litigation Settlement, Interest Rate Â 1.50% Â Settled Litigation [Member] | UNITED STATES Â Â Â Litigation Settlement, Amount Awarded to Other Party Â $ 9,853,958 Â Settled Litigation [Member] | Commonwealth [Member] Â Â Â Litigation Settlement, Amount Awarded to Other Party Â 141,041 Â Settled Litigation [Member] | CONNECTICUT Â Â Â Litigation Settlement, Amount Awarded to Other Party Â $ 5,001 Â Israel Tax Authority [Member] Â Â Â Income Tax Examination, Estimate of Possible Loss Â Â $ 246,000,000 Foreign Tax Jurisdiction [Member] | Israel Tax Authority [Member] | Tax Year 2014 Through Tax Year 2020 [Member] Â Â Â Income Tax Examination, Estimate of Possible Loss $ 246,000,000 Â Â X - DefinitionInterest rate under litigation settlement. + ReferencesNo definition available. + Details Name: opk_LitigationSettlementInterestRate Namespace Prefix: opk_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionEstimated amount of loss resulting from an adverse tax position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15 + Details Name: us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount awarded to other party in judgment or settlement of litigation. + ReferencesNo definition available. + Details Name: us-gaap_LitigationSettlementAmountAwardedToOtherParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMinimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=opk_CommonwealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_CT Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TaxPeriodAxis=opk_TaxYear2014ThroughTaxYear2020Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Note 13 - Revenue Recognition (Details Textual) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Sep. 28, 2023 Mar. 08, 2023 Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Contract with Customer, Performance Obligation Satisfied in Previous Period Â Â Â Â Â $ 2,200 $ 19,800 Â Accrued Expense, Payor Overpayment Reimbursement, Liability Â Â $ 4,900 $ 4,900 Â 4,900 Â $ 3,100 Revenue from Contract with Customer, Excluding Assessed Tax Â Â Â 173,632 $ 178,595 529,504 681,591 Â BARDA Agreement [Member] Â Â Â Â Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax Â Â $ 24,100 5,500 Â 12,800 Â Â Merck Agreement [Member] | Merck Sharp & Dohme LLC [Member] Â Â Â Â Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax $ 50,000 $ 50,000 Â Â Â Â Â Â Rayaldee [Member] Â Â Â Â Â Â Â Â Contract with Customer, Liability, Revenue Recognized Â Â Â 5,800 7,300 19,900 21,700 Â Revenue from Contract with Customer, Excluding Assessed Tax Â Â Â 15,865 16,090 49,447 47,940 Â Transfer of Intellectual Property and Other [Member] Â Â Â Â Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax Â Â Â 13,218 6,246 34,272 165,938 Â Transfer of Intellectual Property and Other [Member] | Milestone Payments [Member] | Pfizer Inc. [Member] Â Â Â Â Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax Â Â Â $ 7,000 $ 4,900 $ 18,900 $ 11,800 Â Transfer of Intellectual Property and Other [Member] | Development and License Agreement [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] Â Â Â Â Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax Â Â Â Â Â Â Â 7,000 Transfer of Intellectual Property and Other [Member] | Development and License Agreement [Member] | NICOYA Macau Limited [Member] Â Â Â Â Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax Â Â Â Â Â Â Â $ 2,500 X - DefinitionAmount of liability related to reimbursements for payor overpayments. + ReferencesNo definition available. + Details Name: opk_AccruedExpensePayorOverpaymentReimbursementLiability Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12A + Details Name: us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=opk_BardaAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=opk_MerckAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=opk_MerckSharpDohmeLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=opk_RayaldeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=opk_MilestonePaymentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=opk_PfizerIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=opk_DevelopmentAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=opk_ViforFreseniusMedicalCareRenalPharmaLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=opk_NicoyaMacauLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Note 13 - Revenue Recognition - Composition of Revenue From Services (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue from Contract with Customer, Excluding Assessed Tax $ 173,632 $ 178,595 $ 529,504 $ 681,591 Service [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 121,271 131,679 377,557 391,100 Healthcare Insurers [Member] | Service [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 76,184 81,469 229,600 238,934 Government Payers [Member] | Service [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 20,368 19,909 63,561 61,250 Client Payers [Member] | Service [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 20,773 25,906 71,521 77,973 Self-Pay [Member] | Service [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax $ 3,946 $ 4,395 $ 12,875 $ 12,943 X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HealthCareOrganizationRevenueSourcesAxis=opk_HealthcareInsurersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HealthCareOrganizationRevenueSourcesAxis=opk_GovernmentPayersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HealthCareOrganizationRevenueSourcesAxis=opk_ClientPayersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Note 13 - Revenue Recognition - Analysis of Product Sales Allowances and Accruals (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended 15 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Sep. 30, 2024 Total gross Rayaldee sales $ 173,632 $ 178,595 $ 529,504 $ 681,591 Â Â Rayaldee [Member] Â Â Â Â Â Â Balance at beginning 10,928 9,918 10,920 8,278 $ 8,278 $ 9,918 Provision related to current period sales 10,098 8,766 29,538 26,265 Â Â Credits or payments made (12,349) (8,347) (31,781)

(24,206) Â Â Balance at end 8,677 10,337 8,677 10,337 10,920 8,677 Total gross Rayaldee sales $ 15,865 $ 16,090 $ 49,447 $ 47,940 Â Â Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales 64.00% 54.00% 60.00% 55.00% Â Â Chargebacks, Discounts, Rebates and Fees [Member] | Rayaldee [Member] Â Â Â Â Â Â Balance at beginning $ 2,743 $ 2,330 $ 2,578 $ 1,532 1,532 2,330 Provision related to current period sales 4,005 3,446 12,224 10,702 Â Â Credits or payments made (5,058) (4,125) (13,112) (10,583) Â Â Balance at end 1,690 1,651 1,690 1,651 2,578 1,690 Governmental [Member] | Rayaldee [Member] Â Â Â Â Â Â Balance at beginning 5,991 5,954 6,150 5,063 5,063 5,954 Provision related to current period sales 5,776 4,998 16,325 14,604 Â Â Credits or payments made (7,013) (4,207) (17,721) (12,922) Â Â Balance at end 4,754 6,745 4,754 6,745 6,150 4,754 Sales Returns [Member] | Rayaldee [Member] Â Â Â Â Â Â Balance at beginning 2,194 1,634 2,192 1,683 1,683 1,634 Provision related to current period sales 317 322 989 959 Â Â Credits or payments made (278) (15) (948) (701) Â Â Balance at end $ 2,233 $ 1,941 $ 2,233 $ 1,941 $ 2,192 $ 2,233 X - DefinitionPercentage of gross sales for provision for sales allowance. + ReferencesNo definition available. + Details Name: opk_ProvisionForSalesAllowanceAsPercentOfGrossSales Namespace Prefix: opk_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of valuation and qualifying accounts and reserves. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4 + Details Name: us-gaap_ValuationAllowancesAndReservesBalance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase in valuation and qualifying accounts and reserves from charge to cost and expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09(Column C)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4 + Details Name: us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in valuation and qualifying accounts and reserves. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4 + Details Name: us-gaap_ValuationAllowancesAndReservesDeductions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=opk_RayaldeeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_ChargebacksDiscountsRebatesAndFeesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_GovernmentalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationAllowancesAndReservesTypeAxis=opk_SalesReturnsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.3 Note 14 - Strategic Alliances (Details Textual) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 15 Months Ended 19 Months Ended Sep. 28, 2023 Mar. 08, 2023 Sep. 14, 2021 Jul. 06, 2021 Jun. 18, 2021 May 05, 2020 Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 Sep. 30, 2024 Sep. 30, 2024 Jun. 30, 2024 Oct. 01, 2019 Revenue from Contract with Customer, Excluding Assessed Tax Â Â Â Â Â Â Â $ 173,632 $ 178,595 Â $ 529,504 $ 681,591 Â Â Â Â Â Â CAMP4 [Member] Â Â Â Â Â Â Â

collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_OwnershipAxis=opk_Camp4Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=opk_LeaderMedJointVentureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=opk_LeaderMedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=opk_Camp4Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=opk_DravetSyndromeProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=opk_NondravetSyndromeProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=opk_BardaAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=opk_MerckAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=opk_MerckSharpDohmeLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=opk_DevelopmentAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=opk_NicoyaMacauLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=opk_EirgenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=opk_ViforFreseniusMedicalCareRenalPharmaLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=opk_FirstMarketingApprovalOfRayaldeeInEuropeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=opk_GermanyPriceApprovalByLocalSickFundAssociationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=opk_TransferOfIntellectualPropertyAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=opk_PfizerAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=opk_PfizerIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.3 Note 15 - Segments (Details Textual) $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 Dec. 31, 2023 Number of Reportable Segments 2 Â Â Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark [Member] Â Â Â Number of Major Customers 0 0 Â Customer Concentration Risk [Member] | Accounts Receivable [Member] Â Â Â Number of Major Customers 0 Â 0 Intersegment Eliminations [Member] Â Â Â Revenues $ 0 Â Â Interest Expense $ 0 Â Â Â X - DefinitionThe number of major customers. + ReferencesNo definition available. + Details Name: opk_NumberOfMajorCustomers Namespace Prefix: opk_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.3 Note 15 - Segments - Operations by Segment (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue from Contract with Customer, Excluding Assessed Tax $ 173,632 $ 178,595 $ 529,504 $ 681,591 Operating income (loss) 14,216 (64,407) (118,926) (87,975) Depreciation and amortization 24,163 26,183 74,137 79,315 Loss from investment in investees (3) (20) (7) (99) UNITED STATES Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 132,663 139,043 410,422 462,987 IRELAND Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 11,514 8,654 30,579 121,249 CHILE Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 16,576 16,932 49,067 52,427 SPAIN Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 6,297 4,349 17,828 16,427 ISRAEL Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 196 3,155 797 9,388 MEXICO Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 5,630 5,897 18,621 17,447 Other Countries [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 756 565 2,190 1,666 Service [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 121,271 131,679 377,557 391,100 Product [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 39,143 40,670 117,675 124,553 Transfer of Intellectual Property and Other [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 13,218 6,246 34,272 165,938 Operating Segments [Member] | Pharmaceutical [Member] Â Â Â Â Operating income (loss) (32,196) (25,375) (84,697) 57,210 Depreciation and amortization 18,043 17,807 53,899 53,649 Loss from investment in investees (3) (20) (7) (99) Operating Segments [Member] | Pharmaceutical [Member] | Service [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 0 0 0 0 Operating Segments [Member] | Pharmaceutical [Member] | Product [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 39,143 40,670 117,675 124,553 Operating Segments [Member] | Pharmaceutical [Member] | Transfer of Intellectual Property and Other [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 13,218 6,246 34,272 165,938 Operating Segments [Member] | Diagnostics [Member] Â Â Â Â Operating income (loss) 58,541 (29,081) (2,443) (113,344) Depreciation and amortization 6,120 8,376 20,238

25,666 Loss from investment in investees 0 0 0 0 Operating Segments [Member] | Diagnostics [Member] | Service [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 121,271 131,679 377,557 391,100 Operating Segments [Member] | Diagnostics [Member] | Product [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 0 0 0 0 Operating Segments [Member] | Diagnostics [Member] | Transfer of Intellectual Property and Other [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 0 0 0 0 Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Â Â Â Â Operating income (loss) (12,129) (9,951) (31,786) (31,841) Depreciation and amortization 0 0 0 0 Loss from investment in investees 0 0 0 0 Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Service [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 0 0 0 0 Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Product [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax 0 0 0 0 Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Transfer of Intellectual Property and Other [Member] Â Â Â Â Revenue from Contract with Customer, Excluding Assessed Tax $ 0 $ 0 $ 0 $ 0 X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 - Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of realized and unrealized gain (loss) on investment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_IE Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_CL Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_ES Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_IL Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_MX Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=opk_OtherCountriesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=opk_TransferOfIntellectualPropertyAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.3 Note 15 - Segments - Assets by Segment (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Assets $ 2,256,103 $ 2,011,698 Goodwill 535,868 598,260 Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Â Â Assets 466,451 49,181 Pharmaceutical [Member] | Operating Segments [Member] Â Â Assets 1,271,781 1,331,764 Goodwill 316,161 315,235 Diagnostics [Member] | Operating Segments [Member] Â Â Assets 517,871 630,753 Goodwill $ 219,707 $ 283,025 X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -

Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=opk_PharmaceuticalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=opk_DiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.3 Note 16 - Leases (Details Textual) 9 Months Ended Jan. 02, 2023 USD ($) a Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Operating Lease, Cost Â $ 15,200,000 $ 12,000,000 Finance Lease, Interest Expense Â 2,500,000 2,200,000 Variable Lease, Cost Â $ 1,500,000 $ 900,000 Office Space [Member] | ModeX Therapeutics, Inc [Member] Â Â Â Lessee, Operating Lease, Term of Contract (Year) 10 years Â Â Area of Real Estate Property (Acre) | a 33,056 Â Â Lessee, Operating Lease, Renewal Term (Year) 5 years Â Â Operating Lease, Monthly Rent Expense $ 243,500 Â Â X - DefinitionAmount of monthly rent expense under operating lease. + ReferencesNo definition available. + Details Name: opk_OperatingLeaseMonthlyRentExpense Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionArea of a real estate property. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfRealEstateProperty Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionAmount of interest expense on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_LeaseContractualTermAxis=opk_OfficeSpaceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=opk_ModexTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R71.htm IDEA: XBRL DOCUMENT v3.24.3 Note 16 - Leases - Lease Balances (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Operating lease assets $ 62,812 $ 68,088 Finance lease assets 6,544 10,101 Operating lease liabilities 12,741 12,996 Accrued expenses 1,855 2,827 Operating lease liabilities 52,057 54,140 Other long-term liabilities $ 4,689 $ 7,274 Operating leases (in years) (Year) 6 years 3 months 18 days 7 years 1 month 6 days Finance leases (in years) (Year) 7 years 1 month 6 days 6 years 2 months 12 days Operating leases 5.30% 5.40% Finance leases 3.70% 3.80% X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for finance lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 83 R72.htm IDEA: XBRL DOCUMENT v3.24.3 Note 16 - Leases - Undiscounted Future Minimum Lease Payments (Details) $ in Thousands Sep. 30, 2024 USD ($) April 1, 2024 through December 31, 2024, operating $ 3,043 April 1, 2024 through December 31, 2024, finance 673 2025, operating 11,772 2025, finance 1,813 2026, operating 10,937 2026, finance 1,334 2027, operating 10,775 2027, finance 806 2028, operating 10,785 2028, finance 203 Thereafter, operating 26,534 Thereafter, finance 1,959 Total undiscounted future minimum lease payments, operating 73,846 Total undiscounted future minimum lease payments, finance 6,788 Less: Difference between lease payments and discounted lease liabilities, operating 9,048 Less: Difference between lease payments and discounted lease liabilities, finance 244 Total lease liabilities, operating 64,798 Total lease liabilities, finance $ 6,544 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_FinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.3 Note 16 - Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Operating cash out flows from operating leases $ 15,101 $ 11,704 Operating cash out flows from finance leases 354 327 Financing cash out flows from finance leases 2,118 1,919 Total $ 17,573 $ 13,950 X - DefinitionAmount of cash outflow for leases. + ReferencesNo definition available. + Details Name: opk_PaymentsForLeases Namespace Prefix: opk_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest paid on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeaseInterestPaymentOnLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration EXCEL 85 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (F"9UD'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\QO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*1#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M ")@F=90HV^P>X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$Y&!R;UI:.G#@8K;.QF;+4UBQ-C:R1]^SE9FS*V!]C1TN]/ MGT"-
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
8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=
<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71%B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8]*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-;/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 (M F"9UFGG(*)U04 .P> 8 >&PO=V]R:W-H965T&UL MM9GQ;Z,V%,?_%2N;IDUJ&C!)F]
[:2&G:KM'UVK3I-MVF_>""DZ #S&R3M/_] MGB&!M#(O&;K<#U<@O"_^^#WLK_'Y2LAO:L&Y)]JQE*B+UD+K]%.GH_P%CYDZ M%BE/X)>9D#'3<'KG'95*SH(*(XZU'%..C$+D];@/+\VD8-SD>DH3/A$$I7% M,9-ÖESP2JXN6VJI<> KG"VTN= ;G*9OS*=> IQ,)9YÜ2)0ACGJA0)$3RV45K MZ'X:>=0$Y'?\$?*5VCHF!N5%B& F9!Q.-^DT.#S O3/&1B/X, [VX:/5;). SED7Z2:QN^1JH9_1\$:G\
M?[(J[NUV6\3/E!;Q.AA:$(=)\9>]KCMB.\"I":#K /HAP*U[@K<.\'+0HF4Y MUA73;' NQ8I(HF8.\;_)HH D3D\:IEO!K'"%Z<"7\#+*BR3)R'6B0_U& MQDE1'J;,VT0MF.3JO*/A:2:FXZ^5+PME6J-
\1KZ(1"\4J 8\>!_?@5:63:6; MIEY25'#*TV/B.4>$.K1K:<\(#[\7RV/BN+;P=\WQRI[SJW]L759(=ÑV2YI7]I%+F\XL6O).*RR5O#7[ZP3UQ?K7Q?B>Q=_3=DKZ+ MJ0_6I3*"#I L@CX(^"OYS-]LT+B2 __.NMV^E*"GJ -'$(=!WDMWT1L M;@/$XV/1L?&M.0[ZSD._M??'D6 M:^EPK;II XUJR.%A3K"U;&>Z']9@QJ;F, MS#B:"JFMB+B6EIEU=,'#FB+2"I'NA[A^Z;#!98=4:6UJO0TNT)2U\CHN:B\V MJA3F017F7@?))RY6.UW@<4TA*TOC[N5I;L*(D_LL?N'2"K?+SKAMS^O1OA7P M$';&K?R,NY>A&2>^D)"[W+(>D:F&HB5"DI'(P,V!J1.!08AQ]:MK*_(AC(U; M.1L7MR9KY&?V2L8!%'
X" _W"JB,9QB5/>VW:A=?4;ECQX*:\E>EQ<9^RYÄT& M :BKH\T!R=U-7JE#R5D]&"[@ M.3TKUB'L$:WL$<4]S9W(%R0+D6"SZ0Z1'@RV7==QK'R'L$2TLD04=S'/H0:? M(&;$I3^__$*FW,\D9-(*B2N-1!S#A#35PO]V1%)8X2Q9E''RHW/LN"3ELO@& M9^V#0S@F6CDFBIL=<(-!F,S)]"U^$9$5'1=XF'RV8AW")]'*)U'+ $ MUY#/J_R/MY?_N8ZYG)L7\S=0T
NP"'*$FMJ=PC6@N)Q34$K^^/A[F63 MR 6'1&)XN$P]WB%LD%?9( ]W,)N1]MTKF=W=Y>"D3[M]SZ&PD%UN0W:V]A-- _>7;K(KXYOM L;587BVW8,-(
ME"+39@H._;B1I2EF0EX_'N<=#$\TPP\O7Z9_>?>>##F@;?B1I;_%+G>72^2 M!E_E,^_2J.!H5FODR6;?^)GHY8O$!9UVI9'0<#@ZJH#__YYZ,C3@:0 M8&8 /0Z@7SJ '0>PWM
#L]ZL6Z[YYDK))Z0,&F8S%[UO^M%@35&;UWBO%?Q: MP#B]N9%U#B]%Y BN6ED6.==P\YZ7O,X$NC<3M^B'FTXI46MT)U0A<_2QYEU> M /!'M$(?[V_1#Z]^1*]04:._=K)K>9VW5VL-
],Q#UMF1ROL#%3I#Y5XTKQ'# M2T0Q#1S#;_S#;T4&PTD_G)T/7X-3!L_0P3.TGX_->>>9H,F];<,$;ESV"'0+W M!"8!W[0-S\3U C*L%6HO%IOOOR,1?NNR[ÄM-=F8K&VQEOMDW-[S=+5$>C\
MVQ5[7H+E+8+W"#%X< ,\5*LB,\%A<"YW')X1]<\PY6._"7 48'RUWI\:.L/2 M,$G(@#]S(!@L"+P6O,LRV1G.2F0"#'@HQ1+50KMX'F8*3P@0'(5Q.N!Q@%'&
M3F!G1,.!:.@E^J'>@SNE>IZE%UK/#=,)Q-V-BH*HS1VDXL&,0VF7K51- C)C%/C@7?LY?V7U+R<\'91 MC&VGT31BT82C#6,X#>+(33(92"9>DG<*Q%=I>/$-%%?=^]5D6P.JJ&>C(;&X
MQ)3&9,+8@0H#.N/5="'<7@A5S>O' E+IZ-)9DJGMUX"P=.I7&Q8'F",,39/@ M4)]I+O+Q_MD3)_*LK228[8Z<3")K6 1[" M13BA,_1&Q2)^R?H#EX"$T"EK!RS! M23+#>E0IXI>I0X'UT'.
(3A*2:;H[8"E.YE[Y*WKTV',NIA9XL.I6%$,)OR MA<6 YUP5+TQGB=-0WZM>W%^*- M5/W:%UAG$LHSW!EQKJ5VTZ8.X8JGZN8 S102.@H;]0N;@["I]/[.E("E8Z_ / M/7%?4%-;W BC=%JM'3
(_72FKZ G*T"_!)ZWE2>+D6"OR0A- JLIW0U=40D2L^H@XX0N+)574 M6='PLGPV\:$5S_0YPGP+86]R%"[;(N_SP.P10HV9U!VG_8[U7A3B8&J^#8.% M6#*SR**C=%* =!ZJC--
Z)UM;'6&QA>E411VX@-* SD@]'664^F7TR/<"2UL* MDY!&B<72L70$EG.[+&S43(:]C>)/L++6S\[>D'G5]FM[PV\UV[F=H]2R"U(K MJPI"_5[+[!-:H5?X-28@J0KM>=F))2)+&N(E"(SY0^V. PG$.
[V3JQA/Y&]1 M3.@2UN!+BJ,^8>*$+%,6+9,D?($7;6MZ.Z[1O6BTJ!X@6U\V:OLQMR([?GO< M?UV:A7@C^CWZ\MGY$FS-!B;3G'.A$CI3'=DH[.R"L"M0R$X]#VZCZ3(!%Y$X
M7O8&)P3!T\]DUMMUN %8G3:3MY$79N_)=#(83Z"%EL-O56 M18TRWA20U4ZR=@/ 0A+%;*JW+F# &,8S_2\;>P5V<7.WJ[JR/YF0ARU*64$V M[#B!+4CJW\G;^;H\W>N
M'HNZA2Y\"R/QZQBL5H?3Q,.-EDU_(/<@M995?[D3'#QN /#[5D)'>;PQ9WS# MF>[F?U!+ P04 ")@F=946ZF]H8" !X!@ & 'AL+W=O%E"PL0PADAQK_>,QANZ83[MXR?
W[[YVK.66&5@H\9>7MIH%64!*6+-6V&NU^P%]/1ZP4,+X?[+KX)X_(J]@+Z44'2"Q)?:$?FR[IBELUSK79$NVQT"2"28+("MG;,C)HM4:I"5+
MT%R5Y$:RMN28>$I.ELRM5&!YP80Y)5_)%Q(24^&TR4.+C.Y.8='S7'8\]!6> M%30CDD1GA$9T?$2^>%M^!07*8RJ/GLM#W)EA>^BP/=3[C5_=GKK&APV/H;@[M(PW39,M$"^2$2U(J(9@VI
'=E7MZK-S.?^K]W2NUG4>C*,[#[7Y1[R0]0T\& M].03Z*RUE=+\/YZM8^^.YRAPYYKNL<0TC;K? ?:'4I !CP?X\2?@N3'M^^#C M%S33F-(LH='D@/M(9A:?)Y,L2X]CIP-V^B;V;VRDIM4/9-6!=V6-
;Q:VRV'C\L,)/ VB7@.MKI>Q3X+K/\+&9/P)02P,$% @ "8)G64.8 M9R/R" "S, ! @ !X;"]W;W)K5CL@V(SMC"RY)5HI[._?BA9L2SR MBHUG^)+XX_!(Y_*2]UQ)OGFNZM^:M90*?=L497,
[6RNUO9[/F\5:;K+FJMK* M4G_S5-6;3.FW]6K>;&N9+;M!FV).@H#/-UE>SNYNNL\^U72D_U:C9 M;399_?M[653/MS,\>_G@<[Y;J_:#^=W--EO)!ZF^;C_5^MW\R++,-[)L\]I$
MM7RZG;W#URGK!G2(?^?RN3EYC5HICU7U6_OFP_)V%K1G) NY4"U%IO_MY;TL MBI9)G\? >M+9\9CMP-/7+^P _=N*UF,>LD?=5\6N^5.O;631#2_F4[0KUN7K^ MI^P%A2W?HBJ:
[B]Z[K'!#"UVC:HV_6!]!IN\/S/OO6!.!F@>> !!!] S %L M8@#M!]#7'H'U]AKCQ#V SKI\X/V+G!)IK*[F[IZ1G6+UFSMBR[ZW6@=K[QL M$^5!U?K;7(]3=_ =5N=33+I=(OVJJ(E]F2KJY4/J?S@?
5H.H)_:*5=;:.X,N MOI;9;IEKS!MTB;X^).CBAS?H!Y27Z,NZVC59N6QNYDJ?6.\7,=D6-8R$M8WA,GX8/<7B$:O$4D(PXG_O7 M#Z>0G+]V]/1/'WT4#'K,$=KQT0F^SW(ORYULKJ&0)/0QE\-
!VF[MNMME"WL[T M/M;(>B]G=W__&^;!/Z"H^B1+?)*EGLA&\6?'^#,7^S'^4/@/(WDWLBT*^SLL M**?D9KX_#2P$B\(X',,2&Q:2. S8&);:.![A,,9'V$AF>)09.M/LOFKT=J,W
M$"2_;=L]*4ZXT&?"^21+?)*EGLA&,\&/,\&="?>@ZW9>KMZBE2USEJ]TDY(M M=?G)&]56@KV$9N9 &IZD11R1@!JI:*,$(2PP,M%&$2KP28H=H@3 B.""PYDH MCOK%=Q9<([-
ZL>YT+_7J*ZIM6PPAT<(^@T@(0\Z]C<(QH^;RLU&"B2@V- .H M ,5*(IZMI MD-3X*#5V2GVWJ6J5_[^3U[];O%19NYH#1LW@];6.4%%(WME1K&#'-3LXTCC 8!,87;,.XBC31U
MVSC!XŸ!/[&28#.*)4WSOWHE(JT%Y@KX;6*UOB ME2WUQ3:>G,'48K>K_5 JJ7E5/S_@7#![D<4D,O/11L5F 4X $,.F34X!% V$ MF,C#P=ABIUL;I/;I!VH-@=4B:!B;:@$8WV6;&3:+'6]55V5Q*TK
C'W+23$"XB$]8*#W82N_WD:!\:[T&@:MOAL8A3:Q^V87I_U2;!% ^8 M3Q)%BIQ)03X>L*EM>+"6V.TMSY5ONS[*B-F$W@.P2TQC@4WY-DXOJ\@JP =
MH5$XY3X&MXG==O/#:=E%C_*IJN5+,%3V31X\25[N]0;1K@;4 B?,B>T)M9<@ MIOL&8)@X"& ? M"0V)83GN(1P/A+DB0#KM3(P I1 .ZP4Q8[M"LA1!.3S>-)G9$,C@_PIRV?+PCZOX$->NLEJ
=)TX3>:X=]\]6 M>&5+?;&-)V7PJ.1['A6B8FU7-@J,"G]5 M5&"RJ:@,;I:XW>ROW,TX(XZ;G!: BQ"$) ^OR \@:(&LSG@=-IFX[?*#WMGRA43_^2@WC[+^ M+Q@)\791<$G6^*5+?7%-
K[O._AS&C@KM?O.K]/;GWWKUR=;XI4M]<4VGH6A M6Z#N;L%U_[>CO7+W4U4M#_/2[] ->]@* MZ%F=]SWCZ()3$$7,[-9!'*=6NP[@* F%U:Y#.$H9G\K)H6&A[DO5G^IJN5LH
M9TUR4YR=D%X;%:]LJ2^\V\60,C0IU/R;BKDE>GP[QRI9X94M]L8UG86B-J+LU M<&@&$LN+E+I!".L'#]3@8=^ATJO%0D9]=T=NKY M9$N\LJ6^V,;S,714]'N/JIQ?D>R&13>7H=DM@;#03-
P$@/$X"JV$!+HD)O#$ MU5(Z=$C4W2%]J;.R>9)U&X/VSF+1/G2]RPJDR]16UNKW+B:'FR[.BN6UB_+* MEGAE2WVQC9_>'+HH]A>Z*.:UB_+*EGAE2WVQC6=AZ*+8G^^B&-0=$6P^:0#
M.#%OER4 BC(BS&<-H&/R,*:1L3_,3Q[NW\AZU?VJHD&+:E>JPS/P?C\;Z^Q\#G";Y.#[_+&.@//Q/YF-6KO&Q0(9_TH8(KH?>R^O#+B\,; M56V[GQ8\5DI5F^[E6F9+6;< _?U35:F7-^T!CK]_N?
L#4$L#!!0 (F" M9UG44R0P*P, !$* 8 >&PO=V]R:W-H965T&ULK59M M;YLP$/XK%JNF5FK*.R%9@M2\3)NT;E6S;I]=< (JV)GM).V_W]D0FA"2=5N_
M@&V>Y^Z>N\V8,/XHT@)O>BIR*D8&JF4R[YIBC@E!197;$DH?)DS7F)4[XP MQ9(3G&A2D9N.905F@3-J1 .]=LNC 5O)*/DEB.Q*@K,GT,J MFE$9C7,D&A?
=,"I3@:805=+"GYSF]T[P3],ZN>3*^6Z6FB>T3F-YD2 MCN*]GL\HS DZ5_(O+A&%3,!_(?%3ORT9WJDTJIV_+Y8X)D,#/ C"U\2(WK^S M ^M#6X>]L';)6QJ;OI&QO2+Y=9'\D[TX3C%=J+H@."OA-
*"P67).:/R,),=4 MY+@\AVB"V)_JV5;"TKN_TUM=RPT;[7P(ZO1\WVMT^3/V MLA3460I.9^GO1 <'/Y1K]YRFZD-4I^=93K=\GKR8KZ\+-U@OLBH M0#F9@ROKJ@M5XN4%I)Q(MM0G[.3<%
[K80IW-L(5 +[/&9/;B7)0WMP^CWU!+ M P04 ")@F=9-"*T/7L0 "?Z0 & 'AL+W=O$;.7O\A7WZYJW?_ M<'YY\5A^J8JJ_N-QOFF^.S\]M\N':K5=KE?:IOK\\>Q7\DMA&+L!^XI_+ZOG
M[9NOM=VO\FF]_G/W37C[\4S?'5%U7]W4.Z)L_O>UNJKN[W=2###M@0'T,(!R Z9#]AA M _,&6'1@@'$88/ #V, \$# Y I:.,#T,&#*#6#3@0'688#%SZ /#+ / VS^ M=Q@:.,#L,F/$#C*$3I[^>.9T?
8@X-.9YL_FQ/!X>\GF["GV\V=+{)ZPDG_!FG M0V>MI)[[Q;0T->3SSASSP='/)ZZ@E_[LG0 MW9&\GGRR/_OG+W^]^S]]IZS+RXO-^EG;[.H;;_?%/C_VXYN_^.5J%W5%O6E^
MNFS&U9=7Z]5V?;^\+>OJ5BOJYG]-CM5;;?U9< _]Z6M9_:S_^L2J?;I?-SW_2 M)MH?A:/]^,-/V@_:=TKEI_M*R]9UM=7^FU8/GZK- YH?/3PT:5C4ZYL_C \JF.KJ^Z?Z MO7F8V#YM_GZ9[.?
7J263.M_Z:^WSVDN46ORL=EW7POF=@% M3'Q]%6J_UO5F^>FI+G<%];HYA$USYF4S>]_KN1Q\WSUFH4#?=U_(Y>JHLUPH;L=U\QMVAYTWC\+'AV)Z?"BF M>\<8<'XK[\O53:7]V-QNV[OF-
]S^]6UYE0W'S1&?M[=DZCH@5:[[IXJ_;)] M+&^JCV?-P%,_?8[E6'KY>639@^)5/CXOSKVZSN5T[LJ6GJ-NT6SI"MT'B.1(K M0%@GB=DQB=E)2?R2OOO'A=<$9B=%LI2?&\E(S$%B+A+SD)B/Q
(D%B*Q"(G% M2"Q!8BD2RUZP*1?)7!KWBR;FANBOM5S*#$MXC(7@@T@S'*39J+)K4IG?&% M1;^0F+N'%/M8UXD]XQA[AC3V7E[PF>Q>.;[5;M8/C]5J6^Y?D*Z^[;ZN1%$G M)
<=&'1)SD)B+Q#PDYB.Q (F%2"Q"8C$22Y!8BL0RH[>FU+F<4U;,^Q6V99A< MP"F97%E1*";])IY3#13FFA956OWZZWP]6GIR+'!A<0<).8B,0^)^4@L0&(A M$HN06($$B26(K',5
:7LF*NK%@H*)^Q810RFP^N]1UG?B:'N-K*HVOZ_JN M>>:Y6XEMJKO=]H*OU6'<2:6Q<&$'"3F(C$/B2E(+$!B(1*+D%B,Q!(DEB*Q M;-
I[OL;'F;)B/E7&6;]BP@C_7#17.D7_6+I.)\JL8Y19\N>6WZK-S7);[386 MW+R\T;3=OW^U?MP]P]QJY>I6>RXWFW*W^^#-6R"BK)-.-3;KD)B#Q%PDYB$Q
M'XD%2"Q$8A$2BY%8@L12))99O7PQ=-.BW$MGU_TR/O"01[5 8CD2*_HW!+$M M9M6%&I2=6RH(3$'B;E(S$-B/A(+D%B(Q"(D%B.Q!(FE2"R;]9+$LHE% MB&US[S5<]RL'-
LH@CV^!Q'(D5H"P3A(3_1C%N]Z1$[+X)7_KPUZ9EQ V3DIE M^01C8QFJ.5#-A6H>5/.A6@#50]@60;48JB50+85JV4'C-LYP:\9K095HY\RA M[&V*,X/IS.!?U!043HRI,>,%%?#)V!9D99F-R*U)!)3$,PYP.
()XA;UJIR'O6 MI='32I& 4G9T B(U!ZJV,#:CY4"Z!:"-4BJ!9#M02J15 M.VC<(G4Z8X3Q MBU1!Z< J%7J("ZB60[4"I773F;;I?%[I="F;G;5,0QMMH)H#U5RHYD$U'ZH% M4"V$:A%4BZ%: M52])8=-
-5"M5\E7*CV^W*802U]9O +54$##YO.#/[]=U$= ML:>ZS?B73@65Q&0F&]KF3=KV%B+O;WG71F^Y.3K^H%TM4,V%:AY4\Z%: -5" MJ!9!M1BJ)5 MA6K909-MGE27S
4EC!*;#STEE*M+"M5X%16=<-M+:9A<'7)G*B;700EDYEI\CW(;JD0'$]7ZL9;V^Q"Y-TNT"WB M\KE&YQ^T(0:JN5#-@VH^5 N@6@C5(J@60[4$JJ50+2/]?I3N_N=#!BK;5N;0 MXUI
M1RJ%R@21>=RI(YZ;>NT-X+A,H^GUQ=4@@.A@Z]/-BVR!!YC\Q[=Y'+V=$A M!VV.@6HN5/.@F@_5]@60K4(JL50+8%]*53+2+\Y96A+N:!T:+<.\A 74"V'
M:@5*ZZ9SV^)#3NOQ^8Y]Y=!V'ZCF0#47JGE0S8=J 50+H5H$U6*HED"U%*IE M!TVU7:=?)=RNT^\.&MA7+F@C$NXK%]0-[*OO5TKWE=.VQX:>UF,C^6!P80+* MV;$)"-4T;);&"A2MLHE+?
8O&M?N=P<'7_8"]A@KV"#O80-]AHVV(O8 M8*]B@[V,#?8Z-M@+V6"O9(.]E$V_':67?HO'LFKQZ?-C=WY+KNPF##MI]4J20CE9-^K:%IKF2UG4%;M7&[5- M&WB*79=R;G3$(34'JKE0S8-
J/E0+H%H(U2*H%D.U!*JE4"T[:)V\L'2]>5YI M\F^\0">0[4%5,NA6H'2NLG=]@I1>:\0G]S"M(;V"$\UZJY4,V#:CY4"Z!: M"-4BJ!9#M02J15
MHX*&FR:M^:!&SCFG@G8AB^GFC%^_JB^BHRXIQ+-9YM K MDFU/$97W%,EZP.5#1\!:BY4\Z": M#]4"J!9"M0BJQ5 M@6HI5,NHNAU'73*GRCZ:A:!D0DS;X$-.W9$C.)ZNU(VW MMBF' B]5#-
AVJ!^BR$ZI((>DPQ5$N@6@K5,JAV#=7F4&T!U7*H5]"T;F2V_2Y,WN_2 M1J8P)OO;WWLQJ2QQU^6NNL13E_CJDD!=$JI+(D$),8EM<76QFDK4)>F)LV7R M4SWZ#QJIS:'. JKE4*U :=T_:-
K^09]V813)!^$8PC]U:.,&5'.@F@O5/*CF M0[4 JH50+8)J,51+H%H*U3(F:(,@E-J,\LUFUX+2"9U9L]E,Y 8%SJ"'N(!J M.50K4%HWGMMV$R9O-QGU23CBH(8VGD U!ZJY4,V#:CY4"Z!:"-4BJ!9#M02J
MI5 M8_W&DR:H^1?F!%6B!F,FN*B*2:86?ZG"A:!PPF93PK\K+*JCNC73&??0 M4 @JB:$SX\V'^G2SL.U^8=)=TZ=<856<@,BMW5=0S8%J+E3SH)H/U0*H%D*U M"*K%4"V!:.BE4RPY:9ZE*+6)-*:-
\#/9+!Y>JR&-<0+4= MC+G$JCBGH1TI4,V!:BY4\Z"#]4"J!9"M0BJQ5 M@6HI5,M8OR.ER6G&1[2@ M;T6T4NTW?S#3T U^!;H0%$Z,Z=3D+[$JJJ-$9S/:6ZGV*PF;F6QPI=HVGC#%
MQ6S>\U$XJ>5#-AVH!5 NA6@358JB60+44JF5,<.T78M@SIM/>N^/(B>=0 M;0'5U7+*1^'(B=%I#6U<@6HN5/.@F@_5]@60K4(JL50 M+8%]*53+F.@R,,:,#VKDG',F:G-

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lD, M,<@9?:+ #/Z6]G]+@#'[@,&@N6)M]JP*QM52-^,\<%G>#I?LS=>,QF0V MFE6'U)S$B7M.9[VNLW"TR6IJIDM4#0=7-"[]9M9?CO$L(2/];"D<)3.W>EFO M7A94[VS/V\U[;>5#;S[& M>)>X1'7'=XL%5D'[E7/GLI[;,SM2UI:8S]VZQM' LRBH[<>_MZ)YG&JT%^#* M-=0[=>OHWW_):/3K' M06NN."O%/V")242O;J$N>XW ED+4&UFS4D?/4CR (-):EJ3X#DWW.;&%ZCF M^5:9#.6T+[8TG\YI-A\;:(O%E%*/@7@P$ <-7*Q8=%/"R,!TS'84Y#%:BI!F[5^M:B,)AS M)_AN*/??[U2T1::QJ:F<:@[,CH.H Q@MN5(&Q;#&.6K8 WIUPRN^%,UKM%'R M3M0^K1/;N>G<\|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}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{:%-CKQ(P%>SL&KVGFZ6NFXU%9$\'KG M$.HVX.:[C2:XN)0&\04+,> BX&@M)$XAJ98"EF1/X-XGDP7G+21C"$^0K7P M:I?I'YN:-Y FC]3[7AR.Q\/QR1E^G1T-3T\GXO.VMK!)XST6B^/AP70B?OCN M=#J9OGZ\S#B[V(O*5V)R,#P^/MJL_.(B\FNW?8<[#1R6;F7_3Y.02E.H! $V M*GUA,E4M[5H41H:=$(8,*\2S@P:5+PR3!A.,BI"D1277I4ZBJ'@!8HD;4/C MV:4DN%&2(G5F](#"?$2'FH5%*NEAJMO/P M05@]$4PC<67OL-QY4F6N?8CY,RZ]4D\FYG-/#\1/SI4K;0QKIY'Q=J$I=9*<MXFCTLH"[2,ME 4_#@,E66LZ0<)'$!;FF2G:8-0&R!'C#53.@,9L1T:0+Z@1@ M<=]C!5A^""+;&BOQ$)9Y:4Q:\YGH.1_B%=DRY')R(GL QS,+0$_TIY<5"ON M#\1A,-A6#OC\DZ[92;VLM,P#3TP;\ M@?.^$TTCS;4G8""3+]&D@5>@6&)W0S'XTRX40RXJPN^J#2A;IKBLN^O>TOXC MU&!3BAI-!$HQ*P/=&#DZ[B/Q&X)&>>JC-_QUA-Y6FG6@)/" ? L1VX[>($S;X MDL+,L1T1BV0#=.#!6:ICMA>>#P$.X=:5%Y"M,D!,-5(?#4I9,UZV,G>5Q&; MPS9)\L>+$OX3(OZQ_W/:@D/GGY5"4Q_>G \.D1_:PR77RN4!$12+_H2;B36 MUYJGA$4#U';H8V5-Y5V:81?X_3#L4*5S(@N@*N*G9BT"JF:LCAYHTP65[>,XNCISG%>7,Z8?LEZ4.>6O* M('OGS)UD<*ZE;_.QD-ZO&9NY>^&DM(EFO]K%P(+3&-,0$A9-U:0:FRTI$ZQ0 MWF!M#U*;V$!79(<.W.^VC<&<*CR;<)<8A-RJ# _Q.1'K]E//T8<)9(!?J < M'F1'>P=204H1]E)O'^6;0RIC(MG4R&* 3TPB)2=!$ E0LF)S,T7E%?QJ)O8?Z/.F7+1EVJO<)1$4(-T]!LZ4>#DVT=[:[+P%+&J6%K]![5R5&/:=N1L1(TXJ<>!WFK!6]IU[Y$0=S*UME)M8Q[00??,_V)*X3<8CNC@3D\/#"W$B3D8DP+5WR)Q(M=O(G!]DM3I!PS9L&.&H!MUQ(^<=Q13J0N$DX E>%LL%#(9%)?562 MF-O\9\X^KGJCWB_THQ(NMI\),IH!G;J7E9YU'*6I*=>V*PDJJ5-G0'I M.!U/CD@KZL\Q\V/B;+98B./Q\7#S@&&-4L5C3,OH^8X/-6F_*)U?7(&Z M/K]PADITBI!UFF"+=$;4B8'HYZ.0.6[#6:N*["[@ZG3V1+-/%,O)-:Z%P*!7?$6OFFT4&]/=SB,%PH MFC/7BAQ7"5>%0_N(R?J'[TY.9[\=(;L8R2Z.H_:>\\,S06KG5I$8MGEG#- M;-TD&#>&Z@E<2I=P0;9?*'OP^).9KNL)B/?]Q?\1797Y +;RWJ M_.D_-P7.V];=G>1"0?4$63:=?P^F!.,M%^\C:H_ /02H1M'<%OA<6<86[7BX MX3.?OKIZB?E@.8F6^>0;O3XC"-X:Y[?_<"\(1U\.6O*]%K)".]$W"BO= Q1, M-S@JGY,7P>Y :L"]9ALU;Y$Z1!U%$?%B M)EGQ"@>S7T@Z@0[!._P_/39TPA:0,4//Y?#5 *7>;SK7&LXT<^F(H[N/L)VT3J^#.=]0_SJ MWC\K'X2M6!@H+#ET-OWE3<*;'5MU/R'3QO:X-<3--@YK?MW0!@=>+PWOUC) M"<;W&PO=V]R:W-H M965TN_?D;UT2CK;KV(C15)?WZ4AFW>CN8#-H;G_5B&>G&_OF;6B[4C8I?ZVN/ MJ_T-E5)7R@;MK/!J_G9P,7EU>4CK><&O6JU"[[<@36;.W=+%5?EV,":!E%%% M) H27W?JG3*&$&,/S+-P88E;>S_;JE_9-VARTP&]3S7VQ?-/+BIQ(/;$3** M<'-QHQ=6SW4A;1071>$:&[5=B&MG=*%5>+,?P9BV[Q>9R65B,GV"R9GXV=FX M#.*#+56YO7\? F^DGK927TZ?)7BCZI$X& _%=#P]?(;>P<8*!TSOX!DK!!&=M^*BMM(661MQ$&16B+^[4-Y$[W$V.$NE5J&6AW@Z0*4'Y.S4X_^&[R?'X]3/" M'FZ$/7R.^OF?N$?\ZXNZC^+2N.+VW[MD?Y;Z;MD__?+E Z+D4@8=*$+XB86%M*+$F8_K(YTA8%X4%.0'WP'8SY3<^XF>57*<++'^OBKQBPBL.Q+77L'QM%',H MG U0]$PLO@9%-U6(&HF(%>]D6 Y%@4^A FCTG33D*2%M":0:TO>LBJC(]/QO3 MWY>E$G-G@$%DJRAG1D$+=Z=+4)/8!{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{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{:%-CKQ(P%>SL&KVGFZ6NFXU%9$\'KG M$.HVX.:[C2:XN)0&\04+,> BX&@M)$XAJ98"EF1/X-XGDP7G+21C"$^0K7P M:I?I'YN:-Y FC]3[7AR.Q\/QR1E^G1T-3T\GXO.VMK!)XST6B^/AP70B?OCN M=#J9OGZ\S#B[V(O*5V)R,#P^/MJL_.(B\FNW?8<[#1R6;F7_3Y.02E.H! $V M*GUA,E4M[5H41H:=$(8,*\2S@P:5+PR3!A.,BI"D1277I4ZBJ'@!8HD;4/C MV:4DN%&2(G5F](#"?$2'FH5%*NEAJMO/P M05@]$4PC<67OL-QY4F6N?8CY,RZ]4D\FYG-/#\1/SI4K;0QKIY'Q=J$I=9*<MXFCTLH"[2,ME 4_#@,E66LZ0<)'$!;FF2G:8-0&R!'C#53.@,9L1T:0+Z@1@ M<=]C!5A^""+;&BOQ$)9Y:4Q:\YGH.1_B%=DRY')R(GL QS,+0$_TIY<5"ON M#\1A,-A6#OC\DZ[92;VLM,P#3TP;\ M@?.^$TTCS;4G8""3+]&D@5>@6&)W0S'XTRX40RXJPN^J#2A;IKBLN^O>TOXC MU&!3BAI-!$HQ*P/=&#DZ[B/Q&X)&>>JC-_QUA-Y6FG6@)/" ? L1VX[>($S;X MDL+,L1T1BV0#=.#!6:ICMA>>#P$.X=:5%Y"M,D!,-5(?#4I9,UZV,G>5Q&; MPS9)\L>+$OX3(OZQ_W/:@D/GGY5"4Q_>G \.D1_:PR77RN4!$12+_H2;B36 MUYJGA$4#U';H8V5-Y5V:81?X_3#L4*5S(@N@*N*G9BT"JF:LCAYHTP65[>,XNCISG%>7,Z8?LEZ4.>6O* M('OGS)UD<*ZE;_.QD-ZO&9NY>^&DM(EFO]K%P(+3&-,0$A9-U:0:FRTI$ZQ0 MWF!M#U*;V$!79(<.W.^VC<&<*CR;<)<8A-RJ# _Q.1'K]E//T8<)9(!?J < M'F1'>P=204H1]E)O'^6;0RIC(MG4R&* 3TPB)2=!$ E0LF)S,T7E%?QJ)O8?Z/.F7+1EVJO<)1$4(-T]!LZ4>#DVT=[:[+P%+&J6%K]![5R5&/:=N1L1(TXJ<>!WFK!6]IU[Y$0=S*UME)M8Q[00??,_V)*X3<8CNC@3D\/#"W$B3D8DP+5WR)Q(M=O(G!]DM3I!PS9L&.&H!MUQ(^<=Q13J0N$DX E>%LL%#(9%)?562 MF-O\9\X^KGJCWB_THQ(NMI\),IH!G;J7E9YU'*6I*=>V*PDJJ5-G0'I M.!U/CD@KZL\Q\V/B;+98B./Q\7#S@&&-4L5C3,OH^8X/-6F_*)U?7(&Z M/K]PADITBI!UFF"+=$;4B8'HYZ.0.6[#6:N*["[@ZG3V1+-/%,O)-:Z%P*!7?$6OFFT4&]/=SB,%PH MFC/7BAQ7"5>%0_N(R?J'[TY.9[\=(;L8R2Z.H_:>\\,S06KG5I$8MGEG#- M;-TD&#>&Z@E<2I=P0;9?*'OP^).9KNL)B/?]Q?\1797Y +;RWJ M_.D_-P7.V];=G>1"0?4$63:=?P^F!.,M%^\C:H_ /02H1M'<%OA<6<86[7BX MX3.?OKIZB?E@.8F6^>0;O3XC"-X:Y[?_<"\(1U\.6O*]%K)".]$W"BO= Q1, M-S@JGY,7P>Y :L"]9ALU;Y$Z1!U%$?%B M)EGQ"@>S7T@Z@0[!._P_/39TPA:0,4//Y?#5 *7>;SK7&LXT<^F(H[N/L)VT3J^#.=]0_SJ MWC\K'X2M6!@H+#ET-OWE3<*;'5MU/R'3QO:X-<3--@YK?MW0!@=>+PWOUC) M"<;W&PO=V]R:W-H M965TN_?D;UT2CK;KV(C15)?WZ4AFW>CN8#-H;G_5B&>G&_OF;6B[4C8I?ZVN/ MJ_T-E5)7R@;MK/!J_G9P,7EU>4CK><&O6JU"[[<@36;.W=+%5?EV,":!E%%% M) H27W?JG3*&$&,/S+-P88E;>S_;JE_9-VARTP&]3S7VQ?-/+BIQ(/;$3** M<'-QHQ=6SW4A;1071>$:&[5=B&MG=*%5>+,?P9BV[Q>9R65B,GV"R9GXV=FX M#.*#+56YO7\? F^DGK927TZ?)7BCZI$X& _%=#P]?(;>P<8*!TSOX!DK!!&=M^*BMM(661MQ$&16B+^[4-Y$[W$V.$NE5J&6AW@Z0*4'Y.S4X_^&[R?'X]3/" M'FZ$/7R.^OF?N$?\ZXNZC^+2N.+VW[MD?Y;Z;MD__?+E Z+D4@8=*$+XB86%M*+$F8_K(YTA8%X4%.0'WP'8SY3<^XF>57*<++'^OBKQBPBL.Q+77L'QM%',H MG U0]$PLO@9%-U6(&HF(%>]D6 Y%@4^A FCTG33D*2%M":0:TO>LBJC(]/QO3 MWY>E$G-G@$%DJRAG1D$+=Z=+4)/8!{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

!X;"]W;W)K&ULW5=+;]LX$+[K5PSJ%/ITL#2F/AX.=;;$BND# M6:..@DT*JBAE:JL50UPI9[IBJ'LI&8+O$7S1_U5T6K82$7SGN-*].5A/YE+>V\5U?CJ(K$%88F:L!$;#
UY@65I!9,;/5N:@4VD9 M^_.U]"OG._DR9QHO9/F#YV9Y.I@.(,>"-:7Y)E>_8>O/V,K+9*G=%U:>-IT, M(&NTD57+3!947/B1/;9QZ#%,HV<8DI8A<79[1<[*C\RPV8F2*U"6FJ39B7/5
M<9-Q7%A0;HVB4TY\9O99&H0C>]7C"OXSLH&X0:9;A12Z(T^&1K28FF'62OQ MW$M,GI%X!#=2F*6&2Y%COLT_).LZ$Y.UB>?)BP)OL3Z - HAB9+1"_+2SN74 MR4M?
<%F#D7#%!1,99R7<&F:>]]>+&^T79ZOF6-,T+O ,XT]9=L&?:L!T[VM]3O;07G4&TRG$K8H*+* MHFU_*)V)355;;=H[M$=7ZV2CT=IJHV(CT?>O<^; 1K4Q-/^;XD02%2+$E- A
MI"$(::V6!5"B4Q;.*1#K;(<)Q!'$*514'39ZA203R+O5'#"J'4JMV#UO+?N M6!P:I:R!Y*.-AR)#-!2RI*ZLCX.K#7TO-MK2[#4L^+VA*LH#EPR: A#X]@JW
M?"%XP3.*4."#9K4HD)0B:NN4YS9Y,O)'SFT*LGE)01*;1=#ZR47==$/P]EI0 M &6CR7W]#MY^P@YF23=+W\&=-*P,SIR#+98?;;P86L*B*BQI_=MQRZHTDVL\#YMLZ%US
:3<)IFM(LV?+ [X__!>&/ M5*<>$-QY=T)1/M+\L[MZO89F?SD&IYO^[89H3:GF,T#"HA]3O\:6)^(P;G78R^0 MG8;0"\I9GG/?E^)D'$Z2*+A8,K%P]^
&^>/@6F1E8Q5S^W[7]$[V'M2HF.=/ M)F$RCH)OF)64X*YQN HB*EQ;30\ _L!L[W&/-O3E]S8>Q^&40O^N;_6>&W0# MS;[7V+#W39?T&X7*$M!Y(2G/VH55T/V8S?X!4$L#!!0 (M
F"9UF Q!1EJ00 (P* 9 >&PO=V]R:W-H965T+)/#F6_>0YZLK;OU2^9 =U5I_&EO&4)]/!SZ?,F5\@-;L\') MW+I*!6S=8NAKQZJ(0E4YS$:CPV&EM.E-3R+MRDU/;!-*;?
C*D6^J2KG[=J;]*C@N6K*\,6N/W+KSX'@Y;;T\4OKQ'LTZE'>^&"K M5A@65-JD?W77QF%#8/([@:P5R*+=25&T\D(%-3UQ=DU.N(&FB^AJE(9QVDA2 MKH/#J89*8D1O;,F.,3+GPP#=
CG,&_QSA->]AN\-_0) MPDM/[TW!Q5/Y(6SK#,P>##S/G@6\YGI >Z-=RD;9_C-X>YW#>Q%O[QF'/05+ M'[11)M>]JI.N@ J/0MON;X/:WPTG/'/M:Y7S:0U-X=BON35^]&!^.WCYC['YG
M[/YSZ-.-G%P:'UP3K21E"OK(Q4*;!9U)6>N@X=2%]GEI?>.8_KWANT#GI^;]U(I-TNFN2W1S:(^J%G);4OK'Q)9.5;:T4J5#2=;A1:! M#"(MO6CG9!N'[NGDJW2!J<]K>2.FA,
M509Z)^]0$BKT?,Z"+8D'NU3(W-D*^E/11HB% M-7.J,5_;T*#V%?L(%;4*:0$LW"25;5 L*B1!^%#&\4%2E@.ZL?2]04+GK;[' M2GJL'U((S"W1\P-5-SOC484)*58-:(?
N8AA=;S!#/O451(51N6BX!BU M3(7-(W9JL1:M'1C)5&TP*+H.%$K"%C0EE>;R%*EJX7E:OF)];-(__\ MYY;OD+>W_*O&>I+-[X^WDDWQF9S;;;9X6YV,$*K==0_#(;^&,S]O2-\QQ#'
M_Y:1*!@G!W09$+]R2@#WXT-&$(O$\1+.4@&C \3H3^)3;_MWAENO! J=HOX M#O+0B$).CX6.VCVUSM(+XY$]O=,^*8>+QZ-WYQ =#8X.>I@,\>V3-L'6\;TQ
MLP&OE[A&PO=V]R:W-H965TTERO_Z>\69#D"!?-GX9CY]Y M><:3PYEU3SYC#C0OV"KDV?.?(5T6AW.*4MG@#BG),@&A1^GGG$>2Z* ./W4F=K=:4<7!\WVB^B[;!EK#R/;/Y3IR$[
M:GUI47AWLZ^\]*>/=&7V-S'+\UJV3W'SL[(B32TR2":&D\#G#82E(?@L*MQ+AS?V,#4 M[],.W7.N J=TIUQ8T*-3QJOH.7_8#;A)Y+O)4NMIK77PCM8#NK8F9)
[.3M+=6M_NV.F'.5U^JA(]:H(9G]\RMXS\^]/=[WS: W5V!W=VD_?C] MR-"9]DEN?>68_GGD>:#3W"9/_[YEP<8[WK;@YO;Q7)+C)U/.2'VRDXE.F*(@ M39PMZ,)9'Y
[<."Y%P_2=YNGVDQ]FZZN1K3]QX\M/V9,(UN4RBS(SI *JBR=G6L4*LX7M+\%5]%=IESA%Z B_T?*I*\7 M-!@ +;ER4P9.V4] 6V=S9,>4/&0Y0\1P-73]S8:#3MH2LUFFDRP>;B!D"@AH
MN"58V/E,EY +B*0/'3I)54%7=JKR=@SL QMM'?V07+J#B$Y!NWC_*-,\62/E M;0RW:PM61:EVB+-=A]1Y!20N.X9ET4""\1?/':*ME_@# ZV/K5Q ;)6G?&< MMGN=WEY7UP^TW9?
A>6[G\^7X5-N1ULKKR#1Q67)[PI&I31>T$,&ZLX4 MLAAJ=2+.$EVB:IE9,8E"IEVZ'.]WZ,PA_W,-7;_89;8RNO9Q=.XH4QI/EZEC
MWWBZ35[#27@3)8C"]/$HXUWO4S.E%$@(N+K2NM4?$$;+B_W&A)WZ+:29WX, M[1KLBOZZPYG,- FWR:$70'XC*9&@"4J5ET%:)< @N*381$['@N+YF1TBO]*G
M>1V0>#;)*ZDB=,K)DQ@WLGB"9>L2OIVZ6"O/;D[HD9/,V-Q.144=ECIT<"[* M3H*2M/#@5K.)YZ".V3K^F-FETBE]"3V\02#'-:TZ>.P,WR9B=Z/O?45F%G6
M12F'1]+*"6+Q]WM2($A9(&X%:&Q9K# 6)'.MB7#E4>4FINEZCZ6L8ON.6KQ# 2+:^" E" MR3@;)&%6I3I&35))/NS)7IJ$!CKX #)D*0NTQR RB@_'YXD5N=<5&?,BN'3O9
M*4$>]+#H5B5;X>L$ CY*B->K^'K%X0K0*RM>+%TWX2T'C"N/$'H?4:4V5N/- M97S3[I#>ZA"Z:QU=P:C/$ESD /@=ZN9NM;IJC4_JCO!%O.ZKKU'>-=Z'G"A)L&?O#L0WH-N,PB]5-
!+ _L6B6EA.Y8/6'X?A_4$L#!!0 M (F"9UG@H1(M3 4 *8+ 9 >&PO=V]R:W-H965T]1HI%E) M8\=_OX?2>.)BDSS8HQNI0_*0XNG&^;M0,4>ZEXP[V.3&]:!2*BFL5AJYA MBYVE\
[6*F/K5*#2>59F$:C.:CL=O1K72=C _36O?_/S4M=%HR]\\A;:NE=]> ML'&;L\%DL%OXKE=5E(71_+11*[[A^*/YYC$;]5I*7;,-VEGRO#P;G$_>7\SD M?#KPE^9-
V!N36+)P[DXFU^798"R V' 118/"9\V7;(PH HQ_.YV# _DH1W!_O MM%\EVV'+0@6^=.:G+F-U-C@>4,E+U9KXW6W^Y,Z>(]%7.!/2/VWRV:/9@(HV M1%=WPD!0:YN_ZK[SPY[\?
@)@6DG,$VX\T4)Y0<5U?$4NPUY.0UM,DBF)FF MTU:">,S>K&[VN#I)GO>A0460?#9 =@?V:!_.7 M+R9OQB?/@)WU8&?/:9_&QSZH$-A7&@]T^W?!_IPKCB[I_'C'C^FB]?;S*
M&ZXM7?'"MTA3A.'U\!-YMZ:NE#UQPO6!/TW?GB>#H= MG]P\'#C?'4A;DY/7!\3+):<T0\PTI/H?4SA0=IY$K-UX:F1UUHLE(AW'"WA3%X M43B8U:_/AG3E74T1KX-X6KZ
RXE[C_U^(FS(#87X^)B"YF"E)Z.C7JGT.B!0 M8KCS):H!,!:N]8'%Y$4;D"4A#.EGI0W+/86RX@;D>:F+F 3Q"&B\$9!H8^`J M)&EXA:*"57@O)
("J*'PK0(Q6"XWKMRFZ^6#Q6TYO*K8BLF"C&9S>!54'6@] M+G<+M3#=QKY&B=B"66PJ6$

M#)N!@E(J_\WO@B!Z&XY':S:D84-*='M$1.4[[OCI&Z/GS.!]@(8_B%7:#<1) MA5JY<0:>2MCG3F_D5,F)S+AR["S+=*V<5%-VI0N926'9B^;7+V]V'>##7;M9
M@'WN8:=K8)^PCUJYF67O52[RY?V[0&=+;-H0>YY& =Z(:LCV1@.6CM+]"+R] MEOD]@K>W!MXJAO\Z&UMGP%C^NXIA#V]_-3STH%>VXIEXNP,N8H6Y%3NGSW]*
M#D>O(]3NM]3NQZ"?GG,K+=.3GIX&GNX%^RM\?Q9WCIT7.ONVDOPH@M7DMUCI MEG*]=1)" MCK";RUO>0'6LS$_432K^4&4 M Y8A8M$A)FI@C3,R8; YY#6YVQ@L7Y[S@*@-
/HFSL-*V%;(D8 M;9V!/$MT>\OB8&[145)!,%&DO\'8,V^6N6B#UVRU=P#]IZQ_=%H,#HZ@5\G M!X/CXX1=+W,+,JF-@<7L<+"7)NSY3\=IDKY^N*S0:OK2"5.R9&]P>'C0KORL
M'2_6R'>P4L!VIN=J2Y$@2RFP! 2T+'TF,&7%U8)E!;<6LB.8 >'*09E6 A0C M"@(,2BJ$ T9\,# BEXY9 5) 2Y+*UH94BH07@JC.CC0LY)4,">['WN1FP^4R" MIB4J.2MJ2)O(F@;>#"RW
J6@M'H9Y#RX9U9KC&D8<^GCUJ6/HRYJJ6X!HS:+ M35TX"G:U"S>X4/(3::P+GVYFA%B;;V)/H[GFI!7!250$OVJ=SV51D#XO(1>J MJ<1@<18TLYE7JB(P;G 9KUY2CZ&&.=0Y "N
M+KWIC6L+A%EP %V:I'*6"PXL,ZS,P%$L*(1" MG?D_Q.7(6-%*T6>(!O IJM#ID33H%96@G$ERNSUDN M,(RAR2'D#AGB>]"@0?!JE-OEU?
5S7E:OWPU838+$_1@&T]%K6*5+P4KA9CH? MTLWD-;NIQQ;"(897GQP UQ)ATV7K@-Y$*@EB+D"0J\P%=03YWGFM8'P"3I6J MB3%.XOHC+"PZ@8%L"[9=FR7@&(Y-
CF:F28Y@BR@#Z(BM5E@Z MJ)YYWB?8K[30,=(2A(T* %$-V9?"FVP! ;:EO<\B;+;+(%$?3W+X3V#Q#_4? MW!8P=/J9"S"*9\=[A\-]:#>+@BH>Q02'K 04/PD;DO6EHJY]6D.BA)S!>(45
M%2\&G>'WS;#-M.1[WFY?KK';(>9HNVS%,Z&P/ *K0_?%6,*PB\.6_"5&5NS< ML8T)\0'LM8L0M163NB O =B7:,'!\-!$^1@4IY7(!XU&=29I7\=(IFT@1)80 M-R5I$2)51;4(F1HOK
[R,.1=9#EQ1LES^B;[>29MV.H]2-WJXE90<*ZX:?PQ MX\8L*#93PA4.J3S,?H'A+!&.4X4:(V%EE[4O:X(D0TN%?@-K>R&U=27"CP"MXA M+76B32TVP:**1+R#(S<(K?
WX[,'UNW',J\?)L #S%3<"] .A3G!T8[/)G(R M Q.A-%YB*4RD+\7\%\',?!%KV7L)R!7MNN8+7N1B907W,):@ MZP2_7N$@6/VRI3QG_X'S#YA!^*@WHTNVAU:6CMA"
<&/)B6&Q;\J6H/LT35[6 M\QN,8ZV2E/Y1I6LRZ@9]HVCQ^@&-_2MEZ8]@=N!T)740FQ6M<22KJ]8/77U0 M=ICMTPS@$I(/[EU9;DCEY](4IW 6 RV[(7?ZN\ZG395A1"CR,))!M#) FH\;
MP;6@&.7>W6!%4H7>W6[%4H/F<0_H'-3?1QC7[[Z7Y76UZ:P+QZ' BFRGY'2M1 M3)%--742;<^2WB0WB<\'FU+]HE>J;ZK>*(HU\Q9-LT@*,HT*B-^&R1AW:<==
M&N7N'42T6^Z\GV[(5!3R:J8Z=+W8" V],_4&QHQJ349#O#AAR?[^&3MB1\/' M--Z-KY/HO/GTRF@(UPX[\H*'H(RSMFHKS]YBMMT14+4$B(: 'Q;RNH%Y$I^8
M7W;I#USRG;25MJ!&<.'?<0#U.Y5=VS7O<M-"C[%M&[(/6 !CQ)9EK* IA\4B7%@+J@H-%B*=?CI MF*XM<; ,IP&;@(CLAPK=8H:T037%O_F!'?:?2S$,DS]E!>0!R?7$864GH&:E
M(2""\4V=IYAF#)$SD:.\/ZL&Z>6A_#/(5'9Y;9J;V5OOL9'C2=F6]&60- MQ9IQ"M$H(5FE*%7Q?[0>Q7D=:J_*_@09PG[8+.0D%6 M3S7B+4Y"&O0],;'#T>& K:3++A-
F<6DSJYF@F6'M6E70[5'5@G<(6+(7#__= M&4ORR"&+!KTC+43H-13_W;A9]#^8D.WW^:L98F$;@9.G0CU3'BL0LT$6DUX
M6FCL8;N6:\9O2>@"4NX83];R1M83@9[H>R>+4WQHIZ",5QA$\394'7AJ._ ' M)'T0V%ZALSTI3S^Y%>D&/IDNL%?SWKKPH\S,G\]T9$ DHC&\Q3ZN"2S48(#] M:# 9?
ZZ#@S"+X^X,)53OQ?$0 P\"B%:&]L14\I<:=NZ?/G/Y)]C^S:X9-R0I,Z%'POS^(M>E5WS)'$SSEN'#C(3$.+:NS/5$ZYC8\\XBA6NQ+AA4C3CK2AN)H:7@9OVN(M(9/S-
]YWM'*O'>^_'?IN*)HUN7 MMWHTY#T:P@@275>:/'P^MKJ;VOBY)DTAUNVAZ%I_U E3!WQQ0V M3" IY@?[C2FB:W_3>/M[$R93UTV=N+'DM^A]&Z1=<>KFNAMQ
6_PEQQ$G3#M M>N TW@/?S&15-8=NO\%'@1?DA4]F> GMK$%+QC%\K%])NV8VC3>S'T*E M>4')"#E9.D\$U'2CV&JN$<>]9FP5",H:@ER'_X?%G:ZW3>.][;WWGKY";T7)
M_A+;)6$A_BBW1>:*8UTMJ!:W;'#C/)I:F,.XY7?-;/8,WL+<+<9:\0!KW_] MP&,C#M#$'V&DZW#2>(?S2P_KB!>[0,]P@?#>GY P00\[$+7P,U3WY3!B]S"9BQ6QU0C$X. M_O4 4#K
VT,/$SX.D/)0=:W2_F[OO5LHS:?T=G&8;_A7<-N[[1O,9_Z]W6ZY M?_WY(S=3"6&M$!/8.AH>@=D:_T:QOW"ZHK=XQ]I!'T _9X)#D8H+X/E$:]=< M((+VO>[3_P-02P,$% @ "8)G6=2
M+VY @ " 8 !D !X;"]W;W)K M&UL?53;;MLP#/T5PAN*#4CK2RY-V\1 TPNVAPY! MTVT/PQX4FI&%RI(K*4WW]Z-DQTVW-"\V*9&'YT@B)QNE'TV):.&E$M),@]+:
M^CP,359BQ:O+!#R7F%TG E0>J M&ES&Y[.!B_0(H<#,.@1&OV>\0B$<$-%X:C&# MKJ1+W+6WZ+=>.VE9,H-72OSDN2VGP3B '%=L+>R]VGS!5L_0X65*&/^%31,[
MHHK9VEA5M M<33PZ8$M!9K/D] 2 X<39FVU65,M>:?:&=PI:4L#-S+'_&U^2,P[^LF6_BPY M"+C ^@3Z40^2*!D/T#QV&@T;=/7I,]V)_M&NC?8A'T<4!;H..V^ 0>KJ@ALS7
MT573%3 I-Y8]P\K?DS$RBM@5^>/#S@ MBX694-GC[WTZ#E;:KX..VF*U1-V=-UQCUJ[$?J7_RBMS!N[P^@B#*.I%IV=D
MG0U[XW$,]VBLYIG%)KQ'[UUK"H91KY_$689>>\Y,5UP:4#@ MBE*CD]-A +J9.XUC5>U[?:DL30YOEC2J4;L VE\I>N"MXPITPS_]"U!+ P04 M ")@F=94F$H],L# #-" &0
'AL+W=OK9?,-A G*19@#8*Z73X,^T!+9UN(1&HD M%:?_?D=*EKW",3H$L8_D7//O?#HZ4[(%[5%U/#6U%S-G*W6[;7GJ6*+#5-7
MHD5.)VLA&Z9I*3>>:B6RTH*:V@M]/_$:5G%G/K5[3W(^%9VN*XY/$E37-$Q^ M7V M=C,G3@"9/X[@' A)9W[\BRO&.:S:=2[$;;;)F!!NJ11.Y MBINB++6DTXIP>OXH-
$(,'^&>25[QC8*+/X12E_"$$I9;)A$NOK)5C>IRZFER M:&!>,1A?],;#=XSG\%EPO55PSTLL_XOWB.C(-MRS781G#2ZQO8+(=R'TP_B,
MO6B,/K+VHC/1*^CC.Q5>CXY/H\U]N58M*W#FT(50*%_1F?_Z2Y#XOYWA%K< MXG/6YTNZ?V57(XCUH3AC55Q8,%45P'@)=U7=:2SA+QL(?,4W#8M:%"]_GXKI
MO%=J==!;I'^)"$U?/C3E TJ^QF9%#$P%]HK$ZZS>Q0,G/=$I8JI"CJ&E M4V6[JZ2NO;3U-!_1D?38-2B9)C^/-)PJ7HB&FK$VW>F:FTC1?X P=K/<)^$B
MB]TXC>#2R$GJAI.@EX,P=*/,I\5-65[#]=(Q=) (X'<3*#O@8"N@/D[I9/# MK>"O*'5ETMOK)VXVR8XQYM88_57WG<@5+Z9L[V"C< ">B*L<:OD!HL!-L^#G
M(KM#+F@XV&1=V/Y09/B0]TMXMN.)##,B0],6R"M5K2\"$>^TTJ1)3;;/;9+' M;D(>XB2!=!*XDW#B^GY*^[F/]#,WCV.[GP:)F^0AW*_7-&E-V#8&FK6@L.AD MI2M4U[#4PB2E-
;-809JX>;A/PS.3DG&MAN7'X[K$F1OFD\-^="*?!U@44??Q MRK2,/TA'7%:OW^3%::1RX0>KO2?^/A.Z+ MFN>9&R7D+_JYE-J>&J_*H>G]*S\V*>!?!4,KD.2/4D+2C]!#7Q$X.@\^-;R\
MHR>&KN7&/J2*@NZX[E^;<7=\JV_Z)^J@WC_TGYG<5-0#-:X)ZE^E$P=D_WCV M"RU:^V"MA*;GSXI;^KV!TBC0^5I0>8:%<3#^@IG_"U!+ P04 ")@F=9 MPHNW'O0& #O#@ &0
'AL+W=O\>ZYY^[(LSO3?[);I1R[;K6GL^VSG6GBX4MMZJ1]7I5(N9M>D; MZ?#9;Q:VZY6LO%!3+T00I(M&ZG9V<>;_7?479V9PM6[55<_LT#2R?[A4M;D[
MGX6SW8]KO=DZ^K&X..OD1MTH]UMWU>-KL==2Z4:U5IN6]6I]/GL5GEXFM-XO M^%VK.WLP9N3)RIA/]/&N.I\%9)"]5>E(@\3K5BU579,BF/'I'.VWY($#\<[M[6^]
[_!E):U:FOH/7;GM^2R?L4JMY5"[:W/WHYK\\0:6IK;^R>[&M5DP8^5@ MG6DF85C0Z'9\R_L)AP.!_#D!,0D(;_>XD;?RM73RXJPW=ZRGU=!& ^^JEX9Q
MNJ6@W+@>LQIR[N)7XQ1+V NV-$UGK/90F35;JMXAI.RM;F5;:EFS&R>=0C@< M6\J.EEDV_RA7M;(G9PL'4TCAHIRV01RW%<]L6[#WIG5;R]ZTE:H^EU_ A;T?
M8N?'I3BJ\$9U+UD4<"8"$1_1%^UQB;R^Z @NEHW^/>7>*!T_+4V9=&H[6:KS M&5+%JOY6S2Z^>R9,@^^/V!;O;8N/:;]8&H#6GE6Q2UDC.HK=^/S]RVO+/JI[
MQRYK4W[Z^RG+C^I^VG* B]"O5.\1?JW*Z2/D;/ZN96YK!BO;RIYX].D1L5=E M:8;6661NJ?0M6<99J]SI4S/L6Q8&.4_RB$8BX5%6L%^4M:=,UJ@;WDE4(%;V
MJM*.U<9:A&!#$[&0D2IC+! M19JPD&=1R*[E';+4J1Z98V$3CXN0Y;S(P\DM/1GUP':4V3SB62;(F93':>B= M20H>!V12FO"TR-@'MP7NY=#WE(<2(, J(\352=UQ=1]1\S
!F]LZ6EUB#$ MR9(@^^^R44HO@>_[Y6/@[E5O5^4\BS-&/P,0W;UA5)6 %F!)6&6[2!8)%/(_SR=#'S8$!3](((&*5A,T67:I0)RWB:4=23C(N8PB9BGH04-2?;
MC2:,1C]WL?,UT2NOI2]#6]U9'[6@/%."0AS&1/,CSO2FZ10XHZ\A5$5+X@Y#]T"-]"5@$E)+K5OL6CR51!%;$ M(MCG[,/$(:A:#1I$DUM2K%:20J)W0+ %]BZP7R>)%B; M"^*L60-L;
8'UXHBCPJ1P,DX"Z9DZ.2#3P1P*(IBB$=YS*[-@ZP=>4G9 0+% M$QI>F2MY4K7FC8Y MB-MAJ*@^Y?%!]KZ'DQN>8ISDM$ADY MU8*U(/"!.2QCN\J#&!?(661
6%"N1JBU@6=/QD,H.=+H@KT_%ATN1 +\,^CQ.(7*56F[.UP=!@OG2IP:6R1LN46Q4P=3N\X1I9]W M7V_ U5;B1%JJP5&N6K;\[?K75PA#[&G^+0]%YP@68Z"CR]\ M^[]
[%TC]/$&L)U\)/:*S4G^R'*4I#9Y=-$U_N/KY [O4 MOE:72*<(E1A4_W+UG(K@;M++++?:TSR-Q=>K*_N=6G0OP,X[$!QPC^_.7I)E/H. N:@(=#QC:CSN!>JE]#:E41T-,J?
S//%P24$_7GCKUJ6^;/> M>!_9_]W?YEZ-EYC'Y>-5\+WL-SA7H%2M(1J\S)#9_7B]&C^&PO=V]R:W-H965TC91:RNXQ&L-9ET43&_G*-1F&L3!SO"=KW+K#.%L4K(5
MWJ"]*Z\US<(&)>,%2L.5!(W+:7 1G\\;K_?<,]Q8P[&X#)9*/7@)I^S:1 Y M0B@PM0Z!T>,1+U$(!T0T?M:801/2.1Z.=^A7/G?*9<$,7BKQ@VG529:;4"[W83F!CY5[TWDN'2'<;(=+L+E:
M&R8S[9%$# MHR_-J#M(8AAT>Y3=#ZH:=)K/*Q5'47<8C=UH MV(T(KT7!@T;!@U8%WTE*0/!?F,%':@C0^:(,J8P]>\VU[(==G<-.\+FI>AZUK](7"GY]2\4^9!K26A_S5=8[D0
MD*/(@%F_6V.IM'6^&:/N0 +9YW-.).%!^RE0KWR3-9"JM;15)VJL31^_J-K7 M?GOU$?"5Z96KDL EN4:G(U*!KAIK-;&J],ULH2RU1C_,Z9U![3;0^E+1!5]/ M7(#FZV;V'U!+ P04 "
)@F=981Y Y]D% "##P &0 'AL+W=ORYNY9Y2A1[* M@LGSR5ZIPX?93*9[6A)YR@^4PM0LKRD3.:<(4&WYY-/[H=%I.6-P)\YO9>],=*>;#B_U1^K['SB:(-H05.E M$0C\W=$E+0H-
!&9\;S GW99:L3]NT3\W\&7#9%TR8N_\DSMSR?Q!&5T2ZI" M7?/[7VGC3Z#Q4EY(XON:]D A--**EXVRF!!F;/ZGSPT<>@IQ,X+"KA1P,;N M>B-
CY0519'XF^#T26AK0],"X:K3!N)SII*R5@-4<]-3\=ZXHBM![=$$W"DUO MR*:@\MW93 &VEIBE#B*,2U?X-N5=K^\/:FAH?Y(&D]'P"9U]2<4# M.>A-64Y%\UJX" SC[T!Y 8-1:X->"#E
M^\T*]@/;"^)NO]^NOD[(@PM]\!,M"#L%NDXZ$"F@F:YZL!<;(>1:RWW>4%! M 9Q$ZP-AN=P;#=E3<5T[T 4 \SO"D77#%2D@2K[OV$GDPPC[B>WY@;4@!6$I175E
M3LE!@\DA8])>_%B7&:>7E4&CGJN9="8!PJYO>Q#W@;V>1DI'\4DP(.,8(QS9 MN W'C=[Y6"IG:5%!G8 !*D#FO;&NR,DF+W*5FTS'=AQ'/XL3&F%?T+$O&&6? M-
O*],;+AWCCK1L&&6?><6LE _"^!BID.2KUDVAXW>4<7N4QY!;DP%JZDK,SA M2+E44--,<-H#0]01K0V%\"_"JT?='I!L[S0*H%X &P,?6!$ +1PT;0?OT#2V M@Q## "?
8]A./,I7ZR/Q+VF.3::NSU@=]:,Q,?NQ'NW6/L4$< +&P%^IS!;.: MYVRGSP_:DER@.U)4QD3:QBZC(K\CNM-W.#C41>@9?#-]3=."2)EO\[2S=PA-
M<42_5[GZT0%,W<"UXTA'X"EV;^F:'BJ1FO(T!>H[?7'7]KP8RHV/IMAV_!B6 M>FD\KM6F'L.Y3R([/"RCG$U=]^PA&H$Z? #S7&R&;7T>X4C8<21\=8?ZTA38
M95T#/I.T)>WKVM;H3B\0Z((7!1%2)[Y'I#98WRHE%4SE;&>M&-02*A42!&XV MD,\-%^ L+$D=U,9HTR1&FN$7"M<8,90"*,7@,!R#QP;YI LYIY#D7U[@5].&
M5HI4=;L*3@,M#>T#M/Q0-Q(<^I99TT'6_0J%IZ$6PN;\1*X+0A&.K<5J>7F$ M4@L ":'?@HCG6^N4*RBKM8RQ*S RGNT 9!*[UIHP'3OPL8\4V Y(8:/D0^M
M>DW32FBWCXWVG6?$LBXA%QD_$O0;-"^ 0F)[CF#H5O_?O?&G%Z>3YNITTER>OJD]8 [?!X9N37!&H7R>H 1FAZ,\ZSV,
M2BIVYODGD>E#]1NIF^U>F)_JA]6C>/T_4K$+F<2%70+J@XW@E4Z$%8'W+P?GF0V_0O;OG_P%02P,$% @ "8)G6T&' @ ? 4 !D !X;"]W;W)K&ULA51-;]LP M#+WG5Q#>,*1
5CMVTJ9=8J!I-ZS NA5-MQV&'12;B8WJPY/DIOWWHV3'2X$T MN]BBQ/?X2(J:;I1^, 6BA2?!I9D%A;75>1B:K$#!S+&J4-+)2FG!+)EZ'9I* M(\L]2/
PCJ*34+!2!NG4[]W]=*IJRTN)MQI,+033SW/D:C,+AL%VXZV<%]9M MA.FT8FMW6JRPHXE+P5*4RH)&E>SX&)X/A\Y?^_PH\2-V5F#RV2IU(,S MKO-9$#E!R#&SCH'1[Q$OD7-
'1#+^M)Q!%](!=]=;]D\^=\IER0Q>*OZSS&TQ M"R8!Y+AB-;=W:O,9VWS&CB]3W/@O;!K?T], LMI8)5HP*1"E;/[LJ:W##F 2 MO0*(6T#L=3>!O,HK9EDZU6H#VGD3FUOX5#V:Q)72-
65A-9V6A+/I5V41)O > M+K*L%C5G%G/X9@O4<*D$];EP#7A$^**,@?X]6W(T1]/04FS'$&9MG'D3)WXE MSAG<*&D+ Q]ECOE+?$B:.^'Q5O@\/DBXP.H8DF@ <12/#O E72$2SY<<*
(2! M)K]]Z37HT7ZT&YUS4[$,9P'5S*!^Q"!]]V9X$GTKhW4:1L=8D\7-(IYS1'4 MZK]]NI:9$@A]UZ\C^.43@GM\LC#G*GOXO2^WP|'I]M/=EKVLUAIE]MSK7TNP MA-H:
DSG%L)I)0X)HR!SQIG,$)B%*\Q0+$E?,O1-2N M])//($HB..HUTK,7 MTKF_8L/!>#(FCQTJZK5MN=J&>ZZSP?>4+Q:VF8XNMWN M:;EH)NJ?>_,NW3"]+J4!CBN"1L>GXP!T,^N-
857EYVNI+$VK7Q;T/*)V#G2^ M4G2U6L,%Z![<]"]02P,$% @ "8)G6>!7ZU%]! Q@P !D !X;"]W M;W)K&ULW5=?;]LX#'_WIQ"\8F@!7_TO=I,L"=!T MW:[>NBUW>[A< ^*K21";
[I:JTTPY]-*KPB#T1]K^X$ M[/S62DY+PB3E# FRG+J7X7B>:GDC\(.2K>S02$>RX/Q);V[RJ1MHATA!,J4M M8%@VY(H4A38$;OQL;+KME5JQ2^^L?
S&Q0RP++,D5+_ZBN5I/W:&+"4@IZ:_<$502/T&_J"J4 _<%$3=$NP MK 6!IU<2G3[B14'DV<17<)U6\K/&]-R:CGYA>H1N.5-KB:Y93O*W^CZXV?H: M[7R=1[T&TAUCN+
0U$0#7KLQ6WLL;$7]\0ND8WO4'A6>W!86U?+6%8X(U,7 MRD$2L2'N[..', T^]?@V:'T;]%F?/4#UY75!$%]VH/'0I90$4,$L1]\H7M"" M*@I!-
)#E"!+]GF2U$)2MT!Q+*M'?)D+T2)X5FA<\>_KG4+"][AP.UOBU,2E3 M=E,&2^TUH*5(N2"BAZ(K1)]TXV#X0957=+L[I#4-JS6L)[R;/T.DWLB$%
M"ELJ:JGX##URA0O'/O38@1PF+\AZA98UZ*,3%"<#+XDO@/KX81B%T:P O]P'V+H8'\-7<@_#Z6RP$UF <@W/DQ4&Z#[-F M#YU.
(QD[*T#RSG*H'<+@*]C?]0AFQN*3@_J6@;9=]N>GIBT/3'I[8G=/KAX M@>Y68)9!FP^WN0$.[@Q>]*4VI=YEH?V:=CZL358V M:]2LL0.V1NB*LPT1BFKG[9<)4N=BZ*6#1.?
<*/72Y"U\>SQM*.DH!^UO)QO? M['M025M4TJ-1.?*3Y*'OG8I&-[J&M0QG&6AC4P_'P=CKVM$P7L,VAQE%)SU@ MH ?.]UC:JG-V.8?5?O?KX'"9Y]0VX3!*O#0*G*LU9BL"
[:I3^F/GAF5%K2^F M>L*5,$F:Q@HCM\!6/TJ]* D<>)P"JMET2?,\($5V7N=$T W6C58BQ1&QO>8T M3$)O"&B?=;W>C_X_LL'OS)8E$2LS04MXJ9HI.V:VW'9(O[2SZ:NXG?!OL5A1
MB*D@2U -SB^@"(6=FNU&\!\R2&UFXV^H/WK,OL7 M4$L#!!0 (F"9UDD3TGJ10, ,P' 9 >&PO=V]R:W-H965T9!;6T[#T*0Y M%LP('2<"5!XV8>G,73 MY=C9>X-
/''=F;PPND[52MVYRER M2B"HS;XN5])87=&5(&6XA)5E%MW,F5URR63*F8!K9;@[\4.X9%S#)R8JA"\^ M4;C!>PM+H=+;KX=R[F:U9()"(*Q\MR]*/H:M1?E M-F$@][_2L)-E>583(S
M SI.1:FDX^FD=-3VL[A!>4S^%_EOB._A/ M[;KCW:0:$8KZ2]*[DK\)^)X<.O9_U[15\K"F6T_?E7LP[=4W;;]Z^C M" :/J_]0OA^3<7_TG+XQN=/_ C83%Z!]P!<_ 5!+ P04 M"
)@F=9P+6DX22?I MO]^14ERG2-T56 88UE'B'9^[Y^Y(GMQ=^M7Q@1XZ-K>GTY6(:R/IU-?K4RG M_9%=FQZ_+*SK=,"A6T[]VAE=)Z6NG7)*\VFGFWXR.TGO+MWLQ&Y"V_3FTH'?
M=)UV'\]-:^]/)VSR^.*J6:Y"?#&=G:SUTER;\-OZTN%HNK52-YWI?6-[<&9Q M.CECQ^F;:,AA/'W M:'.R73(J[LJ/UG].OJ,O<^W-A6W_:.JP.IT4$ZC-0F_:<&7OWYK1GP2PLJU/ M_W
_S,W+"50;'VPW*B."KNF'IWX8X["C4- O*/!1@2?M M\8>U8*L=^K2MS.I%:\,;=F+IU9ZL2"76S)^3,!AAOS$.\"M=7M7\]AWVO]>>PW M*V<,= -G)G(&&/%@NKEQ*>P?T,J^[P?
O>@@KN_&ZK_UA8BG^B1WIK=%M6%7: M=6A2OW'&>7@%*B>LR% H&,GR$@7.2Y)3&B51D%)(N],Z['7A!@K3]&/4Z) MR M@)2EI";D@,F>0,\
(EA8NV>3I3*80A<68.BA')&2A%2GQYBO'&J1X$*;,< M,B)*"8R30J5'F0FXL4&W"(5Q-*Y8E 0CN8I !9J14D6I9(0AY#WDRRWY3'^QVR^,=48%4:&RHY1D!C'
M5X#%+.G(*]DE'X#H\@#QSBSG @NH2Q*P&X@Q3Y.F2",\42B(@JK&Z4R2ZPB M0E6PEV4U*TF6J1=FE;XXJ[LU.C J!!UJ5(X1$O&)'9=]2XD*C$YLK276I> < M(ZKR? ^;&6%
(_&$4.%6)U30LL#[55Y@4 T])4B:J3*9QF;AX7X6H'FV#[H MRU(I_\"386(1<03G30?PU0,"1X;X#?4)VZGE /+<(O.H)18GSGAV-7VU' 'QD @>3NG;
MM]L[SMEPM/\T?;@@O<<_V3]02P,$% @ "8)G65G\V:Q(!0 ,PT !D M !X;"]W;W)K&ULM5=;;]LV%/XK!VY0. !7BU=)
M:6*@278)L*Y!TFX/PQX4F;:%2)'TG&Z7[]#2E9C0'7;AS[8.J1X+M^Y4N<[M8S^ZM=8>GIJZ=1>3M?>;L]G,E6O=%.Z5V>@6WRR-;0J/2[N:N8W5Q2(R-?6,
M)8F:-4753N;G<>_6SL_-UM=5JV\MN&W3%/;3I:[-[F)"]_N-NVJU]F%C-C_? M%"M]K_V'S:W%U6R0LJ@:W;K*M#+B+RAIY=RG ^'OBSTCOWC(: Y,&8CVO
ML[B8),$@7>O2!PD%/A[UE:[K(C-^+>7.1E4!L;G]%[Z+Q$[8GDHG+XRJ5_5 MPJ\O)MD$%GI9;&M_9W:_Z1Y/-+ TM8O_L.O.IGP"Y=9YT_3,:$%3M=VS>.K] M\(PA2[[
P'H&%NWN%$4KKPM?S,^MV8$-IU%:("+4R(W&56T(RKVW^+9"/C__ MPW@-5,)/<*]7Z&SO8/J^>*BU.SV?>500CLW*7MAE)XQ]05@.;TWKUPY^;A=Z
M<<@_0\,&Z]C>NDMV5."]WKP"GA!@"1-'Y/$!+8_R^!&T#CI\8_ Z;C'.>KC MS&V*4E],L "_YL7=$NW&F,:/CCSZ@[_:C;K8:E-0T$.ZI2 MNS.X71<(O=1;7Y5%#2?
P\D7&*'O]%>]Z*E:M<#+).!FDG@[R30>(!EHTUBVWIQ[#PG%#!D1) MRDJ"5)HB):,F@5+Y 9*OV?<]2+Y%]P$.;XO6+3&@F*-5Z[&78G/=(@X$N-'6 M?P(,+AA,!SL"E7+":
(:$(DRHH%^@(UEXHR3)>?;#@'Y=\SLTOXB55K6E:31, M:^/$Y@I. \TDX>BN2&>"J#R-M$Q17W(1V9$"HH<.4DRBJ>FC AT M/A(4S>-"(/D9TY2B%I:'USG)963
;$LSU5.9H%$5120T0)HJ0432Z4>1&:VQOLNJZ.8A1JIH0GOY+VZ,!2PC2

RR%^PW>VD)-8-H*3,$\!IIEX71X?^-LH6L(V(,0P@;0AQ$A(?F MH,1ARPG1Q$&%(2(IMO+/R2L4!AB;"J8#C0(881+K+8F%1Q),*Y5G*LQBUU5 MUV-
C"U.$*AHIB;4N@R$OSFI,4&P;+.$E8#"_')%&A!_NM,/N\$7PIKL@*FLR:L4XV6[*WJW\&83 MK\4/QN,E.Y)K_*K1-AS]TN#E\5^$10,WTGS_P%02P,$% @
"8)G67M3 M6MV9! G@L !D !X;"]W;W)K&ULC59M;^,V M#/XKA-<;[@ W\;N=+@G0]E;L@'8M+MWNP[/BD,G1FW+)\E-^^]'R8F;MWK] M8EN4^) 4']{Q#3,6]4D5?X($
V9Q0%GF)E.:[GS#3J2 M.>=/>O%M,;$<[1 6F"J-P.CUC-=8%!J(W/BYP;0ZDUIQ]WN+?F-BIUCF3.(U M+W[D"[6:6(D%"\Q84ZCO?/T';N()-5[*"VF>L&[/QI$%:2,5+S?*Y$&95^V;
MO6SN849M?;OR>@%G6_ =VSP'"_HP?.[6'V#Y_?$*J&-[1XK79P6EM7 MQX6L68H3B^@O43RC-?WU%S=R?NOQ+>A\"_K0IY=2HI+ J@7%[G*4=J4 M%=I
^,=X#8_XHN"JX.G3OZ<"Z#?Q.:] K7@CR8C\ M<%DS+/\I29\N!Z$^&* M%:Q*$6:F(U &%)9S%%T:X"NF&XEK)#YL7+^O41!4M81,PG8:;'097+.L_/F M[FKXP;>U
/@GJ14*\VU.2D,I>%/YN\IB:A;*C(X<@. M@P!_1J,(+M-4-$B. MO%"?E.^B9+L!$8:=A"%0T%X,M[Q:GBL49:]S?7NA9SMA#&%@NX$#]Y1' 46' MNGMR_UYW=\X@L*-D1._8]N(?
IA^1H&Q9S*\I,2A[O%O#ISRF-H'D>P5F2"" M10,?XH&[;W/OA-Z-!MZQK44N4][0)1(X'AL)"?D3/0-Z'J#[@YB$_B"!3SU5 M&795&?:63%M]=ML;.SX1 >_:Y+Y^L#![K9SN+ ?
5^G8'VX#O4\5U';J;PE0K MP9OEZJA TJI;SN!KZLK]K4H!->UX]C3-'2-)-(U_)CDOA^H"6QEL1Q"(D3 MZ75BU@F1OXD!AD1B&+,*@$-N6& M.S5[U34K(?;M)(BH;&,J>GW;%_
USS)"UR'.4:T1JT,E7?<[%HZY/*)P$_"H M$[0.G6)[%-CQ*-$?IF7TD"7JR!+UDF5&].B(3)0N<^:NBY0NTOFKYE2/,I(U1G$5.ZBG0;;A>*UF<#F7-$\9SY7-$"CT =H/^,TF6P6VD WDD__
M U!+ P04 ")@F=9@"DPLH# !?$@ &0 'AL+W=O"R'J?@^A8COQI9C/0<>V&:K=,">C%*Z@26H+^F]P)9=L80LAD0R MGA !Z[%UZPP7]T_[[@YW<>R9Z)BO.O^K&QW!LM?2
(() :0:*/X\P@RC2 M1#B,;R6G54EJX/[S,_L\GSO.944ES'CT!PO5=FP-+!+"FF:1>N"[#U#.IZOY M A[)_"9E7U;%@DRJ7A<@G$$,4N*7_I4KL,> 'GJ 6X)<%\".D< [1+0/E6A
M4P(ZIRIT2T#W5$"O!/1.!?1+0#\WJUC=W!J/*CH9";XC0O=&-OV0^YNCT1&6 MZ$Q<*H%O&>+4Y%>N@#CDFDPSB:^D)#0)R6]B0Q/V-\VSY<(#15DDR6=X4AF-

M+K'WEZ5'+MY=DG>$)>3SEF<287)D*QR2)K:#4GY:R+M'Y-ODCB=J*XF?A!#6 MX+UF_/L&O(U+4:V'^[P>4[>1< GI#6FWKHC;=MZO[;U.?- M\#LJ;H@[.*]^:
(9[$*"Z4Z=^8$6[2LUVSMTCJ_)ZCO1X29?)?GS#N(5B+_(/V29 M;S+(K92@I":8,OX :Q"0!+#?\1-=!5RD5:@N"1KG<>:2STR2>2);)?)-D:] M^@_>B^JX,*1YD"G]*E/Z;]PH-.+/-
=XDF6>2S#=)-N_7&?_*=T.2![X/*M\' M_\?68_!JXKAC>)7QL\:QG9L&IVGZ)C7G)LD6ALB*/+#WSK,QB$U^52%)P+-$ M%>>'*EK=AMSFEP OXE-G.'-JXIXS]
(O+CA_TQ=4+GH$V#+0, *T+ 9 >&PO=V]R:W-H965TL"_K76YW#53J MC^^L[;B0.%:0^(*]ZWV>F7EF9IGA1JHG'2,:V*9YGMW:CR4F>&)P#L%.DM3IGY, MD_L"G/>@Z$F38R M+
<'D09J(XLFVI0X[-]_ ^"7 /\%H-U]] I 9WW6NB6@&ZN3!*%*KD/ #!L/ ME=R LJ>)S;[D8N9H"C\1-NWW1M'7A'!F?"L-@@\?@%0DC01W(8QTN.3.H MX31
PQ*NX0&W)F/\#$X@$7"3<$YITT/7D!.6R@U+@]/"H/^&P4NXD<+$&CZ* M"*-]O$O.5Q'XSQ%,_4;">URUH..=@^_Y7?AZ'\#IR5F-7[/WTW1JX$$S/,"0 MX.T"7N_%7G2=*C^=G+?
[!N\D#+,TXY2+"+Z8&!7,9$H-'MO.6R-? MI=9GYU469YE2*,(?*"8T 2W/3:)_J."HIXUYW!+-XI

]JV>CX_:ZNM(K%N+((7]O^K4K;'8;?4KBWO: M=2OMNHW:O2IIVM@P%<$_-Y@^HOJW+O1&R@.CFAV3+#@2V9Z4O4K*7J.4 :ID MS>P53:636?
%L]5P+;51F"TK#)^11G9X%;V\GL=Z+.FJT?*A(K\WU_/HJZE>A M]\?NK2-Q#A,4ID)4Q=O(]FA]7-,LJ#_JL7\UF6]-A>5-A>-VE37S$R*D,I M%1?-/-
%/59/!3YCC&D6&,*6S,4T7>Q_+6^V9J:DW&YTY5-MCD@3'(MM+PJ!* MPJ Y":^T/X<[5':/!K;/GV7V^O+^M.=;R+_5-!HV^'1N[N##(I MJF4^$&H(;;,5$T&U6\VK$_;5_-BM'Q-TTQR-
XPM4R$!HX+HO1:%W17 MJ&(X+!9&KO)QZ5$:&K[RUYCF:53V 'U?2!J9RH4U4$WHXU]02P,$% @ M"8)G6?,J?A@[#0 Y80 !D !X;"]W;W)K&UL MO9WM;]I*%L;_E1%[M4JEM.
W7KJ)I"2VQ[EJNZ'4.#V-0V>;G: M/WYGC(,9QADP^]Q^(;QX?N>8>7(\/H^!LZ[U^=Q%&2>?BK'SN-KLX M2U=%"'7L-B/Y:K$(LYU9\6]YF_%%W M0YE$"Y;D49J0C$W/.Y?
&Q\!QQ(!RB^\1>\]W[A.Q*P]I^D,\N)F<=WHB(Q:S M<2$0(?_SR*Y9' L2S^-G!>UL8HJ!V_=?Z7ZY\WQG'L*<7:?Q]&DF))WAATR M8=-P%1=WZ5/
JAT]$QRG<5[>DJ=JVUZ'C%=YD2ZJP3R#192L_X;/U1NQ-< T MWQA@5@/,W0&C-P98U0#KT AV-<#>&6 Y;PQPJ@'.H1'ZU8#^H0,&U8#!H0.& MU8!A.;OKZ2CGT@V+\.(L2Y]()K;F-
'&G%$0YFD]AE CMWA<9?S7BXXJ++VG! MB$7>D_NU>$DZ)??1+(FFT3A,"G(Y']>KI(B2&;E-XV@,F$31K& M>_KQHWWCJ7Z\86H 7?Z6;MY7_5]O3*UQ-_#Y /IC4Z)V3-
M\NW>)2>_O6MZ M8_28>[;\0*R>C"'Y/,Q8T]OL'DZS-$EY1R35\63'B>618F,R;NGY(O_$0MS.>O M]:%1(=*6K*V*DWE)-EMV,I2"H=7;;6MW0&O+OR4%G#@=W?+0?(O0Q0-'G: MZUZKH6^V?
EDM'E@F>FB\)*1947HU]VPFYKRQBZ;GM9YC),V%TCQ#;82:NX*! M-EZAM !%DX55=V@-?8N6AE%"3L2*XMTI\=.,1;.D6G*.7\A77ECR<+QN^CPP MOC8MS[D;!0?
MVU8TR:,UU**B;O7>4IM]#9LI++^)I;8$*70W Q1-GORZ=VOH MF[?U\D)4ENMTL4@3LEYY_/LS$Q7G/XU3#6WJ0FDNE.9!:3Z41J&T $63E5AW MG@U]Z[E#60C/4WINZ
M>G*A03THS8?2*)06H&BRNHVLZEO,]TD65)V1^X3I,BXZOX4W)U>>=>:M=V M>FIKB2%I+I3F06D^E$:AM !%DY58M[+-(UK9X;1@V=NV1Z,TH;UL\Y!+A5UH
M3.^@F#XT)FV(J80,4"%EA=3-;E/?[+XN/S?"]< KE;AB)%M?,787Y?6)*%^! M-0AI^^7/7#UC<1HAK@-8/X@F^F*[Q?0VDNE.9!:3Z41J&T $63I5SWYTU] M?UY5\.8ZJ'#6O*B#=N.A-
!=*\RK:2+H:JM=W=NL?]$KJ-X(.=BO@7]'?-^O^ MOJGO[V,JX$TRB1ZCR2J,R2T'"&] 7_^@)@&4YD)I'I3F0VD42@M0-%G(M9]@ MZOV$(^H?U#B
TEPHS:MH.Z7(W'6KH$%I1=NY!K5G[M:_O*),&LGPM0[$3=Y M%K*XO"*O:O@6+_K2!?4@H#072O.@-!]*HU!:@*+)&JP]"%/O06Q=4^P]AXO- M1R6]O(@6XBKX=$IN^;EI^?F5-
T]2H48$E.9":9ZIMN=-NZ]^&!(:E4)I 8HF M?]*Z-B*L/49$.BV>7L]8-P]<]LCB=%FU[O(]:SA]B+:"@])<*,V#TGPHC4)I M 8HFR[(V*"R]07&;I4N6%2]\Y1:+
[]00ZO1^KJ+E^@JS;SF;KF+R*9HRY=@M<*R",=SOE7V(A]C]940:EI :2Z4YD%I M/I1&H;0 19.569L6EMZTP"SXH#[&GHP=326$>A9'Y^%#\Z!06H"BR7JKW0Y+ M[W8T5$)_E?
&C\:HZ%_:C9W%_SYDOU+V TEPHS8/2?"B-0FD!BB8+LW8O++U[M@2F4-C3\:Z0@@U+X[.PX?F0:&T $63]5;;'I;>]F@HA%>K*"Z_,4MH;_@ M9K',TL?R(WY[BB+4%X'27"C-@])*
(U":0&*)HNT]D4LO2^"*8I07V1/QD9/ M4Q6A)LCQB?C01"B4%]!H\A>6UKZ(K?=%&LKB=S:/QO&>%:$>VU9D4)H+I7E0 MF@^E42@M0-%0*=>9>B/T+O!!]C-:Z/-
H+@>;A'9V'#\V#0FD!BB;KK?9"[#U> M2/B\UPO1(UK+">J%0&D>E.9#:11*"U T67:U%V+_ B]$'Z.U+O49FYHU'C01 M[_A$?&@B%$H+4#19<5O?2K_'#=DI=$>Z(?HHK34'=4.@-
]*\Z$T"J4%*)JL MS-H-L7^!&Z*/T5J7^HR'FE((=4..SL.'YD&AM !%D_56NR'V'C=$K81N"'Z M(*T%!W5#H#0/2O.A- JE!2B:+,S:#;%_@1NBC]%:E_J,#5-3":%VR/&)^-!$
M*)06H&BRXFH_Q-[CAZBE_T0_0!6\L/ZH= :1Z4YD-I%$H+4#19I+4?8O\" M/T0?H[4N]1G;NG-EJ!]R?"(^-!$*I04HFOSC6K4?XNSQ0]2R>) ?HL>V%1F4 MYD)!'I3F0VD42@M0-
%F*M1_B_ (_1!^CM2[U&6NND('FX1V=AP_-@T)I 8HF MZZWV0QRI'W)SYWVZ_.(VJ@AJ@T!I+I3F06D^E$:AM !%D]56VR".OI>O_1U+ MJ+OAJ%_+9/5LJ7>#H%&]
Z/ZT*BT*6I_H/P>1("**D]^[4@X>D?B)A'?.CL6 M/Y5[Q_%A-IZ7A[?MS^-J5UM0*P)*7Y:^.C:S0\[QD?_?+Y;HV_.%N&,_8Y MS&91DI.837FHWH=[AZ*'M"C217EWSL()R\0&_/5IFA:O
M#T2 IS3[4>[.Q?\ 4$L#!!0 (F"9UEJ6Z]%FP((H& 9 >&PO M=V]R:W-H965T G:B\1E9CA#4D_35JI770(8\EYQH6=
M:4Q]Y_LZ*Z&B>B1K$#A32%51@UVU\76M@.:.5'$_"H*)7U5FO/G4C:W4?"H; MPYF E2*ZJ2]J_CP E^W,"[V/@37;E,8.^/-I33>0@GFN5PI[_J"2LPJ$9E(0 M!<7,NP_O%F.+=X!?
#%J]TR8VR8N4K[;S/9]Y@34$'#)C%2B^MK SJT0VGCK M-;UA24O<;7^H/[KLF.6%:EA(_IOEIIQY-Q[)H: --VO9?H,^CS.82:[=D[0] M-O!(UF@CJYZ,#BHFNC=][_=AAQ
F)PA13XC^E1#WA-@%[9RY6$MJZ'RJ9$N4 M1:.:;;B]<6Q,PX0]Q=0HG&7(,_.?T@")R15)NV,DLB IVPA6L(P*0^ZS3#;" M,+$A*\E9QD C> V9%!GCC+JS0,Z"ZI*
<+\%0QO4%0I[3)3D_NR!GA GR5,I& M4Y'KJ6_0M%W:SWJ##YW!Z(3!%.H1B8-+$@51BL7N)E4@J-'O/9*8UW#$SB*-QS>0@*CCM, M!H?)_SGD4FRN#*CJF,?
D8/DPGDS&>R8/42=,C@>3XR]-/DE#^<<.[AWYI;L(MZG,,HDO9"GOI30ED(46.)0_GI*7Q \]I!:8&7Y75&+Z=1ZRG1R_1^/ 2V1*] MG_P0=NP2^3N5PE;I'U1MF-"$0X&\8'2-,JJK?
%W'R-H5CQ=IL!2Y9HD_"U 6 M@/.%Q +2=VP]&GX_\]02P,$% @ "8)G68P&ULI99K;ZLX${;_BL6G5LHIA%MHE43* M;;5'VG,V:O;RV84AL0J8M4W3_OL=&TIN)%2[7Q)LWG?
&\VBP/=YS\2IW (J\ MYUDA)]9.J?+)MF6\@YS*!UY"@6]2+G*J<"BVMBP%T,28\LQV2>T<\H*:SHV M"OQCLY=$ST96\7H!4$&L=(1*/Z] MP0*R3 ?"9?S3Q+3:E-
IX_/P9_1=3.];R0B4L>/8W2)1N8D4622"E5::>^?Y7 M:.H)=+R89]+\DGVC=2P25U+QO#'C"G)6U/_TO>%P9, XW0:W,;CG!O^*P6L, MWEA3 MTY]< ?')-[*BHF#%5I*[W[B4]V0-
@FQV5 "Y6X*B+)/D#WA7%2>>1'[Q0.TE610)\W]YV_]XPV]CZ6W][F?]<_=FP V4 M#\1S!L1U7+]C/8NOV[VNV2#<25
M8(H!PGZ/LPIYDU3PG"QX7E:*FN^0Y(S^,'D^%RTNA&X5N- RBX%2YZ@CI>F'D/4:M\(2= MW[+S;[(SE7^;XYZ5&$*XE=:(9D+08@NXMRKR\D&.=6OZ8:9G>RJ2 ?F]U 8Y M0-
X@8B:1/)$K(PG?2S]7I:7BF$T"LY4R]XXJ[XX)_2"EEYPFY[B\2OY+F6% M6);8=\6V*7Q0$T,JSR"58+%"12UOL/W$TQ3[$,^-%)BJ4-L'*^B%U:M87BH" M_S&,1F>TKLBNX
I;7&%_L\F&UX%09V\=VF] :*KP(SV0Z@,5]H*Z5'1UU:7* MBWQO%)W!NI3Y3C!RAV>P[*/C+@>Q-?<,26*]Y]2;73O;7F5FY@0_FY\/GQ;#
MCODE7GWJF\HA?'UO^D"%EA629)!B*N=AA(L5]5VD'BA>FL/VA2L\NLWC#]JO M(+0 WZ<<#]QFH!.T%\+IOU!+ P04 ")@F=9KOEUQ'4% #O&P &0 M
'AL+W=O\I8(<\C^F/.YR1UYL%7+P]^)P^[[A\8*R6 M^_@9;S[.V-]3<661D&_R MYF-RLS#EB'"&MUQ2Q.+/"U[C+)-,8AS_U*2+ID_9L'O]QOYK*5Z(>8P97I/L M:YKPW=U8C"!/B^IO
M_+TVHM- *@;H+H!&C:PCS2PZ@;6J3W8=0/[U!Z M 95HP28O2O?+UL*OM)"!LN%4O$U%.[[Z@W ,;')HI@6:?',P,7OA+'WX!Y3 ML-G%%(MW&Q&>R2'#@#QI7X&$3@HMW[\$[8
FWS*0%N"A2#G[M(!Z*ZR\[M$/XU)J(W$^-0EG"#]U? ,C\ 9");,9[UZ3 /BQ2P"!"EM_VVI-M-()MK>S;)+D&,B6 6/X>#S^$Z.TWF3#"U@"L M2?&"*4\?11+)E%-&?
=6!TQF9A096C"$#L\))1*1#]*0[C73GW!E/TNS E;EY MYXS\MZ#G#V9I/48IYUP!4\VY J:;<[<1[F]%?RT_0S@!L9A<\5D%PH-<3'^] MXHGO,N-
BB1/+99T#X")]>_M>Y8T[FAHWL%V$;-<=^#-&>@YTD&.:WL B%6?@ M>DY@VP.7E)P>=-T J7WR&I\\K4\;3F0N[&5IP*8\\:C$,8)L(8-4R$242D M0_1T^HU.7Q\/.:5QP2U$9E@9T%
[^$9%E,.R_5YE3T M7G<.KTQ[Z,L8=6E>03CTI(+Y]C0#C69>\0*U%]!SK*B&QXGFH%49EA#,\8H MI1GH)#/49,?,:$M#]*\-O^RPK(>,MOEF(M#3+#] 4O5C__!%WS%U4!/BM;.'M;-
!=;?T[:NA6>4+A^+#@6Y%P6KT?KTYJH M6T8-RS8%9+B 3T,B+:0OLZU1X4216D;!,U0YAHU43D(B+:2O MLBU(H;XBK1-,L>'0)YN6]>QDFY,MG)4MFHNM/S]M(0SUE? 9R>:-
[H8Z_M3CUQO!E/,Q%%,Q#U MO6WK<*@OQ.LLM\[-T8"##3Z(K\\H3XZ35Z5)UP\F^ M/#YY))R3O+SD9P/93!V_5DFC2M,&KA_9'_O)F\F M,Z8*1H)_81.=#:+]"$U@2N=<7XK%!UA-
J&OSI8(K]Q"L6<56**1B"U>:;H/2MHD3+*T96F&LSST&A$ M2SM,H53/8?X-#5=(4!I'I5.=P*U9!$M3ZC6D62&XF-TCMPRJRF'T&S7I8*_0AJ;WJFGTVC?=+]$+>Y]
M%;O_7SQOT.A>H0T]/ZBF<="^YWX)'#8=)S54$F^RD0,72'0)G#I69*Q\=I?[M13:T'*^1$;=O>D"C&S:])A_VHZ^!Z0W:W"^RJ>DU^0$6^!C0:+"FXQJ1V,_(M"RE^F#=,8_J,*2V=\
<]N]#8@BFN*XBU@-*#18'6I.8K](U:WJ3-VT HKAF* MMP#1@ 9NT.8U1[$?I.>B2,T7 IBOA:.9!/W0-H)DL[,A\5^8&3:UHXD:B0Z:?;7[Y7D MF+;X2%)DOB1^'%X?\I+WG"OI]%ZU?
W0;*37Z5I5U=S;;-V\F\^[?",KT;U5 MC:SAFY5]*Z'A;;N>=TTKQ7(85)5$$D7QO!)%/3L_'3Z[:LJ/U5:712VO6M1M MJTJT#^]EJ>[/9GCV^,%UL=[H_H/Y^6DCUO)&ZE^;JQ;>S?
=1ED4EZZY0-6KE MZFQV@=\M..D'#(C?"GG?';Q&_51NE?JC?_-I>3:+>D:RE+GN0PCX=R<7LBS[M2,#CSUW0V?XW^X&'KQ^C_SQ,'B9S*SJY4.7OQ5)OSF;'#!"WE2FQ+?:WN_R5W
M$^)]O%R5W? 7W>^PT0SEVTZK:C<8&%1%/?X7WW8+<3 ,\\ LAM GCN [@;0 M8:(CLV%:'X06YZ>MND=MCX9H_8MA;8;1,)NB[M-XHUOXMH!Q^OR+TA)Q=((6
MJFI45PQKJU9H(5L-FP#]7-2BS@M1HALMM(0$:K0030_K8-0-;*OEMI3]$!?T M4SWNM#[JCQ\DA"R[GV#2Y MVM:Z@PV>R^).W);2-:X=$"0<8TB41) CEK5P6&I6JZZ0S"V-(?D#E!
H%FQ!VHR(W7[;GRYZW MIM?[-7V#Q$K+%ET<36(Q3N(2)O$&+;9M"QO0-1=FL<11S ^6=9R, T:H=_7Y M?C8\.)L%G)MMU4\"*F3?E(5[O(]XS'!Z82BC2(\C9F;B/QG&
<9PC$NH)XL M4=.JY3;73GZQ]\'.@.$^)FU^RYY<$^?T.L@!5XP3HY;"57>P2>UU(MS"?D;!!.*'9S2_?F3X!GV1SO.[M"W#XRSQCT?1P.& QC[/$0_! ,'&0X,)DRD]&\4([J78"!
.*]!5*QM1+)'\!F;4(SC8 MUI*,6WO0@8IQXDNQ41PIA:%0$AV7D M%[T!_3-[T+V&#A7A\=1E.% DQKYM:%0$AV5D8.AD9:M"1K)I=7:@8']2#RNC
M'3@L'H^9_3AN/02N$XUK>0'61X>- [8E [8DFQH'!XPPCCW&1MMP6%QV1FW M/-]6VQ)$9HE$I5I=_&^PUT["MI"<<)RPR!I##B!+TSCS> EL5 >'9:=W$UJ>
M7$*OMH1N0(MZ7?3FYW&Y?37>5I>889I-'88#!],CJ6>C$"-#)"Q#'ZNF5]2 MHEM9RU4!]K/?*IWL:ZJG(!!;<."H)U.3[("1-.,>5T2,+I&P+BW@@R*'[DM[
MW0>QY88F9'KT'*@D)IZ=0 Y:H[N08-9%;KO"L>US%6MBWHMH65TER]BJP_& MF$W-D@.61JFGPA(C4B0L4M!VM%O9:P#8.=DY=REQR$]$+((VBL211T6)$2D2
M%]E_MM#H(*U0+77OU>^*SE,&B$.I(FIUF58J T_OH6F4BH25ZM.!X^S5"I;T M=JM1K71O1E61RZ63LT.5J-5@.% XYK[#;[2+/-D"#5UE*078$]1MH,R>P#:H
MG$QMI<(IMPZ5C2(I\3@58O2,/*5G:@6R (F'@[^2GH-D"Q(#,SIE:*,H2WSY M-ZI%PJHUVM%&/'OACAZ(DZI538=,"BO'GI>A8GZ[5@RBUKP(YU,4RR0X0
MYLQ#C!H!HFS!&LKED%GW!1E;13"W2H\+E1*/U% C-30L-5YO1QT"@PFWKA,Y MNJ,H\95$:B2&/GGY;:C9EX6X+7&HVA88WY#(5O+=9R5&PU&.6EO-7! TT=+0\G M4Y?
L0"5)Y+NV:>2&AN5F4KI+5:^]E9O:ZL'BU")JHQ*2^,ZWT1@:UI@%V)6 MY!J59K,Z23H:H2G#$.28GA$6A8_Q%W7#?#F=6_N6 $1DYH6$[&9NWH
M@']1=1XXX[9NT)C;EZYM&$EPZN-K]{6&]64QW,(!RM>R'/JT;E,T'?KW9UG= MRO8_3L;!B/U]O7==(W)Y-FMV%_%FYW__&XZC?[AN@+Q6M.-K]T;&6%C&QOX/ M-OG=Z*4?
^S^QZ__6O8MU7J5WM$D\C=CT,I\#1S%/?#N-&9%C89'[*O--K4JU M?CAY#[7$T;T&LQB._M(LOE:TX[4PPLK"POK]670T9W"JDJE1<>$@C3X]8$9B M65ABO[9B*=$74FYF
MQ)N%Q;NOY*IJ'"_6+=2CA<+@FD+!GQQVEXITC25@3]Y^[ZT.5I0DN&I M3_# /#:6&:_ PE[A$IKXNBOJ];.S%HSWXJR]4K3CV1M'PL*.Y/NS9EN.F&*K M,CI0).*>G!E?
PL*^Y*I5_Y7@/J_ENNC B Y/: 1S]JJNY+6B'=^#-ZZ$_T6N MA#MN*B;4NB_O0F6>;HP;1*?T?:_T:($0[XT;:\5[7@!C WA?Y$-X?:C-"$ MI_?JG"CK\97YP<-6_9-NGT6[+FIH-
>4*AD5O$TA[.SX\-K[1JAF>O[I5&E]! MX>5&@BMI>P!\OU)*/[[I'^G:/\)W_G]O2P,$% @ "8)G6?+ R5]]!@ M[BD !D !X;"]W;W)K&ULM9IK;]LV%(;_"N$5
M0PLTM<2;Y"XQT"3K6@QI@Z3=!@S[H$BT+50274F.4V _?I3L^+BCR#*R_"71 MC><<4GH?4:]YNI;EEVHA1(T>\]RHSD:+NEZ^'H^K>"'RJ'HEEZ)09V:RS*-:
M[9;S<;4L192TC?)LC#V/C_,H+4;3T_;8=3D]E:LZ2PMQ7):JE>=1^>U<9']] M-O)'CP=NTOFB;@Z,IZ?+:"YN1?UY>5VJO?%N2I+FHJA26:!2S,Y&;_S7YP%I
M&K17_)&*=;6WC9JNW$GYI=EYGYR-O*8BD8FX;D)$ZM^]N!!9UD12=7S=!AWM MJ MI[ONXL?NGF-KP%NQ?(6(]Q)A#U/T^?82/7_VPA*7[(:1M'&I(>YCWU^B>2FK MSIYN O
V0*.5^RDG'(?D='S?D9CN$E/'Q&F^C-*RN4%=V3=1V%[V$Q)ZV)"= M[;(SQ^Q1_'65EB)!SY.T4@^2VI*S%UV5,+T23H@?=E?"=Y5PQTH4J904"R0> MXD54S
42LYE"0%;#F]V!KHJLD9L7PNMJJ4*?C13Q*U'>B]'T MYY]\[OUBD()+9AOGN2;7DWR.N/[AHMB'W M:_$,=6"H P\OF6U,ET* G;X;/#OS&>=\@$S?SDRS8FZB;U&6"&$5C3UZ3]7X
M@%S?E;E&W?Z8T.* P/L?6"L[PK9'RA'!ZOII@%?7?3>P/DDU.G%-=0!M?3MN M^ZDF['C3,$,I %#?C:"=&75VALR?&-XU&.")[? T:T?-%,4G$2^LVK%'[ZD= M#.C%KN@U:@?
KI/5];APXH"UVI:U=.U@'[(FM * L=IVBN@L(.],7 WVQZXSU M"0+"^OS55 B %+N!M#.?3E!3/J GMM/3+)TKF8B_U'>2**-E>[IZB=X7L5U) MUF1]E00XQJXX-
BM)IZ_ZXN"F<00"8U<"_T!).G1-N0&YV'72^@01Z2@VU$$ MP\1U#OL$$1%]0FLJ!(A*W(C:F4]'J>4!(!28D>I64@?KW__B,Y3F+-+_ JGC]U4/8)@<![!T0G;]$4VQP
MVP"\=!CS@#JSE@]KZ?#& 74V#BCPEQ[!.* =\]K0-Y0"&*7]K0.]\Y,P;DJY M9[CV=0]:[;P3458OT*^K4B[M&K+GZ:DA"B2F![_L(5 =O@ .#0TJ!O708&X$Z MXY8";NGP-
@)UMAH)@>P4:@^HPV-!-6K[NPA4AVA F.%3E %$65\3H970 ME7A(8VG5CCU!3^TP(#$[V$=@'3Z"9WAL&*"7#>,BL"X7P9@><,N&]Q"8LX? M@,'L"!X"2-FHA1%;)^[V'
MQ#/]ZL"!O7P8]X [XY8#;OGP[@%_XH*#O14'QUARX#RGYLL[A@N @<*\X-=!*Y#UP\F@'6'T @!O,(R-$'2L M0; 5 , -AO<2 F<0!P#BX A>0N"\"" $ I ;]G81 7[OU_WSCO25XN2CG[4+#
M"L5R5=2;U7B[H[O%C&\V2_C@\LU*R*NHG*=%A3(Q4TV]5X'J9[E97+C9J>6R M7=!W)^M:YNWF0D2)*)L+U/F9E/7C3I-@M\1S^A]02P,$% @ "8)G60H# M>3@8#@ /J@ !D
!X;"]W;W)K&ULS9W_;YM(M L7_E5%N=6JEI#%@L-U+(R6&^;+:9'--MWNZT_U [$F-BB$+.$E/^\[7<9)_V%L5QM??XQ,?HRZJHGC@\/KH)O\A+6?
QVI0G)Y/6'O1/KO?"QK]'RV+U86^Z M1Y;R.MS$Q/C\MA^^'Q;A\5&6WI&L*EW2JC^V#MK6+C_S**G,?EED MY:M16:\X/D\+23QR0$1R*_.BM'&1DS>^+,(HSLDG>5]LPOAM^?
IOESYY\]-; M\A.)$O)IE6[R,%GF1X=%V8@*=;BH!4\?!.UG!"UREB;%*B=!LI3+COISVU9V.ZD%_]:[J]'6-9Z]3YZ_KNS!7_WF3/-=XS0C.[KOH;'GC M9W@G>2Z+SJ^4L5YU/'R?
WX0+^6&O/.#E,KN5>\=__8OEC?[69:<'F+>%5;*J7"Y"-HST;QY"BO&=/!4A4,\=X9XZQT1R_ M1.%5%$=%)#L=8JP\U"$/,/?)^S%U;6_J-0S2+N;9]G@R:_@#V33:KVD,JR
MRS]&_%#_N.TW;#1JF*==9M(L$R ;17LTBB$%>8\>"I"(AEOYQG/Z)F++%U(MND]I)EW*QR;:CS3ZAGP_.19=IC/RAID'"?"0L0,*HUW+% MV)LX5L.(7NN(Y'ACO0Q'CN
8)H1)SLC3HQ&%,DB74ORYID#[7AI/7Y'#0G1DB]8-+ZI _LQBA!.]HT:1BFH\BL<8#BR'8+$$PSS'1G MF*G1,!_EK4PV\L$J_)L+ L717GB7*S(?'O*++-
]$MPOXLTR2KZ0:EY=_K^:.&N,*:Q?SII8[M:PQ1'-D# 8)I;IKMW#0SSZQEN)396>F/?YW)]97,_DW^).K)G],H*2=.Y>"S MR>2N2)>/C#)#?82$^4A8@(11)(PA81P)$R"8YF]KI-
;X1D:'GT5)FE7'4Y$4 MLA0H3PLN5V'Y!Q%YOBD]_B9*2+Y]YFWGBMZH/6F9-$_)Y^9&#+4LE!9 :11* M8U :A]($BJ8;]\GBM&4T[N7F*H^649A]VR>_WB4RRU?1#;F0V:(N';T;3YJN-
;9@L&N1M !*HU :@](XE"90--VUMG*M_2.G MI[7:TU,$:]1<29BVS38QTA: *51*(U!:1Q*$RB:[F,51UCF/.+Y1<7SM#QE M3_(TCI9AM,KX\)J4),T(R]+-3;62]/AD;IPTF]LP=-8,I?
E06@"E42B-06D< M2A,HFOXM4+F+90Y>GD_ES!4'6[N/=@C;CNI=)RV1SJ*C:9MCT#S%:N==W2TC4%%>9=H MNZ<"):I[1 4MECEI.9<%T1:Y]ZN']?
3O(LVVEWV=%$4676V*\"J6I$CK8VR1 MI7%<%7L\=>\T&32(@=)*"V TJC5CED.[$DKI6-05=ZEZK15!4I5-ZT*92QS M*G.Q"K-U_BTI5O(_YAD<-
'^!TGPH+8#2*)3&H#0.I0D437>R2HLLADF5.G^:_S"_.P M"HV3H#0?2@N@- JE,2B-0VD"1=.O6E:IDFU.E5X_K)H%AEJ\IC7'I&;R#A4- MH#3:KPL,*LJA-
(&BZ:94B9%M3HS.Q=FE<5@UUQ_L.6AZ!*4%4!J%TAB4QJ$T M@:+I#E;ID6U.CP##*C*$F->TYIAD-8=5:&($I=%^76!040ZE"11--Z6*@FQS M%'0:I?,P6T:A>6R%9CE0F@^E!5 :A=
(8E,:A-(&BZ39668YMSG(8RLT\ZEI M+XZM2-$ 2J/]NL"@HAQ*$RB:;DJ5(-GF!&D>AWE>!>:_AUD6)D45HF]_=+Y/ MSC?56%N]IGZ/0>9A',LEN?KV6"'?USJ\2(K$B1%Z=OJ
M0N>"7&11M0\8.2TGNM?1HOHUBG%0-JL/=2R4YD-I 91&H30&I7$H3:!HNO]5 M1N:8,[+7#\IF@<$6[_RE5FM0[E3U2@1'4;J:#*,0=5P&&T MK'PILVIQZ^3 +DO*:YEEMZ/K8<[?
4C+30<<]K)TFS4-=#V*Q= 6T=[JC*H*N^I*E"JNI-4 MI.68(ZWVCD"==H&&6E":#Z4%4!J%TAB4QJ$T@:+I-E:AEO.]0RVSP&"+=R9" MS1U9?*AH *71?
EU@4%$.I0D433>E"K4<R(WKB8)H)(42F-0&N_S=@B4 MI.Y(%32-S4$3DXGT[PE/XVJG"_,^4&;48.M!?Y<%I050&H72&)3&H32!HNEF M5G'7^'O_+LLL,-
CB=MICY@]W6OD?.S+9;BYE0T0!*H_VZP*"B'$H3*)KNR2>W(#*G3^T5 M]GIA_;(PK^TNFYF#_;CN!W8.5-OUKIJ"H;0&D42F-0&H?2!(JF&U=%0V-S M-/3Z6]V8!0:
[M[U!W]AK[0#F0T4#*(U":0Q*XU":0-%T[ZHP:FP.HTXW>?E, MGI.31>G7/*HV"RSGG)LB+\)DNX-@/0AS&9Z+IPUFS7+<6@G![JFVTCE0F-S+O3Y5)3G,HM%-=95NZ.^,Z\601,B
M*,V'T@(HC4)I#$KC4)I T70[JX1H;$Z(7CTJ0O.AFJ9O.=L:$Z'I$)1&H30& MI7$H3:!H^FUD58CD]MK4;[>D^?1&)?.GMWQXN,R4E%/03F-+^=)4U-R0H0YW MNW;.:]YR%OKC)RB-

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l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l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l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|"^X#^S5NY/?^7.UTF'#3KL M02]H3^CV%/HB:C4 CR4'7C=M0%,70!0,D=''UO3ZXFL1 >]TJX5]R#:]F+)B MT$UKS:8OK18AT*Y"CJW]H"E:!B.)W:8^A6B!6K5 NVPYG/KYJ2HT0-%82GN# M]!3*!&II NW:I%,36SNN*5EDOS7$NSUL7RPM7*!=N?23^M!4+A#A81OM%.H% M:?6"[.K%VF) ?H9WP-HZ*C*%#L0C!%O4]JSZ4FNQ@^QB9[8B^9*JW88%20]P M)>FF')W-$A/3(MD2M2?4"6F*'S1$07NRM2?1%U(+(&070*^ M#6H*9(Z64\A ME) 62L@NE.YIE!+.DT42-5VY@U-B OIMDX@?G:BF8AK (Y" _84D@EIR83L MDNF>KC=%M"*\NW-V;(C@P#,83]%[D-8]R*Y[7F#HVB;![6T2>XB^"%K,(+N8 M>0'!E"80MK6W/4)? BU,D%V8Os!@:HX!\GRC%4XA.9"6'*CW=@@RQ04:AX'Q M!62/T)=]PMTDGT1]/+&B#UP3S"LM04^PLX(-@7# $(X'(?M/>M32 :L)0,^ MZOX(-B7"($2PK=?M0?M":8F WI'4CO8WXN6AHGB@<=?UWl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

,WN:PM&LK[7QMIR;B7+6/NIG)^4"V+ZZHG Y M(TLBZB-,V]O>@E;5X;_7OS8?0G.@/Y*WIQJ2\P]!?>5ZQ&R?$8YRV,E4QOU, M3B!67V/JAJ"'ZIR^I4*>^JO'5-[\@*D
^7Y'Y5F]::@$[5UR^1502P,$% M @ "8)G6:B\.[WT! O!L !D !X;"]W;W)K&ULM9EO;]LV$,;_"J$50PMDD4C)_S+;0)NL6(%F")*V>S'L!6,S,1%)=$G: M;H!]^%&R(EJF=)
(R[TTB67>GYX[2\[.EZ4[()[5B3*,?29RJF;?2>GWA^V]Q M8@E5YV+-4G/D0\8VSG3K81EDK]T(\93N?EC,OR!2QF"UT5H*:?UMVR>(X MJV1T?"^*>N4YL\3#[9?]' /F33/W5+%+$?
.)EWHU\8>6K('NHGUK=C]SHJ& M!EF]A8A5_A?MBMC 0XN-TB(IDHV"A*?[__1',8B#!!PU)) B@71-"(N$,&]T MKROOZXIJ.II*L4,RBS;5LHU\-GFVZ8:GV3+>:6F.L1#&Y9=
[\YY_P,/BU M;FU.5*S2>E2V'H&M7XN4/9O[1SX9AWS8-%Q\^QJ#@Z&'@V@0CH[6IB:,1$%4 MOSB#4N&@R[6DLG7);Z\Z@0/GS#@,CM35Q."&"V=8:AN>_CH?.CKJKO.:J,;K M?
%3*'8%R+T62&$LR'KIX*@0]?T>EI,;8ZJ2.'!'D2"844=$X+C6.08U?A#;& M2G-CK9,T=DX81<-Q.#C251-&PF!%MK4"P1%]K MF+CCG=3W@ ,+N*##A&/+]UK<@#7ZME%4Z]3'
;CQ?W!M!.\Z#/B4KC=:G:'/ M;.MBA$%SA\ ;;N_<35:M.R9(8PRCN9O\D5:'KXMKMGAL 8QA GNMKD^6*-W&RZ$ MF[JP!,8M"'Z]Z1/8]$_*[5-5J_[ZLH@G,.*
[F3YQJ7Q\PX,A57&6VP3F=B>O M+VJ VJ"0JK:#WZW_QP]7%XJ.5BBDJM4RD\#,[&WPQ$7C\==Y,*2JT[*3P.QL
M,WCB\L^1!85495D^$IB/G7P=KM'7%8B+SZ:OP<3RDW3A9XNQPS5Z]^&BMK$/ MRUG2PMG7.WL(.CM\WMZ]GZA:=4H6XP3&>$=GA\A;]-$9SL3"F3$YP/C(SD/M71?
L=+=;YVY9[H;5(\LT5HTLFLP!S_$$(M_;*3O< I7]C-_P502P,$% @ "8)G6<^@,EU4 P 61$!D !X;"]W M;W)K&ULS9A1;]HP%(7_BI554R=U36P@0 =(:[MJ ME=:I*FWW,.W!P
6L)G9&F&VBE_?C929I0$3SF5E5?($Y\KL_]<'1D>BLN[N0< M0*'[.$IDWYLKE1[YOAS/(;;RD*>0Z"=3+F*]]%#,?)D*H)-,%$<^"8+0CRE+ M0S$ONW*KOH>]QQM7;#97YH8_Z*5T!D-
0-^FE MT",_K#)A,222\00)F/:]S_CHF&2";,8M@Y5WC=U'4*]%V+M(&9)_DWO"Q!K D*V"$@A()GO M?*',Y2E5=- 3?(6$F:VKF8NLU4RMS;'$_"I#)?13IG5I\)TK0%WT$9U1)M M MC1:
+H#*A0#-7DG]Y(0*\<"26?&4)A/T12JFB@?B%]A!+T/6<+Z2N*'N^TMT83_ZX<'Z<.R=;G \A M/42-X "1@#31S? 4[>]]>%K&US!*(J0D0K*ZS2UUK^=@2G:?6,\;PY7[/^@*
M4BX,@@UHY:RZIJR+FW?P2*9T#'U/OV02Q!*\P?MW. P^65IKE*TUK*UE7=29 MRF5A)C/O\7* VYVPV>KYRYKEFN5RS1'9EW2Q)=-^;=_.LK*BR*7A3Z!M6]':SCNSQ M6E!C-
_J%;H$K<;<'H=VJ*_&PO=V]R:W-H965T-/8E7K'?-[CJ!O^_LVKA!)&E?[+W,.7/FXO%PH_2S MR1$MO!9"FE&06UM>A]%)5(@PCJ)^6# N M@_'0G]WK\5!55G")]OI,511,OTU0J,THZ
3O!P]\E5MW$(Z')5OA'.UC>:]I M%[8L&2]0&JXD:%R,@JO.Y63@[+W!$\>-V5J#BV2AU+/;W&:C('*"4&!]'0.C MUQJO40A'1#)>&LZ@=>F V^MW]AL?.\6R8 :OE?C),YN/@O,
,ERR2M@'M?F& M33R)XTN5,/X)F\8V"BM"MC%5% R8%!9?UF[TV>=@"Q/$>0-P 8J^[=N153IEE MXZ%6&]#.FMC4N=5TRPEGQ!^51;B +W##N(8G)BJ$&3)3::34
M6T,W#Y@JF7+!F<^C6L(=KE% %VZEL;]JJ[8ZG:!D7YH004]1\S5RZX89+1F F MMHU/X8ZS!3%:C@9^S;!8H/[]0<0IV9>5-VV3^"#A',LSZ$:G$$=Q#Q[G M4S@^.CG
VVUKT_6\O3V\$R8H=PC,4D93'SUT.]Y-=U?8-5O?L[F/<3V.AN%Z MAX!>*Z!W4,!5EG%7\YU)KJ')EK=.G/3C/2Z3UF5RT.6M3$5%97$UUFCHVS*N
MXV@(;;972O))2MR/DSU*^JV2_D$EU/;"&<.7/&T;W]4@<^]RML,-6 7X4G'[MMDM:_Y.T+YVD"+>&2(%ZY4>E@515 MTM;SI#UMI_%5/83^FM>C?,;TBDL# I<$C&PO=V]R:W-
H965T(!5=,##M 8R67?:WE/"[=\GAJ[X$>]@LUQ@N:N M&"N:^35+PG,4FDL!"F=][ZQU.NC:>!=PSW&I&V.PE4RE?+23JZ3O!38AS# V MEH'1;X$#S#)+1&G\JCB]^D@+;(Z?
V$>N=JIERC0.9/; $Y/VO<\>)#AC969N MY?(2]WI<@K',M/O"LHH-/(A+;61>@2F#G(OUGZT]'1J 5N<-0%@!PG\%M"M MVQ6ZSLR5-62&13TEEZ!L-+'9@=/&H:D:+JR+$Z-HEQ/.1#?
2(+0".((A*KY@ M5E082&$4";QI>;*V%^0.1HPKN&=9B1J82&"L4*,PS/E!^\,&D9<,!%SEL&5 MT$;59#S1[0_1,)(I R*FDPFA^5PP@PDP#9>85#F8-0#PXQKS:]?%'W&<+^ MW@'L
1?P/96EIAQTSS>D@JW%CZN*S]<5AV]4/,'B&-K!(81!V-D"'^R&#S$F M>,O!VYMPG[2O#0AK T\'UWF#;R#SG.2;&!D_PK?":JE]>&!*,:M8+< ?DH6$ M-5:60[C!9VVV2;#S3-
L93G7!8NQ[A?50+="+/GYHG01?MPGR3F0;\K1K>=H[MY6G?B$2MN_QZ8F3A&N54&FJ[;IC2 MPXC*!M#^3%*SK":V]!9/;?074$L#!!0 (F"9UF:O-K-I , $8. 9 M >&PO=V]R:W-
H965TRDIJBPK6KKIBRV2YQ[R7!Z^ MYDVK<($,JJNQ0XXMFR%S*C&HHQMM9- HSPH2VW/ M<<9V1AFWEO.\[EXNYV*O4\;A7A*USS(J_[Z%5!P7EFL]5SRP.-&FPE[.=S2& M-
>A/NWN));MBB5@&7#'!B83MPGKKW@0S@\\!?S XJMHW,4HV0CR:PH=H83EF M0)!"] T#Q;\#K"[-#1$.XTO):55=FL#Z]S/[NUP[:ME0!2N1?F:13A;6U"(1
M;.D^U0_B^!Y*/2/#%XI4Y;_D6&(=BX1[I456!N,(,L:+?_I4Y]$6@#SM 5X9 MX#4#AB\$#,J P6M[&)8!P]?V,"H#A%"CR *&0$43DP@=-6:HN,0 9D4NOF%.-3521]O#%C,?D U=:
[M%DFOQY M!]D&Y%^(_[3VR<6;2_*&,$Y^3\1>80]J;FM49\9HAZ62VT*)]X*2 ;G#82>* M!!R'U!+O=\?/.N)MS&J56N\YM;=>)^$:=M=DX/Q$/,<;MHQG]?KP09N<_]=[M\)]
/[TG&H/+9(.<;OL!7.-B(7*5KHLFV6"YYQSF-VNK *=2!U64H>=4@-T=F1614WS.\8I#QE-:XM ?5L% M_Z#QP:1Z9M;> :1FFQ3,4L)5YE:XMG1UCL6<,C=]1T-86'B,*) !D8__N". MG9_;'-
DGF=\G6= 3VS M,ZEF9I*3!R?G_FGNGRV0P:1APW-,<^]L8?$F[1Z<5BJGG2KQH9O?]1OUM^[-RFVI M]_&15+QIOM$7+ZP[*F-S74YABUTYUQ-<*+)XM10%+7;YM7PC-%
[R\\$'WH@ M#0#;MP)/_])@.JB>CLNO4$L#!!0 (F"9UDJ*"!.5!$,L+ 0 9 M>&PO=V]R:W-H965T*#K9\ M 3()5<2ZWT*1]$Q/=_4+86^PZL@2+9. \?XM6T;+
M2_9C\>E'EO]1+*4LQ>,]28O/1\NRO/]XYE6/[G-\E545M_F M=R?%?ZCQ6;1*CG1!H/IR2]*TZ,+3YO+KO*+3]FZ3.)47N6B6*]64?[T12;9 MC\]'PZ.?%US'=\NRON#DXM-]="> R?
(O]U=Y]=W)B[*(5S(MXBP5N;S]?'0Y M_!A.1_6"S37^.Y8_BE=?B_JNW&39'_4WSN+ST:"^13*1\([FHNJ_!SF325)+ MU>WX9X,>O=2L%
[[^^J=N;NY\=6=NHD+.LN1_XD6Y_'QT=B06\C9:)^5U]L.6 MS1V:U-X\2XK-O^)'<]W!D9BOBS);-8NK6[*T^?_H\=F0[Q:H&EO+-"!:=KV M@N$;"T;-@M'V@O,W%HR;!>-
];I*D63#9=\&T63#==\%IL^!TW_MPUBPXV[?" M>;/@>3'-\%P\'/1VZPO63ZUI*7!WO[T1Z^N>3GPSW6_'S ASN/^)OW MY>=#/MP\YB?/0[Z;WWT*]L+3WGV0^3U]2NO_F*S
VW65[_R<5KOZ]_*O/II M7*TK+*LE&(X%\6US*)2KD05U%>/HGO>906T69_+1ZV

R[%QN+N:1J^:36$!B(8E%)!9#6*.>3A_JZ;2WGEY>N,%4 M^A]7K#Z),'^[2F1O^Z$EDL04$E-)3",QG<0,$C-)S"(QF\0<$G-)S",QG\0" M$@M)+"*Q&,
(:I7OV4+IGO:4[WG[:I(LTR>_>2/Z7M<@W-^FM%(A\+M9% M2%ZVGE=#Y&RYK ;#NX6Z2GQO/T-+/(DI)*9^PZI)SHCMZ+PY'-+(+G42 M,TC,)#&+Q&P2L M+%T7TN]ER=
[FXF$@+OTI.2)9B-P5BV<6Z2KDO9T.+>0DII"82F(:B>DD9I"8 M26(6B=DDYI"82V(>B?DD%!I82&(1B<40UJCWIP_U_O1'3EOW=C:TSI.8 M#AV-
1LTAMDKV]&83F(&B9DD9I&836(.B;DDYI&83V(!B84D%!$8#&&-^GWV M4+_/OG.N)4CR\F57L>Z5AQ9K$E/.NB9$IJ=/]C79I49B.HD9)&:2F$5B-HDY
M).:2F$=B/HD%)!:26$1B,80UJO7Y0[4^_ZMG5QJ+]$VY]*[)T.I.8@])J22F MD9A.8@:)F21FD9A-8@Z)N23FD9A/8@&)A206D5@,88V#@#QZ. I4(]>>PT"0 MW*W*LKZ1BDRZF/]
[FY;UW5P7HNRKJ&Y,;U3^KMK>[P\M[JBF[+7&3$O'5 O; MJ89J.JH9J&:BFH5J-JHYJ.:BFH=J/JH%J!:B6H1J,:4UR_BC])'\@^YSZ>]H M<#TG-
66O/9F,F4V>UQ.R4PW5=%0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C5 M8DIKUO-Q7<_'_;,S+]YRW@\,KM.DI]":BFH:JNFH9]":B6H6JMFHYJ":BVH>
MJOFH%J!:B&H1JL64UBSG=2!3_J&)S/[>!M=^-).);JK<$1V_M<'!9 M)S4%U=2]-GM4UB>3T\EH=/:TLI/=ZJAFH))]:A:JV:CFH)J+:AZJ^:@6H%J(
M:A&JO936K.QU9E3N#XTV)U^D/R4E3SZ+0HKOUHMR "^D(,\6VWFQZ9^@01.C MJ*:@FHI]&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%E-8L^7745'XI
M:_KL8%X1G\4RNZU^D-QT*39%MA;W0_O.PH\F3%%-035UKSV>G9ETS,Z@Z5%4 M,U#-1#4+U6Q4PIZG)1%_,!2 MCH9(44U!-55NAU+/1ZU;)36T4QW5#%0S4:CFHUJ
:B&J1:@64UJSSM>)5/F%2.K3>7]I1;G54,U#-1#4+U6Q4QU3+EZ^=C-G>WBZ_E?NK+)UX+!='QZV6(2N6TQIS>I91T"_5%0^(M;^GL;7#C1
M3"BJJ:BFH9J.:L9>:Y23J=PNG.W%9JVLE(6NFHUJ3L<6R..S=MU$TYFHYJ-: M@&HAJD6H%E-:LPK7Z?WDO>3@TLMFL)$-175-%334OE)H'+F>A:V>CFG/@-KAHKQZJ^:@6'/@7"0]
<+AJWT\NS\]9B,;41S=I7 M!QG'KPXR[FK?&\E_50S4>UX,"_2'C@<-R? M![RXOL[%=?7HLE_+:K@IS\C3;"T%>3HO"^1RF4RH MLX/C_NR@6Y;N/SKN7Y#^E+[]JKH=[5;Z>
[*Z_:>D9#AU1K5-%334N$X.35"<'!D>_^KH8.TR?M+-[9Z;AUH5Y!>U5134,U'=4, M5#-1S4(U&]4<5'1-1S>OXS,CMCXR/=AJ@6HAJ$:K%E-:LO:.Z5B,)P,ML4W1>
M=NSG!]=G-.&':BJ::BFHYJ!:B;]6:AFHYJ#:BZJ>:CFHUJ :N&DG<0=3UO' MJPCM-*:T9A6O\WV3_GS?XU*=K!>2D\[%>B.Z9\P]\!+_UX7D)O-D6RZY2JOK
MJ8]^KZ:Y+M:]D^?]JS.XZJ,9051344U#-1W5#%0S4'.B-8OOR1D^>]O0VN_:2FH)J*:MI>>WHUH3DLT=$^#50S M4I'#0/EU4\U#-1[4 U4)4BU MIK1FK:X3B9,7'DY)3IVC<414
M4U!-135MTI&$D[M*-1HT1#43U2Q4LU'-0347U3QU4\U$M0+40U2)4BRFM6=+K M>.-D4+SQ?D:F*NC+Y*X<9_>5<#3FB&H*]JFHIDTZPE\=!1R-+Z*:B6H6JMFH
MYJ":BVH>]OFH%J!:B&H1JL64UBS@=49S,BBC^6P!ER(Q%^4BBS?2Y7:U7>Z6 M[ZSJ:%03U1144U%-0S4=U0Q4,U'-0C5[THX1=LVTH(^=1#4/U7Q4"U M1+4(MU6)*:U;U.F8Z>?
5C)P.1I]E"TLHELB_5E+B6YIO]'IC5]HJ0)LO=@PZDG_XE MDKSS:Z_[NQY7GM\)\!IZS*2C_89H%](:A&JQ936K.EU2G7Z(YYCV=_) MX%*./L<2U514TU!-G[8SBN-
1^ZL:#+17$]4L5+-1S4$U%]4\5/-1+4"U$-4B MLIK5G,QW4Q?W6,U4V^]JOM2HK$=75--LOOVI6],IK:W^7@THY&6U%-134- MU?1IQX,UV_?R&&BG)]I9J&:CFH-
J+JIYJ.:C6H!J(:I%J!936K.RU!'6:7^T M]=F[:[Y]>>^S@_7NDH[F5E%-0345U314T_=:\V$Y734=3:2BFH5J-JHYJ.:B MFH=J/JH%J!:B6H1J,:4U:WJ=2"U?_C^X"OOMMATWR?
\0Q6Y:_O8VSSZ7RV=7 M4I3<)3M:BFHIJ&:OJTG=.= M=)Q$H+E:5+-0S48U!]5<5/-0S4>U -5"5(M0+::T9DVO<[73_ESM#SJ)T$7U M8*F[^P=0W9]"?
+J3G*P2XG3^AZ1MRQ4HCQK9/-T]>FKHN00:\T4U!=545--0 M34U -5"5(M0+::TYG&GC@-/^^/]+D$&@9& M-0755%334$V?
MD.M[3O]#+1/$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(LIK5G3 MZS#PM#]9NGO2[)7(JRL#YKH0RZ68%)OJI*"Z,I 7=[LS#+^X*1?Y40&Q_E4> M?&!
0\2HIJ*:AFHZJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&HQI34/('6N M>-J?*Z9/"M!P,*HIJ*:BFH9J.JH9J&:BFH5J-JHYJ.:BFH=J_EY[?!+:OJ 5
MH'V&J!:A6DQIC9H^JT._L_[0;W"5_J<<[W=>3]C_SES/W_8.XON[&%K(44U! M-175-%3341G;>SX_ZLX]G1 M[=!*T*)]^WE0G0;(E2+*:U9A\=U'?[Q8=
[^+@<78S3,BVHJJFFHJ.:@6HF MJEFH9J..@VHNJGFHY]..@&HAJD6H%N^UQO>I-]BS=)>IWEG_6G>_1#[35G M5TFZKH;1@R[F0_$_+]#KYENN]6&7;[N_]C<"U'4[RHIJ*:AFHZ
MJAFH9J*:A6HVJCFHYJ*:AVH^J@6H%J):A&KQK)VV'Y_WU/(ZQ5N^[!^F=\^0 M.&GR*5VFQ5UG[>XU!]=N4E-0344U#=5T5#/VVN/1PI.S7?/E12QTG6Q4 M?1?
MT'NY0Q_M,'BYP_#E12)TG6)*:]:W.C0ZZP^-#KW^5[[MED/::GJB]Y(@ M&AY%-0755%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"VFM.8QH Z9 MSE[U\-;-&TE-YC>'?45P?
Q>#"SZ:[D0U%=4T5--1S4 U$]4L5+-1S4$U%]4\ M5/-1+4"U$-4B5(OW6F,Z8O3\;$4=VYSUQS9?,YK?7VSL'/ZVX_OKl-KH6;Y-?I>B,MQ56Y"J.WI^4929Y>WSS\
M4&2W^X[D(^E35A39:O?R1B0+D5<+E+^_RK+B_H>]@RJ9_L=N,S_^'U!+ P04 M ")@F=9-?W@45@# /#@ &0 'AL+W=OT
MD_;C=^VD*73!E"DO8#L^Y_H<7U_9_37CCR($D&23Q*D86*&46<^V11!"0L49 MRR#%+PO&$RJQRY>VR#C0N08EL>TY3M=.:)1:P[X>N^/#/LME'*5PQXG(DX3R MWR.
(V7[@N=;3P"1:AE(-V,-^1I[[K M*("\)36"M=AJ$R5EQMBCZMS,!Y:C5@0Q!%)14/Q;P1CB6#'A.GZ5I%854P&W MVT_LG[1X%#.C L8L_A;-93HU$+BPRAP7-
8SEAZ\l0"NHHOH#%0O^2=3G7L4B0 M"\F2$HPK2**T^*>;TH@M@.?M_7@EP'L!<-M[*T2T'H)Z.X!M$M 6SM32-$^_M^%3289^S->%]-K*IAC93HU%^E*I]GTJ.7R/$R>$7)H&X'?
*!3&&)^RD%.?5! MTB@6Y!XV,J?Q.W)"HI3$^! AWZ^ [JEK59K8T7WO?9N;)##AA"S*!C'%)9S%4^UJW;05=11.I"K$: M>GU[M:W?&% 5I9[(: #"ZN. +X";_CVC=MU/M:YT1#9CC?
MRINVT9NQ/DOH MSIBE ?K!J:XJDT@\DN^WH(SI0?Z@<2M(<%$L^D#$G&,((T"+%* M/@/KO#4NYTCGQDV2^0V1[6Q#I]&SBM3]);^9+PRM38I. _^DI_,B/0_.\(W+
M^4^QW4ILMXF6+D/M:&ALAV;'"=YZN@'T5'LDS?QV=,8H'2S1!?;,#5!/R^8'@G+SLJ M0/4&'/X%4$L#!!0 (F"9UF3%)>C2@D +=+ 9 >&PO=V]R:W-H
M965TV_.!;%OXK@'2Q:H*W%EQ[=)$!J<3$!^@B2 M='>!Q?ZAV$PLC"UY)#EI%_/AA[(=,Z*N*3NY8V P]>/P4)<\8O0S;9T\%N5O
MU52IVOLQG^75Z6!:UXN/PV$UGJIY6GTH%BK7[IP5Y3RM]=/R?E@M2I5.5HWF MLR'U_6 X3[-\<':R>NVR/#LIEO4LRI5EZ57+^3PM?WY2L^+Q=$ &3RI<9??3
MNGEA>':R2._5M:J_+RY+_6RX=9EDJR> M/?::4FZ+XK?FR<7D=. W1Z1!EPWW%JG^YT&-U&S6..GC^'UC.MCVV31_OC) M_9^KXG4QMVFE1L7LW]FDGIX.HH$W47?I5-4*
[K4K^;Z7;UV=>B M5AX1WGOO6MWK -25?OAMH[NB>>5^*O)Y6GLPG:@*T3]SM8T?[MH1Z*[7C0I_'X1)V&UVKQP6/^.X_ZE
/',]J_.8/*>5WO\L6]MP:#;E#Y4GEW93'W1GJ@2WU>ZX#64V^TBJ8JWWGRQWBVG&3YO7=>54K_-_%N MTA]0%-:=!:O.F@7LX8R$+&#T9/CP?(0A621BT98E79F@L?!Y6R:[LB
B(B9; M66MD^'9DN'-D-F>(+CK+QWHSHJK>0E6OC<3SBB, X%7+785BV<52=*_S$:9^EZB<\G7CHORCK[_^H%]':1.0S* M2<"LV@%50")+E715(2?,&B)J&)&=M0=:,L.G'5_UG.
[/@FR_$%5]6HYU O? M^IE2X,(7=*? +AR04-\J&]#8-0.2.(8K#K<5A\Z*OW^]N)&)=WUS?B.OH>]< MS9NKFX_5(AVKTX%.3*7*!S4X^_O?2.#_ UI3,CDSL')F+*_GY_&L"5>EL
M>&@N,*:;T;_F,G<]-;*'!'$^DL^ F11("Q5 JB8+\+8"B;4 M)R64[U@WR;/K:>(QL K)@=S8-7! W
M75Q<7YW+SV"1SH8'AQ/3+4%UDUAN[2DPG$/%)MHE&!T:^S/.$2#C&M7M3^@!&2%A$ H[JH".T7$IXRZ_WA74[3$-_XM6&QL[LV M@F1AU/DV " 3+(KMO0Y0%NS:ZF"&\:
(G2[^S#/^ZN#UVU4-T25#>)Y=:>1,,_[*C\P[H<8G^;E9YZ6!WH>1W%T?'&A41D)UDUAN[4DTC,2.RDAL/T8"9! C M
3*0D2"=@Y&8823F9J271AR+K=R'=_!I@,I6J&X2RZT]T8:MV%'9BNW'5H , M8"M !;$5U*>#K9AA*_8:MDJR]#XO*GT*N'<1W)T<'&54L$)UDUAN[>DR8,70 MP(I!6U6"VY^^ K+W-
/8C8@<5TG%[\9>0C!#&.-^15 -6#!FL6)=Q F(SPPA0 M1P8-3?&CTA3?III/X7DG2+Y%.27LL M##EQ-SD]_0;V2BV:Z]#_IU^.."IR<39K:K^HU?R=']-2OY06ROM:Y-6FA3/*
MJ"2%ZI:@NDDLM_;T&9+B:"3%(;1UQZQG55 %\?")BE(QD@8=7ZP">HBONMW MJH:D.#))\2[6=,[37DG2+Y%.2?OWJ8:=Q%_ 3]*?G?HE2;]$.B7MB@T[B;XO
MU;UV9=]3I=S'<>ABA>]6H+I)++?VC!]6$D=E*=& ,]4O2?HETBEICX7A)M'S M>R6,=._#4>[C.#C=]!R%ZB:QW-HS:CA*')6C1#]']4N2?HET2MIC\>QV"FZ.
M0DDW%E>YC_7@,P"5JU#=))9;>]8-5XFC&PO=VIR M:W-H965TN*B6P>07*,]?WO,C-&2^CJF%:"R^,IAH[:6Q*0R$^+&;"[F0\-:8#;ZP?O[ZKD,9D94S
6V3<^UZNADSAD@NVSO2UV'R M)]'0^$M%]IJOLJEMXYY#TK72(F_R"#G1?W+[II";'H4P"_?A_"P@:0% E M6C.KTIHPS48#*39$&FOT9A95;2HT9L,+
(^-42SSEB-.CCT(#H2%Y0Z:P1'FT MPN694H"+V?W#0W(T $EZ0SRNQ5JR8JX&KD8YQZJ9- MZ/,ZM/]$Z"F4)R3PCHGO^3T+?-P-GT"*<%K!@UVXBT5H*^&WE? K?[TG_-5)
MV]*H<5&%,W^+VY'OAQ'U,.KM-E^+G4=IU$];NQUB04LLZ"3V7HCYAF>9C5J- M#++"AD&81,D>,XM9/_$CSTZLUQ+K=1)[:(YK*
(74O%@>XS(51E'4"^F>:A:S/DVH7;2H915ULKI:,;S]4EAKGK*L M58+\(I]*0)V,F9G.U4)&XK$A^H4_Q(.K'-$[VA;+8!0&- MHYY=JJ0EEAS\QT\>A0QHA)\]9C:ST]".[%^2ZS?26S"V;
(0"CM(_4<#=<;X MUP9Z)F<[Y:#>GY>H=V +-<"=JQ<[*-X7RF(7!5X-)LS+333K>CWU!+ P04 ")@F=99#MQ]X\# "]_M#0 &0 'AL+W=O17*&.6 5=,<")ATO%,&R>#1F
2:&RDB(7V;P M?MSQ A,1I)!H T'QYQ;ZD*8&">/X78)ZU9K&/%+[TKA5AQ M"]L';+2(7SL$&YPB$]Z'+D.S=*A:94IJ%@=!E33;EN*!9'&&M',@Q73>B-] MQLV^#[7$MPS]=/>3T$:+?
*&? 243Y&] 6C*4D6NX4[/:;K?]C6N8ZS]I,3L M%YCA!LQCD M+Y2N";_GA#&EXD3E-(&,A[5 @;P%K_OJ1:,5O*V3K !K63!3)FZ[C1C+!OZU M_=M546H,"[L'PS7:S8IVTTG[G'"*$UB2?
L\U8-B:G-UA=5-0)X 3<%L!"K!X MA5<8U_&OL0L=]..*?NRD?T,EHZ,4_K7I3I1M.<FXKXX[UF0\]F0\KPY MUYR.VRJX([U!1O!0R\6;'?^VSXJO3<:.H_#$G>U3(?-
*'Y,,+U,@C0&^GPALE\N!6:"ZGG7_ E!+ M P04 ")@F=9>Q;MB10# """@ &0 'AL+W=O?EV/+T42002*U!5&'9YA"EFDGQ?&G,;7:-;5P M?[QSOZN25\DLB(
IRW[114S'5FRA):S()L/;/L)FH0"[9>P3%3_:%O'AD,+ M)1LA6=Z(%4%.B_I(7I" EP<$2 &P$^5> U J]*M':KTIH1228CSK:(CZVE
MI@=5;2[URH86^C;.)5=7]=+)R30*+E;R;VW07@OI]4+>T4+?D'<1;Y=@?_'ISN$AT&N MHWYF0K\E],\J8T;)@F944C""^H<,./+=#]DI:C@,S:1!2QKTDMXD"=_ $L&+
MV@Z%&2\X7#@.@@[=81".<62&"UNX\'^6,3Q "+ 31!U00Y3O^HZ9-&I)HWY2 MF0)'&2O65Q)X_AYI=/!:^&$\[(>!D7JJ3!SQBUG?$Y%U9ZFMJ]7(%QM:A>_ MU?'2A-
OO&=8&R$,Y*V0JD!NC)7DU)3[M=XH:)[=V0]'!YTW:PS;MX>D[0EN) M]SN>@EJGW.^S*QYNBX??2]IU_GW1G+/NMO'S5%L,]QXS9^ $7N=A/!)VY'%T
M]SZZ[AEWQ@CHFE;VNJ_UD:#NI\;>:Q!T=_:5\#4MA%I_I73.(%(; Z\;GGHB M65GU# LF50=2#5/5) +7 >KZBJF^H9GH-J1M.R=_ 5!+ P04 ")@F=9 M[!]]+&4# #A# &0
'AL+W=OV[8\9E 0><5+8'HEY:(@2D_%V9:E M ')J@HK<=ATGM M"F;7;-,]NQ6[#*Y53!K<"R:HHB/AY SF_:"UL_7[PF9XS M53^P=YN2G.$.U$-Y* 3,[K.<: %,4LZ0@'1KO<;7-SBI
YH=7RAGK>74C""'HZI3$/WU"&\@S^M,FL?W+JG58]:!X_'O[&\;\5K,@4AX MP_.O]*2RK15;Z 0IJ7+UF5_>022Z;3W3I]CH6.E92\;(+U@P*RMIO M\],KQ"C =1<"W"[;7BW0
W+/5%DMQ\@D2]6V>K!XW4)EJ3HZQ^*W=*Z%6] MX]3N$U< <(A>H0^@Q4D]>& G*H^\8@I.Z&VE*@'H(V6TJ(IVIS[HE/_6+41(] MWX,B-)"4).\F-K32W&L$^=CQN6A[N H\
[**^0Y[Q$KN/ZZ.%N MCYX_>_%G&EM+Z_6YO3ZWR>LOY'U="IHCW.55F>#5.4-[.$)Q (&\;N4ETN=< M$$79>8Y[BQ$V&/4Y?]QYCN]M[,<99E[/S/L_S%+*"#O"'*\6(1CQ"J,%6GY/
MRS?2TIC!2C7\"2K&4>3.XP8]:O $7(/68(H:XP6Q80\:KH&&*V+#*:R3>-$\ M;M3C1D_ -8B-IJB>Y\^#QCUHO 8:K8B-9\1&43"/F_2XR1-P#6*3"6KLA/.8 MV!E\S5E#C5?
4=AG^DALOR,4C2\5/@#8([N+'P*ZS<)3QX'38;'7W&>A[.54@ MUG2[4_@P6#I>>#_T;':T,0&3^JEKX21(%M 'W\)FX[KGBN2H&E]>:7MY%=WE ME3>75]E=7FM%FKI[?:9I*.37%,
(KC!8Z#*V*S+7X *:_1 MGJ:I?]$:&AU 70#87]20ONK12$>[FE-RH#E5%%9+//76Q/&7V_>BLWF^O_8 MFRH_=6C77_H%#0Z-S1;='HY_KN/4MD,_2I8*.?@V-
AOW(AM379))]Q0&D\+8 MHX:U;OX_$G&F3&JL5(IV^+^7\WN%U!+ P04 ")@F=9,6AJ4I4" #]!@ &0 'AL+W=O M-/\[[YCG']4FZ%?)150";/#>,]IE3 M:=V>N:
[**VBHFH@6..Z40C94XU2N7=5*H(45-1!B$ @$&NC0/%QQ,L@3%CA!@_ M>T]G>*41[HY?W"]M[IC+ U6P%.Q'7>AJ[IPZI("2;IB^%=O/T.<3&[]<,&5_
MR;;/I1R2;Y0632I&@J;FW9,^]W78$:#/N"#H!<&^('I'$/:"T";:D=FT+JBF M62K%ED@3C6YF8&MCU9A-SJ"!^=D"-2Y)%1Q*\0S(CUX+K2I%/O(#BM=[%K(;4@I?
4%L%!PQ6T$Q)Z'TC@!=$(MS_+OY>$!G"'H=&C]HG?\OK4@L7I\37)34[Q1I,2Z*E)*T1 Q[#)[#F/UZ_P3 MZV]NYU/FQ[[GI^[3;E8C4?[4BX:H5_#1 !_]!WQ9<\IS.(#>N<<[4&$<[8&/
MQ 33<>QXP(X/8E]:L'_'CM\@!;Y_NL?]-LB?^;-Q\&0 3PZ"WPF\?&-$R=O3 MG<;3<]I)"]D[O3-AJ0:]M-%"AO:0 , "X4 - >&POJ8-(BF=(Y-;:K9V%9:$;3$DBY"#NM5ASFE$LR&LA%?
I:,,IBJA31#TFN& M G?[F@Y),_Y(B+][\6RER_"]S][,/96>OA\GI__*("+DGH%>T> M(7K5PG4MADG'1TD?4,;$>[O":Q_G5]HQ=8Z1^Q[RAHG2DN/R=#A3:*YZ+?^2
M*KE]>EB7RVB0*;FIFHBX :M/E#)M4[.I=)5;!?!_9[4T_> =0\,:KMJ=+MD0JIL-,E$Z9;H)TR;KH=% L SL:#Z;P]VH M(@30&)7;1LKI3$E:>5@SZH:5G3(A[N
Q_YGM:"^SK9VK]DTV36NH;CH9UP']M;36GO2T;O4@W*/BC,E\6=CFRZD.UL5O-,KZL^LNL,8"IMW%U6A1B]5GPFI9TJS+:9GAGCLGZ/G? MYGG&)--4;)NVM?
^6L_QBQU'OM2Q7WRK]AKT>ZW?W6S?9/063\2F8/(F:[)^" MR>0$3/9>[5OSH,FP/F5L'65V#C+-; 'QB'Y 0=0L0D:3!9<&"[KWIRG*9// MSC-6WM"}_6-H1]_.3UE&%\+<-^"0;-K?
6=+,NH5$U+,V[6^PO';W#O?12NWU/AYC^$HS]02P,$% @ "8)G69>*NQS M $P(L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/ M:(7->=I3W;+T]!;X"O M.DQO0FE(2S,.\,W2?
S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B';5_ M'FY@UVSFMJ- M$;RU:R%)ERJR8>CQWM=FVFXHYUHG-0*#OH#MU(\V*?S?I?=2ROO M9"?=S^/)N-
V)">NEDKW\)=KCR6S"[%H__*F-_*65X]VB,;KKCB?9]L2M,$XV M+PXO/.0-OI/C$*A^3]AU,NE;,29;H9>*+>-HQ&=!U1V+3=V
MPA3OQ?'D\1)VHEIVKAP$B5VH[:W@6O]+X:LOVNVO=H ;Q- <2CAA+MH1?'>0 MIUJU0EG1,MBRNI,M<+3L(^^X:@0+('.$,M\CY+<\@"P0R&(OD N/ W\:0)8(
M9+E'R"B2%0)9[1SR9?R<97K)SO\99 !9(Y#U/B-9!)!S!*^6\@OT(6SC+UE M'PB+KR** F+NP#R'0+YC@ R!\A/V@BY4NS\I[/F:B48]/K"!#O M$.76T/C\DPXQ
M,;]D.Q:,B/G>]SA<&G;+NT&POP2W@QE-$V)BALEVK)AM[ST;G[&1][SGN=XV MSD#.&S5$3#$9B6.\9+Z*[0. Y@92W1O#E>5-B(E))].P3)9O^YQ>;E_F48<^
MHF%2D6&:R2@\DQ5C-.^%@H;Y530://-LR]!CELDI+)-YS2R@+3]QD@T[Z3KI MAPQAN\PQQ^04CLF\9!9B];SKSM'1#(56,N^52^ATXHAA2LEWK)0+964+736\
MN2WD#NS$&)^&O8@=9IA\QX8)@&-Q$"<6KKP^FG8)".T%F\2H@)IR"9$B3*$C%+PXFG()".*F25(R]":>@ M$$XRRPAKD 6FG&*?M;-O95@9QJ3[K-V%D6SQ-Q34K@GB1E%$W-
/2>&>9,X6 M11-S3TGAGB1F%$UTVH;"/4G,*L3$_%-2^.=%!GPF')>=93X);MX,G><+$+%126.@EYF1F5 "O,0A6%A5*8\40R9J&*PD(IS&BBJ<(L
M5%%.YCQOFW$T,0M5^YS>B9Q>HE28A2J2^9U$K2-^A3 +523S.RG,L&W6F(5]DAF>Q*1>%,T:LU!-,L>3F-2+ M,3$+U21UN$2!*\;$+%3OM0[W-L3$++%23U.%2T8Q>(;OC=\K?T-
,S$)S$@M%F'^K5MIQ=EJT(29F MH3GQLH.Q(+O9=.,$/^]"3,Q"\]%"T_%B^^&H%4NI1/L%OL+"\89WS;5A_F.[M?*^L_']Y:!UIW#L2EUJWCXNQW_\5X(/_P)02P,$% @ "8)G6;?' S!"
M @ 0BL !H !X;"]?A)Q1JA 7/X!^H2 MQY=R:,9]>QIV^VY8?!X/IV%5[<:Q^U77PWI7CLUPUW;E=#ZR:?MC,YZ7_;;N MFO5[LRVU+)=1]ID.Q'8G1#O1*"WH-Y"H+>@WD*@
MMTP>M@GT%M1;"/06U%L(!!;46PCT%M1;"/06U%L(]!;46PCT%M1;"/16U%L) M]%;46PGT5M1;"?36R]G4!O1[V=0&!'O9U ;T>]G4!OGWRL)-#;46\GT-M1 M;R?
0VU%O)]#;46\GT#M0[R#0.U#O(- [4.\@T#M0[R#0.U#O(- [4.\@T#LF M/YL0Z!VH=Q#H':AW$.@=]'<0Z)U1[TR@=T:],X'>&?7.!'IGU#O_I-[#^'4H MP[7G>XW7_TFJQ_.YY7KYR_)
[Y^16N>!^TK=B M>7OT%&>'OAOBJMBEY+\S%NL=]3:6SM.05[8N]#;EK^&>>>5OO[3TQL5@85KLA MT9#F::Q1K)<_.:6L?NC3[=<&@]8-JR)0%XO9C]/&,6M56.^[MK8IK[/'H7F7
M,GI.*//):4_Y0T%^S!A7/E!P/.YWX\40MO0:&-#NK%]WL4.'8OIV%$L MSY?XH$>WW;8U-;Y^Z/.1,OI MHD[HM1WY:GHU?GDE&^83I_\XORIS+G O',3 MG(IY8H$^'_)Q?VTSPBFQZ7
MW_';&;_6_V0? J0/"=*' NE#@_1A0/JH0/KX!M+'-4@??('2"(JH'(54CF(J M1T&5HZC*45CE**YR%%@YBJP"15:!(JM D56@R"I09!4HL@H4606*K)%5H$B MJT215:+
(*E%D2BR2A19)8JL$D56B2*K1)%5HLBJP*15:% M(JM"D56AR*I09%4HLFH4636*K!I%5HTBJT:15:/(JE%DU2BR:A19-8JL!D56 M@R*K09'5H,AJ4&0U*+(:%%D-
BJP&15:#(FN%(FN%(FN%(FOUE;+>.;?_S_'3 ML^QM.[SDL^E_I.L_4$! A0#% @ "8)G60=!36*! L0 ! M (! &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4 ")@F=9 M0HV^P>X K @ $0 @
&O 9&]C4')O<',O8V]R92YX M;6Q02P$"% ,4 ")@F=9F5R<(Q & "<)P $P @ ', M 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 (F"9UFGG(*)U04 M .P> 8 " @0T(
!X;"]W;W)K.R%4' #?'0 & @($8 M#@ >&PO=V]R:W-H965T$UL4$L! A0#% @ "8)G65%N MIO:& @ > 8 !@ ("!HQ4 'AL+W=O&PO=V]R:W-H965T M$UL4$L! A0#% @
"8)G630BM#U[$ G^D !@ M ("!Z"0 'AL+W=OPQ=<% !J# M& @($N0 >&PO=V]R:W-H965T$UL4$L! M A0#% @ "8)G6>\M_B<\ P .P< !@ ("!.T8 'AL M+W=O&PO=V]R:W-H965T$UL4$L! A0#% @
"8)G61!1[\.?! >0L !D ("! M%%4 'AL+W=O&PO=V]R:W-H965TYA !X;"]W;W)K&UL4$L! A0#% M @ "8)G6=VOIF?;"0 ?!D !D ("!=6H 'AL+W=O&PO=V]R:W-H965T$UL4$L! A0#% @
"8)G68#$%&6I M! C H !D ("!\GP 'AL+W=O&PO=V]R:W-H965T$UL4$L! A0#% @ "8)G6=8Q9'41"P W!X !D M ("!,8T 'AL+W=O-4. "U* &0 @(%YF >&PO=V]R M:W-H965T$UL
M4$L! A0#% @ "8)G6>9MN[32!0 Z0T !D ("!5:T M 'AL+W=OLP >&PO=V]R:W-H965T$UL4$L! A0#% @ M"8)G6=2 M++Y @ " 8 !D ("!VL, 'AL+W=O&PO=V]R:W-H965T] 8 .\. 9 "
@&UL4$L! A0#% @ "8)G63?Q7MV9 P MZ0@ !D ("!]]$ 'AL+W=O&PO=V]R:W-H965T$UL4$L! A0#% @ "8)G6>!7ZU%]! Q@P !D M ("!E=X 'AL+W=O&PO=V]R:W-H
M965T$UL4$L! M A0#% @ "8)G65G\V:Q(!0 ,PT !D ("!RNL 'AL M+W=OU-;W9D$ M ">"P &0 @(%)\0 >&PO=V]R:W-H965T$UL4$L! A0#% @ "8)G M67,I%+%Y P K0L !D ("!&OH
'AL+W=O&PO=V]R:W-H965T$UL4$L! A0#% @ "8)G68P&PO=V]R:W-H965T$UL4$L! A0#% @ "8)G6;*)"!>" SB< !D M ("!(1L! 'AL+W=O&PO=V]R:W-H965T M$UL4$L! A0# M%
@ "8)G60HEVZ_Z @ B D !D ("!N3@! 'AL+W=O M&PO=V]R:W-H965T$UL4$L! A0#% @ "8)G6;+0 M 0)R! =18 !D ("![6$! 'AL+W=O&PO=V]R:W-H965T$UL4$L! A0#% @
"8)G69#CC)-!@ O"X !D M ("!4FX! 'AL+W=O&PO M=V]R:W-H965TAW 0!X;"]W;W)K&UL4$L! A0#% @ "8)G6:B\.[WT! O!L !D ("! MJ7L! 'AL+W=O&PO=V]R:W-H965T&UL4$L!
A0#% M @ "8)G61J 6-C& @ =@< !D ("!7(&PO=V]R:W-H965T&UL4$L! A0#% @ "8)G697TH;H^ M! 3!8 !D ("!O\\! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "8)G6?
=6]R#X!@ =2L !D M ("!DZ\! 'AL+W=O&PO=V]R M:W-H965T!16 , \. M 9 " @1_+ 0!X;"]W;W)K&UL M4$L! A0#% @ "8)G69,4EZ-*"0 MTL !D ("!KLX! M 'AL+W=O&PO=V]R:W-

H965T&UL4$L! A0#% @ M"8)G67L6[8D4 P @@H !D ("!6=\! 'AL+W=O6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ "8)G6;?' S!" @ 0BL M !H (!)?,! 'AL+U]R96QS+W=O XML 86 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE') {var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 87 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 89 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html5724441false1830false8 falsefalseR1.htm000 - Document - Document And Entity InformationSheethttp://www.opko.com/20240930/role/statement-document-and-entity-informationDocument And Entity InformationCover1 falsefalseR2.htm001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)Sheethttp://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unauditedCondensed Consolidated Balance Sheets (Current Period Unaudited)Statements2 falsefalseR3.htm002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)Sheethttp://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticalsCondensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)Statements3 falsefalseR4.htm003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)Sheethttp://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unauditedCondensed Consolidated Statements of Operations (Unaudited)Statements4 falsefalseR5.htm004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)Sheethttp://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unauditedCondensed Consolidated Statements of Comprehensive Loss (Unaudited)Statements5 falsefalseR6.htm005 - Statement - Consolidated Statements of Equity (Unaudited)Sheethttp://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-Consolidated Statements of Equity (Unaudited)Statements6 falsefalseR7.htm006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)Sheethttp://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unauditedCondensed Consolidated Statements of Cash Flows (Unaudited)Statements7 falsefalseR8.htm007 - Disclosure - Note 1 - Business and OrganizationSheethttp://www.opko.com/20240930/role/statement-note-1-business-and-organizationNote 1 - Business and OrganizationNotes8 falsefalseR9.htm008 - Disclosure - Note 2 - Foreign Exchange RatesSheethttp://www.opko.com/20240930/role/statement-note-2-foreign-exchange-ratesNote 2 - Foreign Exchange RatesNotes9 falsefalseR10.htm009 - Disclosure - Note 3 - Summary of Significant Accounting PoliciesSheethttp://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policiesNote 3 - Summary of Significant Accounting PoliciesNotes10 falsefalseR11.htm010 - Disclosure - Note 4 - Earnings (Loss) Per ShareSheethttp://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-shareNote 4 - Earnings (Loss) Per ShareNotes11 falsefalseR12.htm011 - Disclosure - Note 5 - Composition of Certain Financial Statement CaptionsSheethttp://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captionsNote 5 - Composition of Certain Financial Statement CaptionsNotes12 falsefalseR13.htm012 - Disclosure - Note 6 - InvestmentsSheethttp://www.opko.com/20240930/role/statement-note-6-investmentsNote 6 - InvestmentsNotes13 falsefalseR14.htm013 - Disclosure - Note 7 - DebtSheethttp://www.opko.com/20240930/role/statement-note-7-debtNote 7 - DebtNotes14 falsefalseR15.htm014 - Disclosure - Note 8 - Accumulated Other Comprehensive LossSheethttp://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-lossNote 8 - Accumulated Other Comprehensive LossNotes15 falsefalseR16.htm015 - Disclosure - Note 9 - Fair Value MeasurementsSheethttp://www.opko.com/20240930/role/statement-note-9-fair-value-measurementsNote 9 - Fair Value MeasurementsNotes16 falsefalseR17.htm016 - Disclosure - Note 10 - Derivative ContractsSheethttp://www.opko.com/20240930/role/statement-note-10-derivative-contractsNote 10 - Derivative ContractsNotes17 falsefalseR18.htm017 - Disclosure - Note 11 - Related Party TransactionsSheethttp://www.opko.com/20240930/role/statement-note-11-related-party-transactionsNote 11 - Related Party TransactionsNotes18 falsefalseR19.htm018 - Disclosure - Note 12 - Commitments and ContingenciesSheethttp://www.opko.com/20240930/role/statement-note-12-commitments-and-contingenciesNote 12 - Commitments and ContingenciesNotes19 falsefalseR20.htm019 - Disclosure - Note 13 - Revenue RecognitionSheethttp://www.opko.com/20240930/role/statement-note-13-revenue-recognitionNote 13 - Revenue RecognitionNotes20 falsefalseR21.htm020 - Disclosure - Note 14 - Strategic AlliancesSheethttp://www.opko.com/20240930/role/statement-note-14-strategic-alliancesNote 14 - Strategic AlliancesNotes21 falsefalseR22.htm021 - Disclosure - Note 15 - SegmentsSheethttp://www.opko.com/20240930/role/statement-note-15-segmentsNote 15 - SegmentsNotes22 falsefalseR23.htm022 - Disclosure - Note 16 - LeasesSheethttp://www.opko.com/20240930/role/statement-note-16-leasesNote 16 - LeasesNotes23 falsefalseR24.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes24 falsefalseR25.htm995469 - Disclosure - Significant Accounting Policies (Policies)Sheethttp://www.opko.com/20240930/role/statement-significant-accounting-policies-policiesSignificant Accounting Policies (Policies)Policieshttp://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies25 falsefalseR26.htm995470 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)Sheethttp://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tablesNote 3 - Summary of Significant Accounting Policies (Tables)Tableshttp://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies26 falsefalseR27.htm995471 - Disclosure - Note 4 - Earnings (Loss) Per Share (Tables)Sheethttp://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-tablesNote 4 - Earnings (Loss) Per Share (Tables)Tableshttp://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share27 falsefalseR28.htm995472 - Disclosure - Note 5 - Composition of Certain Financial Statement Captions (Tables)Sheethttp://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-tablesNote 5 - Composition of Certain Financial Statement Captions (Tables)Tableshttp://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions28 falsefalseR29.htm995473 - Disclosure - Note 6 - Investments (Tables)Sheethttp://www.opko.com/20240930/role/statement-note-6-investments-tablesNote 6 - Investments (Tables)Tableshttp://www.opko.com/20240930/role/statement-note-6-investments29 falsefalseR30.htm995474 - Disclosure - Note 7 - Debt (Tables)Sheethttp://www.opko.com/20240930/role/statement-note-7-debt-tablesNote 7 - Debt (Tables)Tableshttp://www.opko.com/20240930/role/statement-note-7-debt30 falsefalseR31.htm995475 - Disclosure - Note 8 - Accumulated Other Comprehensive Loss (Tables)Sheethttp://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-tablesNote 8 - Accumulated Other Comprehensive Loss (Tables)Tableshttp://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss31 falsefalseR32.htm995476 - Disclosure - Note 9 - Fair Value Measurements (Tables)Sheethttp://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-tablesNote 9 - Fair Value Measurements (Tables)Tableshttp://www.opko.com/20240930/role/statement-note-9-fair-value-measurements32 falsefalseR33.htm995477 - Disclosure - Note 10 - Derivative Contracts (Tables)Sheethttp://www.opko.com/20240930/role/statement-note-10-derivative-contracts-tablesNote 10 - Derivative Contracts (Tables)Tableshttp://www.opko.com/20240930/role/statement-note-10-derivative-contracts33 falsefalseR34.htm995478 - Disclosure - Note 13 - Revenue Recognition (Tables)Sheethttp://www.opko.com/20240930/role/statement-note-13-revenue-recognition-tablesNote 13 - Revenue Recognition (Tables)Tableshttp://www.opko.com/20240930/role/statement-note-13-revenue-recognition34 falsefalseR35.htm995479 - Disclosure - Note 15 - Segments (Tables)Sheethttp://www.opko.com/20240930/role/statement-note-15-segments-tablesNote 15 - Segments (Tables)Tableshttp://www.opko.com/20240930/role/statement-note-15-segments35 falsefalseR36.htm995480 - Disclosure - Note 16 - Leases (Tables)Sheethttp://www.opko.com/20240930/role/statement-note-16-leases-tablesNote 16 - Leases (Tables)Tableshttp://www.opko.com/20240930/role/statement-note-16-leases36 falsefalseR37.htm995481 - Disclosure - Note 1 - Business and Organization (Details Textual)Sheethttp://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textualNote 1 - Business and Organization (Details Textual)Detailshttp://www.opko.com/20240930/role/statement-note-1-business-and-organization37 falsefalseR38.htm995482 - Disclosure - Note 2 - Foreign Exchange Rates (Details Textual)Sheethttp://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textualNote 2 - Foreign Exchange Rates (Details Textual)Detailshttp://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates38 falsefalseR39.htm995483 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)Sheethttp://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textualNote 3 - Summary of Significant Accounting Policies (Details Textual)Detailshttp://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables39 falsefalseR40.htm995484 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Reconciliation of Cash (Details)Sheethttp://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-detailsNote 3 - Summary of Significant Accounting Policies - Reconciliation of Cash (Details)Details40 falsefalseR41.htm995485 - Disclosure - Note 4 - Earnings (Loss) Per Share (Details Textual)Sheethttp://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-details-textualNote 4 - Earnings (Loss) Per Share (Details Textual)Detailshttp://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-tables41 falsefalseR42.htm995486 - Disclosure - Note 4 - Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details)Sheethttp://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-detailsNote 4 - Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details)Detailshttp://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-tables42 falsefalseR43.htm995487 - Disclosure - Note 5 - Composition of Certain Financial Statement Captions (Details Textual)Sheethttp://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textualNote 5 - Composition of Certain Financial Statement Captions (Details Textual)Detailshttp://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-tables43 falsefalseR44.htm995488 - Disclosure - Note 5 - Composition of Certain Financial Statement Captions - Schedule of Financial Statement Information (Details)Sheethttp://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-detailsNote 5 - Composition of Certain Financial Statement Captions - Schedule of Financial Statement Information (Details)Details44 falsefalseR45.htm995489 - Disclosure - Note 5 - Composition of Certain Financial Statement Captions - Schedule of Goodwill (Details)Sheethttp://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-detailsNote 5 - Composition of Certain Financial Statement Captions - Schedule of Goodwill (Details)Details45 falsefalseR46.htm995490 - Disclosure - Note 6 - Investments (Details Textual)Sheethttp://www.opko.com/20240930/role/statement-note-6-investments-details-textualNote 6 - Investments (Details Textual)Detailshttp://www.opko.com/20240930/role/statement-note-6-investments-tables46 falsefalseR47.htm995491 - Disclosure - Note 6 - Investments - Schedule of Investments (Details)Sheethttp://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-detailsNote 6 - Investments - Schedule of Investments (Details)Details47 falsefalseR48.htm995492 - Disclosure - Note 6 - Investments - Gains and Losses on Equity Securities (Details)Sheethttp://www.opko.com/20240930/role/statement-note-6-investments-gains-and-losses-on-equity-securities-detailsNote 6 - Investments - Gains and Losses on Equity Securities (Details)Details48 falsefalseR49.htm995493 - Disclosure - Note 7 - Debt (Details Textual)Sheethttp://www.opko.com/20240930/role/statement-note-7-debt-details-textualNote 7 - Debt (Details Textual)Detailshttp://www.opko.com/20240930/role/statement-note-7-debt-tables49 falsefalseR50.htm995494 - Disclosure - Note 7 - Debt - Schedule of Debt (Details)Sheethttp://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-detailsNote 7 - Debt - Schedule of Debt (Details)Details50 falsefalseR51.htm995495 - Disclosure - Note 7 - Debt - Schedule of Long-term Debt (Details)Sheethttp://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-detailsNote 7 - Debt - Schedule of Long-term Debt (Details)Details51 falsefalseR52.htm995496 - Disclosure - Note 7 - Debt - Schedule of Long-term Debt (Details) (Parentheticals)Sheethttp://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details-parentheticalsNote 7 - Debt - Schedule of Long-term Debt (Details) (Parentheticals)Details52 falsefalseR53.htm995497 - Disclosure - Note 7 - Debt - Schedule of Line of Credit Facilities (Details)Sheethttp://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-detailsNote 7 - Debt - Schedule of Line of Credit Facilities (Details)Details53 falsefalseR54.htm995498 - Disclosure - Note 7 - Debt - Schedule of Debt Instruments (Details)Sheethttp://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-detailsNote 7 - Debt - Schedule of Debt Instruments (Details)Details54 falsefalseR55.htm995499 - Disclosure - Note 8 - Accumulated Other

Comprehensive Loss - Changed in Accumulated Other Comprehensive Loss (Details)Sheethttp://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-changed-in-accumulated-other-comprehensive-loss-detailsNote 8 - Accumulated Other Comprehensive Loss - Changed in Accumulated Other Comprehensive Loss (Details)Details55 falsefalseR56.htm995500 - Disclosure - Note 9 - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)Sheethttp://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-detailsNote 9 - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)Details56 falsefalseR57.htm995501 - Disclosure - Note 9 - Fair Value Measurements - Carrying Value and Estimated Fair Value of Notes (Details)Noteshttp://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-detailsNote 9 - Fair Value Measurements - Carrying Value and Estimated Fair Value of Notes (Details)Details57 falsefalseR58.htm995502 - Disclosure - Note 9 - Fair Value Measurements - Reconciliation of Level 3 Instruments (Details)Sheethttp://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-detailsNote 9 - Fair Value Measurements - Reconciliation of Level 3 Instruments (Details)Details58 falsefalseR59.htm995503 - Disclosure - Note 10 - Derivative Contracts - Summary of Fair Values and Presentation of Derivatives Financial Instruments (Details)Sheethttp://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-detailsNote 10 - Derivative Contracts - Summary of Fair Values and Presentation of Derivatives Financial Instruments (Details)Details59 falsefalseR60.htm995504 - Disclosure - Note 10 - Derivative Contracts - Summary of Gains and Losses Recorded (Details)Sheethttp://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-detailsNote 10 - Derivative Contracts - Summary of Gains and Losses Recorded (Details)Details60 falsefalseR61.htm995505 - Disclosure - Note 11 - Related Party Transactions (Details Textual)Sheethttp://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textualNote 11 - Related Party Transactions (Details Textual)Detailshttp://www.opko.com/20240930/role/statement-note-11-related-party-transactions61 falsefalseR62.htm995506 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)Sheethttp://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textualNote 12 - Commitments and Contingencies (Details Textual)Detailshttp://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies62 falsefalseR63.htm995507 - Disclosure - Note 13 - Revenue Recognition (Details Textual)Sheethttp://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textualNote 13 - Revenue Recognition (Details Textual)Detailshttp://www.opko.com/20240930/role/statement-note-13-revenue-recognition-tables63 falsefalseR64.htm995508 - Disclosure - Note 13 - Revenue Recognition - Composition of Revenue From Services (Details)Sheethttp://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-detailsNote 13 - Revenue Recognition - Composition of Revenue From Services (Details)Details64 falsefalseR65.htm995509 - Disclosure - Note 13 - Revenue Recognition - Analysis of Product Sales Allowances and Accruals (Details)Sheethttp://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-detailsNote 13 - Revenue Recognition - Analysis of Product Sales Allowances and Accruals (Details)Details65 falsefalseR66.htm995510 - Disclosure - Note 14 - Strategic Alliances (Details Textual)Sheethttp://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textualNote 14 - Strategic Alliances (Details Textual)Detailshttp://www.opko.com/20240930/role/statement-note-14-strategic-alliances66 falsefalseR67.htm995511 - Disclosure - Note 15 - Segments (Details Textual)Sheethttp://www.opko.com/20240930/role/statement-note-15-segments-details-textualNote 15 - Segments (Details Textual)Detailshttp://www.opko.com/20240930/role/statement-note-15-segments-tables67 falsefalseR68.htm995512 - Disclosure - Note 15 - Segments - Operations by Segment (Details)Sheethttp://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-detailsNote 15 - Segments - Operations by Segment (Details)Details68 falsefalseR69.htm995513 - Disclosure - Note 15 - Segments - Assets by Segment (Details)Sheethttp://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-detailsNote 15 - Segments - Assets by Segment (Details)Details69 falsefalseR70.htm995514 - Disclosure - Note 16 - Leases (Details Textual)Sheethttp://www.opko.com/20240930/role/statement-note-16-leases-details-textualNote 16 - Leases (Details Textual)Detailshttp://www.opko.com/20240930/role/statement-note-16-leases-tables70 falsefalseR71.htm995515 - Disclosure - Note 16 - Leases - Lease Balances (Details)Sheethttp://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-detailsNote 16 - Leases - Lease Balances (Details)Details71 falsefalseR72.htm995516 - Disclosure - Note 16 - Leases - Undiscounted Future Minimum Lease Payments (Details)Sheethttp://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-detailsNote 16 - Leases - Undiscounted Future Minimum Lease Payments (Details)Details72 falsefalseR73.htm995517 - Disclosure - Note 16 - Leases - Supplemental Cash Flow Information (Details)Sheethttp://www.opko.com/20240930/role/statement-note-16-leases-supplemental-cash-flow-information-detailsNote 16 - Leases - Supplemental Cash Flow Information (Details)Details73 falsefalseAll ReportsBookAll Reports opk-20240930.xsdopk-20240930_cal.xmlopk-20240930_def.xmlopk-20240930_lab.xmlopk-20240930_pre.xmlopk20240930_10q.htm http://fasb.org/srt/2024http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 92 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "opk20240930_10q.htm": { "nsprefix": "opk", "nsuri": "http://www.opko.com/20240930", "dts": { "schema": { "local": ["opk-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["opk-20240930_cal.xml"] }, "definitionLink": { "local": ["opk-20240930_def.xml"] }, "labelLink": { "local": ["opk-20240930_lab.xml"] }, "presentationLink": { "local": ["opk-20240930_pre.xml"] }, "inline": { "local": ["opk20240930_10q.htm"] } }, "keyStandard": 377, "keyCustom": 67, "axisStandard": 49, "axisCustom": 0, "memberStandard": 69, "memberCustom": 106, "hidden": { "total": 38, "http://xbrl.sec.gov/dei/2024": 6, "http://fasb.org/us-gaap/2024": 26, "http://www.opko.com/20240930": 2, "http://xbrl.sec.gov/ecd/2024": 4 }, "contextCount": 572, "entityCount": 1, "segmentCount": 183, "elementCount": 788, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1491, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 5, "http://fasb.org/srt/2024": 2 }, "report": { "R1": { "role": "http://www.opko.com/20240930/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "opk:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "opk:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": null, "uniqueAnchor": null }, "R4": { "role": "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R5": { "role": "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited", "longName": "004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R6": { "role": "http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-", "longName": "005 - Statement - Consolidated Statements of Equity (Unaudited)", "shortName": "Consolidated Statements of Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:PaidInKindInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R8": { "role": "http://www.opko.com/20240930/role/statement-note-1-business-and-organization", "longName": "007 - Disclosure - Note 1 - Business and Organization", "shortName": "Note 1 - Business and Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "longName": "008 - Disclosure - Note 2 - Foreign Exchange Rates", "shortName": "Note 2 - Foreign Exchange Rates", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "longName": "009 - Disclosure - Note 3 - Summary of Significant Accounting Policies", "shortName": "Note 3 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef":

"opk20240930_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share", "longName": "010 - Disclosure - Note 4 - Earnings (Loss) Per Share", "shortName": "Note 4 - Earnings (Loss) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "longName": "011 - Disclosure - Note 5 - Composition of Certain Financial Statement Captions", "shortName": "Note 5 - Composition of Certain Financial Statement Captions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.opko.com/20240930/role/statement-note-6-investments", "longName": "012 - Disclosure - Note 6 - Investments", "shortName": "Note 6 - Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.opko.com/20240930/role/statement-note-7-debt", "longName": "013 - Disclosure - Note 7 - Debt", "shortName": "Note 7 - Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss", "longName": "014 - Disclosure - Note 8 - Accumulated Other Comprehensive Loss", "shortName": "Note 8 - Accumulated Other Comprehensive Loss", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements", "longName": "015 - Disclosure - Note 9 - Fair Value Measurements", "shortName": "Note 9 - Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts", "longName": "016 - Disclosure - Note 10 - Derivative Contracts", "shortName": "Note 10 - Derivative Contracts", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "longName": "017 - Disclosure - Note 11 - Related Party Transactions", "shortName": "Note 11 - Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "longName": "018 - Disclosure - Note 12 - Commitments and Contingencies", "shortName": "Note 12 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "longName": "019 - Disclosure - Note 13 - Revenue Recognition", "shortName": "Note 13 - Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "longName": "020 - Disclosure - Note 14 - Strategic Alliances", "shortName": "Note 14 - Strategic Alliances", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.opko.com/20240930/role/statement-note-15-segments", "longName": "021 - Disclosure - Note 15 - Segments", "shortName": "Note 15 - Segments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.opko.com/20240930/role/statement-note-16-leases", "longName": "022 - Disclosure - Note 16 - Leases", "shortName": "Note 16 - Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "opk:LesseeLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "opk:LesseeLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies", "longName": "995469 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "longName": "995470 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)", "shortName": "Note 3 - Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-tables", "longName": "995471 - Disclosure - Note 4 - Earnings (Loss) Per Share (Tables)", "shortName": "Note 4 - Earnings (Loss) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-tables", "longName": "995472 - Disclosure - Note 5 - Composition of Certain Financial Statement Captions (Tables)", "shortName": "Note 5 - Composition of Certain Financial Statement Captions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.opko.com/20240930/role/statement-note-6-investments-tables", "longName": "995473 - Disclosure - Note 6 - Investments (Tables)", "shortName": "Note 6 - Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:InvestmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InvestmentTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:InvestmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InvestmentTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.opko.com/20240930/role/statement-note-7-debt-tables", "longName": "995474 - Disclosure - Note 7 - Debt (Tables)", "shortName": "Note 7 - Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock",

"body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-tables", "longName": "995475 - Disclosure - Note 8 - Accumulated Other Comprehensive Loss (Tables)", "shortName": "Note 8 - Accumulated Other Comprehensive Loss (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-tables", "longName": "995476 - Disclosure - Note 9 - Fair Value Measurements (Tables)", "shortName": "Note 9 - Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-tables", "longName": "995477 - Disclosure - Note 10 - Derivative Contracts (Tables)", "shortName": "Note 10 - Derivative Contracts (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-tables", "longName": "995478 - Disclosure - Note 13 - Revenue Recognition (Tables)", "shortName": "Note 13 - Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.opko.com/20240930/role/statement-note-15-segments-tables", "longName": "995479 - Disclosure - Note 15 - Segments (Tables)", "shortName": "Note 15 - Segments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.opko.com/20240930/role/statement-note-16-leases-tables", "longName": "995480 - Disclosure - Note 16 - Leases (Tables)", "shortName": "Note 16 - Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "opk:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["opk:LesseeLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "opk:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["opk:LesseeLeasesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual", "longName": "995481 - Disclosure - Note 1 - Business and Organization (Details Textual)", "shortName": "Note 1 - Business and Organization (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:EscrowDeposit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-03-28_CounterpartyNameAxis-LabcorpMember_DisposalGroupClassificationAxis-DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsMember_SelectAssetsOfBioreferenceMember", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R38": { "role": "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual", "longName": "995482 - Disclosure - Note 2 - Foreign Exchange Rates (Details Textual)", "shortName": "Note 2 - Foreign Exchange Rates (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "longName": "995483 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 3 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:InventoryWriteDown", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:InventoryWriteDown", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details", "longName": "995484 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Reconciliation of Cash (Details)", "shortName": "Note 3 - Summary of Significant Accounting Policies - Reconciliation of Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-details-textual", "longName": "995485 - Disclosure - Note 4 - Earnings (Loss) Per Share (Details Textual)", "shortName": "Note 4 - Earnings (Loss) Per Share (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details", "longName": "995486 - Disclosure - Note 4 - Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details)", "shortName": "Note 4 - Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "longName": "995487 - Disclosure - Note 5 - Composition of Certain Financial Statement Captions (Details Textual)", "shortName": "Note 5 - Composition of Certain Financial Statement Captions (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "i_2024-09-30_RangeAxis-MinimumMember", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-DevelopedTechnologyRightsMember_RangeAxis-MinimumMember", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R44": { "role": "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details", "longName": "995488 - Disclosure - Note 5 - Composition of Certain Financial Statement Captions - Schedule of Financial Statement Information (Details)", "shortName": "Note 5 - Composition of Certain Financial Statement Captions - Schedule of Financial Statement Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details", "longName": "995489 - Disclosure - Note 5 - Composition of Certain Financial Statement Captions - Schedule of Goodwill (Details)", "shortName": "Note 5 - Composition of Certain Financial Statement Captions - Schedule of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:GoodwillGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:GoodwillGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.opko.com/20240930/role/statement-note-6-investments-

details-textual", "longName": "995490 - Disclosure - Note 6 - Investments (Details Textual)", "shortName": "Note 6 - Investments (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:Assets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2021-09-01_2021-09-30_CounterpartyNameAxis-LeaderMedMember_OwnershipAxis-LeaderMedJointVentureMember", "name": "opk:MinorityInterestSharesIssued", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:InvestmentTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R47": { "role": "http://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-details", "longName": "995491 - Disclosure - Note 6 - Investments - Schedule of Investments (Details)", "shortName": "Note 6 - Investments - Schedule of Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:EquityMethodInvestments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:InvestmentTableTextBlock", "us-gaap:InvestmentTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:EquityMethodInvestments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:InvestmentTableTextBlock", "us-gaap:InvestmentTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.opko.com/20240930/role/statement-note-6-investments-gains-and-losses-on-equity-securities-details", "longName": "995492 - Disclosure - Note 6 - Investments - Gains and Losses on Equity Securities (Details)", "shortName": "Note 6 - Investments - Gains and Losses on Equity Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "us-gaap:InvestmentTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "us-gaap:InvestmentTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "longName": "995493 - Disclosure - Note 7 - Debt (Details Textual)", "shortName": "Note 7 - Debt (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ProceedsFromConvertibleDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-7", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-09_2024-01-09", "name": "us-gaap:TreasuryStockAcquiredAveragePricePerShare", "unitRef": "USDPerShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R50": { "role": "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details", "longName": "995494 - Disclosure - Note 7 - Debt - Schedule of Debt (Details)", "shortName": "Note 7 - Debt - Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LongTermDebtNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R51": { "role": "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details", "longName": "995495 - Disclosure - Note 7 - Debt - Schedule of Long-term Debt (Details)", "shortName": "Note 7 - Debt - Schedule of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_DebtInstrumentAxis-The2029Convertible144ANotesMember", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:LongTermDebtTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R52": { "role": "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details-parentheticals", "longName": "995496 - Disclosure - Note 7 - Debt - Schedule of Long-term Debt (Details) (Parentheticals)", "shortName": "Note 7 - Debt - Schedule of Long-term Debt (Details) (Parentheticals)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "52", "firstAnchor": null, "uniqueAnchor": null }, "R53": { "role": "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details", "longName": "995497 - Disclosure - Note 7 - Debt - Schedule of Line of Credit Facilities (Details)", "shortName": "Note 7 - Debt - Schedule of Line of Credit Facilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd", "unitRef": "Pure", "xsiNil": "true", "lang": null, "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd", "unitRef": "Pure", "xsiNil": "true", "lang": null, "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-details", "longName": "995498 - Disclosure - Note 7 - Debt - Schedule of Debt Instruments (Details)", "shortName": "Note 7 - Debt - Schedule of Debt Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_BalanceSheetLocationAxis-NotesPayableAndOtherLongTermLiabilitiesMember", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R55": { "role": "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-changed-in-accumulated-other-comprehensive-loss-details", "longName": "995499 - Disclosure - Note 8 - Accumulated Other Comprehensive Loss - Changed in Accumulated Other Comprehensive Loss (Details)", "shortName": "Note 8 - Accumulated Other Comprehensive Loss - Changed in Accumulated Other Comprehensive Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_StatementEquityComponentsAxis-AccumulatedTranslationAdjustmentMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R56": { "role": "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details", "longName": "995500 - Disclosure - Note 9 - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)", "shortName": "Note 9 - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:EquityMethodInvestmentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:InvestmentTableTextBlock", "us-gaap:InvestmentTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R57": { "role": "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details", "longName": "995501 - Disclosure - Note 9 - Fair Value Measurements - Carrying Value and Estimated Fair Value of Notes (Details)", "shortName": "Note 9 - Fair Value Measurements - Carrying Value and Estimated Fair Value of Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "i_2024-09-30_DebtInstrumentAxis-The2029ConvertibleNotes1Member_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_LongtermDebtTypeAxis-ConvertibleDebtMember", "name": "us-gaap:NotesPayableFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_DebtInstrumentAxis-The2029ConvertibleNotes1Member_FairValueByMeasurementBasisAxis-CarryingReportedAmountFairValueDisclosureMember_LongtermDebtTypeAxis-ConvertibleDebtMember", "name": "us-gaap:NotesPayableFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details", "longName": "995502 - Disclosure - Note 9 - Fair Value Measurements - Reconciliation of Level 3 Instruments (Details)", "shortName": "Note 9 - Fair Value Measurements - Reconciliation of Level 3 Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "i_2023-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "longName": "995503 - Disclosure - Note 10 - Derivative Contracts - Summary of Fair Values and Presentation of Derivatives Financial Instruments (Details)", "shortName": "Note 10 - Derivative Contracts - Summary of Fair Values and Presentation of Derivatives Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "i_2024-09-30_BalanceSheetLocationAxis-InvestmentNetMember_DerivativeInstrumentRiskAxis-CommonStockOptionsWarrantsMember_HedgingDesignationAxis-NondesignatedMember", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_BalanceSheetLocationAxis-InvestmentNetMember_DerivativeInstrumentRiskAxis-CommonStockOptionsWarrantsMember_HedgingDesignationAxis-NondesignatedMember", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details", "longName": "995504 - Disclosure - Note 10 - Derivative Contracts - Summary of Gains and Losses Recorded (Details)", "shortName": "Note 10 - Derivative Contracts - Summary of Gains and Losses Recorded (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30_HedgingDesignationAxis-NondesignatedMember", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true },

```
"uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_HedgingDesignationAxis-NondesignatedMember", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "longName": "995505 - Disclosure - Note 11 - Related Party Transactions (Details Textual)", "shortName": "Note 11 - Related Party Transactions (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OperatingExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-05-04_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-RuenhuiBiopharmaceuticalsIncMember", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R62": { "role": "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual", "longName": "995506 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)", "shortName": "Note 12 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "longName": "995507 - Disclosure - Note 13 - Revenue Recognition (Details Textual)", "shortName": "Note 13 - Revenue Recognition (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details", "longName": "995508 - Disclosure - Note 13 - Revenue Recognition - Composition of Revenue From Services (Details)", "shortName": "Note 13 - Revenue Recognition - Composition of Revenue From Services (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_HealthCareOrganizationRevenueSourcesAxis-HealthcareInsurersMember_ProductOrServiceAxis-ServiceMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R65": { "role": "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details", "longName": "995509 - Disclosure - Note 13 - Revenue Recognition - Analysis of Product Sales Allowances and Accruals (Details)", "shortName": "Note 13 - Revenue Recognition - Analysis of Product Sales Allowances and Accruals (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30_ProductOrServiceAxis-RayaldeeMember", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "opk:ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R66": { "role": "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "longName": "995510 - Disclosure - Note 14 - Strategic Alliances (Details Textual)", "shortName": "Note 14 - Strategic Alliances (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2021-07-06_OwnershipAxis-Camp4Member", "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R67": { "role": "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual", "longName": "995511 - Disclosure - Note 15 - Segments (Details Textual)", "shortName": "Note 15 - Segments (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember", "name": "opk:NumberOfMajorCustomers", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30_ConcentrationRiskByBenchmarkAxis-RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember", "name": "opk:NumberOfMajorCustomers", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "longName": "995512 - Disclosure - Note 15 - Segments - Operations by Segment (Details)", "shortName": "Note 15 - Segments - Operations by Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:GainLossOnInvestments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R69": { "role": "http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "longName": "995513 - Disclosure - Note 15 - Segments - Assets by Segment (Details)", "shortName": "Note 15 - Segments - Assets by Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:Assets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30_ConsolidationItemsAxis-CorporateNonSegmentMember", "name": "us-gaap:Assets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R70": { "role": "http://www.opko.com/20240930/role/statement-note-16-leases-details-textual", "longName": "995514 - Disclosure - Note 16 - Leases (Details Textual)", "shortName": "Note 16 - Leases (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "opk:LesseeLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "opk:LesseeLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details", "longName": "995515 - Disclosure - Note 16 - Leases - Lease Balances (Details)", "shortName": "Note 16 - Leases - Lease Balances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "opk:AssetsAndLiabilitiesLesseeTableTextBlock", "opk:LesseeLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "unique": true } }, "R72": { "role": "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details", "longName": "995516 - Disclosure - Note 16 - Leases - Undiscounted Future Minimum Lease Payments (Details)", "shortName": "Note 16 - Leases - Undiscounted Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "opk:LesseeLeaseLiabilityMaturityTableTextBlock", "opk:LesseeLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "opk:LesseeLeaseLiabilityMaturityTableTextBlock", "opk:LesseeLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.opko.com/20240930/role/statement-note-16-leases-supplemental-cash-flow-information-details", "longName": "995517 - Disclosure - Note 16 - Leases - Supplemental Cash Flow Information (Details)", "shortName": "Note 16 - Leases - Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "opk:ScheduleOfSupplementalCashFlowInformationOfLeasesTableTextBlock", "opk:LesseeLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "opk:ScheduleOfSupplementalCashFlowInformationOfLeasesTableTextBlock", "opk:LesseeLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "opk20240930_10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": [ "http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsAndOtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details" ], "lang": { "en-us": { "role": { "label": "Other receivables", "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r83", "r960" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details" ], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and
```

service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r242", "r379", "r904"] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r883"] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AccountsReceivableNet", "terseLabel": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": ["r808", "r882", "r987", "r1175", "r1176"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Accounts receivable, net", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r1066"] }, "opk_AccruedClinicalTrials": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "AccruedClinicalTrials", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Clinical trials", "documentation": "Represents the amount of clinical trial costs included in accrued liabilities." } } }, "auth_ref": [] }, "opk_AccruedCommitmentsAndContingenciesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "AccruedCommitmentsAndContingenciesCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies", "documentation": "Represents the amount of commitments and contingencies included in current accrued commitments." } } }, "auth_ref": [] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Employee benefits and severance", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r86"] }, "opk_AccruedExpensePayorOverpaymentReimbursementLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "AccruedExpensePayorOverpaymentReimbursementLiability", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual"], "lang": { "en-us": { "role": { "label": "opk_AccruedExpensePayorOverpaymentReimbursementLiability", "terseLabel": "Accrued Expense, Payor Overpayment Reimbursement, Liability", "documentation": "Amount of liability related to reimbursements for payor overpayments." } } }, "auth_ref": [] }, "opk_AccruedExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "AccruedExpensesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details"], "lang": { "en-us": { "role": { "label": "Accrued Expenses [Member]", "documentation": "Represents accrued expenses." } } }, "auth_ref": [] }, "opk_AccruedGrossToNetProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "AccruedGrossToNetProvision", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Gross to net provision", "documentation": "Represents the amount of net provision costs gross included in accrued liabilities." } } }, "auth_ref": [] }, "opk_AccruedInventoryNotYetBilled": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "AccruedInventoryNotYetBilled", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Inventory received but not invoiced", "documentation": "Amount of inventory not yet billed included in accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Accrued expenses", "totalLabel": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r86"] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r86"] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r86", "r908"] }, "us-gaap_AccruedSalesCommissionCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalesCommissionCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Commissions", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r86", "r908"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses." } } }, "auth_ref": ["r251", "r252", "r253", "r254", "r601"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r19", "r20", "r105", "r243", "r705", "r747", "r748"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r12", "r20", "r568", "r571", "r636", "r743", "r744", "r1037", "r1038", "r1039", "r1051", "r1052", "r1053", "r1055"] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-changed-in-accumulated-other-comprehensive-loss-details"], "lang": { "en-us": { "role": { "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": ["r3", "r12", "r20", "r103", "r104", "r262", "r263", "r610", "r611", "r612", "r613", "r614", "r1037"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r97", "r960", "r1211"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r767", "r1051", "r1052", "r1053", "r1055", "r1136", "r1212"] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "opk_AdjustmentsToAdditionalPaidInCapitalRepurchaseOfConvertibleDebt": { "xbrltype":

"monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalRepurchaseOfConvertibleDebt", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "opk_AdjustmentsToAdditionalPaidInCapitalRepurchaseOfConvertibleDebt", "negatedLabel": "Repurchase of 2029 Convertible Notes", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from repurchase of convertible debt." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "Equity-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r52", "r53", "r519"] }, "opk_AggregateTransactionPriceAllocatedToRemainingPerformanceObligationsExcludingUnexercisedContractOptionsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "AggregateTransactionPriceAllocatedToRemainingPerformanceObligationsExcludingUnexercisedContractOptionsAmount", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_AggregateTransactionPriceAllocatedToRemainingPerformanceObligationsExcludingUnexercisedContractOptionsAmount", "terseLabel": "Aggregate Transaction Price Allocated to Remaining Performance Obligations, Excluding Unexercised Contract Options, Amount", "documentation": "Represents the amount of aggregate transaction price allocated to remaining performance obligations, excluding unexercised contract options." } } }, "auth_ref": [] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "AllCurrenciesDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual"], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent", "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Current", "negatedLabel": "Less: allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": ["r244", "r380", "r389"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "Amortization of debt discount", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": ["r7", "r113", "r471", "r1159"] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "Amortization of debt issuance cost", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": ["r113", "r471", "r1045", "r1159"] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "Amortization of debt discount and debt issuance costs, total", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r471", "r936", "r937", "r1045", "r1159"] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Amortization of intangible assets", "terseLabel": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r7", "r407", "r414", "r932"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r327"] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfRealEstateProperty", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-16-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AreaOfRealEstateProperty", "terseLabel": "Area of Real Estate Property (Acre)", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r557"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "terseLabel": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r149", "r160", "r235", "r280", "r331", "r339", "r365", "r369", "r386", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r447", "r448", "r559", "r563", "r603", "r701", "r813", "r922", "r923", "r960", "r994", "r1111", "r1112", "r1164"] }, "opk_AssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.opko.com/20240930", "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-tables"], "lang": { "en-us": { "role": { "label": "Assets and Liabilities, Lessee [Table Text Block]", "documentation": "Tabular disclosure of lessee's assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r227", "r248", "r280", "r386", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r447", "r448", "r559", "r563", "r603", "r960", "r1111", "r1112", "r1164"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsFairValueDisclosure", "totalLabel": "Total assets", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r578", "r579", "r952"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-details"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r427", "r1178", "r1179"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-details"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r67", "r70", "r427", "r1178", "r1179"] }, "opk_BancoDeSabadellMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "BancoDeSabadellMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Banco De Sabadell [Member]", "documentation": "Relating to Banco De Sabadell." } } }, "auth_ref": [] }, "opk_BankOfChileMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "BankOfChileMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Bank of Chile [Member]", "documentation": "Relating to Bank of Chile." } } }, "auth_ref": [] }, "opk_BardaAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "BardaAgreementMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "BARDA Agreement [Member]", "documentation": "Relating to BARDA Agreement." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "opk_BciBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "BciBankMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "BCI Bank [Member]", "documentation": "Relating to BCI Bank." } } }, "auth_ref": [] }, "opk_BeckmanCoulterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "BeckmanCoulterMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Beckman Coulter [Member]", "documentation": "Represents Beckman Coulter." } } }, "auth_ref": [] }, "opk_BiceBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "BiceBankMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "BICE Bank [Member]", "documentation": "Relating to BICE Bank." } } }, "auth_ref": [] }, "opk_BiocardiaMember": { "xbrltype": "domainItemType", "nsuri":

"http://www.opko.com/20240930", "localname": "BiocardiaMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "BioCardia [Member]", "documentation": "Represents BioCardia." } } }, "auth_ref": [] }, "opk_BioreferenceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "BioreferenceMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "BioReference [Member]", "documentation": "Relating to BioReference." } } }, "auth_ref": [] }, "us-gaap_BridgeLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BridgeLoanMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Bridge Loan [Member]", "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place." } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingAndBuildingImprovementsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "opk_BusinessAcquisitionOutstandingSharesHeldPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.opko.com/20240930", "localname": "BusinessAcquisitionOutstandingSharesHeldPercentage", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "opk_BusinessAcquisitionOutstandingSharesHeldPercentage", "terseLabel": "Business Acquisition, Outstanding Shares Held, Percentage", "documentation": "Represents the percentage of outstanding shares held for business acquisition." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 }, "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Contingent consideration", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": ["r554", "r1044"] }, "opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "opk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwillAndIntangibleAssets", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Goodwill and Intangible Assets", "documentation": "Represents the amount of goodwill and intangible assets acquired as part of a business combination." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": ["r138", "r139", "r140", "r141"] }, "country_CL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CL", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "CHILE" } } }, "auth_ref": [] }, "stpr_CT": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "CT", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "CONNECTICUT" } } }, "auth_ref": [] }, "opk_Camp4Member": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "Camp4Member", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "CAMP4 [Member]", "documentation": "Represents CAMP4." } } }, "auth_ref": [] }, "opk_CapitalizedResearchAndDevelopmentInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CapitalizedResearchAndDevelopmentInProcess", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "In-process research and development", "documentation": "Represents the capitalized costs for research and development in process." } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": ["r75", "r76"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r26", "r230", "r902"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "us-gaap_CashAndCashEquivalentsFairValueDisclosure", "terseLabel": "Money market funds", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1137", "r1138"] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r27"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r26", "r120", "r277"] }, "opk_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsCurrent", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Cash, cash equivalents and current restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r26", "r120", "r277"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r120"] }, "opk_ChangesInFairValueGainLossInEquitySecuritiesFvniAndDerivativeInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ChangesInFairValueGainLossInEquitySecuritiesFvniAndDerivativeInstruments", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-

gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "opk_ChangesInFairValueGainLossInEquitySecuritiesFvniAndDerivativeInstruments", "negatedLabel": "Change in fair value of equity securities and derivative instruments", "documentation": "Amount of unrealized gain (loss) on investment in equity securities and derivative instruments measured at fair value with change in fair value recognized in net income." } } }, "auth_ref": [] }, "opk_ChargebacksDiscountsRebatesAndFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ChargebacksDiscountsRebatesAndFeesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details"], "lang": { "en-us": { "role": { "label": "Chargebacks, Discounts, Rebates and Fees [Member]", "documentation": "Represents Chargebacks, discounts, rebates and fees." } } }, "auth_ref": [] }, "opk_ChileanAndSpanishLinesOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ChileanAndSpanishLinesOfCreditMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "Chilean and Spanish Lines of Credit [Member]", "documentation": "Relating to Chilean and Spanish Lines of Credit." } } }, "auth_ref": [] }, "opk_ChromadexCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ChromadexCorporationMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "ChromaDex Corporation [Member]", "documentation": "Represents ChromaDex Corporation." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preserved stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r180", "r239", "r240", "r241", "r280", "r310", "r315", "r324", "r326", "r333", "r334", "r386", "r438", "r441", "r442", "r443", "r447", "r448", "r477", "r478", "r480", "r481", "r482", "r603", "r758", "r759", "r760", "r761", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r800", "r822", "r843", "r876", "r877", "r878", "r879", "r880", "r1004", "r1046", "r1056"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r483"] }, "opk_ClientPayersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ClientPayersMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details"], "lang": { "en-us": { "role": { "label": "Client Payers [Member]", "documentation": "Represents client payers." } } }, "auth_ref": [] }, "opk_CocpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CocpMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "COCP [Member]", "documentation": "Represents COCP." } } }, "auth_ref": [] }, "opk_CollaborativeAgreementDelayedPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CollaborativeAgreementDelayedPayment", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_CollaborativeAgreementDelayedPayment", "terseLabel": "Collaborative Agreement, Delayed Payment", "documentation": "Amount of delayed payment under collaborative agreement." } } }, "auth_ref": [] }, "opk_CollaborativeAgreementDelayedPaymentReceivedCumulative": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CollaborativeAgreementDelayedPaymentReceivedCumulative", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_CollaborativeAgreementDelayedPaymentReceivedCumulative", "terseLabel": "Collaborative Agreement, Delayed Payment Received, Cumulative", "documentation": "Amount of cumulative delayed payment received under collaborative agreement." } } }, "auth_ref": [] }, "opk_CollaborativeAgreementOptionSalesMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CollaborativeAgreementOptionSalesMilestonePayments", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_CollaborativeAgreementOptionSalesMilestonePayments", "terseLabel": "Collaborative Agreement, Option, Sales Milestone Payments", "documentation": "Amount of sales milestone payment of option in collaborative arrangement." } } }, "auth_ref": [] }, "opk_CollaborativeAgreementsEachMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CollaborativeAgreementsEachMilestonePayment", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_CollaborativeAgreementsEachMilestonePayment", "terseLabel": "Collaborative Agreements, Each Milestone Payment", "documentation": "Amount of each milestone payment under collaborative agreements." } } }, "auth_ref": [] }, "opk_CollaborativeArrangementDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CollaborativeArrangementDevelopmentCosts", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_CollaborativeArrangementDevelopmentCosts", "terseLabel": "Collaborative Arrangement, Development Costs", "documentation": "Represents the development costs related to collaborative arrangements." } } }, "auth_ref": [] }, "opk_CollaborativeArrangementDevelopmentMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CollaborativeArrangementDevelopmentMilestonePayment", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_CollaborativeArrangementDevelopmentMilestonePayment", "terseLabel": "Collaborative Arrangement, Development Milestone Payment", "documentation": "Amount of development milestone payment from collaborative arrangement." } } }, "auth_ref": [] }, "opk_CollaborativeArrangementDevelopmentMilestonePaymentShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CollaborativeArrangementDevelopmentMilestonePaymentShares", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_CollaborativeArrangementDevelopmentMilestonePaymentShares", "terseLabel": "Collaborative Arrangement, Development Milestone Payment, Shares (in shares)", "documentation": "The number of shares for development milestone payment in collaborative arrangement." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": ["r166", "r168", "r179"] }, "opk_CollaborativeArrangementMaximumRegulatoryMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CollaborativeArrangementMaximumRegulatoryMilestonePayments", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_CollaborativeArrangementMaximumRegulatoryMilestonePayments", "terseLabel": "Collaborative Arrangement, Maximum Regulatory Milestone Payments", "documentation": "Represents maximum regulatory milestone payments under collaborative agreement." } } }, "auth_ref": [] }, "opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale": { "xbrltype": "durationItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CollaborativeArrangementPeriodFollowingFirstCommercialSale", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_CollaborativeArrangementPeriodFollowingFirstCommercialSale", "terseLabel": "Collaborative Arrangement, Period Following First Commercial Sale (Year)", "documentation": "Period following from first commercial sale for collaborative arrangement." } } }, "auth_ref": [] }, "opk_CollaborativeArrangementSalesMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CollaborativeArrangementSalesMilestonePayment", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_CollaborativeArrangementSalesMilestonePayment", "terseLabel": "Collaborative Arrangement, Sales Milestone Payment", "documentation": "Amount of sales milestone payment in collaborative arrangement." } } }, "auth_ref": [] }, "opk_CollaborativeArrangementSupplementForAdvanceOfDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CollaborativeArrangementSupplementForAdvanceOfDevelopment", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_CollaborativeArrangementSupplementForAdvanceOfDevelopment", "terseLabel": "Collaborative Arrangement, Supplement for Advance of Development", "documentation": "Amount of supplement for advance of development under the arrangement." } } }, "auth_ref": [] }, "opk_CollaborativeArrangementUpfrontPaymentShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CollaborativeArrangementUpfrontPaymentShares", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_CollaborativeArrangementUpfrontPaymentShares", "terseLabel": "Collaborative Arrangement, Upfront Payment, Shares (in shares)", "documentation": "The number of shares issued as upfront payment for collaborative arrangement." } } }, "auth_ref": [] }, "opk_CollaborativeArrangementValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CollaborativeArrangementValue", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_CollaborativeArrangementValue", "terseLabel": "Collaborative Arrangement, Value", "documentation": "Value of collaborative arrangement." } } }, "auth_ref": [] }, "opk_CollaborativeArrangementValueIncludingMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CollaborativeArrangementValueIncludingMilestones", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "opk_CollaborativeArrangementValueIncludingMilestones", "terseLabel": "Collaborative Arrangement, Value, Including Milestones", "documentation": "Value of collaborative arrangement including milestones." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r128", "r430", "r431", "r884", "r1098", "r1103"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r984", "r985", "r986", "r988", "r989", "r990", "r991", "r1051", "r1052", "r1055", "r1136", "r1208", "r1212"] }, "opk_CommonStockOptionsAndWarrantsNetExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CommonStockOptionsAndWarrantsNetExercised", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock options, warrants, and restricted stock units surrendered in net exercise", "documentation": "Monetary amount of common stock options and warrants surrendered in net exercise." } } }, "auth_ref": [] }, "opk_CommonStockOptionsWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CommonStockOptionsWarrantsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details"], "lang": { "en-us": { "role": { "label": "Common Stock Options/ Warrants [Member]", "documentation": "Represents Common Stock options/warrants." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r96"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-

parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r96", "r800"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r96"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "us-gaap_CommonStockSharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r13", "r96", "r800", "r819", "r1212", "r1213"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Common Stock - $0.01 par value, 1,250,000,000 shares authorized; 712,283,206 and 781,936,885 shares issued at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r96", "r704", "r960"] }, "opk_CommonwealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CommonwealthMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Commonwealth [Member]", "documentation": "Represents Commonwealth." } } }, "auth_ref": [] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Compensation Related Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": ["r136", "r137"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive income (loss)", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r21", "r257", "r259", "r266", "r695", "r714", "r715"] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": ["r102", "r265", "r694", "r713"] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r34", "r35", "r77", "r78", "r377", "r883"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r34", "r35", "r77", "r78", "r377", "r750", "r883"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r34", "r35", "r77", "r78", "r377", "r883", "r1012"] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r81", "r170"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r34", "r35", "r77", "r78", "r377"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r34", "r35", "r77", "r78", "r377", "r883"] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": ["r181", "r201", "r285", "r559", "r560", "r563", "r564", "r644", "r890", "r1019", "r1022", "r1023", "r1110", "r1113", "r1114"] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "documentation": "Entity or group of entities consolidated into reporting entity." } } }, "auth_ref": ["r181", "r201", "r285", "r559", "r560", "r563", "r564", "r644", "r890", "r1019", "r1022", "r1023", "r1110", "r1113", "r1114"] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": ["r158", "r181", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r285", "r331", "r341", "r363", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r438", "r439", "r440", "r441", "r443", "r444", "r445", "r446", "r447", "r922", "r923", "r1020", "r1021", "r1111", "r1112"] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": ["r158", "r181", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r285", "r331", "r341", "r363", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r438", "r439", "r440", "r441", "r443", "r444", "r445", "r446", "r447", "r922", "r923", "r1020", "r1021", "r1111", "r1112"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r59", "r912"] }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)." } } }, "auth_ref": ["r58", "r60", "r61"] }, "opk_ConsorcioBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ConsorcioBankMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Consorcio Bank [Member]", "documentation": "Represents Consorcio Bank." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiability", "terseLabel": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r485", "r486", "r506"] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-

financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiabilityNoncurrent", "terseLabel": "Contract liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": ["r485", "r486", "r506"] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r507"] }, "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "terseLabel": "Contract with Customer, Performance Obligation Satisfied in Previous Period", "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price." } } }, "auth_ref": ["r493"] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "2025 Notes (in shares)", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r29", "r30", "r31"] }, "opk_ConversionOfThe2025NotesIntoCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ConversionOfThe2025NotesIntoCommonStockMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Conversion of the 2025 Notes into Common Stock [Member]", "documentation": "Represents the conversion of the 2025 notes into common stock." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ConvertibleDebt", "terseLabel": "Convertible Debt", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": ["r18", "r152", "r1174"] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": ["r130", "r450", "r451", "r461", "r462", "r463", "r467", "r468", "r469", "r470", "r471", "r933", "r934", "r935", "r936", "r937"] }, "us-gaap_ConvertibleLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleLongTermNotesPayable", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Long term portion of convertible notes", "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": ["r18"] }, "opk_ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ConvertibleNotesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "Convertible Notes [Member]", "documentation": "Relating to Convertible Notes." } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Current portion of convertible notes", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": ["r86"] }, "us-gaap_CorporateJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateJointVentureMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "Corporate Joint Venture [Member]", "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project." } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": ["r16", "r364", "r365", "r366", "r367", "r370", "r1061"] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r107", "r108", "r654"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-1-business-and-organization", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": ["r217", "r218", "r282", "r283", "r453", "r479", "r642", "r650", "r699", "r909", "r911"] }, "opk_CreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CreditAgreementMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Credit Agreement [Member]", "documentation": "Relating to a credit agreement." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r437", "r1108"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r437", "r1108", "r1109"] }, "opk_CurnaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CurnaMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "CURNA [Member]", "documentation": "Relating to CURNA." } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CurrencyAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual"], "lang": { "en-us": { "role": { "label": "Currency [Axis]", "documentation": "Information by currency." } } }, "auth_ref": ["r1156"] }, "opk_CurrencyConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "CurrencyConcentrationRiskMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual"], "lang": { "en-us": { "role": { "label": "Currency Concentration Risk [Member]", "documentation": "Represents currency concentration risk." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r123", "r377"] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r56", "r1086", "r1087", "r1088", "r1089", "r1091", "r1092", "r1094", "r1095"] }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionByUniqueDescriptionAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Conversion Description [Axis]", "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction." } } }, "auth_ref": ["r29", "r31"] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionConvertedInstrumentAmount1", "terseLabel": "Debt Conversion, Converted Instrument, Amount", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r29", "r31"] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1", "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": ["r29", "r31"] }, "opk_DebtConversionDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "DebtConversionDebtIssuanceCosts", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "opk_DebtConversionDebtIssuanceCosts", "terseLabel": "Repurchase", "documentation": "The

amount of the debt issuance costs on original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [] }, "us-gaap_DebtConversionNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionNameDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Conversion, Name [Domain]", "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r29", "r31"] }, "us-gaap_DebtConversionOriginalDebtAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionOriginalDebtAmount1", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionOriginalDebtAmount1", "terseLabel": "Debt Conversion, Original Debt, Amount", "negatedTerseLabel": "Repurchase", "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r29", "r31"] }, "opk_DebtConversionOriginalDebtNetAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "DebtConversionOriginalDebtNetAmount", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "opk_DebtConversionOriginalDebtNetAmount", "negatedTerseLabel": "Repurchase", "documentation": "The amount of the original debt, less discounts and costs, being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [] }, "opk_DebtConversionUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "DebtConversionUnamortizedDiscount", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "opk_DebtConversionUnamortizedDiscount", "terseLabel": "Repurchase", "documentation": "The amount of the unamortized discount on debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r129", "r279", "r422", "r423", "r424", "r425", "r426", "r436", "r437", "r449", "r455", "r456", "r457", "r458", "r459", "r460", "r465", "r472", "r473", "r474", "r616"] }, "opk_DebtInstrumentAdditionalAuthorizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "DebtInstrumentAdditionalAuthorizedAmount", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "opk_DebtInstrumentAdditionalAuthorizedAmount", "terseLabel": "Debt Instrument, Additional Authorized Amount", "documentation": "The additional authorized amount for debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details-parentheticals", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r18", "r85", "r86", "r150", "r152", "r285", "r450", "r451", "r452", "r453", "r454", "r456", "r461", "r462", "r463", "r464", "r466", "r467", "r468", "r469", "r470", "r471", "r933", "r934", "r935", "r936", "r937", "r958", "r1047", "r1099", "r1100", "r1101", "r1158", "r1160"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentCarryingAmount", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": ["r18", "r152", "r475"] }, "opk_DebtInstrumentConvertibleConversionPremiumPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.opko.com/20240930", "localname": "DebtInstrumentConvertibleConversionPremiumPerShare", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "opk_DebtInstrumentConvertibleConversionPremiumPerShare", "terseLabel": "Debt Instrument, Convertible, Conversion Premium, Per Share (in dollars per share)", "documentation": "The per share amount of conversion premium for convertible debt instrument." } } }, "auth_ref": [] }, "opk_DebtInstrumentConvertibleConversionPremiumPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.opko.com/20240930", "localname": "DebtInstrumentConvertibleConversionPremiumPercent", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "opk_DebtInstrumentConvertibleConversionPremiumPercent", "terseLabel": "Debt Instrument, Convertible, Conversion Premium, Percent", "documentation": "The percent conversion premium of convertible debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleConversionPrice1", "terseLabel": "Debt Instrument, Convertible, Conversion Price (in dollars per share)", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": ["r131", "r452"] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleConversionRatio1", "terseLabel": "Debt Instrument, Convertible, Conversion Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": ["r48", "r89", "r133", "r134", "r452"] }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "terseLabel": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "terseLabel": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleThresholdTradingDays", "terseLabel": "Debt Instrument, Convertible, Threshold Trading Days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "opk_DebtInstrumentEarlyExtinguishmentPercentOfPrincipalAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.opko.com/20240930", "localname": "DebtInstrumentEarlyExtinguishmentPercentOfPrincipalAmount", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "opk_DebtInstrumentEarlyExtinguishmentPercentOfPrincipalAmount", "terseLabel": "Debt Instrument, Early Extinguishment, Percent of Principal Amount", "documentation": "The percent of principal amount required to be paid for early extinguishment of debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r450", "r616", "r617", "r934", "r935", "r958"] }, "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "Issuance of 3.75% 2029 convertible notes, total", "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period." } } }, "auth_ref": ["r1047"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details-parentheticals"], "lang": { "en-us": { "role": { "verboseLabel": "Interest rate, convertible notes", "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r88", "r451"] }, "us-gaap_DebtInstrumentIssuedPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIssuedPrincipal", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentIssuedPrincipal", "terseLabel": "Debt Instrument, Issued, Principal", "documentation": "Amount of principal of debt issued." } } }, "auth_ref": ["r758"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details-parentheticals", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r18", "r285", "r450", "r451", "r452", "r453", "r454", "r456", "r461", "r462", "r463", "r464", "r466", "r467", "r468", "r469", "r470", "r471", "r933", "r934", "r935", "r936", "r937", "r958", "r1047", "r1099", "r1100", "r1101", "r1158", "r1160"] }, "opk_DebtInstrumentOwnershipInterest": { "xbrltype": "percentItemType", "nsuri": "http://www.opko.com/20240930", "localname": "DebtInstrumentOwnershipInterest", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "opk_DebtInstrumentOwnershipInterest", "terseLabel": "Debt Instrument, Ownership Interest", "documentation": "Pertains to ownership interest in the aggregate principal amount." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information by period of debt redemption feature under terms of debt agreement." } } },

"auth_ref": ["r156"] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": ["r156"] }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodOneMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period One [Member]", "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": ["r156"] }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPeriodTwoMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period Two [Member]", "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": ["r156"] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentRedemptionPricePercentage", "terseLabel": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": ["r156"] }, "opk_DebtInstrumentRepaymentFeePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.opko.com/20240930", "localname": "DebtInstrumentRepaymentFeePercent", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "opk_DebtInstrumentRepaymentFeePercent", "terseLabel": "Debt Instrument, Repayment Fee, Percent", "documentation": "The repayment fee percent for a debt instrument." } } }, "auth_ref": [] }, "opk_DebtInstrumentRepaymentFeeRoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.opko.com/20240930", "localname": "DebtInstrumentRepaymentFeeRoyaltyPercentage", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "opk_DebtInstrumentRepaymentFeeRoyaltyPercentage", "terseLabel": "Debt Instrument, Repayment Fee, Royalty Percentage", "documentation": "Represents the percentage of future royalties payments that would be considered a fee for repayment of a debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRepurchaseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepurchaseAmount", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentRepurchaseAmount", "terseLabel": "Debt Instrument, Repurchase Amount", "documentation": "Fair value amount of debt instrument that was repurchased." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentSinkingFundPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentSinkingFundPayment", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentSinkingFundPayment", "terseLabel": "Debt Instrument, Sinking Fund Payment", "documentation": "Amount paid into a fund, which is used to retire the debt instrument." } } }, "auth_ref": ["r48", "r1107"] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentTerm", "terseLabel": "Debt Instrument, Term (Year)", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Balance, discount", "negatedPeriodEndLabel": "Balance, discount", "label": "us-gaap_DebtInstrumentUnamortizedDiscount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": ["r1116", "r1157", "r1158", "r1160"] }, "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration", "terseLabel": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]", "documentation": "Indicates type of variable interest rate on debt instrument." } } }, "auth_ref": ["r698"] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtWeightedAverageInterestRate", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtWeightedAverageInterestRate", "terseLabel": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "negatedPeriodEndLabel": "Balance, debt issuance cost", "label": "us-gaap_DeferredFinanceCostsNet", "periodStartLabel": "Balance, debt issuance cost", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r1116", "r1157", "r1158", "r1160"] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Deferred income tax (benefit) provision", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r7", "r176", "r1049"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": ["r531", "r532", "r702"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r7", "r44"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": 1.0, "order": 15.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r7", "r331", "r344", "r369", "r922", "r923"] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "us-gaap_DerivativeAssets", "terseLabel": "Common stock options/warrants", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r249", "r250", "r578", "r579", "r592", "r602", "r779", "r780", "r781", "r782", "r783", "r785", "r786", "r787", "r789", "r790", "r806", "r807", "r861", "r866", "r869", "r870", "r871", "r872", "r911", "r952", "r954", "r986", "r1139", "r1140", "r1141", "r1209"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual"], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r787", "r790", "r805", "r806", "r807", "r809", "r810", "r811", "r812", "r814", "r815", "r816", "r817", "r830", "r831", "r832", "r833", "r836", "r837", "r838", "r839", "r861", "r863", "r869", "r871", "r984", "r986", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1149", "r1150"] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_DerivativeFairValueOfDerivativeNet", "terseLabel": "Derivative financial instruments", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": ["r602"] }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details"], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments, Liabilities [Member]", "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect." } } }, "auth_ref": ["r593"] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details"], "lang": { "en-us": { "role": { "label": "us-gaap_DerivativeGainLossOnDerivativeNet", "terseLabel": "Derivative gain (loss)", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": ["r1133"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r68", "r71", "r72", "r147", "r787", "r790", "r805", "r806", "r807", "r809", "r810", "r811", "r812", "r814", "r815", "r816", "r817", "r830", "r831", "r832", "r833", "r836", "r837", "r838", "r839", "r861", "r863", "r869", "r871", "r911", "r984", "r986", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1149", "r1150"] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts"], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": ["r145", "r566", "r573"] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "us-gaap_DerivativeLiabilities", "terseLabel": "Forward contracts", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r249", "r250", "r578", "r579", "r592", "r602", "r779", "r780", "r781", "r782", "r785", "r786", "r787", "r789", "r790", "r814", "r816", "r817", "r863", "r864", "r866", "r869", "r870", "r871", "r872", "r911", "r1139", "r1140", "r1141", "r1209"] }, "us-

gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": ["http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DerivativeNotionalAmount", "terseLabel": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": ["r1131", "r1132"] }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNumberOfInstrumentsHeld", "presentation": ["http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DerivativeNumberOfInstrumentsHeld", "terseLabel": "Derivative, Number of Instruments Held", "documentation": "The number of derivative instruments of a particular group held by the entity." } } }, "auth_ref": ["r64", "r65", "r789", "r861", "r862", "r865", "r986"] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": ["r14", "r62", "r63", "r66", "r73", "r284", "r304"] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual"], "lang": { "en-us": { "role": { "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": ["r142", "r1086", "r1087", "r1088", "r1089", "r1091", "r1092", "r1094", "r1095"] }, "opk_DevelopmentAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "DevelopmentAndLicenseAgreementMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "Development and License Agreement [Member]", "documentation": "Represents Development and License Agreement." } } }, "auth_ref": [] }, "opk_DiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "DiagnosticsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Diagnostics [Member]", "documentation": "Represents Diagnostics." } } }, "auth_ref": [] }, "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "Add: Loss on buy back of 2029 Convertible Notes", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units." } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Director [Member]", "documentation": "Person serving on board of directors." } } }, "auth_ref": ["r1024", "r1065", "r1210"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-tables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r1118"] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-note-1-business-and-organization", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-16-leases", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements"], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-1-business-and-organization", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": ["r225"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-1-business-and-organization", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-1-business-and-organization", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": ["r4", "r8", "r15"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration", "terseLabel": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 2.0 }, "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "negatedLabel": "Gain on sale of assets", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": ["r420", "r1045", "r1096"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-1-business-and-organization", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r945", "r946"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r998"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r999"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "opk_DravetSyndromeProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "DravetSyndromeProductsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "Dravet Syndrome Products [Member]", "documentation": "Represents Dravet syndrome products." } } }, "auth_ref": [] }, "country_ES": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "ES", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "SPAIN" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Income (loss) per share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "Income (loss) per share, basic (in dollars per share)", "terseLabel": "Loss per share, basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r267", "r296", "r297", "r298", "r299", "r300", "r301", "r307", "r310", "r324", "r325", "r326", "r330", "r552", "r556", "r575", "r576", "r696", "r716", "r914"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-

share-details"], "lang": { "en-us": { "role": { "label": "Income (loss) per share, diluted (in dollars per share)", "terseLabel": "Loss per share, diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r267", "r296", "r297", "r298", "r299", "r300", "r301", "r310", "r324", "r325", "r326", "r330", "r552", "r556", "r575", "r576", "r696", "r716", "r914"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r306", "r327", "r328", "r329"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1153"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": ["r281", "r534", "r546", "r949"] }, "opk_EirgenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "EirgenMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "EirGen [Member]", "documentation": "Represents EirGen." } } }, "auth_ref": [] }, "opk_EloxxPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "EloxxPharmaceuticalsIncMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Eloxx Pharmaceuticals, Inc. [Member]", "documentation": "Relating to Eloxx Pharmaceuticals, Inc." } } }, "auth_ref": [] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "terseLabel": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } }, "auth_ref": ["r146", "r1139", "r1140", "r1141"] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Balance, embedded conversion option", "label": "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet", "periodEndLabel": "Balance, embedded conversion option", "documentation": "Net fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as assets, net of those classified as liabilities." } } }, "auth_ref": ["r9", "r1139", "r1140", "r1141"] }, "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeFinancialInstrumentsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details"], "lang": { "en-us": { "role": { "label": "Embedded Derivative Financial Instruments [Member]", "documentation": "Derivative instrument embedded in host contract." } } }, "auth_ref": [] }, "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "verboseLabel": "Change in fair value of embedded derivative, total", "label": "Change in fair value of embedded derivative", "terseLabel": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net", "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period." } } }, "auth_ref": ["r1134"] }, "us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "us-gaap_EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity", "terseLabel": "Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity", "negatedLabel": "Reclassification of embedded derivative to equity", "documentation": "The amount of the liability for the conversion option reclassified to stockholders' equity when the embedded option no longer required separation from the host instrument." } } }, "auth_ref": ["r74"] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r996"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-document-and-entity-information", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-tables", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-tables", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-tables", "http://www.opko.com/20240930/role/statement-note-16-leases", "http://www.opko.com/20240930/role/statement-note-16-leases-details-textual", "http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details", "http://www.opko.com/20240930/role/statement-note-16-leases-supplemental-cash-flow-information-details", "http://www.opko.com/20240930/role/statement-note-16-leases-tables", "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-details-textual", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-tables", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-tables", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments-gains-and-losses-on-equity-securities-details", "http://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-details", "http://www.opko.com/20240930/role/statement-note-6-investments-tables", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details-parentheticals",

"http://www.opko.com/20240930/role/statement-note-7-debt-tables", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-changed-in-accumulated-other-comprehensive-loss-details", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-tables", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-tables", "http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r996"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r996"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r1002"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r996"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r996"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r996"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r996"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-changed-in-accumulated-other-comprehensive-loss-details"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r13", "r223", "r261", "r262", "r263", "r291", "r292", "r293", "r295", "r300", "r302", "r304", "r332", "r387", "r388", "r419", "r484", "r544", "r545", "r549", "r550", "r551", "r553", "r555", "r556", "r567", "r568", "r569", "r570", "r571", "r572", "r574", "r609", "r610", "r611", "r612", "r613", "r614", "r618", "r619", "r636", "r713", "r743", "r744", "r745", "r767", "r843"] }, "opk_EquityInvestmentsCarryingValueOfEquityIntruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "EquityInvestmentsCarryingValueOfEquityIntruments", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-details"], "lang": { "en-us": { "role": { "label": "Warrants and options", "documentation": "Represents the carrying value of equity instruments held as part of equity investments." } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": ["r383", "r384", "r385", "r548", "r1006", "r1007", "r1008", "r1124", "r1125", "r1126", "r1127"] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Nonconsolidated Investee [Axis]", "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": ["r226", "r280", "r386", "r603", "r657", "r658", "r663", "r670", "r677", "r678", "r689", "r691", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972"] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Nonconsolidated Investee [Domain]", "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": ["r226", "r280", "r386", "r603", "r657", "r658", "r663", "r670", "r677", "r678", "r689", "r691", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972"] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]", "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity." } } }, "auth_ref": ["r1026", "r1048", "r1071", "r1152"] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EquityMethodInvestmentOwnershipPercentage", "terseLabel": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": ["r383"] }, "us-gaap_EquityMethodInvestmentQuotedMarketValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentQuotedMarketValue", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EquityMethodInvestmentQuotedMarketValue", "terseLabel": "Equity Method Investment, Quoted Market Value", "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available." } } }, "auth_ref": ["r385"] }, "us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentUnderlyingEquityInNetAssets", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-details"], "lang": { "en-us": { "role": { "label": "Equity method investments, underlying value", "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity." } } }, "auth_ref": ["r1070"] }, "opk_EquityMethodInvestmentVariableInterestEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "EquityMethodInvestmentVariableInterestEntity", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-details"], "lang": { "en-us": { "role": { "label": "opk_EquityMethodInvestmentVariableInterestEntity", "terseLabel": "Variable interest entity, equity method", "documentation": "Amount of variable interest entities included equity method investments." } } }, "auth_ref": [] }, "opk_EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-details"], "lang": { "en-us": { "role": { "label": "Variable interest entity, equity method", "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity for a variable interest entities." } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-details"], "lang": { "en-us": { "role": { "label": "Equity method investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": ["r331", "r350", "r369", "r382", "r1028", "r1070"] }, "us-gaap_EquityMethodInvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Equity method investments - FV option", "terseLabel": "Equity Method - Fair value option", "documentation": "Fair value portion of investments accounted under the equity method." } } }, "auth_ref": ["r1029", "r1137", "r1138", "r1148"] }, "us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee", "terseLabel": "Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage", "documentation": "Percentage of ownership of equity interest excluding interest in entity that is consolidated and equity method investee." } } }, "auth_ref": ["r1010"] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "us-gaap_EquitySecuritiesFvNi", "terseLabel": "Equity securities", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": ["r236", "r599", "r905"] }, "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-details"], "lang": { "en-us": { "role": { "label": "Equity securities", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r236", "r578", "r599", "r699", "r700", "r952", "r981", "r983", "r1139", "r1140", "r1141"] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"EquitySecuritiesFvNiGainLoss", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-gains-and-losses-on-equity-securities-details"], "lang": { "en-us": { "role": { "label": "Net gains and losses recognized during the period on equity securities", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r720", "r1069"] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-gains-and-losses-on-equity-securities-details"], "lang": { "en-us": { "role": { "label": "Less: Net gains and losses realized during the period on equity securities", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r718", "r1069"] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-gains-and-losses-on-equity-securities-details"], "lang": { "en-us": { "role": { "label": "Unrealized net losses recognized during the period on equity securities still held at the reporting date", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r719", "r1069"] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-details"], "lang": { "en-us": { "role": { "label": "Equity securities with no readily determinable fair value", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": ["r381"] }, "us-gaap_EscrowDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EscrowDeposit", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Escrow receivable", "terseLabel": "Escrow Deposit", "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy." } } }, "auth_ref": ["r148", "r885"] }, "opk_EstadoBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "EstadoBankMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Estado Bank [Member]", "documentation": "Relating to Estado Bank." } } }, "auth_ref": [] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": ["r463", "r602", "r934", "r935"] }, "srt_ExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ExecutiveOfficerMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]", "documentation": "Person with designation of executive officer." } } }, "auth_ref": ["r1065"] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-tables"], "lang": { "en-us": { "role": { "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": ["r75"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r463", "r510", "r511", "r512", "r513", "r514", "r515", "r577", "r579", "r580", "r581", "r582", "r591", "r592", "r594", "r645", "r646", "r647", "r934", "r935", "r942", "r943", "r944", "r952", "r954"] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details"], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": ["r583", "r584", "r585", "r586", "r587", "r588", "r593"] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": ["r463", "r934", "r935"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r578", "r579", "r580", "r582", "r952", "r1140", "r1151"] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r587", "r589", "r590", "r591", "r594", "r595", "r596", "r597", "r598", "r692", "r952", "r955"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r463", "r510", "r515", "r579", "r592", "r645", "r942", "r943", "r944", "r952"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r463", "r510", "r515", "r579", "r580", "r592", "r646", "r934", "r935", "r942", "r943", "r944", "r952"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r463", "r510", "r511", "r512", "r513", "r514", "r515", "r579", "r580", "r581", "r582", "r592", "r647", "r934", "r935", "r942", "r943", "r944", "r952", "r954"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details"], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": ["r583", "r584", "r585", "r586", "r587", "r588", "r593"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-tables"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r583", "r588", "r593"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r578", "r579", "r580", "r582", "r952", "r1140", "r1151"] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "negatedLabel": "Reclassification of embedded derivatives to equity", "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy." } } }, "auth_ref": ["r587", "r593"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details"], "lang": { "en-us": { "role": { "label": "Included in results of operations", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": ["r584", "r593"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": [

"http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details"], "lang": { "en-us": { "role": { "label": "Additions", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r586", "r593"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodStartLabel": "Balance at December 31, 2023", "periodEndLabel": "Balance at September 30, 2024", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r583", "r593"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r463", "r510", "r511", "r512", "r513", "r514", "r515", "r577", "r579", "r580", "r581", "r582", "r591", "r592", "r594", "r645", "r646", "r647", "r934", "r935", "r942", "r943", "r944", "r952", "r954"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r952", "r1137", "r1138", "r1139", "r1140", "r1141", "r1151"] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseInterestExpense", "terseLabel": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": ["r622", "r626", "r959"] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-supplemental-cash-flow-information-details": { "parentTag": "opk_PaymentsForLeases", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-supplemental-cash-flow-information-details"], "lang": { "en-us": { "role": { "label": "Operating cash out flows from finance leases", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": ["r624", "r629"] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "verboseLabel": "Total lease liabilities, finance", "label": "us-gaap_FinanceLeaseLiability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": ["r621", "r633"] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Finance leases short-term", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": ["r621"] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "verboseLabel": "Other long-term liabilities", "label": "Finance leases long-term", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": ["r621"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "totalLabel": "Total undiscounted future minimum lease payments, finance", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": ["r633"] }, "opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "opk_FinanceLeaseLiabilityPaymentsDueAfterYearFour", "terseLabel": "Thereafter, finance", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2025, finance", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r633"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2028, finance", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r633"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2027, finance", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r633"] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2026, finance", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r633"] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "terseLabel": "April 1, 2024 through December 31, 2024, finance", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r1162"] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount", "terseLabel": "Less: Difference between lease payments and discounted lease liabilities, finance", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": ["r633"] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-supplemental-cash-flow-information-details": { "parentTag": "opk_PaymentsForLeases", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-supplemental-cash-flow-information-details"], "lang": { "en-us": { "role": { "verboseLabel": "Financing cash out flows from finance leases", "label": "us-gaap_FinanceLeasePrincipalPayments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": ["r623", "r629"] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details"], "lang": { "en-us": { "role": { "verboseLabel": "Finance lease assets", "label": "us-gaap_FinanceLeaseRightOfUseAsset", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": ["r620"] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details"], "lang": { "en-us": { "role": { "verboseLabel": "Finance leases", "label": "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": ["r632", "r959"] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details"], "lang": { "en-us": { "role": { "verboseLabel": "Finance leases (in years) (Year)", "label": "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r631", "r959"] }, "opk_FinetechMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "FinetechMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "FineTech [Member]", "documentation": "Relating to FineTech." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-

of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Less: accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r233", "r395", "r413", "r932"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r406", "r408", "r409", "r410", "r412", "r413", "r416", "r417", "r655", "r656", "r898"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Finite lived intangible assets, gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r395", "r413", "r656", "r932"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r406", "r408", "r409", "r410", "r412", "r413", "r416", "r417", "r898"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsNet", "totalLabel": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r655", "r1092"] }, "opk_FirstMarketingApprovalOfRayaldeeInEuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "FirstMarketingApprovalOfRayaldeeInEuropeMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "First Marketing Approval of Rayaldee in Europe [Member]", "documentation": "Represents the first marketing approval of Rayaldee in Europe." } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCountryMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Foreign Tax Jurisdiction [Member]", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": ["r534", "r535"] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax", "terseLabel": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r605", "r606", "r607", "r608", "r840"] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": ["r604"] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeForwardMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual"], "lang": { "en-us": { "role": { "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": ["r806", "r811", "r816", "r832", "r838", "r867", "r868", "r869", "r986"] }, "opk_FrostRealEstateHoldingsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "FrostRealEstateHoldingsLlcMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Frost Real Estate Holdings, LLC [Member]", "documentation": "Represents Frost Real Estate Holdings, LLC." } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "opk_GainLossOnConversionOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "GainLossOnConversionOfDebt", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "opk_GainLossOnConversionOfDebt", "negatedLabel": "Loss on conversion convertible senior notes", "documentation": "Amount of gain or loss on conversion of debt." } } } }, "auth_ref": [] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Fair value changes of derivative instruments, net", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": ["r68"] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_GainLossOnDispositionOfAssets1", "negatedLabel": "Realized loss (gain) on disposal of fixed assets and sales of equity securities", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": ["r1045"] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestments", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "us-gaap_GainLossOnInvestments", "terseLabel": "Loss from investment in investees", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": ["r111", "r114", "r1003"] }, "us-gaap_GainLossOnRepurchaseOfDebtInstrument": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnRepurchaseOfDebtInstrument", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_GainLossOnRepurchaseOfDebtInstrument", "terseLabel": "Gain (Loss) on Repurchase of Debt Instrument", "documentation": "Amount of gain (loss) from the difference between the repurchase price of a debt instrument initially issued by the entity and the net carrying amount of the debt at the time of its repurchase." } } }, "auth_ref": [] }, "opk_GeneDxHoldingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "GeneDxHoldingsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "GeneDx Holdings [Member]", "documentation": "Represents GeneDx Holdings." } } }, "auth_ref": [] }, "opk_GeneDxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "GeneDxMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "GeneDx [Member]", "documentation": "Represents GeneDx." } } }, "auth_ref": [] }, "opk_GermanyPriceApprovalByLocalSickFundAssociationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "GermanyPriceApprovalByLocalSickFundAssociationMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "Germany Price Approval by Local Sick Fund Association [Member]", "documentation": "Represent the Germany price approval by the local sick fund association." } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill", "periodEndLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r232", "r396", "r693", "r923", "r931", "r953", "r960", "r1075", "r1082"] }, "opk_GoodwillAcquiredDisposedOfDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "GoodwillAcquiredDisposedOfDuringPeriod", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Goodwill, acquired (disposed of)", "documentation": "Represents the amount of goodwill acquired (disposed of) during the period." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": ["r1073", "r1085"] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Goodwill, foreign exchange effect", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r403"] }, "us-gaap_GoodwillGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillGross", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "us-gaap_GoodwillGross", "periodStartLabel": "Goodwill, gross", "documentation": "Amount, before accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in

business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r398", "r405", "r931"] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss", "negatedLabel": "Goodwill, impairment", "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r398", "r405", "r931"] }, "opk_GovernmentContractBardaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "GovernmentContractBardaMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Government Contract, BARDA [Member]", "documentation": "Represents government contract, BARDA." } } }, "auth_ref": [] }, "opk_GovernmentPayersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "GovernmentPayersMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details"], "lang": { "en-us": { "role": { "label": "Government Payers [Member]", "documentation": "Represents government payers." } } }, "auth_ref": [] }, "opk_GovernmentalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "GovernmentalMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details"], "lang": { "en-us": { "role": { "label": "Governmental [Member]", "documentation": "Represents governmental." } } }, "auth_ref": [] }, "us-gaap_HealthCareOrganizationRevenueSourcesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HealthCareOrganizationRevenueSourcesAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details"], "lang": { "en-us": { "role": { "label": "Health Care Organization, Revenue Sources [Axis]", "documentation": "Information by major payor source of revenue for health care organizations." } } }, "auth_ref": ["r1118"] }, "us-gaap_HealthCareOrganizationRevenueSourcesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HealthCareOrganizationRevenueSourcesDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details"], "lang": { "en-us": { "role": { "label": "Health Care Organization, Revenue Sources [Domain]", "documentation": "Major payor source of revenue for health care organizations." } } }, "auth_ref": ["r1118"] }, "opk_HealthcareInsurersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "HealthcareInsurersMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details"], "lang": { "en-us": { "role": { "label": "Healthcare Insurers [Member]", "documentation": "Represents Healthcare insurers." } } }, "auth_ref": [] }, "opk_HealthsnapIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "HealthsnapIncMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "HealthSnap, Inc. [Member]", "documentation": "Relating to HealthSnap, Inc." } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details"], "lang": { "en-us": { "role": { "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": ["r14", "r565"] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details"], "lang": { "en-us": { "role": { "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": ["r14"] }, "country_IE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "IE", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "IRELAND" } } }, "auth_ref": [] }, "country_IL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "IL", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "ISRAEL" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": ["r0", "r127"] }, "opk_InCellDxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "InCellDxMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "InCellDx [Member]", "documentation": "Represents InCellDx." } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": ["r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "opk_IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "totalLabel": "Income (loss) before income taxes and investment losses", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": ["r159", "r721", "r916", "r1058", "r1060", "r1062", "r1063", "r1064"] }, "opk_IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "opk_IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal", "totalLabel": "Net income (loss) before investment losses", "documentation": "Amount after tax of income (loss) from continuing operations, after deduction of income tax expense (benefit), but before income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 }, "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Loss from investments in investees", "terseLabel": "Income (Loss) from Equity Method Investments", "negatedLabel": "Losses from investments in investees", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": ["r7", "r106", "r154", "r331", "r346", "r369", "r382", "r710"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-1-business-and-organization", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": ["r945", "r946"] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": ["r276", "r534", "r535", "r537", "r542", "r949", "r1123"] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": ["r276", "r534", "r535", "r537", "r542", "r949", "r1123"] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": ["r537", "r1123"] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": ["r537", "r1123"] }, "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationEstimateOfPossibleLoss", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss", "terseLabel": "Income Tax Examination, Estimate of Possible Loss", "documentation": "Estimated amount of loss resulting from an adverse tax position." } } }, "auth_ref": ["r1122"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "opk_IncomeLossFromContinuingOperationsNetOfTaxBeforeEquityMethodInvestmentsAndNoncontrollingInterestTotal", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExpenseBenefit", "negatedLabel": "Income tax provision", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r163", "r177", "r303", "r304", "r331", "r347", "r369", "r533", "r534", "r547", "r722", "r949"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and

liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r260", "r529", "r530", "r538", "r539", "r540", "r543", "r757"] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Income taxes paid, net of refunds", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r28", "r276", "r541", "r542"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": 1.0, "order": 16.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable, net", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "totalLabel": "Net cash (used in) provided by operating activities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": ["r1044"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Accrued expenses and other liabilities", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r652", "r1044"] }, "opk_IncreaseDecreaseInForeignCurrencyMeasurement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "IncreaseDecreaseInForeignCurrencyMeasurement", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Foreign currency measurement", "documentation": "Amount of increase (decrease) in foreign currency measurement." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventory, net", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": -1.0, "order": 18.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherOperatingAssets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": ["r6"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Other current assets and prepaid expenses", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r6"] }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "calculation": { "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details": { "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "terseLabel": "Warrants (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method." } } }, "auth_ref": ["r311", "r312", "r313", "r326"] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "calculation": { "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details": { "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "terseLabel": "Notes (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, "auth_ref": ["r320", "r321", "r326"] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details": { "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "terseLabel": "Stock options (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": ["r311", "r312", "r314", "r326", "r520"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r406", "r411", "r415", "r932"] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill", "terseLabel": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r395", "r415", "r932"] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r406", "r411", "r415", "r932"] }, "opk_IndividualPatientsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "IndividualPatientsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Individual Patients [Member]", "documentation": "Relating to individual patients." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": ["r1000"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r406", "r1092", "r1093"] }, "opk_IntegratedDNATechnologiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "IntegratedDNATechnologiesIncMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Integrated DNA Technologies Inc. [Member]", "documentation": "Represents Integrated DNA Technologies Inc." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpense", "terseLabel": "Interest Expense", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": ["r331", "r339", "r343", "r349", "r369", "r615", "r922", "r923"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpenseNonoperating", "negatedLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r343", "r1041"] }, "us-gaap_InterestOnConvertibleDebtNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestOnConvertibleDebtNetOfTax", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "Add: Interest on Notes", "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash." } } }, "auth_ref": ["r309", "r317", "r326"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Interest paid",

"documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r270", "r274", "r275"] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r86"] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InterestPayableCurrentAndNoncurrent", "terseLabel": "Interest Payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": ["r151", "r1173"] }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterimPeriodCostsNotAllocableDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Interim Period, Costs Not Allocable [Domain]", "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred." } } }, "auth_ref": ["r33"] }, "opk_InternacionalBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "InternacionalBankMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Internacional Bank [Member]", "documentation": "Relating to Internacional Bank." } } }, "auth_ref": [] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntersegmentEliminationMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual"], "lang": { "en-us": { "role": { "label": "Intersegment Eliminations [Member]", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": ["r158", "r331", "r341", "r363", "r364", "r365", "r366", "r367", "r369", "r370", "r922"] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Finished products", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": ["r1030"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Inventory, net", "totalLabel": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r246", "r903", "r960"] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": ["r165", "r229", "r245", "r391", "r392", "r394", "r653", "r913"] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r1032"] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryValuationReserves", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryValuationReserves", "negatedLabel": "Less: inventory reserve", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": ["r125", "r1034"] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Work in-process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": ["r1031"] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryWriteDown", "terseLabel": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": ["r393"] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": ["r331", "r342", "r369", "r922", "r1040"] }, "opk_InvestmentNetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "InvestmentNetMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details"], "lang": { "en-us": { "role": { "label": "Investment, Net [Member]", "documentation": "Represents Investments, net." } } }, "auth_ref": [] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalanceShares", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InvestmentOwnedBalanceShares", "terseLabel": "Investment Owned, Balance, Shares (in shares)", "documentation": "Number of shares of investment owned." } } }, "auth_ref": ["r779", "r788", "r851", "r859", "r874", "r986"] }, "opk_InvestmentOwnedSharesSold": { "xbrltype": "sharesItemType", "nsuri": "http://www.opko.com/20240930", "localname": "InvestmentOwnedSharesSold", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "opk_InvestmentOwnedSharesSold", "terseLabel": "Investment Owned, Shares Sold (in shares)", "documentation": "The number of shares sold of investment." } } }, "auth_ref": [] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": ["r717", "r753", "r754", "r755", "r756", "r853", "r854"] }, "us-gaap_InvestmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTableTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-tables"], "lang": { "en-us": { "role": { "label": "Investment [Table Text Block]", "documentation": "Tabular disclosure of investment." } } }, "auth_ref": ["r1015", "r1016", "r1067"] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments"], "lang": { "en-us": { "role": { "label": "Investment [Text Block]", "documentation": "The entire disclosure for investment." } } }, "auth_ref": ["r1015", "r1016", "r1067"] }, "us-gaap_IsraelTaxAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IsraelTaxAuthorityMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Israel Tax Authority [Member]", "documentation": "Designated tax department of the government of Israel." } } }, "auth_ref": [] }, "opk_ItauBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ItauBankMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Itau Bank [Member]", "documentation": "Relating to Itau Bank." } } }, "auth_ref": [] }, "opk_JPMorganChaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "JPMorganChaseMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "J P Morgan Chase [Member]", "documentation": "Relating to J P Morgan Chase." } } }, "auth_ref": [] }, "opk_LabcorpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "LabcorpMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-1-business-and-organization", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Labcorp [Member]", "documentation": "Represents Labcorp." } } }, "auth_ref": [] }, "opk_LeaderMedJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "LeaderMedJointVentureMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "LeaderMed Joint Venture [Member]", "documentation": "Represents LeaderMed joint venture." } } }, "auth_ref": [] }, "opk_LeaderMedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "LeaderMedMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "LeaderMed [Member]", "documentation": "Represents LeaderMed." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases", "http://www.opko.com/20240930/role/statement-note-16-leases-details-textual"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": ["r635", "r1013"] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases", "http://www.opko.com/20240930/role/statement-note-16-leases-details-textual"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": ["r635", "r1013"] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-document-and-entity-information", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization",

"http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-tables", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-tables", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-tables", "http://www.opko.com/20240930/role/statement-note-16-leases", "http://www.opko.com/20240930/role/statement-note-16-leases-details-textual", "http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details", "http://www.opko.com/20240930/role/statement-note-16-leases-supplemental-cash-flow-information-details", "http://www.opko.com/20240930/role/statement-note-16-leases-tables", "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-details-textual", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-tables", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-tables", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments-gains-and-losses-on-equity-securities-details", "http://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-details", "http://www.opko.com/20240930/role/statement-note-6-investments-tables", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details-parentheticals", "http://www.opko.com/20240930/role/statement-note-7-debt-tables", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-changed-in-accumulated-other-comprehensive-loss-details", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-tables", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-tables", "http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "opk_LeicaMicrosystemsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "LeicaMicrosystemsIncMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Leica Microsystems Inc. [Member]", "documentation": "Represents Leica Microsystems Inc." } } }, "auth_ref": [] }, "opk_LesseeLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.opko.com/20240930", "localname": "LesseeLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-tables"], "lang": { "en-us": { "role": { "label": "Lessee, Lease Liability, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of operating and finance lease liability." } } }, "auth_ref": [] }, "opk_LesseeLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.opko.com/20240930", "localname": "LesseeLeasesTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases"], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Text Block]", "documentation": "The entire disclosure for finance and operating leases of lessee. Includes, but is not limited to, description of lessee's finance and operating lease and maturity analysis of finance and operating lease liability." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total undiscounted future minimum lease payments, operating", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r633"] }, "opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "opk_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "terseLabel": "Thereafter, operating", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2025, operating", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r633"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2028, operating", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r633"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2027, operating", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r633"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2026, operating", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r633"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "terseLabel": "April 1, 2024 through December 31, 2024, operating", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r1162"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "terseLabel": "Less: Difference between lease payments and discounted lease liabilities, operating", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r633"] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseRenewalTerm", "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1161"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseTermOfContract", "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1161"] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-

sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "terseLabel": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r18", "r85", "r86", "r87", "r91", "r92", "r93", "r94", "r280", "r386", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r447", "r448", "r560", "r563", "r564", "r603", "r799", "r915", "r994", "r1111", "r1164", "r1165"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r101", "r153", "r707", "r960", "r1048", "r1071", "r1152"] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r87", "r228", "r280", "r386", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r447", "r448", "r560", "r563", "r564", "r603", "r960", "r1111", "r1164", "r1165"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesFairValueDisclosure", "totalLabel": "Total liabilities", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": ["r579", "r1137"] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesNoncurrent", "totalLabel": "Total long-term liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r18", "r91", "r92", "r93", "r94", "r280", "r386", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r447", "r448", "r560", "r563", "r564", "r603", "r1111", "r1164", "r1165"] }, "opk_LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "LicenseAgreementMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "License Agreement [Member]", "documentation": "Relating to license agreement." } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": ["r57", "r528", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1121"] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Line of credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r18", "r152", "r1174"] }, "opk_LineOfCreditAndNotesAndLoansPayableCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "LineOfCreditAndNotesAndLoansPayableCurrentMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "Line Of Credit And Notes And Loans Payable Current Member", "documentation": "Relating to current line of credit and notes and loans payable ." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": ["r84", "r90", "r1047", "r1108", "r1109"] }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Interest rate", "documentation": "The effective interest rate at the end of the reporting period." } } }, "auth_ref": ["r84", "r90"] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLenderDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": ["r84", "r90", "r1047", "r1108"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Credit line capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r84", "r90"] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LitigationSettlementAmountAwardedToOtherParty", "terseLabel": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "opk_LitigationSettlementInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.opko.com/20240930", "localname": "LitigationSettlementInterestRate", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "opk_LitigationSettlementInterestRate", "terseLabel": "Litigation Settlement, Interest Rate", "documentation": "Interest rate under litigation settlement." } } }, "auth_ref": [] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": ["r1099", "r1100", "r1101", "r1104"] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": ["r1099", "r1100", "r1101", "r1104"] }, "us-gaap_LoansPayableToBankCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableToBankCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Current portion of lines of credit and notes payable", "documentation": "Carrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer." } } }, "auth_ref": ["r85", "r795"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt", "label": "us-gaap_LongTermDebt", "terseLabel": "Long-Term Debt", "totalLabel": "Total", "periodStartLabel": "Balance, total", "periodEndLabel": "Balance, total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r18", "r152", "r462", "r476", "r934", "r935", "r958", "r1174"] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-details"], "lang": { "en-us": { "role": { "label": "Current portion of notes payable", "terseLabel": "Current portion of notes payable", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r237"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "Long term portion of notes payable", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r238"] }, "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtPercentageBearingVariableInterestRate", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermDebtPercentageBearingVariableInterestRate", "terseLabel": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate", "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time." } } }, "auth_ref": ["r88"] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-tables"], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": ["r129"] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-details"], "lang": { "en-us": { "role": { "label":

"Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": ["r231"] }, "us-gaap_LongTermLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermLineOfCredit", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LongTermLineOfCredit", "terseLabel": "Long-Term Line of Credit, Noncurrent", "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r18", "r45", "r46"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r18", "r1099", "r1100", "r1101"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r18", "r47", "r1099", "r1100", "r1101"] }, "country_MX": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "MX", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "MEXICO" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": ["r377", "r941", "r974", "r979", "r1118", "r1177", "r1180", "r1181", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": ["r182", "r184", "r186", "r187", "r189", "r221", "r222", "r432", "r433", "r434", "r435", "r517", "r525", "r582", "r651", "r741", "r742", "r749", "r789", "r790", "r850", "r855", "r857", "r858", "r873", "r896", "r897", "r928", "r938", "r947", "r954", "r955", "r956", "r957", "r975", "r1115", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171"] }, "opk_MedicareAndMedicaidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "MedicareAndMedicaidMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Medicare and Medicaid [Member]", "documentation": "Relating to medicare and medicaid." } } }, "auth_ref": [] }, "opk_MerckAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "MerckAgreementMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "Merck Agreement [Member]", "documentation": "Represents the Merck Agreement." } } }, "auth_ref": [] }, "opk_MerckSharpDohmeLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "MerckSharpDohmeLLCMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "Merck Sharp & Dohme LLC [Member]", "documentation": "Represents Merck Sharp & Dohme LLC." } } }, "auth_ref": [] }, "opk_MilestonePaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "MilestonePaymentsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual"], "lang": { "en-us": { "role": { "label": "Milestone Payments [Member]", "documentation": "Relating to milestone payments." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": ["r182", "r184", "r186", "r187", "r189", "r221", "r222", "r432", "r433", "r434", "r435", "r517", "r525", "r582", "r651", "r741", "r742", "r749", "r789", "r790", "r850", "r855", "r857", "r858", "r873", "r896", "r897", "r928", "r938", "r947", "r954", "r955", "r956", "r975", "r1115", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171"] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners", "terseLabel": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_MinorityInterestOwnershipPercentageByParent", "terseLabel": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "opk_MinorityInterestSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.opko.com/20240930", "localname": "MinorityInterestSharesIssued", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "opk_MinorityInterestSharesIssued", "terseLabel": "Minority Interest, Shares Issued (in shares)", "documentation": "Represents the amount of minority interest shares acquired." } } }, "auth_ref": [] }, "opk_ModexTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ModexTherapeuticsIncMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases", "http://www.opko.com/20240930/role/statement-note-16-leases-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "ModeX Therapeutics, Inc [Member]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r1001"] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": ["r377", "r941", "r974", "r979", "r1118", "r1177", "r1180", "r1181", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207"] }, "us-gaap_NatureOfExpenseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfExpenseAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Nature of Expense [Axis]", "documentation": "Information by type of cost or expense." } } }, "auth_ref": ["r33"] }, "opk_NeovascMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "NeovascMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Neovasc [Member]", "documentation": "Represents Neovasc." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r273"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r273"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-

unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": -1.0, "order": 17.0 }, "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "Net income (loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r109", "r121", "r155", "r226", "r255", "r258", "r263", "r280", "r294", "r296", "r297", "r298", "r299", "r300", "r303", "r304", "r322", "r386", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r447", "r448", "r552", "r556", "r576", "r603", "r712", "r821", "r841", "r842", "r992", "r1111"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "Net income (loss), basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": ["r269", "r296", "r297", "r298", "r299", "r307", "r308", "r323", "r326", "r556"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "totalLabel": "Net income (loss), diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": ["r269", "r309", "r316", "r317", "r318", "r319", "r323", "r326"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "opk_NicoyaMacauLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "NicoyaMacauLimitedMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "NICOYA Macau Limited [Member]", "documentation": "Represents NICOYA Macau Limited." } } }, "auth_ref": [] }, "opk_NimsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "NimsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "NIMS [Member]", "documentation": "Represents NIMS." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r1001"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r1001"] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Non-cash financing:" } } }, "auth_ref": [] }, "us-gaap_NoncompeteAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncompeteAgreementsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Noncompete Agreements [Member]", "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party." } } }, "auth_ref": ["r55", "r1086", "r1087", "r1088", "r1089", "r1091", "r1092", "r1094", "r1095"] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details"], "lang": { "en-us": { "role": { "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": ["r14"] }, "opk_NondravetSyndromeProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "NondravetSyndromeProductsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "Non-Dravet Syndrome Products [Member]", "documentation": "Represents non-Dravet syndrome products." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Other income (expense), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r112"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Other income and (expense), net:" } } }, "auth_ref": [] }, "opk_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "opk_NotesAndOtherDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "NotesAndOtherDebtMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Notes and Other Debt [Member]", "documentation": "Relating to notes and other debt." } } }, "auth_ref": [] }, "opk_NotesPayableAndOtherLongTermLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "NotesPayableAndOtherLongTermLiabilitiesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-details"], "lang": { "en-us": { "role": { "label": "Notes Payable And Other Long Term Liabilities [Member]", "documentation": "Relating to notes payable and other long term liabilities." } } }, "auth_ref": [] }, "us-gaap_NotesPayableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "us-gaap_NotesPayableFairValueDisclosure", "terseLabel": "Notes", "documentation": "Fair value portion of notes payable." } } }, "auth_ref": ["r18", "r85", "r86", "r1138", "r1148"] }, "opk_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "opk_NumberOfMajorCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.opko.com/20240930", "localname": "NumberOfMajorCustomers", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-details-textual"], "lang": { "en-us": { "role": { "label": "opk_NumberOfMajorCustomers", "terseLabel": "Number of Major Customers", "documentation": "The number of major customers." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r917", "r927", "r1059"] }, "opk_OfficeSpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "OfficeSpaceMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases", "http://www.opko.com/20240930/role/statement-note-16-leases-details-textual"], "lang": { "en-us": { "role": { "label": "Office Space [Member]", "documentation": "Represents office space." } } }, "auth_ref": [] }, "us-gaap_OpenTaxYear": { "xbrltype": "gYearListItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OpenTaxYear", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_OpenTaxYear", "terseLabel": "Open Tax Year", "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format." } } }, "auth_ref": ["r537"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "terseLabel": "Operating Expenses", "totalLabel": "Total costs and expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Costs and expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating income (loss)", "terseLabel": "Operating income (loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r159", "r916", "r1058", "r1060", "r1062", "r1063", "r1064"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseCost", "terseLabel": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r627", "r959"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details"], "lang": { "en-us": { "role": { "verboseLabel": "Total

lease liabilities, operating", "label": "us-gaap_OperatingLeaseLiability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r621"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details"], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "label": "Current maturities of operating leases", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r621"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details"], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease liabilities", "label": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r621"] }, "opk_OperatingLeaseMonthlyRentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "OperatingLeaseMonthlyRentExpense", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-details-textual"], "lang": { "en-us": { "role": { "label": "opk_OperatingLeaseMonthlyRentExpense", "terseLabel": "Operating Lease, Monthly Rent Expense", "documentation": "Amount of monthly rent expense under operating lease." } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-supplemental-cash-flow-information-details": { "parentTag": "opk_PaymentsForLeases", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-supplemental-cash-flow-information-details"], "lang": { "en-us": { "role": { "label": "Operating cash out flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r625", "r629"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details"], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease assets", "label": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r620"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details"], "lang": { "en-us": { "role": { "verboseLabel": "Operating leases", "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r632", "r959"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details"], "lang": { "en-us": { "role": { "verboseLabel": "Operating leases (in years) (Year)", "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r631", "r959"] }, "opk_OperatingLeasesMonthlyPaymentsYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "OperatingLeasesMonthlyPaymentsYearFive", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "opk_OperatingLeasesMonthlyPaymentsYearFive", "terseLabel": "Operating Leases, Monthly Payments, Year Five", "documentation": "Amount of monthly payments in year five for operating lease." } } }, "auth_ref": [] }, "opk_OperatingLeasesMonthlyPaymentsYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "OperatingLeasesMonthlyPaymentsYearOne", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "opk_OperatingLeasesMonthlyPaymentsYearOne", "terseLabel": "Operating Leases, Monthly Payments, Year One", "documentation": "Amount of monthly payments in first year for operating lease." } } }, "auth_ref": [] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r363", "r364", "r365", "r366", "r367", "r370", "r922", "r923"] }, "opk_OpkoBiologicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "OpkoBiologicsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "OPKO Biologics [Member]", "documentation": "Relating to OPKO Biologics." } } }, "auth_ref": [] }, "opk_OpkoChileMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "OpkoChileMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "OPKO Chile [Member]", "documentation": "Relating to OPKO Chile." } } }, "auth_ref": [] }, "opk_OpkoDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "OpkoDiagnosticsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "OPKO Diagnostics [Member]", "documentation": "Relating to OPKO diagnostics." } } }, "auth_ref": [] }, "opk_OpkoHealthEuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "OpkoHealthEuropeMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "OPKO Health Europe [Member]", "documentation": "Relating to OPKO Health Europe." } } }, "auth_ref": [] }, "opk_OpkoMexicoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "OpkoMexicoMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "OPKO Mexico [Member]", "documentation": "Relating to OPKO Mexico." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-1-business-and-organization"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r82", "r143", "r751", "r752"] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "terseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r86"] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "us-gaap_OtherAssetsCurrent", "terseLabel": "Other", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": ["r247", "r960"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r234"] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Change in foreign currency translation and other comprehensive income (loss)", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": ["r5", "r12", "r144"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-changed-in-accumulated-other-comprehensive-loss-details"], "lang": { "en-us": { "role": { "label": "Other comprehensive loss", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r5", "r12", "r144", "r256", "r259", "r300"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss), net of tax:" } } }, "auth_ref": [] }, "opk_OtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "OtherCountriesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "Other Countries [Member]", "documentation": "Represents other countries." } } }, "auth_ref": [] }, "srt_OtherCurrencyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OtherCurrencyMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual"], "lang": { "en-us": { "role": { "label": "Other Currency [Member]", "documentation": "Currency classified as other." } } }, "auth_ref": ["r1156"] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": ["r932", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095"] }, "us-gaap_OtherInventorySupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherInventorySupplies", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Consumable supplies", "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r1033"] }, "us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesAndDeferredRevenueNoncurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "us-gaap_OtherLiabilitiesAndDeferredRevenueNoncurrent", "terseLabel": "Other", "documentation": "Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations and noncurrent portion of deferred revenue not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid

after one year (or the normal operating cycle, if longer). Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 }, "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-details": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 0.0 }, "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-details"], "lang": { "en-us": { "role": { "label": "Other long-term liabilities, principally contract liabilities, contingent consideration and lines of credit", "terseLabel": "Other long-term liabilities", "totalLabel": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r92"] }, "us-gaap_OtherLongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Mortgages and other debts payable", "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer." } } }, "auth_ref": ["r18", "r798"] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Other income (expense), net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r115"] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "us-gaap_OtherPrepaidExpenseCurrent", "terseLabel": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r1035", "r1072"] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaidInKindInterest", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Non-cash interest", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r7"] }, "opk_PaymentsForLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "PaymentsForLeases", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-16-leases-supplemental-cash-flow-information-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-supplemental-cash-flow-information-details"], "lang": { "en-us": { "role": { "label": "opk_PaymentsForLeases", "totalLabel": "Total", "documentation": "Amount of cash outflow for leases." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsForRepurchaseOfCommonStock", "negatedLabel": "Share repurchase", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": ["r118"] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "negatedLabel": "Issuance of 3.75% 2029 convertible notes, debt issuance cost", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": ["r25"] }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireEquityMethodInvestments", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireEquityMethodInvestments", "terseLabel": "Payments to Acquire Equity Method Investments", "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } }, "auth_ref": ["r23"] }, "us-gaap_PaymentsToAcquireInterestInJointVenture": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInterestInJointVenture", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireInterestInJointVenture", "terseLabel": "Payments to Acquire Interest in Joint Venture", "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group." } } }, "auth_ref": ["r23"] }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "negatedLabel": "Investments in investees", "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity)." } } }, "auth_ref": ["r23"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireMarketableSecurities", "negatedLabel": "Purchase of marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r1068"] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireProductiveAssets", "negatedLabel": "Capital expenditures", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": ["r162", "r1128", "r1129", "r1130"] }, "opk_PfizerAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "PfizerAgreementMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "Pfizer Agreement [Member]", "documentation": "Represents the Pfizer Agreement." } } }, "auth_ref": [] }, "opk_PfizerIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "PfizerIncMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "Pfizer Inc. [Member]", "documentation": "Represents Pfizer Inc." } } }, "auth_ref": [] }, "opk_PharmaceuticalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "PharmaceuticalMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Pharmaceutical [Member]", "documentation": "Represents Pharmaceutical." } } }, "auth_ref": [] }, "opk_PharmsynthezMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "PharmsynthezMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Pharmsynthez [Member]", "documentation": "Represents Pharmsynthez." } } }, "auth_ref": [] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": ["r600"] }, "us-gaap_PostemploymentBenefitsLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PostemploymentBenefitsLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Employee severance", "documentation": "For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer)." } } }, "auth_ref": ["r1119", "r1120"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0,

"order": 0.0 }, "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Other current assets and prepaid expenses", "totalLabel": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r1036"] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r906", "r929", "r1072"] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Taxes recoverable", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r907", "r930", "r1072"] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Issuance of 3.00% convertible senior notes, net (including related parties)", "terseLabel": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r24"] }, "opk_ProceedsFromConvertibleDebtGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ProceedsFromConvertibleDebtGross", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "Issuance of 3.75% 2029 Convertible Notes", "documentation": "Cash inflow from convertible debt." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from LabCorp Sale", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": ["r22"] }, "opk_ProceedsFromEmbeddedDerivativeDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ProceedsFromEmbeddedDerivativeDebt", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "Issuance of 3.75% 2029 convertible notes, embedded conversion option", "documentation": "Pertains to proceeds from embedded derivative instrument." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfDebt", "terseLabel": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": ["r1042"] }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of 2044 Notes", "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer)." } } }, "auth_ref": ["r24"] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Borrowings on lines of credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": ["r24", "r1047"] }, "opk_ProceedsFromRepurchaseOfStockOptionsAndWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ProceedsFromRepurchaseOfStockOptionsAndWarrantsExercised", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from the exercise of common stock options", "documentation": "The net cash inflow or outflow resulting from exercise of stock options and warrants." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfEquityMethodInvestments", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromSaleOfEquityMethodInvestments", "terseLabel": "Proceeds from Sale of Equity Method Investments", "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } }, "auth_ref": ["r22"] }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Proceeds from sale of equity securities", "terseLabel": "Proceeds from Sale of Equity Securities, FV-NI", "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": ["r161", "r271"] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Proceeds from the sale of property, plant and equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": ["r117"] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r939"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": ["r191", "r192", "r193", "r194", "r195", "r196", "r219", "r373", "r654", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r900", "r939", "r973", "r975", "r976", "r980", "r982", "r1025", "r1105", "r1106", "r1118", "r1177", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": ["r191", "r192", "r193", "r194", "r195", "r196", "r219", "r373", "r654", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r900", "r939", "r973", "r975", "r976", "r980", "r982", "r1025", "r1105", "r1106", "r1118", "r1177", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProfitLoss", "terseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r226", "r255", "r258", "r272", "r280", "r294", "r300", "r303", "r304", "r386", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r447", "r448", "r552", "r556", "r558", "r561", "r562", "r576", "r603", "r697", "r711", "r766", "r821", "r841", "r842", "r950", "r951", "r993", "r1039", "r1111"] }, "opk_ProjectRegistrationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ProjectRegistrationMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Project Registration [Member]", "documentation": "Relating to project registration." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Property, plant and equipment, net", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": ["r1014", "r1097"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": {

"role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r10", "r634"] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r10", "r171", "r175", "r709"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r126", "r634"] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ProvisionForDoubtfulAccounts", "terseLabel": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": ["r268", "r390"] }, "opk_ProvisionForSalesAllowanceAsPercentOfGrossSales": { "xbrltype": "percentItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ProvisionForSalesAllowanceAsPercentOfGrossSales", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details"], "lang": { "en-us": { "role": { "verboseLabel": "Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales", "label": "opk_ProvisionForSalesAllowanceAsPercentOfGrossSales", "documentation": "Percentage of gross sales for provision for sales allowance." } } }, "auth_ref": [] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_PurchaseObligation", "terseLabel": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r182", "r184", "r186", "r187", "r189", "r221", "r222", "r432", "r433", "r434", "r435", "r509", "r517", "r522", "r523", "r524", "r525", "r582", "r648", "r649", "r651", "r741", "r742", "r749", "r789", "r790", "r850", "r855", "r857", "r858", "r873", "r896", "r897", "r928", "r938", "r947", "r954", "r955", "r956", "r957", "r975", "r986", "r1102", "r1115", "r1140", "r1167", "r1168", "r1169", "r1170", "r1171"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": ["r182", "r184", "r186", "r187", "r189", "r221", "r222", "r432", "r433", "r434", "r435", "r509", "r517", "r522", "r523", "r524", "r525", "r582", "r648", "r649", "r651", "r741", "r742", "r749", "r789", "r790", "r850", "r855", "r857", "r858", "r873", "r896", "r897", "r928", "r938", "r947", "r954", "r955", "r956", "r957", "r975", "r986", "r1102", "r1115", "r1140", "r1167", "r1168", "r1169", "r1170", "r1171"] }, "opk_RayaldeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "RayaldeeMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Rayaldee [Member]", "documentation": "Represent Rayaldee." } } }, "auth_ref": [] }, "opk_RecognitionOfDebtDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "RecognitionOfDebtDiscount", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details"], "lang": { "en-us": { "role": { "label": "opk_RecognitionOfDebtDiscount", "negatedLabel": "Issuance of 3.75% 2029 convertible notes, discount", "documentation": "Pertains to debt discount." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-tables"], "lang": { "en-us": { "role": { "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": ["r42", "r43"] }, "opk_ReimbursementOfTravelExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ReimbursementOfTravelExpensesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Reimbursement of Travel Expenses [Member]", "documentation": "Represents reimbursement of travel expenses." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r378", "r516", "r640", "r641", "r703", "r708", "r792", "r793", "r794", "r796", "r797", "r818", "r820", "r849"] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": ["r79", "r640"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r640", "r641", "r1163"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r378", "r516", "r640", "r641", "r703", "r708", "r792", "r793", "r794", "r796", "r797", "r818", "r820", "r849", "r1163"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r637", "r638", "r639", "r641", "r643", "r763", "r764", "r765", "r825", "r826", "r827", "r847", "r848"] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfConvertibleDebt", "terseLabel": "Repayments of Convertible Debt", "negatedLabel": "Repurchase of 2029 Convertible Notes", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": ["r119"] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfDebt", "terseLabel": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": ["r1043"] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfLinesOfCredit", "terseLabel": "Repayments of Lines of Credit", "negatedLabel": "Repayments of lines of credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": ["r119", "r1047"] }, "us-gaap_RepaymentsOfSeniorDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfSeniorDebt", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfSeniorDebt", "negatedLabel": "Redemption of 2025 Notes and 2033 Senior Notes", "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period." } } }, "auth_ref": ["r119"] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-1-business-and-organization", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual", "http://www.opko.com/20240930/role/statement-note-13-revenue-

recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": ["r217", "r218", "r282", "r283", "r453", "r479", "r642", "r650", "r699", "r910", "r911"] }, "opk_RepurchaseOfCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "RepurchaseOfCommonStockMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Repurchase of Common Stock [Member]", "documentation": "Related to repurchase of common stock." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r527", "r898", "r922", "r1172"] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r526"] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details"], "lang": { "en-us": { "role": { "label": "Restricted cash, current", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r26", "r230", "r277"] }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details"], "lang": { "en-us": { "role": { "label": "Restricted cash, long-term", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r26", "r164", "r277"] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": ["r32"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r98", "r135", "r706", "r746", "r748", "r762", "r801", "r960"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r223", "r291", "r292", "r293", "r295", "r300", "r302", "r304", "r387", "r388", "r419", "r544", "r545", "r549", "r550", "r551", "r553", "r555", "r556", "r567", "r569", "r570", "r572", "r574", "r618", "r619", "r743", "r745", "r767", "r1212"] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "verboseLabel": "Total gross Rayaldee sales", "label": "Revenues", "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r157", "r158", "r331", "r340", "r341", "r363", "r369", "r373", "r375", "r377", "r504", "r505", "r654"] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r377", "r1011"] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r178", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r899"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition"], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r178", "r487", "r488", "r489", "r490", "r491", "r492", "r494", "r495", "r508"] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RevenueRemainingPerformanceObligation", "terseLabel": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": ["r174"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_Revenues", "terseLabel": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r157", "r158", "r264", "r280", "r331", "r340", "r341", "r363", "r369", "r373", "r375", "r377", "r386", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r447", "r448", "r603", "r697", "r922", "r1111"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Revenues:" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Assets acquired by finance leases", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": ["r630", "r959"] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets in exchange for lease obligations", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r630", "r959"] }, "opk_RuenhuiBiopharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "RuenhuiBiopharmaceuticalsIncMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Ruen-Hui Biopharmaceuticals, Inc. [Member]", "documentation": "Relating to Ruen-Hui Biopharmaceuticals, Inc." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r1001"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r1001"] }, "opk_SalesReturnsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "SalesReturnsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details"], "lang": { "en-us": { "role": { "label": "Sales Returns [Member]", "documentation": "Represents sales returns." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual"], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r377", "r1011"] }, "opk_SantanderBank2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "SantanderBank2Member", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Santander Bank 2 [Member]", "documentation": "Relating to Santander Bank 2." } } }, "auth_ref": [] }, "opk_SantanderBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "SantanderBankMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-

credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Santander Bank [Member]", "documentation": "Relating to Santander Bank." } } }, "auth_ref": [] }, "opk_ScenarioEventofDefaultMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ScenarioEventofDefaultMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Scenario, Event of Default [Member]", "documentation": "Pertains to the event of default." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": ["r518", "r1017", "r1054"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": ["r220", "r305", "r518", "r1005", "r1054"] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r20", "r1154", "r1155"] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-tables"], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheet [Table Text Block]", "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations." } } }, "auth_ref": ["r1018", "r1050"] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": ["r18", "r48", "r49", "r80", "r132", "r134", "r934", "r936", "r1050", "r1158"] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-tables"], "lang": { "en-us": { "role": { "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": ["r68", "r71", "r565"] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": ["r69"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r1057"] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": ["r383", "r384", "r385", "r548", "r1006", "r1007", "r1008", "r1124", "r1125", "r1126", "r1127"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r1137", "r1138"] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": ["r931", "r1074", "r1075", "r1076", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084"] }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Line of Credit Facilities [Table Text Block]", "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": ["r84", "r90"] }, "opk_ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ScheduleOfProductSalesAllowancesAndAccrualsTableTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Product Sales Allowances and Accruals [Table Text Block]", "documentation": "Tabular disclosure of product sales allowances and accruals." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r39", "r40", "r41"] }, "opk_ScheduleOfSupplementalCashFlowInformationOfLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ScheduleOfSupplementalCashFlowInformationOfLeasesTableTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Supplemental Cash Flow Information of Leases [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash information related to leases." } } }, "auth_ref": [] }, "opk_ScotiabankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ScotiabankMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Scotiabank [Member]", "documentation": "Relating to Scotiabank." } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": ["r1135"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r995"] }, "opk_SecurityBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "SecurityBankMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details"], "lang": { "en-us": { "role": { "label": "Security Bank [Member]", "documentation": "Relating to Security Bank." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r997"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r157", "r158", "r159", "r160", "r331", "r336", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r350", "r351", "r353", "r354", "r355", "r363", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r377", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r418", "r428", "r429", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r919", "r922", "r923", "r931", "r978", "r1177", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": ["r183", "r185", "r188", "r190", "r197", "r198", "r199", "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r375", "r376", "r657", "r659", "r660", "r661", "r662", "r664", "r665", "r666", "r667", "r668", "r669", "r671", "r672", "r673", "r674", "r675", "r676", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r781", "r784", "r786", "r852", "r856", "r860", "r875", "r881", "r886", "r887", "r888", "r889", "r891", "r892", "r893", "r894", "r895", "r901", "r940", "r962", "r963", "r964", "r965", "r967", "r969", "r970", "r971", "r977", "r986", "r1118", "r1177", "r1180", "r1181", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207"] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments"], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or

more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r160", "r331", "r335", "r336", "r337", "r338", "r339", "r352", "r354", "r355", "r367", "r368", "r369", "r370", "r371", "r373", "r374", "r377", "r917", "r920", "r921", "r922", "r924", "r926", "r927"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r356", "r357", "r358", "r359", "r360", "r361", "r362", "r372", "r375", "r918", "r919", "r925"] }, "opk_SelectAssetsOfBioreferenceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "SelectAssetsOfBioreferenceMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-1-business-and-organization", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual"], "lang": { "en-us": { "role": { "label": "Select Assets of BioReference [Member]", "documentation": "Represents select assets of BioReference." } } }, "auth_ref": [] }, "us-gaap_SelfPayMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SelfPayMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details"], "lang": { "en-us": { "role": { "label": "Self-Pay [Member]", "documentation": "Patients who pay out of pocket for a health-related service in absence of insurance to cover the medical or surgical procedure performed." } } }, "auth_ref": ["r1118"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited"], "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r110"] }, "us-gaap_SeniorLongTermNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorLongTermNotes", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Senior secured notes", "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders." } } }, "auth_ref": ["r18", "r960"] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "opk_SeriesA2PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "SeriesA2PreferredStockMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Series A-2 Preferred Stock [Member]", "documentation": "Relating to Series A-2 Preferred Stock." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": ["r939"] }, "opk_ServicesRenderedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ServicesRenderedMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Services Rendered [Member]", "documentation": "Related to services rendered." } } }, "auth_ref": [] }, "us-gaap_SettledLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SettledLitigationMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Settled Litigation [Member]", "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval." } } }, "auth_ref": ["r1104"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Equity-based compensation \u2013 employees and non-employees", "terseLabel": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r6"] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": ["r1117"] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": ["r1117"] }, "opk_SharesIncludedInBusinessDivestureCashFlowImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "SharesIncludedInBusinessDivestureCashFlowImpact", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Fair value of shares received related to milestone achieved from GeneDx Holdings", "documentation": "Represents the cash flow impact of shares included in business divesture." } } }, "auth_ref": [] }, "opk_ShippingAndHandlingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ShippingAndHandlingCostsPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Shipping and Handling Costs [Policy Text Block]", "documentation": "Disclosure of the company's policy regarding shipping and handling costs." } } }, "auth_ref": [] }, "us-gaap_SifmaMunicipalSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SifmaMunicipalSwapRateMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "SIFMA Municipal Swap Rate [Member]", "documentation": "Fixed rate on US dollar, constant-notional interest rate swap with its variable-rate leg referenced to Securities Industry and Financial Markets Association (SIFMA) Municipal Swap Index with no additional spread over SIFMA Municipal Swap Index on its variable-rate leg." } } }, "auth_ref": ["r1135"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r122", "r278"] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r157", "r158", "r159", "r160", "r224", "r331", "r336", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r350", "r351", "r353", "r354", "r355", "r363", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r377", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r418", "r421", "r428", "r429", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r919", "r922", "r923", "r931", "r978", "r1177", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r180", "r239", "r240", "r241", "r280", "r310", "r315", "r324", "r326", "r333", "r334", "r386", "r438", "r441", "r442", "r443", "r447", "r448", "r477", "r478", "r480", "r481", "r482", "r603", "r758", "r759", "r760", "r761", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r800", "r822", "r843", "r876", "r877", "r878", "r879", "r880", "r1004", "r1046", "r1056"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-changed-in-accumulated-other-comprehensive-loss-details"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r13", "r96", "r99", "r100", "r223", "r261", "r262", "r263", "r291", "r292", "r293", "r295", "r300", "r302", "r304", "r332", "r387", "r388", "r419", "r484", "r544", "r545", "r549", "r550", "r551", "r553", "r555", "r556", "r567", "r568", "r569", "r570", "r571", "r572", "r574", "r609", "r610", "r611", "r612", "r613", "r614", "r618", "r619", "r636", "r713", "r743", "r744", "r745", "r767", "r843"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": ["r183", "r185", "r188", "r190", "r197", "r198", "r199", "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r375", "r376", "r657", "r659", "r660", "r661", "r662", "r664", "r665", "r666", "r667", "r668", "r669", "r671", "r672", "r673", "r674", "r675", "r676", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r781", "r784", "r786", "r852", "r856", "r860", "r875", "r881", "r886", "r887", "r888", "r889", "r891", "r892", "r893", "r894", "r895", "r901", "r940", "r962", "r963", "r964", "r965", "r967", "r969", "r970", "r971", "r977", "r986", "r1118", "r1177", "r1180", "r1181", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1205", "r1206", "r1207"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-tables", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-

details-textual", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-tables", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-tables", "http://www.opko.com/20240930/role/statement-note-16-leases", "http://www.opko.com/20240930/role/statement-note-16-leases-details-textual", "http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details", "http://www.opko.com/20240930/role/statement-note-16-leases-supplemental-cash-flow-information-details", "http://www.opko.com/20240930/role/statement-note-16-leases-tables", "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-details-textual", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-tables", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-tables", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments-gains-and-losses-on-equity-securities-details", "http://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-details", "http://www.opko.com/20240930/role/statement-note-6-investments-tables", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details-parentheticals", "http://www.opko.com/20240930/role/statement-note-7-debt-tables", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-changed-in-accumulated-other-comprehensive-loss-details", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-tables", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-tables", "http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r291", "r292", "r293", "r332", "r619", "r654", "r753", "r778", "r791", "r792", "r793", "r794", "r796", "r797", "r800", "r803", "r804", "r805", "r806", "r807", "r809", "r810", "r811", "r812", "r814", "r815", "r816", "r817", "r818", "r820", "r823", "r824", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r843", "r987"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": ["r220", "r305", "r518", "r1005", "r1009", "r1054"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited", "http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization", "http://www.opko.com/20240930/role/statement-note-1-business-and-organization-details-textual", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-tables", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-composition-of-revenue-from-services-details", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-tables", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments", "http://www.opko.com/20240930/role/statement-note-15-segments-assets-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details", "http://www.opko.com/20240930/role/statement-note-15-segments-tables", "http://www.opko.com/20240930/role/statement-note-16-leases", "http://www.opko.com/20240930/role/statement-note-16-leases-details-textual", "http://www.opko.com/20240930/role/statement-note-16-leases-lease-balances-details", "http://www.opko.com/20240930/role/statement-note-16-leases-supplemental-cash-flow-information-details", "http://www.opko.com/20240930/role/statement-note-16-leases-tables", "http://www.opko.com/20240930/role/statement-note-16-leases-undiscounted-future-minimum-lease-payments-details", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates", "http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-details-textual", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-tables", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-tables", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments-gains-and-losses-on-equity-securities-details", "http://www.opko.com/20240930/role/statement-note-6-investments-schedule-of-investments-details", "http://www.opko.com/20240930/role/statement-note-6-investments-tables", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-instruments-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-line-of-credit-facilities-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details-parentheticals", "http://www.opko.com/20240930/role/statement-note-7-debt-tables", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-changed-in-accumulated-other-comprehensive-loss-details", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-tables", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-tables", "http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r291", "r292", "r293", "r332", "r378", "r619", "r654", "r753", "r778", "r791", "r792", "r793", "r794", "r796", "r797", "r800", "r803", "r804", "r805", "r806", "r807", "r809", "r810", "r811", "r812", "r814", "r815", "r816", "r817", "r818", "r820", "r823", "r824", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r843", "r987"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "terseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": ["r13", "r95", "r96", "r135"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation", "terseLabel": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r13", "r95", "r96", "r135"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-details-textual"], "lang": { "en-us": { "role": { "label": "Exercise of common stock options and warrants (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)", "documentation": "Number of share options (or share units) exercised during the

current period." } } }, "auth_ref": ["r13", "r95", "r96", "r135", "r521"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "2025 Notes", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r13", "r96", "r99", "r100", "r135"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "Exercise of common stock options and warrants", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r13", "r96", "r99", "r100", "r135"] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "srt_StockRepurchaseProgramAuthorizedAmount1", "terseLabel": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": ["r1117"] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchasedDuringPeriodShares", "terseLabel": "Stock Repurchased During Period, Shares (in shares)", "negatedLabel": "Share repurchase (in shares)", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r13", "r95", "r96", "r135", "r761", "r843", "r879"] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_StockRepurchasedDuringPeriodValue", "terseLabel": "Stock Repurchased During Period, Value", "negatedLabel": "Share repurchase", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r13", "r95", "r96", "r135", "r767", "r843", "r879", "r993"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-changed-in-accumulated-other-comprehensive-loss-details"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Balance at December 31, 2023", "periodEndLabel": "Balance at September 30, 2024", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r96", "r99", "r100", "r124", "r802", "r819", "r844", "r845", "r960", "r994", "r1048", "r1071", "r1152", "r1212"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityPolicyTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": ["r11", "r846"] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions"], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r1027"] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL INFORMATION:" } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-tables", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-tables", "http://www.opko.com/20240930/role/statement-note-15-segments-tables", "http://www.opko.com/20240930/role/statement-note-16-leases-tables", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-tables", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-tables", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-tables", "http://www.opko.com/20240930/role/statement-note-6-investments-tables", "http://www.opko.com/20240930/role/statement-note-7-debt-tables", "http://www.opko.com/20240930/role/statement-note-8-accumulated-other-comprehensive-loss-tables", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-tables"], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "documentation": "Information by period subject to enacted tax law." } } }, "auth_ref": ["r1122"] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": ["r1122"] }, "opk_TaxYear2014ThroughTaxYear2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "TaxYear2014ThroughTaxYear2020Member", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Tax Year 2014 Through Tax Year 2020 [Member]", "documentation": "Represents tax year 2014 through tax year 2020." } } }, "auth_ref": [] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Taxes payable", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r85", "r86"] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": ["r17", "r1086", "r1087", "r1088", "r1089", "r1091", "r1092", "r1094", "r1095"] }, "opk_The2023ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "The2023ConvertibleNotesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "The 2023 Convertible Notes [Member]", "documentation": "Represents the 2023 Convertible Notes." } } }, "auth_ref": [] }, "opk_The2025ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "The2025ConvertibleNotesMember", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "The 2025 Convertible Notes [Member]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [] }, "opk_The2025NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "The2025NotesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "The 2025 Notes [Member]", "documentation": "Represents the 2025 notes." } } }, "auth_ref": [] }, "opk_The2029Convertible144ANotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "The2029Convertible144ANotesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-longterm-debt-details-parentheticals"], "lang": { "en-us": { "role": { "label": "The 2029 Convertible 144A Notes [Member]", "documentation": "Information pertaining to the debt." } } }, "auth_ref": [] }, "opk_The2029ConvertibleAffiliateNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "The2029ConvertibleAffiliateNotesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "The 2029 Convertible Affiliate Notes [Member]", "documentation": "Information pertaining to the debt." } } }, "auth_ref": [] }, "opk_The2029ConvertibleNotes1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "The2029ConvertibleNotes1Member", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-", "http://www.opko.com/20240930/role/statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details"], "lang": { "en-us": { "role": { "label": "The 2029 Convertible Notes 1 [Member]", "documentation": "Represents the 2029 Convertible Notes." } } }, "auth_ref": [] }, "opk_The2029ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "The2029ConvertibleNotesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "The 2029 Convertible Notes [Member]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [] }, "opk_The2033SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "The2033SeniorNotesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details", "http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "The 2033 Senior Notes [Member]", "documentation": "Relating to the 2033 Senior Notes." } } }, "auth_ref": [] }, "opk_The2044NotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "The2044NotesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt",

"http://www.opko.com/20240930/role/statement-note-7-debt-details-textual", "http://www.opko.com/20240930/role/statement-note-7-debt-schedule-of-debt-details"], "lang": { "en-us": { "role": { "label": "The 2044 Notes [Member]", "documentation": "Related to the 2044 notes." } } }, "auth_ref": [] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-details-textual", "http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details"], "lang": { "en-us": { "role": { "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": ["r54", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.opko.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "opk_TransferOfIntellectualPropertyAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "TransferOfIntellectualPropertyAndOtherMember", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "Transfer of Intellectual Property and Other [Member]", "documentation": "Represents transfer of intellectual property and other." } } }, "auth_ref": [] }, "opk_TransitionServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "TransitionServicesAgreementMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Transition Services Agreement [Member]", "documentation": "Represents Transition Services Agreement." } } }, "auth_ref": [] }, "opk_TransitionTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "TransitionTherapeuticsMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details"], "lang": { "en-us": { "role": { "label": "Transition Therapeutics [Member]", "documentation": "Relating to Transition Therapeutics." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockAcquiredAverageCostPerShare", "terseLabel": "Shares Acquired, Average Cost Per Share (in dollars per share)", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": ["r50"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://www.opko.com/20240930/role/statement-consolidated-statements-of-equity-unaudited-"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r50"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares (in shares)", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r50"] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_TreasuryStockCommonValue", "negatedLabel": "Treasury Stock - 29,800,177, and 8,655,082 shares at September 30, 2024 and December 31, 2023, respectively", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r50", "r51", "r99"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r557"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies", "http://www.opko.com/20240930/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.opko.com/20240930/role/statement-note-15-segments-operations-by-segment-details"], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments-tables"], "lang": { "en-us": { "role": { "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "documentation": "Tabular disclosure of unrealized gains and losses on investments." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": ["r536", "r948"] }, "us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnusualOrInfrequentItemsDisclosureTextBlock", "presentation": ["http://www.opko.com/20240930/role/statement-note-2-foreign-exchange-rates"], "lang": { "en-us": { "role": { "label": "Unusual or Infrequent Items, or Both, Disclosure [Text Block]", "documentation": "The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": ["r116"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.opko.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r36", "r37", "r38", "r167", "r169", "r172", "r173"] }, "us-gaap_ValuationAllowancesAndReservesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesBalance", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ValuationAllowancesAndReservesBalance", "periodStartLabel": "Balance at beginning", "periodEndLabel": "Balance at end", "documentation": "Amount of valuation and qualifying accounts and reserves." } } }, "auth_ref": ["r286", "r290"] }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "crdr": "credit", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details"], "lang": { "en-us": { "role": { "label": "Provision related to current period sales", "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense." } } }, "auth_ref": ["r287"] }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesDeductions", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ValuationAllowancesAndReservesDeductions", "negatedLabel": "Credits or payments made", "documentation": "Amount of decrease in valuation and qualifying accounts and reserves." } } }, "auth_ref": ["r289"] }, "us-gaap_ValuationAllowancesAndReservesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details"], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "documentation": "Valuation and qualifying accounts and reserves." } } }, "auth_ref": ["r286", "r287", "r288", "r289", "r290"] }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesTypeAxis", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details"], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "documentation": "Information by valuation and qualifying accounts and reserves." } } }, "auth_ref": ["r286", "r287", "r288", "r289", "r290"] }, "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Variable Interest Entity, Not Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity." } } }, "auth_ref": [] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-16-leases-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_VariableLeaseCost", "terseLabel": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r628", "r959"] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt", "http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "opk_VbiVaccinesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "VbiVaccinesIncMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "VBI Vaccines Inc. [Member]", "documentation": "Relating to VBI Vaccines." } } }, "auth_ref": [] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VehiclesMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies", "http://www.opko.com/20240930/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"], "lang": { "en-us": { "role": { "label": "Vehicles [Member]", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "opk_ViforFreseniusMedicalCareRenalPharmaLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ViforFreseniusMedicalCareRenalPharmaLtdMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-13-revenue-recognition", "http://www.opko.com/20240930/role/statement-note-13-revenue-recognition-details-textual", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances", "http://www.opko.com/20240930/role/statement-note-14-strategic-alliances-details-textual"], "lang": { "en-us": { "role": { "label": "Vifor Fresenius Medical Care Renal Pharma Ltd. [Member]", "documentation": "Represents Vifor Fresenius Medical Care Renal Pharma Ltd." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "totalLabel": "Dilutive potential shares (in shares)", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": ["r1057"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding, diluted (in shares)", "totalLabel": "Weighted average common shares outstanding, diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per

unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r309", "r326"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.opko.com/20240930/role/statement-condensed-consolidated-statements-of-operations-unaudited", "http://www.opko.com/20240930/role/statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details"], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding, basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r307", "r326"] }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WriteOffOfDeferredDebtIssuanceCost", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_WriteOffOfDeferredDebtIssuanceCost", "terseLabel": "Deferred Debt Issuance Cost, Writeoff", "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt." } } }, "auth_ref": ["r113"] }, "opk_WriteoffOfUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.opko.com/20240930", "localname": "WriteoffOfUnamortizedDiscount", "crdr": "debit", "presentation": ["http://www.opko.com/20240930/role/statement-note-7-debt-details-textual"], "lang": { "en-us": { "role": { "label": "opk_WriteoffOfUnamortizedDiscount", "terseLabel": "Write-off of Unamortized Discount", "documentation": "Amount of write-off of unamortized discount" } } }, "auth_ref": [] }, "opk_XeneticMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "XeneticMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Xenetic [Member]", "documentation": "Represents Xenetic." } } }, "auth_ref": [] }, "opk_ZebraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.opko.com/20240930", "localname": "ZebraMember", "presentation": ["http://www.opko.com/20240930/role/statement-note-11-related-party-transactions", "http://www.opko.com/20240930/role/statement-note-11-related-party-transactions-details-textual", "http://www.opko.com/20240930/role/statement-note-6-investments", "http://www.opko.com/20240930/role/statement-note-6-investments-details-textual"], "lang": { "en-us": { "role": { "label": "Zebra [Member]", "documentation": "Represents Zebra." } } }, "auth_ref": [] }, "opk_statement-statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-10-derivative-contracts-summary-of-fair-values-and-presentation-of-derivatives-financial-instruments-details", "lang": { "en-us": { "role": { "label": "Note 10 - Derivative Contracts - Summary of Fair Values and Presentation of Derivatives Financial Instruments (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-10-derivative-contracts-summary-of-gains-and-losses-recorded-details", "lang": { "en-us": { "role": { "label": "Note 10 - Derivative Contracts - Summary of Gains and Losses Recorded (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-10-derivative-contracts-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-10-derivative-contracts-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Derivative Contracts" } } }, "auth_ref": [] }, "opk_statement-statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-13-revenue-recognition-analysis-of-product-sales-allowances-and-accruals-details", "lang": { "en-us": { "role": { "label": "Note 13 - Revenue Recognition - Analysis of Product Sales Allowances and Accruals (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-13-revenue-recognition-composition-of-revenue-from-services-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-13-revenue-recognition-composition-of-revenue-from-services-details", "lang": { "en-us": { "role": { "label": "Note 13 - Revenue Recognition - Composition of Revenue From Services (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-13-revenue-recognition-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-13-revenue-recognition-tables", "lang": { "en-us": { "role": { "label": "Note 13 - Revenue Recognition" } } }, "auth_ref": [] }, "opk_statement-statement-note-15-segments-assets-by-segment-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-15-segments-assets-by-segment-details", "lang": { "en-us": { "role": { "label": "Note 15 - Segments - Assets by Segment (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-15-segments-operations-by-segment-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-15-segments-operations-by-segment-details", "lang": { "en-us": { "role": { "label": "Note 15 - Segments - Operations by Segment (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-15-segments-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-15-segments-tables", "lang": { "en-us": { "role": { "label": "Note 15 - Segments" } } }, "auth_ref": [] }, "opk_statement-statement-note-16-leases-lease-balances-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-16-leases-lease-balances-details", "lang": { "en-us": { "role": { "label": "Note 16 - Leases - Lease Balances (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-16-leases-supplemental-cash-flow-information-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-16-leases-supplemental-cash-flow-information-details", "lang": { "en-us": { "role": { "label": "Note 16 - Leases - Supplemental Cash Flow Information (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-16-leases-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-16-leases-tables", "lang": { "en-us": { "role": { "label": "Note 16 - Leases" } } }, "auth_ref": [] }, "opk_statement-statement-note-16-leases-undiscounted-future-minimum-lease-payments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-16-leases-undiscounted-future-minimum-lease-payments-details", "lang": { "en-us": { "role": { "label": "Note 16 - Leases - Undiscounted Future Minimum Lease Payments (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-reconciliation-of-cash-details", "lang": { "en-us": { "role": { "label": "Note 3 - Summary of Significant Accounting Policies - Reconciliation of Cash (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-3-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "opk_statement-statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-4-earnings-loss-per-share-schedule-of-earnings-loss-per-share-details", "lang": { "en-us": { "role": { "label": "Note 4 - Earnings (Loss) Per Share - Schedule of Earnings (Loss) Per Share (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-4-earnings-loss-per-share-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-4-earnings-loss-per-share-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Earnings (Loss) Per Share" } } }, "auth_ref": [] }, "opk_statement-statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-financial-statement-information-details", "lang": { "en-us": { "role": { "label": "Note 5 - Composition of Certain Financial Statement Captions - Schedule of Financial Statement Information (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-5-composition-of-certain-financial-statement-captions-schedule-of-goodwill-details", "lang": { "en-us": { "role": { "label": "Note 5 - Composition of Certain Financial Statement Captions - Schedule of Goodwill (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-5-composition-of-certain-financial-statement-captions-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-5-composition-of-certain-financial-statement-captions-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Composition of Certain Financial Statement Captions" } } }, "auth_ref": [] }, "opk_statement-statement-note-6-investments-gains-and-losses-on-equity-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-6-investments-gains-and-losses-on-equity-securities-details", "lang": { "en-us": { "role": { "label": "Note 6 - Investments - Gains and Losses on Equity Securities (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-6-investments-schedule-of-investments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-6-investments-schedule-of-investments-details", "lang": { "en-us": { "role": { "label": "Note 6 - Investments - Schedule of Investments (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-6-investments-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-6-investments-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Investments" } } }, "auth_ref": [] }, "opk_statement-statement-note-7-debt-schedule-of-debt-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-7-debt-schedule-of-debt-details", "lang": { "en-us": { "role": { "label": "Note 7 - Debt - Schedule of Debt (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-7-debt-schedule-of-debt-instruments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-7-debt-schedule-of-debt-instruments-details", "lang": { "en-us": { "role": { "label": "Note 7 - Debt - Schedule of Debt Instruments (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-7-debt-schedule-of-line-of-credit-facilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-7-debt-schedule-of-line-of-credit-facilities-details", "lang": { "en-us": { "role": { "label": "Note 7 - Debt - Schedule of Line of Credit Facilities (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-7-debt-schedule-of-longterm-debt-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-7-debt-schedule-of-longterm-debt-details", "lang": { "en-us": { "role": { "label": "Note 7 - Debt - Schedule of Long-term Debt (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-7-debt-schedule-of-longterm-debt-details-parentheticals": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-7-debt-schedule-of-longterm-debt-details-parentheticals", "lang": { "en-us": { "role": { "label": "Note 7 - Debt - Schedule of Long-term Debt (Details) (Parentheticals)" } } }, "auth_ref": [] }, "opk_statement-statement-note-7-debt-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-7-debt-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Debt" } } }, "auth_ref": [] }, "opk_statement-statement-note-8-accumulated-other-comprehensive-loss-changed-in-accumulated-other-comprehensive-loss-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-8-accumulated-other-comprehensive-loss-changed-in-accumulated-other-comprehensive-loss-details", "lang": { "en-us": { "role": { "label": "Note 8 - Accumulated Other Comprehensive Loss - Changed in Accumulated Other Comprehensive Loss (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-8-accumulated-other-comprehensive-loss-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-8-accumulated-other-comprehensive-loss-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Accumulated Other Comprehensive Loss" } } }, "auth_ref": [] }, "opk_statement-statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-9-fair-value-measurements-carrying-value-and-estimated-fair-value-of-notes-details", "lang": { "en-us": { "role": { "label": "Note 9 - Fair Value Measurements - Carrying Value and Estimated Fair Value of Notes (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-9-fair-value-measurements-financial-assets-and-liabilities-measured-on-a-recurring-basis-details", "lang": { "en-us": { "role": { "label": "Note 9 - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-9-fair-value-measurements-reconciliation-of-level-3-instruments-details", "lang": { "en-us": { "role": { "label": "Note 9 - Fair Value Measurements - Reconciliation of Level 3 Instruments (Details)" } } }, "auth_ref": [] }, "opk_statement-statement-note-9-fair-value-measurements-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-note-9-fair-value-measurements-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Fair Value Measurements" } } }, "auth_ref": [] }, "opk_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.opko.com/20240930", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480463/815-10-45-5" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-13" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-14" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Paragraph": "2AA", "Subparagraph": "(a)", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "15", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480960/815-15-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" },

"r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220-20/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic":

"10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Footnote": "4", "Publisher": "SEC" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4",

"Publisher": "SEC" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",

"Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r419": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",

"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12A" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r547": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-5A" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-

45-20" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-15" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r676": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-33" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-35A" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r798": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r856": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r914": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r915": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r916": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r917": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47",

"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r918": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r919": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r920": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r921": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r922": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r923": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r924": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r925": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r926": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r927": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r928": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r929": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r930": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r931": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r932": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r933": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r934": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r935": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r936": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r937": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r938": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r939": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r940": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r941": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r942": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r945": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r946": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r947": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r948": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r949": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r950": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r951": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r952": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r953": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r954": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r955": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r956": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r957": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r958": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r959": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r960": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r961": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-12" }, "r962": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r963": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r964": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r965": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r966": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-34" }, "r967": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r968": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-3" }, "r969": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r970": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r971": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r972": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-7" }, "r973": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r974": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r975": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r976": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r977": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r978": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r979": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r980": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r981": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r982": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r983": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r984": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r985": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",

"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r986": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r987": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r988": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r989": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r990": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r991": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r992": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r993": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r994": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1001": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1002": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1003": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1004": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1005": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1006": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1007": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1008": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1009": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-1" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/321/tableOfContent" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org/325/tableOfContent" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "6", "Subsection": "04", "Paragraph": "12", "Subparagraph": "(b)(1)", "Publisher": "SEC" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "712", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481179/712-10-25-4" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "712", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481179/712-10-25-5" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "15", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815-15/tableOfContent" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1180": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 93 0001437749-24-033931-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-033931-xbrl.zip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l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

M5T[]MUK%\%TN1B^)NHI9$1Z%.] /'1DY_EBGSRN2@C(O9G4I2B[-&D+@ES7:!70G;W>EB.@NIR,,/OKU2)&4E5S8+;W%D7__ M35T.PKF(=5'Z6_YU.F5*+)/\!'=I'>Y1WQ'AYYVG-X1&2"?=O=J=RK%E,J8 M@55+3K4N8"SI\,...$A^[AO].R*#U^"ZY10+Y5<|'*TF9*'1U5RZ/"|"X,.. M@KJ.:*;TM|8F(-&RVD"6((FT3=S4*:3#976"+(PS=U6:2KJL2I!%04"PDIVP M@ <@\!A$Q>"=QS]V\$,1)/H'X2&,&S&+9SZV0SG17'8\S/?YI\K(]NDC%ZU[] M(5LNW=Q8:0S5)TC^96]OS_,]LXQ7^><)#[USS=:[G+-]OUOCM2!&HFAXPW_1 MOVMM(LN<4;1EK *O?[ZZ=W M%4&WH*L;0'!0OACZ..YFX"3RM?6S Z&0$IV7)O"N0; NGS*Q-QJ1_)NC>SL>8U9'3 MGX4MD!PO@J0)&N=:B"T<^K=RHL;^,!)?OU6O8N)G"RAO5NI-0"+O B7:P@;-MR$5,_7U_D"C&*73Z&!U#;1/._EHGVNXLUA8(?L(8FZD 1JQ$4OCC$W#V,,#Z MF/'V@+=W4^+]PHU]X ^%I&S$?5R1(WQ$?=S1L6KTTUZF+3/_;#0SQC@7*6/O M/&/LW2'C%V[C0U\EDPF1,^R$%50/&T+0AI-?@5Y^9GSD3Z&'#-AZ=E^*CRTL MO#5B08V14QH1Q'\0F/& D M\DLN'9GJ<'T=$*S&T!9]HT .=;.82&5=@-3J;R+7*J2)WF:2?7"H?/&9_R1 MJEB[SNM HEJ0+5.?&$V-,<'EG-L+-^'?D@\3JVRTJP9;1#H|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|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|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lO,OJ;PQ&Q4D[H/I\-(3B:C#VN8@(H:;#M">XY#UQCR+<<=4]+5G?BU1*TW&%W".!HXYE]*41#@ NUU!QBDI:\$N)35R%"5 Z-W1E'6"X6%4972$PF@.;?AUI]>303-00T' M94HZ@.:@AD.$L@A%QO&C5C%8X%&8+}+9"'1C3V2R?GEC&G@~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|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|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|N;9"0C<<F<#M/9:4IY4\)('A.I(- N|LJ_YE|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|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

[WFA_K/O*H%N*0!HMA SN!8A M=;_:LY.B);,<6;^]E[LJ$$VXV&OUP_L)(X\DKPC_;TSGS6,L:OZ,QO13Z=!! M)(OZAE!58"/5<%4%)W',=X9D4S%X$ZTIFSX2MFH*(U_0?
5RGT4.;I0>I4+;# M6&,XY;=")"'9W9-1U477(ED>1IQ:=C(FSRLXAQY2CG#Z\9(Z]+ M^33JU+,_W"ITZI"J.#2;-N]!YI!N>/_7\Q2DESE-XP\IK0JFMBS ?9N
WM]'YNO(LA%VA!,4&%K23J2.T:728US'Y$E:JB7V]4[\-!%5JWWFE&D*T"_FK= M?5RCS0X'G/)H5J#M-DFA$1)4*[3O4P3Y G;TT4&QC=&ER]C@+B M,:A6K',5%_D2M?
JLL/@GNB0OV^U(&WU&@lCJZUH$X-!EN5E^B--M[8.9GG-Q_XP M*4$0>,\C2=\ZTK%BK3EH#<:TT\^=@>10C[VV\O'GG,=DI\9$]MOF'"]9S5 MHXKJEULB7@=?
OZU'6/&\O+_DY(DK4F6'H^W"JQ[0P.^! \ QO52N!SR-97K)?Z7? M^'E[F;*B%+0"XM"-,K&E&."!#]8;GM9-T ""LG]_4E>K5>.QN:3L)'FLU:'9 MWFPW00 =JSEB9O4S?$
MFZA:/!=WS)=WZSQA=$FV&2MRV0#-K66Z2-F&J,\X)F:2*IQ&WJK%BD*\F';/W= MGU32)2%I@4\R[RLTL"Z@E-8_ZX+PC4@^_L%O?]21[GTMO^*1*/!EX$<3^#*. M%RE>O@P)/E ?
SRC82CC-B=8K9]##*P*N'=>WE&P)7Y^UK!O"8BY=-">G:SZ3 M1&8PHOE_]+QI(L%G/1X^]#<1.XRA68S@%>$V%'O/3^}_5RDC6T&O\O07$*$%G MV-LS\THF[:;@UEY-
:2\X5CD'72GWA=G_Q Y7>__HB K,1\@,/CX0*S.HE1C MA/4-O$2!ERCP$GDD[SGT/U"-(P ;@B-F5FIW^5* WQ4;DC?"$04*P%&ST!%/&0*Z8//-QA;XEUR"D]S5ND\')#EF7K
M*T(SH0%:$>T0#4 UB?O2&X_D/FI->@^:J:HR.ZEA'CF]^6EJ;!_)'=.N6(_Z MGWE2I]KK:8=^JOGD;D).%BAE&$ %3[/AV8+ @A$XKTQ:#LB[4*COPS&*8U$@^W^Q5L(MQ-
=Y);HM*QC?EVR;BCP!R,W]NM!ZW5V@.E(_>IYOC"W,,<"@?X-"5#KVCD@ MWE^1X>U430=54_REMCC\N/I"4"C\,:AI>FI2*%HLJIDE%RX4[A@T,D-R:2AT MO.H:A+@?
BA*3CN:"Z!^*>PSJEBDM-Q3[&-0N4XIU*'8LFIB+2R&@F+%I8QTJ MF:&.$VRZF %Q"A0B7GW+X';0'5@/EXS]/-DX06UO%M,/U*#K^SHQ!$A#C%]
M"F@O4@UW4]CG2JSGZ>Q3]",*MCM.V[T#ZH8>V6+YDJCW%BT/;UO# >0$<-]V M-QV#K,.RSL6Q<)\)6C8XOXD9JTC5-<]^L:L*WPNH7>IL67T])'B^6$?NJ9!R"
M=CL&+$.SWKT2;OTLGH)6!=IM:"RB&MD,QNL>PR(0TIA-KL,>XT4P[,K8G/T' M\JG9%&&]O"+9.KPW]UQ+))>T\B_I1H>_R-)EFLLOP#'JXQ7%5H6\)2O*2G$ MWVW,$@D$?
0=,_'/*KV'4=PA426;W/N!*A%9N]IH)XT&7::RW=Z#(8?9(7<, MV+Q$,U5-]DS:T>1=:E>GRD82C/[G<,*^%IW6.>T]:Z X8=NJ?/ M#O.; Z'B(7]R1<)S?/OUH6+
(^;J#08+ZN_P>FI[S>+!]P9)9"G(+ S%A2AF% MQ/>]9N'\,LE(5!#;'!S=,'XR<&!2A/R;-Y=_\XDFY.E^05BT(E69QH7JPG%] M8VMYIK-9&I.[512W)U,HV]@_G6MUD2"]N!:KY1-7-
!;9^E:X>UI#="9=_&:F M,!*)8YQ/F7HGV'*52"("NN9>9;],;FY\%V%?&LDE((!]1HJ3^ M?IA;8Z3^?R-3;X3Q #,_&A @%O8(]D(A(6%',+8(0?$AX4 FC2^0Q3O9\4 MU7(9L?
6$SB9%.L]3KO|&_->HR9K@OF?3UCNJ56+=\V=I7))D(_;+?]AKJ4!K/:;G$J97XG7ZRAU'0854 MT/15;)^'T1#DX0#!61X*OJ3^AY&[94,.:/ -(:-M.IP](W4/69VW(_4:=3U^ M1^9
ZD&5]&G4_Y5OG0_EI(@7)*DR(NS.C.;SDK!E\TLGB]UT5"_F>#>A@]U] MS+9V:VKF.9\,9S1_)$PH*.)O5T51"3?
C"YK[O)4M@M^&B5\TSDGC!\1@D%4/$\CG;]3M7RW)*;S9B\6U_@\E(HO MJFUK+X6MNV<9IT08.!:W';U]P%3UMWK]CD9T%S$+R3@ +W\X[F*N=*=274 M/$7BN[SA@/)N;;
[6@]NDRX 8KO*8B=#D.6G^>TE9P\W/50L0(L@ ^(]O,!4 MB::EOM,1RCYH.<+)+H?0:I'$_SVAFA#&2;/(4ZD- M324K;U*?JA.7D8IJ_U3 MT]GACW)0W0<:&.]'OA2NN8H_S>W@
L<9&.UG>DWS.6&GZ:QB];5_S2'#=?DL M*HITEHJ+ .]*&G]=T"SABH!P8$D+_=P_P&\I$1>U3G@^M+M43;S*N+WZI-'^
M53X*@QXA!AIBH, .;4PO4%@)CD+1IZ9*V^ABO%!K!TU=_A[T$X>'%0A;3A&R$Ð(W01P 7!F@9:1*"K1TVTCP$0[_2-,/0)Z#D9:NR VMD16MF,<3 M1U:UTB4D"82(Z7928'@3B
S;:1@)P'TH,=VVC7 04+S;-QC!2#(6)3;^! MQY&A"+&I,MTBRU"TV%0:2T[H?/N%?A0W;YF\LN/UM$;$X>HOAK M\:RPW?*_ET3H<)=$DY6 Q1)I5*WLA%3O1C*O93;I3=B=5U
MLEU<)P4WTL3]'M-9[3:I?VT1KN,([MG2T3KBJIB<6;]]@?5S:Q2WI*Q8+I]' M\D;VT73-1>PWS5XY97>$/:9QV\W,NF:^9!1K:O-X^6WQVK;CD';0C#_-94L7
M3W%6)2(64Q2"B2]YCYY>87,P4LA[.0JBW*RJO2//NWS1E%WRR4Z*TR@3_R01 MWZ@O(E2-4I#<4V%(\7]7$]A;C84([3D1&QG_5;9R3+MCPJ;*V3;I>DR8!CVA MU
+>KU=>DRWSB%/L/?+L97*)372ZS!!ZSC?J,W>,MH4R2Z+$EW:I-'WHC8^ M!%3I>'XF^I%D6L*L:313&[;W4KT/!=6,M3YU,$S&GC8DG?L07;9E%Y ZCYM?
MD"&!.R1P'U\"=P<'#K]Q052D!,'B!Q;!E0WKPX0+#8$*&MO+A WE@PHZWB= MUY2*YWN.JSS9&%(DFVRN,I*%);H.@PJK9$EU[8X. MVSU_5M?)>= ?'[IOU ;;KC<>9+=$G-AAL<-
M$7Y*5GL.HWAE_'>)+)IV1XD->'+8#H<2N^8DZ3H,6JRJDZ7S.'C12D^: MCJ/@0VIR\M@/B >_X4ED-997U!(9);@TK4-Z:Z!U>W:T8DK7"K'($(L\OEBD MJP-VI %*6\MVI-%)-
X;12*.5=O[$D84JG5@/0,S8"!DZ^>: 6+&P,CBRA(&H ML1 U6'J6@6BQL#:X<>U %11L)%C=0B-0M%CT,4>Q52AL+'J894 <"G>L^E24978H)=Y34ELU^#/2=P4P7+-2;B?
VQ'"&@\B]RV)"7^/7)K/I(1)K^KB&P,_ MD9/M89@2R00#M_32S/:V-\)>?)0 MU#5(&$E?M_4J-5!!2YK7?.CU[282@67-/,OZ? 7$!IJ+^CJKS0$C%1W4:R@D
M^[*HISBLDU<6LEWE993/ MQ7=O]@W^CI[K&35RFW3UC.F13UK*UO)ITM;$;RK=;EI*1&QI,92$@@8#>M\L MM-M06-3I([*-IE ,S:&OI$"4_)II'D-?^6%;OU+3*-^>?/?T-
,J_:B:+KKUG MZ1L%1&QM15D''Z1R2UMB2*Q5OW18)PPXM#,?W&] -+?I?,$-WB]%<\B#D$CZ M^$4A3/B-7J+]#JJV_J4VV3SU';S*?\/(*DJW3"?_-]IM>IE;=#3,R+*YW:Y
MOLFBO"9QX4I,[1 6)'U[<:17<[X.ZN]YE,()BI$X;2A3\F3_BGI" 'U8,\< MXV64YB2YB%C.]XOBA:BS-YEP3>T6_) LE3REX8_Q(BI:A*.0(,,_!%A(2 MF^A0#(V-H>_@5?
Y[<4MDQ=:U6(T/4>5V#4/!42A@"@4$(4"HE>0 -$4O\L_M@$PM,^TK3P#=%]:^A^>&X'@\NCHP,$:YQQM=D1<8DI'1B*ZD"SY%K4'Y2R@V M^'Y^;5QTA5X&J!'97B0(M?J@"4YP*
O.@,%('B+=J[*24)G>QA#A.33HING M9BA-0K?HC!(SJ";Y=.B,$C.HP"P(=%:*(4HW2].?:>%D:5J>__Z,B\ZK4Y^V MB\ZT,,.]#3NB,S7,\!DE_.*S/0R7*3#=
Y_UT7FW'8\)TADB/F&$W311#9YB8 MP=5E$Z$S3,$@F963[, .0=OQW*'8T-F$-B85;^".L0/^A(',DP%##P=;XZG M8W?\;"]43/.*:]33Y\FR/99.R8PRTJSS3Z1^W.MW](JB_)B)KAYQ?
A91N*RXAK+)F""^375X>87Q'M@NW>VS M-PM6[F5N\K_MYISNYNV-[+!;TON747[G^:&@BOO11R&MLUVG$[/!7K)&/5E? MI#F\@F'6R2N.TZK@2F=1<$W](D6\ML!O"[A81(YKZ
M EWS064_C8HT!@K^HNV@4I^G6;6GQEYDVEWSWP4.LVST3B?0QBD^)3FE/$M=ZM<\HWLY2@2[53R>@:0 M8, W;/-N*B7V.3X'Q*8Z#; +)5>V\,[ATSS M[9OWNI5/*KZZN5?
9^6ZWF]02@5O;^)5R[Q.WHER^O4QB77L MU"\;U,^<2"*?R6G4:([H]M]I$&_ZB1I$GO]<$(# PG]H4@AAGX*"SA[/]8-J;A/K>6A%=M),>]3QAU.8 M!6C2(<6(4
($_'[$P"H46(6.CU5(;02B.=^TXAY"ZFZFH]E'S3XET+F(IOJ MY7Y1!0!+J4"W'(U0=G%HN)NU1H@-_(;H*B*,@ Z2((6ND,+HE9DDV:&KH3!" MZB2G"EV=A=$KT 3V@.#\U7MW
R>+HZ';VV"JAV$L&9T* I?_%8^A/M,"G2+2 M$2LP*0:=%M();KD&$$=]$0-^-+\L=LX6%XN%X8_VIMNFZ@\C1/=*0%3:F%5(.AT6:W8"H@M M$79T^JL-OM:Z$G0]JPE"B]P)=.JJ
]RPW)@=\N')&>*H6$QF&?W6&SF#Z@DH MR!GT @9RAC='SM!XO(NK_#)*6A%+%"=X62I7-MB%$&,\[YO99*OQ9K_-#>R+I[B>9[=GI'LKK;B?\X(_
)IDZZ!$,VI:^[&Y$.23JA^#M,.S [Z(M:?_9 M* %#]XTR,-+M7;@FG[2ES\ HGJ?2AL%>X]L,P'V!H?"_6BY(0U*SSP+@VMQ9O MS8W6VXO!.$T&&XO"3'=TM[;R39?5YKY[]G;MW'<2$.8#
(,6GXZ[J/! &O(TZ M:_$]%0,@Q=?M>P(&PH#7W*O??:! W]=&@%?'19XGR_:*=I&^)H(E>B(\L_Y^ MJ<+JJX'^=RIR;I7$C_*&GN5=UX;Z)67[TNKHJCXS"'] M4!6@QR
([NE)_.]9<^%*E?Y7?50I$D:L<8N/)G-N'$4E=+SR&:H83%_BMA7 M4@I[?Y?; 06IZCLLJ@W)1QJHOJ4 W,\W">)SXL+>/:@MB20&/09#T.0JI"); M83K;AF?
EUS"H"B[SPPKBWUSTT6Y:+62(BZ:DG>LAC!,QWGZEDC@.US@IZ#@"L M'&W[P:1OMB+@JS][%=ND>$^G7'3L#ZDIP_-;9)7^38VRC7EQE A+^!*ET&S M'0\=>LE=\1;X-
2/Z)3O=5.201%R:2O)"E6.A;AQ(98^ 5/:N6]T: K0HVR;$ M;AC1="X.DZZ!6#40!0:BP$ 4^ J2KX._3 M?ADGR*+;1(9X;;[(!H%.,1+@A?.H*L'"^)U]8HCW!K$_T1$H#?&B
M3)*VT5$F^7QA_55JHZ-G\OU:H479Z"B9AEBPF E[_7%"#:.6&Y3!037B(IE2CEY,AP1"=,I53W-$GQZ.3J?J:U($R_1;9HIS0QUFCTZ M1@)P-?@CJT7W1GA9GZ ZU[&HC)8:);7\KH9=
X9 M]U_?'KW'>X*.+$29ZB.9\-?= MWW5Z@"?AN%8/+&BX7D]?GSS>Z_7L+XO9GTB-MK2]_?F5Q 8] I'E@91URE'+ MJWN5M':/3Z>";\9-C6C]MZRI/WA..-
^^[!M1^\=_*+D]]U#5.0KW](9O^5(R MI4%D0/&6Q6<'R*QAVG \>B!N\4_<$DA. LE)(#EYJR0G1\;FT7S/88O#D=,AI22:_3-
(=Z<.DB!AFZ#]VW6\%6LN!'.&8_0NOEWTT9P!XWREG$V#K-YS5;P[9,X"I_S<2P=_MW MUR$6WB*5BU]H&OYJ7)I7;K+M7F;_PM<@R\2:WKY!OJ:U$\3V,[/SROZ;:ZZ?KTI6@9O
M7O#F!6]>\.8%;YZ?/%N'[(W8_'J6FB]^'"XE:CMS"UT9D5NPKC\ZMLK2KCH_ MNB(A$[BF1@"ZF]!N8#L: >A]@] KO*O7"UTE$.QS:VTCG][]OW*M[]%\X>&N M_Z&3/Q\XF!Q23=[
M&7?EOY_YG"[D4BD;6LOQ7S>?^(X8Y6>B3%LJA**5M03B+6]?\7A/_;>_#'!+5W)-7/AE)IVCN2ZE=#J33MW4CU_GU3 MD0P02-
'4C2P?/@"D:&WDU9MY&F6BCNIN04AY+1XI%+/#;1]:?'#96T]/>(>Q MRN],'^B"HR:)>;[$0#%[Y T'E/=SM"3*MZYK/D;9!YTO@ NZ![^$>U^ ,V4P M5-%R,
(FU$5QU8_]U#CL9]AAL6\].TVXAEAEBF<_^'4RQ3#40L,)%S=4;C#@5 MJ@$U/8I%%Y.&ZD?H\MFUWX,:VX"HPN]N9J=55-Y?L-KL8X+<#.B"UD88M3X" M=-%ILT\(\E^A"TH;850X6-
!%F:' M$Y<= %E*#)SS[W?3=3A40]SI*$[\ $] M)H7'.U">]6XT[I&<^?#O>6T5FT&G"," =W,V^ 4;W?@=@'K M
B^=^P\>4P_Y#*,3/\2GCRX^W6P6NTU"&Z/6=PBQW1#;E=I]@WK2WDAL-SA$ MX0XT"ID)E?OE^/RDP8.6/&C'I4&S<3AA-.\M2/I^X
M2DB8HFY0VLCZ^1_I(V'Y4B^#NJ&U'\@458NXHB1JUS0(R@DT36UM[+5NY9 MU_QON]G"_R"N/DVJN)RRNV8UMTP973-?,HKP_.;Q1>NB [4=A[2#^@N;27G&
M)^54Y&6E?];VS6VS]]_1BG$Q%3YHT^[HL"E]O.8#'"N^0>?H1B!Q8 ,9-[D$ MO;7@,#FKBI(N";MXVMR8*?AX^/\2^9TY%B/Y]7^2;,:/*V4146L;SU+6VYA& MRI8VP?<=?-
=34T88]1T$U4ZB>D;"X*@[#8P# M_%%477QC$ OP@JL0=$W(*K[YS$@A]N,H MNR1 ")I.0^"XI>LH W\#6>LA)+^+^/98']_U&P7)K^[C%T66T6^B\NV2LG-:
M/92S*CO<12&0!GE*?%@B0?*4WD14:JQL/(M+9\E;4V&D?$V^O:)GWMMWE10VV&D_BW*]LVE> 5ACXHZ/%V'8>3_G;*O5SDW MSF,B/>_4C;W*?9W&
(O4PGY_,6$F2,91VAI:]WX(P*O*+5]0D0/'U'?QRF0H' MK:D+"]9I !SU40B1O:VA?WD/M!35Q 'T& +!9A^Y$_?:?R6N6U8WR[TW:T_R MY)S,")\'\R>;Z13V1=(5$RX MV=3B'S0;0M;
[Z$EZ7K0U":7O1U#Z7G]1D+- T=*OQ"1>Y#2C\W6=.VZDLQGU M]8N*10D1OC - $FS4&3NI=.G+]CK8HO7.(EVU>M?OM_+EZ#\G1#5^SI #'4^XBNWM,!=J#C&%W1IP5T@[QB
M=)6?#KXXV&4:Z","?809XD ?\1J229H\.F4""+%[@BHZ9:+K1Y55#:#3&("W ME "4^@T F@UO#YK!=VI;PA-D;XP6@X';4+,:-D98/DR(R5>D*==C95-09$M M/U:N!'E<::P4"="X,10?-
@U$';&$HL*F=G0HD85!:&Z +D4%S8=!#C3 H M4&P:B5EM!!0E-NW$MH('BAN;VF)24P UV[$I,B95XU",6#0;("T)%!86]<:" MTP0*%9NF ZF.@6+#HN^8<+]
L6%1<,Q89*#HL*DYSF\6_PF;?F/"9@"%B$V[MT2;308%A4U] 3!Y0YSM2OO5"\P&%B$5M>6D=PDJ)H!BQZ#"O/J,K>-CTEHZI M_E"X6%09XTH3*$ L^HSRQ+<%B4VMZ<3%
P6+3$YI\HW;%D.1!,N>/Q(V8+7X@?97GX-U9+2_IREE8A\D_+B3\K+*&UD_GZN! M>21|<,NOUD\\3Z-YSO6U-&ZO^U&VL7XZURQ(2>*%]-'M#:R?^W&S\$_B?U*1Z/>I
M=I.I23//H^N+,^5O2BDK&APN4B6\N$ID;#R M9LAH4(K)QXRDM<=S.M*E6D#$G1XSW4^@9[K*?O:BVQ5? MWY.775@MVE9]6!^6^Y4[0M?RHH'F#_""3U7WL%'&BY:SU9J()?
8DV5[_J=KK MZ1& V[L|EE\?+U"6+6R4P:VEU|*)APC YS+G_F*>[U13E2T%M0D%)D908.*A M?,H!]M
LY4M3]'[QN_!H%LX*,O2NDV]JE1T,TH,52=L&]=J9<5GCM(ID&F"L#@ML<6D MC\'^;'PI500&RF["@T85"8."1:WPKD\JEU:2&@& [M_>0?&K? (FQ]'=.W-&N/2MXX4!
[<4QY"DCML@<,6^+O< L.7SX'NB,W7U(%M MAKLLLRXW53_S">*I>'/\C3^Y^O^(]^38O),HMWAR':[J2YO<+*-ZJY@V#^- M>?
_4?"20I!'I0A_($XGI4GI:1"EG0XL_Y_]@T]2F>YOCQ+QN6/UZF4CG=U=%QU(^#XJR1TH5-)+= M-2E(]5:@4:#*S>_]S=\,!]9)>+D@N'VT*])&[.0++=CU(55&)V=8"I
M8%N#B!4)GTY5KY>(=']W[<=MU>"E0DZC$L(MY?-^Y<%(8A)-(MYTO*]=K*:% M'"KN7?=]:<9[!F!>%'6R:YJ>GQCO\ 3O"*^%HYLI3W9 FXT!B]<#;DW*W9#7
M9%6N/K,L8W\GZB:*C@AG#T^WST1T#,4:HV]B"1 M5GSG+$QA:D/J4(AX'1A E@@*$]\CHX]+NW5$ W4H4(?&1QUJ&I6@H#*ZC5)[MO+
()KJ=DSE@&:#^>4. 3,CQ$-.$B3+J5=WMC'[$%+2AU2F$2;0@Z0L7X,A! M\JT81FYT<<)%<@DEL);&S%KJG,DX.:1X: VS7V<&KB4MP1 MD.J*62IEAZ6UUTQE=F\-.,;GA45W-
=;6LR?'\GKG;@QE=M(463)4UD(MA^R1W9'3NSC.<%IZJ_\X-E' A4E5;4)6=DQ%"4M6/3G@BVYXYG7'UNJJTPP M9)'=%IA4CLEW!P&42\E@\\<&$Q2Z)++ZN[!N+@VJ\
(J=T\602@X1O!#!&U\$ M3[>V#S109]5;=QGJ^C1Y)DDVV9!E27D_D+S,;%UR(R)9MDW2E|UOHO8&S8MD M505C3AJQY^I)+<-:_;W?24BK; 5#&&O,8:SFVXX6E/_MXR5+-
Y1/&'R6N!7V M(;_N"")O2:M/YV_Y0:.6KH'3#>5C;DC>TS6?BFE\L6)E6ESQL?A?,12_)+E8 M3/@(5D;_6C[DC>]TS6?BFE\L6)E6ESQL?A?,12_)+E8 M3/@(5D;_6C[DC>

W_(_MIR== MOWS/OOWPXX_?L?^VGY:ID,?TDX_?/?OGS\]Q!N\C<[2'#@2 Y8R_:EDO_Q$ MXJAB;)P< A)^ ?\Z:SX[@U^=??C]V?0#-_C%8+_?KF_ M%M+\\3OXXKL; J^&VV5%<=
,JK<= ME8TRW>XR_+OOC)'>X2(ER65N&?)PMTZP/U114;E ?]JQ9?R/I(HRN\A/N[2- MF9HP;!GS29>6,=]@R_)QW*$]O!I JU.0DN@R^.H3_:G^$#H<,;J,7FW">QWC
MUPK3l;BVFFW?)#X8!-G]=@8KT_L?OW_/4-)?_.V"Q/LMSJME3DU%E59OU_F* M%%MFW1LB#"1K+_4YQY3!$D&*>K0'XU7K]BSKL+W!)]D7,%U1*&99\ MG)]]>?
C=_VQH(TH<<>]H1_Y?ONO G@YE630\CHIX EO]Q7/L@%Q M46NH(3AR!%R+$*! CP2U.% +!-5(4 W%NS@I3@'1YZNLB,&(RL:+747E$QO3 MOCQ;1!'N.Q"`[W!6E];I*5WGZ2J-
(_IS%,=D3Y>-?'VV(UD:I[AL?Q@PYC:ZTS#Q)F1=*]Q# MAP,M6QSHKB;OW=A;F2)BF^_6A3BGJ]/9]V?E?KN-BKUA'%L#-7;A3E#V;^L8:!WL&Y_@^YP@1X R'S$6WI^IF19C>EN
M!/>'LYAL=Z1,V7:6ZE2,"[K]R,]6S;ZDUR*,=O"9CJFW0<>FP)O@\;(,/U!E M..\@P@)PSB$,;H';/XCS41,K,SZE0O:FT8UZ_?$LS9]Q6<%O=-1FK+U-=1BB
MXT7,_TC%_+HC/1_Q'>7\E%A.L!.-N/WI+,%/E8:<#3:T*6 !+Q(UI^H9%U0 MFO.1J6$F3\G2".?<"-&?P9?>;_<9NQHBU8:?6/]E"[S!>9D^8^ZMJ_N95LXZR M/3[;XJC<%UAW$9?
MRZ:H3]'T(MT_4NF^HC#07P$&^MR#,1^!EIZ=*1E68[D; ML?WPGJX6S4DWU:"*])82VCE>K(ILN,4O0CLA_?,:6BO/\X;$/,15\EYF1)6 M%69[NW3\1/+U(RZVG](TXZ$](>S$]U_5]Q
M:ZOB>$+%CPS"0>U#37A&@B?F^:2T33#2D8C]\2RC/K/6/;*HK57O.J+A1[C@ M>/03(SLCT1)Q>U*P1EDX@P@&,*YYG&9IU%XG1.6&.LHL(,]99(,T13RAK[1 MX*\$SV]&!L%>
[*!Z(XBR#D283:%8*H@\]WR'$L&[MP&2?8=!!T3<::Y55@GZ"DA2 A8]<@K6KQ@L+D?B[&:Y.=F5#/R!*>\+G%#75 M"\30AVG089&&'GL'%3X>2P/\G(.WCBS%T*>]QV=SM!?^9=!-
A)BQ8,W5[JP) M25[2+ MC8$34YV5)CE%^12;CQXKZ?TW;(\0?IT9@7"9\\(_VT?1,K2'(6AV!M"S>= ! B#O5(K?I_F:%FZ17G"]@&XI*,:C?^^3ZNW MLQ4U1@A-
(<^#5;8DH1A:ZBMEI-+AA$]M!CGKT=Z,Z^F M50;3Z32"O*_M[!<:>B39E8,H@@IAA=M>"^E@5'>]UE$=MYOSN&R"S;;'7/JG2Z-;?F* ?/"] MQ76'Z2O1BLF9U-
US3$Y/T(>S\8;.*_T@S>6^UU ;/T@"/,W51#RKM[QPT<.' M@=)OE:#-0)E/GRQ] KSH^[GO[&U+A[I:&DRYQY=+5;IF^!YP564,^7(+KZZ6 M+U&10&T;M@V\BXKJ3?BH2:,/[?
=."K3\/852 *7W2LKJ!42;+2(4 =I@3@H M5*-"%:D/$21&[NQME8YP$BN\]YM4]?>(LK-(?)^-YMJ=V]&O?WU@8+LLA MP%!A%$WRY5[*0MFB4XB M"L$I JOIR,)(T_-
L.29QSTW@=/3MI/@$N MGY6X>$YCO4,WB^0\I 13@14T<=CI&ZSFHRN*E3K>'.LLM=*B1&CF(].?9]Z M&>51]@9'I;3CKB#)/J8M(\A'%&49>8$ZS-R<1'%
<[""RS)Z"&M/VH*W:&$.K M[K(&#GI[QX&C!P".EBUPML@N:^!?D1Z;"XZF4EN2!F_G;^QHX""$XCJGA@E? MD0*GZYPGXS!/VKXSY_,OD/_?\=
[/?/N'B=M4[6_D+SA*!6DNW,ZYM*C??VU; M 1"SVK;61F=4VW:!. [^OKL[6YLo>GR/=EQ>OP5JW4EUQUGOZ8[' 1\?P)3V_- MK[4\:-5.7243'B7N/\WIH_S-*959Y#E>3$"A/C7NI[K(#%
[,C_9 MH2MY%Q(.(NMUQ./7(^?3\Z8BXY*3X3HG-_O/V5.4\?V>CFA+]N4F9_F]VB)D#Y@HHB'^TK#68]J'YW=# M=>V)';^/@&-?]G8'46\)+B5,RBT:#4/C%-
ML+*X"OT>D9*#0HI!GP;^*(09/ MXO9*8)T=]6[Y>E<1A6OEO)VZC5V@'%<@YU7T^M.LKF9UYU/BTM5HDCRN(U%> MWG'#\T@^1OEO4ZO)O/?::XJ@WP
K"VV(61P23\K$(@[F8*&G.$^4V>E-S)]$ M1[>K[LZS=I=YG;>.U>VJ=;;NZGA$>'+!7EP\XM?](\7VFT X'5'1%&G+:%PK MPF%.JC;HO7^[GN:](@8'-4X;V(O^&]E?'T'\$(P L2'Xl?
A=2P7Q--7>E/2< MY,^86D$Z:6S?4]N/\05!KI&F"HUW'F!IB#M ?$D((M&2/"=ZC/0F;]0QDA2R MD2\U)6N1]?BQ$@&=2'&V$@4>.--0EBL-TZD"X9.?]\I+<)^7>"^W MNXR\8?
P1YWB55G*K[T0CLR58T+EK66K(HJ>:+CL4*C%UJB$L*N1"-L7NT]5, MBH=^#_)5'3VY1B;'[L%=.6.Y*E\5M[M4C1QC37QM:9^""KUI1@"\CH:86TD&JI0K_>0 93!2
,=)DW)"%<6WZ!A3T2 M/R?;;5J6*RG#?SL\J6X)AI$B.L:>^B RW?$O474%6F,&)LBLL M>>8TTA.M+OB_W479;7.>K O]]3Y%<
M5Wa;7J1EG!'(@SIUO:G1@Z;8*5!R+8,U%$0*U(%!#,T"?OF15)L%ZH"A7T/? M-^I,$[' >]]F\IZ\19GTF;SH:S/#>-RK:VELZ86TA$)6GIK $G6&^0LEZKW_J)]B/FPPKCK[6$[&"6ET
MH1LI#*>81/_UE1#08Q-+WULPR_@&I-#[']' MV?3[\K!M8.G;?N7DP@C1,/>(%$O\>5(L08#(<3KXHZZ?Q%,0>#J:X]2T@A0T M<>H2A]9)P+9AI3%E5/6^B_.DVA_Z@C[.OD98,F
M<^(K1=T1],;G&45#,XSUG&(DD>2.-PMZ6=(QO5Q@EKM68$@'O]&TIP=],.]U M9L10@6.=X#9VHJ=XG M7)8_H5Z57!1)#]61*AH()
[''\3DH]0T6K5!RC>PK*^U\!HD)45A60JUQ:7CI M',(9PX Z$'7>NP6:')E_G>O+DYQ^G3#39[3S,9++USC;)VF^_IF0Y"7-,H%&
MJ335CX2>).%:NWHR%]4REP>2.26.$Q,VSL&6_UR04G1P(]O,OCUGW;N6.4X? M9"46;_FE5*\;[655C9PO!U85EXY+ZW[L&LM*JGVY?$U%#LG8I]IQ%*==NM;$?A5E M1A3]"F3#K
JC/!TNB"Q@5#")N2#;*!6=*8Y_;$E]>*0"U4:@-Q#N\6Y$-8]3K1SAZB0LQ+A#Y'PQX/'N"950"K MYB01.YSW)M 3;]\E=]:7FVKB=GIU)\, W>$B)NU1UY>U_84M1Z4FB 5T.;;G"%KNM=
M1/V\DZ@BZ(;*A3C)ED&GUV'3*HQ("ADFIO>[+W+YS8;JR?Z3%/HCU0S)?K' M=,U*!7],Z0.'@IG5%W %PK MPF%,JC;HO7^[GN:](@8'-4X;V(O^&]E?'T'\$(P L2'Xl?
A=2P7Q--7>E/2< MY,^86D$Z:6S?4]N/\05!KI&F"HUW'F!IB#M ?$D((M&2/"=ZC/0F;]0QDA2R MD2\U)6N1]?BQ$@&=2'&V$@4>.--0EBL-TZD"X9.?]\I+<)^7>"^W MNXR\8?
P1YWB55G*K[T0CLR58T+EK66K(HJ>:+CL4*C%UJB$L*N1"-L7NT]5, MBH=^#_)5'3VY1B;'[L%=.6.Y*E\5M[M4C1QC37QM:9^""KUI1@"\CH:86TD&JI0K_>0 93!2
,=)DW)"%<6WZ!A3T2 M/R?;;5J6*RG#?SL\J6X)AI$B.L:>^B RW?$O474%6F,&)LBLL M>>8TTA.M+OB_W479;7.>K O]]3Y%<
M5Wa;7J1EG!'(@SIUO:G1@Z;8*5!R+8,U%$0*U(%!#,T"?OF15)L%ZH"A7T/? M-^I,$[' >]]F\IZ\19GTF;SH:S/#>-RK:VELZ86TA$)6GIK $G6&^0LEZKW_J)]B/FPPKCK[6$[&"6ET
MH1LI#*>81/_UE1#08Q-+WULPR_@&I-#[']' MV?3[\K!M8.G;?N7DP@C1,/>(%$O\>5(L08#(<3KXHZZ?Q%,0>#J:X]2T@A0T M<>H2A]9)P+9AI3%E5/6^B_.DVA_Z@C[.OD98,F
M<^(K1=T1],;G&45#,XSUG&(DD>2.-PMZ6=(QO5Q@EKM68$@'O]&TIP=],.]U M9L10@6.=X#9VHJ=XG M7)8_H5Z57!1)#]61*AH()
[''\3DH]0T6K5!RC>PK*^U\!HD)45A60JUQ:7CI M',(9PX Z$'7>NP6:')E_G>O+DYQ^G3#39[3S,9++USC;)VF^_IF0Y"7-,H%&
MJ335CX2>).%:NWHR%]4REP>2.26.$Q,VSL&6_UR04G1P(]O,OCUGW;N6.4X? M9"46;_FE5*\;[655C9PO!U85EXY+ZW[L&LM*JGVY?$U%#LG8I]IQ%*==NM;$?A5E M1A3]"F3#K
JC/!TNB"Q@5#")N2#;*!6=*8Y_;$E]>*0"U4:@-Q#N\6Y$-8]3K1SAZB0LQ+A#Y'PQX/'N"950"K MYB01.YSW)M 3;]\E=]:7FVKB=GIU)\, W>$B)NU1UY>U_84M1Z4FB 5T.;;G"%KNM=
M1/V\DZ@BZ(;*A3C)ED&GUV'3*HQ("ADFIO>[+W+YS8;JR?Z3%/HCU0S)?K' M=,U*!7],Z0.'@IG5%W %PK MPF%.

=.]6A!V[+WQ1LFM51IM7(VAD"]>O1QH!Q463GY3_8V8R)S,)1(.S_C)#\'+KY14I[O&.SLHF*O'M MZIQLMR1_J$;RFDDWU,T+,4G 6[VI221:Y:9LCL\DH_O#!NJ\%2V&,+DNY,6)
MZ//0Z;7T U7MJ$C)E[S]/'G"&HH/H?OH M+HOA" MYC;64KC3],?ZTV%T ==SH6YW[%',,D]^B8HBHN[6#:XN7W$1IY3LP)V<4;1?$FQ?!7MB3]C'-\\8K^0E@9 Z6EUPL[=&_R
M=_2O[,T3Y(UB<2XKB@*E#$:/5VD-'53VJ0:/D@9]@%M_34DF%N;#[<:Q2=+5 M[%0&LFM/?]>S;1SJS]^A@O!$V=-,)-*<,?3"\I+0Q8)\C/+?A#%0(U[I>58G
MO7DX]>1$/=+MRZ7K]$VS3G3+\LJ MW<*; ,=1-OQ]'6C?N,H2\A> ((M(+S#!WD7A98P#O%@WJ Z+Z_ MA@3^2 ,*38_9V16TLC02),+S$A'42>94;2?+ _'^6:??DS);A-1
QSC?97&40:G-$+)EF^D(>73G3N_ MZ:,(SOZR3]$IA@6B*+[5U@ 78S/7ALGQ>E<.!0$C>ISU&'VZW15X0[4X?<9\ M&W)#JLFJ/++-M.-0Q[OW<+77T4?U#O0=[+^^00 D?
$T>Z0D@NESU5QLJWN!D MG]&-[C*FMF+/KEW88_=6M*F5%W?\3.X<'920\@XBD& MQJ3_5P8T>/2UK=DEC],,>Q3W[>H"/U779;F'32]\0A167YUN81BW/="S[X#M M
0@EFD=IF(S\0T6YWH@J9^_^V??O@G1$7@1T15Y!D7?%GOSS*D-IYY00A&BM/D\ MIAB#AG./B== '/W)TTVT'2O2/=W]#KMI&/W+QC;FZ26]@(! M]9 UN248/713-,&lP((U6EE8IHE5X?
+S&&9,O$(6$Y9B]Z2(!2T??)D?T(Y ML5J>+=:_[8NT3-*8/8^=E;F2-U6S,E.*)LJ1>?)NF@[E:%YV2<4F!;5'%VD9 MK=<%YA?!MZOZOECJ8$JIK6ZJ'1D:[K-8]T' !K9YSS.30R2UF2!&
[/4FFO"& M,5WGYQ!T48R'!HQ]JBEX0UWZ>&5*:0Y8MY!A :/,)2H'8?",:)00"=;:,NDL&=_08="'"]A MAA9'I!5@V-!G9>E[Q]UA1V1REM\E*H$QL7/_L#@+C9,\+*,8A -3OJ+8N!%
MIXY+34DE:E-JJQO/($/#>5 #*[>=)XC]T,,QO]Q:2E-"C/AL=*_$[JSRLBK8 MM4:K%U<8WY.W**O>[G !:;^B-1ZX:[)HK7'_I$#%M00JPE&]IW(Z4HTU#/"@ M#A
$R]>0$,5$_\E1H9F.V.KKX5T+ -:\U1Z>T:*"@4MQV=[BT6\CZCR3?9:@ M)[B]SLN49P.(T 3)YL4D*>LYA[M*:KON]O!^[\'U%%?8CAOWE;491S#CA3>
M/H#UI',U47YENH'FVBGNV+6YZBBCAC3ZM2$>9F64X#)19YV_4+|TG:>K-([R MZA3;9$2?4F/=P#TI(L[C\SH4:% *0WMHBG-I$!CL33YO=SA_C%[_ T>B,],! M+S0EK=>3KS."'DG-
S'J$Q+%K':UZ0W MN9VO6F--,9!SFG?$1G&"* M..E-0>"D"AX"5QN2=,4);NAX(5E+EB8P6?P/>"QB4[L?3;52IN=:XS@@Q!&A M?KV*(U"H014RD$I_NHBU.?#W3*4@,
<9)"9>)39! HWJ?2+Y^Q,5V9%E0:;[[M@$62C/LD!]VCC]^__\,? MI49%C\79+^]736_&'Y"XJ1O'_99 MA&&&-IOZ& PK:$>+-FRPC]WIUK7O#*> Y(.7ZR^?_]/!X]52[Y)K-
^L0I[O=SR+,)OO M-RF7=U$!MX/?:#W9M3ERC4/+AGX;%Z@0N.3!AY,([Y'FH#?->HQ>[W"1DN&J M2A-?:6K046^NM0:.N3F]L%9;Q$0BR1G_,C%R(C+XC:D\^#C)Z$M#N!.*8?8-
M24+ DX5?<+K>T$5C2>U4M,8W>_!X+])L3W_'$[K?[JNRBG)6,27YSSUW(02 M8]B;IFQI4O5U@JT)3V?XD]L:)"NI!J:WL# 9DQ-E1YR6OTBAKZB!0%Z;^<<)E M<;2HIE)++$^
OR@E.@U)/2]/-X7*?B-O$ 23K@#LW]J_U=UF540#;7DAHM M-A:>FE84T&2S;W8)QL8?)D)*V!UCS8@+FEL#OI(40<5-5B;34.+%C91#5[P
M"!!#W"15#FYX[.H(<3JEN4XH++3"XZR:C-2C4/TD58QCN/.,"0];"D:5.(P MAVVA$$<'(E3YL$$Q(',"A*;\0EJ'=VN>%URB?",P>\M1&@<6|!LB2., @&F< MAN%HC%_.,?
KL"5W0X1@^F^L-*&L&%L,R.@R; :"&)-1MAGF/2]JHL2/.,"] MRE@N[NN<"@\NJWO*\8'%2K:)5B+X\;Y]/#.:P]">'-[VF#14NP.!.A20 YOC M0/,8F-
[RW0ZB@)H^>Z@%2G6]'6_9@@N1"U]258@.2\.>E-VN1)M[E1.RZ5YL MGHR)]:FV+ T<%'$\;65;?@Y$.B0+E"',\GN!TO!S0. ESR@:?9V02_7I/Y*B(" LQ(3*Y!S\Q6D6"ZY?+?
B+YF_VFDJGMZNK M-(_R.(VR.U*FL+Y-O E5::K[7D^"A//7>@T&$+,6!6I@A'XSJC0+Q(2U_D++ MCL[[:A,L"A\;_UHW1&RX5T^I'-]EK$#CGK))3\2[B^T"A]U-P#"M.6T!G@#07#W?
MB:F;!GME^!]L11B3W=%O+:T&7F11N!9T@N=F)= RK3[#0FXQ]PE&)F\2A M^RACK[W&XG>G&VC*E[ACU]+%**,>:02TPT;X2K"9J/,NA.EZ]$C\VX9D"5U6 M^#,1>1LVW=;+5]?
1C_C.IG1/.Q;O(S,6SH9-D;U.*-1*=/?6[1VOF(M61?9NG#QZY,.GK!SLWLOK_Q"WMF;>)\5,0(3-^'F8['^'E8_ZW<+)Z"'41G M\E%_P_=A_?@:RH^A 8-X3!5(SMCTXA'>H0F$#.8EBP#
M(CRDX9G&MVF>;O=;E+'-26/6%VC%80?7LE%I$ZC:-)O#ZMN7WCQLIR2_:4 MFO\UJX>OXCD]\]3D3FFUW,3,9DF]P:_5XPO.GO%GDE<;T6&7;C>.EMQCNH?
&0,':&VBHC@0K+\#AK9Z.SD+#*\85HJNI1:T<;6E.9BV+6 M<%SHH_9(]=3PC_-6PV/I4M"^049Z4[HO>8&C+/T'3GZ.TASB5F[S+F%=*54; M6JL/3054HN5:#3LP"-
"@=Y]82!/)>XD.R[G4C=;;)6*%]?-:0R@MW3.5D_8N MUQ&@,ZN5! Y6TOT1JNWFOSI*UA-#J1,=3TY9>;L5/"*SHV!!O:;.U1 (#,G M_0,\KM1/;ZQZVO?G^6O?@80I*M\I*\UTKRRJGM[1?
W4Z1__Q-Q90U!5IOBO(MNHBVRWVU(04LUOPB*Z MM\KLI-SX]-#%L,P7]6E4P1=#!>$3+(FJK'>[,((Y/#$=@\'\LI_K+(SCW3H/ MJ!8L"&%":693%0Y%T",!B*DY3ZV)D(^HJ//%
N0_/EJ2O:/"$S V>G3G<(]! MJ!-XGWI%;6:4C=3RU>_(O59YD. L-LV#R*QOGRV-7RF^K>X K> M(%-'X3E-AE7Z3,+WYIXKJG?D:8*JQ-TGI,;7]2OV(MT M]F!HU4!!48OEIR=";# YQ!
['C;+FWNZHYE2-RK"(G>SMGJZ$PZ\L5)IH9,V= MZMI'UMPI#*K)9>V/2<.]:T$T;RUJ' B R+VW\#$RO;2Y=2$(LD+;>E0%C IS M%'4>7=)R@/D!_C/H2JL-
T>&NOR1#]Q4&@X1YXIW'Z!7.X^QCO)YZTFSFEM45 MICR/,GBIOJ?:_W;PL6"ILBS;@(C.^ M7"LN)X@81>W*,A90&Q>6(7P@)8 (L(H*98!(LRCQ5-0!!.5"99W0T,WY8Q.+\YN(&BQ+
M5DSA(H9W@3AB]N2JAQDUH"$6MX6-&.ZYQ..Z$07B97Z]Z>0Y*78$:FO<0%F* M-9C!P<5&^GM-71'VZUSN.3&X@R-%Q?*SM@L^E>CK"F\7J$6'*+RR;B&W8CD2
M]NEY(,K,#9+&Z"$"!>*)NC[C:D.27LB[0 B5VUM(DZTM*"8 @JN5?)0/JEL@Y%E2YM5?Z1\I4I$(JK76%4,Y*MY6!SDX6FN#JY'JK Q-&HB*H!I-ER.4_1-
/#=._"D^+IYP^2_+;I\.WPT7U=D=GI:* P!W= M 7CZ;@9Q0+E.%B.65\S3\)-9[CE6?%81;&Y MK64X]*&%'Y4!QWEF!RJ$CBVTL[K.*6M4'"'>1659ERD8*0,P^;UI M(8KC?
IW'+ *]MO!$R (TZP=JBPQSB]_%S8]&*-U<\0?ZE[1G'3H6V1"UL<9 M82>1YU& N_;! F/47ZF+32K>JFOU9GQ_KD35YTUY PRBH= #KT7'P#$/NX8W MOPMQO5D92-
IAZ>^EQ3G$7=^O)S1?1U_%I[M8]'P8SOB"]20#Y%U0UI>B"KC_#W*(7F"RW2=PX9V-/!CY$O=9S6G/;I6!/ZQAC,U'@G3<)JAG85HN%/7 MHM0(3H]LR#W-
!&>)&KL"2I_HGF;]^GOIQ8X4'R",EX7V7CW?I.?[HN!W M!W11COD_! *GVESWS98D&=>"6)MERV0,&^%5)E.3#89K[G:BBHE)3A(;N]VG
MH3L2^^'9)U+,\2[&U]M=1!4LZ04X\%^! GZ:%G'I]H;B/TG'MVI, C)1&YNC M-5E7.G5*6_)!=4I>W ;T39&K ?:P#5+Y+:RPA?$.]J1GGQO8AOC\-K%BA@_N M82>XZ$W&
[O$SR9[3?'U.%2"MK]*8)?L;/?N7:I,I9Z-]NY:TECCBU%%#/NPE M@!R_B183_06]'$ 9N100?Z@;]'+2H?- E6/I"7<1,,)-(L^B@$^!A=&YHH,, M]1ZL/0<64O+[^K#:T"U^_4)V-Q;I'?
QIHNP$C;Z3E>1Z($LW'I0WJD5:^*BRB!-]$6T^,,N)WB3I3E)3CIEQ+":.'&,&^P_I20 MCT26.>&.!*FQ2_8L*1G/+2+JG"IJ9^LH_IC_8.?XQT'L';$;C.IDE.4|VJ55 ME/$\G0EIBC^3$WNA.
(V=UH]ST9M.?4ICG)>0-GA=8!;+/YVV)[_7U"%AOZYU MIR6..LIA+?(TBXDRWIS)TRWUMXOKO(L3I^R6K9')4JBA:9,C?3L/TCD$8= M[2957%#!DN$TT6"?-
^&ZSN."R7B4G9/MEN0LJKY<5E61/NW9U>M/5=B9IK'>_@ MG#$\0VM5N(-:W:DAEO@]%TGN,,+N>_3TS* G-Q(]1#&\5"\0PX7X\UE %O:
MSF3:Y*5]>B[FY<,UKR5Q4N^;E[#>K/%8A@Y[';OTZ$8!S,JQ&T7JS+^SS!^= M0N;L/3WAOL[7X>O)2;6JRZ//X^8C/>VU*O3G:"0^JR, MAABFNQVA1$YC>!8M$E;1G^&?/63
M!115V^L_\):CX_[9=WX6LY*)#?E Q1&5&4^,N>E5*LEVARLL>79W+1(<)FHL\ZG,\2+:^'R+DJ3&RPR:N(//5V6HPI=[^Q9B;4*2*(= MI8&C+/T'3GZ.TGSD,8M:8XO/,GO8BN15F&-
CA+H&X@ M?%TTE710,EE2T>.;WY%YG'CQ.S4Y'O-8/>.,['#RB.--3C*R?F,Y:L?76=311QQ V'57ENM$DY5!#:J&&75H/'V93+JHH36EQ:OAZ5K,
MV1A$53,8V/AU2L'.ZY3B;Y3:ZD;7RM!P'G+;@CAC*.86GJ,V$<2(NQ[W*.R- M0EG>XQ)3>AM(?\EM>5=J3[AM46BKO9.1H.%^_V[J=]7%<58W..,Y98K-^EN?(V7:*'[PDK<
ML_.'5C5I=$ [<.E9"483+*YY7*^;8A!3Z15&OM1>BT]Z=+_R-B31KZ'3)XPQ ME"AP*82LR*24G/K<7&]\II(\$)U9Y-^89/"P%,TA>:3\PEOGSC?VQH[Z<>Z/ MU?1\16LH].)S_
P^HI44?;)"U"E-9,88W"T]%DDMQW20TQY/X9^]+EW\7Z,B M!9O-7T MBE\5;U]!0O40.Q[(/(!0*8Z-<.*.HA#74E8B[FQ,%,^;,<8+?2YU[NTLO5 M"L?5;E=-
CC1)'),.A*UU9HD'1M))9)\A."]0*N6I[V;^@I@L#F%:*\ M_Q'QR+V*23^+80PC]B9316SRW^.NB2OA;=Z; M!7NL;?KAZC5^'V2;*=]CYJ MHG\O\MH::BJSX<12GM=$FX'>!.
[*^*6D1@^:0]A R;4X7HV_CGQZ.WA)%O"Q ML,[L$ LLGX, *SR0U.S%OB"">!@Y+LQS>Q2I.U5R4CVCQY 'VWJ9(RV;QU4^ M+@*5]W(*5Z3 Z3KGQ8+BM\@6%!A6E"KL6N
M*RZPXE@0?HTW\ P78;;##5II0&$B!DH-]'(W8.+EH9A/@9"J-;:6;GF(B-[, MRTV69<6H7K\#U#A5/ASE0SW*NH!;AV>!KOYZ=G,]DS32HS(WFD%ZFL_^DE.2 M?
$TG;,MJ"%*B(T<48Y_J]J0K/X: .SP*UB)#L>)T^:U(1 MPY,W3LK<]GEP=AZ5&^J]/*<)3CZ^?6$/7[H$$)!9F]DO4_D^M#O2/X)3).@\ MCIIE_\C(2^WAI@T4%+58 N4$T9\
<8H_C_A:>HUOJ"=&=^EQW61%TZRG# S]\ MA4>B/*%2&,F;Y"U195@P*9H*RY[\WI(<>0O,;@C# HP8Z?"Q_=-,'A&HT,'9 M[4*9 $L*GY(!^L"R9=;LL^K\G;5^YWP%D"Y!^V[
6E*OMQB!4@ZCK'3$6NX MQC4>Q "A'O4%JC'!\9GTH)U=H*A+)+' =+]A9B5>@]]^F:7;-&N#7@G+\/QZVD.BU_,VQ_KLIML7?L01)/P8BCP>.8K3 MZL?@E$Z)GJ_U0AF8SJKA8?
0::\?Q&6:'#-703D/Z#[Z:9H?#LTX]Z276)B6T M0UA>I&5,MV_[Z4V'1@]V'<(A2NY#2 2>48DZ-,'W*CIS,^T:33-<2WQ+''^[M)L]T7-3Q*MZX]-;_Z 2W_L7?SC\=R>/I'Q3%K.O
^3'=7ZX_77H5B 'F$/&(M?:8]+7!4X@O,_WN=+V,&]KR+WL!""KU;R7;Z25'"U>7D&=1KHS>X]3O"6%;^X*|(83]YV*K:V\A97 M2"7,NULA'/,WMA9'.N,]:0<',3R+T)>CP2LF29]
[F>'*MK5)K MVTIY2,5]FENAE#+YA&2C%$SHE+=]R(C]&-LGHF@/KX0 T$]:>U$4%LJI$&OW$LDK)8\C05J5YD);)H&&OA]#@&%I*!OL?6I$XZ##,/@XHFV_9]/#; MV)VQBY-
W_X&C(LSCU1'!$*K *;<\' -?/@B,@;L_:!X#7SZX%MV'N^7U39!C MX!YSB'C$@>S5_^TYS==7^[RI5BIEO<3-K-BRT^[#6+93',9VSL;8;%BI&@<" M($AJ=%LWXAD"8WA%$L#Z=;QP?
45*;B_(JXX]Z!%7T;(^0\QJ@L]Q5KM N^_[;_WP3SS/6MS+LY9#0JL%8MDI9B"B4M,B%%9Y7@<2VUX6KD=*H(0$J8]% ME% -NXC>Y:[DGU8$=X)6F%6C@E0YLN(15';6%-
ZH*A;W!:?PS(JI:;C]:Z5G>0>,@/>I?F*"%9%A5E]TIW#@?.,M(IH\KCDQ!> M=5M3TP4IW:Y8=C^&][%(UVO)@ OM7ITM]J/4@N M,$PW"[]ESCA< GOO<./2&;Y[>9%9HX!,Ja4|-'7N-
TZZ@S=S@;EPH M8GD8P/N(.Z[L.#)(I'QP*Y< 6]-V5-]ZM6:&.DWLS(N_4AY16OPURO;X,X[@ M*2C _26M-E]R\E3BXID_<-[MJ_(>]?2+&5R< _I:.$5-)1S*C^ET1/]2_76 MY(F^SN-
LGT!6KR9WCL!W\4Y?MWR(+YP>LGHQBE3!$/ULG_'T+_7I.J'VY+3,=OI%S B2'')+63?D: M_9$#1=5Q1TXGPILW0B8O[X\TH?3/V@&S%]?.O= [R_+6\N@H3,]]A#
MQ&,.FSFEV..D<28A!W*>L,JXMTU\2^]OPO K.]W:S+NB0#YH*A,%G-;RN#CE MC6;IO1B2D+_;EVRG^ UUC7BR;BBSVD9:I?*1SR?KBXZ<3R6%T9X@'TN!*(56 M]P?
=IHDS6'LS5'+S,FJ7%)CMG MVN7MOBHK.A'B6'&9)OI;.&'7'O=P0@:R:FSB+8]JQ!T(/5514:B[^QRAC;ZO@ M&HM=\4SMX?R-YC)7C']7'HN[_>BT)A =YGD-9?D%I^M-
A9/E,_6.UC*9IB5; M&82MC/3N,UAE!(9NB(K5D6D>)B]0@P+5,-IDT.$20,L*%='D9T#7\'#SL2Q+ M7,D?!8PUMN8(#A$)MZT?0F-G\VXX3I-76XPTBB0&X\VI'16M45]VFH^!HC'9
MU>[#(CL),;O,FXSL8 [E@S.GF5F(QQ63"A&**\9A'8MH]P)Q4/-*'2VE 1?]=I8$[Z\5B)X1U-,D">@V%:==F1A9BG:,0.]()L3 0:1X%W(#>%?@7 MI'L.,;V8FK1X4AD(*+4UB-
A\,,3;O1U'=5 M$5/%%42)M<60V)] 0(H[XI>*/[2B?#X]TU/*YAKF MS3?MC$-HYW1$(H1Z$-]O0<-0%U]H2LFK)2W3U64YNS9S6N\H1R&1)A7:0Y7 MO SJ5!"-<7^;>]--
UWE@3>V*Q7_?IP4/ 5QQ'%+KF",I-9\F8IWWLY+Y0P6U M(?43/3J4>P%EUY)_Y+"A]">D=79GOZCWJ&D.=V8<*#L)3/_DCQEZ3K@@TH; MTZFH'U)S-(^-RSV&NAI-
'Z'D@>@Z3[<;%QN7 7*!-BXL5.H-1T7YC51]BU" M=;"5&< U R=-03!EMS*3$Q#HTN\JBO&2I9.0NN([_=S*A5[7;9B;K8Z^-3V6 MR5ALW%H!?20S&"\75 ,"
([R.GN6.6R'>7YAJJK@H*(&EF]5G;8>1AE.49A MHPRPZ;CL5/|M4,Q'?83B-%)T;8R7?K/,@..,\H;4BTS4{"G#(\6 51I M:I+W?H*$^]0Q#$=[X\?4)6(XD MD+!%))7FX3B9O!)S9Y^?
]=U^/1917JZH ML;G=TPW<)_R,L^\%8NR4EN>\2Z.8?*U"3L#K+%ZAN6AR+4P195%9[JLT9I@@ M.PN4+4[@-7)"5?8Y@MSN):H(PG_?4[!?508K.>6QD*U*82Z]6;>;]*(CN%TU M-]
[BFL\C7VI:EH$>7=L%3A($N"8:LH;S&$>) IMFOQ26@CQMK"_+2Z$4+<]+ MX2BEN2^%H^!]+H66N6C\#;]T 6.82$LT/J+VK MV2&>L>,/7Y4?(&#Z%?.8 PLB7%;:+# MPMEO6
0+--2S%J;\ M@?A#PS=X78>NQ?/@=?G8U7^$FP./V$0L\K?BQQN<[#-\NSIT10GA.AS M.6P28+@(!],+4V:*A1?/LUOM),(A$T8>\1%FM)>??':'+;U1!&14MY@7(< M)K)#2;RF?
S]WU:IA5^H.Y1&F,>+0#>T3IGO8S=)_@BJZGDKN&Y-A"7[-[WC*%# M<0]>\V8XB/IXFW02:B;],Z4_OK5[CG,("Q@Y*Y9J8[JU'>K;M;2W%!$C&?($ M68[!0_O.:
<;Y%ZY>&O=Z6YS<'NUX3_;'A]OCXU&-;D>[!T345(A?XT&>.HPQR6I&;6VX%19UTD7 <;-;@A$6:+G*?(7* ^>,30HT/X M01HX_.T-]_7/SY_?O%%>&O=>A:,P\=J3$DA4I\+?30;
Z%Y-)=[L!)\O\X+08AN,J0;ZMYD3!+P MI8G32'1TTL7X-!X"T8NE*+@B(1 M?7[.PJ",K>+2[1R8$Z_K^B00V^JE.3H7MF06X[-I/69G,81^AR('O=D+"!& M" &X2) :<(]^JVD7!OMT?
NI^&!?Q;^A-ZCACB1*W L8Z7.?/.*>SKU+->*"- MM>B&7M_APAIZ(.S$,^B-RL3J-A3?YA2^,"0XHW$+0K[Y].6I^3]G-3S* ME.2WJ_.NGL<#'|R-U0>WTJ>)3Z=+V[5&4N[_ DM
J6TM#,OQPZ$'69[$_AS M4NP(U*CY-Y+FU5^I^NV+\8<9$BTTA76D9[>BV))&C#:JB8=|E"'#::+!/G^> M:YIC*NX%3E)(WL5CUWLU99;57?,05>3/JO>@Z^7*4_*2^:>I'17&V]5@.['
MR]#K/#\78G^\W;%W*9>ON(A3NAM46]PE.K*[HH\0=!X.6!."CDAUS M$ Z$74J\1$410:2MC5-2Q\/7.=#] M=G5%BA5.8=55W JH]^O">,C0]WH$; +4NFUQPQWM(V0.<_@F"E)5-
F#K"^7: MQE# 8*5[D.=M69140M;0[,]D4(?Y<_2:;O?;CZ0HR L=RGFTHW\15A;0Z<*B MRRPBY7P#QU @^C%&<4U3QP:X'9.&N@,@T-EZ@ VF!:I1H186.I<:M\P9Y!@?
VBM@YSL6]@S3_3@X!)S_CF%.JY+$%$F>!\|)V[W'&:OM&Q5UNLHH M9K@^OO7_,O+V1[T#W>(UTH1/Q4^O;[0G)T=^@Q1G ML4\?AF;_U,\2!W2/_P 7KSBY?
<9%#H68>+E!BACN)Q[(JAA/3J?66E?OY;@X3U?#8: 6!V]!+Q(M[QYNK^Z_"9S 3G%&B"&;@QX)?<)Y@HM1[T>VF<6CGW|WIA_E"TY%.(BPKI$T M[R>,\0.]9?
I5NURF6>4"E^2SYSG61[XP1V$W2\ MYK$:-,ALESJ/5\;JLS.8S4Z)Y4&=A)'SNJG/+3H%7C+T\#6?9^@.=_ VR=6) MY3[@H5KO13RUSVP7MR$996K)/:/ML56DBC*U MXXM':(*R7D8)
<$D"EO62%BBBRTEO*G59%TV[:&NFM?DG;E>G?[S!HOJQ^AUI MJITZ0>U'+G>&=7D676VZN VPKV\1=;32Z="-;) ZLKF.WZSVD/Z,.S)9!NI) M[#'>WWL1NG-
[@[,QO",%E*[G181;L!=I&6>DG'Q#HM>+[KL2-6KN; 4XC#I7 M7]\D0+@)G]J30BQQVD,",\K^0Q$Y_8-F KLO#Z[%YLO-]>/E!7IX7*Y>/@3) M8]=C$A&/?X>5IM!T8Z?
==*=*V^K)3M3QZ/%Y\'],."%QEUO0Q!U !:HE_,4 MZLR>?H(D&3(/[^14J/5I%,'L> P4JJ(TQ\EE5.1T22J7<;S?[EDXR@<5>I7$J MVG#)-]0.)))HBX+SL4D<1)9QDH" B:583??[YNRWK@+*
['(AS*/ &YR75A^L\ M)EO\B90E>VSP&+V*;LOT>M&]+5.CYE,R";L/B_N $'4?PT0$Z\X*L<1J;T(, MB6LZ1WWJTFOB:TVA%/3J6OA8J]&.;OBL0U/<)8HL"YAYZ';'X3:;/>* LAC+
MI[(JHEBT"*MW8"TGD8B0\"!#5R)LU>_45GBBI_&|T[G?YI)7I_)F1A-\B/' M7F^2RO+/W$5O<$D|<% A$$_)5IHR.=&[KZW?! R='9[UD6ELY,)E')*5&]+) ML "A,N=1N5GF"?
P'KMN>HXP50P*X\O$R*IT8!\W($/,9.0- F*5G/_0@S2]R M1FF>!L-GU)GO3:;;=>D3K%/MZ<4-9="^*"A,@1A+M].4W,G^U87U&1=/1-5L
MMCA0!D#ZCHG.2N!@6&HZ]#T>1VHF+T=$FXNAE4E-A=PHCB=UJ6-KCD5K@4@# MRZ+6^/((!>3G"*6A)(-WAUR/^=YDF3$TV@%N((-37BM$/7@D,-T5D,?DU: M$PPB*B.,)/+
<"6T\SW7AIC(U M[5HU4+DA175&#?4V3-4Z&5DA.IP+JR&3'^3W)5C;UQ/|>E|T\9E"# @3,=*FQ M/B@CQ6F-1^|&=_D*K$OD)=V#R_';U=?2KR$NQLD)TW0QHJ/=M1W(!>-WV.9
M>V?&HS$[&B]_!E9G>TEQ^3%,Q.)C] Q&^6BO[=FF!+' I>QSI927@BKH^DV MUWU|)DG&VQLT23Q:;]&#%V^QO13'NROH[93?;G081'-62BT")QU[;;'!9W4
MMI3<3^@B7:TP]>.H@_J$JQ>,\R,-9Y>C/7.@?Z8>P@1,RK:L/9";JK";1Y4M MHXN-8NB[G14'96V/Z,L8#1*?S_90>E,X UVX*|(\3G=1UJS?$CHA;&-!-T|Z
M]J0C78XX=O]#]A5:9>2E1##?C:)('7-[&:.YWIR "*X_8K$2Z-$$'SV&H%,/ MH,)CXE_C%XO^9'UYSCE?#=CF0K[9#TT=[=AZ9S\BAE]%$5O:)W3YSV-VA7
MD.>T#/4$7I;Q1).:\ICP]/9C_X&CXI'2-#VC..G'\6%%2V6FYPA8"Z/+PQ& MK[&YH<+UIUEO3$;E4..00I2K0%9TU"[K;[\:#Z@*Y.6HNX'*MN'ICU]/; M/W]-
>GL@@YIJ>\K<(%LGN3LTB186MDUA[L\.;FH-;L^LCL1\:W0$(?C&2.+F M3)[#LUO?;O!KI?B"LV?\F>351I@#U+ [Q^O=,=FYK7O'^%RN?^:\T%L'?_A:
MUD&AC&JLA^/,GIVV,Z_[A=C8B':]^-B&OI"YJ70-R_D65&?D>@K\QZ]%@8_E M3W?[>8&UC)7!62;_N2\K&(R=[# ZE-QFD%%!Y,LT M.("N8SYFP4$-$]-/UL-
#9@^0(PX=O0/PWRQ0C1\U T"]$:!N"&V9ZDENADWU MHZ5BZNF |&?=7SH I?IY3DKD!:F"5R<8?P*Z+$]50QCIW__CS[_\.'_07B[MR\@;KC.KYQ12^QNM.GB!2]V-U;2#@&R6P8#?
Y(1)52!?]6Y.Q>@=I-YF\V: M_U3!Y5A9%7O@+H_T^2"\^%1K;]"42X:.K\5;%H^.HKD;JX;JL;1D'9H%;O&@ M#M "R80(.LQ3IB2!Q)35\|%-7MR2%[W4UM#!3ESIZ0&QV6CK
2HG.FLX;G>: M>U!&-G@M6$UA55'ID9F8UPG;/8;">PDN;E=7:1E'&1PSF!RVC7;H\MQMD/"L MCN &$3H[C;/$#YU=\ZY(,_1A@4 D4;4IR'Z]01EM25.D_V+8 X-31K.>D9#4L+^I8?-
'UFFISW,,W23+.TS;W<,#1 M30(+7_->@3_@@-^DU.*S"^X8 "X0>Q\6YHQ'=7Z(*=,#>:RW1;IF"#/XK)*!@?KW/;[95RDK*S:2"%9I;96S(AI?,\!T*U",? MLNZ1&O^%PBC%U$ """55]>?
ES*1D_=R*V'7=>I:T15W6.0%^$D."P5+Q+9 M7GQ3(P[,[5V!M^E^*^6^C[2SXKG== M^=M6=C3U=E@FF+4VB[* G3D6 Q-.9#@B*[9D]QL3Q?<_?O^>B2/|17T6>7@$
M^9GG87T;K5RAUUA1A-6(N!9NCF2!&):NF.4"-7"4JU3X'6U"8G;C-&!4QDQ] M]+3/HH(Y1'4M,.HC'22E8K$N/*/!0>)>..L\R&[09@AY^]:KDFD**S&;$PN*
M.1WKNUQ1:R=XQVG!R>G]'B M1X=@@3(&\Y_+0RM%GK)TS3=Y*U(<)M9BOSG*.(Z2/4:.8_2O^Z*B)HY=Q*$W M.C#ZJXP:/);3I4Y?WOOKM^CR-
<[V":M@1SM(M\P61GF^IU]0,BE)2O3R_[?W MKJ9G9F=3Q+5;6NV)6HEc-[_K !58%DC8L%;E51 M;OK7'X!ZL$@64$#B15]/0:)4)IE+V, J&"3 7MG>[+2E.UM_&LK10DT.=]5H4?Y[]
M.R2,/E)QT*R^G'D?0^@N89*8$'RR524@'*%W+,%SBV%+L%F:;V4)CHK(X& MAQ:"S[LM6Z?"5@= @1<%RPQ.Q[H0V;4PX) M;!I4JH:S:IE<',96D>2=7T[;H87@?U97&4P^3
M964<.M?X,RT;3'/+73H&L(#/8(4XRY\A-5U<#JB&[FP12+4]3W=52WF([W!V MCK!JY8I+M805S&$=)#)HX*FC-CD.;K'&99B@=)-P-HYT*!.)O
MF^Z:"A_[+CWRG_TOJ_K0(PB3!K0JWU*YS3S(X9 MUT7*_X=7$WG#N7#EM0.^QM]#G6A=/*'"P-H$02+"'KD%F-I[6I]\V3*7P@S M#<)A^ M"E%U313>M5_0(3RC 27\9,UI<7
SX8l1EU<00J.@@IVDHR.\DBM5@NK* MRDIY157()2^<<<<.@7E.DIH=#Q]+'MV]IVP="?Q2I89\#E!V$S2^%T%"S>; M0VI01XXPGLU2@2X0O_Q:+YQZ(()L*(+M4 1B>85?
5"'5I+9RMU]$MQE>%;2] MLT2^?4C');3&2SO&8T'A. UX8!H:\4?T!!>L>4:0+4D9)2X^XK3<9.0YB6-S46HI5=O"=E M\LOUJB3B5D1]%U7# '9Q#)QOS1 X48\4;!C=T&
[OPZX).F$IO'54J@75E5

S=?\GW=%@;$#+7<@*GVO]@.!*!E2$,7]AYYY&GDZK7:D.1T*XQ(EI.JI@5HI1'-BP+*(#]#(/ M1&8.@"S3W3 (YX"KXR.ZCOMU#$A#
M/6WHDOFW3>A)!QQO>H[[W!V1(',D+WQ@)+Q38;-TJ:-9L;)@#SONXRR6]_@? MM)SO&)8-4^.1(Z4>"'+!#XP!#F)IQS:KR17] (/1H.:K12!'T7F 9R07/2L;
MP4K2$1%^+4]H.-476<#7':*@S<_<(D-'XLW+AH'?:AR#|^\)?G#U>SJSQ]G M5^__5=R6_.G/'V9_^?BOL5__^8_=|*QIZX%K],O4I"WR_[XM_|^_,2W]_W&&

*MV"=;DG"SG>\C/121S"O5G:Q@FOI,BHR6XGW-:,!F7^8*Q"V+XGT MXC:>M$,N2]HM'!O3$=YF-<[Y&GPB%6%0>';AP*^Y*QY+FK 3W]BAR/ACR%E(M&XEOM;DKWFT;3-RL"$K:C@P]+<;NOD?FG(0$DP.!3:\)D9HO8QIE!6I%%,'/ M-]=&:C<+P2QSG]Y{!L]\7,7QQ^OAUS5WR$0JXO5K59Q/497F%%5L&*K:E>6;*4H3Z0FGSI4PE,4OK60TX!^:@{ M/>JX!U@CR4^HH5J<,0)V37K,=1^FFH[=R;ZP#^.=0@X4T:N;O*=#]"YZSI,.MM,>#:VH1619;P2G/A$[_1K.B_HELU-J.;?]3QFA0Z14I5/\%6%K42.!&+?)P M4I135JP#(0? N_B&X>YOHB5'89%IQ]*$$=[^++:WM(U\WB_S-4I?X]AT+2_ M$9!A4O\$8O1/>+/!*Q+Xs2/ +@W0"2_6ZJY@+U}*H$IMJ(GXUCD138IV70?B M>+0KYZ&!&M9Q:"_M+LYI.)&PRF8YN7E+0?MXSHHFXS2$83[:&?.TQ"&T,3 M_MLC!Y7:5=N>'6;,];2U&68F;!%",V^B\R3DQ2 "NU:*0PK1OT.DLZ4:W0B MVVQZ-MP<8:.//+>Z,*]&/)]8'DOB'D(C'CHFCOJ5X7(^X7)3/O#1;*F),CZ04 MJV7:^YKZTMX3DV$(ZY7UF5EBUTBYP2DK7N^N:,;31?;3))>1CWU_2$& HY@;$C MIPTKS-."^" [>)'$'I7OSZ:P3DZ(O@#OV!{?^I?"4PBOP/W4'.EPU\F M.'<<930\8XFV5\GN'IF43TQS-TJ0JX7LB%NW9D+Y2@S"UE",>;=I-58++ MWZMM4B_'"7ND,+5Z:?0SI?U-_ "C*.'\N2L_ 3DKJYH|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|C6-L[LDYUGA[F*: J;G4PIR')#O:Z:\V M9Z$0.lO@)!1G+QN7VNDI"+ZGC5X)':H#?6;$-+7P=|POI"#+K/YVAEZ9&\G/ MPQ +KNLR8[^*SM&\H-R1:$3#3"Z;F3CBXC3-3O -B25"X&@C)#Z8[PB7K6&M M*8VFH,&.;P=_/4L9%Y)SFF04\$!V LV_%]R@0UN&+\K12B8^JBD3KS[N<{)F MJ)B8GB^6XWL]<<8E+! (U^@U$A*#A][=01Y2W*)\);D;M|GTB"6&_IO/=9I=+(@2/&UPZ0]2,O783A'WCI4F,WBLD?__8/NSK;^)-]05WW MA5U],W0Y7G\W*9I/1$5UTI;[D\?8)L4I=$' MYO#Q\S32F(^?IZES]2(%SA_7N-S@+[6\PB'H M>X"],\+CV\0)8E!/#6K)09P>) A"#46(D?0=.%CCF6?K]6LFAN%G%;::U%KV M5NOQ4U:N2"%=;F_ U;3$(SOQ<)P? 4*\"P{!5;QQOJPROOZ$33*9$$NW\ MI"67Z'7=MZ7[_W&;54E.*UDW#PL(P"M+ TS><|,;4GA'YD-KHN,4Y9B|B2!S M0AT(VGML$QC)]!RWO)0HI8|8W$5%("^#0=O0XFD\|:/1A,+RB]++F3L0 M;/[""=Y]R399K:C9VI^>*.%K C%K,\+(ZSIBP=LW&^(10 M1V=*4:B)X((Y<)^,MQ@FBR68 \. @+HPIF@<>/6GA)OD2G3C0M% 7LK:R MS8_+[#=23]?_*;TB!U);A@P11+O^/S*#EN#IB..'5WD*YFB)/DNLR|8WYMS|6$LWA>8UYYO(]P? :R M!7';_WQAZM$T'F8-_N!(WV#]ZP:25@U_ I:>T -W7N5]\&!0B"-D)LIU;AB[? AJ:ARLP^XY=ME'+FA3-IMY2+Y M]|5SA?U$!:$7W7W%%.$]MT?]60F_2]X5VUU=?>'/33X]8W0;?[CNCN>0?=N] M0]1MAAKL,R3PHX]Q0V\ZTA[;(:=$;+4[?D_*#2[VCR6O0;?=EO0-YS?[+VR^ M\^4S\W.OJXHFF3 8T]"%%&HHP]|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|&%;'7%/#H#B[>SXM85PENT:< MC3=T{$XXS!UYZ&=|(.(4(D&BN9\4$QUS1MND!1=T6SMP2<-*K&0% MA2)0/2G9*>N:/Z)C^UU_$/\>9P5O77A7-"VYGDFR*[.:;?F?WXJ,+:;MLF_MB6=K=T55ESOIXU;'H"$+PQ$)01["_]+5>|&&E]%?&AD59,4CLF81[H9<_DY@ MR>-B;R(NQ@LJ-#U'JYY6L:6E/:7\5OUW\)")'X>]=41*<9[^1%*T8R5V75O&> MMN_"R_YN(CVT:?*'4UY1=C)OV;U&B5CTU.2A*X*007[H>@; T>PMJYM$O6I M(;:6O5R15YS\4O$*:EPC]B? VWI7P@C3HG!.##^%668M%-X=F0,=,]13,D.M M+6(9<&K6@HXW1]TIGR/>2TO]Y0#W)2.PRC(U4T'[(VRIRFLE?++!OF240OXZL-B $2.4V.TSF*OE&RE=]>F?=4R4N8OOT%>41 M%6'V_]"VIH1FOA >PXH2??&|<*.ZWA.S]0D.2+HYCF)EZ')G:1B/$;?V1RIQH M2H0"=\ 53!U,@97Q>BEQ466BY @IWS(>)OFLA:K|# .;*". @<% M4SVP9;WY*SD-OX3TM8]"9&JWQ_/..]6^]-?D-WF!5>D@R$Y}!LQ[F=4!1GB= M50=DVY=.;'1 182^0]P'5$Y)EX9V"W'Y5%-0Y_QE4*.< QG\!"(+HJ*-#:G6 MRMB@CU%S9F2BZ91(|)P)_/6_ ""ZOWG_XP\NZI+O5NO_+U?NY.Z'< >2AF(;N MW;7 7Q"B#@1]*4"#?YZ]1[N6/A@S[[8"^-MWW-XVHM#@X!26_V/U8DO2L6[$",1?F9IL [>1++#Q^K6J2YRV!P1, MJ35'Z#'T"R,A!2W;@8D=+IBV(=]0@W-/R;U$2;"TFA[J3N&65W&0K#S.?_0BJ M:ML!\:XHB_DC/ QL0:9]HD)=1'J-&ZMGT4K4P+.\[&&:"28H2U&# <2DPI#5.1GI>P/V49^;?7^~M(T"9#T|*^_#W?VS16LX,)D.FL'=/\=H_G8VO50MC&!^Z3.39?NVK"\W|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|> ?.M,APT<0[EUSIZT!$0? F.73#F=%HR5*AZUL%@=L7IK\1O*VW84|&?P M%4!:.#[UOL0K$KAOV!#1-8*!1\|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s#G\8:U3?NS56L)?A%>U.KI#385H;9/O MR=?Z@C(KK;>KBRPO'+> M^;^0NG@'*-Y#GC\^/5S#B]G9$JO@X+Y*.7G1B:93@C$]N*K54F(M^\+L&K-K2 MB?]+Y2T[Z!6KYDG5B#]:?0C05#T$U6KHV)V.% \3=I2PL[K$Q5&PW'EK97S M*-5^6%/N MR /IZ8CCA,C4@6I*RDIK/V<%]4FREBKL^ " KAX#|VF'-L+PP964%MR[76S M8R&\5DKFG$Y+QNY&:U ;4%"U(PL-Z)A 66H;47/:9NAR^;?B:.W[0G@ MSAX=2* (IG(_6C$]TT'5Z[62'#SQ%N)F$KU[J9FJL+-A/KIE/.$DX 7=%(MU3 M5<. 5F@,G/=JM3=W]$/*GR1^!]YIIW5!OOJT..0JO^$]5H+J2"F>,&>>[IH!4 MGM-? ^2,TGO_TQ"Q/^4:J]EW:B>;#OH66;M;!$>KU!!8QD$>(GKBT?4^)<(U> MR2HK"K:T+HXOZ"M+SA4I)IZU^*K*;,1D]4DK8,@MQE>%;127CQQE/3I&V=M61O M%W#);,GKO!.&69Y+!T$"9B< ?,>/)S1IPXC//^8 =D.)H8'K$0XFLOU@.I) MZ4)L\BU)=PG_55:VS_1S+Y;W@.8RCBD'>MQ[]"!>CRN"FKGT36,NT4MRB_?- MJZ4-#EPW":QNVCN(3*Y6FP:O5<]K+)##XS<.GKI8+IX4LEMWO;:67L1>Q4!"_M#<<4E>_%UK:.[P6N!$1 MR&>=G[,1M%X6G[:EL]|&F3ZJ W'$_B5X>X;KD-I.A)WER>G7KX]K7&YP(A]0 MX%R9;Z U'F);5'"]URGDR-$)IE=+H)CANQ=/063X1>*EA918TE.+87[K*!E M5_,1K;4FP>>NJG:CI1AUA@,6@@ILB$U5A=]T#;CE!;!I=@2@CH)9E[;7$(&^ MR8HV?9;@QJ4SPREI4?EA'9[/^R4G^%415%-4P89ZU0R1&&%K>$"3#.8;ZLH63"#D#C>@-.1)~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}$9G63N 3,-O'"GX/< MDVF>(V2CF.@:A0HX_$/ %QZOE\1!Q@?9/O43P+QO41TV]+/ %_EUW[$ OY[S MC4CELDJ0/6*>+"C1% $GV7&&DP755BL(IZ\D)9AT8A71#>G?Y^K6J2YS(_&)T<"U!+8'J_^J#HT6# (TV'.2+U8ON"OC[04+4+KNLQ>=S4_E;U0 MY=G'$52@3EIB]ZV!2C>7#.E#.2,MBN^ZFBGJ?RQC.D-SGDWW.DC0|! M$VUH'B4_7D#*FVS)9H_WM6_:*CZ1),=5E2TSDKY0T39W37-V?*F;^L,2O7>/_M +@4W\$2*J;@CF)(E"$FO !QAXY<=*"7M]M #"'^TLCN(*L,'@ST1W(2(15X0?!#!-GVG//940TI.+)1'LP)-3_I;4TY-^S M786?EQ;%"'-$=NP&PW%FEB?PF5N3-U*^4E-],E_S9FR\:<$29R5ZP_F.2!;& MK.E6X,96...?>-#%&F^T+Y=?5WL$)0}]PTKY%S":.[R\DSG4L?)$]39[17 2S M;(-7KKR'5%-=26*]E&.!%FH49B@?[YH,X>3^GA$ M<_Q>)N9'CSUM2EZQ(AFZIUD!7F4C" 34PAG>C2F M;?P]$&_+A]O=2P$$82@BK!3.K\|BO-2WECNU%]8=B|!,1D/^>\<6>'.S)/ M625_Y:GY!>0[#IQRI]XA%BQX=X4>< /@3'M_757BLQJD34"^1STU%)?C>_5 MTV(^Z-?FG-N\ (!/OF!+]+WK80>[K*4.?9.V!"TKPIP* <0H&@#00&HK_F#^ M44O0IZ^)"#.S__P5E^GHGF7R"=.+4H$.M>XZY*C%KKEF>? *#M(1-(1(_^)3 M,S'!>8)!O$0!-Q?^3B[NH>'A.HU+TB+_I__UYZL/?_JKUF6S/U:V[#Q)T^<: ME[490VT6';(U0J98K 7T\<,,,57]&)>93X5A9L" E6=F.EI>W@M>_A#IZ.,_M,? !%W,K\TCTWI-Z/=]5=-TQ[7=W3LE[AU=GSV;Y=@3_M%/ 6HSZY3-.07+BO!!+&\Z%0<=?K2UU3?-N!O^-GZ[!G$M];56Z=*U]_\3 +5=> 6'D6GA@-M4WC4+W?YG=HT:'Y&990 M[.|\=;!Y?X]RN!OMZ4$#@F: /AK^;TR-YFG\^M1<^,$;+.;3(:+_GBYH:LDB. M?'0TE',.T'\5:8X25;R^,6D[9D9J0B^7)C404<@S=]'(B<4787_XO4$L#!!0 M (F"9UG:EC&F:) $D"#-4 ;W!K+3(P,C0P.3,P7W!R92YX;6SL MO5MSY#:V+O@^$?,?)[G;+M<9;N]H_M,Z%]M?525.1+*O?=^<5 D,A-=3"(; M)%5*__H!R+PIDP 6"!($(42XNR01 -?ZB,NZW_W\LR_>X9T1R3L,?O_O+ MCI|_A[*8)#B,_W\+P^3LX>+FYOOO\N+!*$NBE&3H[!!GY/O_]W__7W_Z? MR>0CRA"-"I\)J3^]G%19@FBEV2)OONO\,O;IR:?_?C+?!S_7EB:9_(73^PT__OC^AVWK[S?-^=.DV'4X;/SS#_7#7=.3H;^]K!J^^^VW MNGHZ;YKBI(1OTW0__]>GV(5Z@933!&44E3[YG[_W70T=)2FZ1[/O^+!?[F]>O9.LOI*_ MQ&3Y X?\O]_>__@#;_4#H]A 2Y05DXP4,/+NQPG[6OB9T?R,)C')^AK%1 MT]D]*S45Z*5 ,'YN4-P2DI+X%936[SQ]P7D#08(6 M.C2=3 GVAS\^L\^0/Y)KG+%5@:/T8?N!\K.GO/H:1\3H=6]-V2S*GZK%5>:3 M>12M:N!06N3;O^P1W/SAC\$O+5+IA]YR6-459\@^4S-FV>]:S1{C *+_$>9R2 MO*3HD4VN+RDU0V MH?'DJ1BM97C61T:AX69S3^CE"VV__]>R:JL"P#_]D.CJM*I$O;;9!9A.GF.TA)-EBCBA%6TZZEARF$L*6) M.H(]%E2QH(:,1@VY9FOZ=[ZD]Z3E*HT7U"8-FDKC\QYU!PN^(5$479#D6.(1/>Z3FI+RE77-5D^4_C>*Z%667+*/UT29 MHFF/5%YN9E'!|CM$,4FNV=^,-$!E6VMT)NKV"*T*/]51 2PLT/M*('<9T'(Z55T+QW;B\0SP5);YAX]_*_T5[C MJ|=__21Y9)D#P43_1\63-G(IV51Y5KAK$EHA'?JG_):+*MW0/9B_H4,10Y(M\|ZI=<6#4;_N:HDH#TO\2,FW8L%UPB@3STUIZ|YIO<8I^EPNGQ 5$GC:Q I5 M|(+M*7-"Q<@UMNJ=-]J64S;-*U&PVO@N2,FVE]5T4P?ULD |D)XB'V+F(P8 M;5:MA&A9]|ZH4=SS&TM6?$Y6HPA;6[6.W4/"Y2FJL7=U*A_RI91FIZ7.1/# MHY>;A%ML9KA.IU5L/HKV8_=&Z|}$N/%A03+OGBU]TB-5#R@N M*0/AW4)/C[AHU*)%32Q0=?42+Z)LC@1[B*09C\0Q)9/+* A*98 A&Y"<_$)'XH\!0 MO/<#"IC'"8S*!S|0 3]XP+#\ [",L H\:&)1?_ +EU!\!1N)7OY"0.K; H/S5 M+U D_D@P)+_Y!8GB+$:1D$X-I(M4!7 M/!P73R1;D/,?CHHG@BW<-MI#BIRJ0\12F_DF&2+Q J\DETLM8D50FG,T2K97M&>8N>0W%4(SIG9;$@-M%/^)$C4GHA[#M0504[SW3V:GZ0+7D#*FVS)9H_WM6_:*CZ77VH4-,YG2@+T M*O*\KF;N9A)?\U= LK*\/Q&LK>;8X%5V0G2O_8GQ]N)Z0QV9=J6FM,4U[R8*-M%!ZV# C7Y;V$I4FX!$/BJ!U9#Q*@'&+-I%%?8SAYVA@IJ[)%C/DHPW_J56"" M#F2ID"V8DF!+Z,:6T%B]EBU3'C'V"36D! J?*

^U0SMY&^}Y2BN#C+T]:X-%OU'6_-WO%S,%#584;1BN11^]&2[_V\)D]< ?469:< M)4EE$HO2@ULGSM=:#$}6O=V76\5U>B!47^Q\?'P_RY*[VG^P/ZXEZK@=UCW MJ9K@VPB5ZN6J?:A4'RK5!P^#!O-*U8\8:5ECAT=7%2"M)6Y?D+(L/8D ;RO@ M^O(9U.XR++>W6%^>0Z3KN3H?T!5'U1!M"G_(%7?N[J;[MVCL/ZXQW@:1S.)0KR-X;U-_1]_[(89_#29L;T?SI,)VF1<3MBQL0]] M@,48]$:Q%& (\,@NJ#.C(C7M;5N^]O>4K?]RQ]G:5]G(<88Y8U&>TC3-U,) M?[AHB WT:[:.8\1K8E;5EG#^5>CV!_;P*6*B753"!B=1-$+#X]VfFO++[=O M;OS"BE:L7:.9M@Y(VBQC.A7]1L0VfU@7M8[LB2>.FBWH7GAM0WUU#CN,2P' MG:]]277:PZ[G'%\'/&4?T99M;$I68!T&8B'FXQMSE4N-%"Z#++>V*'QMD0 H+:,.D^8*0V@T#MAZ,W3^IN?UH6V-] MP:?5E)'8S7S!I].V+8Y\4;044N-W, M_SB1{D)E'""TQ&T}E#$-E6AOA[$;!O)_DY9))">)F4URMRKKF&'V-(IC'B^' ML_ED15+,]?XMG;# (F#8C6XJ6:4^:201-?3G1)H"F_N4@?]; ^PQ\W5T=&W=,' M(3:F]]B8C^09T:Q.!*IU\7-VU$7"R!A0>V.J;K(&/^.$[2IW;"%P<[;0(%53 M8UH^H80M&8K.LJ3^$3<[W4!M? 8H8;J1OGV$VG1V4H1(B!FK?>\S0I^A?A&D' M>&6B#9EEJ>(!I]/9JX\EK@:"XKB0*6N@ML,$;A^>,9)=1-D^A,E[M$"; -1-D^A,E[M$"; -1-D^A,E[M$"; -

MZ8&^@J2' SP_"7>$6K{EY8KM4=A^,/J?2?K,Y9374HS\;FM`ZM<5-GZ*)FR-MZ9MQK7Z3QI'-*S\'F5$!/YJ]+7,F#U9?MK-++9XMHT|EA]MDKH=OT8I#"<<*
MT,4N#^'V[9{H)/"7O3;>7)9TG5=%Y07_*$[-M8^(%R0M!AJIn]X&X.XPVDLJ@XH96Z:WR4Z8\/^5R4]>A,O9LA#(.J(!^=4?8-M%QC7Q:,A_O9P?[N@K/AI9A!11.B,G>MFlY>HU#.1
,4G3.#1]D34T7>8)+D@-M1-3*9SRDJC2B9\'R!1.-F"_A=@.]J_(%+XED2=KHCV/'19TT2;1R0,>.AT(:-M%;XA?V_SD-LPD(H"OB-AOR-(D/P^=N;ETKND!$%_EP;X]-$!^>8^3-"M$T)6
MT,"760'+(E9_]{5\)!5-1%@_[(9\)--3_5IWR9.KIREC]K9>SI;9^-C2:U=MQ.]=M5GJVRTOM-(1#DK8X<,=*KKE>8#0?+X?8!0?5!T!K{3<9%3#1R.WY*IGAZ-MTO>'^%'$1@AY@B#<.2704-(
(*G*Z_ER^L! 5+PNPS[,[X)X..'C^R/@=7^\| MA] ?1:#UO3APL/S1"%I?D@2WJOJ]$JB+R<,Q\D,M$;G JZU*U1X>?V1_C6J1<'C\D?++;5!V'XS1^^5W{GDX./[(ZOH%R> H^264
M;!U7"@?)+[&[_6V[<,3\D;WA%9WA+GI?A>VFFX_@[(Q?O#Z5&06Z&EKB&CD*T S,SQ[=X?N;LK6?N]/[*\]FPSE0/>CU_>;E+;S.;//V*V[!89./[^_M"-2W!G<9P?'R1[8&7^0 !Z$@L.
MVQ@EZF;%S.C>UCU\?_OA!#U&Q-?Z676(W"/9M_Q?[_IB\),.]04J M?T@0K&C@^SO5Q@5NT_K]2(OA]_B[@_FT>I3-U^.G4[L0Z8Z>L55F*$;?0;CB%5@T>A%Y9/#Z(M#VE
_SL',#R]^D#*C^AF@7!;E)>,F^+ZBH)U$XZ;*]{6;@GQ_]{7X->NCP:5#7X"Q48G!T0(V8ZC$P.,B$QF#H4-'EK5KUWCW;D)1RBGB M8Q#SQ[+>];8#7KK[$%,5L[$;BQ
UZ[ZLN.OO%0N2W+"}RH0P)/30PCOT M3_?+HK%=#9C\U>,]IQA[W0^;-R,T!D!<%4Q3 &<#0:DKH:SZH\^BZO$3W94 MQ @_]{=,.M M62%R!T#OOG TB&IQG>EAXHZ['-
%=^5T0"T=]G.!C7-%%S9OXKC2%,O0+W^@ M;P,H5RC@K$6A0YL\X65=Y92GZ^=,K#]+^=OY%Bj;>SI=+?-T.'>2\RCEB=%U#]KB0%W&7@;Z,[ZN(^K5EV4.1+-T_L@;6Z7[+G
GF#"/BYP MD9^O@Y_H?Q;) "%G(.0.J',&-'V0(1/_TR SHRN1-]v{&U:0A%;&),61QB! M"XV>HP2!12'[^(@^-vQ.@.G %TQD%H?CNU2TK'&* +.'1.3FDKB?N2P=1N>];/ M^/4%KY 4.)(4*
(X++COI<&]+0"\S!'ID QSSODP/Z*(!Q?C!"[*Y#8IXS70;M"33V==6EBMXFXA9>D,Q_(RE0O^FE*;^"\66{UH!%,]+8GZ]DD25$9 MN^C7-53"S)]QGUU=.P6M0@'&3;MP_TAQ$U3/
,,D7=!,`G#B),KO!.&D7\A\G M3AJ%0\#0:9?Y'R=TTFH^< '=45=9UVA}JVW T7)4G^E\^Q+7PH!C[4.4'75)
MG[%+]>9&%77AL[$+1.88Z18G&KMH:HX8M'<3!2,MZ(QJUK";7V"5Y<]L,I&+! MV&TT+J9?)V15Z?-F@;%13=GPQN5Q-V=E+HZ U*?!SIC@'3>NZ;/UY6$;*45.1 MN_X,)>=
:E40HS\|;"3XB&N>]*=^.0M-BPH7_4DTSJ+4NL)))?Z%LUBU3?GO MSRG@'%3=5CCOSR7@'"#@ZA@]6OZ=!054N*Y'(]^SP.@4">K1L.\L/]VKF/1H M4GO6++(,"
(WNXK%P.]-.$M5GBS:>+LH3]GO%-$S'%)G>#]1R=%M7!!F19W!+ M4+4%TW5=\&+5R[{6Q>8/?WQYV+YP4]_B]$&/-P1=A?N*-C?6+)K@3H@"5Z,Z*KTH4G1\V5@#-
:HN'5;2'\L="H_1"S<%_?3CNP^/"TK*M^6+WEY]^%-<>A_?)OSHSFG-\/BR0I]%JP<-_A(6OE6WH!W:[/0!$!6*5K4U MWE?R8D5K;OE!Y2RW_ZX>#REZ?5?
K=8WNB84X3GW_O.=7EH,6=;4F75')'=[! ?HU\1^X(O*.H*N7.,D.,G[@ M7N4%7K+M:#JJ(WG.E65Y)6-K8;B78DL.+ M*$?3IW1#DH#FTX8#S8YZWB9[#*4+6-$Z5*.T7YFRC33X-
F9>2L.>V/NC^3A%G MP3+R!_=WZ#B'5YL@Q/Z.(>?@@7N)+0#OY]0](RR$K%_8S+/JF+(AB'@6F/-M"OQN091!N'<(LI9-&+Y9G,4Q6XG))E'K+EH3.GU&=%4GL]TJHW&+HR>36G
WPW\B>E)/ZX @00OC-!]ZRA-$!*^N+F!>3(%SUV CIP MQ@6Z-$4Q!W1;LX7M'Y40+,ZJ;-'=F.;?\$O55G7VIT(W50U[SW-HO*M\0..")@/
5FD8:PM M1[*Z07)"LK(^"8;]7?A_8_^>TBU.!>;,^"!$-E\&9Y)W\3#U4N(_9?\AB]""!H,=)0@>@AG+L7.OFMC-/9P8XG"^N6M0U!TR%HVON@::F0
M2;3D.Q_@D.H%Q$A@'#L\L#V3="1T^H"6/#Q%K>++Y$)FBVF4AAD?@E,@&+0W M XU]EF@$@JHE-E_4&ZT.-?)V%>/%AP@=X OB,C/%K6)<^P+!2*P*,T-8Y\,
M4!!@/KNQAS[J:19*=^K8X8!.#@-?CB]OY* 9HQ\4,'9XH#,(YOP>^WJR&5OL MZ(0(L<5R.$Z9)7?TZ:-Y0S%7\6QO*.RX&[?H&PQ$[L"-:#E2^<,D+_@%D',<
M3Z(TQ?P_,2U6K36FK4CC%D2%2.4^(Y7G3(YEIQ8Z,.G246[B3*M1>0(/+{P ML/72>-CEN^7T)4.O3\G#;$5MB[UT536IDJN- M-M55G5VT(W5OU[SW-HO*M\0.."@/
5FD8:PM M1[*Z07)"LK(^"8;]7?A_8_^>TBU.!>;,^"!$-E\&9Y)W\3#U4N(_9?\AB]""!H,=)0@>@AG+L7.OFMC-/9P8XG"^N6M0U!TR%HVON@::F0
M2;3D.Q_@D.H%Q$A@'#L\L#V3="1T^H"6/#Q%K>++Y$)FBVF4AAD?@E,@&+0W M XU]EF@$@JHE-E_4&ZT.-?)V%>/%AP@=X OB,C/%K6)<^P+!2*P*,T-8Y\,
M4!!@/KNQAS[J:19*=^K8X8!.#@-?CB]OY* 9HQ\4,'9XH#,(YOP>^WJR&5OL MZ(0(L<5R.$Z9)7?TZ:-Y0S%7\6QO*.RX&[?H&PQ$[L"-:#E2^<,D+_@%D',<
M3Z(TQ?P_,2U6K36FK4CC%D2%2.4^(Y7G3(YEIQ8Z,.G246[B3*M1>0(/+{P ML/72>-CEN^7T)4.O3\G#;$5MB[UT536IDJN- M-M55G5VT(W5OU[SW-HO*M\0..")

*M>'\&65QX;P%97!Q;//=2OE!S9)'IF">H!)>_#61D9^QXSWJJZ1J.-3Q_-C@-M&XNlRZWM1-;EUB8BZPIHZVZO<\JZV'^M3MW7(NMS:.F1=;FT=LBZWMN[R+]>L MN[Pf=5N'K,NMK4/6Y=;6(>MR:^NN\QJ27Y]\#A-9EUM;AZS+K:U#UN76UMWF MU4VY/?FX#EF76UN'K,NMK4/6Y=;6?:?U73EGW]5^G;NN0=;FU=V25%%*UH9^""H.QQ(R? F/WJ8G9!#74\(=9WP;\G^DH-E]Y8 MY@3NA1M5YY_,&5^ZMF-,YD?C1#SF>3;U>H,'MZ[=(R<.%KS>3)D%*K8BT?[-M?@.-0PC=3.S3R*(@!'4N3 U^O8\AH!_*A"][VARHW'N.GZZS6K,TX./HVR\Q5R>>^:RU6#,V=@EE*M7>4UC^W@\'MP_T>PXHC_?O#^'F=_M\.OM_9?GA_N2Z*QUMPC?QN3EP+GO@8L9L*EFX>G MK\IGT\)PY'L7?' %fF*@;AEI*;E"M3=;D1X"[PF>+KWR>N=6)B\}//97Q[+0+A M.[6S7K52_KO0SXOG]Y3KZ ME&@:,T;SOVWP"IP*_HW3[ZN!6]?FR\H3!."^F!M;,_1/I.)R6\ 9P'.KSQ[!2 M2RS3^SQPS.DG[Q&<3/ $)3-+|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{[K'=%=?*#6'0]-G^)B\|S2MUG\G;KKWJK@L*)-6OG MK-=NEFL-N,Q7U#<2SHOPMP? HB^QWYF0[*F;KEP0 %=-2Q-Y=Y?]=B]D:4T6* MP!R*;,Y8(/MPQ4^L$3'8G^+OGQ-!21XZW'YX^C#XH%Q/IKHYXY4%X8DO M-4'Y-S^L5G:@$_*K")IZ.1W)-5C3Z/S(_XPRCH=.EYZSO_"$O:'3]CMKK G M3--T*J]6Z6N:16W;_\|=.)W5!!JE>]9K_"H5Y8+9*ID95+G07[4/LJH6SQ1' MRU182]{($; >;7L+'!^O9_)' M'4K9[VO#.:R2D-/0- ;__9XK(HI)*,4'ZQ&L M+C/4!,O&W>I9[^;N_5%M.9Y'$[P_?_8U',1=AY-[:Q7KU?KI7BH'1H>(0V6 M=POJ\XB[!8\6P(5-B:Y^!1 M5,9/L?+_U43?HB2A!-1! BK-5?S__)X4WIE IL:=XS!-Y'-WE?I"'H,1\&<-<],3GB M[\SH^Q_7|@]WMDK@ 6@QBSD,'F\).E.+:LK4M6R7YRX<4X$!A%-H*5"BJH3V!YU-5^665A$R/O@-GDQ!IO.(.@;"BI0-W5,C!%\82@_Q@R^ M64AFA$+//PACC;.OG&;5VHL:@+CW#P3.7L@Y< QU>\E94HLY97H+E7^N_*A M4N55$HH[CLRL-%5O3[/W- 1E:^UM#XUDY ML/$S11U3]3N_AWT(A793.Z+6'/_\%SY[>If_&- BBQ4Z32&Z#K?PFCCNXOSA M,N[@@%_S0OT;X,F^C^/]M%KGJ4^O&LQW=T)>4@ 0[@+QR[P.3-'@*M@??NO4 MHBH5UJA:\YXG:C=MY2=X*.!)L5W0Z/;8Y.L_08V6.s.RER4'V1YO&*!4?S8 MG\W/)848FO)3+33E%X FW3R'PXD^)&X'W!)Q^._3'08$B.1PR6VHW0KWA.T M,K,_Q&56_.+C\%? OY#8N7% M:O&,U/2JU>^^_PQDS M&R9%IGP5-4[^E)1$SYO27)BH_?.'I7*$-(0E1%M.6E]V$@A+-V-A65O<*'D0 M+BDVO&D8D<.(S5;P189& XAP3%A<&T=^R^/]PM9=R+3"M87MZ MHBD%);SF)G)\JZ^\53=E;=DMY;"O497'$U^43%F7 ,Z1:H2]X^[;28DQ=1&7@FU!..3N1WU_O0M9+JEYATM+N8? M=+=- >TM:]U+=9DM:6H*\LH8:+[PC=EY"&,??I<_XRW\P>#6\5:C@HB8/]UZ9+8WAY#4!< 0_D)V"UB:Z[@?XO(M]>?S=3;1+OS(S'5&65A$R/O@-GDQ!IO.(.@;"BI0-W5,C!%\82@_Q@R^ V4@.;?)Y_1MS%Y8 (KM-TL_]I^>E=L/RLWM?2_^\K9_ MIX_\?#TM?\L.AIZ>Z@%6D@H9HRDUM85PM6%72U[EX1/H(@3611K(/)3I.3P M__U\R)T_VI5UV;H!['->[2PUP[GY2_F8?\ M\R/ [#2HLY)+K*[N&ID)_K*IR1<[10Z BZ)1@Z=?%F=&P1\71 ?&4 5B<^K8 M?.<^N#/K#?/$PO<55?UOO=BPKOSD&L35&#SHYPRP7LUNRZ2(%E;HOCTM@46^ MJPL^BN?JAWC6:WE$\.F12!/+!D5FJ"80#\T:G<@OMP'HGT/(BSV"ZCT'!D0% MA@UX4E#NY.4C%[-@S$;<>+'CT2\(W4ZA<0/0#Y2YXGR2]H K%DSJ12C?M YB! M9;GC.5J+CODI[J4X2-8]H&RA?P6HIZ]?(=-X%$D/?*E&0 "-XE"\A_=#B#U6;G3SQU"\ MC_4 (WN=HM7;_HB3;=%@HI'<+AG4KRR1W[/$[5=?35?B6IFCHE> (P5G6#8E\\8E@_\5T@U85"C[5&F4\ MQ)!>JUD*5>G:;]NAY7Q1HYE%VZBX.>8:1"NA\M4Z4:%V@4WSFM>ZT"+EF+ M$I9,]LQN/R@/S[]>/\518I9]08ML^E3G1Z'G5]/FN9XK;+PPT"GF((864<,8[IT_\HKAP9D2,$PAY80 M4'KGM.ZU4BBME4UXS?SN56SF6'93);MW9,2MX;4>@>LHM &1"RFS]"V_? G,K MQT*;+MVOO1^AA5T0-Q5IE6U-SV:C5'=HP%2(@Z[9V1)]>ZVM"[.":;HM>(Y1Y MRT4EW&(FU&,FU&0FAB[IGB.L*$JZ7:76'KAS8ZF5)RSU4%]_%FHOM>DM"Qf% MSU",.RWCMU?B_U>?OW?!F.4_ECX?L6O5&N5W,%R5@.])VU<%3\UK"ZM=4/&N M2&=[?,9:XZKXME;':V9UV?,&:T+Z3_]6!L_]Y^NOU_?/RM/UE_[3U>W]%^7F MX>F? \+^\]_#P&_]['>]2/ZO@^+/*_-A6QK=M<"70|O#'3[7YNTOX 37Z3/%. M3N+G_[$^=#1Y,^+1H^$&79P\ :$9C^(]

*M8H=JTN|XO#E^33)=)2|&3T,L-IO>=+1;2"T7X2BRW2G5V|(5C18\/,RK;*33-M.",WLM%HENH-R>IC4#8DE8UT.G+D1C;JU6JI(_E.4EQ(W#6\@TA.F5KF*I.!*
MER<0NV&VB:NN=/J%-^"K)3S)=4(,.6>*6A/52LW;<9D+)TI0%-] H,UQFTFE0 MDJ;,M$H5V1KWXW(@BLQ"9-+IB)*JF0$?MGO:&929#3*33@N6-&6F6BDU
MFI(E17#U+^/P\)XZRP=4+E8 -<<%/%A7SSH+?/@U9S.GW+9)3@)*"(>@9+TD5 MDWCJ&JJ];?"16*:NB]H$+W/U;#HH$1(^A'[=)')C414;I52 MK2/9/@)W*7,E:F1-.8,0)+
M&S+#2|. G<.N8FS\|F.+-?;EY8783#UT:CF.-(R]+&OHO#UKNZ;O??^0$*@QZI(E1A)E>S[!|YR3J0V$$" @9SHGL8L4BKS.?OV
M"5$2V1R5PC;'S>WUR7GE;,>=R65'FS0+D13V^;9U5E;>(@_O-G ?&]N5L^IN MO55S]G6;GBB%_4U@/RN7;I%K=NO8WZV726'_0+&?E0"WR*>Z=>SOMJZ_";/W
MSGNZK%U5EA&5.8UXKEUE6O8D8*:RK/:#U>1RFJPDP;(LJTN.DS5LJ]WF$LB. M-VD6(BGP\V5L5O)96,;5>LA7U15" Z,1GY4[5I9U52+ZE7VET+\!|&>E?95E
M7Y6(_H.SL/8OF.I/ALAGIF; 8QO#!|#*X\@+)*/*UQO X >&@VM3D:LU M%B*AD57/2I'+-:(R&4T(H!|'S^WDI<^\NR%JL!^+X;-60*05;>BM6DUOM9+1D M/ON%16D6(B-
19+60RK6_=D<4|695,[.:.>]6RVX+?@\"B- N1D2CF)#K,-\MV M*2FZ>]O=U+LL;I%V$%B49Bs$R$L6<+(CYUMIN)46[VM);W=1^$,7!A\AFZ@)V M9-*IH-F!
<:4Y^2GE&'7"B33#G%,E2|UN1Z^WZGJKKLRZPUF(C&0Q)W6E'+.N M,+)0AMTA+D1&LIB39U&.85TVX2TV%OC#E[W?7,= M?P1_&'V;T1\??
S6M'_Q59N'VSU.+_/FW>$&T'OHS+,X6M=EB6>F"MW'.7;9N MLO0]/EKG3R.F&0,PP<:&\P[[Z Q)]:%]MFM&\#5 U>[<-$2].$M>$4]W0S\ M_-IR#&=@&;;V&, ;O
|\H$8SL!=VP)X]~&AL>('rF'K5@Q*$O! <%[Z MTR4H=<'TGRAWONGL(1:@/\ &]J\'_7$R#;I*Y;>LI@3B'>(s)8PW=/7NWYZ MB"Z89"!B75KB0\]Y!V2 MB^Z89"!B75KB0\]Y!V2
;'CJN:.^14V#JHP&S;>W^\^YWK{GWR#?:I_?WY%Q0-MHM:.2"%$>>IU\N4HTM*:)>SP|AC;RD"'_+7 -)RG,OXJ-L({G M6|BG@9\=?F/ZS:BE0_KM4LILGY#@(;WB+
6DTX^_&N=%T9!XA2_HBYSDBK!, M;89G%FP8DO19)?9]8RQT 9/YV@^:,W! S@V|"_=_=_ MW&F_;,,.1KIVXPS.@(,.VN.D[UNF!??&B0+]K3-+>(Z+N]O+]]O'JTL-7CW>
M?;FY]#W\'X](/\>O5[=(C|K=-7ST?]ZG?XWLT_KQ0=X^/NUCM+!]"N?5A MG']^MUG99H@2U)6!.\EK0V9T.ZMZ&F>I.\KEV.9T.ZMZ&F>I.\KEV.9
;Q^8_)E0N[EV/%P9$(G11R3.F=MZ ;8#SM;Y[V/68@UAM_V MMJ?Z*&L#TCUV/[*7Y%I0Q{(@%@L^NG8]U&_A7X\O[04^':2D: V@#$V=C4'C!-ML-+]%?WCK^SE7/S?
%IHIE=306T'U *]@,)Z$$B="<4J8;$&!=84!99"@>B< MW@OR43#;96F$LE7OUG9K5Z^QX4=A6!\G+>7K$%G9?NA2N"FB6HK#S#9#!%6M M-?
5F4{(WA4I:HIZGD3:.ZK#YOVG6.L4I;FE.JRI#FNJP[]#FO^B<7-U>AU MJ3D;3M.RI_Y=O/T?\?HCFJ2!". /ILS>9]-]A+(+<./ET6%^)O> V#EX?WZ6[B=.EIUM.IHU=&]
MHU5'JXYV)UN^\{9)DO5#ZN?AHS<83%XFMD$S\ @D_>UT1Y^%,A4'.#P.H(YV MFT>K&N3NWWV.'++J:-71JJ-51ZN.]AB/5AF(RQB(IFEAMI%A'YE]|%"R!$JH MQNO(.*
(DQ,%*''6TRH&P9U!2,Z[*EVHY'UVX+R^NHST&[N![P61)2"2]GM20%% 49D&RII4 MUN2>0VGGG.T]?9'+/(QE5:N\+8=O%VZMFUX"G *<(K!*;P=(-X4@U. VZZO
MPQA;8?3(13@CA=P.&Y.H4VA:4ORE VM=14HP"G ;0=P3^X^2=,9QY*^%_%/H M)V7!?3\9MN$,F&8$VC\F#DLW5CGP!HOE-D1NRI\M3,.^E8G=]U)4E&I.V3NN5 M?
T6MYJ[^/;&"=XP@N@XVJNJ[6?XISZRAQ)JOU)8GT7>1/ P9G1?#'W /Q-TD M\ /#$:Y^WGJQ4KCUXUWI\XKY=4V M0GD9'4_IBR/7AC7[_'HKCXNKR35S0Y'9LFLLEN>,;*
M)!>7CV(N\8TC0BA;U2_K>K-1T1M5J6:.?*AU3D=U"4==:G>]B;-MY\Q=W(_H. M+;W5W*U31)D M$$S9&[YF1Q#)E-6;NZ &J5.KUO*+D+;"P^4JL"/|R'SQTJU4"LUW+C=<%H^Q
MIY_<.6X1?H?YKG3(BZB%9G40GE!?"1THWBL<PWEQL#ZO+56!F]=,5*C>'RWBVVGGWH9 M!+-&V&57-+3 'I_]IZG"79SR?K!TAI:G/NB5#5%&XI-
M*HR4RC^KI82/EPQQ*#ZJ:$0R&LE+F^U6JSN*8VR04!:,PIWF;NN8,P(IP)-G MY:6.7.(H)4B^9G1"210E4?:)9DH)C"\3@5 $#@A$,@+)5[F*Q;R5VK2LV]0*
M)PH'#R@"I7D12%2@0%IN44I$?^EN.?35F(F8EQ./Y# /2?(,-ZOV.*LV1$ZW MKE=]+.F9B1QH5 30K1:+RF^@:=H<^*\3AJ\VN@KU"O4JQ]$PHC"B,+(%Z=G= M<9W"1B1I
\S1NMZJ5I0P542PT"59*R407&.KIE7H0?DB%6643AFE1\]7{I^D MR$ &3!X'&>1J2;5B@=[=^ Q TVDWY78;J+3]PI[W6Q: $8?:@O*Y*\-:B0R9 M,9(G,4HI7%
[2*PV\@OL:.'!0%40]D"M&J#"R:T982GANQ49"BB$]L&\5[.T= M>]\,5X!?@MPKX4F10U#*=*_ K\&\5_*7$3E?QCA="^}(*>;921<4E15Z"NWU
M8E%2!5R5;KZTTYND/C7HC\3^\3C!UYAE+P/7*+Q\"3U)Q99^K'+J;(")9_5* M*?%=TH_SPA"H0D2]&[X9+S=NQXNMA<$GM6?!$;?9D_NO>'\//??3]%&TJ&A1
M"0D%3%F!F2*+F?ILI1\@)(B M1ANBT04)NVT=-D*1J2)3F0>IN$OB!X9B@,.S:3*I=K>FU3EVO5:3K)B4K C?]W/^U7Q30J&R$ N;5
MAXY<&R25SZ^WLKRMUO9@EM/AP5U>'I];W=RHK@SQ(C&+,3'IN,"_UM7;W:[> MK,1EHX(#[_^R) P^GQ0]&Z6+.^F "]@^/]PK[" I*Z3GUEZ*_ ;.P.O:>N M-
ZLMO5UORH9\6161(X1_/NMQK([_$KM_E2H*ZEVI597.&E"R0'YB;*Y,#"LW M_"H5^36!TN[JE;HR A3XEU6$6O.QOR5EJHW*G6]494.O?D1$?C===|UW_A*|
M@>$C^N/CKZ;U@[_*#$#\/+7 GW^+%T-K20491(Q!A!C2"QMO\R[A0\%!X*-J M-V;;8\-$-P;Y+_!O?VP,HK]MPX<3'EK.$W[_9/KP*I6?4L?0':]!!D11EF,R
MAT[O+2LV*=XA@@N/6!QEXB2E+V#K)@)=\U>Y/" E>\Y;>4)8Y)ACH ##"O%,Z0 M7$?[TI4Y^WR!.2G[F]B7C_WHSOVMWEA!0$% 04!!0$% 0>#8(-!1$"AR(* R M@T'@_/=)
[60;AS.K\2?76&XV6&RLS"2#93UB.D$,SBD'/ G_JD 0'F9.UM@Q M$/5!LA$E210$]@P"^]3I1SE*%*055U.04!!0$% 04!"0% (26:BETVAU/C7:X9 ,QV:%*DQWJ6YSL
MP!>SS79G2]OQ_66WJGLZM>K_-V M75+X;?BI=]?>,Q7T=)&,JR/_HUU V5@2(=.K.*@+N<=MX_NW,:MG:QO#L7@ M+>.;C,U2]1R M!D,X=$[!AL\P!/DR!@7"()BR-WS-
5$0DVAN;B]W.>7.FDY8HD)@)5X9^-383NF7]. "OYC^?Y?H?YKG3LBVB$\DEFQ0(/@-J: M43Q5X6-%GM]ME,%35W35*]ZJ;&>I.\KEY.\6RZ"=-?S]NZ*?!<9W6^!VZH]$
MY+RC9.*G5@H)E1,V4.)(T=(^TU*]#%I.:)?*@"$<1CN39>KF$TRA$.'+2P$'H M8JHB9 -!D#?F#2R?:>X08R#8Z]1'\UQSQX@!7S,<4WLU/]NX:N B)2,J;EI MAW=F(C%]]
<;W)\R\G'B@!'".Q).*Z<,[#]$08N:J-23U3D.OMSO2\R7D=$/1@)QWE,S&:V_+7;]AR9!MNI%04++;;(HCB!%%* M3L ZI29E" ?ER-
A38MA^0"HWX[G:W7%$;DQJ4B)%N:HJ$W"YED1++2*2?'MHK*$]0!J?'%%,*T9Z %(HE(\BF 55D\Y^F-*"]MJV]>31L A%S>$YD=]DDW;LD.YRZ\++#[;6U&
[=@&TI.L:3LHAUMJ,1OF,GGK MR^4V!=,U++ED_N"\P)N@],7NBA%#<%RX#M%'WV8$$RYTR^\=AG?Q8?EVPT15 M&7%S9E;WT\5W6!B7:C&R$EPQ-(]M$MR2^D.2%!-
K>60#^&9@,7!O->3# K]4 MB]DA)>9KV@43&THFQ35:]ZTH POW5ZM5]6[CH7=].VYFF7>@6_1K*BK;2GU,IUL+-WU;/OA3IOQRPM)0M1
M&B^M3,9%6TJK/*AU*/Y\.&PF()5;T%XK M9?;."O&E#1+6@H[E-,W3W.EDD3GGM)LZ[?VE)@DE5,'LBHT&B93$.@!LR[(.M"6FLE-$RRT1^%$$=
)!E6<=N"""I?!2R6#*'4N!74N+VK79.FB2AE4VM>!!O5 M2G1/"VIS>4)4UPWX%6&Q07LZ2.F4"K#H9K5_0*$"""EV9;#-.EV:$= 1^6,$EJE M_FP.",T\|[6)!"1)@H:BG(.@')FC5(=PM%
(M1N'L8(16JL7LL UCKB90+V4F MSKK50F5K!3@-O@XJ=5Q>U>",:YOL38S]VJZI5F53+,,,S$"K.!>$.[%8K@*N?MA^:YMF82HBJ[A/QJD52T+KWX/_$[E MGH1"ZKXB-
4^$EE+/OF0(8)X]A1(8Q/"=\,EXNW<]7&PO"#RK/PF,OLV>W'O# M@W1>AA6EB%,11Q(C"JG[@]0\,5)*)'G%0(H2)XI(MTRDVX[NE$.DI51BKQ$$
M4H2J""4'TG2;'LO'I=]W)+;2!E2|&M#5%O4I5K5FYW&?+P#HK&#HYX[I*.MEH]L4H,3HE7)5Z5>"T@7IO%$D246-R"6%15.>7'(S)8YV@%@#>%KFQ4%XN$D8
M!{$]=8#0\]=S7* U@ZJ.!LVWM_O/MMZ^Y]TC07S4>?!82\W1VPOX()]'U(O(+ MJ22'U.OER%*4[W/<^7YU:^>KC[_7':NWZZ>OB[9MBOQKL?$CEF C@L]>"_:2/& M=
[&&G4]%EL3?*O0__^-U, H7XZ.37K!W_3)(Q_'HRMCOI[N++Y;S/;J':?EC MVWC'>B<;]*33O@V\.BV>Z-.)7 Y#&WG(Z?\&;/TDA?%7L1$6" ,+TR7XV>$W
MIM^,,BO2,Z'.GZN<0IZ0:RJW1U]3T^P7^^7MT^6/4WU|K5_WRI M>?]_C[_V%["S\M?UR[>05W_8^JUO'&#/IIL0W'!,.DIT-V#O?:!J"~+1V/]"MKEI7O95\ZS&40*8&-@S37N!*
(U]C(,#.VZ5!R\)&(P0J0 M" -VUQ1S:/=1'$ =[6$>[4PAG++]I;_/D4-6':TZ6G6TZFC5T1{CT2H#<1D# M,P61)2"2*MI5 M0%% 49D&RII4UN2>0VGGG.T
]7;>3DUIY0IOV\';16O;A[< IP"G&)S"VP'B M33$X1;CM^CIXIT %_6X|0 .1{(HM"FT;4F>LJ$UL (%. 6X[0#NR=TG;3KC M6,SW(E8;NE:K=W;J1=P>%-+'G1CC]
(^)PI*-5%3;R4\Y5UKX,:.I4|5:WKE=WU]%[*3!E10:WCOQ=$-M>]AS=+.5ES6=: MG_(V.Y^IL],&I8K.E$PKVE2]FS6.]1AIR3F.]:.WFDV!T]GME/CD[!*MQ)M$
M1)@U?*D\(CSXX4N*YA3-+.M29LU:*D9R;2A]4Q^WAU!AUB2E8D2XNTE*C92RV6E5]$Z]HHA.$9T\1)=+ MU.N-SN$HC4O&++V6H@MA5_))#Y[1OX+0CG(H$BI-!,&5O
M^)H=02!35F?N@A*D3JU:RZ]\V@H/E_? C@0C\\5+M5))BQ=3B)?V:.4J7A.8 MD[EDM*QG_C7Q QIZ]N3.<8N0AY^8SD6'YSPPN+UO!>R1>3^L ;N'77#-!S9P MGQVZRC\-
>\+FR;FA]<,;T_\PSYT6<1&MR*06R@OB(Z$;Q5L51M;AK;4R>.N*.MD1K%8Q7I[#OIU,N@GS7"+KNBH85!G%IUM[X(]-[(-&*6143A1%B25%3_M.
M3\TRZ&F5@(@B'D4|^TX\K4+$(R<='(9>IFJWBL<*'(YBPM-E2>Y&GXT-C.Z9?TW\!_*_F/ES;'-RMQ*WN4@PFP<&M_>M@#TRI[XP+Z[YP ;NLT-7^:=A3]@\|
3>TWIAY^A_FN=.R+:(3R26;% @^"H1/%7A M8U6>6BN#IZ[HJE>\5=',4G>4R\G?J9=!.VOX^W=%/PN,[X[>;NQJ&JXBH?T2
M/XU22*B(Q;U.V'DQ=9QT;YE)SEI,+[=],!H!G9A;35V\]^\+,RXD';^8L MBF<9TX=W"'(A),U5BTH:E;;>KNTTV?(0D^O+.B2DH,X.8DASZ(?D>C[Y+"?L M=U[(=0AXE64=$M)-
=UMQ@<U+H&R;D82/!$,C(8!7EG7(1T3=4A(8UJF+*4,.(M2>UU.03@RK*.#4?;YBPM-Z6Z6]UQR&U+]ER<@UUKMR6DIRUF8!\$*4DHBTI)-M_"BS8=))K6.?
2:H4K)!5B[\4=2CUB$Y]>1K=L4R0.33SG9;&U=$.U,%1ED! MM_4*C&Y9H-G4EE35$;F<=Y7O(2$^\D1-L7R/+J\'\2>?05\\=M^/(TVJI52HD*K^)Z+P3S/&=B(]ENJU;3ZYV*9*
_Z&9;>XKW8K%;!=U#J3&1 MU0I,&@)UV(I4A%WXQ<,X2'(NS2XZ]Q6.CB,I2KW)\12|Q6I>3*T ME,X#2P8!YEE4*(0'!M\-GXRW>]?#Q?."P+/ZD\#HV^S)O3<\N.=AV%&*.!5Q
M*C&BD+H_2,T3(Z7$DE<,I2AQHHATRT2Z[?A..41:2MG\&F$@1:B*4'<@3;?I-MLBR\^GS/9BF9"27%L#9$M45SB^MZ5;(!3(7/> ?E80='O/LG94M)ME@E"J?$
MJQ*O2KP6$*_58BDB2BQO2RJNISRXY&?#-MP!DPS NV1C0,2'5H=MA^QO>N@ M9%T*M@>KT$QW @2YEWQO_O)S^5XU8R+9AIKE;6
,]WF[4]7;U:K>ZOHJ)WY1+@ESV=5 M;S0:>K/5V5,RR!\T!J_]KOG./X(_,$1-?WS\U;1^\%>94.=WF;K)TO?X:)T_C9AF#+_*U'#>@9, -HT)&$G,U&[= M*X>N-J%BY%:'JZ"5Q0<1[U-
Nl8 M(T%!U7A>74C&TV@Y.1C*-GAOO?YZO33PU7OC]/>]=/5 MP]\UPWVV0QC$/P&&I)_1-&S&^C3405)K(D?A;A?X'OYM)GQ ?G?R:M>6_ M7V9O.9Y=&1O^=-'?
QQ7*<1_NNN"

M.G\;H7@%34$(^8S>(;PBV> A//2GRY!F .&)3[Y>PH' MJ ULPP> WG_^],?)-/8]J/G,EM6+=XCPZ2VAA;6O=_WT$%TPR2_$NK3$34(M M+GF!T?#4W^\^VWK|GW2%!

*M3*C=$WO|\FY($.M6HTH(01Y MZG7RY2A29.][GZ],/SU<]?XX[5T_73W\73/L5^/=#QL18$;PPU)/_ILV8GP; M;^.WWS2A_ZM0O^#W\VHQN*CDU^SMOSWR^PMQI,K8\.?*

*[BZ^6,[WZ!ZFY8|M-M W;26I5/R|;D#9K5B1V M=F<<<@$^^=@_AY-$&>P@CSS1 BO NXJ_Q!'#|V#O[N[_N--^9X8=C'0-9.P9 M^1 ?)WW?,BVX*R;T]*

*[?.">$);N^>KAX!T[K%W>WEU>WCU26^>KS[X(__MKF[N>[<7-{TOVN,3O(%]*QZU7R+0\"&U;#QWP@4_D"DP<)E_.WF!0QX44\73*

MB39WWK/A6/^A7,18!L$?/<>\|!T%GI#^O!M&0BF62=CHQ79]T&.>X+:?D$A/-MN)5.[>;U7KS1&.@T8R1:W@3%G+SS4ASG7 M/GU[O+F]>GS4>K>7VMW#Y]

*[MS?]\/[4*2^[X5W6,>,4 .?98ZXR:L'R?(4G!#) M\"4(NN%_(/&(EP;_SR48^Z^@O!R^IOXO<8 MDQ4?7G#5)_P\?/N53,\S\=/7<+WP$W?BB8\^\(/LT(,T0#^&?(<6[$HC>HX!*

*M*D=\U0*%R B_Z[^OI&*\G@V,U_)' 1SX@?>,^;@HKJIC5W?(K<91A5LV#0&-MHQ#&V#+M=PWDXRM^[869Z[_"W?W.0+_2IB:>-@;-_I48L GYCK2^4.RU(3-0 MK_>!-,\?C'?#-*

*AE#A4R'=?\[>SS3KEW71-M<>I-GK6> ^@*B!5=`F:N& ^7E_V MPN?6C#%.ND3'BP?71K|C1&*? ,6;!CS.Z'W,/- &C6#T|KG _R7Z$*/O[_*

*M15>"IS3,B0VZY*L5C%!EA"?.H9X6!GH$T >> ^XP;,OK\^^G% MT_T'W#_7&3"0YNP[',YH H1!1P1/,@+\|HS?*^'P(1>5Q:A&OC[T7+P\U%%)OL:*

[/=,6TXK@K@]8+^5&#}G%VB+,];ZIGV MP)XGMA&X<#C\|,!4H^MF?3VZ87R^<.&I)S-9N$4T?V-DV:;'"%J78;HV<%FR M$>B1^PP^ 7A,1+SLQ07B

>)\IXZQ6>'G$"NPT>BNQ>M|9M#A@NQ?OCP;N*Y M8P97A/<3L+WZ%NWB5 ,2AXT.?_ /TA3URX,QS -?LH!}>.8J/CS%58!IQ=H M0-Y\ 9CB@4!$_NGG?P^^CW-)N/U_=?*

@'-J+8;OYUI3P"ZR?-(S:1!VS8]I4__M'=6^<:+'3?[fFNQ_X2H,2)XHV=?3T OA,\$Z^2@XJR(O<$CX?Q9=Y8=C*TQ M0\65@XX9GOU^RLG->GF9.'@<>$\+K4#D.U1$,_ B%*

(_VQG&!.2)'U(2FG4[M$AJ[EEFPO:#//3NNCR<4L5I=^V2YH.H =+"$,50$OWRYB(XO^87X%$F&C, F M #;BCQFG:#A'V^BCD$.JM9PLU--A&HIO +W1,7&L$HTPXP4><$!SB-*

V(,1%N M84N !YB301 ;[XB ;.0K+8[% _^""'\&4<{!$)4$?=^@WPPQHPS]R W8)I^ Q,&;@=?VB_+%XD+>_^# M+CBFYW%^[/UXG_!4F1HD01T-]P9>

J48];024A+H9P^#>4T"%3'(&,5S % M6?I!P1;VW7 :M$];@,=&S/%!2P [$\0K4B2NY]4%[DH.X_9OOM 'CT?P M_1 K?;_"PX!1ZP5X"R &|@>K! !W^-

QX^Q^;A;0IUYGL#$(!/A7X\VZC1FD:.%^PLP M!CUG/'KW0408F%7QS!R Y0#T"OACY/ICD+8VO.2[@2^BDX&E#8T)LY;3&1A MN,B^NAZLK1+1'-@XXXZ^V= VM#HT

*\4J)>GOIY86'D. "D8IPPW"K M#-1,>+T4O),Z7'BR+5=?C2]**ZS1V;)6#5 M$LCRUZ/EH>B+%.HX?!FX$/SKQZHQ.W7- W7'F:!;9GB(ZH.1L6:H:I!1<[V1+[/-

MG%=GF>1/#TB;;[Y14DKU+]G>,F5T=P-Q&A2&DHF1EE%KU_PGDW!,NIE*Z=@-M6,>=F7&{#]^#5AE5M#M\VZQ9]TT; "YUVZU;QHHS%8C[!ZX%,!1_F,X]KQ^ M3DIBZ35A^+"_W(A;$A>L^]DKMZ*7=_!^? CB0_+/GH-@PQ_GI\%80Y Z^R@F MU#)7 6MM/SV1^1XS14L5$O@L3S*QU4CR_6L:9.P!S_Z MFG 4I:TS3_<\'E9]QQW$Uf/HM,*X_Q4!3}_@+TX/#!:5TLW1HQ3Q08/V+"9Q MX<_$Z[,F,s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}>"[#K- ;_3M'#L!R3[[ATD3.L.& WT M=F$L3:T)3\#"Y!O^I5A5)*F?K2LJ3_|-WUAQB[ENZG-O'I&0:"G8+&-J3;_'M96G8B6@KI[_#& <""^9)+"\3<++0\LAE,$8K05Q&'AJ;4U^2M9TT<77DF<;[?B MAKZ>,%,ZL&"+,C5PV>8$;<[YA:U"D>%3X<0<]^P$_2I*@ L>(P4]T7*NA/@;. M7; %L3)6G^@++H*9 +'"%C>;B* <:WG%4&9)"ONDI<*$HP2!_B!Z-X2.9N4-- ME:60P6JY&S;HQ\DKH6!=[!)V#HCW<58IMDHD=O;X0S;!*L>PI^'RUL#F1@@3 MW#Q0;\280SB^6,62> =ND|H;5+ [X#0'"'"8*C%3C2&*E$0YK=']XK8I/T--030: M-.'U)E9"F8EXUAR,C0K12B*^=)QT* M^@7+|643-5FWR^CG 2TC_V#L< U8P&QS:9E'OY^P[8D9N=CM((+5GR97?8> MSN?,WRZO)LH[A1.L-AO[U:8ITA^I8Y;V,Q=/?YXO+V-(M-Q?%_>GQ]<7[Q[8:_7?Y M<_..7)U>DYO?C]//[V_]@34^"6#DZ%MY%HMHZ'TG]"=\\F\3(%&C0 M C [/OZ[.VY]_8 ML71SM&1XJ[6:?OBJZ:GV,T'#B,4N_-%AN'>Y$QR&D823|)WCC5'8]ZB)AAZ> MI:Z=[&^RW7'93OKY%YQ!F O*AZXP3EV;N?*>^8W\X"3/ZO$K]5<>NAY\(L(M)PYPF:OC <2 J&3_KMOU'=*F#OLA?K+ ^<=V4Q_DVQ4.L@FY/UH+>9Q@.;@?, M+MK72;=^Z?&0AD)!/T.SQ M*9.YV;X5Y5NI8)W##3P(#+; ZE["!U1&3;RPLAIO- &34|HGQ$P@L$@/2-L4A& M:?"8@/0%'-M_\)RW$0!7Y QI'O:N?$|'V4!HFB-N6$>_ 8O6'I7CK8U@I, MV\OILI+'= 1LY\CW@FF[B8K:.B,#H>GR/>=6#6N#CL;!0M40R,'? #@B_X&]N M18!T8$|+M/Z8*91MTFV@T^^]W'PE#,)SEOGUS9[FN-<=':(F0V$61HJ60O#_WJ$RD<*@VZPFF763-B#* MSD#Y=.&5|97?EID5O<7+V&*E:B*=T_IK H+N7=>0O+%0Q*K*_<4D>]=^_/_M()F8|SUS_;|C>;|4W@^" M9\UC7 FGO8135))PDE*)PFG1L*IJ=(IT%*S5=)6#[31[]@6ST-=:B@& -'K MA7UK@TC>SIA0WG_I_D _Q% (BWU|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|!1NH>SGE"M5E M2/9X!ZU6J6C#,^<79P>?!N*<,.AVE-Q@T)033%%2]8@ G53=DYGG4!^!AOZWT M.WVEU1[* $L "P GE3AD9G;4*8"RF#85\;IG@2P!+ <%*U0Y8N1|T2>-@> M*(-QCXO,I\|OU;3@90189AH.#]|##Y(|YR\0|R_O+ ^_ZN_OW3/I9ZA+"66 M6 M4=V1?AMKUYHV+K1+UYG-S8E-LI:(:(O&9;_9[YS"RO1 &7<;J4=+0-<"Z(U+KG8,Z.2"8H;E1E842QC7 N.- M2ZTDC"6,FP?CC4NL) (REKO2I$=Z3>>N5F"G<+O%;!W#]TWE ;E/B5^<&TO?C>>KBGQ* ,'(/QN/%!3XE=V@|0061#S,Y0# MIQ7-5]Q"*K#^X0X1/"*3PT;218-4_1&2F?<;Z*,D)BO!?,53=G<)>;WJ324 M2*\%Z16-X91(ETAO&-(KFM,ID2[C(<4LG*Z]-Q$^6%!'XMP,\W470|@+!OYZ/$>RUXSS>+ M5.)=XOUEX#W?%%.)=QD/VFD\:/PIXD%/ENC]B&G(GRX>"*.9>@:HWU+(?A- M[QHG4G(O.U/RY*OG3W>_C!OE?EEG5W5;7670&BJ]04-ZP6V)OJYK2$L5B5? ME<)%^9H(-)F+GAS]@ZD;L->V1P_>5S8J0P+^10 ^7[L!"7@) ^|<"^R-"23@ M"R)!QJ%2[,"O? NO0!<#&='75$*.V)!*GVLDR0Q&I+ MJF4,BVK8;ROM83TC0IM_&MQ>[YF_AF6IX.A9/YIG$-4.HQD&,$PY?1ID PC M&>;5,$YPC28DP^1AF#Y(S+UJCXU@;QYMSR MU^!>&6LDZ^=5T-8I^X1P))U).N$K).O/UA#6*?NX<.2=23KA*R3K^%80UBG M[K");&.J&/+^\OIR_O+^\OI[\'H<\SU>?YW7(AY_3%S+ M50UB34D$^.)X-L)Q_;8=*5-]!).|.FK=O[RJM84\9)/1P7^GB@BC@ MK7W(C6M-?I)'+E-"Q4+)%%9*W!DEL)")9[#EXD^$>4E,ZA(C9GKB2MDO/M%Y M%-[,IO33>SK_3.#!]LPAU,2G9?R$W-"%RWH6D6X++'O '1\| M(VCZ]Y!D[$*%-P-LNZ 0I8CPKY(.5,^AN%3=AA__"V,+(_)H>89&9NH#A4NH M"?CTO);EG-T_XJ\>7.DW M,%*ZXU%#>0G>=7D6(NP..V6EVHZ_FD-?KX!?\WZ'$E+))Y- %Q.54T#._GCN-1 MC;\@<)]NB6Q.]N7E I\-;$OMB>ZDZIV'#IT@4SY:MN90<_E$-ZU5-K3G7UN M$_=?*YW&Y>@WF6J^31T7U$S,2\7+CAJ56fN@N7TS+*G5'<].I69<(&-L(.G M 490_N#*'?('U.-,:UGN @^W63XTV'5]CFAZPZR<;XNS=MA1 0N](."G)H. M$X_E[4VRA)92J/]S)8\0RM?/|24*H7)TQ*J$T%KUJ-\;@YVQ6I=5G2S;..1? ML2Q;WZ)PU%.ZPP3U48JDNA2C[GJ9-&PEQ>HV=P24)I/6XJP]4H;|:{}',*

WR\M]A_XW4I*H/CJX'TB:7[[FDP: MC"J60YC;RY/ONODS>(JF.PM#?<9=-.#H.+PS ,KQN#-[>)0 *@&U%QCT%X#] M00SJCV(S=.!A';'+J8Q7+'\8P#S^<2GA_%L,L7+^-- $I[GQZKVZ$"L;S.1Z* M,I7/:TO7)$5D02?V=WYC_AU_G,^Q7Z0SY)<$H?>8F&(F1A?5 ,%\K M]DP,R\$3XA9N^06I>L#E<6GF9Q;!$]LGECZO+F_/;\\L+_KC].*6G!Q?X64WG]|??5XC>7]=>H%?-WZ#! E;C&Z.[7ZXF,G4PND(>8T\YR'JBLHUYZLN8T;6)Y879]5T%HV9"8Q=$]\Y)6%V39BO="+HTJZ(+KNI@UY/ M "&>AB"=TFL;2E"S@_\? KZCF*&)WK47JIVUE,+;U9R/P4UK@-B?+,MQSGQ;#LZ MDZ:[45IXNS52^]/BU8Z%]]=DHK]&%+434-0|;'<.N^TZ4-3I*]WA:HK]SE#T MJE2A7C]-8'^GCH-Q \-Z9%$QS)F>V%33>3;UAH-JUZ]9>/FB:FL%W%C*G+.J M^3WZK*JVT;M3N%3P2?VF65_M;P[=^H9JSR^'7MWE-86+;.JW-3 Y<;8'F5#?YG!NI4PV!8-NW>MXI722GS4[I5G4%Q0 M=UMS8J#T=ZL(EM1(7@*Z,8#NEV?;; _H3G?7EDTQ0+\]"RC5&7QN/L"?EJUC MAHYT LN[2"PMDI@$\MTO#G+\7$PWTLOVXOP&MUWPZ(ZVZ4[HI8OY9YO!$&* M'FX#I=- >K<;2OM]F@V=45#\]%3R=OC(:[-0K](H5GG3Q?*:;NC.C&EG8EN9- MW*8+YYI<6VM8:EQ4'@?(-Q%ZD/&XD7CI)0=Q<(KA< MO/25_]CX2+9=B>"7KB'_:=D_"6P32.)=:0 +L)02'LS00P4N'3OV7 I:T,N\7[+$L-N!SQ>ZT^PB|<"CDDA58WD_1_I(;"'LVN.:D+VZ[*<+A3TU7FE.TS M< =;GSEE 7>@] 8|7@J2B"KWBR0^39[D6_3*1R,#'CK@A;- K^F/E5YKIR%(MF2_VTO!;.!Y: GX'?64P7NWYV@AROEI)34]C 7 R81G!!+5<:CKL&9["YLN M5#A1Z1,V;J..S!N3=ZDX;ZQJ_*ZL63GNCBL[IY<=4? #JF/#7KY.L6KB7FE/I*%Y:C%SKZ>@>?.]W$GJ8O MA=RO%U6%;XMSH6JJ/U'M\&IJ6\NZU/_^.NJT.Q_K1=2K4I32@VJWZA-E?1\L M>+4L;?S0P-A)MW"= [Q774!E="GNNAH.=FBK-#[#M"VP*E]26)N>TMEBFK3, M4F=.$TRYS?VE(GL_BV5SA&R*AZS'(D MM05U=,8[K:HKB:P2M+6!MG (LC30#I7!<*=:ZR7Z/@)"YDGN1*]G;- OXH()F^ M+E<&I_6'2]>W!QWV)*R;"^MMXZ,5P+K34_KM/8#UJ|)A,AI'NJIYK^->\;1@ MV3Y2WN4EI '7[1LX\1QX >:]-5CYG3/3%TWWWS:_"6 OHY+W/|A;RJ7?]0>J MA7*- GVE?GG^H?UGV"8[@/7[2G4.?/M=1\OQ@(SVS3\Z,A[",),H7;"HZ45ITA M%XG'0GC,*-#=:SQVVWUE.&[^:*.7H9]E)"33RAE5OALQ M:$"(YR^]LWI]C:PZ:H^4\5"V$- H#,&:4[+X4,';;2K_5_'/CI=L?M[:J449R M>6P4X=2,SLB;<2K2X0+)4"-3]L;*L%\C3TK8Y81=/Z/!\I["KOE9A"_=A#BQ M'JBIXCQKTW*):P'"Y@OJR@SN(@R:T;!Y(P:]L$Q!AN-[F] (Y$*Q.5FUWE"%; M%DGN 0 S6D#O/0!KG $AS0;Vl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|/?\APX M]IUWG][C+\LFZF8LW]D)Q^\;P_ - QP8$FJKD7ZKJ?8S:4=.]P9P8XW/E1#* MA-")-_?0I_T =LY\H>HV.N5B2)(8DAC*QM!Q) JK$ S+6WY,-BB(ERB2*,I& MT9EP2= G;B1+[$CLY,7.%]5@9=YP;J6X.!H GX:4%C7()+F:]?"K"?78&R:7 M?Q:F4>F\6_(-.\U?8O-O*#=1;F(S;B@W<2\V\=7Z!3,Z,?Q^?7'<\-8+267; MC>H0.&YG|)[ZSXVKNBS=Z8OGZ"9UG!MZS[*?>#Y93 T2N1,WWIT3O>C$LTW5 MSY_(*FGQ V#,.5BXM4ZM<|,E M.>^#83@AD-FFJ!X#GS*%+M>#+A;D:JG0=. MQN||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~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|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

M9:H;G:0\T[+-YS42;&LM=*-)#9'DTE4!%=;;&$$>Y*H3:.5\(!H/2C 55430 MIKJ!9$8WTIUJ_K2]A3L!W3/Y+'KD'6G7]?3VSZQU^NO)\8\KD=%S"Y^I"\9 M3ESB9O:]X,(8;R/D +O;&F'0R9@LOZ4T5N>+WIZP?E*-/!.]O-SSQE07OKS- MW,S*# &^#@?6L3_R=-7AA56?:1G?R+)!7@J<>RR&*,*1JNO;:DO9X K1+&#% M+&^+Y7*F6MC6@ZY1S!QF=\U(%6=!M\#Q&L;5153.+?,_56=5H/"S/C@'HKYE M7%#<>%Y9$%YVF>AT)E2=S#"=`3/),5P',V/!@V:4W?C9#T2OD6-')'FL 8K MM3]FH543=!MSA&,@\I6_$+A"1P\[L>XPU,_NP,U&O&-8,.RN7^N$M,YJ8'EG< M3DL<>4KB&L|?))4;_.RV/G=!"@8Z({|\!I1";>#2 MC)S_+"9U"_?\@A&V RX1.\-AO]T#8XR"G%E@T,_VJ!]J^\1:+8G8(\M7Q C> M0M60]X*_G84Z"?[FL;ZI;K*G!;&Y6,!RL\!K?.]:BR?,OQ:]H!K0:;R2;EWP M"K"K)G,1K8M@;]4'O[QD],CZQ/+B&?/IK)GQE>_\1SD1%Q$Q,2#RU?RDM1?8 MT=Z/O ^!?VINV_H)D1E#I8:')CNP/_ +\;Q/Y*#SV_9^UA'QHV%508?JA!O\BZO MXBX-T35VPU+,"$KDJ413,TRU(%KH$!;VM)48P-NSUO$93:$[=

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|;S-@M^(E%GR9XE\PKD72& M >*0X%U!(A_^U$W^(#" X9&"T);G B%,]@Y)*L]FF#SB)PVYC>B6CSI?ATW_ MZ^DV?S*LF-T9M1TX]C54&M9(TI38^]8RP5K\7)(\UU10[8S2*VI/HLDUF\G& MU8#F&R >\-648L@,7\@4Z@+C*]PNVW\Z7C#U8.\VIH("NA1%7OO//W::Z@!M M4%PM_/!1=ZA/)V 2=(?@"A2?,YSJ8SRWP&@!<\7F N6%$)Z<[#, MU9^4Z8R!8,.'81\\CEW86& 2U7[F/!&\3_0NG$=FZ@,-^3UB ?BR @0L(82 M42Z EX"0["7A@P5]!!O3BL"+ L.A)N&"<%#AOIELD.(YK(-3E609*=/+D@& M3W=F^)'@ALOIE;\=2Y;8!NS1!F&=8(F]\;<0-!Q75XT2A%(2LADF%B&O<218 M$]#_4(Q:=HC8O#;76-C5*LL"B:V_AQOI ?>X,F)%]P -4!?L=B%_A]G%F 9 M<-0L0+(TD]Q0L0NL1$[_48@2-F=]2&L%ZJS8X)M#+N-4$+N1(6CV/P5H@BQ#H^V[OE)$Y7 M62H-L_\MWJ]4;5H6G]RT U\]!J1+LO LJM3.E:V1%2B^?BO= *,-B*]1[6E"^ MCU+X'7EOZC$C?T7O%BH"V0 !1W5U9RKV2T TJL=NH*_&--5J2[*[E9N2YQ=G.+], M:;78_Z\Z3_78%FP@"7UC,_0<"BO84=%W"(:LPS F\9O[RP?%YN2>H/%H;7F M>WJ%W%U&JQ)*LMQQB]![R \"X:NDE-_(NC/T>Y6_JV<'XC<]76"I]WA#9I3R M%\"3(I#!:'8(CZW]@%GN;'S"1EYAPTU-<"TSAH#%.&3B.:XU1X4]2G@XPU6V MTSS#$-_*1/4<=/7HM^R 5QUBZ'/=%=N'W <|>.=2S0130($OJ8DT@^=]@;3Q M-P,X =8,D,(%(;3Y"C3=65B.[HL:OF7-\>0"*] (GEGKI!PDU_8%,#%@G2/QO M9[?7!_X"HX%BE.O4_DC]&>K]2;(CHG>838]M*W','%FZ;L)!4E^]>WB]Q^9 M3TE^^?2A2V%\-@-8?0ZK(&P**PO>(/)'[-^S((_HZOC;Z>&7Z]/C?Q\>G]V> M7G^ 0^D1[%L_>(LD,6EL@SZ2&46?,-!B\?21B/2C7UKL/_"[E7)]]U\V?P%(2RH3[C+F+ER.&=84U^QA,(V,.C!%#)S,;3 MYA?7FAS$H/XH-D-(8I_*>,7RAP',XQ_[,@8]IP= !_|FG2>E8M]SS-<6Y MC2[RI*?WZD:H8,=9C(>B3.7SV\HUU?']^C@X-E9$[$='56;2!'O'D1/B-8?) MSTVQ@"Q+3S4]/(58]#QBZ#W2[<+D:4E?[TA3#D1K5O FS_%A< G$.,HUME!8>5/1I 790I'@+6,4#4^Y/BIX9K%[8 M<(]'N?8X>\=N0,'\>4U]@:%]9<%6$,*ZI?VA&AXM>'3UDTZN8-NXZ0O"Q(RB M&J2'':R$Q\ = <8BA#)EC=@\NEUF_#HU<[)!D$"<+:)>C1P6]K9,8OH:"9 + M+&0+Q!;2D?D9^6L[A ($)O@I$]@8WIB!Q7+/9?>*]_+=#2#IU/=P+MQ:S_8 M&'@>,"6F-? T ?&6T1T2KGBX.+X.C'D)A\?$ /,:4.FHAG_+=9I4/R55)!-P M *4;7.8R\&YMJCJ>_SSA8<=C{ &<_'>6XX:_*'8X:QV-6X/5"ISXOL7V M;%WBD!!>SS3[XBAH/+ ME*A1:=NS+Z9$/MSGSEU.8I1@IV*V :)Z.2Y8,1_FS^-->D[0MM--X5,R MHT80CDLBTDI*0OZC=5#H:"U$'?^,B//=:89U85OIY;7:XM@=9ARO*,9&?<>>Y M:?D9:WT;*^KD.C]|@H(7B3C4KEVNJYX20IMKVND7CMV9PG&;#>Z>N.J11UB MO$G+(3M2VG%4X;XXA4LP2?@K928EB/,S5;>9&7XY7?W2[VKP7!2SG?[1(!VT M# A<7[Y2\72XA?_XH,T,-PKT'(GT]7H *]8A&R.\$A1=8O5:85L_N/87= MB"Z+Y=W[RV%G$]@JAO4LZ/I%-ZTYFM;?5==% W=N:=0X(O^F&)=?>"+4K,)Y M-N>]Y,7Q O? %IZ@<&'Z'+'92D$VXP.LQ@9%8S/V|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`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|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l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|T.]X?1.(%GQS+_[J%*H"43!Q@19=$R6:IWD@<0;\NA?'_4FFJZB!1IW> MM*G%F#L-PQ[>T0H%Q*]8H19/JB>\"S_@_485+& L; MWG@69N]+<]2};OQ%9H/.BH_[P9@- XMQ!7S<4 4EZ0'6^XS>YA,N,>N=3]N& M!0@,1,P$'>]NP*3;^2, ?.Z'ISQ^]&:+"03A9P~7_F9^[V!@LD;'/]I$\[[MUP4ADN=6I:DBTH_,)QJ$/N:%$SY;+1KNN6C"9^1TSQCUN1@?Q LWSW[_D#W< M[K>/5DG0!. F.2R+N/:<:)(G%2QW94S V2O?UH#'Y>;[1$TQT9E(4_ O4V!=++ &G"=Z& >AA C?N5M@[3O= -"NI!.[:AOU'N MT-8)97;A28#;\$V>9/;>^FS.<*1ZBF M)SWME7]K#98KZL0E.-:WMXOKAF7;"O^\30J:] MP'\M>DQW)\B9,;%D%>1<5V[X3$WER/S%AI7_,-9140^H:Q_V!%F[IRK'2YZ M-JLI778VC)X*_13ZA>B74H(6IL=N%_T62.9:76]WYEL-[@P%|*ENF.M^]HW M JK 5 KW>JDVI5YQL=! :" PRJ!K-I##>;\/--T; MO? D8O=6('51KAO4J2G=>+\UFM&7/EQ ($?@!X5$2];E]VE;]\X+D(S6?\LC MXVXTZ+K>4AKT@:#D4L&\%5!R2;6F4RN1,U AW H(ESZ/88$2O7V$]^F=^GSS MY+W1HX_1__SY^OQ2^9_73[*UI8*6G\T!4_YGI4"O%1/3XI?+8Z+2GA4^KH:/ M2T7FEL7')369NM[$SNH*WPX W]+B;XN5Y^WB&VC.#>6!WBO-^7[@^*;15ZKS MV@EVJ0!E!

(XR*,_UC/'T2GG>,^&1%KY8QG5GP;=<X\6A85Q>?^"28!RHT-VS$D4[E.NY@ (-MQK4AE3YG]=/M$O%
M*$.0*">TTJ/7BHY+E1CFH^,.5.DVJM)5I4H?!E+6EXK1K824R[L'F_/SHQ72 M[2/2+55.N'6D Q.NN3.YJSS2RRG4@,D MNU3PDL-#Z=!*AUXK+BY56)B#B[OQ1S>5/_I@,'*IF-
WR&+FT,[K1:BF,.PB, M6ZJP<.L8U] ;U1)EXRM?=(&ZPO-KI4"OGV ;RY45#LRR:,\],?HP)$=CN;K" M#$14184*'5=#Q^6*"I=#QV6UF&9;(=M!(-MR%85;1;::WJZ7"-V4V[E *VC4
MLFQ &<+5RH1XRC.]6,T^=VS/<0%3E(I] >I=*H09 M@0]LZK7R4A^(,%FJ[# ?'7>3YE%7:1Z'@I3-I6)X*R'E 22N*HQ:. >.6]CG< M",:M4XQ$.:T+S6$9.-H%T^Z-
OC%DEJ44ZO62[G*!383*!9,P*8-*W01C^;2S MJ[Q!I5*O#2&7*CUW6B6:5E#D6?_]5^#X'V:>R+]<(X)NY"G=E9XR M?X8IF+\ <9>*_JV(N#M4O%<\WW)AS['@Z%(EC0I'E0](>?
M>DDT]M9I8U?V^ 8T=FUB#(>@-58X3<.WDU\;Q%)@'2[_XTS7,L MK_75%+0WBI\B%D4L"6)9JFQ5$95/EY@YX?89,8[.&S$+& M#L_7AD[0M]BLX/FODI@UV3O,Q=6RJ-
JEZM:;4M0L&SW&8FAR*!;9% M3@!Z\^G5-;VC4%RA^(91/*>=[.HCDT(6GIC.YF=ZT7QA&4 '_K.<"I^A$\& M+,L_R3?[$3R!'C807VY,79_1T$EIC_8_V[IVD3W%G_E>,_TQQ ?
^]MVS MB4_6J 8B74/V^O$=>_]D@;&:>]\%&XC::G1;@V[3-7_,M!>&%,:&F@$VF/'(MX#ZN$VLN*,4:4(3N)H%^.MISD@:;$ IK+X:G&9.)ZX"B I=94RV';NK=W$16
MQWZ$)SY=L+[_)TP,L'C]%(HQ(%W_RE>I+7[9S.IUW]KFNPZH3!IV> \^G.:&.6-&&?[-? "H9,\?E=[5P^7=>\VP M7HRI)_D^@L1FB0/ZH(T)UP 6H%EHPH_S6Y7^!_?-N7C$3V
MIX'FZT4Z:%"0 MK 1DE;[E#'XF%0UZ>!P AC9VD?Q^\YW!20+5 M7\1AF$"A)N(NAS)>,?MEB.;)KPLX['2.';KF =A':;'M!Y2=R)//D=?8OO?Q MG?
$JK"!:3!!0G*@DOKVW/=P,\+.\!%OJ,+..$ MR_EZI[.JH8U,FTCZ M9%:#)P[\.DF2/+ JV8.2&<0U\%*YZM?LPLV>#MX.SM_&\LV/PGNEW)0,FIA=
M*UJ*5DK0@R"'V/[$1@1]B#2C;'Z08)#$&-89@5 PVP3,XL)I.R K??RN4]UY M,N1'1, $\H'UY("9#';2>RXY47!^T$X^O;FV0>XZ@0=BU7O[\1W>N26ZVQ*A M%,XH*
,]A6KA6H.O:\JI4(#?*. ;I0)\:9/.=]UL)7!=M$LFCDO^-+]$B;8 MWJ6>IZD6"Z,?M?HN\M!;>2F%GPW+L ?L?LR8_\T9D+ CGR59E[<<.CU[>(/F M,3HW'YC[],TT^AC)-
IE7*U*W(9FET"$Y?M[5;O[5:JG<+00CN9E\NT;CG:[M>SRD8HON@)U*)$(6S0*P5S!>HUD1OFQ(&.UWV1'(;; /?F]T MSP_''JS$11IZ]X;2;=NO%%T4B(ZR0M=[R6==/1.?3>--
Y69N+107BF%7N71 M;9'++)=(U\YK5K1M;7[9^D^]VMA-5YCB,% 9IWM/*7DC9/:!4IHGG[H@@G?3 MDG0E2E&)]\4? S!FPE\[DRH#.!*X3#-\#1=U
D\;&GB9:]B/F&\RD&U3Y_%2K<_@<; ^O0K".Y'6ZHGGYB5QYCE%[V#W/'/SNVEC MJ4ZQ-APQ4KIE+H8RC$?VF>_TGV*C:TCCK)[.*[R_:\%$\YW\5\YK@AQ[95Z=
M5*!7;]9EKIY]#X42G/TLY,4LYYP#:U3SO K)'**(+4M^C+_O,->W=CJOO/R. MI[%TLEW>0>69E24_J/KIO)MEX4&E9Q=RA!2H!EQQ8KB8%&I--8^!E0LXVI]2
MNKTS&ID#IF&2&.*K]MD TK$DW'F_J8 _X_30.S__X_L?WWH/EQ?:S,=*P97C+DI6M4V;\2-[@E_&GL9@B?S$W0P>I&N#,8HH#^FE-Q@$ M3X%E(-OG_'P01RK->
(:EP;Q.XQ:,.@^F1(Y=,OSUK;3C] M5N77[G&:I>\:MF<1H%2VY<[#:!]PV@9YAM'OEF**]E3*51[])M=?GY>G=N^# M3HY.CLN_ M.?HE[NV%A@1DZ/F-K^$-
%3;_COP//QIB+>^GL?5/FQ8P'!>/PA MR_GL-0_,#/XZ^0344&WL:J#8V_T0DML)BM?.8GEI_:L2DHK8[)-+K/HS/B/ M,RS]+?"-/#_!#^;?C!Z,7[<\-;_G^Z[9#\@5\.#
<&LOGYD1,IJ:WSG8S\:

H6*0YXE1>3DD84O86\SE23A_#O5%?XIRET=7;M7*PEFR0Y/"6]>0= MK#>0L(N@T)5ANO\TK(!=F-X U)W 91EM&9KEB@B)9CU7O>L[[9^];W]<:M\O M>_=_W%U^O_SQ<
1!H#\!V]&+,]1& $+M&6'HH?@P;(W],GUM AC!L,D4Z!X> MW"F[JO#N)/ G7/OB!-90Z]-2#)23(;8R>-CI!U8Q/ \#.2Z("9-^(&_$".22 M$19M3#$J!-<215I3?HG@?
WWFOS!FXZO\A(4H*#LP)_":WJG6\S0O&(SUV.XU M$_8OKJ[T#0]V\\0,Q$CJK#)D6"YBVAC-I1\=VF+P-,&G>?R%4IXE7C+P*.*+
MIX(G$7^,\&5.-3C5P(>__P/GE(=]_MAE/,.1&4TXD=A:C.&SX0[&4UU[&9N# M,3[2@;M@38\ 8-]3 +85X#O CO@[4LY.N @%M&'#N#:%M-]KW]@SL_*V)#H: MP#F-Z) ,3W/Z'G.?
19H./13/"_!5DAP#>$(1?8,ZD,FSL_[L/AQ]?G'B6?P MP"" PU[T& XSC-@SDV>'F("(/N 10 7P/?P4OLc'2HE8N+G& ,8">_XT8$,< M1 !\'WL^N;DQ54=$5#F.#0W?0$KS?-
X+R&4@1Y&20+ZZ L60[(!&@':&N&5G MHIEX0"\)S"U/Z[=M=Z"B5DA+Q:1%-RE&N@S/\J#,2]Y_R98_/#%_[,0YI.;0 MF6MO %](I XU<\K;0YN>^%9'+>G%0';+@V.:#&0 #O
(.8E?5(0PVHWX^PPO MZIA3;1(.P"6Y;WBL;4J?^ZI=@W(FHZ;EM'C(6GV(QSV!>@&LIKP6=Q;9"G
M6@7HR+"]P"*N;X3=J>B&SZ9S#B]B&G2,0H@@8W(9C^R%XC3(K$2.T.@IA>2 M$?!?PW6)R5+>W_G-^>VIT%,2V\94(> !N/C \,;HZ\='N09R6LK.>0*-=RI) M:P1FGL?% =
OV$6F80EV+23"<'Y+1@$6R0DX6M,,TZ-$@RX\AC1>?KIC4E%- M&B5GKZHFC:I)X]$T:;P!3C[# KF,BU5-9_%$U(^1O8.<0BD 2K/)TR,/O,E@ M:-+VZ+AZ]C!1FL'/ZL:^DR?
S&0\F-6GKK'?5OFQ\;E2:G>[G2K/7N:CTFLU6 MI=H\:UPTSZXNNKW.C%5,6S?M@ U[_O^:K MSKLLYZV$W5'Q3YD=-7+<_>6?1P4Q2GE3L-H+6"GM1$E+)2T/AYY-S%5 @.TO
M-1\5O*CT; 6PO0!8/'-^?T&F)*:2F(@N3.5\B+WEY2/"EB\5$D!2P%+"4DE M)%.)0>1[M^]DG.96->97&_X<5SM;>E2I]6T-\]].L*^D<, 8:"_C%"7TQ^
M*Q'DC[,)V&+MBM6A5I.+:>6.][E2FN*[WJ*Z_>Y+BK'T92ZNZF>U#D] M'5OU=DY/Q[ )P>=I^.=7V4V&]&UJIAC^=DV>0_JAQCLZQI?X'M5!7V&#*>P[
ME+P_=H47=C8HTAKRW/#&/7N(_\'.D,^&A4NDM 5<=IYZJZFW&KN9%+TY+%7X M#_C?V0S^U_<+_T?F+S:L_(>YSBSJ__=O9_5:_8-"_<-#_;PAIBN@?D.AOD+] MDJ-
^WC#;/<';?5-9CMPAEFWO7,[V_]P[':.]L7 XDMR'.'+U M_.-<;GK/I]K.)O8LB7\Y/1;7B.4;>4IWI:>D!&7FR6=B'4N\VK-ZU#L?.684L#ECI4^2Q M GEL*,R_"^M'D8=2F%ZC,!6,\)
<:;_=,VU&QG@QCZ=QY>G*PN,P9_)2#R9:S MCY0T7$$:;BCS8;LVU 5SS6<#6XKRG'HE\Y3,DPA>,+^AW-90401?(!SKY9&+ MBK%OEK$W-Q3KWZZ9HQB[8NQ9"%XPG%\"[-
P?KGSDH9W,4DTJJM5DHZ6-!'$T M,1HR7F*[U0S5@B6^\C+?F61>L[MDU[6^1"[[V5 2Q78-)\ZWUN=]:3;;^EFC ML1.&EDI 10"]KJX&BO2/A/0+II:4VZ1<-
^GO1HM11%.>CE\HM]0LLEV]>E7 M$WTY2\(4U9>#8 Z?Z@OFT12)9 NIZ*WCH=N$3P,^])WA5/P(G[+.O\D3^1' M\,1<C7AFVH$1(N%Y]:+3:;>[E5:C
MTZDTNQ=7E<]79^>5R_-BV[[XNSBO-:1OI6/|"+BF/[G!)V_S++$<8>?O8DQ M"#];A@KO*2#-QX"$ZZ1*G$V>>_S82^99VG:SNEI3=:N3
MW>K6_E,LY_HIQG(UP].3/_VL^^>0=,,L?0;/Q_ M!X[/AJK9>'*YPV@VOC_+J?-6YWU0'?R4J%]_D] ?01,/VTEK0Z1FO=G.77> MZKR5M%+2*G\^V@!3M/975!T5L-0XYP-
GOONSW&&;-X#R."^\L_ MCPIBC@]_*5CM!:R4=I*DI9*6AT//)8](,#VEY]/"EY.WV/N,^:K*(#M!< " M^O! IB2FDIB*H+DS5=1 [BLI'Q6P3*HS4,!2P%)"4@G)5&
(0Z=ZM^N_99+"= M&ON/2.H)L _9P'$I'_Z]!B?$7,NTV0?MY-,;:UOSQT[@&?;0>_OQ'=ZY):)1 M(\?GB4@,G*^I@?-'#/VZ@OX10[^AH'^,T*>^.*6"_&LUK0/KMYJI7?$RTO?*
MLE#+]>74[7&E-\5TWY/[NV&R]\?PA;03'L'_35_=G[*(GK2UQHU*K5QJU M_6D?M_')S76]66V6ISVF0O\UH?]96G?B-:#_=ENHK8S^Y>RNI%!_HZB?UK=X
M#:B_W49B"O45ZK\>]=-ZYJ:@?IGQ=L\TEB-WARV]%TWD/PM@I<;_^LJ2N MN7MG\:QKIC.PBEJM1&/*%*ZO%=?3FL7NG7SG&EQ7ZMSNWV(WJ)[6(77OS!F%
MZF5!]9):+FE#@[=KN1RJYJ'B,?D6"I^5JU6T4=39E(]+W3N+I=R"+&TX\I[: M)YNG*P=LP9_!3&D??NQ7!=6'/)P,[K MV,U:IS]]
[M'KG6BU!8E:>,>YW&=#613;M=8.9[SYT0U66S_9[6Y.V@)2*YBU M46X3<*]GM6^;NI2P*[>PVU#]Q';M3"7LE+ KO[KF+E1 CHY.$EUY)' S-)=
M*K+69..MC<3\]F4L<>E'#B_@+AM*EMFNIX;KVB<1UC5=C9OMZ"3YL1)>P?R= MT74\W)'[/+-3>]X<]\5PAZ3,H,C?1AJ/ M2FZ-ZY+MZH::],PJQR:F>>QO["WV::'E,WS.,WE-
RU]102Q>,5CT_!\H()5&5!T3UBT,K-E9>T846PWE;F1F/'?G5X MOC9T@K[%DDY2>9WO3/; ^;[:6^3RH@WU!MJN515C8@<7&UL-]EL+H"E"W_U; MY!+ZAI*]MFM8+D?
HY51@%*$K0M\$H6\HN6R[-K22Z(K0%:'G$WK!C+;24>F1 MBN.$;P(^])WA5/P(GPQX$/|$;X^ ->W H-?G7Z>Z#_XV\Z9_*S)A+S%/3^YT MDO>8=7@I9CP3%&P]^?0P9MK <-
TIH)QF/#F![6N&/=28YP-.^&R8Z#0WTIS MU7)& ()=&D"H';NV.3.00#^<'S8/2Z;?VN+WTJ7ZYKA:2 ,PEH7S8==&I.) M90X03O$MC:7TU(*7+S+9426AFG#YDV;
[B7P:GUF.2^G6@_X+,+5L*RI3C\G M7Q&_VN=SJM6@MX M,0-N-X%U?#=@TF7X40">6,;_G& (&S!*2-KPLS9:8,]^ MT$X^O;E&\]U)/+"+O;V55D%5=*D5>07XID$>?BJ; ?ZS@
MIP"B5E.P/UK8UQ7LCO;VC5+!7]4(IZO5&%::CRCMW52GO9GBUJZGE0&(F-2_ M+EC?OI8]WPTP*D_A^HW2R?F'9LXKL^&/8JUIH3M MQ7K?'/L10X.XDX?IA/%%HH?
C]T5R!&B3M\84HUGK2Q*H=<[T=K-5GLH#11;K M(HNTC/3-D<6ER#.X&857[BM--+IMO=W:31LU11,;I8FTY.VUT,1ZZSKVDZS* MF36J*&JC%)66);T3BLHOH-
A/BE*"ZEC)*BTG>2=DE5^NL)]DM4>"JKR!3)%\ M"7N/.4@2OI=$SG*ZJR7K<3S%=]NDZP7V'1=R.SSML2 ,IZ>RX32NHXN9$*M
M629T?'Z5)OI5JMM@(B7!844S(&,WLD|!5!*,()H5@&FGM"-=!,,HC M4Q)%MR0DH$@N)+FTWHB[(+EC<]DH,7>\-)?6D7$7-*?
\.3LGN5<5L$G3MJS;C.XO7YAE>LG8]K3I^41WXYB"QNR?O& 53"N/9KX$5#)DDVJ'Y+.O- M;[](A?MS&]8YZ[=?OGQQ_?%Z9&O<+=&O# '
M.P69A&P,=A:^0>Q#XN]QZ+&^[7VYK'R^N^S]H*[>KB\>Z\9UHLQ]606(H($ MRTT2%?ICAA(:8#'Y]4$3CN[?JO0_N&_.!RY^.GF7"IJO%^F@01_\>@#S<'/^
MS;1_AD\9FM[$,J9XBEA+4^ECPX.D"D(/CP/ T,8NRL???&=PDD#U%W$8)HA0 M$W&70QFOF/TR1//DUP5:&>L<.W3- ["/TL)SU% !F=0Y*C0V#G$P7H45)-@2 M-!0G*DEO<|?
LH*/*R+$LYP7;>? &%"X#)6Y@PE_(H/L,5K"IX0IV6K%1_@-2 M4]\+3S99*'7Z^LD$NN3))36X8T==EHB MY?4/.VJ:0FKOG0"9285MZ5U'SDK4=>05I+G&?
B3KRLY>B;&\IL)@(P]:IO9@ MA8VLORIAI=VDDWO: <19P'(]20K7,*SR0GO8F431STKTLS>$<0E$,1PRFH0% MR.*!:-HB992JH&<5R BY>M:*JZ9?/^B38)ZMCM\9!,M!@XW1E-
+HR;< FT["B4(Z7,%@7QS_2.@G_:?KC.:/62UJU7M(&#K=) M:Y5S8M8R6' 82LNN^%W275 [HZW('KKK'\1:1GY7^)EE8W$S9U 9?K,CX789 MS.[:\X+EAJ]A7D:]I;?K:\C-
*!_+.V(5+Y7EG8\-^Y%A_^THP/I^UU:;>M"1 MN"S*00J--FWEVJ;X&K77=YD76#X/6TT8;P.HM()2:P5=I14LU]^&*;]S?$\ MB>K7]]7A8LQV64VAWM;K+:4H;(8[KK>]<-E0JE 4
*,0QCU\OL)LS<"WMP9AA_(GVR*_EU\DT MVM75*B/$CN%SSQY^94/8YF,/Q],18D4< M59Y2>W%Y=_W/WL/U/R^U\YL?#>W>]\X?[C^_ZGQ9DQJX7L*7(6_:")[@/UO9F
M*DMXPC%^-W&9!\N$E@[F+D=&CC:2K_..<05.9;QW,$M>& 6P5]$LS1Q4NH! M-/?/>[_18X^?1+VUF3SD'\&8#0.+W8Q2*>?:OH?C(XY^,PI%Q:WC480M9/RI
M)-2NEB@%>0XU]W'PHY!(,^X%%8.QO?L;\R MZ-QYFC@V7'S8\N=U8"P-1UNFDF?O\2QO&(7#QMGY;+NG)!'S>]CRMO_Z"5.A[^0_I*5"8$RM^38VOWOC/X
MJ?'Z*^_=B^&Z!G6;6",#VK+79EW:\;7]S#R?&+*NV86<-(?2C[!0@',I1^=% M(%MY[O.-K_*;!> MW"U",Q?,@W>/'O0#'?#*S8L$H:,Q32E7SKNU8;M+CF30DVC.$3L3QM'(4OL
M%/:7$ON5L5:T;AR7% KJ N#CQ!3R@7\](?M,H#Z?]A0LQS/PU96-A)!\]OT MP^7]L%Q10- ;#-P _F2_)A@+]DZ54K)IMIPW;"":3+0LX70HP%6',0"8,7NOR
MUX![IP35E(8IEZ+_I]))UH_\N>G9[;3) 0N5DL/#_GR51,--P%^@FW1W1 8Y MF=1ER,0KD#FTY0RN/YE&3G>0JKZ#L$;TTS#]D]F#:2B*F4#(F$Q^,?TQ5O)-
MV,#'LA1,SG(!CZETY=>$4OBH7$7>Z@)^:D-S-&*X-J:#P>68-S9RG2=X_C-L MQ'&GVB1PX0ZA"UC,][&E,2PZ<-G0]$^U/S!&BH_SV+RJH.-7FF%/^>.,OO/, M-
/BFSRSGA2>D(0>G7W7MA=0*9QO)K]L:4KHCV&+9UQJ^]B>.+544>6[04/16_ M>H2U;.V@@5*8E$XWPCM8E*N8;+:HFZ9AX9B#X[V5P#L>B1.-_+Z1[Y^[#U] M:&-
@&8A>BGB0-6"',"M3QLZ UJ;IQF*U7@NH0 ,;U@KLQ#@&[XVKH8]4CTO]F7R@7"+ 7?9CPYOQ.J9 M\-TSQTL-WI4E5CS5>OXRC547M?Y.ZR4$M^G%,BJ'YH*^XMS7QP^?
0)=]H@"C M/L)6RB$$*+VZ=XK:.FCN<$[65)*<\V@##8M&BG#MXR2)Y/+U41.$^2+P87S$C M&33,C<1E;L(*XU.M0+ZJ,$/PX!\->&YD=T@2SSDR?^PR5JQINVF+"Y_@E[&'
M+7U9/JSG<42C%18*<2*14FQF^, V\Z.C0IQ4[-DF4LZ#?#W]/S86HGR8S?5 MHC?:VE=FX
N<+/#9E*!BMP2=)L*,C+;]>+B6CH[E9==>6=HW[5E7<]U+l'O>05INTIKTZHU5AFL(T MQ=,4II48T_:%I^UA%[/=*;VQ['UTE&IOT'/Z5G4W50]2#U(/4@]2#RKI@_;0
MS;4[*4]CTH^TCUZ!?+1NN=HT=S+:B'9FVHA>L+X?Q4LIB^QAS.""[CG-B//- MOL4(]+4B66MRPEQ^]IJ-9;')<,^-7984SLTW7%8$6&X"K*408",BP(8B0$6 MB@!7VU-
NJG:G7JR3]E%38'ZO[%@>=SD'$+Q5E%@.2LPEQ$:Z**PI47A@HE"Y MS5]A4*_0;^) F%O19Y9.LV@6-:[+57>^1MT@7N-5*QUK.GBU8&IIU74*CX*
MRFET%.DHTBFF1+>+6K,'3#DE%#7E1> C(9I\>9,VPSK5]#Q@]HEY<?RM;,U6*!;;C%R6 ZQ@LVACU9C4&2*9)HV M+/NUYFZYR721PEVO4ESE6#-B*CH]
#Hl*SAT^7#I].Q.B5-%IB4@TUQS_BPC MJ>I5YOP^TVEDRI]5U]#V=S<@7LWD/^]8\8/C&]9QF/D+\2LV@WD&P4,'9.GK4EX($-]#E M7IMYI;7LU]*M@-
FO@14,F=SRT'R6W6EOOUP]W.6VX8EUTHVZW<96&()KO,2 M^05F?L,&O=KMEQ|_?&"_<]=S1>_L6<6]$-EM<1IUWOXY!"+L+'R#V(?$W^/0 M37+;^W)9^7QWV?M'I7?
U<'GW7C.L%V/J22Q"D. 4\42KX3%#;@.PF/SZH GO MRF]5^A_<-^=X$3^=O$L%S=>+=- @0]\, \WY]],V??XE*!32QCBJ>(()(K M?>S_7HM\H\[0 MV*?\'+DKU0 8K\(*(NL$#
<6)2M+;S#5IO !!\(E6YS?QZ^1S5F_:?<%RYCN=K=\RPM$L/NZ]K7QT+&XP#$?S[=]ZJP3R.>O4#OT[^1E_6 M/KS%QO[?
3=B^KET!#S*'AJZ]P,DS:O<_<4U[8$Y@:?:+#0+J/<5WP$>$63A] MAPU/M4LYJR&WH7XO> Q@#WQR0E/GW?1?Q$ 4&C3F.SCE ;#8'M(X ?B,^^#O
M;CRZC$\9H%$HR1?"2T'S<.E*FBM ?\4.RIA,7.<7]"8^LZ9:KNZ5-A*1_'^- MVK^RJ.KS-/X+#X'@#A$R'#!RJ!^LP9Q&UH.=S])O#UF[9A=?^LZ$P9KAYI8 MM;
F=OWC"H<$Z:WJ?'&IYOT5(#!'-'7">9L\[.JL MP7-YEV_D4 NF@(Q.UQ.C4Z:P(_B%^ "..'#%L.S L.&= [-RC[M;*?]17P&"7 M31"J-M9VV"-_'!VVKDVLP$.DMLP!G^\"VP-
V;/SB5.$BPS9QW QH0QZ7()HC MWS6<**DCP1#!XJV,#X29&.Y/N&C1 *?M64];?ORUG2M/_VX MIB1Y."\K=CG_&ZB70[M6'6X1N7A-%O(]#P<#(K0\@#7 M7\/=NMF.QF[\S]
<7K'l$]$=0*9[PSH?IA(GZ@O!B_+Z84R3^Y&MZU5NI$X64 MV"Y.B:V33YW::0K? T2R\'R,1U!R'E&+BW0O,=QL65CU0&&S3%R2SDB.CHN^ MOA7SWUR *.!/.#\.!5<^
#,&I^=#K3$+M8T"[0K$T6*M>DXWL^R#.4$N,RQ!U,0/.U9I]7C 8IQ+&J7;/.&3R MX-GAP*2!B,.AB1NA"7#\9>#30D'VMQE1\K>"7LVX#(EY9G8NP&IR!=C-P'=P M;DNMSH?
I"2&&9'/N/$UPJN2L;7A)=6+,!:ONPL0!A0!8A',O:1S^@,W<@FH& MZ[B3T :6WTKK5]<,[=%R^FC@5@9R7:&YN\0-7\8FX,2%>RKL3>?%]D!7PE&; M8S15\^G[=XX1$N-
BLS0U)"I,HG0M-6CG8]Q1"-^CP,9.1PM([!A- #POG8M T=C![#M#URN5^/ 1L?UY=0_.\#B*!90EABI M \ ,1R4#%10T6& ,TRYB@ _#F8NI&[>]'6TRP 50>W^VQ|\K.++V
$%O@(' M#|=Z0=\SAR8LRK5+B2:X9GARTA!+G"P_0;,80D;#_FB@JL_$ %($VAS,4*+F M<_FV'LTH!!T7SCW:+-P<@345A#%>D@(>G*((<'T$?=[7>IYI;$-;#O\YFZ/\ MVED9-.
<%C.>[,=6:A7E.S\,H%A^;"A"$C\'39(;KO,$%!)N)7=^+T$\XW(@] MW07,KGP-3.VSZ4S&!KR4)!U@]=?VX!0YTX-AOA@V3MV%^TTPC"0;DW?'G7@1
MG_H*.."D*ELE:%3K:>.VZZV*M7FOZ+9CY=_!;"-[Z"6.,-KT \HOI;YQG[M 21(F@)N=1R8\Z\)+SFG-H"\G7."I3_S!IB!ZXW-R2W2@NT;CY%A7*D75A]
M:!C/Z0Z_Q_AU""@#2YXBL"3OP'[IH.P)='NP6L@:S=(@1:6+IC$:-S.>BY[M V/(GDQ#NS=M.(PYI1O6"":<_(7C"'E.GM+7J6:D3!$$8W]F>#((5M_X;D.4 M%1K@]N"?
HC9*]\>#TQO0]-OT/7C+>OEJK:I>37&*(OW!O2@+X.@G#D:*<)PO ML"UXI ,\.G3I@4A=X%SJ5)LY]+4O($$?U3F(8J/ON)04T,/J_$>^+P-LD^#I MCCT&\#*.._TNSTD'
<$GK*UNSUS4A"A-@\33<4SCDG&.0.S*I/S0?0***^X'1 M(C-WG2EH'=,0G*=<<.$A:4CW)BAAEB?T+YR^#G>2F2;'GH/8]7Q8"9\94NL< M6R#+8HX=Z-PK)NY%'
/)ALP'&^CA['?/%]O$)X48-PQHT/L,&SE:+]D"6=\# MR]S2ZET2]W4A[@. (Y(D#:.6 \E1VT3O)?S-7^D+L]G%+UW+5@XTHEA2S\!$ M=)\I-):N%>1>F50/Y',G@>L%!M,#(RQ2:Q
#1P=AV+.#Y"77&D.WJQP$W+STK&Y!LYX4+N>0DQ0B+$+*-_1>"! M ["(3 T##9?B99=UO)S.UT:%?A=DCR&JN6B/X4$'H?F;2PU@;)=N]GL,AP8" MAX8F+(+#R^0R%8\-
*N:ORM@< H=Z'^+*V&I++Q=9>%MG>[C+DKRR!1. MKNG4,A(2*.O[%7K!!1C- S#)UF$ZWJ+!Z$U!AK+_S*?FP(]S[INDRV;XF?-Z MNG1IFI[V=XK$!3(IOCC2"Q!>FQ[/" &
(8^L'?J:$7&+2HHGJXH[%C#;G!_W] MXH!1'(L)'5';X%#K9;F4-LQ\,0[|0YN\QDHOR-1<$=>S.?6&QI/VC?GT;!X M .">V28H/?_$Q,=;N,0<2D_L^=AD(RWL-Z_=4&XB!FX00$-
Q>#& ED<#V'X" M*6(WG'+H,D/<_G^L[QK:FP@*N4C=R$]E5'3MK%[=W =>4[G5]:QV\M9\5W,62_,+))GCC'WOW1-4\^54^K\TVHX/"T\YOS M6RW_M%H;.RUG,-G]Z2!BI1[-
C^OO]PN.)B/'9O6C^6$^>:4XFGD?+Q[-I>7\ M^K7@;#+RM%<_&WKX;0DC5IG']=ETS@UW:!H+CBPC.6CU(X,-#&@#I3TD4AF^ M,>"=H$\-BS#QC/3KU0\KW$4I#JLYWZ_X]
[>GH(8XSX8WD '14!5^81I/QLC7 M@>O5C7$NOK'=GUT#I5Z*T N56:$YO*#!P..7E.YR/P83_@4]88 "R%SX&6L+ MLE-$)"-RL5,F#4_(6>@L-=TA=
[U@_8+/S9P%N8DB:^6%"7<=;#[7)UY/#T+7 MJF'-.PZ \:&WA5H3/=&]O.\)9/J&^V\I'H YA,#:].L.!,F ME/& QVRTGZ).9%A12I/'$DKZ"]9BR04 "XW$3$U'E/E8^:C1E8I+!-8OHQF
M165;8$T8CV&HB6(\\[879=V_@SWU'>QX[;()?(OD(3?NC\-T%!/W"V8%1D>Y M;6'8L9WCU<)O&Y9HO?EA>$/CK_?:GU_NWT:K4SY9/BO9F#;-MRAW6 J.%XL"#MCI2[*NVV?
$J,ZMN1:3;/ZM$Q @__'7. ZMLG])>0H.1\; MIHMA5_*$2:^)G@)WX(C^3DIH3#*!7 *!$O,O@PSS\1O,EI]JMT@7H4YF;2>4 M N$?MH#IFNN \S'1D_G!%@QT)
(7I8(25LH0#25K>.P9>*05K6>R^(;BR1*? MV> GOMRY \B//V%Z^:-+G/'B1T][D$%E7$+DTY'RA^E6W\V!ZWA3X -/\L

?>#WQ=D5$75:8F4H1O)M1[+LEH[WUTWF_:Y2+ MDW]":>-!5CNA"-X [CBT"^:5;?Z\&J6,7I@A3,C[(\C?VG. MJII[5B)+!;08"SA,I.*]KN-
N/_1%6XD^.!$U,%PIAW@'S* *&+GTKPA5GYM MGS/+0@W$"+,EXO8CUQ=S=;Y&FOFX%@M";F[WVEZ&PQE0'P"%&=]A4.2(XQ8N M,Y_Z@0MV!R@\?#N\% >-)Q&2]TBS")
3U=:9*Q%M43-R2-\,C2)>C@\]DNE. M+,.6;@VX\):?VQ0^7(?U->1B5$F:QI=EWP.V4.)[6K13D$5]CBCR@0L?^P< M$!9 4Y(G78$J64]/GA]B=P5?
XZL/W*C3,3H/=*.0J;PT:Z&N24JE)^#?#+W MK&'+'E6A9&\R?HO,CTV>>8E3NUYBP!O*Q$,]'BQ>?=EI%!Q:FY<7>"=W0:P&
MY2N(/IF[]_K,P$MY]B(\NBF9_SKG236MK#9TGBS4CQJ+\R_5.5=0P#1.YT5, M>-"SVE4:(_'I7))LB#@]43:5[D6LJ(3TW5@K?:?IY2F]B8\>[YK=%,_X:P@\ M8ZC3;
/,HS_HSMEI2INBS1%X&3]MK?LAQYN/VU3YN"H?]YBZ8F+[")/"/%GKV M$%\7K#!F#TRVL#%FHV2-,45'V_.;[]^O'[Y?_GBXUWH_+N#SCX?K\U\N?YQ? M7QY!;\P%3;*N6-

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f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|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s+25R)I MP3$G[I=735T;2>D?QT7*C%K+Q.VKY2LC6JVN-YK+]SU:!=>.P;V>S'))]V(K MM?9=^N!6)R, (NX_]IPK!LB80LM[N+M_OY2#=.>7'WHS0;+DU\-6"NDVITU(I M!'N&I^WMX&FY4EWJ#94ZN&=XVED-3W>';6=ZN[/#8,S:_>$SJ'=<'X_$L/EH M\E()#=[-\ [2P_XW(#S+743ZQGEJ8K%569E"Y=23RF51(4MY#4$=9LE7V_"B5 MOE)87SE;7S"F%(UGT9_8TL_:.TS@.X;(/[>]4:HN]@U)2M_,%B/4!'+"7"R) M- !ZI'9F2WDKDJ*-41UDVZ5W&9+RSM,$G*POLV\E\09$(6>_=\MY M]WH"()M^C64U)5Z85%=/_G4WK(7]O>X@"Y=6W=X-".MB,G&2D/S6?9*NOUR M]7"7VR AUCQ)=F9*K# >55SG)?QI]C?LT:3=?OGOQ_?%;1@*=V6*GI;7O:MQ MQKN$R8V]@YV%;Q#[D/A[".I7M[TOEY7/=Y>]?U1Z5P^7=^!]!7@QIIYL?(* M##8\2G27&C,DUO=:?? +K@R;4LM^J]#^X;TYC$S^=O$L%S=>+=- @[JT', \W MY]],^V?XE*!32QCBJ>(W9P]?6S^E>1&]/ X QM["*M_^8[@Y,$2K^(P^"M MC2T)9;QB]LM0*4Q^+1%@I;DCU P,I4T/@L>N-56$'DFZ"A.%%Q>I-4EW:E MZ(%F1$RW4!^TV=YI9[5ZK7U5K;OZO4:EV:NW*MVS9K=RWKB\M3:I5]K<[73 MWFFO %)^5[5H+U^9@3L^66#$[&[H8[$6;)L> #G;<6V1>;/.,3[+]-G9S9S8 M[4$G[0!FK-RM-6O;W>!@A7+[@G)+-()3:*70:A%O:[)G,(HA5&+.,HU#>RV MC4_;\< OY8#R6*+P!1N/(.&:[/-_']/+2S17,M\-.#L^P>1S FKU2J-V1%G' ME"776]%29]VUFZFKBAY*3P]I;5DW0 _E MRJ*N=>N*A0]I-%#6J/75]###FNML#%A*=G\=E*/]]*\VDQKP_W@$FO(I=@F M8VBF9UDL,9>P3);6FELHU?5Z?? D4#B5:#XUH,E*33-D@T9>[(6&OKC?KR>C=?*>VV2K)\]JZ+5::3R&O-L=6KH MZ)WZ\H.L%#4<#C5TJOE-DO?&XEJ9&KK-TNB?BA1V2@H9=?Y;-K!61NA&3>^< ME8VIJY#7%EJ/[@=;V-]@>+>:,;-W'XVJ738R5<[)@Z;2C-G Y3:K=MDP5=' M0=/#EMI?ERNE<)7&K(H>#IH>5FRHO:\-8(\[6K7E>D6UOEI?K;_65^N7<'WE M#=QDO^Z]08/B_1A7>N0:.C7NX9$JD.W=D2J0[8/EK8S\0D;^^M)LRM(UO=G5 MFTUE_N^=/K7['NQ*5NR#K-CW117(JF[(P39?FMDYIWS2K77K5>: M]5:WO$PAW1H[M@B9$&5"LXQ(ZO =^ 3#"UOL?M/FVWGCG1H87+=.G=/%IK+T;Z>PC"Q!C[#7$ M6R3(#'B/9')C MK";C[X'-9#G&ZSH\OQ[G5UVP[+-4N[6SU&Z"U?;1%5#4]49C>8MV*<"4? 99@ M^;&WNQWL+5-A0TOOKE#8H/!T%WA:3^]\OW49>5/!04UO-Q2>[AF>IO>>+XRG MN\.VK@ZJ3.GGIV_:U[A1+3S\ITM/VDQCX.T390D')G?K]90P42,:F-S8SPKG M];:J:^C-9EL)F-+CF=]H[E/+'X%Z?4>S7TDWV>"@RMX59/:U_^OXK M\BNW1&OJM17&#"P%I*]_!3]7'WHRP;+GU[!7PM*UWFEM6;12>KHJGZ:.Z2ZZ"K\I/ MNTW%3_<,3]- ':.!!O\M:56\TMJR&;]0=/H-IQ_7Q2"R;-7106YJ)K6>5E3G4 M6FK_=WP(ZBA+MLJ>'Z526(HK+.N+Q92B=U>3)HU75QA84CY-IK2R=_?=MA2? MW/TA]*,LV2I[? I3ED=YE3,5KIHTN7%E@[Z#/4_WDT[:K#54W\QN3]7OS/2* MQEIY/9NBO7QE!NJX9(&BMKO6],4:/&VZK>IL/Z=M=D!=IC/(6EO K=HS9 /0 M23N &=5\:_VA5GF[-;; <42A78I1;HB&50BN%5HO0ZG4=L!1&*8O:A%&O:;FU M;7Q2;?^+I#=>L('(;JQ1=F-=S50O4X_J9CLE.Z)>]=4KC=]QY4]V&LO7O6YP MO(BBDMU326<[5%*FG,R67FVK&=**'E+I(:V1Y ;HH5RYG^TS10^*'E+I(:TU MY2OH89N=Y3O4['ZHVC$.J=U,,[;]8!+[-0&H54V/#-?VNR/$>IN^U*IZ MIZHL+T4TDF@RTBDV2#1E[B%7;^KMZO)9&8H\#HT\,MJ%;I \RMRLKMO]*MI0 MM"%H(Z/]Z!*T41X,K[?U>GOYZNC=VVC'& %;2U\]Q2*6P]'<'CVMC&;O>VZ3 MK=Y;]JJWRN/@+-QY2M'O]D=8HGLWIA@U#-#7>^NT 994<,A44-&7]>]L;A6 MIH9.=?FN)XH4#HD4,FJ3MVQ@K8S0=6SWNGRG\A^%M]L+9TOH;U$O7 MTE=N#X]4@6SOCE2!;!]L;F7>%S+OUY=@4Y8>S\V.WFTNW^/YN.W^W9<2;])= MM%+%#D%([/OZ"F1[M_X1@FR_5;'RI;'E:E\98WI7T[YVU+"[- !'UO6SEKNM[A/BKC%RP,"J;%!MBC800]N#80>K<7;]W@XSI7\ M:<+O$7YRF<9(=9<+RPM/=_;^.$[NC^8G8>OP S&!O.GH067%@P-]U9_2F3H^ ML/MPELD1'M6?#-!EX#S:L-0,AL'1:& DVMZ(N:C7IY_B[.9R[%W#';4XUBS M &-MC^G FZ9V4PPX4@GY#?ZCDO$CF?_#HR,@?,$! M P013\1_SPZ#)&)*7^G MV@-N@+E/'CX==N.QV,^:/YV@269- 86.$;:*X#LDH\,B(R1'OCLU(MF-5WI/C M,O$,N TY,UC!>(AVQ64CL V1;^E:,*G P< #Q!M2)^X\=Y@+$\EL2"P\6?3-_%!Q 0 6ZS3>]D9"%<#<9<"1E,*W6Z8-W 9Y[^:RSBIZ6A^*- +L=PN;%WL+/P#6(? M$G^/0]?(;>_+9>7SW67O'Y7>U%1^]+_X+XY9XOXZ>1=*FB^7J2#!C6-10#FX>;\FVG_#)\R-+V)94SQ M%"W39I6^Q0Q^)O55>G@< (8V=E'G^\UW!B<)5'\1AV&"6F@BG(HXQ6S7X9H MGOQZ+>HX#?5 HD6O'W*?C^^,5V$%*6L)&HH3E:2WN6NV3/>@6H>L5)_ERHND M#? NP\?; \L'&(2B4-=>@(? B<\S1%+U@L \@6!-%8"K3Q#O&)C#S',*$-:8: MT:84748H4X"-9]LK/VWGI3)V7G2A$$9R(T-HG&K7P.*16G\A(4-Q"G@=R78A M!28N/%['%\3YW7)*:;3Y'HDKLX53[D^\9 M/L$)O'&QHHB]A1V[X:MZ.2_H!0 #PA_31WD+(.O39?2=H7G -\P1*"NV3WCE M@MS&Y2;PP70*#UXI](%Y@%[V3+02+;\84",QC 1H7V!:=,[V:9(S9[UO"> M8V:'6(G9F;_%"QE#;5^[&38D* OKP,\9P0[_!PZ.:]=CU*LC;$AG3V!G03LB>RA 'S0$% MO(9S,"!U;^":??YJ'$WYK2"4)H!EX?<^I;,(OC>:W2,WBMQ4W?X%B3N^-/P< MJN_1 Z2"3M21^ *NYVP+[2=&O_?!NAN9L?,5:Y]]*&W%!R$\D5:**LDT#C M7@I.09,^4+,X%/W\@XY),/#&#/]H@.4#4 MV S$L&>X4]!?AO\&M);W8H7,/ACC&Y6?$">%(+&>VJ^0 M&Q,4)]DUY_P?N0&@*OXPYIPR^@DB)*A M(S%F6 *^FSA\@_$-O68W7.D(^;KA11(EDW'PNT+6<;1]R.?>W45/D^DM[_EN M$LY@/,OD5J.] MV$/GW<'((1*>W5% *DSHX(U<%S$?;KO/A9,2G]HY$:>1AL@QS I>.C>(%= MS$IX]AOS+6#.V(0'/ E$BJN-_W;6;W6^>!QPK&F2 1BWR[<"S?/^9OM:087 M>^.]C> ^?6WNT&/DF2+L8&- P"#)XDN16W+IA3:%Q@C<# APXL@X:GZ0-PX2?N MO,%?4T_/D\ZD"%Q\PT?+<6](8M^&=O5M&)@$//!'T1"^D:0#:TA?$X#R[0QA)3@I0D_MX?]GI7S;VI:R1='O]U>@U,F-7 4QG(/CZY9'# ^P['@9B ;ZI_,Z1ZT?('G#D0/?@#&&0$7- ^442 MZ/F18LKO# 4=H(Y*)8(19S975Y4*#5#W#<4EXL(X;1'%4IJ!<*6ILS93>TH> MJSVF.6B=:K>U%<*T-) B<9'4,ZUZ,S5,D 0&DXA?UA X#1="'&$/]$=< Y80 MCU(DP:TB]G>A9;M!W%.'OZ.O3AFF;4'MQ1T]'BSE^L UESS8"]<^$W]B M&?PT!>!U\5KR"-A24:(V#6 F5>YBWG45HV \ .[_D!/(U*]GU0)OG]1[(I"I MG1?(="M6)!YY^AMHU5;+LJ(G-J!#XAH2 -] MAN("GC@'MOPC7%$RNEK1H %2@[2"Z,H3WN0]6UB MP*%OWRU":9_,O\:LA(H,3,!"()?CF&!"]_C.\D? 6J70,5NN^.K7E"+_HOE9H MM\<6BKYCLCIRS5&:HH&Y? 6Y+>^Z&IQXO:D9%)V(E GMP<&4A),L30+!YNO' M\Z^?3XWC&R#8P(5?1K\8#=67L1K-V[7E/A9+9#F Q4D#.R!R#@[CJ=>B MQMF[C+,]V-@KS'[3L5U7BM>E6K M75MN_9"0,HN\L(DM"E)*"G=*%G1@E2H K'O)Q30D.&N M\-F0V?>LB.!A\BUQ8RY:[*V\-WX8U&N"<\]3DU']_:\ 5R] Q<\711LK1-'! M2;,?_Y@IBGYA_O#;#:@Y_?>=,8^?S[+ERCQ\2IJC\W0&NLYPKTZ7F\EM T" M5F&KG< V8UY1@&#^B-KJ^EM8FV#'6R-GWL*?-JSE _G9[05(Z2.TUY^!*G+- M7* (<#TSZW,XVK*Z$(NV@.=%A%L5+WN-(I>\ZS_?#F[O@+6:4\F9#3'= ^X MX(\,O0H\))C'&MT#(Z5T&ONMS'C$G"D>A;SF^IMKV]|F7/|7>^@|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|%>%,@[U7+IOMVG*/*Z5<8HG9H73Q#'GN*Z\%89$4^.#YWY0?(A&7

MSF]-9N\3)16&RSC2K,BN3JFRI.+FWT]64TNXE.ZV:1YV:F+/= MT!GE^@356 MJT$OJT/A+LC\L[?<0S-1GM]+8"(E("CQC .&/19 $07Q8^$7F<\18Z(HL1%X
M*EE5ID28$O"0P*V'J7Y6R[N=P=2%%#"5X2]XMA>\7UMNI5P8SOI9GO9Q]&B149I6U2MFNULRD-!>15R=S4$1R;* X[TKMD#)D[Q1K M1MI/@2/#2+V+71G7@?)
MPQ(%*)Q$D#3S:QOTI;,N3XO=I H0Z.J:7A13=,5+(9KF(%2<54Z62REBULX M,/X"8^&$/>&_"Q"90I[EQ@^.%/"X.B"1'0 -+%*M8>^!'H_[#)U]J.JDC'*
MNGS..$YOSHQ;;P[0E"/<=NM=H;FG"YK*T0+.Q*2H%/#)T3@6VB;.D3^ZT#]Y MA+\ID@.B&CS3N-DJ!BDSQH3*06D%=[1+]./*!'Y3CN:1!+%XI51&"TMF7]+]0P:^ MJ34
M^QFZ*_*E GH\QR6>]KYQ9%7@(6Q87!W,708+G!HQ[AHQC3%A^<8(&\C00BB M)%VJED3[VN"I"?,D6IO6I#<3ZO,J>ZJ,%"*6YJQB?O 046OJS,IQ T><7]\^6/
M/);;8Q^5#AQCS#1I*KPM/+%L##T(0,9Z]$BF\?#:5;'EA!F%8G$HN9A./%)^ MA#3DLS&65BZ\'I^)FCI+"=PU \1*G"Z>R4WTDN,#1?\\,4E\309]LF!ERO::
M03$3Q*YH!D%>^P2=1-/0230ZB>9@DFCB[!?(E @DE(6)UY1^BLH^K1)]1,&T MNW1Q,55P=GLUIA+A_^1LPCI:O.B&T.=5C3J*0Z;5UV#IB5$B]D"V8+4*Z;6*
MRJ]QQ2C&A^ZPHE9 NK<]1'$\G364JIBQ\AQ@PV)Q:(*U*M>XGTR$8+?;G8EE]BU\IBMIU2:B.0I 8W*0 &@ M%'(@.Q1>,C)L0_B/*5XV-R[GP 06\-
FCQR@'KRKML,#I7%'CUUP7H#@9989JO MOX0 7D7^N:PHK?#: Q^C\I(KR2MA*2#"LP"3XMXG<#(3U ZBDNI+-=]37C(0
MVRU>R'ME,7HFCP@6'NDYBF2IND3KZLL,!CN*>44S_:D\BMMH_U>X_5.Y^UOO M6N[]*MKZ9;1S!1I_1-N65W7)-WU*Q_Q,$_^@F^-/RJ1#^)]_FJ@A+[#@4ECD7L!SO"\-XN5-
N]!.F36H_XGKB+PD. MZ/V;W3G2 F$8LOC.= MH_9_L; ,?RTJC39ZTJHVTFQ4[X76;.7M3 MU%0@>,TX$T])$PEGO$"F_Q:"1[P8L (3W%'JZY7U [CEGMC0:)5PWCF,0K0=;$U!?
NR=(D47X)"Q\8 M)<9,4'SN%^/%HD:6.6\GBTXG*TX+2KCOC MHH7+84I985$D42SXS49?ES$P/2W3 E3)PI)A- M+:#TV"<"51O'HA2O*';.L>A2>3A+TCHMJUIE]?]+5=-?
CDF0(B((=X+.)VSU M?U,3(Q!AF6@ .YO9(?Q%F0_6T';L4$: I>/\B YD!P+"9D2)<[+^DQS^),NX M,E^E>^\F0X8\?V*YHM>C2(8!90$D\4=T[G+"%#NKA>M@5
^=YX,MNPV/:HD4 MP91C R@OOT@4PWD]"+?!R2KP*^XEV^U!D% S;D%C@6,E$DA@ :H]O)Y#"!OU MS/+/7((;K"TI439-)#_/\Y,*<@@AA4JF;R*%$)',V)*FDGJCK!)"/0,(IDF
MT5#I%1.\U7[*)2D.X9F;HRF(;8SIBP 2H9W;Q'*I"[?]'B%E7]X)@*@13\[] M1P8"85,Q\NU9XQ!#9OAD(F7$]E4$+BJM4G1.BB$.;UGF.[;H^$/QK.0]F^-? M86[E*^I+&6^7*D?
/X5PC%"D EGN?(KMH[YZEOO-7\S#X:.IAK7C)Q2JXA:K3Z0 M04Z&6S,Z#O(*D[5/L#4N,"N8XOA,%+5(J- =BOJ,PRS]P2Z(Z*?C+!48[%-&3G)VI,&DN M50%64>N:%?:)#--
DD=1C=,5?_7ZI\%)9\2A2V30&!\H'<7X\^+".CF[O4+SB.O!> DP"H6 MQ?!3GTU,2T^@MYA\8Y@WX=3E"=%.G^N@)QEXFR@5-QH_W^7 M#RYPFJD!)_E6H?%_\$+^Y/H?
P<\TX'[Q[CO] P9\("Q):'B4G+ M5_!EVM#\Q7:I#,D%&;2"4"WO"NX8 W4G[-TC3!0W'YPT"XO-S:.W[=Z2S/RC MX0H7F2F)?T]B@1AR+HL-P*9R*\X #9YD1;LV7P*%T0.MR Z:8.
MF-8!TP<3,!V)VQ3]2G64R'>&!"U6\R9)GY1H[*F057/)D!B7I[ADPC, V%W M\"9,!(YLGLA]3WBP5U<(BN_E1I\#>LFQX&>SM,YM8SCGV)'Q, M,CC!U*K%_F01T5OO=$A]
<:54<^'&AWHNRUO\'YXF);;[%MA[]X(M?<>:9/R19\]4G>6V5DRI0@2(1_N>,$X,?4FK8:.T@H$1;9@+0Y"OQ=E@E3P.H M Y57-3=@&AG7ZY$(<[;J.Q<MN3ZCBRQ&1#RP>)U<,"#
(WM3(,+FDZP&S6&B%]!RH8+E:O@XPC:*0RSOZX_GJZ M5'..ZG^(LHK91H?WOG7/0N*YH%2Q-# _F2;.^?<^3 ,FW-6XDX#;&P>"U$5 M\055=\5H+ ?
DR8*;/"0%7O(I[YP;S'F9#1Q^;5PX)S\A/HK8&ZP+=*(6EUB/J=3.TSQNG M0!FPQ=,5]+.,XAEN0*7]%@OO37P?HQ]$L4-JF/I?A72F4[.8[S;:CH#QYE[- M"C&;[B,I1F=?
1!7DW>5"M3^J.I*+D*I.4(F7PG=D1=F1LO\RN#>?%K0R3G> M=>"W5:"L]P;P7&E2[4Z\7"MW=0"6AU6;&ZR$TA*M%#N,7-=G?CIP[0 M,JKRP8,"WEYS['BH\,M)SL%&U9QX
'(LX!6EPI@B\]RH.[S>XKTT<> _(SKK, M@#PP)B@N&)-5HU"@"X7Y2V(C\U?#O 7>0@@ M'Y)Y4!$>Q2+QK='?()$M12F9N='_V8D+Y*J63],L?@0"@,UC,]FPCHISX%"6
M"V19K0&?(:"[",+BW0YI/-E\EW'I/6;9G.047@\DAW2(EI&BF,!G,^IC=:& M%(B78G_Y%](PZW@A[5R!N\"%Y-.+B^47,'W00B-YH(HJ2A.)C$;&6P3Z8(P7 M%/N1Q#H1T!I@%J0?
K$U<0ETN#)82-G 5B2+Q:%Q@62:"B&I0E(M8M(41B$(4 MY^T"S.:RD81ET^U2XC]4U48GQ\=O ^W, 4<&+/]5N+=E!;"2@\8#TJ!H:J@ MW(?WIWR-E'O XY$$["9#
X@KX7FNBP^+W1!PI@#8!*P(),(A$Z5_T]4UJVKZ MV8#Q_NO%V>7_GAK4R=00K4P+F.?WOK[G6@,]J%^-?L)"?V[!%1 E*A!X S M@!CT(8T(B.R1;?F/7!?+.E-EN>
M3V.9=N*Y>%8>M^P:UGB,\60A420Q:-R- M8J;K(+Q/^8J7$Q'CEF71?'79+T!&5)3@Q!,\\Q&MN=DK2EE%EZ* %VRS&-XOX/3BY\ >;#\WSWL+$+'RR_FUK(?
MX%R/,>&)D75:%ML3G\K(D4?H_3Q\[P=V('(!N"-QU5IXKM'[DV(Y2KZ%H A M=H!,M2SFYF[I$N%F;&PHSA+Z MD/L#N#J/@+&06^WS\K^FE%#_@D&&!_-]#_AOZ""S
\K#L2*VA9DG+6 MC \\AQ7]RZ:1)KFD2A9$WW:6-2'9Z'IOKK6$3EG%B)$4BX%-(*$/+.#0.89 MN2+L4&0\8ETK8,N4!'-\\?7]&_37.2HH@E,*,Y)UA0D9'CQ/I.SD>4'Y[1%
MV3*\XEI"1WNU MZ/(3\^> K"ZXAR1!*0E:"/9I%;%F1%"TND2.N<:>CI64+=[#E1>K6:J. QM& M:[N,[N%6]UA%W/2Z:*_)WTA,/UA+DS@$&_UZ(8^,]AQ&B?>B^^0<\<'DRTP'
M;8LRII3N[3BKBB>X#)LTH9B",:-4.HAG><= $$,1[M%:]30X2Z7()%>'\<\2+ M/44KFG.,H/ X]RE@7;H6=[BY,BV=*Z-S90XF5^:/5=4NS$R5+K>@!Z_"@(%C M5I HKR$-,#SKF9-
[8=!+_D1.(2K3@0L@:RY?0#"UI,\HMT0#QUW9?%D9?F+E M/8 ."Y%A10VS])9K:7$ZJV@(7[-TS#MD*\50BM0-]NH(_SD(18]0? G8D3V2 M96L!U>Q9U#BC,J59T4
M9D4;CY203NX>3Z2P!,(>LOV*@7,%0VRA!S_=0',E&ICJ9\U:KW,7D7E5C[MK]X#7/('-+6<*?D!PU>.D@I,+R' GP1L^,MHX3\"TH*XKB)4Q*&]?6/@+X$H M]T)
(N6S8)T@N9O^)B394+7:E*+Z9NC=*4LPK?+-$E];5MBE=H-J6"_'/#U_. MKJ]>?TI/Q3KK E; ;W03WD*"K3]MA+H/U"'&7@3&%S8BK_49!M)>,S0I7%&2
M@O$Y'-6B,LQTKL:JHN=/<_:)P9:=?4_RXZ6<5HD9TCX[ETKTA9K9W7B+<*]^.(Y] WYA MWP$UWYB")UPO@L"F8>_?2._@,7SD[__N 0G +^#]!IY6.J5_H(_W\%Q^/+E
M>QKK]!_FWUGVWU@E\-C^_L;XW?K'^C;%@&KX(@9?]BU&Z#"^QG:R^B]>3*M*=L4C1ROTVM'&G+,K1GW9Z:R MKWSI"Q7 2N[.6$4]M3[>FO;W]I0_$#Z
<+C&>UA&L!B/[2%6%'O\&3O(\H]9 M^[D0#KX+52VYL/OS23WW]M36LH94_L=R9<,0V3X"C_@CPV8IQFD0>$!WU#4" MB5B0W/B)@=0[A3,7370IDQ[[>/O?Y[<_/E&I2.*?
C3"T$*@DN%M!_@"_)I, MB*9:RU'W:ZVZG:PLGH0C01;[?;9X2)Q#,0![-Y!M$-?@3 -XQNOP+G2/WO9R M6I?D0Q6<>:.,%_-1+
<>B[J;/N.16QB4WHTMN5N.2;T4;M9XD=3UAN=@^PS'4'T]WA2?ZPY3!H[9R8 MHD+&[8HC70=]OT%#1#E2;RKP4@<5EK3$;]B)TK'".#42$/"AF#RW+B5846H
MPA.;,S7]W7I&7,O.P6F7P2Y?K.](Z:^5,R,=\O*L9@$8\Y+3*H!D8>4]237= MR;^@K,"C5WU!&TN][:-&F:^@9"3]RJA6QUJX6&,>$93HN P\RB#DH@A-(D[H
M)!XG5*2*V&N36/]BJK4,939&(2_8VH7W%4@(]U+A W G R'U**:LL,@A(*E MD,*1W'="<61QRS?O $,&0G(-#86XYC"+C,M*2HPW3%$Q6/BVB@N)7Y([S5W;NG&S
MEQ.U;I>)%$9KU1Z3;46S6[9W473E]A M4@5.N14=%I(?.T>=%P0NJOZ7@1$C3_>Q3WA0>$]SI6;$"2EU5>SJP/R&!F) MP&)J'JH21#7 J%C+$R!R'M-2C\W,:,-./=(LQJ4)#R
M;*E4/HP5=1ZSB_]O#]50O(MZ)XJI2X/3E&Q\1+2+?@M,S\9@>\RZEV%OFXBQ M[!8/0]25;_%[SQ1WGZN#=#KKXNZQ:69V^/RZB/R4UL(!X8]$+:H?$1D0[/"
M>%$&7_2"HDAY*IDLS7TS>W02,N;&#';PQ0,Z@AG%S2O!>Q5RYT!QU/,N0>00 MS8IT:I+8.HKA:G5\"8<;8MW6(=8ZQ/I@0JROEBK9(,5;;5-:*G:'"CA6#8#; M!!#EG@U4
U8,X4<-F^TQI_=3YB8(*$^."6)1&DC.);>(!POSYHJ<(R128"(' M?Z!\Q5(1IY!+_"MR0$DK:)QO4>H?9U@8[1$T*Y7AP_4\.:Z8C:2.(:P&XT=I MGS/&R\9;0W))*5:R?(1!G+5E';
(R(FUMBX:OA($9#D',>_Z.]ZE8;2"6]6H, MC_O_X>U@PIH?0_$0BK4[2)5ZE7$9TQ[).5!G.]30DVQRDZ\%]L-[#WTO0EJ MD].C/.G[#GPIML=0SXZ -,"E1CAO ?
#^036A:PSWAI&6NT<(0R"8CBC'RL\A.K M_9DWR]BR'70(HW%)O(M" B=,\0I?'4"B&@IM88E@V;YR<0Z;2AUCP-'H:#C MM?YZQFMB^;225(FK[!N0ZG?L_LQ8T84BT7T-
'DI@'*L /['I:]D,L?NEH&2S M4 R!B:HA-M,FNH56U$E@1@9C'D0;B)C_+PG]ZZDR.-%%(XBX4>Y>E>OCS9?% MX?$^(ZL9#]/:<3>MK;2M$(9!5+>^F54E/R6%TZ*Q;I2L:0?
WI*V0(.\.O' M\Z^?3XWC+!KR!B[1X$ M\]H>'\8MX@C=I!]'DF:0S.D\@Q.1(MPZ81H-KG7G.G'@^,H"96,N1?I@Z<+@),$\"(?5HI]ZR=_V%P$XNZEK^D931E MK("O
I:H,)MO=$:82T2<^KQ"&)>@UEFL>H7CAS/,4IPF@)R2:WCB3U4Q]"&[MLK'TKIJR>L$:O%D^_/P3+QS,^PI/O'OTMM_)B#9)6/AX[UKR?%K*^*Z949P9 MK:D<>3D,/1*:2?
QI#))]N,7IQ9MPBS*G$\>[PU#F*9YIS@2"X/!FJ$P4P4G* MQR,/!9(D4\/R6@HMO:;R (65[QL"V8+7:1D<6=2S^8@BWRJ M@""*4,[MC/*$R+I>1M^('1]I*6%PS5[N&:_$,F7:
(VL2(1+EXC+[T"5]P3&2 M&FM+EH@E7]T-1Y81FM!MFR*^"S6(@ (@QG84B8*0\@[4V/B,$:=0R?+Y]%:4 M&A)\1$G)*@J /%U\/3*J N?.7-":6(O3Q02$$UY)K5"@Q6NEQ+?
Y9#>G4HFJ MPB%3CV*IK\J88,+#*XJCT'4/4>BE3$C5[9TE:0D%" L(!L;Q&"I(IQ4^O*+Q@7Z[BD'<3/%V24!3^E%!8N M,$("+>S)PZ/=P4MBV,3B1,(SZ?+H.;YC('O-
K)%H(HG&/]560=]11.XU?4[$ M/E(2E"<7)Z4 L6IU.#'S)?(1VUU0H?+YW'F,SQ(M6"Y$Y->)1_E$<)'DUR3C M&OS@^>&*B0],&_@KX::!0TD)6/EL/J.N[.%)3DL"9\S;9?
&]YQA_0]4[]790 MS'H=\!02A':?!X Z6(:=$] R&]O%(@9;=3)5]R:UN=TC(K[DUNXN49&LL#4 MRF_\V,]*F&AC$^]6?)7Z3L> MBFF MUF*?,6*,E!(SI(3Y.#
(R*T,M\WCIK+7P7+:P3H-K9^1!Z+5B2<$K?%P MAYBS/A:#EG_RS9>>_,#7.1+]\X6FFVIL1^59P#@>RH?YUS7K>#:SK|M?/:,?Z M[./C4+9?QS?(/3XEM:,2RF,RE[OH912?
340_!+"^(U9'AG&O@KIWMF^D)3T$Y'MWGH)&/N$DJ.*GK?29V"6G M^/NRERU.65\QJZ>0([J\4B"8Z-4:2;2O60GG6$Q)B\4B/ MM,T@M,,%#XI(1J=0!
@VQLYL4LC=MRKV*#"?$I4N+'F)>/29]8VI9R/M!#LF MX8:RRK#2C"K@7#Z%"I+HH>@M#M&"P:M!15K-$3 92CKXL*595&Q9\),&E[@ MHTPMY3D2?,J8$H5/Q1>7X!*B3V-
5V%'LA)*]TR'/#)DB:KAD:'8'#H>.A& D6 M1G]'5RI*%3=[O4X#8VH82#QSA#)_P8ZV&B]\]_;KY>UYKL=:H.W-^<Z5!Q7_1;GNU$9WX1M8ETV%-QI_!1B9)I:#QJ03^_O)U![!
+\HR;M_ M]#9\'\[[&9]]"Z(D7CP!?36U,&Y4%JBY0KG5!^;@(?(OQ>6_F(!N82[5YDFU:>+[] MTF2KC)I\ [$=J=7S\ S;>5S:A\RQYK6:0DC7(1LQO,LL2JA+W9Q[MC2&?
4$I6=5S^QGV"0# MH/WV&$Z+K&JPL!-YOG1=%!TI(FN85%&E+9RZF:+6+5]1\0X:-[X'IVI'@:P M!X$\89#J]\@YXD-66;"<'?%ZKYWS!CB;.^2D%8*B[@U5>+]]^:;IHB OR%V
M(@^M[Z];+UP1Y,Q/FWRT;&+Y%-J:(J(6+^?$A ,W]BL*PFD*A,"B@, _=#92 M_8598KC(2SAAWL2WYE-@TW9L)11)CY-AJX#@EYVWA7ZY #&76,>V2W*^^O
$Z3$!9740XD%D"><\T2/\QX^MY1,O;J-6LRS:^Y.[XV8':T.*?[WY MU;@'O1@YCD2B.R\,O1E.,7IJW>OU8J\$BW"TD_%AVRA^D-5LG:*W@?D%<3A! M.B0H! >J$WZH\-
C\NT%DGZZB;AKX_S>HNCR]ROC:U603L*P#2!F[5LO!.3_) MTCZ4%2-". PV>LY3PT(I (QEMM"U8*'SR&B1?/4BZMKNO$/ESZ+_]/WM&Y]45 MJ-/\<:=@E
9N))$#;"Y!*2$W[AYELT)_UJ'+TlOD#KLK<(0. *W@B5=:NP ML)HL-#59V A94'% U<-I#4Y[*4XM#4X<3D'1UTN!427"J*G52 FR^M%IO@Z#: MZI=BE"A+0KV.-\:1
="_[%;NU./K\)?7X>GP]?@7'+\@[RS3HE\([U3^-/BWB M*N&/SV2@TC/SX^;$RE6PL(6IEB78H[<_K)AW\&-2F*0\T>TN)<VG_.Z6G-G]=1+%$'4R+0?R*0-
ML64SO=17/F/QJ!2,*A33*GBA!R(!'#0. M9M4Z**[3:AS4.*AQ\(4XV'O9.0R-@QH'-0Z^% ?7-JC3.%AE'-P#C^RX)!EK
M$;0%]SGR%E@\))D5%*A.U47S)N11D1:A46INM$$'8)P=H\4O2>/:Z\6Q%%%5: M8]TC/"0135KP2@Y&!-9XIO!L1;Q06BO='SRKE#-5\S.-9QS/5D05I37//<&S
MJKEGP]OAY_#TRQE0AKTA49JAMFVNO4ZX'9:+>](?4?BM:\/PB5%>NWI=R95X%0[:.W[;K9[55$C=8(M536$>EF3HL-#*'2T-'] 41V-41]C,C"JE16&MZ74FE>#4E44NC3)EQ=
MHZ%0=M\6?0](C4)L944A5D#M+"^[KYHQBP?"S/<,>;("\@8FKDT3) MBJJK@#JID47=5(\UV/0.7!%R5A6).+6ZC$D"-F!$R:= MAZIQ4.!@5H6TK=5CT#BH<5#CX!
(.K@C^V4X]!HV#&@W48] X M6%(]AC*]KZ^29.B\.D5!5@1(%:K'4 Y!J&Z K4X3UVB6C6;M%5%3A&/#!AAV'#8,%Y:#91KFV&HK$?>D"S94-WFOO4%.FLDU$BX
@E7A%,5JJ^QCTA88OBSQD*-A2NP<$7@5:'J&_N(A64&1>^V M.,?!N:-A7A508=CN$"#'.':\('BC:V_H\?7X>GP]OAY_#XS E0CFTK4WRDV6 M/,X3V[O;:5N[Z5Q'-<\%26.?
019[GMAN!'#L\ FTZ*;9&%0F:?^-1HG%H,1V MFM'N 4HT.V:KI+*N&B4JC1+;;3&[!RC1;YO=04^CQ"&B1"Y&;*=O;$4QHGWT MMM,SFXUR2NMK*Z8N
;&)=+\JD8^7]6M!OEX8K+>QKCIVT]?[+0;5:0=&OK+ MD2=?UBIUO_IE\-S'J_,GCPRH3)?4.!EW4JW5L4,-LE]4'3&% U#'A9G]!] MQ8!&HV6VVNV*X8!V9NG*!)M+V"HU?
FWELO.I4<&>HT_-V-H]?6F:C>:@&N2E M\-6\,DY\T)C4*]A6M/*8-# 'G8IH:QJ1#A&1"C8,K3PBM11FKU^14 N-28>(
M205;@^X#)O6K8DE_*B;M@9^N*J8:G:.TE1REWHHPEI2.MRNW6*-M-ALZFU;C MR*Z7G,\K5T2VI-2WG;.^;MMLU\N)Q'H!MKPV*5(C2H0H*V(X&J5PD[B#H6\.
MFGO'5S2FO%Y,61'NT2B9I?1[Y]"D>/>7(XKVV*U,WG[/YC[<.&GQAN6.#&OF MP;;_H2]T"K<>7X^OQ]?CZ_'WP"19B:@7G<)=W52"WG:Z26XZ$RDND\%GA^&' M4W=T&A/-
GFM'[9OUZ@25'H9]=':_08SL-(?<)/7IFOR3#]4:/]J-'?SL]'?<(M/3HMLS^H2+RD1H^JH<=VVC+N%WITVY5$#VT U7G?54QZRJ4G+VN N).I5)"JZ.B!ZP-CPLK9^^XX-S;K9
M+*F5(N^3;M1VVST2TG*%(GEVND68$T*\)IGI1;ODVDZ9J-OD8: MC3250IH5,2-/RC/?(M+T@-.T]JXP@T::UXTT*T)+GI1RODVD&9BMQMZEGFLW MX'HW(,R+M0F,L>_-#-
N]9T&(VCY\%\Q%N@<=#V^E^/K\?7X^^!*;,2X30Z M![W<6+W<"D^#,OK9/3U/ZJ-ENRB<7;H72C![>4W>]@3IO?H*:GN$#V4TN"L1 M']KQ%E^5R?
#1"%$=A"BCW5U%&$1E:BJH?*@./I31_*XB^%"=:@O[TYF@$BK8 MP6>2;]'K\=1XM,'+^M7M)#WJ2=2CFN%J!^(YW"O8AW]5/V]BI-
OCR&]8(NX_8#T@6Y4KR%]%:07;/^V#Y#>;M3-=K.I(5U#>A:D%^SL MMA>0WFV:@WY%#.PZ3O\Y>LZ%SQS+';U"#6>O&CXV&P7[]JTF"Q?G52$+C8;9 M:;2K2!4T;)
<"VP4[G.T#;/?-;D>#M@9M"=H%6XWM VBWZF:G5Q$W<'4 [H!A MNV#3KWV ;=B-V6QY$KBU1Z9@1O'4=EYC-O%^$85FL MP:G:;;E81M[5$IIJ?\.): M2H5@N[OG6LK!>U,N
M]BK[&1X)X1A17Q T\(^ZJ,Z:(QT+X4#=@2L%<$#SPA MYJLR@-TR&YURNM5KT*X@:+=6N,"?$/-5&=#N:<.2!FP%V"O\WT\(^*H,8 _.
M5K^2RK=VHQ134+ZP[_;0TPI*V33AQ[S8:&;0W; K9?G$!?(=CNF>UV M)>FVIJ,44U,NPRGS7Z&6LKG6**76Z5VY[%P*\^) MQC"-80+#7EP:H;
(8AEJIV>WNLXRX!RZV5TD0#]O12QY]:!>KDE 9A.^US&Y) MV>(%S_M@N*I&(H5$Q)^F9G4 G=3R.11B*)1,7J[E0%B3K-@=FIEU-@ M42.11](52%2LP$15D*C;;P
G*L=EOB$DKX1?6\, M'2N H[_Z^.'V^D@N] [F0P:PX_]JR .OUW\\$@,D1IB.3WSO0?V4_FW(',>X M^OCUCR^YLV0[->7EIL[DUV@VXSGO)Z_0F]XE #I!W$8-E 8&WW2_);Q
MB?27RGV=_'HCW.<6$='PQ@:2,.PI^MO/UI.@@M W@4-QI)+XEO5.A//%!)HT M]867AK9C6T@*+\=(9<, B?$-FZ"%[M:#+9&QR0J!^,+P[_#"CC@C:/9Z'="2
MCPP&%'F.,.0OF+RYWX@\"5#^]O'[_@ 0# ;:7C, 9J@G]L.XUA:2U&QY86CP!;@5-U_'S77$\3"LV2O MI4A,)CU6 ?
826Y]87H+AY)#@&$8/R4QLM.HF4>/U;5WUQ>S@8MZSH;B7QI;N M93?!6.LO0)"G'E"GU>%7ZX=9&V2%YXWPDX =D'$]GZCW+R!G Z5%KOJK)9FKV'V^L^WB#[KK#<,0
<(D9UZ!D2V M3AK-DU9CSR&R!+(?(0)*LTPWAO6Q/7"V '0<6YQ;H!RT''QJX8 M1.RBMHZ+'2S4V=.\80_@K[DK=K!+^.NVZF:OTZH\)WA5JL.9Y_1FOBTAF+K
M%R*.O.UNUVQW=LH\-G3[M&K9+@^WVT]E8*;],!N[U9GWVT2\;7QK;07?MA#EMROL>UXP7Z>SFK5L$9N: M9K/3-1OUG0IZQ4], ^]^ &]W-
>_8*O#6&PVS.WA^1\A:#,P^D?/>7$&8 MCJ-]AGJ4+2[L7Y4)6/L,-VN2ZU?79RA)Y'.K_C= 7.MJN_"^0626%[LB/L,7 M0V3';+:>GV&J+=$&F-FN/5O, MTCW(CD7)?6P"]T@&2M&&B0:R)A.?
30!^WO]TJAR8(CPYO*:]FF/$F^R)'M- M%6K3Z#R0< M3784:XA6\.$4]CB9+G5V:5=L:&RZM[;/8"OP48#[[B5!U(*Y?N/1.Q6EU M)2U)K6?GK10BS^\7[*L,??O

G'O>PC)X;FV,AMGKZ:KQ>P!1Q=R13R7(&X0D ML]^H/D'>=PD;+KVK"?(ST.?9O3J*$F249&X?O.>7QAZT=#;['@#29BM;;0Z MS%;K-2455I;\]C3Y?0;6%'/-OY3\3GWVK/[MG #W>KI*W!Z TD::H&P#A/KU MZIXKG6/*2_?4U_]P"2GET)K C]?0$$->O5 M-S_LN_Q[.V4^L\8A\S=+A T1M1+WJF[!{?(R%_V6T:[PZG*Q\\E^P2@N:3V- M/\6;?
RF:=LW.;C75#5V!!NK2@/K)SD@$ZG7L9A/ W# 'G9W6]/1)SG,B:)5 MBP?=:CWBZ=)?>^N.S><656N9_7:)^K>&H*(0M#5'YK,[V?;VH.?UOFL.B/Z_M&._M\1@T"PN&/A V-N.A$"LQYB!+Q8E7(MHI4MHK6WXU_]{\;.$V!X='3 M&?[U3%0?F/7V3E%=[O[I#M>;=?=N&)Z;NVW!KI6/=@7?>]XHVC9[@U(9U.KSVS:T]"\&5#>K'O\ MV3I5IQS55 R.=6)1F+[.>_T*3+-EW++44%+=LDT'JS ^"$'*)N]E,]P9:IT M<5)[Y@61U-0M#IR=H[>-3FTYXMV 4W5PW;B__,WT-["9.+)=8%8C"T)Q\,_< M5;.V[#V7FS(-&'_.X,M[YCR:."SE]^=D3KJV+ @P\S JW& #]/GI.R;QL/4 M'D[AR:&SP#%R3[=?W\|#I_HE #[C\8DC).5,L8' OYA%RWQ!F"FK&LQ"((WW^ MT30RCJ85'4UK=UC4Q?[+M>462L6QJ-
_FW91;8>B|)=_.CK9>21W_LL.AHL?V*[\1&\()"U5%;4)[D)X3]H@L05B3?A M]YIQ,_7\4#2PBDWXA ,"6>_,>*"X>QH7i.,5U#/VG%$?_R>0\WC0"&&"\4@J* MLW(AD:)
<5+H<<;.8SQTZ4E",AU8P-<:.]P!'Q$&'0#; 2C"\BDZPKK3+TOD\ MN8_71FNYW RG;+1PV.4XOM$SV.<'Y,U%M,O+,2%0D%/@I:<+O&RH#L:J#VET
M#ZV:QF["EE=E0S!"Y'9)1I=@9J(*QZKJACNP/5?$UZ;+$AU]L9K5.*34)5V* MZ'7>;FL?*-^^>V$BD9\$3F\1DM),J;OS994\8H'@%6_2DQG$\::I&5"QO,\ M-
R"S8S;J#1T&MF=PM'G+UDOAJ&'VZC]?NEQZ/4[51:\TM:YDL&4GR\]Z"5^% M0*]+]Z6>PE:G1"S3<%04CEI;LM9O#HZ:)59/.1#IFE]@&=1:QS-N*)ZQD^48 M>@E#N/)M
(FYY;Q0X&J:C88.S=6@_ 10[FR8)VT*E!OFH/%]D@+W7<,@N%P= MA;L/H8N=[@MX$[ID)=Y^\'SN5 K4I<[<9#<;<2(L*^4UB1C,D92VE+7BD?DGPB?CKZ,?-J/KW/OAH$U,U
;NX.+V_(O1K!E?3K\"KGTY_W]+#6[^[[_ZS4;O5QCDQGA_<7/VQ\W- MQ>57X_3K>_CG||/_WES<&) MN;PZOS[%'VYJ]G-.\5MX(>'=VM%>_GE^_>?%^5_KM_32R8IL:'O!E[_9;__7
M6QC!U%LXH 8R:V2$4SN@U/I%$*"X$GH3%@*Y%]T"J5^AM1C9(0^-S0J2%09 MRXG"90.,BG;H5]<+$>\P1->C@M8QCBA6GG_K-)OVF1E-?-_#K M-
S4CV5TR=FMBB1@X&RQF!S2!# MV.*]Y]PSPS) A,00/2#ROAU\XV,LW"&H^C 39K&:XM*HT^74"YA<$1N)+(?D MQJYA&.,#B]>'YC)O>')7L$M&AQ>F<0'K29Q5XQ07@>
<4G3,NQ@+ 9<'0M^_P M?M'8#-MEU*42_RLN2P(=,-[)$$'U#1MB@T5;',[Y]^'4-N$0 =")CS+ _)QP QK7U:#DCQO#*@(08 M?]1N:@"IWHBF>>\O)L;I"&M-P:HX03D6./'A_:E
@3>&-9_[WCUL-02R'%+* M =*2 'O'CBS8SO1QSORY!4-,'WW/!E2;J8%N/EW=JI%@E]:(@)* '0X&=MPR M8+"V,9SZGFL/C6_VR&6/B*^4O"#'.?OI?;0@6/R]'<)UN\9[C,< PLP=
M/A*AY%'R YG,X/=P#0 K(BTGW[\WIX0$JR%ET#&E#*>,V,_(9SX*R1IX#M(OH+FWY#JO>$!$B4.(4 @*@^+?G2X!, M4EMF_':*B,%?CO?^-ZR1=OQ/X'22D@'.$1K"!QD_2
NL@I4'7V'1:(K--;1L&Y/6>H1W'(M "[K/)YP$+=GLX6++8UQ)J3K(>*Z""-!OB5Z)X\)Y!:!A/Z@=IB$%B]L9%L3 MUPOP5A1Q,XUWMG?-9$6F3T1Z3>/SYS-U9?
$'Y,V9E+=C3$$_!73'C#A",JS6 M9-UA:#DBELBV2L$N7:5E!)8CN#&'.X)T9LU@@R!5\%[2 L,(!N%($U'BR%* M+2&;<.J:QI/V[\'0\QD'4WR!N*P$"9@_K!G)_="#'C)SW-"=
[X&83!E^_F*& M$!T=&KU.G)OY]_:0<7H!9,]SO F02$!\TV=3 MD-^!KQI#P"'")US/@P<$3,B(@>"U:FMP90A_^OYW^AA_,_<#3LD>,\/L=/ MBP0L9-
%HE.$MRRU^@7!H=QY*.B@] '=3.PM+$U%/5:XII!;"7B;/U L"]A#KAT8QDNC:[H>OK 11>' M%@ATVIKXC*
<6PB(#M!S!OV!N%.&!W..9)6X3GOH<(=*9Y\|%O@8^>4H&$4DUYF4[,A&]!$"\"W8 M"8**"$),.-X=;B&YH]5"DQ%@%N.C%+K-: CYP]1"/4MFQIJ"?+N+,2I(@"." M$82/J#'AKE-
SPVY!XK%)$#H^O;H@^?4B\"WF]$;!N/E@<1> T N2L(D&!W;+ MAM.J0'"POSN|^S\RF6/B/C&YQ9=^$J8@%_L3,@Q6>_&E2 -V>W!.BMP|+%4
M+\$+G01///"7NPCVVT.P%AK66=.WG16_,WJB+-#7YV?G7V^-]^=_GG^^O$*[M_JJ^/WJ"\,/-&]IB+V]"BS+EM;(SE MTD$,4:H'B#)<&R!A!CAY9$@%
(57*]>C>]2]1L8UR""6/^1ZVON8='&Z"+>> M;X,T<$S+ >$4;3W2OINRDY'Q!?]@$]"UKGP&S[(1&>!P8)AE[F%)'2OD6B4:
MWM[C0\H@PY57>OH3&:!NA*+&;>FI(^%7"^JCCW:!$;?O4 5'M>U[RUF0+/Y# MHU&OU:,B,$*'G7M([%!RXD_"&GYHUCNJL(D]%I.R[RAA4>4?X @>-]F3\8()
M8KXLG["#\@G*E)*9OW;THJ#>^D.S6QNH>0-5C0('MH; A[A,F#::P8+QPL\N M_QX?](8H(X#BO4LKE5;QM44K8:-2(L,T>)-]V6!]@I@*\5GF']V<$*;Q, Q MW"(:PC&:@Q\85ZY=$
;1^O0/C8YB(D*(-4'I/#1N3]]O3LZ\T^:AL 7.(%3 M(?*BG=U,'>F(=M^N-:)R,G,I'G-.E[UO:]52<5^V.X;[=/^QT)!JN5P7G%L MSK#5W0NBU:#39URA%4KH>S@Z+S+\W7!U-
J'$G]N>[#4.],R8(H"1%PMC6P$ M1)(M+D0)K]LJVP 1^ S;G''K6V[@[NDG8Z? +P-ZZ#=$'(FR5UQN0%+_1$5OF7"NL3_D MZ*GIN/!5Y'^;0?D=VL,YUT2+LX>^!BX<_R-
HOQ\=)CRV MF'.ILUZ/%\DC4A> J.PN MD/R&@E 'H$2%,HI&B1/1HD9&HVWV!RVSWNQ*<"3] 5WOWREL"<) 9(Q:7P\ M:.'+.^?D^9E4>9N49%>B]P_-3MWX(@Z&Q* ,:>E&Q!.
_&=]3+]"H-![;QC>R1,Z #)KGC M ALL5:#5F?3S2(%=S@GL"06Q1VZA"+W$82G7\CHP)B"? MPZ$A-SU.31D;"V15)RK8FWE<']5 T960%>GLVKB044O&S=6?%!A!S M(.2HH
M8JC3"1EE^+N<"$;7C$&"Z!SS$B (O^(4=Q@Z:HM*"-*VU3HA6J^2X: M^HTH_?X: 5"%A%U^N%8G$]/$+*-=J_]HS"D*7>2U]T@^1TG2HI-(:YS7C)3"D0PR
M2ZN:TFTNED*CIZ!37BB(D^4$B&PTCML_CJ0!+SB5M32"_I_?%7Y3T"U#DN1Q M>Z+61/E/XDV!"'3'R)H)/?DF^V.1,@; %(UX!$_K1[1?P[TS(>FYKL!?+NEQN42<&#PP7]!%
M-KT&BHPC,0SNE/ 7C92>'XF1H;N!<8W*0]G+Y^U 1M!]I"9XV50T*CT0&J)1X4[LH"@)-U_K2S>73C M?#_><$AV#+Q1=>YQQCH@8;=9W\4RHAC_Q
J2LC2*Y4IE%/JA%8$>+.>'3MVL MU^D?'A6L?HD=M22T$:,7%#[&$\DXH$("I%*3'K_,3PM0VS4T1!.GR!8!][K@WDB\K2$]G9JM$XO2$8(KX* ;WU726"YLT9G.%9$0 M&C?
XDZ\2CR4N0(_7'Y);P&G"QIBK)+/@R#')_379P(Q1*NAU'F.R*XPF_ 1R M8S ?7 I:=[@U1:PROL,H-36Y#M3&A%=]*/"*(A/XD$CGZ[5!O=M+CIX8&4U=
M@H6TI77^S@;O*&";W.9!V96"4 MB!3"X!* 'IV&TEXC%JVTED$6E5I2IN#4>D\EG"1,SP:E,2Q7 <@!YI0)->M8 M%*M+V_<*,-8$=UP&H\0FDWO*X[FK3-]LO O0L N[
!QXRB(9FLN5=3?%RY_QET_A2>U_COL"SJ67[&)F(M\YY-;38VSK\#7Z=(CDM,N44#)W%^ %'C4\WX%-B69*(-,:7=Z=\H# _AR9., MT3!1@D>,B-&,XY7V[^CX%%4)(L'A*G5W:P\
[$_(S@2D%B\LS1,M!&L6D+U=& M:V#,I<_0'L>1\X=.IU:4/4,0*S>5)5E6$;L*7-&4I"P,M:5!IH4AC>Z\7C$ ML3+!WBW")1,L^5C62QS[JX9EDN(/"Q\W/O-\9F;9:5,TF:XM29-
SI$9!J93B M$G=$IV^JW:ZUGZ*RQ&?NQ(52A$X>$[>@53P+(9\;165&CP]7A+R.FV6S&A))0G)LC%" MFR/.S8JHN"CSP^[\B/$V!B+F_3^,D!!6?B;"6F2,?3)GG-_*._WO8>D.BIE
M6LP?3[".J37"Y7 71/+]%-*V(F*?E-^'7 8-2 :5U7Z$!P\W$:&8Y!S->EQC M #]$6"W,V\9??%& S4.D(:"T"+$XBJ]LY([OMJ17-3=8VK=_5JKT9*3P?!Q M>T,,HM-
G@YX"GV$&*XGB?/"HC 1PPH7O\HTN1.R5CTZQ)%;%XGA0='>S!TK?>C6@0YQ.> +]Y(R 4M M7@(E,\%$Q#=[OE@)3/$KU^S&I.&,G06D%.5R91.Z_.*?63[$R6F+#=PE# P
MYE!S$M^I/"\KG HK*>PNBASB=<14 !$,0[83?#[,+E=HR!*%W+PP0Z-' /-B M$#$: 882:!,+Q]FI@$JCD6E4*/)8G4I-1C4RX!:N6.#5C(^4D0+J\&*VX.*9
M&CF^\5CFD$GY'CXN%L/N8&]4%HUIHX#3B:A+%&Q$S(H(4$1#IAVBR4-8IG]H M=6O-R$S@XC?M6C?Z)LR ,Y'4NG1*(I[%K"]O5^'*]]D7"S,40)JZ2Y%C@Q45
MR4B)#^:C0=P-1E4=K<1(=J R.H6)B84AW"S@L@>W&/* >!*?<5+2*A:\\F)R M>:(4HTKT#:2Q7WT!6/X=XVL2"R11G$?J*A[;SS&$,,H#=CQ*(/K&&@(Y;.^ MX34DR924Q!S^.9
1GWPG*HJO9IP&/*LR@^XQ+M>[']D_7D+N+F\F2NXNK0FCD M="GS+')KP-$Z,+]P9@RQ0DLH5Y !^G(!G>9V%Y"^$AY&.^*< Z>BI.EJ(?$6DA;*2A<#R>?RVKC!= [_7)^?
&U\NO]Y^ MNC'.O[X_?V_V\PQGM,:9;(>(S7!(7@ M="S1O1BI9S)U<8VT1-223-TH-5F!B#D,?MGM%E/'&G*W+]FM_S["/L*@_XEF M).KO8&X-U=]
<4P0)C!2H;%/"LU>;1NA4*LYWJ6'^QAM4"-@,_=BR/O%:?6IA M+VNH)#%H15^E%VF@L;X;NY]&M8?O%F\/_X)E9+5N7$7F7S)-MCR5M:-43\6"
MJ!RUL'JUD+';;8)=-78X>N:YG7>%^[]M,_L1%I].\T?=TI:DV3TF+*QO$6 M=<3>E$DL%7]KEL32"G>#K!(;1$%U%[?VG%:9&H;V!H9:&H8T#+T$AL[(BJ6A M2$/12Z#H1V.?
X"@M>^8+FG4,![FKUR[1;E"5<7G.?F["8'82VI:?1T^AI]#1Z MFBI-\S2.7;II]"R.G?3>-/IQ)LY[:;)*:1Y#7]42?7N0LX49L]P?/^1//_@Q M*>)2%.YV5]1H-LQFKU'NL>SZ:C0PK
"&5L/L]@8:@P'+T];M3-=KU?[K&\ M>KUKU_RJBQ>M09FH]W2[+4*,Y9P_>TZ2%=U M??U5F+$4@"A;W6F:WM4M, MUM**!KI>W^P,.I4[5PUTKQCHCMOFH%NJ*Z?
P4E^US?=0P&U/0$T;FI\L'F-] M_" ,$F7%=+]#GD9/HZ?1T^AI]B#=09NVXDYB9.?H$Q;&S=OVZJH:(W>VI;9 MJ>MXNTK,6,K]U\W!3MWMU^OZK=/]-L]/?
I5E0WWZE;K,6D,U(4S?,<:@E MW(2YV#"4=UH9S6S7#D*LRGJO):S2<&S0-YM:P*K&C"5AD'/->2]'+5:51%CI
M9D\G"E9CQC+L5@.SW=*&BTK,6(929;;T[5=CQC*2Q$NV5VN[U::\@&YHNQ-L M+8;MA>R1:"&DI2]%6=L#XPRDQ67UFXUFR76>JGD;!T%9CQMFHUDR8WW5L;B5 MO?
D*7'PU[^(P;K]>LBJM#56;$:E.9Q[L_Q]+-FFVW=!R)S9V,]2"@.G*9B5: MK.IFNZ5= 968L8SK;YB=5LE%CJIY&0=Q_2A9UTNN(:TEZU)NOFQI:H_-58;H
MN0Q[B0D_"8EKC4BT0K)Z^MJ.WGZT;!<;P@>6PSNVER%0K3J1G2>5OF =VT;" M%4L[QD+^[<$N1; 5*]DA(=;P\H*E[=H8^@KNJBKKT#2F_"5H>"D +SNUO*V" M%6U^>
[+Y3=;G&BY5)GCU)K;BQ7W$8Z$W7_E,-9#SN=4\BNVPT1F8[<8^U"?= MW(UI #\@ &^V6V:IO@\E[32 ;P! Q@Z/^RVSTR\UEG^C^WG5AF -VT^#[7*=
M4IN%ZSTV=9>GQURX0V_&C&/"'X(WO&\'-N>@&((#4&;VHM-DHVTV=ZI"'*3W M>#]@X;C;-MMUW27KT.&@US>[31U05(D92VE+7LWR+?#QSAL]T@_PV;IS&/^< M[;
(ONL*\FYGS"4;VO3%TK"#X]]'5QW>_'Z7/HU[_4L"%=_0E=%70LQ+CO?A M]EH-&+_I(7-#YO]Q^:18F)\@.GXQ/<>(@$R^=.0.8YQ]?'K'U]RY\B/94@=
M&YP/G\LP.DTY[<\PK[HR]3G^<:HDY:O3C^W[]BV$Y#]9C M((5QE"==EMCYK\:4\6-LSK_:@@!^U]U^A^\MR1[BY^.?LXZ]D_OLX\<[VX3
M!WY[>?;9=K^I.49V,')20WA_$0=BN'=HH=//+PR?27RKY//GU1HC7+>(?1]M@LA6 $0CTUMNBT!#[ME*V:_)1:U4\%Z4A&"A*>;"9&Q^>ED1HI%,U86&I9"?
B(/RY/GBM&$;#MB:N%X >"(=FO_WMYINGGM6V"!T158&%_SZ]'QD(SL*WI_X;M90 ;X13!O_XC!DS&&4:& P ;V3*W_ZTP2Z;NSP=4WS,N\K;>'=/W8BA=A.\\<2#
<#'%RZ04&\16.XH>%,F ML53\K5D2?ROL'.BT?:WC3\K%./M^(>_ALJ7S6+]I3K*?1T^AI]#1ZFNI[MBK5M*]G2+P@QVU18MUZ]
<:NBLC5V=.J;_;:N&%).&4NY_Z[9ZNF.;I68L8QV M0V9[I\9H??N5NOU*5H;1EI G2E,WS'%L=V(;$^8RWW+(3F*-9K9K!R$6Z+O7 M$E9YY;?JYD +6-
68L90F]&9OL$O/F[[^*EU_LVDVVB778*SF91S$$;+=+UJQT M+-9F)*QK%C&#'TY)LAJQ>^9X\QD\H,6JTC!KI\VS-%6MTMUW6IJC5F+&,JI: MMTMNCOVJ0X6]>^VE!O?HJ)V-
25*G,P_V_X^%72/0 VB[H>5.;"Q46DJC9(UC M"L9;YJ!5,II5\RX.XO8[9KVM[525F+$,_MHP&XV2'8%:LBKEYLON#I['/"8,K
M.B6O*NZ^:+!&M$*R>OK:CMQ\M&T0JUP@L7LJ_%'E*-_E^]M)T4W@-+T];6K_9 M:.[)&>EU5)F-(W1\/(T>*G7RS\@;7U[NO5-%I 8+F7.O7H+FV[M_*0==IMF
MK[5++'\N<8#-79B&[P.";]B?V>MJ -< _DH!_'C0-^LI[+#;W<^K-@<1KV'X: M;'=+]4IL%][WV-)=GAISX0Z]&3..'2\(WO#:TMZ<^11!< "ZS%[TF. TS4Y; MYQ%]6""'XL"L]
[4O^=#AH-\SNV7[EE_3:BH#'CTME4OF02I$+;@HVHO#I^Q MSSG_K*2;A).^V7N1DSXMS,C+FN]PSWLV9FCA@WJC][_,"IGS:/S0J-?:!JS2 0'-Y!NVU N&-^9?]6J#'PV0
M[.:6#Z.$'DT>6"#I@7!G>R/#=G&]5LVXG=I!]/Z#%1AS'R;SX1R,$>P#WK6, M'Y]UNIS4@!$?0XHPA4&&CNVBK P($(3PDSV[6_@!P_0= Z1(QHWCEFO\T(_6 M'I/9P:/[1]+?
4>+L*0]<^6Q!LR9V[LUK-F8^A 0;U.G08?QBK!GH,.B8\.'6%W=_PI?RJ! H';= M#FUY-[.[>[+(@?\.IWIDBW3QUUEVRR<+A60&\-'(:QX -X!O0!W\\ #TA$8_ _0Y&"4B6_-@
+AUS[[[\%&1Q8!OB&' MHL7/O1 68P.P($+Y+/0]O.A[&& T]R((<:FPBBES#<;/!59FD J$T))8%L(> MCNFSH3=Q0:1DR+8HFR5\%NO
''3IGA=2X#Q^1&#"B9GQX$HKC1A$!33@S6H*/ M# Y0K_44L,,C/S1]'87M\%PP9[1?YQ$QEP7)C?MLC!!@#*EW8X![8 H\;+AW M>VB'B-]#.@NZ.;P?/$RU*[B,>QL7 V_#H_
3/P.XG27*$$SM<1C(LT+0\)U MDMX"NX";*TS^_OKQ\3;Y2/P,YD!$/6Y]0@'*[@"7^S3X(:30KPZQ_$>1+G+W.]TH]W6Q-P8L_-0/\^JA\90R TPIVM_@[FUE#]K;K0W^*K1VGIJ%
[_\07'D1:8 M$D==GW__5=B*?HN$(6Z&BI;UB5FX^*,UEJD*-BKT;VWJIOW%N_>>[N&E.Q7 M5]_l0QI#D)D>4)GR3+O^\B6O44 /"-X4V9!9]V#^SE8C/R^VIBJ86@/8*A5
M;1C2GKJ"Y!R8GQ-.27FVW6#A,U_[YI*F;Y90A:YK-OHE5TZHIFG\ (&AWS#; MW:KE^NJP[H)4I],'NW7)Y#FW'@^!QA:\]++U9:RV'I1>9BP+5632@ MG1&F_D.
[UE3!L[9K6,.AOI"< * K-"P,_.7QQ" 5B#!S(YAZ?CBV''@(WAG" M$GQK&%)@I871M@N'3@=7^=FZ&WK^W ASH\O_?_;>O+EM(^L; ?_]%"A%GI&K M((;
[$CNJ4F39\9&ULCRS/O4K5NW0+ I8@P"#!;)S*>_YYSN!AH@*"Z20%#L MU&1"D4!O9S]]^M?[SB1K7':F(-T@!VWRQH;LE=:ZLD 4R1[W&LD)!*]O;O=K M_>(2:?
QK!E]@R;AW"T_S-A:XLMVIM5_Q&ETJ^5:*GO-LYP$S;3#?PN,4(<@: M,)&=/(_]S?6# M!4%*)]+Q5QN8C$\#_SX-";(_85FQEOUY?G?YR>O[^YO/[%L-Q[:QY*D?>&\AFA(_'?
U+/QWO>]+' MR EGK@4KZ7@@>NQTZ/KV]ZR71%TGC1IO+0,TS/C7HY\BWS[*\/>]6 @N"JXD M'CZ1_S*)N+)?/XG+2F7I*/@7\!-/\%EGZW*#\]DXV/QG;E3_7-,M+$AOXI?T$]R-
L6C4S+B:$]PJNV59RI:S^D6 MZB,/AUV]_7+8Y?YW"H=>)MP_/*M$7;<^G7&PIS.J+LR;8L@_E8+B19Z>.J.1RXH5P;I3YD<_7AR1-(/O"8-OS[:[MP3Y_NJ77^XUK^]?+0I-
E*:H#W)RLX'8/(O9J+#G-"3BD]FXKD?8_NMB=^OT2 M32!:=- ^>Y:[.IGU\I5O=;VMK7%OB\]Y6ZTR4?^VQ5H_"'"5_(-6#@QW6'3V&
MX;0KOY8M*;Q(FM]NHZW*@59ZE7N'F:XUU!R8'WJGU=M3#CSH.D/:&EI9P^)N:P8UM++F MH2?@H8I#*VL>JCH/7=!%/9J+-!<]AHM>&?O 1WH[?
NW*6L)B$.],;PW,1ELC8FM>P$K'NMGM MU34O:%XA.CMIF)UFF66'!6-X_9+98+T>=T'Y'5_>]?I53I0\O=M%4(UC%H@] M1.9BD5ALN>B/S6"=9OEZ.-)NI?
OF3WE8:72)73MT3=:9K-1YI51^H#HY:LYQF.7/0*_,8L+Y$Y.!9KM'8#X;;WI/6"4SRI%O=F7H"F.]%:O_X M94AQIVFV2H7_T<[*P?-<&[R5AG:0-<^5J>?,=GM/;SS3++>?+/?
B_>.#S30? MT=U)(66+LY<#O-C2#]V-[D9WH[O1W52U&YW;VGZ7>.$JQ!>>W*]H:WUTUFR; MWY"L?;-?G^GI255)<9!D'|@MCH#3?TJ]+@#ZG=T
MVNI%>%47/M[N<8L7D=B^%SHCAKDJW]->52)9S\?&A=<:_N.G?K/1W#$D036I M<1":];1A-IH[=]LT|L)N\E0{)WPU:7$8U*_OK4NE$U6J2[7&[6 OW+ YTI-
NFF>TSRW4\=$GQ\\-'[;#W;3&YWI-LSG0V"Z:YTH%/3";W3*Q7;2CK'ENIP<& M-1#=L8,$R7]O3AN5K_E6G8_G1F M!=!
Y*_==*O&6[R9.&'2BW%OA88+4V3NW+"B*'"&,1$-6W;]>WC]VII;[@B: M#RT7F>1^XM@3<=@X@HZ,.[5^.L($T66S:6>G=-RKM623?-#0&/^ +8;6E!G@ MFSK^R' \/C?
CHV=8HY&#[JH)TYMB2A>'X,=!2@IX&F\A"3QR:RU7<7'A!['P M)K['0)(-.PX"YMES8^S&>&T)?!]R0]_PV"T=K89E:Z0+;WD!5_ICWG*]UMG:2N3'JG2<,OPH)CZW@.F<<834
M%#H6QO4#7AZ'+#*&H#BM.S\@J5C0J>R'35>F2XLRL4 ,C)D?.JA7A58U2&PS MXT'= #TYWJWA4!^JB2R1GT;.G6&[5AC^>G3UX;<_CO(.6+W^JBAW);XA'Y&^
M$EFD;'OO;ZZ/,OR:NWU>Z41FH=0&)N/3P+]/\U/9GVQ0GL;5A_?/CW8Q\,+ MEULR6!_>EV%TVK+;GZ'?Q$5,/JL?)TDB[NK\P^7I;]>7YW^R\S\C3%A?!F;LQ]O#)&_^ZE._\!
["ZD]\=/1ST5+_ON[XB5' MVCW%@M]\N?C3\;XG?8R<<.9:L)*.YX(-.!VZOOT]&TA0UTFCQEO+ D>_WKT M4^3;1QG^OA<+X7@@/9C3X\3#)_)?)NF_[-
=/$BW=D*B#K**10\OS]F?K;%UN M4#X59S[_F1O5/]<,7 K.O.#*[LQ"K('8HU0CH/G8Y(T"&\^WP+;@LVA\C? MX6?2=>HHKA,^@,Y4)[4[0MGX(*1#UQLA1K-
6NM5ZOXL.E;&0S[5*("F/53P M$^!M1E[\F(4A=]S'C(4UXUQX_):+8V#3F>O/&3L-F$NA2;(DY+S8Z'BAEY9: MQ*1K,&!?/_S#FL[>G.-
G=+F6!0HOT&59AG"0X*5CVWCUA2Q7K._P'K]U)[< MA_7:@UKW8=9;.1ELU(U'*%C$"%SH!%>XR6,F>-D!ZE%@V=3OB29.,#K%7^;& M+40NHL9H#,8('1?
@\!#_2P,$X^1:8.1XW;YU"ZM&7GO-N/R1ZRP9DPWJ #>D MJ%4PC*?I%[@N(!3P,$P5:#&=8<1V3+L".3$_>#6\L1Q 9@&C 'UZ)UCTZ1B
M>,3"+D&C:X+XEJ^38]UZX(XY=NKQ@:0%&([0 \!E\1AZB0."O_%!S^#Q.[%.LX ! MZW\'"B5?TX/)I$*P$3!*TW#&\,(*!2XJR#3*"]F,EI7[9P2H]5P=\3;AS_NM1_&.3CO M-ODIA"
N^9O[PV/'(S>Q.&#:>K1Y7S!7\?E#^M%OT_PT+P1(A_4[L#4,-AE8 M56L#9##2@P7;79W VV'6;WBG\/MEXC<,SW9Y2P>0#3C0^_6HNSK2W6VI2GE4 M+%J
O.Y[V'$K@Z+;%U+M6:&/(50F++Y"APQ#9*+8IU*01V8,E%HUUTA?7I35]K(1&@ M[S]3W>ANG]";/2,6]W& 4N"-?,HD^X1]HI3:T(%%NZ6,7%HAI4O(2W<'EJ!G
M:]PGS0LXI+99[^X8^TG[A$^HD*_$=D@8Q2/G $ZR;Q!T/6.*KPA+L]O7\.35 MZ'$':K57.6QZ[>4^0]GZ873*[XW1S=6Z==>ZM=G<\0G(BI+B('1KHW*&53NL
MV^O62RMP'1:AQ%^D"(/]^)PP,V*&]>?@0U8.'IUZ\RGU:T,UGULQKPM06*?"3AMFO MEWG=Y_:0NB\:"NOI^:V:T*8G+;._^VQ38VD-]K7WWQV6A6]U9>A.]N)7LV(+
M6''DQWCP+\>+E:MN6G_HI=\FO^;(#C.6.% F+/U.^Z=DPHWP'Q=/LZUU%GDY M9Q8>>%X&4_1XHT$'S1_*MJ_&87D8WFL!94O@GZ3'_2/CDS]B_[<((R5%3;'P
M@/K0X0@F>$(=2[7] -$-Z)@_AE#@&MQ'$EXPO'I,A&5:BC.\NS>5 E[\FQ M/$1AD;_!,KCSW!:N28_*@2_;?WAIH &$_K;L6G,. U?\ZRK@E*7 /4CROUG@
MFX@XD8'0;*08<82<%H0(WC#.E.EO! KWI"-OK0!0Y-!P!-AIA6$\G7'HS8#= M6@%Q+O7F3/$C3,JR)P[,D>0/.3V.XH#A]%D8^9ZOQ2|7?WPQKIEGN9P[9SY"
M5#D(#C(%#QG8>V;-Y0 (. 7=:-_^/O%=F"ZA/*1MX-!@)3S$H?Q("T+&$(? M$G1*&(,RD=B-EOU7[(1.-D'! 1 ;+Q$ <8UK:%$65CZFPGAV%3Q-#@C478Y% MM1T 46Y$4DX"-
D:D40[Y8>7&3*0-"+%S8? (@RGA/>.0C6/7<&& 8/]NW.3/A0/"8=CVR@PC"/L M@B!;!I_+*9]+?C4X7%DR!Z2A@;AEZ'Z=(OB=,;1"L&2(+6,@4 Z(K3,E4Y&L
MW)BAN6,+0UFS59B/$Q2W2X3$-?A!OX$Y:C0)*ZL^Z31)#-NFH(FV9'=:C1) MC2:YCVB23Q;PO!UR#S.8H7=,R.()P$ZY'L1S=: QI7:7D-WI0>^= S55"X%I M7;!\C0+QQ-
T\)]-58X8OJYN72;_\9M[^F1/IX7::NX0H7!_AK#3[UM1 A.N; M00YT5F6P0\!#+PT,7M!NAN4AST6.XZ)6Q#WRD"\G6="[QFJQD M1UR#,NIN=#>Z&]V-
[]8Z>:.*)XFJ400NH$C6N&+M O JWCK?:-IU@?ZZ+SF MA3>(9CMH]34K:%; D]Z-CF:%2O2X"^KO&$SCE4ZA/(D;MNQ8QWQD*=G<(;KM. M[?WC@TU32F
*>V&C43O#+T1XFV:CN1_81MI@O!">&YB#3IGP1IKE#I[E0,OU M=IJ9?5KL,UR>\!R.TT'E^ 5'VS6^.CL3S\,.?BG/Q,H) ?@$>_%'MQ)Z1[M
MP<%P[@SG1F,;B[!MQZHR4Q1$>&M..!87"HP&^%PX82+)LDAI1(100TW&ZU MU,D M;(T4S4VP>_95!F'N'_%(& L1^,_VIXQCX.6^-!XM;LW:0)4V*83+)&Z1_YW< MB!P54A2'-
G>8.Q) KU^:=E4I*\0Y1UH) M))@"Q$:^1$NOUD(M1'M317L4[364AIS")'2"'T@(2@IQQ\ACA:'.5Q*Z2A,;6/SG=IM_I2+1YI$5 M1VS,J-&QXUF>38I01=@0.@P17]-F?&>L"
47[PQQR(+XXS$"$ KF!4: EF(G MG$BH4&1>/X["R.*7BI \+1]\P&9Q8$^P'WA9S+:S^,)AV.F8L(--PV,1%XV-7]M2+YJJ'P(J4$*!*)JQWU>_3^%Q\VKR

M73JXG)0HO@HWZAP\EH&G;9!<>/8IFRR" M3JN#*5>B@98I303/&%\+OO?AB_^RZJI- X M05QO@20+/Z."_;H27?A?,>@Z!((UWG--:;GA:V#8.$A@DM=;I'O4;C8FKD=R
M.6!TQZV.8E84'H^XTI7CSA@D='SE:F$;_5HK;YE@F?S@%%%6DR4\'XT()!FE M20P' E:$=K6,6\LA&F#TD"(!4Q*8VSD.%-DP6_VN.0#[$TY@+*17Q&J.-EP0 M4%-
Y*596I:U$-4CU9.44YFB+F2E+0\&(E=CK?M)&ZB0LL-;+ XC^R-?'7QP:CQCX/CDZ6Y*PD6G&'@[!-H[8\>V2"A5YZ) PBUC MY(3P3,04X&A%5ICQF^-?HT_#T'&Y"2POM"A
K1G_0-)/-30)NKJ5Y$PN/ MWD\<>V*,?$+$YD\2.#P]..@'01'SM%X48YIG*M]K;8ZUIF0-,=L%0!A]R5QS\9 M$Q#K_V'&O") BK[FJ1'P4RU.O.36!M0)/GL,0Y!S\D7N*&6Q&#.;S)M!
<$3@K MR"0P!XLL8,R(V1//=_W;.9%2E9@47! 1_$%X(B9,'G(J< 6BAL,H_HJ=:&YP MA'T:L, 6EPP=LLP<"?2-;@M">4.,?/_6;C=Z; M=+UPJ04^^Q16VN%V#N(A\#)
:LCZP2HZZ%M&I!OF'(8K MP%;. 0:56%>_VM;%SFC.*LB'!E97ESRWV&\48/6N[%8#[VM@]7T$5G\@/_TF MF]Q^4Y";?B-
Z/%6I[\.SIEVOCYO=+XRUBFV58+$)W#6^$^26>H64$3Q!>\?"* MB745Y=N?L=6'\-]?9"*]0FQVUO=<\KT^F3;^0CLO'E4_D3OL%E3O2./#A[K1 MN]QL[%U_7O!037TGDNL.;&?
%(!P/H%6JT-2U_&08N5G+0)/,[6C6V#)[]: M!M9'C=|"BI7QB>%F&$]"PJ^0CK4AZ*I!I^=HI/&$WMNI']@Z[N(@V6HML1;T M^1,8W.3?
P8+Q/1UPIV;!DQEA'$Q&]Q=Q@9B#WOHB5+KP5IY;F6R#)+N%GGXL M7NS3J_.-H,U7S_CI88,U2;<@Z?I(XYJD^T#2#0&;-5'W@:@;XW _(UEW<>AG
M#8[9J==RS>Z8%V\"I[US1U0WIAO3C>G&7D#X6H[RYT4E#VA_GB(.67#GV-L! MGCR6O%NW^TQGL[;JM]7KF9U.KXPI/L]B'@21!@VS4=\4.$P3J50BG31:9J>]
M*9K@5EUM>F1Q9_1YNN.'VY&D'&KL&J1AOTSV+/|'L1WME\G>,2,W&CVSV^MH M U UNC3;X#V5HF4T7391,%VSOS&N@#;%ST]1BIOB0XR>>=D:"_@!IXBY>)8^ MMEPJ?
H8%X%7;/C^4_0S6VA"%4&I>_/EBA;*!S9YS+Z35-IN]31$TGG- ST0S MS2#;(L=V.UO>TA/;DSI:EC:^[H:0K2]ZR,H5,L M|&^[L\ROXTCP@=@9UlY:I82ITQR8G?JF]S!H8WPX'-
+M-\S.8%- 3,TAA\,A M)XU.TZSW2]BIU>[:'G+'QG":%7777E0:;FD%X\7"C3VZEE$WIAO3C;W8Q@XX M:E^^&X-V #=?1-
RN2R(VJ8GKF%V]I5XYNK3K?;/1*R&2U739L#R@:78:NB:B M2B2I>GGBBPK&EEOAK\QU"15N^2T"VC*OSW#-5L|LE)'+U!9@,[HTL8BTE#HL M39<-%FL =EF7]E:-
*B7LUNW^>L?*F^9K%C(KL"?B;H<[YOHS!##5]GA|)NNU MS5Z_A&H.K6 V(TL=O"1-EJJ1I6UV!OJD9=6H4LH!91THKTQ7$WPZWD*"D*W.
M2."S:FN\B=CWFXUF*2>AM8;9*#]J$CR;3H]6A2*E$43+R294*0>'0D?&*VSQ M>>X^1,>++.^6+ABTPI#I_6;<%NW:3:UUU\|LK3+0E319-G$50)I*;?R0KM*
M:U)$[R1G"LAAQ(H]S9CJY1>2-/J);5XPULM6<'3V@2Z>]0(;)|_1^"Z;W?,> MU=BFMZ=A]"4#.&DT&V9[\/0LOZ2_9SOF<.!T?*Y,R-ZL[@NBI9;)ET+'9PCO
ME]%0Q_@/GQ+B9[KMA;-"!W.Z6SX6^;.ES^S#^;SUYM%M]\UVJX0L1.FKK[EQ M_[BQUOV8G0JAPVAN/&1N)/^RT=HW=CR($_*'QHE[QX253]OMV,_^L^#&X3W;
M/=L=Z'VC;PZ:Y8"[:G*L)$>_9P[*P0G7U%AC5Z9N#CJE'(3:(VKL>*.L'.%8 M8G+A8W+C.GS&"][YYZ>ZV3!SCZ%.=>OY(3@'8#B= ML[<_#\^>M]OXS%C M"N]/0H,!S4?
&5S:+V'3(@/4OD9SVH/;X?>CL>JO8R5C2D.H\D]SU:[CR[>H M S/D'#';YX'F+P:L#PM<4"=O#/!//GJ@7OPXM+Q1"$X=OGGV_,KD8*]Z;M:;
M[2I<\ZQ)^I0D;6F2OBB25NG&7D#TNNO3A9EK D,6W#GV,]4=/EOQPO8NT&[VB]:_^Z_7,SN=*ET$L5^G
MYUXP9PP:9BGGLS5G[!EGG#1;Y1REW=WE,3NN@MN"K=R#HKJ6_TV=,/TK7Y[M*4N'XH=I#M'^F.80[9=IYM#.FLZ9Z3O]=&.Z,=V8;NR@8W9]I]]SW.G7[)B]
M02E8W_N5F-XU75HML]W50(Q5H\M)S^R6 =&P1]GZ75.DA&O8=2RVV@CK*_V> M%O2[VS":]5(N#]4&8!.Z=%KF8%"*SM%TV6"Q>F5:S#)@0396-%]N4H]!ZJUM? MZ??
\>M_LM/65H=6C2E_?5E YJIPT!_K6^RK1HQS/2,?(^@:A,G5_TQQHY5\] MLG3,1EM'8E4C"]X@5-I:]@'8Y.V=[M!>PP_N<6F:K M#".IR;'.]F6C;@[JI=P@I/:-$(:RM898$C3OB?
VUXS!E)3]2(/>!-042X- M'SEN#&K]1 O @^&,T7S=.8F+QV[L%DR:G49A"3:!',?XH3$FG!"\ \ 'CNU$ M*/LVK0U1$NF%BPL3'R,/HG3Y0^!W07YW^VL>RB ?E1I>,Y19
MW@GCR]B<_7ACB,#[ISK] ^\MQ/3BIZ.?BY;\]W?%2XZT>XH%O_ER\:?C?4_Z M&#GAS+5@)8'M0>A/AZYO?U_DNS=)H\9;RY@$;/SKT4^1;Q]EF/Y>+(2#]@@U
M/R<>/I' ,C$2V:\E7?_Q5^Q';W+4Y5^N$]"C,[J/$&7U GY"-?+V9^ML76Y0 M/AV$[;U95'%H7\(/A[H/%'5FSN*TE)P/PAUL^QZI P+<:0=SS]VXOOIRBUQA MF??
Z/._5E]6[U^=S63=CEG7=3\D7%O;JSWQAX1M](V&%Q4??2(@225]J)&PD/ M;^,.6O^=66XTH92'XX5QP(+]VI@K2@ROV(YH-)\K[]UL#LQN&?5E^[8?42TJ
M@=0.6J7LX>V':_7<.N:##R/WIB*SMF\:9LUVGXU=NRVST]5[G-6C2\-L=G:C MZP_24[EP':U!MN*?7L/L-+4&J1Y=>N:@MQM0A(/T0Z[X]M[AG.
[9+8.O/TAG'/:'0TJ!C!)HRVJO@G509RE+$>UMIY3<%8R!?1NC/P8]Q4W MN^6T+#%:/L"=WE M+/-8KQ8P*046E;^]6N_!PM]FK;5MX6]^G&D5\D(!L.O?PZML.G/1.6/&A%DC
M&XM*L0IQ3'6FWJWAQP$6#L+GF I0P^A4K13&ZB0L3PRVI) *2>$Q*\K4[IIJ MA2).9>K\P#%B;3#U$5"!)8PKP#_3HDQ>+8KET]G:8M\+X^DLXF7+R5"3JIO(
MF5*SXT=5$9=57U,^@Z]Q=X&"XX#<QER%_Y[@9"<^+[$AM4'T; M*!2DY=\PMJ2LV:,B:R A*L%@5=LKZO6VV/57]OC5"3=;NDQO_PJBAEGN?*=P
MT&7"G<,R"Y]TW:"N&ZQ>->L!UF[IK+:KE/N R!WO/=L)W5O75 M,.MUC71>+8HT=W0W6T4=E>=5+5\@,@SP%@L6>):[.B+4N^35V@/MM 95W@#5
M[+%C]NB44.&EO;E'[H]71>WJ[= M!UC2U8)Z__SE,$PIMQ[N8O?\"3<%.A78 M@L&-%75/:Z6JWFRO< F,U5J[: BL8.& 8C>2.\./W=<^W(VV-6]VPXVVE8\A M2>6F;[.VR._YIKO
^2W?K?:8^PH#LA%MRN) M66-+"S,^7)Y9=@D5,DKQ;QM1V23U &S44$#M%*"]9<2$'T&L;=K\VY MY]TR+G&+9DTHO^??C:|\8X\G|-Y._<#6L9(Y?
5FCTVE]T*+#WE+751(OCJ25 MJ)+0)'TRDEY0F\/FZHLBZBNC.F0]O#TPJFBBHSRBP'SO'%_=F&Y,-Z8;V|. MM-0*A\S=,|/ QPVI_:I/W0*G\!DOM^J9W3)@4?:M9+521&JVS4YG-
QA.FDAK M]GO2-?N]4JXDVZ,[^W9Z0=Q)*97X^EK6Y>8YPCWD,=:QIIPNIKHEMS.8 M[9SJ#GRL&=>%X&4(Q=IC;+7-9J^$UVV:SNYOKCS59
M'B!+P^P/=+EGU>@\9HU)\<=CYD>0< MG+U0?]T=LDI)3;/5-;N5.LRB#6[5.*1E-OOZ1)SFD*6)V:KNX,;M#1_[E_ M5$EW'';Z#-WD/_TP?&TXGNU/!=04XDE1!FV_L"!WB%?
7;YO=,K(4>[4GLBMJ M='IFLU%*[GW?lD-V)A^-=L,K#[_]47R5VZ);(XA*M!7\K:V3'OO;ZX?O+5!Z4OZ"&H#D_%IX-^G MKD/V)[R4SKCZ\/G;I14W0RPX
\M(>73&^S*,3E!V^S/TF] M^:Q^G"0^TM7Y MA\O3WZXOS_\X/7]_A]XE5%F>2>,+V,3'&=#N%8_U>D? M>&_!ZQ(_'?U+/QWO>]+'R EGK@4KZ7AX2=/IT/7M
M[XM7*KY)&C7>6L8D8.-?CWZ*?/LHP^3W8B'X1;"N)!X^D?\R\>:R7TNZ_N.O MV(_>Y*C+OUQU-^31&5UJB+NF6+X&; 3NGW6V+C63.,G+KAA= I^. M-XP6_F3@!:-
K72$K+XT=&<===Y9Y:>+U3ZJPR05BF,RO JV#IME&^$NFTW*H9 M_YDX0.1[1@G8P,'[24?&!/@/GL+[4$/CSG=C7#3'XX-1.\,V3+RL%\6%]OB M1:A3/\ [3"W<=!^`+#*&-
=J@[>YFOX=WCLS,W= M#DTDJ1GG$+;S-O!JWT"E%%\ & Y2UYI;[H@Q)*BQ\=6PG"3'G&=#N%8_U>D? M>&_!ZQ(_'?U+/QWO>]+'R EGK@4KZ7AX2=/IT/7M
R1($/K<&_RW18&N29'[JQ[_Z8@7X8EZ'+>]3M5 M:-]JUUI%M)>LT>THO"$9; 8T#P3I\0)I$+2$B0LO) >S>AK!ZF-++(S@3V-F MS?&
<1XALQ9P[EO"0B4+KQIBU,BSC>%"OU9,!B)=@KL[M+<.1@@CCB-Z_.^?2 M>8="-S8^?[C_.>YPGGB1 M-=UQ2)WP1\YO
T:7G_,E.K%P\F.@V4B<80GMP!GR^7SV(V8TVK0$H!O^%=/- MR; N[QW\/FPPC2$?5V_9L/[|_M/%]=7BA#\PX$T/5]IFZXX:#X M85A0 ,K%T9EQ?79L?VY)^O*_]!BV]R8TPG@X=
<)0E#?A:2(0&%Z: MQ^GAJS%HM 6\0/S?/AAYGC JKWVF^11^.:U8I_OG6@"0VG4^]JN3X1RF:[G M_/\^#G!.;%N55>%KN;;);PN91U^BT53&D2SO;^?7(.+H\P66+6G\"*D[7$NU
M@#.#KF#NRXU<"=41;*?LC'HML0K^F,^["YYAWC%N@3 HQZJ MQ#6=N)KQCH4S)V*)8SC*^9/*;?>8<>I6OAE0HH*R:B1[K/4.9 MQ9' ["Q[XL!OW!=-
%D,H30L78NAX21WH&#C;#V"0[Q=F8\=! %[P/.N2SOS0 M09P"!0LJ8WF:F%,*!XP+F!Z'[Z$X.1O)E1[5Q%W]/V%#I+6(]^4XL"26]&
MZ]^C0QY!%U8@NH95HVT%EQVNB*T!+:&4EJ#\;?+&9I*)#7$!0L8\;JO^'OYV MW&ZH,@LTGH%I[J9"WDDC*&"$3JWW*E7)W N<,TMU!5/)0E8*-YD6RK80#1'J
ML>G,]>>,G0;,M2*AZM$X,G(NH+WD9?F$T/G+HK##YY;_78A9:?H%K@@H>G@8I@KK/^5Q@"V]H4!.W]N+4^<+(!IP!@P;W4',0).*H9' MR&[!8G+G&]?)L6X]4-R.+5- !N8W
O22Z %@Q!@M$S>,ZK)2G5S-^ \YOQ 9 M):L:K"3$$,WH"&8U$BXRK.B46&N&0S1:Z7)$?"CXFXP8>+##E0$#YO\.%,K$ M0.FD0I 'K"4$E6-
X85XS/N:IG3)%7MLD3X0QSB5$5P'(C&LY!'T&+KJH$OPK M=J+YZ9#<"71NX"U.>=%"S?A"?G_":L7"#U_&!B:?5)J83R;^4&4)(V6MJ P M"V=NR?
&+BE(J96QSPBRN7H'4CDOOK]*5.\F5YE7DICLL:*'&()W^/;EYY&2% M\10=RK^A8=0L2$'?HS +! 6MR4IR_?*\@\XM#!\UW[/X]:A^9&#R7Q3Z)'^' MX \F?_-M
@B7*'M>O(^TV5Y,ULS4J:J()O3')',*%:C(S94>S/2YBU7>#K/& M]IW",>)L1V>/3^D_? [F?__+!OLG_7MI]*S?8E]_:-5=)+*!4LX5,F_2 $DH+\H0-3OZ4<05K7LD>EX%M<
M9OY$AJ8(D+1I=@:Z'KG:1&K4S7IK-["QA^<'Y!71%24F/W\"!W&(^>9#@7O M6#Z>CW7-5JN4.P?V2[WLFBPML]\KX:2;]FR*%(H?1J=\]P)=&ZU5MCA%U=#X
MNI4C2JN]&T6O791+*W =%IR&D77+Y*ZJUB@;Q4$=LU/7]V54CBZMGMDHY_"R M]E0>NI=A>96$5C.;J)F^V=#Q4 7I NJ_OQN?\O#<%VA]TIHHK60VB8[,@;YD
MJGID:9GUEO9D2E,Q-P_7[3Y8K[N-NGG@=!O!#)X0GVNSC\4EZSYN+$L5I05_M"-[:D*J-NMGO;AK"/7; &GMW.ZI9*?ANHV'NB5<^K<5=QR>/YC\2Z=6LA7&
M@UF*S[L;+W%!T%K/*6@K>0AZ-T9^C)7@.2;:T?;T^@,LZ[["14=4$OBFYI@M M!UC658J/X!B-&E9]U+"![%:CAFG4,(T:MN!DB=/"3WL&V%2P%E+H!CQ^"(P9 M3?"8.)ZQXP ?
N4#<&RT]"B['0H?.0Z:@,M!1XZ(3O%:*0Y0 "?G&5\OSQP[R M!D*/I' W4VO$)-;) NB,>.FC=_JG8U-%:H(_8RI0%2EL#_QA"0 %B8F3@Q/B M2 T<4H'?0*$XK\&Z(0RP'0H7@T
MV6"])KX+$Z7#NVD;G.T]CW&8$]QV8(A[9&9$&Q619?\5.Z&3S01R1= X8("[M-2XM1$%9^9B"/=<>U-H9;#EPNR>;293$E\AU+,4E =K"!JW3Z8G:1? M@I*+')?
&0]!R[CR/]"!+=NCX/RH(EX$!]!G?9CCD861!I_*R%4,IL$/YBGL M00J$9]*XB'A<&Q2_S <7&FR2WPNIZY _JN!L=L2>; 4F$@> OZ=:?H(((_M&SHAH0@8"(F
0&!3,ES)RHT9QX;)#V7-5F$^3E#<[B(L9Z-)["""KX L>=R9? M%9)F9VT)?2P0P-LA-U7!#%TDPNY^3I(_6Z<:?:#JI\3*/.Q?XBG^-1$9]=G, M)R#TWD[!P-;QDEOX,@G5:9;
KH)*+D.O$>)2DU?WB_"K',S'+:)-X)MEHJXT M#PQUA4-.[!Y:19/T*4G:TB1]422]H%R-)NJ+(NHKHSID/;S"%92JA3NC-6:, M;DPWIAM[L8U5,A0M];SM&JCM>W9@95>7;
[8:9]^ASZI4C")]39$*4>2D5PH^ ME[Z;=DURE$.-[>]^?PF15=[B+BM-*Z?B?V^.UCP3TZ\QNX.JOL?=Q9),T=I M].B4@'N@F6-/F:-1 O:.9HX]98YF"?'(VH/9WC%
[":F0Y#"FO9#XUKY8I82& M ODJ'7+66K5R#-)OEP "JQED3QGDI%,EITPC;%2',4I(@:W/%X>=*8/6_\2[MXPG/*+WP5N_K9?.+(K9-;:\)3TY&JMU/K9 MF]+5;Q9O2B=L!
<]V9H1Y(,Z]/E"7DKG^FM\RG3TA34=@<:I%TWN15T/SPY6$ M2%O&P#7Z+3-L*YR(N_O8-ATL'IHN99GP[H5X'#0 M\PGV!?G/^/5OCG_-QC!S>,^X"2POM.P$E00?<$+$#;"9;
?"B+;QV8\]>G-Z M.8PCU$J.<^1Y_!0))O)!H[5]S$HA\ =C-!"E!=837^$ M].$8 1E&RB):)#S%P:@%NW%R/$BL(T!0FI0>(AGH(G6"3L0^;\RSX&)?&7P M*KQ)3Q
CAL3#D8>@V"$'(9/CAT/>(D>HW#!=9X;\'ZWEENS!(8%6(,8$ANJ1T/C'9,>,2FX;&(R];& MKVVGMTUBM.-F5Q'55&G7%2@*-9C_+0+SYC'7CW85'\ B,11NDC?UXRG&JLB!5R%
M,\GXC4:_UET<.??4&X/:8*58F(6N2,+W^)?*^UR%*QX-//,!O/MW/XS??1=U M>FB<0(L2M 9^1KDPNA+6Z%\Q& O$G#'>%K4"-Q@(L%9HF9;R-+F3+
M@%^/^PIF6KH0HYAPF?)#!-ME3^BV.U@(9^S8A'+EXA M7' <^,X|\-'X.!HTCF:-YN+28BY*_JWET(B.5??@GN.<84YYI#/)6S"/PGMD M_BSYIYE() QUM@N17BNQFZ^-
,H$@T#FM&8*0QHMRZ[U3"@&@94PX ^&-:1 M,H^L'PA-=N>$"2 BAT%;_'7[["JVF9#L9S75Z6JN!S%>\(%T,@GX8<*J48A-1/DI[$#SP[0X)R.? *Z$XX,(D#2
MHT.P_&,G.ERW.MV-3;TV6DC^)V,",?$_S)A8%*_1USP/"[&-Q7D(F(Q?YTE^ MB8>@K=$$([=[2F]0T@K9@)I 7Y$T'(@C\"@#GVH.P[,G'MB7VSG1-@1F0\<+ M$2]32$W$\ 3?
+&+"WT0ICGFV#$;Q5^Q$,5$()2UD.6F2)G+,I#T(O& ME*43GH81+]*92-; L28$.,?/_6;C=Z;=+EPI04,XQ06&E8)V +\0P<<>I!= M$RD B^A@" O#@;;F'-
@P8#AJ"C;X(&O&:EY0H])>K9[%BFQ]F"@?K|E&)-1 MH*JKR+TCD5"MK+%[@A3_GQ__]>WCNX\W_VN77U5G_O=_1\HJC1AJ0\"I1)8>[!"1C2-:TH M=T0&;27@+\Q/D7P+E1=B
AC<5Q1^5)ANZ*?YY'5VY92Q+=N$DT0IQFK'L=^) M$1 A%/5#:>;D=Y'A:W47L_$;$"0E1IH;(#Q?0@C+2<+GFD.%9X3$FNI[/>?(K(M\VFR@=%DT:]#R%A0,CL(;(>
M$A!#*.)\,+,P4'-A!PD?PM0F\|"?G/QA>R6DRE,Z(AQ\.U,MET\P?E%3#-KPBBG?HE$^!./\!Z.)@F>GJ_K#%TF';-*8A VE/
M>&D6#UW'EIO@=R@E$+G:";ZX8"&YL4*9MWL,>1&%G<@!8FP]+N<+Z\YR7(DK M'A_JQL1'U4IP"_')'[' ;U#RA<-$*[5)%S>],/D'IR/C>K9^#PS9AF%X,I &Y)I>1GS(!39!
>!M7Q,H-PP8!0Q[%*Q?@ M_PG:&D01)B;8%=_X]/7F_-J8HMN9Y! 1A<-Z%I[N&P:^A2(<@T(&?T]1&<_ M:$K"R/CN^?>>(9:4&//K^?77TPO_WZ=-OL>86Q(^46D#*
(W,'_DG>JCH6Y(T MBL?05&:N%E"U.LTY.P%0=!'#L$M.!-]SO#&8).]OR\"%\+B0@9\Z\6$YS&1G MS\#*9W*PW81.:6$+!@42?QLEU'+%>.\'W^6E&U-_1+$$MT?*[BZ&V'0*$E?
MIZQR(39@^-XM!/CU-, 7.=1 M2/+1%_,P/GT!9H;U!V?USK%-2+Y =+L.4#Z'3NE5+384HXF@1,?GT!9H;U!V?USK%-2+Y =+L.4#Z'3NE5+384HXF@1,?GT!9H;U!V?USK%-2+Y
1/JD,U&3X=QPLU8N*84%83RCN*"0I&#>?!B5!QVZRQ@4KP%)&,WDZF\& M05/"^6),4B1($L*,ME,?1SJB=4+Y.!T2V6#L8 Y"(5R%PZ#X,SN0='=[>OWY
M'(7T9V"Z=_#Q#E;"#T(L!$@X3>H1@0$/6BB_&BGO9D8@4/EQN+(/R?HCAM#U M0 7@1\L53L\Y%\T"5Y<8__86;Z>(F+A- @SC5*#KP_2&C&C'O0=B"GFK"U U MC(?
_99Q@1OPY@ENDL$(W2]>&<2>8EEB3_+H*-E]E(QJ8HO'@VI*%O=[<#)A M2:.KTN]",A]SNL,DGO(K !Y.>ZEW>G"Z_6D-T8=.+WT(&57(B5! *"C1TS^) MR*$$4DH8,
<8DI8@DD>"K44;I)9'VOTWUCF M""Q4491IX52)%[FH5DPL#)\)D5AA3(3@SF+FY=\2AKQ M*&$8A^BX\CN?;(KE,/R1.@06Z-;SX5$[Q-P*,,HINR',6&6B[>KH"3<^S J
M:)]_!R,*.!U"B5"\=P)\[<@B!S45&62P_T4%A>_C'_\#BIC--RA!?*%B\HY< M(6Y@\6)KXR^^KRN*G'(2$_KNR&B8K7[7'#0'BKN?WY>UN>M/]^=@700.S(\I MQ$;G>\9D?
HTAP=H M@Q2\+FN$?XE(%&-F=NN#+TM6*S52W$FP;!OLD(BF2<#2$>5<-\6D@9=VBJH? M^\(!0;3KV4CYG6U\H4CK/$?BTY\U+61)W;5[MAS+Z_ (BAYP;
[I?/X$^;0F/7NAF()"%BTG5XGD^F%YQB1YCQ$33%.T?>&+(Q(@+]^U\W.>(\>H_GO80>WGHX7^A'UA4; D\ZH&\9>[=R^KT=!*@ MVMMF?]
RZ\VN9%_4S^!]*"4K(]5B@(>P*LU5%96DZU>6U:\T=/V*KE_1]2MK M.QD]98\KN50/LTPB6>QC"8C8=SYN=E)O0O5D1:VR3!M4[)@AA?OIR_!M<#3"L$MJ\RD:QEX*[6 M-
)ZF+\OZF7:M_HKB"!>H(VB'OXBLH&SIU/?@AV2RPM-)=\3' M3A!BP PF=YU[%\:UX-7\3^6)W.2ZS)]2\G"KF[!N5&5]<%OM-OGZ\L!7R%\ MAW]:
(A'9O88AW\$9LN@>=W\R:1>Q9_B1:]RDJ: JODS)O=]DW$4A_[FHO=E4 M20YT\2ANS>_3+NXX+J4\>,9CS$2,&"6!@+7&3!S,2*_N3-@NU,%F/?OE>YHB92Z9(UQC3LC-
:T1R$0J6' /_D$M\;HJ-3U &1#^ M>YI2(7.NC-)/);B=6*[D2O'C>FU0[;YX23-5 MCC+R%K*9%5# LWH!J&>9OE3N7RZR6>HQM':M]9 '9HX0,<7'ZLK:0,]0V$S
MGW0185F6:V".RNW"#ZNT,(;%]>@86H8;&3"KS3>Z[4DF]$5CP_.W,0T!NNO6 M6@]R:2)2]N9=29[TCG?. F3\CAN].M%/X^KF>K<4.QZH%RF5#DP M@WF>;
('B.1)5'%#WL1&OFL1$:HI#>@WU(/.:KF*.S.?CL>.B,'%:\50TSP+ M[F/VC0*+R=L0EA*Z%W%_WDZF[226$CC_*M?URMX>7JUUYKS853H@JJ%6CYT> M=SIK.RG%YUM-
"&C=Q)DNZA2FY-\RRBS)E%=&]>1.H8&C$^"DAW$$_C7M""4. M+VT[8QG<^T2$28W(.9F88%IR#E>+Y=GOW(KP04PM<=;?YDO%:WP3E;:L:I M+$X@2RJ 5?Q
-4FE[0KR=\C"]AZ.F4CA],?M\\9TH+WI^Q7=LA0]_GW MI*/3<"M5X;83V/$4"6JS\!?CI/%:9N=H>Q-K+4<0<,DM':H\%G5KY%G1J/-/ MB<-QOL<[_T35@.*$7-
LXX>=BZ:A"D/!@OI'75-:,S;L6QFI4P8QV+_57"OTI MW R*@%W@)4D,89=$9AI6,#.1.B=Y8Z_51&5R<)_UJHO M/&YD>DC6P!3 #R)5;Z9S4IZ7ZK20M(L+[(3&+=7&(P&P/"=
(G#L1R+3 B1%M M*CERSJNAX#N;#C#C\4?U&654;XR3IKH(HCP*YKHX^0R'BL7B+$*>%&E >0\N MFGSM!$>-SEDSD2X2('2'C"E0-
N;;".)Y>K+QYC5J9^Z1D)62&Q$X3U%$#L_+ MP[)FO2XH6^2KR?$B7J+5*2#4&N,BW]AEM*]LB9D/^@E9Q,ZT_',C+I=6LYBT M/*\A*$O"E:$IS.JD]=J(9T*W^+8XG\KK+_D.1
9$", _#1]'RD]CUY_H1DR.W M6);D9=CD 258,[X0SO)_/*RXXN18Q"-T(SU&:1PLFN.^^62U,A=L@*$4Z$((M%^F\]*T5C(BJ@G!XKHK7":8;2#7C&ZZN0A,JJ<+V/M!&U SY*9
5@K1SAK7 MIB'+C6K(3%F:L3R2I)"T,]#QTLJ/!+7OF7(SB(I/#K?8YV:R*$,$(N((M/).L@NUW![5.M]/D?Z7+FR)AOKF)#W>0!E+3_9>H+<7#C] YR_"]*5A_&L> M2N9GF:DZ?
\AUR1::I25!RU1)Z0#ETGG) 6 MIN-Y[-:QD:5%E6RB82W0KZ"87:8]]23$C(+S=VH)M95 MG(UVID,P>TR< AB33YYVSF^324Y*"HP[,>XPN\"P1+Z(+^Z3, 3BQ>-F.PM+ MM-A)
[O1G@3DS:7BJ99[0&0IQL#"9B\1C&L>N>Z . ,*!M>]3U1$26// @5%:LV"A+E @Y5C;8S M^W+Y+-3:1[*Q]+*;G@#_#U\E3YPEXQ61^!GID*9(B]8!ZR#9"-7'#2;2,1[R M?#S4$
65BX=+JB(K0P"U)&K'I3W;13*K-_OW^T\7UE6E\=FQ ;A'- M+LX_7?$R)%1D#&;H",D3I2EIJ3VH]C"'H"*M[B*B0TLN]U;2(U5A6M:?VR1=
M0#2Z9TH13)KFD93&^J=,B8G4N71@MVB_-R!Y:FG9X_[O:;B<21)&H0[!-=# M]B2#^!149@&X(5D%:25#A)LA4SB21VTYJ,1#8P2/#/T@N79IN9SEW5)I#E8C
MH(DPL'[!12"L6Q0.: (/[X_\>)A^2;-9,A-,GH<)>]@P95(M^<0*0O(\WHI M'9=6*:;N7D)6U-5+F*N06,V>NI6\BEA@/F.7GXM+B:,>]"#D>I(U%@7-[RY2: MS??
OSKENNB,:+IY[X_@B_8Y2L9^ BHDMP&1(?+7AP^NTW2SF!*Y4<]!@ MP:&(7.[#/TCO1N;@92$].16:REDB>+) (T5.&C.X5NS9$S.IMZ+DOZ306^?L
MV@+I&S%"0\^@@!O'J7$J&DVBG.XE+%8J0+R^-7OLK[7(=A\8GDL6&>R$_Y!(MN8&)VR4V&L^M1T>R!"DE!8TVU+N$:9H MM4&(9Z 4T?2KAF'!*A0-
T%++4>@UL:))]G(;QL.IDZ "*U(0A'B3A3F MC<']& 7QK=PBC83310ET2EX2X[W#1RX)I$YF,""<\RSD"9Z!YS#]JVQ;D8@O MG.V]P]S14N$BYVV+V5)0
MN@XTIOH/(AFYR(U),+L1)L"'L"C X:%B&X2B"=-'G+9" MN.Y'J.LJ=0?%6 M02U0PB(#]83G4'FLD* CCN0E*\]I5+I**0MF1M=>"$066)FY+WI"!^CT109 M"!*?
H<"9<<*DN)S"^#",IPD$#"P,'M1$V\<$K,=|X%-&4XP[Q5X0-7F$5\#D M^<[D< GE"1B?59(\$'.2V870!ZT@:H3PT 5MSD:XF4V0,&#OQF3E."!#1GD) M$(H@!?
DTE:/!$@R39%@-%<1Y5WJ32UJ4:3<+BA2FU1"86LEC_X0D"QB5CP4TKUY"*C,=\%K5"4O,HJ1+GDXF+1/=+X02SI$@WA45KRBEP/XX(%AIM:Y;_A!)+3:M8
MY&1$//=_Y(LB3*%\#(?^PE)=_"^\P:O9\ \LDHTX:H)5^EXHQ0GS(-U(:[< M;)C;KN5,0 +VN]&,8&F7:S#P5(3Q)IEN"?"]]7YB C]F6<602Y9Q"'N) <** FN M#A
ICERY!&N0GVN7I$VY-86)2*^36UQ6J?)?1F:Y35?8J=!\;X0:<";H^:@ MZ2&&BL.A6UQPAUQY_(#?#Y%EW(\WYP:")?&&7@OY1HE.-"1\'3GX\& M!B0?8RP=?GQ1IF+Y:<L22G_,

<2AMQ2T1 U;;%DD9OTRBP;4YDOH$F7"_P\?U :'JZ MQ:EZ>#:ZBF)9%45+5U'H*HI]KJ(HK[9320A)/'K<,TR4HD'BGJ6XW'*6@8TYND.3QHL8U)U.%_SOIZRE"U?':X)?
CVJ'QDH4C.T M?!YM\GWPI-G! M4G+Q?Z_?&%3."I95LN;0CR)_FJJ2l-+B]0MW%B8FIMWLO<)!/Q\QDW\'"X0] M'1!A+PK9+R1*+[FL^?'S;KQ:>A$U4 :XQOOUJ+G:&&XWAD4?
0!W5TP'X*\,6 MH\Z Z5^GN)TY="/X;F?+_\+Z>&+6$?WV*C&WE]*'IE'U^] TJGX?FD;5[T/3 MJ/I]O#0:P#_7N\HNLI?N=Q^)LILL0:[M4W";2;),@J!2FB\T7Q3P15?SA>:+ K[H::[0?
%' %WW-%YHO\GQ!!P)ODAS MA^:.!>[P\459HS-\@9UA/QM]0\'T;_ %;I9)K_C!Q7IP"S5=^!5[W/G!KA#@ MK=M=E)VCL^,5>[W/G!KA#@ MK=M=E*VCL^,5>[W/G6K!5$/UM)\= 8LU>GWRYCN\RQLA0C66X-
>6_7;-@>= M@291I4G4Z&@"59E 5"+?+&6*FDB:2)I(FD@[M4C]TH[@&-S_I M5 [>'[)7,..]P1&P'34 M\;BHH]/4,4?5-%##[+4U5:I'E59#N[95HT]_KFE2-9HTZRU-
DXK1I*$WX"M(ME:[9:>\FBZ6W.-8/-? N.Y/?UHX0+:#>"BXVWB8"V6A!MA2!Y^BC_JA."HHP M%X5KVTW:1P=$E5GD$OKHE4''1F_36&8W-#Q4&U3U8@@M6UI':CIJ.NX#'1N]
MOMD=;+K5INU=J9$PT*C?WI2^WM:?29IF45>M.T?#F]:5J^_MG-XT+5l.;\l*RV:[8[8Z3U_DM3>KJVGY9//5.VGK[Z3[F;W.7%?M;9GP:;3,
M9K.ZIU)TBE"G>C4=-1TU'34=-1TU'5\]'2ONBS[?%MKNW,^]VD';<;3U1% M61C1?;Q.-.77^SWC]IJ*)OA\&"7K(1=6)UQ;>\]-L]\K85_Z:1?P@)CEF?3I MVF-L-,Q6OZ<91#/(
PS2+>$\E&:0/6:0=@G'@#2#I#&#=$LXO:<99$\9I-TM M 1I#<\>^>3L):SREA*]D'>C=&?HQG.7/\4P& M^_4'V^F;G3) O-4^YIR1MO7Q\K;K9;>U 76N&V5.&:;;,0:\$R#K-
M,"^%89IFHZ\9ICK3KSS#U,U^0S-,=:9?=89IMSMFNZTYICK3KSK'=.L-L]/9 MP3[:!ARCI"G@X] ?S>D'^&S!Z_SS4UU"*'("^+.:!6AV,A48LPSQ%,2$&;. V0PYWZ#)PQ)"7YX?
&8YGN_&(P7_'V%[D^)YQCO=J&A&\9DW] MV(NHVAS_I(? ;O1,;%CP"#9@QT$ O;ES8\0B%DP=#SLP1C M +M:A1P-^#9)PYOKUJ'YDV,QUA79(_@YGEBW_SB77:L7-
45*%OK9U=,3A'3"%G@C(NKJ/K-9O?- M&CDN*X[\117NV@Y%?P#>!94>QY698V_$,V_<\9G-I<**)8;N.AY0S(N [M%QJ]GSCVQ,";5@T?R&I$!]XQ9U8 /R&^632Q(A"
(&8//T,8,6@8F,9@7@"!@ M$5'-0+&,,#LHI R%C/W -YPH#F ^3BA:P#>A$1)(/EHOG@ZA4WA#M!R*IMF(MNK="(XSMB4GOV&*:T)Q/(AO.F.V,Y_3CU/KA3..I',,]?C,W,'M6RQ-
T'76] MI4I+U57@CV([,ES'9EX(+'L;,#;E/#H>HU#=@?V) VD:7!:&G)<;'2Y"AA\@ M7Y/ _)@Y@6*5AG/X93C ;_4?YHR1G>#C> %UY_1,\]#J.A1X7-5/YVY
MC']'5N$7&X1K'+N+|NOSNW,4D<"_@S]17O#U]_@E2%4 /7DQ4WNA47,+5#AR M^4H$R\Y0(%T7?^9F$J43O#7'=E"LP3KZQA!\4LL9D75U>,L>$ F6&=H1:H $ M/,
'YR1G\!R#QT%9A!,KX(<@_3@P+OSI%$;W-?+M[Z@[;"L$TP>+CS_Z,UP. MQ2JC?;-N02G=HCJ(9SB;XT:S4ZOC?%UX>"M54.C._C/'4__<,)98+W1X7+QR
M=/9V>'9Q_?'FX\7YG\;YQ<67;YIO/G[^8%Q|^?/CQ;CY_. M;^"OMS\SYYW/#LEX#G[AG%-_X&!40&<.>6"#D(7(+LI4=.*2$01YL-$$H MH#,?;)
[#...'X#CX,CIQ(3P[!+X'!L9WW\-08(RG?W"&G%A@$"<6\'K:FS,% MHT%>'[[PK](@*X >(L?B-'2C"0E!=$BA"?:KMGBI/P(G7EQ>7GV\R?'C]Y3-\ MOKC\!#]\?>GL]|8Y.T]9*HR
S%8P"D$E1D)O6B/0:6P$Y'96K$1IT73)O7_T MC'?,9A0#->O-%H]SWI]__0V"IC &@3C_^LWX[-?HU]/ZP#0^>F ;F7%C_8 A
MG=SX,\NWZZU^,CU.T@L)#A15.GS3>,:'M^B%%8R?DH=3?8,NB5?JF\>:U MC ;G_L@9H_SC:(+810OEH2''1B)H;Z2T!ST%[*_8 34#/8,RX=^)1YAQXKP6 M@1]L,U
8IO_4#A_P"WCP:KX"!QV$[KF-Q&W?BP$OXJ^@3;"&T%1KEPC)]2&.AX M,7*5/Q,^"EA^-O8#I@Z28M"07AXRCXV=R#@)V27"1/#0 M_C9V1G2YDJ/&/3!X:,O#&!ZF[/@CI
PNT>1RAC&D')VHT. Z>V:<6FA[B>Y M1]<.6IQAI!/A(BDMCJ5QX*,6:!@DM46%A,]<:QE(SXJ7!?5 M?"IRN<*(EJ911\X=..U6&/YZ=/7AMS^*(\?%;+GXAO8#Z"L92V;:>W]SG32H
MAD80L ,')N5SV(D,+-4&)N/3P+]/0\[L3QCR&ENV;)F/SGA? MAM%MRVY_AGX3!SWYK'Z<)#'SU?F'R]/?KB_/_S@]?W]S>0UAI'MOS4.YOX"$ M\EAFYF\,T!>TC$V(+0U1TOA3G?
Z!]Q:J'<5/1S\7+?GO[XJ7G$>CCU_PFR\7 M?SK>]Z0/8.F9:\%*.AZ$?NQT"-KK>T$@G#1JO+6,2<#&OQ[]!''448;Y[\5" M0 R)DBB)AT_DOTP8/_OUDT3:-
Z2@0/XQY.8',:VS=;E!^50LV0NQVJH!%A9_4[!?Y2?PQ(HE\\V%_J2?l M)=6Ll.!63U!SAQGO"*U0"&N)W@_,&TC >Q"^!'\ B&)37XP@48IDK3>,HF 6N7Y NANP.HCEF
MX6PH%2.^A"5$_TH!!6TD7+*!YXL0HZ>%3(TF3,)^A3P8Z!$N)#[GHV9 _PUT7I,Z"US(& MZH %Y9F9E3X+7])X-J((6,0M#WH-_ W:9>1>#LX,<[CTG8R#LFZ%.W_0-]+.
MQ0/.A=I_$ARH#IC]M3'%P98-":IN)VS:V9SZHC(5UA) $P1KNU!?V^ M9=_"Y/%E>>)&0?&"!#2XOOT2W%]>\S=7.BA&E\ _A1TR85_PD1IQ"_OE/2N ME/
L4C!-.:)./)XA#$L_ FK)[/_B.# K"!!$ER(AL5ZB<<.*, M:44IJXI[,D(2HWO_=.:XKA7@\8^8QB/[O^+?WJS[R2A +&]=?XBI9.N'B#O' MO@TCP3C(DS^*7E/=POL%!?
%*/C(%%P&W'E,]@T$9AGXUXXNWH%.:?$4OOX%> MI>])WD(Y%XSA,/E-ZT=++]:NT7L3YKN4'?%=IU=<[>$+TC:F$\>HGKDBG,<-%E)=ZG(KAF-QK?LDP4A;7(%
(EN.BDBP$(IJ- M4)7S%4,C1KJ67ZC5I-2,?P.?^G&HO$*1'_- M_%HC_Z&>]$>L.$;\!$]:I<> M(6TGQA,NKNCB(I*&E;L>2(1)$NJA*"9 MN\>,+&ID?R%-
*G*R1%46QFXD5A8U/$79W!(D.Q#&. XH8G?!CH6@IBE$11Y$ M\TZ,.L)9AE' ?TN#>;[D?$CW,)>$'6@1N77AM3-\;+1)(=<_Z4Z*)F[V X75 M[Q-
:*"OUB5CPFEA0;I;XWNFWKS3E3$8"=_"Y7L'!+BK,-1SBI4'9@X=P5!NT MIN^[$X_["5+4$"DYHU^/_OIK- V.#')L0_QEPBAX#F(33Z"/V"T:GS+!/Y' MY2)]$ @^F<]-P"\&1)
(LP%CMC7%T]]8N342G FL E^X\F_5S3XG7^Z3%?QG MX+D[X?>W/V,O9R\]3?Y!8&@$^C[HB"$F;CWP4J"&:(W"*310'] A;O!#;B5(MR@X^^"YH622\RDRB\)=M,%;_,$U%]D*H?
V%*G,\GC)$:"#ZM2J^7":<2&*$\9., 4"<@@O*D (P.VQ MA,7$@@ (3\&MOLUK@H<:/P_SHY2S@JG?0K>AV#7 \%S6[R5,J Z US@$&(?" M*/WQ.,0L_7RQ$1E2"BV&
(^8.8C*HWWP11!=W)-ATX44; CW*.Z!]%LL)#'1H MV,A$MR])N:FT0H341@@AM!056KJ%08L*&-K]9E: 68.0_#%1C4CY8%2F!5(/ MLL:W5L T.G?<^]6#)E$,+'*A,%\$(XR%,S>+
YS_H6KE+W%FR81K2[XTWZHD MGSV,UA,DD]@#S9TWXMS'1!1+#$N"0\W85HC<@_4W(S^O4APY;3O@K"C;N>1
MTNJQ&+?,PYTYZ%=NG\8\@)&O\&TZT;@C4H6Y/O%K#)1Y<6[3M78.F_UHVP5 MK8@I%9' > 1\< @=*-U5I!KX'TOU0LARLLAG29N@Q.\;HB^_IJL7;N./+7(=]LA6R(5LF
MM#>%=\!#17^LNA&VW.3TL$",%)Z8/^;R1)PG,Q;P6^P)PY&RL]#2]I&K&2B2 M:[!WZFYPL2I>XHSS(1;K6^UK#98'@T9:5O69D-,^L[MH]";!BWBSUQK?+4H7PVO(?
C,,2L"XE]RHE]+YO[UZCU^6$5#9NB:*T5KW6>\(;2F,H&:(?)"$/&!=ZNN(+22 M),OE[' S4RQMLMO0:IABOQQL,O6A&74CNCA"38+;U-#*=$ 2=*GVN&9\"-">
M6K8=3V/N+B0MJW.W1O^-0XXZ;9)?%^!@+=R3EG5R1#U0E;P>GRKC)[X+&C3Q M5-%/CH!LH]-F;,19[[C5K35EQ3L-LM6N==,O(OY8 T(05=5LO .Q\)GGDW##=;ZCLTYQ
M(@:B(FA4)5L9'T;)C#K(Y'C-Y7DJDY)+_@B#0'#A;?@"2T-(\/@7/,H]3+9(M0/07<\)? CIKS+%.:+YA" MY$+I0-H\E^]2TG@,(;&/\@[ZA1-\R]$>8^-L;XC-W?3OV5ZNK!M
M>5S>!:L56+?RG&XVZTT[J[BMN;@((O+D\2XT,<=RW" ZQ2./AH?Y!\8W8]/C M^%P0>1B9;5$N>,WXC=F62*B2N4_;%#D-)SUFI:PWY79%!T.(MAENWI.L*=F! M[/Z(B ;Y_G-
&\&2@K1QZP;%OZG&Q;V5-0?C I"5"-@HMLGIH.IN'MJC]J!* M\Q&C\V^D3/2>S=EY5& ZB:1X"HF?GB,I0_T%9%!*FD"U.G:2XP/B'+>;]5HC M.3E'(L&#$V1QSNMY?
DZSV%*>U^QO8_84EUNHU5KO*+D'(RI: &H7B %G)F MN+441U1\1/N)ELMK%&F3EA\Z%.XAN6KV'. 0.@S'%^@>!@'2@4.*8.9RKGAD_E"_;VHJI.-!ZS<
M@66=P9JRX$Z5LWL4))EEIWB3=A$)F,+Y&VD\=Y@[X@6B6.R@V [,S7H@;-QC M%/L(OCRCS"LXD_&9$MV"#U!L2N()::Y=0#9';!AE'',9B 0\,T)2/OI7U30@9N2PB8!1 H<$7&>
MG,;NB$@J/V!ZV:0:,CR,.C<3';JP!VMYX$/ LKEL80SX/AAC/Q02AAE"4:GH M E%PH_%&>"O 2^E^(]8L'!5K!(L5,EYV6% N(8@A/+*,*X?+FVC"9&L%*)&Z
M,:7C6WJ;NB"!Q?'&Z^"KP MP:?"K$:EBHJ>8D6=L[2(RE@R:8,?L*W"E)_7GDZ3!(F95N$K-:@\!R><'C8V M+G] S$,: \L8]# +^'YA\GMR2%W^;HHR5%$>R?-
AR28:%FI)17N!F4AOGB1J MTN)YGA:25)JE5#JA#.B8<%] E? JR4;+.FUT3A@_DMKHC,1?W'^CW)Q,VYS; MT6O,J(D1$&+36*D=A8[OJ+B5MJ_ H*2G\?D1&'0,Y)'^?
,'LZ!K#YH@U:,NX MPX&':YP1>L=6Z!.&&M:GO0&5G0K5GV;2U&,N0Y:<<:5!QNDA81]?L!SWZ ZY M5%,!(2=H\26+@99:9AI-/N(PQ(]A/,6MR;]%["H3O:;*X4&F6YYL%
<>7TVWH MM(@:9Y(L^=H57(,^&E1;38_G]"1PGZ],R!M20LGN(^# Z:"%B3KQUG6IGS=2,5#^XN;E^6)C?1$OSP'@4>GB*%1&^/!R$"Q M(W,E^;WP@OFX6:P0DB>'/]
(U&,MJ,+JZ!D/78#RJ!@,_) LJ$4=%$;HV>2>;R.ZM'7_WK(C\#T6"EB6T4_74DA$KZ<+W&8KWP@%K* MNVD6(8*N8Q7G^%<;NH*2]^NL9%7EW,-
LUZC[+F%=R0*_V^7,*F[W8Q[.FE' MW)=$V/D?#\MZ"H](MOQU7+Y#NHEKVC*9>R^\0H28=+7M^7LT MN?%"W+A!.Y^TI1@+_,+,#]$$'Y!F<$D6@,\K207\/R?\B(;(^()F 7*
]RTJ M8V82*EGBI+_^?RM"D(V!TT5@-W8\BG>*(_^MU60^;%D;DCT=UN^,JA"3@>WJ M-MR5$9A8L4[SH;MQ']/!:@XY.KLBW_0AM/>G"Y"+D>^!**BE?CUJKD[(/,6J M;'__QM8
MTU#SH^;'Q_#C)W'UECB0]V^J=Z?-O4_6W/A?0NI6N/-;4C>P9YRHW)ZB7F.T MQ$&NM\$W;O5WYR#OSBG^GQ@43D/N\OH&_2URG^TU;D9:N&_S&41]UST.GK#' M
CVR>*DJOYJT2QQ)1;'555J/&V/*RZ]W0'I3S71J]"C%OHJ44/3?V?TW\R5 MVGFN<7>NU'E\&X>1ZDR);[0[M2!9JRZ2?V*F]IF-9L,GW2M-=OM =LU:MV&YCC-<5K1:,9I(K8KU=-
= M>_3]CMFH=\U!;Z<.<5D;O >:Q/NS7VFJO*=;5NF?Z)YC>MZK2J.P36VSV?%::+=^(=/R7K M*>XQ?$P.$,%G/,E4TDG/C0]<91:7CE>I(\D-(7^:<;23GKBL1TZRA?Z>>'Q2H5E-
K)&^@ MYG*L,D2"S]*JL;6?.Y[IK/l8[LT'=(2%SP'QFW2:!H/'TZ M<@(FD*U&_HQ@V (#[XX2%S0B*+:\R\\4EU38'"PN,.YAQ< "0OQIT56 ''] MB1W!
[;&XI53NU^(PYE:8N8H\!/:_]N[VM[$<2#_7Z%==))=!?R!B6D>[6OKO:\9Y(5!>DC9L:>L/E=HJL9WQ/&.//?., M/XHJ"U,8'=?7.R2G&Z$OBR,P[:CB)+2&
[/#;9E!5!L=\PFK;'N)/5(:;Z.0Y M!2]\?%RJ#F1;*['?M* >]3SL;'6UM1/G+X[PX6/MF);KPVE%36)DF'C,"XZ
MV:!]E7*!KG3>+GG)IN=9!/9LB=E\X=7RW[?;XN93]B1G<\L>V,&+T6!&1X,Y MSP-+.V$MZ@;F.5-,>0CJZ7A7PPOPA"[MNUGFD7$LO!KT3>2..03 M7JOQCH0'V^,%%0-
I)^6[2A9 MYF#EC(E?D5$R<*ODNO?UFGRQP1L?VT.?=+& !7*ZG]G>&!;+GD4!S:0;F!+O MXZ)S WLT7MX*S7;O6Y5TNQU>PV',*T)@\0ES4=-EE>=]*Q7LZLN[JW3@ZW&:
MG9[L?])"G6F!*9/@IX(,!LC>,F)8117=C25U7(DG>E,(M^=_F^[PK[7*BFN&TBH \I@85)54G-X/:^\L7P7>#'T'ZNMIL:,T\TB]26@1% MC64K^6(-B.Q9>"">Z\-
:O:$*4A6W"WZ(A9+!V^5^)"]NUJC03'$S_M>. M#12*=XD]0;T"GS:[=SASTD+6D*/+9" M6 O6+>:=WU2_1DK]'/IYRR6NL$4'A0:]9#2LFBTMHQ7">AW>?#VR7FV33DC7
M'5.GNKGLXXN9+B*LEK!:#2W7#NK)5DO#S9:P6@<\7T_<X)Z<6..%-C8LFK$HY5L4XN+V0L"G"IA34ZL5AKBI=
M7O6%62@JP$L>1DC^^W+3)9=3/^"%U4_=88@W.4+M#W36LFK?[UP(M7^.VM_2 MN3MU)P^PXPW8E%B](<6FU"!@T.?QBP..NVNP$')..A09YC$/V$8^@ O^@4J
M#GQ2LZ@X/3L7J"@9%:<82V@+4+RJ,.C=G D\E+Q([*+*MF+Ol+IF=0&+]42] A);A:=Q01:DAZ4J+S$;F-=O!J6G M 27GML-()/@^]J>U;<:@EAF]*^2*9\X_OXW/&U\M<
M(_!TH*:B5@9"%54YJMAW1X\S?ZH$8U.3?"G.P1%?DA"+@HH/&)L2=V)SU1ZP M(0U]E@UW)HT%$$Y*\GW9%D>G#OJ.!S_T">(QL M3,:S\48%&_'#H95YVF. RP
P"="#9R1RFQG O>TX\,)LYO @?=[WS'/OH$5" MH>W9 WX9G9)PZC$3AL?,]+]+WPLBP\'B34VN>%R+R/V/!]?D!'2'T"__'8SY#Y MP0:-* ;H9R7]D.2GE3O7N'0#(O@@-O%!M 0?
A."#>,=\$)F.8BQMR,;T[?$B M'3/Z8RD?LW_YSU7[]M^;L_Y>DBAWC'/_:!EKTM2SZWM$P/4SM#V^\/EKHBK7 M1516XQ?'MA]XV)2%6<28VL(7]YB(RXMR5J"; 2,@>]R\PA*'*]Z
6=0982 $ M-L1#)>(':&);.(67>'LI69BY@V&B=#&5N9G-SX)1<,M:T.-J1]WN)T<8/!GX MC"MP8!I8W5CCV(V\-S,B\8=0*K M"H[<4$IM2VDIBROBB2;VR?(I5=@KC47"WL4
W8^?XVN/:?6'-54O;EZ',6 M46?O1AM_)?2%>/B: 4TM^#]..HU,.]:GR9/7O& M#>VV^[>UA9.]\=3AX$X3C(+^(_P*.QJ%\W,38T,C8N M:'1M4$L! A0#% @ "8)G66&X#BOI!P NB\
T (! M" @ &5X7S%W,38T,CDN:'1M M4$L! A0#% @ "8)G65B*);R,'0 K' ! ! (!S!@ M &]P:RTR,#(T,#DS,"YX XML 94 opk20240930_10q_htm.xml IDEA: XBRL DOCUMENT
0000944809 2024-01-012024-09-30 0000944809 2024-11-01 0000944809 2024-09-30 0000944809 2023-12-31 0000944809 us-gaap:ServiceMember 2024-07-012024-09-30 0000944809 us-gaap:ServiceMember 2023-07-012023-09-30 0000944809 us-gaap:ServiceMember 2024-01-012024-09-30 0000944809 us-gaap:ServiceMember 2023-01-012023-09-30 0000944809 us-gaap:ProductMember 2024-07-012024-09-30 0000944809 us-gaap:ProductMember 2023-07-012023-09-30 0000944809 us-gaap:ProductMember 2024-01-012024-09-30 0000944809 us-gaap:ProductMember 2023-01-012023-09-30 0000944809 opk:TransferOfIntellectualPropertyAndOtherMember 2024-07-012024-09-30 0000944809 opk:TransferOfIntellectualPropertyAndOtherMember 2023-07-012023-09-30 0000944809 opk:TransferOfIntellectualPropertyAndOtherMember 2024-01-012024-09-30 0000944809 opk:TransferOfIntellectualPropertyAndOtherMember 2023-01-012023-09-30 0000944809 2024-07-012024-09-30 0000944809 2023-07-012023-09-30 0000944809 2023-01-012023-09-30 0000944809 us-gaap:CommonStockMember 2024-06-30 0000944809 us-gaap:TreasuryStockCommonMember 2024-06-30 0000944809 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000944809 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000944809 us-gaap:RetainedEarningsMember 2024-06-30 0000944809 2024-06-30 0000944809 us-gaap:CommonStockMember 2024-07-012024-09-30 0000944809 us-gaap:TreasuryStockCommonMember 2024-07-012024-09-30 0000944809 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000944809 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000944809 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000944809 us-gaap:CommonStockMember 2024-09-30 0000944809 us-gaap:TreasuryStockCommonMember 2024-09-30 0000944809 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000944809 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000944809 us-gaap:RetainedEarningsMember 2024-09-30 0000944809 us-gaap:CommonStockMember 2023-12-31 0000944809 us-gaap:TreasuryStockCommonMember 2023-12-31 0000944809 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000944809 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000944809 us-gaap:RetainedEarningsMember 2023-12-31 0000944809 us-gaap:CommonStockMember 2024-01-012024-09-30 0000944809 us-gaap:TreasuryStockCommonMember 2024-01-012024-09-30 0000944809 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0000944809 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0000944809 us-gaap:RetainedEarningsMember 2024-01-012024-09-30 0000944809 opk:The2025ConvertibleNotesMemberus-gaap:CommonStockMember 2024-01-012024-09-30 0000944809 opk:The2025ConvertibleNotesMemberus-gaap:TreasuryStockCommonMember 2024-01-012024-09-30 0000944809 opk:The2025ConvertibleNotesMemberus-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0000944809 opk:The2025ConvertibleNotesMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0000944809 opk:The2025ConvertibleNotesMemberus-gaap:RetainedEarningsMember 2024-01-012024-09-30 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:CommonStockMember 2024-01-012024-09-30 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:TreasuryStockCommonMember 2024-01-012024-09-30 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:RetainedEarningsMember 2024-01-012024-09-30 0000944809 opk:The2029ConvertibleNotes1Member 2024-01-012024-09-30 0000944809 us-gaap:CommonStockMember 2023-06-30 0000944809 us-gaap:TreasuryStockCommonMember 2023-06-30 0000944809 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000944809 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000944809 us-gaap:RetainedEarningsMember 2023-06-30 0000944809 2023-06-30 0000944809 us-gaap:CommonStockMember 2023-07-012023-09-30 0000944809 us-gaap:TreasuryStockCommonMember 2023-07-012023-09-30 0000944809 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0000944809 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0000944809 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0000944809 us-gaap:CommonStockMember 2023-09-30 0000944809 us-gaap:TreasuryStockCommonMember 2023-09-30 0000944809 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000944809 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000944809 us-gaap:RetainedEarningsMember 2023-09-30 0000944809 2023-09-30 0000944809 us-gaap:CommonStockMember 2022-12-31 0000944809 us-gaap:TreasuryStockCommonMember 2022-12-31 0000944809 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000944809 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000944809 us-gaap:RetainedEarningsMember 2022-12-31 0000944809 2022-12-31 0000944809 us-gaap:CommonStockMember 2023-01-012023-09-30 0000944809 us-gaap:TreasuryStockCommonMember 2023-01-012023-09-30 0000944809 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-09-30 0000944809 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-09-30 0000944809 us-gaap:RetainedEarningsMember 2023-01-012023-09-30 0000944809 opk:LabcorpMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberopk:SelectAssetsOfBioreferenceMember 2024-03-28 0000944809 opk:LabcorpMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberopk:SelectAssetsOfBioreferenceMember 2024-07-012024-09-30 0000944809 opk:LabcorpMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberopk:SelectAssetsOfBioreferenceMember 2024-01-012024-09-30 0000944809

srt:OtherCurrencyMemberus-gaap:SalesRevenueNetMemberopk:CurrencyConcentrationRiskMember 2024-01-012024-09-30 0000944809 srt:OtherCurrencyMemberus-gaap:SalesRevenueNetMemberopk:CurrencyConcentrationRiskMember 2023-01-012023-09-30 0000944809 us-gaap:ForeignExchangeForwardMember 2024-09-30 0000944809 us-gaap:ForeignExchangeForwardMember 2023-12-31 0000944809 us-gaap:InProcessResearchAndDevelopmentMember 2024-09-30 0000944809 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0000944809 country:IE 2024-09-30 0000944809 country:IE 2023-12-31 0000944809 srt:MinimumMember 2024-09-30 0000944809 srt:MaximumMember 2024-09-30 0000944809 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-09-30 0000944809 srt:MinimumMemberus-gaap:MachineryAndEquipmentMember 2024-09-30 0000944809 srt:MaximumMemberus-gaap:MachineryAndEquipmentMember 2024-09-30 0000944809 srt:MinimumMemberus-gaap:FurnitureAndFixturesMember 2024-09-30 0000944809 srt:MaximumMemberus-gaap:FurnitureAndFixturesMember 2024-09-30 0000944809 srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember 2024-09-30 0000944809 srt:MaximumMemberus-gaap:BuildingAndBuildingImprovementsMember 2024-09-30 0000944809 srt:MinimumMemberus-gaap:VehiclesMember 2024-09-30 0000944809 srt:MaximumMemberus-gaap:VehiclesMember 2024-09-30 0000944809 us-gaap:IsraelTaxAuthorityMember 2024-01-012024-09-30 0000944809 opk:MedicareAndMedicaidMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000944809 opk:MedicareAndMedicaidMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0000944809 opk:IndividualPatientsMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000944809 opk:IndividualPatientsMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0000944809 opk:GovernmentContractBardaMember 2024-09-30 0000944809 opk:GovernmentContractBardaMember 2023-12-31 0000944809 opk:RepurchaseOfCommonStockMember 2024-07-18 0000944809 opk:RepurchaseOfCommonStockMember 2024-07-012024-09-30 0000944809 opk:The2025NotesMember 2024-07-012024-09-30 0000944809 opk:The2025NotesMember 2023-07-012023-09-30 0000944809 opk:The2025NotesMember 2024-01-012024-09-30 0000944809 opk:The2025NotesMember 2023-01-012023-09-30 0000944809 opk:The2029ConvertibleNotesMember 2024-07-012024-09-30 0000944809 opk:The2029ConvertibleNotesMember 2023-07-012023-09-30 0000944809 opk:The2029ConvertibleNotesMember 2024-01-012024-09-30 0000944809 opk:The2029ConvertibleNotesMember 2023-01-012023-09-30 0000944809 opk:The2023ConvertibleNotesMember 2024-07-012024-09-30 0000944809 opk:The2023ConvertibleNotesMember 2023-07-012023-09-30 0000944809 opk:The2023ConvertibleNotesMember 2024-01-012024-09-30 0000944809 opk:The2023ConvertibleNotesMember 2023-01-012023-09-30 0000944809 opk:The2033SeniorNotesMember 2024-07-012024-09-30 0000944809 opk:The2033SeniorNotesMember 2023-07-012023-09-30 0000944809 opk:The2033SeniorNotesMember 2024-01-012024-09-30 0000944809 opk:The2033SeniorNotesMember 2023-01-012023-09-30 0000944809 us-gaap:CustomerRelationshipsMember 2024-09-30 0000944809 us-gaap:CustomerRelationshipsMember 2023-12-31 0000944809 us-gaap:TechnologyBasedIntangibleAssetsMember 2024-09-30 0000944809 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-12-31 0000944809 us-gaap:TradeNamesMember 2024-09-30 0000944809 us-gaap:TradeNamesMember 2023-12-31 0000944809 us-gaap:NoncompeteAgreementsMember 2024-09-30 0000944809 us-gaap:NoncompeteAgreementsMember 2023-12-31 0000944809 us-gaap:LicensingAgreementsMember 2024-09-30 0000944809 us-gaap:LicensingAgreementsMember 2023-12-31 0000944809 opk:ProjectRegistrationMember 2024-09-30 0000944809 opk:ProjectRegistrationMember 2023-12-31 0000944809 us-gaap:OtherIntangibleAssetsMember 2024-09-30 0000944809 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0000944809 srt:MinimumMemberus-gaap:DevelopedTechnologyRightsMember 2024-09-30 0000944809 srt:MaximumMemberus-gaap:DevelopedTechnologyRightsMember 2024-09-30 0000944809 srt:MinimumMemberus-gaap:CustomerRelationshipsMember 2024-09-30 0000944809 srt:MaximumMemberus-gaap:CustomerRelationshipsMember 2024-09-30 0000944809 srt:MinimumMemberopk:ProjectRegistrationMember 2024-09-30 0000944809 srt:MaximumMemberopk:ProjectRegistrationMember 2024-09-30 0000944809 srt:MinimumMemberus-gaap:TradeNamesMember 2024-09-30 0000944809 srt:MaximumMemberus-gaap:TradeNamesMember 2024-09-30 0000944809 srt:MinimumMemberus-gaap:OtherIntangibleAssetsMember 2024-09-30 0000944809 srt:MaximumMemberus-gaap:OtherIntangibleAssetsMember 2024-09-30 0000944809 opk:PharmaceuticalMemberopk:CurnaMember 2023-12-31 0000944809 opk:PharmaceuticalMemberopk:CurnaMember 2024-09-30 0000944809 opk:PharmaceuticalMemberopk:CurnaMember 2024-01-012024-09-30 0000944809 opk:PharmaceuticalMemberopk:RayaldeeMember 2023-12-31 0000944809 opk:PharmaceuticalMemberopk:RayaldeeMember 2024-09-30 0000944809 opk:PharmaceuticalMemberopk:RayaldeeMember 2024-01-012024-09-30 0000944809 opk:PharmaceuticalMemberopk:FinetechMember 2023-12-31 0000944809 opk:PharmaceuticalMemberopk:FinetechMember 2024-09-30 0000944809 opk:PharmaceuticalMemberopk:FinetechMember 2024-01-012024-09-30 0000944809 opk:PharmaceuticalMemberopk:ModexTherapeuticsIncMember 2023-12-31 0000944809 opk:PharmaceuticalMemberopk:ModexTherapeuticsIncMember 2024-09-30 0000944809 opk:PharmaceuticalMemberopk:ModexTherapeuticsIncMember 2024-01-012024-09-30 0000944809 opk:PharmaceuticalMemberopk:OpkoBiologicsMember 2023-12-31 0000944809 opk:PharmaceuticalMemberopk:OpkoBiologicsMember 2024-09-30 0000944809 opk:PharmaceuticalMemberopk:OpkoBiologicsMember 2024-01-012024-09-30 0000944809 opk:PharmaceuticalMemberopk:OpkoChileMember 2023-12-31 0000944809 opk:PharmaceuticalMemberopk:OpkoChileMember 2024-09-30 0000944809 opk:PharmaceuticalMemberopk:OpkoChileMember 2024-01-012024-09-30 0000944809 opk:PharmaceuticalMemberopk:OpkoHealthEuropeMember 2023-12-31 0000944809 opk:PharmaceuticalMemberopk:OpkoHealthEuropeMember 2024-09-30 0000944809 opk:PharmaceuticalMemberopk:OpkoHealthEuropeMember 2024-01-012024-09-30 0000944809 opk:PharmaceuticalMemberopk:OpkoMexicoMember 2023-12-31 0000944809 opk:PharmaceuticalMemberopk:OpkoMexicoMember 2024-09-30 0000944809 opk:PharmaceuticalMemberopk:OpkoMexicoMember 2024-01-012024-09-30 0000944809 opk:PharmaceuticalMemberopk:TransitionTherapeuticsMember 2023-12-31 0000944809 opk:PharmaceuticalMemberopk:TransitionTherapeuticsMember 2024-09-30 0000944809 opk:PharmaceuticalMemberopk:TransitionTherapeuticsMember 2024-01-012024-09-30 0000944809 opk:DiagnosticsMemberopk:BioreferenceMember 2023-12-31 0000944809 opk:DiagnosticsMemberopk:BioreferenceMember 2024-09-30 0000944809 opk:DiagnosticsMemberopk:BioreferenceMember 2024-01-012024-09-30 0000944809 opk:DiagnosticsMemberopk:OpkoDiagnosticsMember 2023-12-31 0000944809 opk:DiagnosticsMemberopk:OpkoDiagnosticsMember 2024-09-30 0000944809 opk:DiagnosticsMemberopk:OpkoDiagnosticsMember 2024-01-012024-09-30 0000944809 opk:PharmsynthezMember 2024-09-30 0000944809 opk:CocpMember 2024-09-30 0000944809 opk:NimsMember 2024-09-30 0000944809 opk:BiocardiaMember 2024-09-30 0000944809 opk:XeneticMember 2024-09-30 0000944809 opk:ZebraMember 2024-09-30 0000944809 opk:LeaderMedMember 2024-09-30 0000944809 opk:NeovascMember 2024-09-30 0000944809 opk:NeovascMember 2023-01-012023-12-31 0000944809 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-09-30 0000944809 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2024-01-012024-09-30 0000944809 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2023-12-31 0000944809 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2023-01-012023-12-31 0000944809 opk:GeneDxHoldingsMember 2024-07-012024-09-30 0000944809 opk:GeneDxHoldingsMember 2024-06-30 0000944809 opk:GeneDxHoldingsMember 2024-09-30 0000944809 opk:GeneDxHoldingsMember 2024-01-012024-09-30 0000944809 opk:GeneDxHoldingsMember 2023-07-012023-09-30 0000944809 opk:GeneDxHoldingsMember 2023-01-012023-09-30 0000944809 opk:VbiVaccinesIncMember 2024-09-30 0000944809 opk:ChromadexCorporationMember 2024-09-30 0000944809 opk:EloxxPharmaceuticalsIncMember 2024-09-30 0000944809 opk:VbiVaccinesIncMember 2024-07-012024-09-30 0000944809 opk:Camp4Member 2024-09-30 0000944809 opk:HealthsnapIncMember 2024-09-30 0000944809 opk:InCellDxMember 2023-12-31 0000944809 opk:LeaderMedMemberopk:LeaderMedJointVentureMember 2021-09-012021-09-30 0000944809 opk:LeaderMedMemberopk:LeaderMedJointVentureMember 2021-09-30 0000944809 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberopk:ZebraMemberopk:SeriesA2PreferredStockMember 2024-09-30 0000944809 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberopk:ZebraMemberopk:SeriesA2PreferredStockMember 2023-12-31 0000944809 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberopk:ZebraMemberus-gaap:RestrictedStockMember 2024-09-30 0000944809 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberopk:ZebraMemberus-gaap:RestrictedStockMember 2023-12-31 0000944809 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberopk:ZebraMember 2024-09-30 0000944809 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberopk:ZebraMember 2023-12-31 0000944809 opk:The2029ConvertibleNotesMember 2024-09-30 0000944809 opk:The2029ConvertibleNotesMember 2023-12-31 0000944809 opk:The2025ConvertibleNotesMember 2024-09-30 0000944809 opk:The2025ConvertibleNotesMember 2023-12-31 0000944809 opk:The2033SeniorNotesMember 2024-09-30 0000944809 opk:The2033SeniorNotesMember 2023-12-31 0000944809 opk:The2023ConvertibleNotesMember 2024-09-30 0000944809 opk:The2023ConvertibleNotesMember 2023-12-31 0000944809 opk:The2044NotesMember 2024-09-30 0000944809 opk:The2044NotesMember 2023-12-31 0000944809 opk:JPMorganChaseMember 2024-09-30 0000944809 opk:JPMorganChaseMember 2023-12-31 0000944809 opk:ChileanAndSpanishLinesOfCreditMember 2024-09-30 0000944809 opk:ChileanAndSpanishLinesOfCreditMember 2023-12-31 0000944809 opk:ConvertibleNotesMember 2024-09-30 0000944809 opk:ConvertibleNotesMember 2023-12-31 0000944809 opk:LineOfCreditAndNotesAndLoansPayableCurrentMember 2024-09-30 0000944809 opk:LineOfCreditAndNotesAndLoansPayableCurrentMember 2023-12-31 0000944809 us-gaap:OtherNoncurrentLiabilitiesMember 2024-09-30 0000944809 us-gaap:OtherNoncurrentLiabilitiesMember 2023-12-31 0000944809 opk:The2044NotesMember 2024-07-17 0000944809 srt:MinimumMemberopk:The2044NotesMember 2024-07-172024-07-17 0000944809 opk:The2044NotesMember 2024-07-172024-07-17 0000944809 srt:ScenarioForecastMemberopk:The2044NotesMember 2029-07-17 0000944809 opk:The2029ConvertibleNotes1Member 2024-01-09 0000944809 opk:The2029ConvertibleNotes1Member 2024-01-092024-01-09 0000944809 2024-01-092024-01-09 0000944809 opk:The2029ConvertibleAffiliateNotesMember 2024-01-09 0000944809 opk:The2023ConvertibleNotesMember 2024-01-09 0000944809 opk:The2029ConvertibleNotes1Member 2024-01-092024-03-28 0000944809 opk:The2029ConvertibleNotes1Member 2024-04-012024-04-01 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:DebtInstrumentRedemptionPeriodOneMember 2024-01-092024-01-09 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:DebtInstrumentRedemptionPeriodTwoMember 2024-01-092024-01-09 0000944809 opk:ScenarioEventofDefaultMemberopk:The2029ConvertibleNotes1Member 2024-01-092024-01-09 0000944809 opk:The2029Convertible144ANotesMember 2023-12-31 0000944809 opk:The2029Convertible144ANotesMember 2024-09-30 0000944809 opk:The2029Convertible144ANotesMember 2024-01-012024-09-30 0000944809 opk:The2029ConvertibleNotes1Member 2024-09-30 0000944809 opk:The2029ConvertibleNotes1Member 2024-07-012024-09-30 0000944809 opk:ScenarioEventofDefaultMemberopk:The2025NotesMemberus-gaap:ConvertibleDebtMember 2019-02-28 0000944809 opk:ConversionOfThe2025NotesIntoCommonStockMember 2021-05-012021-05-31 0000944809 opk:The2025NotesMemberus-gaap:ConvertibleDebtMember 2024-01-09 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:ConvertibleDebtMember 2024-01-092024-01-09 0000944809 opk:The2025NotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:ConvertibleDebtMember 2019-02-012019-02-01 0000944809 opk:The2023ConvertibleNotesMemberus-gaap:ConvertibleDebtMember 2018-02-28 0000944809 opk:The2023ConvertibleNotesMemberus-gaap:ConvertibleDebtMember 2018-02-012018-02-28 0000944809 opk:The2023ConvertibleNotesMemberus-gaap:ConvertibleDebtMember 2023-02-102023-02-10 0000944809 opk:The2029ConvertibleAffiliateNotesMemberus-gaap:ConvertibleDebtMember 2024-01-09 0000944809 opk:The2033SeniorNotesMemberus-gaap:SeniorNotesMember 2023-01-31 0000944809 opk:The2033SeniorNotesMemberus-gaap:SeniorNotesMember 2013-01-31 0000944809 opk:The2033SeniorNotesMemberus-gaap:ConvertibleDebtMember 2013-02-012016-12-31 0000944809 opk:The2033SeniorNotesMemberus-gaap:ConvertibleDebtMember 2019-02-01 0000944809 opk:The2033SeniorNotesMemberus-gaap:ConvertibleDebtMember 2024-01-012024-03-31 0000944809 opk:The2033SeniorNotesMemberus-gaap:ConvertibleDebtMember 2024-03-31 0000944809 us-gaap:RevolvingCreditFacilityMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember 2015-11-30 0000944809 us-gaap:BridgeLoanMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember 2015-11-30 0000944809 us-gaap:LetterOfCreditMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember 2015-11-30 0000944809 us-gaap:RevolvingCreditFacilityMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember 2024-09-162024-09-16 0000944809 us-gaap:RevolvingCreditFacilityMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember 2023-12-31 0000944809 opk:JPMorganChaseMember 2024-09-30 0000944809 opk:JPMorganChaseMember 2023-12-31 0000944809 opk:ItauBankMember 2024-09-30 0000944809 opk:ItauBankMember 2023-12-31 0000944809 opk:BankOfChileMember 2024-09-30 0000944809 opk:BankOfChileMember 2023-12-31 0000944809 opk:BiceBankMember 2024-09-30 0000944809 opk:BiceBankMember 2023-12-31 0000944809 opk:ScotiabankMember 2024-09-30 0000944809 opk:ScotiabankMember 2023-12-31 0000944809 opk:SantanderBankMember 2024-09-30 0000944809 opk:SantanderBankMember 2023-12-31 0000944809 opk:SecurityBankMember 2024-09-30 0000944809 opk:SecurityBankMember 2023-12-31 0000944809 opk:EstadoBankMember 2024-09-30 0000944809 opk:EstadoBankMember 2023-12-31 0000944809 opk:BciBankMember 2024-09-30 0000944809 opk:BciBankMember 2023-12-31 0000944809 opk:InternacionalBankMember 2024-09-30 0000944809 opk:InternacionalBankMember 2023-12-31 0000944809 opk:ConsorcioBankMember 2024-09-30 0000944809 opk:ConsorcioBankMember 2023-12-31 0000944809 opk:BancoDeSabadellMember 2024-09-30 0000944809 opk:BancoDeSabadellMember 2023-12-31 0000944809 opk:SantanderBank2Member 2024-09-30 0000944809 opk:SantanderBank2Member 2023-12-31 0000944809 us-gaap:LineOfCreditMember 2024-09-30 0000944809 us-gaap:LineOfCreditMember 2023-12-31 0000944809 opk:NotesPayableAndOtherLongTermLiabilitiesMember 2024-09-30 0000944809 opk:NotesPayableAndOtherLongTermLiabilitiesMember 2023-12-31 0000944809 opk:NotesAndOtherDebtMember 2024-09-30 0000944809 opk:NotesAndOtherDebtMember 2023-12-31 0000944809 us-gaap:AccumulatedTranslationAdjustmentMember

2023-12-31 0000944809 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-012024-09-30 0000944809 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0000944809 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000944809 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000944809 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000944809 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000944809 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000944809 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000944809 us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000944809 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ConvertibleDebtMember 2024-09-30 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember 2024-09-30 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember 2024-09-30 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember 2024-09-30 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember 2024-09-30 0000944809 opk:The2025ConvertibleNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ConvertibleDebtMember 2024-09-30 0000944809 opk:The2025ConvertibleNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember 2024-09-30 0000944809 opk:The2025ConvertibleNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember 2024-09-30 0000944809 opk:The2025ConvertibleNotesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember 2024-09-30 0000944809 opk:The2025ConvertibleNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember 2024-09-30 0000944809 us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2023-12-31 0000944809 us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2024-01-012024-09-30 0000944809 us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2024-09-30 0000944809 opk:InvestmentNetMemberopk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember 2024-09-30 0000944809 opk:InvestmentNetMemberopk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember 2023-12-31 0000944809 opk:AccruedExpensesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember 2024-09-30 0000944809 opk:AccruedExpensesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember 2023-12-31 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NondesignatedMember 2024-07-012024-09-30 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NondesignatedMember 2023-07-012023-09-30 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NondesignatedMember 2024-01-012024-09-30 0000944809 opk:The2029ConvertibleNotes1Memberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NondesignatedMember 2023-01-012023-09-30 0000944809 opk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember 2024-07-012024-09-30 0000944809 opk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember 2023-07-012023-09-30 0000944809 opk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember 2024-01-012024-09-30 0000944809 opk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember 2023-01-012023-09-30 0000944809 us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember 2024-07-012024-09-30 0000944809 us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember 2023-07-012023-09-30 0000944809 us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember 2024-01-012024-09-30 0000944809 us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember 2023-01-012023-09-30 0000944809 us-gaap:NondesignatedMember 2024-07-012024-09-30 0000944809 us-gaap:NondesignatedMember 2023-07-012023-09-30 0000944809 us-gaap:NondesignatedMember 2024-01-012024-09-30 0000944809 us-gaap:NondesignatedMember 2023-01-012023-09-30 0000944809 opk:FrostRealEstateHoldingsLlcMember 2024-07-31 0000944809 opk:FrostRealEstateHoldingsLlcMember 2024-08-01 0000944809 opk:The2023ConvertibleNotesMemberus-gaap:ConvertibleDebtMember 2024-01-09 0000944809 opk:RuenhuiBiopharmaceuticalsIncMember 2023-05-04 0000944809 opk:RuenhuiBiopharmaceuticalsIncMemberopk:LicenseAgreementMember 2023-05-042023-05-04 0000944809 opk:RuenhuiBiopharmaceuticalsIncMemberopk:LicenseAgreementMember 2023-05-04 0000944809 opk:TransitionServicesAgreementMemberopk:GeneDxMember 2024-01-012024-03-31 0000944809 opk:ServicesRenderedMemberopk:TransitionServicesAgreementMemberopk:GeneDxMember 2024-07-012024-09-30 0000944809 opk:ServicesRenderedMemberopk:TransitionServicesAgreementMemberopk:GeneDxMember 2024-01-012024-09-30 0000944809 opk:TransitionServicesAgreementMemberopk:GeneDxMember 2024-09-30 0000944809 opk:PharmsynthezMembersrt:DirectorMember 2024-09-30 0000944809 opk:XeneticMembersrt:DirectorMember 2024-09-30 0000944809 opk:NeovascMember 2023-10-012023-12-31 0000944809 opk:BeckmanCoulterMember 2024-01-012024-09-30 0000944809 opk:IntegratedDNATechnologiesIncMember 2024-01-012024-09-30 0000944809 opk:LeicaMicrosystemsIncMember 2024-01-012024-09-30 0000944809 opk:ReimbursementOfTravelExpensesMembersrt:ExecutiveOfficerMember 2024-07-012024-09-30 0000944809 opk:ReimbursementOfTravelExpensesMembersrt:ExecutiveOfficerMember 2024-01-012024-09-30 0000944809 opk:ReimbursementOfTravelExpensesMembersrt:ExecutiveOfficerMember 2023-07-012023-09-30 0000944809 opk:ReimbursementOfTravelExpensesMembersrt:ExecutiveOfficerMember 2023-01-012023-09-30 0000944809 us-gaap:ForeignCountryMemberus-gaap:IsraelTaxAuthorityMemberopk:TaxYear2014ThroughTaxYear2020Member 2022-12-292022-12-29 0000944809 us-gaap:SettledLitigationMember 2022-07-142022-07-14 0000944809 us-gaap:SettledLitigationMember 2022-07-14 0000944809 country:USus-gaap:SettledLitigationMember 2022-07-142022-07-14 0000944809 opk:CommonwealthMemberus-gaap:SettledLitigationMember 2022-07-142022-07-14 0000944809 stpr:CTus-gaap:SettledLitigationMember 2022-07-142022-07-14 0000944809 us-gaap:ServiceMemberopk:HealthcareInsurersMember 2024-07-012024-09-30 0000944809 us-gaap:ServiceMemberopk:HealthcareInsurersMember 2023-07-012023-09-30 0000944809 us-gaap:ServiceMemberopk:HealthcareInsurersMember 2024-01-012024-09-30 0000944809 us-gaap:ServiceMemberopk:HealthcareInsurersMember 2023-01-012023-09-30 0000944809 us-gaap:ServiceMemberopk:GovernmentPayersMember 2024-07-012024-09-30 0000944809 us-gaap:ServiceMemberopk:GovernmentPayersMember 2023-07-012023-09-30 0000944809 us-gaap:ServiceMemberopk:GovernmentPayersMember 2024-01-012024-09-30 0000944809 us-gaap:ServiceMemberopk:GovernmentPayersMember 2023-01-012023-09-30 0000944809 us-gaap:ServiceMemberopk:ClientPayersMember 2024-07-012024-09-30 0000944809 us-gaap:ServiceMemberopk:ClientPayersMember 2023-07-012023-09-30 0000944809 us-gaap:ServiceMemberopk:ClientPayersMember 2024-01-012024-09-30 0000944809 us-gaap:ServiceMemberopk:ClientPayersMember 2023-01-012023-09-30 0000944809 us-gaap:ServiceMemberus-gaap:SelfPayMember 2024-07-012024-09-30 0000944809 us-gaap:ServiceMemberus-gaap:SelfPayMember 2023-07-012023-09-30 0000944809 us-gaap:ServiceMemberus-gaap:SelfPayMember 2024-01-012024-09-30 0000944809 us-gaap:ServiceMemberus-gaap:SelfPayMember 2023-01-012023-09-30 0000944809 opk:RayaldeeMember 2024-07-012024-09-30 0000944809 opk:RayaldeeMember 2024-01-012024-09-30 0000944809 opk:RayaldeeMember 2023-07-012023-09-30 0000944809 opk:RayaldeeMember 2023-01-012023-09-30 0000944809 opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember 2024-06-30 0000944809 opk:RayaldeeMemberopk:GovernmentalMember 2024-06-30 0000944809 opk:RayaldeeMemberopk:SalesReturnsMember 2024-06-30 0000944809 opk:RayaldeeMember 2024-06-30 0000944809 opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember 2024-07-012024-09-30 0000944809 opk:RayaldeeMemberopk:GovernmentalMember 2024-07-012024-09-30 0000944809 opk:RayaldeeMemberopk:SalesReturnsMember 2024-07-012024-09-30 0000944809 opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember 2024-09-30 0000944809 opk:RayaldeeMemberopk:GovernmentalMember 2024-09-30 0000944809 opk:RayaldeeMemberopk:SalesReturnsMember 2024-09-30 0000944809 opk:RayaldeeMember 2024-09-30 0000944809 opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember 2023-12-31 0000944809 opk:RayaldeeMemberopk:GovernmentalMember 2023-12-31 0000944809 opk:RayaldeeMemberopk:SalesReturnsMember 2023-12-31 0000944809 opk:RayaldeeMember 2023-12-31 0000944809 opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember 2024-01-012024-09-30 0000944809 opk:RayaldeeMemberopk:GovernmentalMember 2024-01-012024-09-30 0000944809 opk:RayaldeeMemberopk:SalesReturnsMember 2024-01-012024-09-30 0000944809 opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember 2023-06-30 0000944809 opk:RayaldeeMemberopk:GovernmentalMember 2023-06-30 0000944809 opk:RayaldeeMemberopk:SalesReturnsMember 2023-06-30 0000944809 opk:RayaldeeMember 2023-06-30 0000944809 opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember 2023-07-012023-09-30 0000944809 opk:RayaldeeMemberopk:GovernmentalMember 2023-07-012023-09-30 0000944809 opk:RayaldeeMemberopk:SalesReturnsMember 2023-07-012023-09-30 0000944809 opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember 2023-09-30 0000944809 opk:RayaldeeMemberopk:GovernmentalMember 2023-09-30 0000944809 opk:RayaldeeMemberopk:SalesReturnsMember 2023-09-30 0000944809 opk:RayaldeeMember 2023-09-30 0000944809 opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember 2022-12-31 0000944809 opk:RayaldeeMemberopk:GovernmentalMember 2022-12-31 0000944809 opk:RayaldeeMemberopk:SalesReturnsMember 2022-12-31 0000944809 opk:RayaldeeMember 2022-12-31 0000944809 opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember 2023-01-012023-09-30 0000944809 opk:RayaldeeMemberopk:GovernmentalMember 2023-01-012023-09-30 0000944809 opk:RayaldeeMemberopk:SalesReturnsMember 2023-01-012023-09-30 0000944809 opk:BardaAgreementMember 2024-07-012024-09-30 0000944809 opk:PfizerIncMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:MilestonePaymentsMember 2024-07-012024-09-30 0000944809 opk:PfizerIncMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:MilestonePaymentsMember 2023-07-012023-09-30 0000944809 opk:MerckSharpDohmeLLCMemberopk:MerckAgreementMember 2023-09-282023-09-28 0000944809 opk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DevelopmentAndLicenseAgreementMember 2023-01-012023-12-31 0000944809 opk:NicoyaMacauLimitedMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DevelopmentAndLicenseAgreementMember 2023-01-012023-12-31 0000944809 opk:PfizerIncMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:MilestonePaymentsMember 2024-01-012024-09-30 0000944809 opk:PfizerIncMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:MilestonePaymentsMember 2023-01-012023-09-30 0000944809 opk:BardaAgreementMember 2024-01-012024-09-30 0000944809 opk:BardaAgreementMember 2024-09-30 0000944809 opk:BardaAgreementMember 2024-09-012024-09-30 0000944809 opk:BardaAgreementMember 2024-06-30 0000944809 opk:MerckSharpDohmeLLCMemberopk:MerckAgreementMember 2023-03-082023-03-08 0000944809 opk:MerckSharpDohmeLLCMemberopk:MerckAgreementMember 2023-03-08 0000944809 opk:MerckSharpDohmeLLCMemberopk:MerckAgreementMember 2023-12-31 0000944809 opk:MerckSharpDohmeLLCMemberopk:MerckAgreementMember 2023-03-092024-09-30 0000944809 opk:LeaderMedJointVentureMemberus-gaap:CorporateJointVentureMember 2021-09-14 0000944809 opk:LeaderMedJointVentureMemberus-gaap:CorporateJointVentureMember 2021-09-142021-09-14 0000944809 opk:LeaderMedJointVentureMemberus-gaap:CorporateJointVentureMemberopk:LeaderMedMember 2021-09-142021-09-14 0000944809 opk:LeaderMedJointVentureMemberus-gaap:CorporateJointVentureMemberopk:LeaderMedMember 2021-09-14 0000944809 opk:Camp4Member 2021-07-062021-07-06 0000944809 opk:Camp4Member 2021-07-06 0000944809 opk:Camp4Memberopk:DravetSyndromeProductsMember 2021-07-06 0000944809 opk:Camp4Memberopk:NondravetSyndromeProductsMember 2021-07-06 0000944809 opk:Camp4Memberopk:DravetSyndromeProductsMember 2021-07-062021-07-06 0000944809 opk:Camp4Memberopk:NondravetSyndromeProductsMember 2021-07-062021-07-06 0000944809 opk:EirgenMemberopk:NicoyaMacauLimitedMemberopk:DevelopmentAndLicenseAgreementMember 2021-06-182021-06-18 0000944809 opk:EirgenMemberopk:NicoyaMacauLimitedMemberopk:DevelopmentAndLicenseAgreementMember 2021-06-18 0000944809 opk:EirgenMemberopk:NicoyaMacauLimitedMemberopk:DevelopmentAndLicenseAgreementMember 2023-03-31 0000944809 opk:EirgenMemberopk:NicoyaMacauLimitedMemberopk:DevelopmentAndLicenseAgreementMember 2023-01-012023-03-31 0000944809 opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:DevelopmentAndLicenseAgreementMember 2023-01-012023-12-31 0000944809 opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:TransferOfIntellectualPropertyAndOtherMember 2022-01-012022-12-31 0000944809 opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:FirstMarketingApprovalOfRayaldeeInEuropeMemberopk:DevelopmentAndLicenseAgreemen 2020-05-052020-05-05 0000944809 opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:GermanyPriceApprovalByLocalSickFundAssociationMemberopk:DevelopmentAndLicenseAgr 2020-05-052020-05-05 0000944809 opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:DevelopmentAndLicenseAgreementMember 2020-05-05 0000944809 opk:PfizerIncMemberopk:PfizerAgreementMember 2023-01-012023-12-31 0000944809 opk:PfizerIncMemberopk:PfizerAgreementMember 2022-01-012022-12-31 0000944809 opk:PfizerIncMemberopk:PfizerAgreementMember 2019-10-01 0000944809 opk:PfizerIncMemberopk:PfizerAgreementMember 2024-09-30 0000944809 opk:PfizerIncMemberopk:PfizerAgreementMember 2023-12-31 0000944809 opk:PfizerIncMembersrt:MinimumMemberopk:PfizerAgreementMember 2019-10-01 0000944809 opk:PfizerIncMembersrt:MaximumMemberopk:PfizerAgreementMember 2019-10-01 0000944809 opk:PfizerIncMemberopk:PfizerAgreementMember

2023-07-012024-09-30 0000944809 us-gaap:IntersegmentEliminationMember 2024-01-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:PharmaceuticalMember 2024-07-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:PharmaceuticalMember 2023-07-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:PharmaceuticalMember 2024-01-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:PharmaceuticalMember 2023-01-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:DiagnosticsMember 2024-07-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:DiagnosticsMember 2023-07-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:DiagnosticsMember 2024-01-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:DiagnosticsMember 2023-01-012023-09-30 0000944809 us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember 2024-07-012024-09-30 0000944809 us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember 2023-07-012023-09-30 0000944809 us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember 2024-01-012024-09-30 0000944809 us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember 2023-01-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:PharmaceuticalMember 2024-07-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:PharmaceuticalMember 2023-07-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:PharmaceuticalMember 2024-01-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:PharmaceuticalMember 2023-01-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:DiagnosticsMember 2024-07-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:DiagnosticsMember 2023-07-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:DiagnosticsMember 2024-01-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:DiagnosticsMember 2023-01-012023-09-30 0000944809 us-gaap:CorporateNonSegmentMemberus-gaap:ProductMember 2024-07-012024-09-30 0000944809 us-gaap:CorporateNonSegmentMemberus-gaap:ProductMember 2023-07-012023-09-30 0000944809 us-gaap:CorporateNonSegmentMemberus-gaap:ProductMember 2024-01-012024-09-30 0000944809 us-gaap:CorporateNonSegmentMemberus-gaap:ProductMember 2023-01-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:PharmaceuticalMember 2024-07-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:PharmaceuticalMember 2023-07-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:PharmaceuticalMember 2024-01-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:PharmaceuticalMember 2023-01-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DiagnosticsMember 2024-07-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DiagnosticsMember 2023-07-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DiagnosticsMember 2024-01-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DiagnosticsMember 2023-01-012023-09-30 0000944809 us-gaap:CorporateNonSegmentMemberopk:TransferOfIntellectualPropertyAndOtherMember 2024-07-012024-09-30 0000944809 us-gaap:CorporateNonSegmentMemberopk:TransferOfIntellectualPropertyAndOtherMember 2023-07-012023-09-30 0000944809 us-gaap:CorporateNonSegmentMemberopk:TransferOfIntellectualPropertyAndOtherMember 2024-01-012024-09-30 0000944809 us-gaap:CorporateNonSegmentMemberopk:TransferOfIntellectualPropertyAndOtherMember 2023-01-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember 2024-07-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember 2023-07-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember 2024-01-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember 2023-01-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember 2024-07-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember 2023-07-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember 2024-01-012024-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember 2023-01-012023-09-30 0000944809 us-gaap:CorporateNonSegmentMember 2024-07-012024-09-30 0000944809 us-gaap:CorporateNonSegmentMember 2023-07-012023-09-30 0000944809 us-gaap:CorporateNonSegmentMember 2024-01-012024-09-30 0000944809 us-gaap:CorporateNonSegmentMember 2023-01-012023-09-30 0000944809 country:US 2024-07-012024-09-30 0000944809 country:US 2023-07-012023-09-30 0000944809 country:US 2024-01-012024-09-30 0000944809 country:US 2023-01-012023-09-30 0000944809 country:IE 2024-07-012024-09-30 0000944809 country:IE 2023-07-012023-09-30 0000944809 country:IE 2024-01-012024-09-30 0000944809 country:IE 2023-01-012023-09-30 0000944809 country:CL 2024-07-012024-09-30 0000944809 country:CL 2023-07-012023-09-30 0000944809 country:CL 2024-01-012024-09-30 0000944809 country:CL 2023-01-012023-09-30 0000944809 country:ES 2024-07-012024-09-30 0000944809 country:ES 2023-07-012023-09-30 0000944809 country:ES 2024-01-012024-09-30 0000944809 country:ES 2023-01-012023-09-30 0000944809 country:IL 2024-07-012024-09-30 0000944809 country:IL 2023-07-012023-09-30 0000944809 country:IL 2024-01-012024-09-30 0000944809 country:IL 2023-01-012023-09-30 0000944809 country:MX 2024-07-012024-09-30 0000944809 country:MX 2023-07-012023-09-30 0000944809 country:MX 2024-01-012024-09-30 0000944809 country:MX 2023-01-012023-09-30 0000944809 opk:OtherCountriesMember 2024-07-012024-09-30 0000944809 opk:OtherCountriesMember 2023-07-012023-09-30 0000944809 opk:OtherCountriesMember 2024-01-012024-09-30 0000944809 opk:OtherCountriesMember 2023-01-012023-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember 2024-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember 2023-12-31 0000944809 us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember 2024-09-30 0000944809 us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember 2023-12-31 0000944809 us-gaap:CorporateNonSegmentMember 2024-09-30 0000944809 us-gaap:CorporateNonSegmentMember 2023-12-31 0000944809 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000944809 us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-09-30 0000944809 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000944809 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0000944809 opk:OfficeSpaceMemberopk:ModexTherapeuticsIncMember 2023-01-02 0000944809 opk:OfficeSpaceMemberopk:ModexTherapeuticsIncMember 2023-01-022023-01-02 shares thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y utr:acre utr:sqft0000944809OPKO HEALTH, INC.false--12-31Q320240.010.01125000000012500000007122832067819368852980017786550821215000008364000001950000002015 2016 2017 2018 2019 2020 2021200000027000001260000900000.290.0375P5Y0000200P5Yfalsefalsefalsefalse10-Qtrue2024-09-30false001-33528DE75-24024094400 Biscayne Blvd.MiamiFL33137305575-4100Common Stock, par value $0.01 per shareOPKNASDAQYesYesLarge Accelerated Filerfalsefalsefalse68248302940640000095881000106579000123379000594080006569700057249000245190006296360003094760007227100075429000641396000740283961400038030000-2079037000-2011786000140341700013892190002256103000201169800012127100013167900037755700039110000039143000406700001176750001245530001321800062460003427711250000-1023000204330002153400062290000645430001214930000121493000-0159416000243002000648430000769566000142160000-64407000-118926000-879750002928000970000413200030770001735900033840003322500010053000-100088000-26161000-82900048636000-116450001288340000-16045000342040000-13971000735800000-2385000048420000-78378000-45346000-111825000235270006075000218980001045600024893000-84453000-67244000-122281000-3000-20000-7000-9900024890000-84473000-67251000-1223800000.04-0.11-0.1-0.160.03-0.11-0.1-0.166946224667515250076996759447517166929983636367515250076996759447517166922489000-84473000-67251000-1223800007038000-9554000-1585000-317300031928000-94027000-68836000-125553000727176232727300O-29799907-17910003540414000-46652000-210392700013953170000027840000027840000-0-02853000-0-02853000148930261490002361000-0-02375900000002489000024890000007038000070328000712283206712400O-29799907-17910003516735000-39614000-207903700014034170007819368857820000-8655082-17910003433006000-38030000-201178600013892190000079830000079830003843784000000-21200000-20800000-211448250000000001518700000151870000-0-02853000-0-028530007003805770000073059000-0-0737590000000-67251000-67251000000-15840000-158400071228326712400O-29799907-17910003516735000-39614000-207903700014034170007816931357817000-8655082-17910003427094000-36942000-186083000015353480000032180000032180001875000028000002800000000-84473000-84473000000-95530000-955300078171188578170000-8655082-17910003430340000-46495000-194530300014445680007813061647813000-8655082-17910003421872000-43323000-182292300015616480000087450000087450004057214000000-27700000-27300000000-122380000-122380000000-31720000-3172000781711885781700O-8655082-17910003430340000-46495000-19453030001444568000-67251000-122380000074137000793150001275300020570001328000908000-7000-990007983000874600094890O0-144400094626000-14406000-725000-00-10230007695000730700012149300O-0-15680000-8741000-6452000-40820008395000-10220000-5640002666000-6527000191000-3575000240004495200O-1374000-139080000100970000-0500000046731000364000145400O-0169000110900019597000132530002103780000236227000-167800002300000000250000000013385000-073759000-0-208000-2730004881000-044845900051531800046530100051959700014628700030000002246380O0-75520002399000-335000324184000-145700009588100015319100042006500013862100012982000107480003801000-8230000713000059660002080003010000668900O0 NOTE 1 BUSINESS AND ORGANIZATION   OPKO Health, Inc., a Delaware corporation (“OPKO”, the “Company”, “we”, “us”, or “our”) is a diversified healthcare company that seeks to establish industry leading positions in large and rapidly growing medical markets. Our pharmaceutical business features Rayaldee, a U.S. Food and Drug Administration (“FDA”) approved treatment for secondary hyperparathyroidism (“SHPT”) in adults with stage 3 or 4 chronic kidney disease (“CKD”) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. We have partnered with Pfizer Inc. (“Pfizer”) for the development and commercialization of Somatrogon (hGH-CTP). Regulatory approvals for Somatrogon (hGH-CTP) for the treatment of growth hormone deficiency in children and adolescents have been secured in more than 50 markets, including the United States, European Union (“EU”) Member States, Japan, Canada, and Australia, where it is marketed under the brand name NGENLA®. Through our 2022 acquisition of ModeX Therapeutics, Inc. (“ModeX”), we have expanded our pharmaceutical pipeline with early-stage immune therapies targeting cancer and infectious diseases.   Our diagnostics business, BioReference Health, LLC (“BioReference”), is a highly specialized laboratory in the United States, with a sales and marketing team focused on growth and new product integration, including the 4Kscore® prostate cancer test. BioReference® offers a broad spectrum of diagnostic testing services for oncology, urology (4Kscore), and corrections nationwide, setting new standards with our industry-leading turnaround times. BioReference also provides comprehensive clinical and women’s health testing in New York and New Jersey. Our test offerings are backed by a team of board-certified medical professionals and driven by the latest healthcare guidelines and standards- marketed directly to physicians, geneticists, hospitals, clinics, correctional facilities, and other healthcare providers. On September 16, 2024 we consummated the sale of certain assets of BioReference to Laboratory Corporation of America Holdings ("Labcorp"), as described below.   The Company maintains established, revenue-generating pharmaceutical platforms in Spain, Ireland, Chile, and Mexico, contributing to positive cash flow and facilitating market entry for our development pipeline. In addition to these platforms, we operate a global pharmaceutical development and commercial supply company, a global supply chain operation, and manufacture specialty active pharmaceutical ingredients (API) in Israel through our subsidiary, FineTech.   Our management team possesses extensive industry experience in development, regulatory affairs, and commercialization. Their industry relationships support the identification and pursuit of commercial opportunities. Research and development activities are primarily conducted in facilities located in Weston, Massachusetts, Waterford, Ireland, Kiryat Gat, Israel, and Barcelona, Spain.   On March 27, 2024, the Company and BioReference entered into a definitive agreement with Labcorp (the “Labcorp Asset Purchase Agreement”), pursuant to which Labcorp acquired select assets of BioReference (the “BioReference Transaction”). The BioReference Transaction closed on September 16, 2024, and upon closing, Labcorp paid to the Company aggregate consideration of $237.5 million in cash, which is subject to certain adjustments as set forth in the Labcorp Asset Purchase Agreement. These assets were part of our diagnostics segment and include BioReference's laboratory testing businesses focused on clinical diagnostics, reproductive health, and women's health across the United States, excluding BioReference's New York and New Jersey operations.   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;

margin: 0pt; text-indent: 27pt;">Pursuant to the Labcorp Asset Purchase Agreement, a total of approximately $23.7 million was withheld at closing and deposited by Labcorp into an escrow account with an escrow account to satisfy potential indemnity claims. The escrow will be released to the Company on the twelve-month anniversary of the closing date, subject to any outstanding or liquidated indemnity claims. The Company recorded the escrow within other current assets on the Condensed Consolidated Balance Sheet.   We recognized a gain of $121.5 million from the BioReference Transaction for the three and nine months ended September 30, 2024.   23750000023700000121500000 NOTE 2 FOREIGN EXCHANGE RATES   Foreign Currency Exchange Rates   Approximately 22.3% of our revenue for the nine months ended September 30, 2024, was denominated in currencies other than the U.S. Dollar (USD). This compares to 30.7% for the same period in 2023. Our financial statements are reported in USD; therefore, fluctuations in exchange rates affect the translation of foreign-denominated revenue and expenses. During the nine months ended September 30, 2024 and the year ended December 31, 2023, our most significant currency exchange rate exposures were to the Euro and the Chilean Peso. Gross accumulated currency translation adjustments, recorded as a separate component of shareholders' equity, totaled $36.2 million and $34.6 million at September 30, 2024 and December 31, 2023, respectively.   We are subject to foreign currency transaction risk due to fluctuations in exchange rates between the time a transaction is initiated and settled. To mitigate this risk, we use foreign currency forward contracts. These contracts fix an exchange rate, allowing us to offset potential losses (or gains) caused by exchange rate changes at the settlement date. As of September 30, 2024, we held no open foreign exchange forward contracts related to inventory purchases on letters of credit. As of December 31, 2023, we held 52 open foreign exchange forward contracts related to inventory purchases on letters of credit. These contracts matured monthly through January 2024 with a total notional value of approximately $2.9 million.</p> 0.2230.307362000003460000000522900000 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> NOTE <em style="font: inherit;">3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i></i></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i>Basis of presentation</i>. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP") and with the instructions to Form <em style="font: inherit;">10-Q and Article <em style="font: inherit;">10 of Regulation S-<em style="font: inherit;">X. Accordingly, they do <em style="font: inherit;">not include all information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Company's results of operations, financial position and cash flows have been made. The results of operations and cash flows for the <em style="font: inherit;">nine months ended <em style="font: inherit;"> September 30, 2024 are <em style="font: inherit;">not necessarily indicative of the results of operations and cash flows that <em style="font: inherit;"> may be reported for the remainder of <em style="font: inherit;">2024 or any other future periods. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form <em style="font: inherit;">10-K for the year ended <em style="font: inherit;"> December 31, 2023.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i></i></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i>Principles of consolidation</i>. The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and our wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i></i></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i>Use of estimates</i>. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i></i></p><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i>Cash, cash equivalents and restricted cash</i>. Cash, cash equivalents and restricted cash include short-term, interest-bearing instruments with original maturities of <em style="font: inherit;">90 days or less at the date of purchase. We also consider all highly liquid investments with original maturities at the date of purchase of <em style="font: inherit;">90 days or less as cash equivalents. These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheet to the sum of such amounts in the Condensed Consolidated Statements of Cash Flows:</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">September 30, 2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 31, 2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">400,079</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">95,881</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash, current</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,321</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Restricted cash, long-term</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">13,665</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">420,065</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">95,881</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>   The Company classifies cash deposits related to letters of credit securing insurance and lease obligations as restricted cash, which is included in other assets, non-current, within the Consolidated Balance Sheet.   Inventories. Inventories are valued at the lower of cost and net realizable value. Cost is determined by the first-in, first-out method. We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value. Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which are used in our testing laboratories. Inventory obsolescence expense for the three and nine months ended September 30, 2024 was $0.6 million and $1.6 million, respectively. Inventory obsolescence expense for the three and nine months ended September 30, 2023 was $2.6 million and $4.0 million, respectively. <p style="font-family: Times New Roman; font-size: 10pt; font-

variant: normal; margin: 0pt; text-indent: 27pt;">   Goodwill and intangible assets. Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting. Refer to Note 5. Goodwill, in-process research and development (“IPR&D”) and other intangible assets acquired in business combinations, licensing and other transactions was $1.4 billion and $1.5 billion at September 30, 2024 and December 31, 2023, respectively.   Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. At acquisition, we generally determine the fair value of intangible assets, including IPR&D, using the “income method.”   Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.   Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment. We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing. Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value. Goodwill was $535.9 million and $598.3 million, respectively, at September 30, 2024 and December 31, 2023.   Net intangible assets other than goodwill were $836.4 million on each of September 30, 2024, and December 31, 2023, with IPR&D accounting for $195.0 million on each date. Considering the high risk nature of research and development and the industry’s success rate of bringing developmental compounds to market, IPR&D impairment charges may occur in future periods. Estimating the fair value of IPR&D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.   Upon regulatory approval, IPR&D assets are classified as finite-lived intangible assets. These assets are then amortized on a straight-line basis over their estimated useful lives. If a project is abandoned, the associated IPR&D costs are immediately expensed. We also regularly assess finite-lived intangible assets for impairment. This assessment involves comparing the carrying amount of an asset, which is its cost minus accumulated amortization, to its estimated future undiscounted cash flows. If the carrying amount exceeds the estimated future cash flows, an impairment charge is recognized to reflect the difference between the asset's carrying amount and its fair value.   While we believe our estimates and assumptions used in impairment testing (including for goodwill and IPR&D) are reasonable and reflect those used by market participants, there is a potential risk of material impairment charges. Based on the current financial performance of our diagnostics segment and our Ireland reporting unit (which includes Eirgen and Rayaldee), we could be subject to such charges if their future performance deviates from our current estimates and assumptions. For reference, the combined goodwill of these units totaled $304.9 million and $367.3 million at September 30, 2024 and December 31, 2023, respectively.   We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years. We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up. Amortization expense was $20.4 million and $62.3 million for the three and nine months ended September 30, 2024, respectively. Amortization expense was $21.5 million and $64.5 million for the three and nine months ended September 30, 2023, respectively.   Fair value measurements. The carrying amounts of our cash, cash equivalents, restricted cash, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments. Investments that are considered equity securities as of September 30, 2024 and December 31, 2023 are predominately carried at fair value. Our debt under the Credit Agreement (as defined below) approximates fair value due to the variable rate of interest applicable to such debt.   In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts. Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange. Refer to Note 9.   Contingent consideration. Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense. Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability. Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.   Derivative financial instruments. We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges. For a derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At September 30, 2024 and December 31, 2023, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges. Accordingly, we recognized all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations. Refer to Note 10. In addition, we have determined the value of the embedded derivative liability within the 2029 Convertible 144A Notes (as defined in Note 7) and recorded it at fair value. Refer to Note 7. The changes in the fair value of the embedded derivatives are recognized in the fair value changes of derivatives instruments, net. Refer to Note 9.   Property, plant and equipment. Property, plant and equipment are recorded at cost or fair value if acquired in a business combination. Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases. The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, and automobiles - 3-5 years. Expenditures for repairs and maintenance are charged to expense as incurred. Assets held under finance leases are included within Property, plant and equipment, net in our Condensed Consolidated Balance Sheets and are amortized over the shorter of their useful lives or the expected term of their related leases. Depreciation expense was $3.7 million and $11.9 million for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $4.8 million and $14.8 million for the three and nine months ended September 30, 2023, respectively.   Impairment of long-lived assets. Long-lived assets, such as property and equipment and assets held for sale, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.   Income taxes. Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment. Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.   We operate in various countries and tax jurisdictions globally. For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results. For the nine months ended September 30, 2024, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.   Included in Other long-term liabilities is an accrual of $9.9 million related to uncertain tax positions involving income recognition. In connection with an examination of foreign tax returns for the 2015 through 2021 tax years, a foreign

taxing authority has issued an income tax assessment of approximately $246 million (including interest). We are appealing this assessment, as we believe, other than for uncertain tax positions for which we have reserved, the issues are without technical merit. We intend to exhaust all judicial remedies necessary to resolve the matter as necessary, which could be a lengthy process. There can be no assurance that this matter will be resolved in our favor, and an adverse outcome, or any future tax examinations involving similar assertions, could have a material adverse effect on our financial condition, results of operations and cash flows.   Revenue recognition. We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“Topic 606”). The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.   We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. For a complete discussion of accounting for Revenues from services, Revenues from products and Revenue from transfer of intellectual property and other, refer to Note 13.   Concentration of credit risk and allowance for credit losses. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.   While we have receivables due from federal and state governmental agencies, such receivables are not a credit risk because federal and state governments fund the related healthcare programs. Payment is primarily dependent upon submitting appropriate documentation. On September 30, 2024 and December 31, 2023, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were 6.5% and 6.7%, respectively, of our consolidated Accounts receivable, net. The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk. At September 30, 2024 and December 31, 2023, receivables due from patients represented approximately 2.2% and 2.0%, respectively, of our consolidated Accounts receivable, net.   We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer’s ability to pay. Actual results could differ from those estimates. The allowance for credit losses was $2.0 million on each of September 30, 2024 and December 31, 2023. The credit loss expense for the three and nine months ended September 30, 2024, was a reversal expense of $75.2 thousand and $67.5 thousand of expense, respectively. The credit loss expense for the three and nine months ended September 30, 2023, was $98.3 thousand and $183.4 thousand, respectively.   As of September 30, 2024, accounts receivable included $1.6 million of revenue earned under the BARDA Contract (as defined in Note 14). As of December 31, 2023, accounts receivable included $0.6 million under this contract. Refer to Note 13, Government Contract Revenue for further information on government contracts and to Note 14, Strategic Alliances for further information on the BARDA Contract.   Stock Repurchase Program. On July 18, 2024, the Company announced that its Board of Directors authorized the repurchase of up to $100 million shares of Common Stock. Under this program, OPKO may repurchase shares through various methods, including open market purchases, block trades, privately negotiated transactions, and accelerated share repurchases, as well as pursuant to pre-set trading plans meeting the requirements of Rule 10b5-1(c) of the Exchange Act, and otherwise in compliance with applicable laws. The timing and volume of repurchases will depend on market conditions, the Company's capital management, investment opportunities, and other factors. The program does not obligate the Company to repurchase any specific number of shares, has no set expiration date, and may be modified, suspended, or discontinued at the Company's discretion. The Company repurchased 14,893,026 shares for approximately $23.8 million during the three months ended September 30, 2024.   Equity-based compensation. We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award. We record excess tax benefits realized from the exercise of stock options as cash flows from operations. For the three and nine months ended September 30, 2024, we recorded $2.8 million and $8.0 million, respectively, of equity-based compensation expense. For the three and nine months ended September 30, 2023, we recorded $3.2 million and $8.7 million, respectively, of equity-based compensation expense.   Research and development expenses. Research and development expenses include external and internal expenses. External expenses include clinical and nonclinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs. Research and development employee-related expenses include salaries, benefits and equity-based compensation expense. Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities. We expense these costs in the period in which they are incurred. We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.   Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility, and which have no alternative future use. For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining estimated useful life.   Segment reporting. Our chief operating decision-maker (“CODM”) is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Dr. Frost reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis. We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense or income taxes. Refer to Note 15.   Shipping and handling costs. We do not charge customers for shipping and handling costs. Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.   Foreign currency translation. The financial statements of certain of our foreign operations are measured using the local currency as the functional currency. The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date. The local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods. Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss). During the three and nine months ended September 30, 2024, we recorded foreign currency transaction income of $4.1 million and $0.1 million, respectively. During the three and nine months ended September 30, 2023, we recorded foreign currency transaction loss of $3.8 million and $1.9 million, respectively.   Variable interest entities. The consolidation of a variable interest entity (“VIE”) is required when an enterprise has a controlling financial interest. A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE. Refer to Note 6.   Investments. We have made strategic investments in development stage and emerging companies. We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees. For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed

Consolidated Statement of Operations. Refer to Note 6. For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value. Refer to Note 6.   Accounting standards yet to be adopted.   In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”), which modifies the rules on income tax disclosures to require entities to disclose (i) specific categories in the rate reconciliation, (ii) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (iii) income tax expense or benefit from continuing operations (separated by federal, state and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state, and local jurisdictions, among other changes. The guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. ASU 2023-09 should be applied on a prospective basis, but retrospective application is permitted. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures.   In November 2023, the FASB issued ASU No 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 enhances disclosures for significant segment expenses for all public entities required to report segment information in accordance with ASC 280. ASC 280 requires a public entity to report for each reportable segment a measure of segment profit or loss that its CODM uses to assess segment performance and to make decisions about resource allocations. The ASU is effective for fiscal years beginning after December 15, 2024 with updates to be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures.   Recently adopted accounting standards.   In 2021, the Organization for Economic Co-operation and Development (“OECD”) established an inclusive framework on base erosion and profit shifting and agreed on a two-pillar solution (“Pillar Two”) to global taxation, focusing on global profit allocation and a 15% global minimum effective tax rate. On December 15, 2022, the EU member states agreed to implement the OECD’s global minimum tax rate of 15%. The OECD issued Pillar Two model rules and continues to release guidance on these rules. The inclusive framework calls for tax law changes by participating countries to take effect in 2024 and 2025. Various countries have enacted or have announced plans to enact new tax laws to implement the global minimum tax. We considered the applicable tax law changes on Pillar Two implementation in the relevant countries, and there is no material impact to our tax results for the period. We anticipate further legislative activity and administrative guidance in 2024, and will continue to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in the non-US tax jurisdictions we operate in.   Basis of presentation. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Company’s results of operations, financial position and cash flows have been made. The results of operations and cash flows for the nine months ended September 30, 2024 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2024 or any other future periods. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2023.   Principles of consolidation. The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of OPKO Health, Inc. and our wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.   Use of estimates. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.   Cash, cash equivalents and restricted cash. Cash, cash equivalents and restricted cash include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase. We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities.   The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheet to the sum of such amounts in the Condensed Consolidated Statements of Cash Flows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Cash and cash equivalents </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">400,079</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">95,881</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Restricted cash, current </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,321</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Restricted cash, long-term </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">13,665</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">420,065</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">95,881</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>   The Company classifies cash deposits related to letters of credit securing insurance and lease obligations as restricted cash, which is included in other assets, non-current, within the Consolidated Balance Sheet. <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent:

27pt;">   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> Cash and cash equivalents </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">400,079</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">95,881</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Restricted cash, current </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,321</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Restricted cash, long-term </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">13,665</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statements of Cash Flows </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">420,065</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">95,881</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>
400079000958810006321000013665000042006500095881000 Inventories. Inventories are valued at the lower of cost and net realizable value. Cost is determined by the first-in, first-out method. We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value. Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which are used in our testing laboratories. Inventory obsolescence expense for the three and nine months ended September 30, 2024 was $0.6 million and $1.6 million, respectively. Inventory obsolescence expense for the three and nine months ended September 30, 2023 was $2.6 million and $4.0 million, respectively.   60000016000002600000400000 Goodwill and intangible assets. Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting. Refer to Note 5. Goodwill, in-process research and development (“IPR&D”) and other intangible assets acquired in business combinations, licensing and other transactions was $1.4 billion and $1.5 billion at September 30, 2024 and December 31, 2023, respectively.   Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. At acquisition, we generally determine the fair value of intangible assets, including IPR&D, using the “income method.”   Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.   Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment. We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing. Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value. Goodwill was $535.9 million and $598.3 million, respectively, at September 30, 2024 and December 31, 2023.   Net intangible assets other than goodwill were $836.4 million on each of September 30, 2024, and December 31, 2023, with IPR&D accounting for $195.0 million on each date. Considering the high risk nature of research and development and the industry’s success rate of bringing developmental compounds to market, IPR&D impairment charges may occur in future periods. Estimating the fair value of IPR&D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.   Upon regulatory approval, IPR&D assets are classified as finite-lived intangible assets. These assets are then amortized on a straight-line basis over their estimated useful lives. If a project is abandoned, the associated IPR&D costs are immediately expensed. We also regularly assess finite-lived intangible assets for impairment. This assessment involves comparing the carrying amount of an asset, which is its cost minus accumulated amortization, to its estimated future undiscounted cash flows. If the carrying amount exceeds the estimated future cash flows, an impairment charge is recognized to reflect the difference between the asset's carrying amount and its fair value.   While we believe our estimates and assumptions used in impairment testing (including for goodwill and IPR&D) are reasonable and reflect those used by market participants, there is a potential risk of material impairment charges. Based on the current financial performance of our diagnostics segment and our Ireland reporting unit (which includes Eirgen and Rayaldee), we could be subject to such charges if their future performance deviates from our current estimates and assumptions. For reference, the combined goodwill of these units totaled $304.9 million and $367.3 million at September 30, 2024 and December 31, 2023, respectively.   We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years. We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up. Amortization expense was $20.4 million and $62.3 million for the three and nine months ended September 30, 2024, respectively. Amortization expense was $21.5 million and $64.5 million for the three and nine months ended September 30, 2023, respectively.
1400000000150000000053590000059830000083640000019500000030490000036730000P3YP20Y20400000623000002150000064500000 Fair value measurements. The carrying amounts of our cash, cash equivalents, restricted cash, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments. Investments that are considered equity securities as of September 30, 2024 and December 31, 2023 are predominately carried at fair value. Our debt under the Credit Agreement (as defined below) approximates fair value due to the variable rate of interest applicable to such debt.   In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts. Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange. Refer to Note 9.   Contingent consideration. Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense. Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability. Contingent consideration may change significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions. The assumptions used in

estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value which may have a material impact on our results from operations and financial position.   Derivative financial instruments. We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges. For a derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At September 30, 2024 and December 31, 2023, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges. Accordingly, we recognized all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations. Refer to Note 10. In addition, we have determined the value of the embedded derivative liability within the 2029 Convertible 144A Notes (as defined in Note 7) and recorded it at fair value. Refer to Note 7. The changes in the fair value of the embedded derivatives are recognized in the fair value changes of derivatives instruments, net. Refer to Note 9.   Property, plant and equipment. Property, plant and equipment are recorded at cost or fair value if acquired in a business combination. Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases. The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, and automobiles - 3-5 years. Expenditures for repairs and maintenance are charged to expense as incurred. Assets held under finance leases are included within Property, plant and equipment, net in our Condensed Consolidated Balance Sheets and are amortized over the shorter of their useful lives or the expected term of their related leases. Depreciation expense was $3.7 million and $11.9 million for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $4.8 million and $14.8 million for the three and nine months ended September 30, 2023, respectively.   P3YP5YP8YP5YP12YP10YP40YP3YP5Y37000001190000048000001480000 Impairment of long-lived assets. Long-lived assets, such as property and equipment and assets held for sale, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.   Income taxes. Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment. Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.   We operate in various countries and tax jurisdictions globally. For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results. For the nine months ended September 30, 2024, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.   Included in Other long-term liabilities is an accrual of $9.9 million related to uncertain tax positions involving income recognition. In connection with an examination of foreign tax returns for the 2015 through 2021 tax years, a foreign taxing authority has issued an income tax assessment of approximately $246 million (including interest). We are appealing this assessment, as we believe, other than for uncertain tax positions for which we have reserved, the issues are without technical merit. We intend to exhaust all judicial remedies necessary to resolve the matter as necessary, which could be a lengthy process. There can be no assurance that this matter will be resolved in our favor, and an adverse outcome, or any future tax examinations involving similar assertions, could have a material adverse effect on our financial condition, results of operations and cash flows.   0.219900000246000000 Revenue recognition. We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“Topic 606”). The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.   We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. For a complete discussion of accounting for Revenues from services, Revenues from products and Revenue from transfer of intellectual property and other, refer to Note 13.   Concentration of credit risk and allowance for credit losses. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.   While we have receivables due from federal and state governmental agencies, such receivables are not a credit risk because federal and state governments fund the related healthcare programs. Payment is primarily dependent upon submitting appropriate documentation. On September 30, 2024 and December 31, 2023, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were 6.5% and 6.7%, respectively, of our consolidated Accounts receivable, net. The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk. At September 30, 2024 and December 31, 2023, receivables due from patients represented approximately 2.2% and 2.0%, respectively, of our consolidated Accounts receivable, net.   We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer’s ability to pay. Actual results could differ from those estimates. The allowance for credit losses was $2.0 million on each of September 30, 2024 and December 31, 2023. The credit loss expense for the three and nine months ended September 30, 2024, was a reversal expense of $75.2 thousand and $67.5 thousand of expense, respectively. The credit loss expense for the three and nine months ended September 30, 2023, was $98.3 thousand and $183.4 thousand, respectively.   As of September 30, 2024, accounts receivable included $1.6 million of revenue earned under the BARDA Contract (as defined in Note 14). As of December 31, 2023, accounts receivable included $0.6 million under this contract. Refer to Note 13, Government Contract Revenue for further information on government contracts and to Note 14, Strategic Alliances for further information on the BARDA Contract.   0.0650.0670.0220.022000000-752000006750000098300000183400000160000600000 Stock Repurchase Program. On July 18, 2024, the Company announced that its Board of Directors authorized the repurchase of up to $100 million shares of Common Stock. Under this program, OPKO may repurchase shares through various methods, including open market purchases, block trades, privately negotiated transactions, and accelerated share repurchases, as well as pursuant to pre-set trading plans meeting the requirements of Rule 10b5-1(c) of the Exchange Act, and otherwise in compliance with applicable laws. The timing and volume of repurchases will depend on market conditions, the Company's capital management, investment opportunities, and other factors. The program does not obligate the Company to repurchase any specific number of shares, has no set expiration date, and may be modified, suspended, or discontinued at the Company's discretion. The Company repurchased 14,893,026 shares for approximately $23.8 million during the three months ended September 30, 2024.   10000000014893026238000000 Equity-based compensation. We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award. We record excess tax benefits realized from the exercise of stock options as cash flows from operations. For the three and nine months ended September 30, 2024, we recorded $2.8 million and $8.0 million, respectively, of equity-based compensation expense. For the three and nine months ended September 30, 2023, we recorded $3.2 million and $8.7 million, respectively, of equity-based compensation expense.   28000008000000320000087000000 Research and development expenses. Research and development expenses include external and internal expenses. External expenses include clinical and nonclinical activities performed by contract research organizations, lab services, purchases of drug

and diagnostic product materials and manufacturing development costs. Research and development employee-related expenses include salaries, benefits and equity-based compensation expense. Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities. We expense these costs in the period in which they are incurred. We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.   Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility, and which have no alternative future use. For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining estimated useful life.   Segment reporting. Our chief operating decision-maker ("CODM") is Phillip Frost, M.D., our Chairman and Chief Executive Officer. Dr. Frost reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis. We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense or income taxes. Refer to Note 15.   Shipping and handling costs. We do not charge customers for shipping and handling costs. Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.   Foreign currency translation. The financial statements of certain of our foreign operations are measured using the local currency as the functional currency. The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date. The local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods. Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss). During the three and nine months ended September 30, 2024, we recorded foreign currency transaction income of $4.1 million and $0.1 million, respectively. During the three and nine months ended September 30, 2023, we recorded foreign currency transaction loss of $3.8 million and $1.9 million, respectively.   4100000100000-3800000-1900000 Variable interest entities. The consolidation of a variable interest entity ("VIE") is required when an enterprise has a controlling financial interest. A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE's economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE. Refer to Note 6.   Investments. We have made strategic investments in development stage and emerging companies. We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees. For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations. Refer to Note 6. For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value. Refer to Note 6.   Accounting standards yet to be adopted.   In December 2023, the FASB issued ASU No. 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures" ("ASU 2023-09"), which modifies the rules on income tax disclosures to require entities to disclose (i) specific categories in the rate reconciliation, (ii) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (iii) income tax expense or benefit from continuing operations (separated by federal, state and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state, and local jurisdictions, among other changes. The guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. ASU 2023-09 should be applied on a prospective basis, but retrospective application is permitted. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures.   In November 2023, the FASB issued ASU No 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 enhances disclosures for significant segment expenses for all public entities required to report segment information in accordance with ASC 280. ASC 280 requires a public entity to report for each reportable segment a measure of segment profit or loss that its CODM uses to assess segment performance and to make decisions about resource allocations. The ASU is effective for fiscal years beginning after December 15, 2024 with updates to be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures.   Recently adopted accounting standards.   In 2021, the Organization for Economic Co-operation and Development ("OECD") established an inclusive framework on base erosion and profit shifting and agreed on a two-pillar solution ("Pillar Two") to global taxation, focusing on global profit allocation and a 15% global minimum effective tax rate. On December 15, 2022, the EU member states agreed to implement the OECD's global minimum tax rate of 15%. The OECD issued Pillar Two model rules and continues to release guidance on these rules. The inclusive framework calls for tax law changes by participating countries to take effect in 2024 and 2025. Various countries have enacted or have announced plans to enact new tax laws to implement the global minimum tax. We considered the applicable tax law changes on Pillar Two implementation in the relevant countries, and there is no material impact to our tax results for the period. We anticipate further legislative activity and administrative guidance in 2024, and will continue to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in the non-US tax jurisdictions we operate in.   NOTE 4 EARNINGS (LOSS) PER SHARE   Basic income (loss) per share is computed by dividing our net income (loss) by the weighted average number of shares of our Common Stock outstanding during the period. Shares of Common Stock outstanding under the share lending arrangement entered into in conjunction with the 2025 Notes (as defined in Note 7) have been excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent. We terminated the share lending agreement on January 22, 2024. Refer to Note 7. For diluted earnings per share, the dilutive impact of stock options and warrants is determined by applying the "treasury stock" method. The dilutive impact of the 2029 Convertible Notes, 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes (each, as defined and discussed in Note 7) has been considered using the "if converted" method. For periods in which their effect would have been antidilutive, no effect is given in the dilutive computation to Common Stock issuable under outstanding options or warrants or the potentially dilutive shares issuable pursuant to the 2029 Convertible Notes, 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes. The following table sets forth the computation of basic and diluted income (loss) per share: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For the three months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For the nine months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> (In thousands, except per share data) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;

border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Numerator </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average common shares outstanding, basic </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">694,622,466</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">751,525,007</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">699,675,944</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">751,716,692</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Effect of dilutive securities: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Stock options </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">76,922</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2025 Notes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">48,295</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2023 Convertible Notes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2033 Senior Notes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,489</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2029 Convertible Notes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">303,607,464</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dilutive potential shares </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom:

1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">303,741,170</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average common shares outstanding, diluted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">998,363,636</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">751,525,007</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">699,675,944</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">751,716,692</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Loss per share, basic </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.04</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.16</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Loss per share, diluted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.03</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.16</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table>   A total of 0 and 83,074,689 potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the three months ended September 30, 2024 and 2023, respectively, because their inclusion would have been antidilutive. A total of 286,281,585 and 82,368,398 potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the nine months ended September 30, 2024 and 2023, respectively, because their inclusion would have been antidilutive.   During the three months ended September 30, 2024, no options were exercised and no restricted stock units vested, resulting in the issuance of no shares of Common Stock.   During the nine months ended September 30, 2024, no options were exercised and 549,687 restricted stock units vested, resulting in the issuance of 384,378 shares of Common Stock.   During the three months ended September 30, 2023, 18,750 options were exercised and no restricted stock units vested, resulting in the issuance of 18,750 shares of Common Stock.   During the nine months ended September 30, 2023, 18,750 options were exercised and 549,680 restricted stock units vested, resulting in the issuance of 405,721 shares of Common Stock.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For the three months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For the nine months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> (In thousands, except per share data) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;

border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Numerator </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">

10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average common shares outstanding, basic </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">694,622,466</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">751,525,007</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">699,675,944</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">751,716,692</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Effect of dilutive securities: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Stock options </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">76,922</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Warrants </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2025 Notes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">48,295</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2023 Convertible Notes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2033 Senior Notes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,489</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> 2029 Convertible Notes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">303,607,464</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">></td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr

style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dilutive potential shares </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">303,741,170</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Weighted average common shares outstanding, diluted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">998,363,636</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">751,525,007</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">699,675,944</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">751,716,692</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Loss per share, basic </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.04</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.16</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per share, diluted </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">0.03</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.11</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.10</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(0.16</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> 24890000-84473000-67251000-122380000100000068580000003200000031781000-84473000-67251000-122380000694622466751525007699675944751716692769220000000482950000000848900030360746 4 30374117000099836363675152500769967594475171669 20.04-0.11-0.1-0.160.03-0.11-0.1-0.160830746892862815858236839800005496873843781875001875018750549680405721 NOTE 5 COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> (In thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Accounts receivable, net: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Accounts receivable </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">108,583</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">125,379</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);

vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: allowance for credit losses </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,004</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">106,579</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">123,379</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Inventories, net: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Consumable supplies </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,218</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,864</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Finished products </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34,206</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35,582</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Work in-process </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,265</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,731</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Raw materials </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,491</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,981</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: inventory reserve </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,772</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">59,408</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">65,697</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other current assets and prepaid expenses: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Escrow receivable </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">23,750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Taxes recoverable </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,767</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,211</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Prepaid expenses </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,177</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Prepaid insurance </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,302</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,848</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other receivables </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,563</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,610</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,295</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,673</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">57,249</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,519</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Intangible assets, net: </td><td style="font-

family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Customer relationships </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">258,048</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">315,799</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Technologies </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">818,971</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">831,509</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Trade names </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">49,759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">49,758</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Covenants not to compete </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,917</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,916</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Licenses </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,205</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Product registrations </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,738</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: accumulated amortization </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(517,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(488,694</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">641,396</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">740,283</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Accrued expenses: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Employee benefits and severance </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">38,474</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">28,952</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Clinical trials </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,725</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,624</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Commitments and contingencies </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,088</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Accrued interest </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,021</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2,601</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Gross to net provision </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,033</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,420</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Inventory received but not invoiced </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,653</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Finance leases short-term </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,855</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,827</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: Times New

Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,375</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,470</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Taxes payable </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">15,334</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,384</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Royalties </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">767</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,544</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Commissions </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,521</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,822</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">31,254</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,701</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">122,806</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">90,086</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other long-term liabilities: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Employee severance </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,284</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Mortgages and other debts payable </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,529</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,709</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Finance leases long-term </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,689</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,274</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Contract liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,995</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,504</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,189</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>   Our intangible assets and goodwill relate principally to our completed acquisitions of OPKO Renal, OPKO Biologics, EirGen, BioReference and ModeX. We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives. The estimated useful lives by asset class are as follows: technologies - 7-17 years, customer relationships - 5-20 years, product registrations - 7-10 years, covenants not to compete - 5 years, trade names - 5-10 years, other 9-13 years. We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred. Our goodwill is not tax deductible for income tax purposes in any jurisdiction in which we operate.   Changes in value of the intangible assets and goodwill during the nine months ended September 30, 2024 and 2023 were primarily due to foreign currency fluctuations between the Euro, and the Chilean Peso against the U.S. dollar.   The following table summarizes the changes in Goodwill by reporting unit during the nine months ended September 30, 2024.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="18" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 61%; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> (In thousands) </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Gross goodwill at January 1, 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Cumulative impairment at January 1 </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-

size:10pt;font-variant:normal;text-align:center;margin:0pt;">Acquisitions, dispositions and other </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Foreign exchange and other </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Balance at September 30, 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> Pharmaceuticals </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12

1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> OPKO Mexico </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> Transition Therapeutics </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,421</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,421</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 25%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> Diagnostics </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> BioReference </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">283,025</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">(63,318</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">219,707</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> OPKO Diagnostics </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,977</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,977</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">636,283</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(38,023</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(63,318</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">926</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">535,868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> (In thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Accounts receivable, net: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td

style="font-family: Times New Roman; font-size: 10pt;"> Accounts receivable </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">108,583</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">125,379</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: allowance for credit losses </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,004</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">106,579</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">123,379</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Inventories, net: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Consumable supplies </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,218</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">25,864</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Finished products </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34,206</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35,582</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Work in-process </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,265</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,731</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Raw materials </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,491</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,981</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: inventory reserve </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,772</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">59,408</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">65,697</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other current assets and prepaid expenses: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Escrow receivable </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">23,750</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Taxes recoverable </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,767</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,211</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Prepaid expenses </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,177</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Prepaid insurance </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,302</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,848</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other receivables </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,563</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,610</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,295</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,673</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px

double rgb(0, 0, 0);">57,249</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">24,519</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Intangible assets, net:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Customer relationships</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">258,048</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">315,799</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Technologies</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">818,971</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">831,509</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Trade names</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">49,759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">49,758</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Covenants not to compete</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,917</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,916</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Licenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,311</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,205</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Product registrations</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,738</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -9pt;">Less: accumulated amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(517,400</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(488,694</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">641,396</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">740,283</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Accrued expenses:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman; text-indent: 18pt;">Employee benefits and severance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">38,474</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">28,952</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Clinical trials </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,725</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,624</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Commitments and contingencies </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,088</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Accrued interest </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">6,021</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">2,601</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Gross to net provision </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,033</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,420</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Inventory received but not invoiced </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,306</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,653</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Finance leases short-term </td><td style="width: 1%; font-family: Times New Roman; font-size:

10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,855</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,827</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,375</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,470</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Taxes payable </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">15,334</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,384</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Royalties </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">767</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,544</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Commissions </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,521</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">1,822</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">31,254</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,701</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">122,806</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">90,086</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other long-term liabilities: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Employee severance </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,284</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Mortgages and other debts payable </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,529</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,709</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Finance leases long-term </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,689</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,274</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Contract liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,995</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36,504</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,189</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>
1085830001253790002004000200000010657900012337900016218000258640003420600035582000226500017310001049100089810003772000646100059408000656970
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="18" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 61%; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> (In thousands) </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Gross goodwill at January 1, 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Cumulative impairment at January 1 </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Acquisitions, dispositions and other </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Foreign exchange and other </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0,

0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> Balance at September 30, 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> Pharmaceuticals </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> CURNA </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,827</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,827</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> Rayaldee </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">84,273</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">925</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">85,198</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> FineTech </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,698</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(11,698</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> ModeX </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">80,260</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">80,260</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> OPKO Biologics </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">139,784</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">(0</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">139,784</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> OPKO Chile </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,642</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,561</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> OPKO Health Europe </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,276</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">82</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,358</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> OPKO Mexico </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td>

<td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> Transition Therapeutics </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,421</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,421</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 25%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 12%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> Diagnostics </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> BioReference </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">283,025</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">(63,318</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">219,707</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> OPKO Diagnostics </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,977</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17,977</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">— </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 25%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">636,283</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(38,023</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(63,318</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">926</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">535,868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> 48270004827000008427300 0-00925000851980001169800011698000000802600 00-00080260000139784000-00-013978400036420 00-00-810003561000727600 0-00820007358000100000100000000342100034210000002830250 00-0-6331800002197070001797700017977000017977000000636283000380230 00-6331800009260005358680 00 NOTE 6 INVESTMENTS   Investments   The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of September 30, 2024 and December 31, 2023:   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As of September 30, 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As of December 31, 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Investment type </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Investment Carrying Value </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Underlying Equity in Net Assets </td><td style="font-family: Times New Roman; font-size: 10pt; border-

bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Investment Carrying Value </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Underlying Equity in Net Assets </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Equity method investments </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,782</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,942</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Variable interest entity, equity method </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">796</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">420</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Equity method investments - FV option </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">92,166</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,786</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Equity securities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Equity securities with no readily determinable fair value </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,521</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,382</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Warrants and options </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total carrying value of investments </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100,609</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,082</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> </tbody></table>   Equity method investments   Our equity method investments, other than in GeneDx Holdings, as described below, consist of investments in Pharmsynthez (ownership 6%), Cocrystal Pharma, Inc. (“COCP”) (2%), Non-Invasive Monitoring Systems, Inc. (“NIMS”) (1%), BioCardia, Inc. (“BioCardia”) (1%), Xenetic Biosciences, Inc. (“Xenetic”) (3%), Zebra Biologics, Inc. (“Zebra”) (29%), and LeaderMed Health Group Limited (“LeaderMed”) (47%). Neovasc, Inc., in which we owned a 0.5% interest, was acquired by Shockwave Medical, Inc. in April 2023. As a result, we received $363 thousand in merger consideration in exchange for our shares. The aggregate amount of assets, liabilities, and net losses of these equity method investees as of and for the nine months ended September 30, 2024 were $66.1 million, $23.3 million, and $27.7 million, respectively. The aggregate amount of assets, liabilities, and net losses of our equity method investees as of and for the year ended December 31, 2023 were $85.5 million, $20.8 million, and $37.7 million, respectively. We have determined that we or our related parties have the ability to exercise significant influence over our equity method investments through our board representation or voting power. Accordingly, we account for our investment in these entities under the equity method and record our proportionate share of their losses in Loss from investments in investees in our Consolidated Statement of Operations. The aggregate value of our equity method investments based on the quoted market prices of their respective shares of common stock and the number of shares held by us as of September 30, 2024 and December 31, 2023 was $0.6 million and $0.7 million, respectively.   Equity method investments - Fair value option   On January 14, 2022, the Company entered into an Agreement and Plan of Merger and Reorganization (the “GeneDx Merger Agreement”) with GeneDx Holdings Corp. (f/k/a Sema4 Holdings Corp.), a Delaware corporation (“GeneDx Holdings”), pursuant to which GeneDx Holdings acquired our former subsidiary, GeneDx LLC (formerly GeneDx, Inc. “GeneDx”), on April 28, 2022. During the third quarter of 2024, the Company sold 1,386,929 shares of GeneDx common stock at various prices per share for an aggregate of $46.7 million. As a result of the sale, the Company's total ownership in GeneDx Holdings decreased from 13.61% to 8.1% as of September 30, 2024.   Pursuant to the GeneDx Merger Agreement, the Company designated, and GeneDx Holdings nominated for election an individual to serve on the board of directors of GeneDx Holdings. This individual was subsequently elected by GeneDx Holdings stockholders and has continued to serve on the board following his re-election in 2024. His term will extend until the GeneDx Holdings annual meeting of stockholders in 2027. We have a shareholder agreement with GeneDx Holdings, pursuant to which we have agreed to vote our shares of GeneDx Holdings common stock in accordance with the recommendation of GeneDx Holdings' board of directors for so long as we continue to hold at least 5% of the outstanding shares of GeneDx Holdings common stock. Other than through our position as a shareholder, we are unable to influence GeneDx Holdings' policy-making process.   We account for our investment in GeneDx Holdings under the equity method fair value option and record gains and losses from changes in fair value in other income (expense), net in our Condensed Consolidated Statements of Operations. For the three

and nine months ended September 30, 2024, we recognized $35.4 million and $118.6 million in net income related to the change in fair value of our GeneDx Holdings investment, respectively. For the three and nine months ended September 30, 2023, we recognized $8.3 million and $19.9 million in net loss related to the change in fair value of our GeneDx Holdings investment, respectively. As of September 30, 2024, the aggregate value of our GeneDx Holdings investment was $92.2 million based on the quoted market price of the GeneDx Holdings common stock.   Investments in equity securities   Our equity securities consist of investments in VBI Vaccines Inc. (0.00%), ChromaDex Corporation (“ChromaDex”) (0.05%), and Eloxx Pharmaceuticals, Inc. (“Eloxx”) (1%). During the third quarter of 2024, we recorded a $30 thousand loss from our investment in VBI Vaccines Inc. due to the company filing for bankruptcy. Our equity securities without readily determinable fair value consists of <em style="font: inherit;">CAMP4 Therapeutics Corporation (<em style="font: inherit;">“CAMP4”) (2%) and HealthSnap, Inc. (4%). We have determined that our ownership, along with that of our related parties, does <em style="font: inherit;">not provide us with significant influence over the operations of these investments. Accordingly, we account for our investment in these entities as equity securities, and we record changes in the fair value of these investments in Other income (expense) each reporting period when they have a readily determinable fair value. Equity securities without a readily determinable fair value are adjusted to fair value when there is an observable price change. Net gains and losses on our equity securities for the <em style="font: inherit;">nine months ended <em style="font: inherit;"> September 30, 2024 and <em style="font: inherit;">2023 were as follows:</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">For the nine months ended September 30,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Equity Securities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Net gains and losses recognized during the period on equity securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">43</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(411</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman; text-indent: 18pt;">Less: Net gains and losses realized during the period on equity securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -27pt;">Unrealized net losses recognized during the period on equity securities still held at the reporting date</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(411</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> </tbody></table>   Sales of investments   Gains (losses) included in earnings from sales of our investments are recorded in Other income (expense), net in our Condensed Consolidated Statement of Operations. The cost of securities sold is based on the specific identification method.   Warrants and options   In addition to our equity method investments and equity securities, we hold options to purchase 47 thousand additional shares of BioCardia, all of which were vested as of September 30, 2024 and December 31, 2023, and warrants to purchase 0.7 million additional shares of InCellDx Inc. We recorded the changes in the fair value of the options and warrants in fair value changes of derivative instruments, net in our Condensed Consolidated Statement of Operations. We also recorded the fair value of the options and warrants in Investments, net in our Condensed Consolidated Balance Sheet. See further discussion of the Company’s options and warrants in Note 9 and Note 10.   Investments in variable interest entities   We have determined that we hold variable interests in LeaderMed and Zebra. We made this determination as a result of our assessment that they do not have sufficient resources to carry out their principal activities without additional financial support.   In September 2021, we and LeaderMed, a pharmaceutical development company with operations based in Asia, formed a joint venture to develop, manufacture and commercialize two of OPKO’s clinical stage, long-acting drug products in Greater China and eight other Asian territories. Under the terms of the agreements, we granted the joint venture exclusive rights to develop, manufacture and commercialize (a) OPK88003, an oxyntomodulin analog being developed for the treatment of obesity and diabetes, and (b) Factor VIIa-CTP, a novel long acting coagulation factor being developed to treat hemophilia, in exchange for 4,703 shares 47% ownership interest in the joint venture. In addition, we received an upfront payment of $1.0 million and will be reimbursed for clinical trial material and technical support we provide the joint venture.   In order to determine the primary beneficiary of the joint venture, we evaluated our investment and our related parties’ investment, as well as our investment combined with the related parties’ investment to identify if we had the power to direct the activities that most significantly impact the economic performance of the joint venture. Based on the capital structure, governing documents and overall business operations of the joint venture, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact the joint venture’s economic performance and do not have an obligation to fund expected losses. We did determine that we can significantly influence control of the joint venture through our board representation and voting power. Therefore, we have the ability to exercise significant influence over the joint venture’s operations and account for our investment in the joint venture under the equity method.   We own 1,260,000 shares of Zebra’s Series A-2 Preferred Stock and 900,000 shares of Zebra restricted common stock (ownership 29%) at September 30, 2024 and December 31, 2023. Zebra is a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drugs. Dr. Richard Lerner, M.D., a former member of our Board of Directors, was a founder of Zebra. Dr. Frost serves as a member of Zebra’s Board of Directors.   In order to determine the primary beneficiary of Zebra, we evaluated our investment and our related parties’ investment, as well as our investment combined with the related parties’ investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Zebra. Based on the capital structure, governing documents and overall business operations of Zebra, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Zebra’s economic performance and have no obligation to fund expected losses. We determined, however, that we can significantly influence control of Zebra through our board representation and voting power. Therefore, we have the ability to exercise significant influence over Zebra’s operations and account for our investment in Zebra under the equity method.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As of September 30, 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> As of December 31, 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> Investment type </td>

<td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Investment Carrying Value </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Underlying Equity in Net Assets </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Investment Carrying Value </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Underlying Equity in Net Assets </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Equity method investments </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,782</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,942</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Variable interest entity, equity method </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">796</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">420</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Equity method investments - FV option </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">92,166</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,786</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Equity securities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">116</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Equity securities with no readily determinable fair value </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,521</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,382</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Warrants and options </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total carrying value of investments </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100,609</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,082</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> </tbody></table> -01782000-0294200079000007960004200009216600097860001300001160007521000538200020002000100609000160820000.060.020.010.010.030.290.470.00536300066100000233727700000855000020800000-377000006000007000001386929467000000.13610.0810.0535400000118600000-8300000-199000009220000000.00050.01-300000.020.04 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> For the nine months ended September 30, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Equity Securities: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Net gains and losses recognized during the period on equity securities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">43</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(411</td><td style="width: 1%; font-family: Times New Roman;

font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Less: Net gains and losses realized during the period on equity securities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">(30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Unrealized net losses recognized during the period on equity securities still held at the reporting date </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(411</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> </tbody></table> 43000-411000-30000013000-411000470007000004703O.4710000001260000900000O.29 NOTE 7 DEBT   As of September 30, 2024 and December 31, 2023, our debt consisted of the following: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> (In thousands) </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> 2029 Convertible Notes </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">178,645</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> 2025 Notes </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">170</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">143,250</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> 2033 Senior Notes </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 13%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">50</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">50</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> 2023 Convertible Notes </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">71,025</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> 2044 Notes </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">245,358</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">JPMorgan Chase Bank line of credit</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,671</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Chilean and Spanish lines of credit</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,713</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,629</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Current portion of notes payable</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,509</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,993</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Long term portion of notes payable</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,529</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,727</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -9pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">440,974</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">249,345</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td> </td> <td> </td> <td>

0pt;">170</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Long term portion of convertible notes</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">178,695</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">214,325</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Current portion of lines of credit and notes payable</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,222</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,293</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Long Term notes payable included in long-term liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">248,887</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,727</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -9pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">440,974</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">249,345</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> </tr> </tbody> </table>   2044 Note Purchase Agreement   On July 17, 2024, the Company completed a private offering of $250 million aggregate principal amount of senior secured notes (the “2044 Notes”), pursuant to a note purchase agreement dated July 17, 2024 (the “2044 Note Purchase Agreement), by and among the Company, certain purchasers from time to time party thereto, the Company’s wholly owned subsidiaries OPKO Biologics (“OBL”) and EirGen as guarantors (OBL and EirGen collectively, the “2044 Note Guarantors”), and HCR Injection SPV, LLC, as agent.   The 2044 Notes mature on July 17, 2044 and bear interest at the 3-month Secured Overnight Financing Rate (SOFR) subject to a 4.0% per annum floor, plus 7.5% per annum. Interest is payable on the 2044 Notes on a quarterly basis determined by profit share payments received by EirGen pursuant to the profit share arrangement with Pfizer, Inc. (the “Royalty Payments”) set forth in the Restated Pfizer Agreement (as defined and described in Note 14). In the event that the aggregate amount of the Royalty Payments received by EirGen during the quarter preceding any quarterly interest payment date are less than the accrued and unpaid interest payable on such date, the excess interest payable on such date shall be paid-in-kind and added to the outstanding principal amount of the 2044 Notes. The Company will be required to pay the noteholders a 3% exit fee in connection with any repayment in full of the 2044 Notes, whether at maturity or otherwise. In addition, in the event that the Company repays the 2044 Notes in full prior to the maturity date, the Company will be required to pay the noteholders a make whole payment in an amount necessary such that the noteholders shall have received aggregate payments of principal, interest and fees in respect of the 2044 Notes equal to at least 150% of the initial principal amount of the 2044 Notes, in the event that such prepayment shall occur on or prior to July 17, 2029, or 200% of the initial principal amount of the 2044 Notes, in the event that such prepayment shall occur following July 17, 2029. If the 2044 Notes have not been fully repaid by the maturity date, the Company may elect to either repay the unpaid balance of the principal amount in full, together with any accrued and unpaid interest thereon and the 3% exit fee, or elect to transfer 80% of all future Royalty Payments to the agent and the noteholders in satisfaction of the outstanding 2044 Notes. The Company may authorize up to an additional $50,000,000 in additional 2044 Notes to the purchasers on the same terms and conditions of the initial 2044 Notes. The 2044 Notes are secured by the Royalty Payments, and the 2044 Note Guarantors have guaranteed the obligations under the 2044 Notes by granting a security interest in certain assets of the 2044 Note Guarantors. The 2044 Note Purchase Agreement contains customary terms and covenants, including negative covenants, such as limitations on indebtedness, liens, amendments to certain material contracts and disposition of assets.   2029 Convertible 144A Notes   In January 2024, we completed a private offering of $230.0 million aggregate principal amount of our 3.75% Convertible Senior Notes due 2029 (the “2029 Convertible 144A Notes”) in accordance with the terms of a note purchase agreement (the “144A Note Purchase Agreement”) entered into by and between the Company and J.P. Morgan Securities LLC (the “Initial Purchaser”).   Net proceeds from the 2029 Convertible 144A Notes issuance totaled approximately $222.0 million after deducting fees and estimated offering expenses payable by us. We allocated approximately $50.0 million of these net proceeds to repurchase shares of our Common Stock. These repurchases were from purchasers of the 2029 Convertible 144A Notes in privately negotiated transactions effected with or through the Initial Purchaser or its affiliate. The purchase price per share of the Common Stock in these transactions equaled the closing sale price of $0.9067 per share of Common Stock on January 4, 2024.   Contemporaneously with the closing of the offering of the 2029 Convertible 144A Notes on January 9, 2024, we issued and sold approximately $71.1 million aggregate principal amount of our 3.75% Convertible Senior Notes due 2029 (the “2029 Convertible Affiliate Notes” and, together with the 2029 Convertible 144A Notes, the “2029 Convertible Notes”) pursuant to the terms of a note purchase agreement entered into on January 4, 2024 (the “Affiliate Note Purchase Agreement”) by and among the Company and certain investors, Frost Gamma Investments Trust, a trust controlled by Dr. Phillip Frost, and Dr. Jane H. Hsiao (collectively, the “Affiliate Purchasers”). Pursuant to the Affiliate Note Purchase Agreement, we issued and sold the 2029 Convertible Affiliate Notes to the Affiliate Purchasers in exchange for the entirety of the $55.0 million aggregate principal amount of our outstanding 2023 Convertible Notes held by the Affiliate Purchasers, together with approximately $16.1 million of accrued but unpaid interest thereon.   On January 9th, 2024, we recorded the $125.6 million value of the embedded derivative liability within the 2029 Convertible Notes as a debt discount. To determine the fair value of this derivative, we employed the Binomial Lattice model. Key inputs and assumptions for this valuation included our common stock price, the derivative's exercise price, risk-free interest rate, volatility, annual coupon rate, and remaining contractual term. We are amortizing the debt discount as non-cash interest expense over the term of the Notes.   From the date the Notes were issued through March 31, 2024, we observed an increase in the market price of our Common Stock which resulted in a $26.25 million increase in the estimated fair value of our embedded derivatives recorded in Fair value changes of derivative instruments, net in our Condensed Consolidated Statements of Operations. Effective April 1, 2024, the conversion option contained in the 2029 Convertible Notes met the classification of an equity component. As a result, we reclassified $151.9 million of the embedded derivative liability from debt, non-current, to additional paid-in capital section of stockholders' equity on our Condensed Consolidated Balance Sheet.   As of September 30,2024 the 2029 Convertible 144A Notes are currently convertible. Holders may convert their 2029 Convertible Notes at their option prior to the close of business on the business day immediately preceding September 15, 2028 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2024 (and only during such calendar quarter), if the last reported sale price of our Common Stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the applicable conversion price on each applicable trading day; (2) during the five consecutive business day period after any ten consecutive trading day period (the “convertible note measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the convertible note measurement period was less than 98% of the product of the last reported sale price of our Common Stock and the applicable conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events specified in the indenture governing the 2029 Convertible Notes. On or after September 15, 2028 until the close of business on the business day immediately preceding the maturity date, holders may convert their notes at any time, regardless of the foregoing conditions. Upon conversion of a note, we will pay or deliver, as the case may be, cash, shares of our Common Stock or a combination of cash and shares of our Common Stock, at our election.   The conversion rate is initially equal to 869.5652 shares of Common Stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $1.15 per share of Common Stock). The conversion rate for the 2029 Convertible Notes will be subject to adjustment upon the occurrence of certain events

but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date of the notes, in certain circumstances we will increase the conversion rate of the 2029 Convertible Notes for a holder who elects to convert its notes in connection with such a corporate event.   We may not redeem the notes prior to the maturity date, and no sinking fund is provided for the notes. If we undergo a fundamental change, holders may require us to purchase the notes in whole or in part for cash at a fundamental change purchase price equal to 100% of the principal amount of the notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date. The 2029 Convertible Notes are our senior unsecured obligations and rank senior in right of payment to any indebtedness that is expressly subordinated in right of payment to the notes, and equal in right of payment with all of our existing and future unsecured indebtedness that is not so subordinated. The notes are effectively subordinated to all of our existing and future secured indebtedness to the extent of the value of the assets securing such indebtedness and structurally subordinated to all existing and future liabilities of our subsidiaries.   The indenture governing the notes provides for customary events of default which include (subject in certain cases to customary grace and cure periods), among others, the following: nonpayment of principal or interest; breach of covenants or other agreements in the indenture; defaults in failure to pay certain other indebtedness; judgment defaults; and certain events of bankruptcy or insolvency. Generally, if an event of default occurs and is continuing under the indenture, the trustee thereunder or the holders of at least 25% in aggregate principal amount of the notes then outstanding may declare 100% of the principal of and accrued and unpaid interest, if any on all then-outstanding notes to be immediately due and payable. In certain circumstances, we may, for a period of time, elect to pay additional interest on the notes as the sole remedy to holders of the notes in the case of an event of default related to certain failures by us to comply with certain reporting covenants in the indenture.   The following table sets forth information related to the 2029 Convertible Notes which is included in our Condensed Consolidated Balance Sheet as of September 30, 2024:   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 35%;"> (In thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2029 convertible notes </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Embedded conversion option </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Discount </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Debt Issuance costs </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Issuance of 3.75% 2029 Convertible Notes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">301,054</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">125,620</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(125,620</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(8,562</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">292,492</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Amortization of debt discount and debt issuance costs </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,585</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,236</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">13,821</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Change in fair value of embedded derivative </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">26,250</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">26,250</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Reclassification of embedded derivative to equity </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times,

serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(151,870</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(151,870</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Repurchase </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(3,500</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,338</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">114</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(2,048</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">297,554</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">(111,697</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">(7,212</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">178,645</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>

   During the third quarter of 2024, the Company repurchased $3.5 million in aggregate principal amount of the 2029 Convertible 144A Notes for $4.8 million in cash. Such convertible debt repurchase resulted in a gain of $32 thousand, which included unamortized discount of $1.3 million and debt issuance costs of $0.1 million.   2025 Convertible Notes   In February 2019, we issued $200.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the “2025 Notes”) in an underwritten public offering. The 2025 Notes bear interest at a rate of 4.50% per year, payable semiannually in arrears on February 15 and August 15 of each year. The 2025 Notes mature on February 15, 2025, unless earlier repurchased, redeemed or converted.   In May 2021, we entered into an agreement with certain holders of the 2025 Notes pursuant to which the holders exchanged $55.4 million in aggregate principal amount of the outstanding 2025 Notes for 19,051,270 shares of our Common Stock (the “Exchange”).   Contemporaneously with the closing of our offering of the 2029 Convertible Notes, we repurchased approximately $144.4 million aggregate principal amount of the 2025 Notes for cash, using $146.3 million of the net proceeds from our issuance and sale of the 2029 Convertible Notes, following which only $170 thousand aggregate principal amount of the 2025 Notes remained outstanding.   On January 22, 2024, we terminated our share lending agreement, dated February 4, 2019, with Jefferies Capital Services, LLC (“Share Borrower”). Through this agreement, we had lent the Share Borrower approximately 30 million shares of our Common Stock related to our 2019 issuance of the 2025 Notes. With the termination of this agreement, all remaining borrowed shares of Common Stock have been returned to us and are now held as treasury shares. 2023 Convertible Notes   In February 2018, we issued a series of 5% Convertible Promissory Notes (the “2023 Convertible Notes”) in the aggregate principal amount of $55.0 million. The original maturity of the 2023 Convertible Notes was five years following the date of issuance. Each holder of a 2023 Convertible Note originally had the option, from time to time, to convert all or any portion of the outstanding principal balance of such 2023 Convertible Note, together with accrued and unpaid interest thereon, into shares of our Common Stock at a conversion price of $5.00 per share.   On February 10, 2023, we amended the 2023 Convertible Notes to extend the maturity to January 31, 2025 and reset the conversion price to the 10 day volume weighted average price immediately preceding the date of the amended note, plus a 25% conversion premium, or $1.66 per share. Purchasers of the 2023 Convertible Notes included an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer.   In connection with the closing of the 2029 Convertible Notes offering, the Company issued approximately $71.1 million aggregate principal amount of its 2029 Convertible Affiliate Notes in exchange for all issued and outstanding 2023 Convertible notes, following which exchange, no 2023 Convertible Notes remained outstanding.   2033 Senior Notes   In January 2013, we issued an aggregate of $175.0 million of our 3.0% Senior Notes due 2033 (the “2033 Senior Notes”) in a private placement. The 2033 Senior Notes bear interest at the rate of 3.0% per year, payable semiannually on February 1 and August 1 of each year and mature on February 1, 2033, unless earlier repurchased, redeemed or converted. From 2013 to 2016, holders of the 2033 Senior Notes converted $143.2 million in aggregate principal amount into Common Stock, and, on February 1, 2019, approximately $28.8 million aggregate principal amount of 2033 Senior Notes were tendered by holders pursuant to such holders’ option to require us to repurchase the 2033 Senior Notes. During the first quarter of 2023, we paid approximately $3.0 million to purchase 2033 Senior Notes in accordance with the indenture governing the 2033 Senior Notes, following which $50.6 thousand 2033 Senior Notes remained outstanding.   JPMorgan Chase Credit Agreement <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;

margin: 0pt; text-indent: 27pt;"> In November 2015, BioReference and certain subsidiaries established a credit agreement with JPMorgan Chase Bank, N.A. ("CB") as lender and administrative agent (the "Credit Agreement"). As amended, the Credit Agreement provided for a $50.0 million secured revolving credit facility, including a $20.0 million sub-facility for swingline loans and a $20.0 million sub-facility for letters of credit.   On September 16, 2024, BioReference fully repaid its obligations and terminated the Credit Agreement. BioReference paid approximately $9.7 million to settle its obligations, incurring no prepayment premium or penalty.   The Credit Agreement had been guaranteed by all of BioReference's domestic subsidiaries and secured by substantially all assets of BioReference and its domestic subsidiaries, as well as a non-recourse pledge by us of our equity interest in BioReference. All guarantees and security interests were released together with the termination of the Credit Agreement.   As of December 31, 2023, $12.7 million was outstanding under the Credit Agreement.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><i>International Line of Credit Agreements</i></p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company has line of credit agreements with <em style="font: inherit;">twelve other financial institutions as of <em style="font: inherit;"> September 30, 2024, and <em style="font: inherit;"> December 31, 2023, in the U.S., Chile and Spain. These lines of credit are used primarily as sources of working capital for inventory purchases.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"> (Dollars in thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 13%;"><em style="font: inherit;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Balance Outstanding</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"> <em style="font: inherit;">Interest rate on borrowings at</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Credit line</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">September 30,</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"> <em style="font: inherit;">December 31,</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Lender</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">September 30, 2024</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">capacity</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2023</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">JPMorgan Chase</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.00</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,671</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Itau Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,900</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">469</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,264</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Bank of Chile </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.60</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,500</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">711</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,728</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> BICE Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,500</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,433</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,734</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Scotiabank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.00</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,500</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,060</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">981</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Santander Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width:

13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,742</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">450</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Security Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,400</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Estado Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,355</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,303</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> BCI Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.00</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,500</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">346</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,626</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Internacional Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,597</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,597</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,197</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Consorcio Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.00</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">346</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Banco De Sabadell </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.75</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">558</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Santander Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.36</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">558</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Total </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30,013</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,713</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,300</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> </tbody> </table>   At September 30, 2024 and December 31, 2023, the weighted average interest rate on our lines of credit was approximately 5.4% and 7.5%, respectively.   At September 30, 2024 and December 31, 2023, we had notes payable and other debt (excluding the 2033 Senior Notes, the 2023 Convertible Notes, the 2025 Notes, the Credit Agreement and amounts outstanding under lines of credit described above) as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: Times New Roman; font-

size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> (In thousands) </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Current portion of notes payable </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,509</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,993</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Other long-term liabilities </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,529</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,727</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Total </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,038</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,720</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> </tr> </tbody> </table>   The notes and other debt mature at various dates ranging from 2024 through 2032, bearing variable interest rates from 0.7% up to 4.5%. The weighted average interest rate on the notes and other debt was 1.8% on September 30, 2024 and 2.9% on December 31, 2023. The notes are partially secured by our office space in Barcelona.   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> (In thousands) </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> 2029 Convertible Notes </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">178,645</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> 2025 Notes </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">170</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">143,250</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> 2033 Senior Notes </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman" font-size: 10pt;"> </td> <td style="width: 13%; font-family: "Times New Roman" font-size: 10pt; margin-left: 0pt; text-align: right;">50</td> <td style="width: 1%; font-family: "Times New Roman" font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">50</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> 2023 Convertible Notes </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">71,025</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> 2044 Notes </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">245,358</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> JPMorgan Chase Bank line of credit </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,671</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Chilean and Spanish lines of credit </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,713</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,629</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Current portion of notes payable </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,509</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,993</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Long term portion of notes payable </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,529</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,727</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Total </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px

double rgb(0, 0, 0);">440,974</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">249,345</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Balance sheet captions</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Current portion of convertible notes</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">170</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Long term portion of convertible notes</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">178,695</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">214,325</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Current portion of lines of credit and notes payable</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,222</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">27,293</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Long Term notes payable included in long-term liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">248,887</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,727</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt; text-indent: -9pt;">Total</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">440,974</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">249,345</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> </tr> </tbody> </table>

178645000017000014325000050000500000710250002453580000012671000117130001262900015090001993000352900077270004409740002493450001700000178695000

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 27pt; width: 95%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 35%;"> (In thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2029 convertible notes </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Embedded conversion option </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Discount </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Debt Issuance costs </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Issuance of 3.75% 2029 Convertible Notes </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">301,054</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">125,620</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(125,620</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(8,562</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">292,492</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Amortization of debt discount and debt issuance costs </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,585</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,236</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">13,821</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Change in fair value of embedded derivative </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">26,250</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">26,250</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Reclassification of embedded derivative to equity </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(151,870</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(151,870</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr class="GFJY4-DGU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Repurchase </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(3,500</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,338</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">114</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(2,048</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">297,554</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">(111,697</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">(7,212</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">178,645</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 0-0-0003010540001256200001256200008562000292492000125850001236000138210002625000026250000151870000151870000350000013380001140002048000297554000

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> (Dollars in thousands) </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 13%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> Balance Outstanding </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> Interest rate on borrowings at </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> Credit line </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> September 30, </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> December 31, </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%; border-bottom: 1px solid rgb(0, 0, 0);"> Lender </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> September 30, 2024 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <em style="font:

inherit;">capacity </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2024 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2023 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> JPMorgan Chase </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.00</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,671</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Itau Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,900</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">469</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,264</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Bank of Chile </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.60</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,500</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">711</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,728</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> BICE Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,500</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,433</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,734</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Scotiabank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.00</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,500</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,060</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">981</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Santander Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,742</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">450</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Security Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,400</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Estado Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,355</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,303</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> BCI Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.00</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,500</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">346</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,626</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Internacional Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.50</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,597</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,597</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,197</td> <td style="width: 1%; font-family:

Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Consorcio Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.00</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,000</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">346</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Banco De Sabadell </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.75</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">558</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Santander Bank </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.36</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">558</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> Total </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">30,013</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,713</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">25,300</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> </tbody> </table>
000126710000.055190000046900012640000.066250000071100017280000.055250000024330001734000.055500000306000009810000.055500000017420004500000.055130001171300025300000.0540.075 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> December 31, </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> (In thousands) </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Current portion of notes payable </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,509</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,993</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Other long-term liabilities </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,529</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,727</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Total </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,038</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,720</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> </tr> </tbody> </table> 150900019930003529000772700050380009720000.0070.0450.0180.029 NOTE 8 ACCUMULATED OTHER COMPREHENSIVE LOSS   For the nine months ended September 30, 2024, changes in Accumulated other comprehensive loss, net of tax, were as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Foreign </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> currency </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> (In thousands) </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> translation </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Balance at December 31, 2023 </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(38,030</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Other comprehensive loss </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,585</td> <td

style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Balance at September 30, 2024 </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(39,615</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td> </tr> </tbody> </table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Foreign</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">currency</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(In thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">translation</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2023</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(38,030</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Other comprehensive loss </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,585</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Balance at September 30, 2024 </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(39,615</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td> </tr> </tbody> </table> -38030000-1585000-39615000 NOTE 9 FAIR VALUE MEASUREMENTS   We record fair values at an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.   As of September 30, 2024, we had equity securities and an equity method fair value option (refer to Note 6), forward foreign currency exchange contracts for inventory purchases (refer to Note 10). In addition, in connection with our investment and our consulting agreement with BioCardia, we record the related BioCardia options at fair value as well as warrants from COCP. In addition, restricted cash collateralized by money market funds is a financial asset measured at fair value as a Level 1 financial instrument under the fair value hierarchy.   Our financial assets and liabilities measured at fair value on a recurring basis are as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair value measurements as of September 30, 2024 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Quoted </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> prices in </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> active </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> markets for </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> other </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> identical </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> observable </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> unobservable </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> assets </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> inputs </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> inputs </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size:

10pt; width: 52%;"> (In thousands) </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 1) </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 2) </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 3) </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Assets: </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Money market funds </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">354,537</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">354,537</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Equity securities </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Equity Method - Fair value option </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">92,166</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">92,166</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Common stock options </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Total assets </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">446,833</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">446,835</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px; border-top: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> </tbody> </table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair value measurements as of December 31, 2023 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Quoted </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> prices in </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> active </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New

Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> markets for </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> other </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> identical </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> observable </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> unobservable </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> assets </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> inputs </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> inputs </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> (In thousands) </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 1) </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 2) </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 3) </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Assets: </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"

margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,308</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 9pt; text-indent: -9pt;">Liabilities:</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Forward contracts</p> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Total liabilities</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">29</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The carrying amount and estimated fair value of our <em style="font: inherit;">2029 Convertible Notes and <em style="font: inherit;">2025 Notes, as well as the applicable fair value hierarchy tiers, are contained in the table below. Additionally, the fair value of the <em style="font: inherit;">2029 Convertible Notes and <em style="font: inherit;">2025 Notes is determined using inputs other than quoted prices in active markets that are directly observable.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="18" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">September 30, 2024</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Carrying</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Total</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">(In thousands)</p> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Value</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Fair Value</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 1</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 2</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 3</p> </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">2029 Convertible Notes</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">178,645</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">396,652</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">396,652</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> 2025 Notes </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">170</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">170</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">170</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> </tbody> </table>   There have been no transfers between Level 1 and Level 2 and no transfers to Level 3 of the fair value hierarchy. .   The following table reconcile the beginning and ending balances of our Level 3 assets and liabilities as of September 30, 2024. <p style="font-family: Times New Roman; font-size: 10pt; font-

variant: normal; margin: 0pt; text-indent: 27pt;"> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Embedded conversion </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> (In thousands) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> option </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Additions</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">125,620</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Change in fair value:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-indent: 36pt;">Included in results of operations</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26,250</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 18pt;">Reclassification of embedded derivatives to equity</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(151,870</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at September 30, 2024</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;"> </td> </tr> </tbody> </table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair value measurements as of September 30, 2024 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Quoted </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> prices in </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> active </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> markets for </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> other </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> identical </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> observable </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> unobservable </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> assets </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> inputs </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> inputs </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> (In thousands) </td> <td style="font-

family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 1) </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 2) </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 3) </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Assets: </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"

size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> markets for </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> other </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Significant </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> identical </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> observable </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> unobservable </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> assets </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> inputs </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> inputs </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> (In thousands) </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 1) </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 2) </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> (Level 3) </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Assets: </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"

font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,308</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Liabilities: </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Forward contracts </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 9%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Total liabilities </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">29</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);">29</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); border-top: 1px solid rgb(0, 0, 0);"> </td> </tr> </tbody> </table>
3545370000035453700013000000130000921660000092166000020000200044683300020000446835000324040000032404000116000001160009786000009786000020000
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="18" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Carrying </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Total </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> (In thousands) </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Value </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> 2029 Convertible Notes </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">178,645</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">396,652</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">396,652</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;">2025 Notes</p> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: Times New Roman;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">170</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">170</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">170</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> </tbody> </table> 178645000396652000039665200001700001700000170000000
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Embedded conversion </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 85%;"> (In thousands) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times

New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> option </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at December 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Additions</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">125,620</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">Change in fair value:</p> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Included in results of operations</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26,250</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 18pt;">Reclassification of embedded derivatives to equity</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">(151,870</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at September 30, 2024</p> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-top: 1px solid rgb(0, 0, 0); border-bottom: 3px double black;"> </td> </tr> </tbody> </table> 0125620000262500001518700000 NOTE 10 DERIVATIVE CONTRACTS   The following table summarizes the fair values and the presentation of our derivative financial instruments in the Condensed Consolidated Balance Sheets: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"> </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 43%;"> Balance Sheet </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> September 30, </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> December 31, </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"> (In thousands) </td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 43%;"> Component </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2024 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> 2023 </td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"> Derivative financial instruments: </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 12%;"> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"> Common Stock options/warrants </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 43%;"> Investments, net </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; width: 27%;"> Forward contracts </td> <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 43%;"> Unrealized losses on forward contracts are recorded in Accrued expenses. </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(29</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> </tbody> </table>   We enter into foreign currency forward exchange contracts with respect to the risk of exposure to exchange rate differences arising from inventory purchases on letters of credit. Under these forward contracts, for any rate above or below the fixed rate, we receive or pay the difference between the spot rate and the fixed rate for the given amount at the settlement date.   To qualify the derivative instrument as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At September 30, 2024 and December 31, 2023, our derivative financial instruments did not meet the documentation requirements to be designated as hedges. Accordingly, we recognize the changes in fair value of derivative instruments, net in our Condensed Consolidated Statement of Operations. The following table summarizes the losses and gains recorded for the three and nine months ended September 30, 2024 and 2023:   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine months ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> (In thousands) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0,

0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Derivative gain (loss): </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(29</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> </tbody> </table> 200020000-29000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine months ended September 30, </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> (In thousands) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Derivative gain (loss): </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">On October 12, 2023, the Company entered into an E-Commerce Distribution Agreement with NextPlat Corp ("NextPlat"), a global e-commerce provider, in which Dr. Frost owns more than a 20% interest. Under the terms of the agreement, NextPlat has agreed to launch an OPKO Health-branded online storefront on the Alibaba Group Holding Limited Tmall Global e-commerce platform in China, featuring an assortment of nutraceutical and veterinary products sold and distributed by OPKO Health Europe SLU, our wholly-owned subsidiary. The Company and NextPlat amended the agreement in October 2024 to extend the term of the agreement to 2026, and permit NextPlat to launch an online storefront on additional e-commerce platforms throughout Asia.   On May 4, 2023, the Company entered into an Assignment and Assumption Agreement (the "Assignment Agreement") with Ruen-Hui Biopharmaceuticals, Inc., a Taiwanese entity ("Ruen-Hui") in which Dr. Hsiao owns more than a 10% interest. Ruen-Hui assumed the Company's obligations under an exclusive license agreement with Academia Sinica in exchange for an upfront payment of $150,000, a number of potential milestone payments up to $1 million, commercial milestones ranging from low to double digit millions, and royalty payments. Ruen Hui is also responsible for any outstanding payment obligations under such license agreement, including patent maintenance costs, and any payments due to Academia Sinica.   On April 29, 2022, upon consummation of our sale of GeneDx, the Company entered into a Transition Services Agreement (the "Transition Services Agreement") with GeneDx, pursuant to which the Company agreed to provide, at cost, certain customary support services in respect of GeneDx's business through August 31, 2023, including human resources, information technology support, and finance and accounting. As of September 30, 2024, the Company had incurred aggregate expenses of $1.2 million for services rendered under the Transition Services Agreement. For the three and nine months ended September 30, 2024, the company did not incur expenses for services rendered under the Transaction Services Agreement. As of September 30, 2024, the Company does not have a receivable balance payable to the Company by GeneDx in accordance with the terms of the Transition Services Agreement.   The Company owns approximately 6% of Pharmsynthez and Pharmsynthez is the largest and controlling shareholder of Xenetic, in which the Company has a 3% ownership interest. Adam Logal, our Senior Vice President and Chief Financial Officer, is a director of Xenetic.   We hold investments in Zebra (ownership 29%), ChromaDex (0.05%), COCP (2%), NIMS (1%), Eloxx (1%), BioCardia (1%) and LeaderMed (47%). Neovasc, Inc., in which we owned a 0.5% interest, was acquired by Shockwave Medical, Inc. in April 2023, and during the third quarter of 2023, we received $363 thousand in merger consideration in exchange for our shares. These investments were considered related party transactions as a result of our executive management's ownership interests and/or board representation in these entities. We also hold an investment in GeneDx Holdings (Nasdaq: WGS) representing a 8.1% ownership interest as a result of our sale of GeneDx, Inc. and subsequent participation in an underwritten offering by GeneDx Holdings. Richard Pfenniger who sits on our Board also sits on the GeneDx Board. See further discussion of our investments in Note 6.   Dr. Elias Zerhouni, our Vice Chairman and President, sits on the board of directors of Danaher Corporation ("Danaher"). Our subsidiary, BioReference, routinely procures products and services from several subsidiaries of Danaher, including Beckman Coulter, Integrated DNA Technologies Inc., and Leica Microsystems Inc., to which BioReference has paid $2.6 million, $3.3 million, and $0.3 million, respectively, during the nine months ended September 30, 2024.   BioReference purchases and uses certain products acquired from InCellDx, a company in which we hold a 29% minority interest.   We reimburse Dr. Frost for Company-related use by Dr. Frost and our other executives of an airplane owned by a company that is beneficially owned by Dr. Frost. We reimburse Dr. Frost for out-of-pocket operating costs for the use of the airplane by Dr. Frost or Company executives for Company-related business. We do not reimburse Dr. Frost for personal use of the airplane by Dr. Frost or any other executive. For the three and nine months ended September 30, 2024, we reimbursed and accrued approximately $0.0 thousand and $23.9 thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives. For the three and nine months ended September 30, 2023, we reimbursed and accrued approximately $49.5 thousand and $78.8 thousand, respectively, for Company-related travel by Dr. Frost and other OPKO executives.   2950026328910001030007110000550000016100000.10150000100000012000006 30.290.00050.020.010.010.010.470.0053630000.0812600000330000030000000.290239 NOTE 12 COMMITMENTS AND CONTINGENCIES   In February 2023, the Office of the Attorney General for the State of Texas ("TX OAG") informed BioReference that it believes that, from 2005 to the present, BioReference may have violated the Texas Medicaid Fraud Prevention Act with respect to claims it presented to Texas Medicaid for reimbursement. BioReference and the TX OAG have reached an agreement in principle to settle this matter and are currently negotiating the settlement agreement.   On December 29, 2022, the Israel Tax Authority (the "ITA") issued an assessment against our subsidiary, OPKO Biologics in the amount of approximately $246 million (including interest) related to uncertain tax positions involving income recognition in connection with an examination of foreign tax returns for the 2014 through 2020 tax years. We recognize that local tax law is inherently complex and the local taxing authorities may not agree with certain tax positions taken. We are appealing this assessment, as we believe, other than for uncertain tax positions for which we have reserved, the issues are without technical merit. We intend to exhaust all judicial remedies necessary to resolve the matter, as necessary, which could be a lengthy process. There can be no assurance that this matter will be resolved in our favor, and an adverse outcome, or any future tax examinations involving similar assertions, could have a material effect on our financial condition, results of operations and cash flows.   The Company and BioReference entered into (i) a settlement agreement (the "Settlement Agreement"), effective July 14, 2022, with the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General of the Department of Health and Human Services ("OIG-HHS"), and the Defense Health Agency, acting on behalf of the TRICARE Program (collectively, the "United States"), the Commonwealth of Massachusetts , the State of Connecticut, and the relator identified therein ("Relator"), and (ii) a Corporate Integrity Agreement, effective July 14, 2022 (the "CIA"), with the OIG-HHS, to resolve the investigation and related civil action concerning alleged fee-for-service claims for payment to the Medicare Program, the Medicaid Program, and the TRICARE Program (collectively, the "Federal Health Care Programs").   Under the Settlement Agreement, the Company and BioReference admitted only to having made payments to certain physicians and physicians' groups for office space rentals for amounts that exceeded fair market value, and that it did not report or return any such overpayments to the Federal Health Care Programs (the "Covered Conduct"). The Covered Conduct had commenced prior to the Company's acquisition of BioReference in 2015. With the exception of the Covered Conduct, the Company and BioReference expressly deny the allegations of the Relator as set forth in her civil action. The Company has paid a total of $10,000,000 plus accrued interest from September 24, 2021 at a rate of 1.5% per annum (the "Settlement Amount"). The Settlement Amount consists of $9,853,958 payable to the United States, $141,041 payable to the Commonwealth and $5,001 payable to Connecticut, in each case plus interest and was paid on July 18, 2022. Conditioned upon payment of the Settlement Amount, the United States, Massachusetts and Connecticut agreed to release the Company and BioReference from any civil or administrative monetarily liability arising from the Covered Conduct. Upon payment of the Settlement Amount and the amount due under a separate agreement with the Relator, the Relator released the Company and BioReference from any and all claims and potential claims. Further, in consideration of the obligations of the Company and BioReference in the Settlement Agreement and the CIA, the OIG-HHS released and refrained from instituting any administrative action seeking to exclude the Company or BioReference from participating in Medicare, Medicaid or other Federal health care programs as a result of the Covered Conduct.   Under the CIA, which has a term of 5 years, BioReference is required to, among other things: (i) maintain a Compliance Officer, a Compliance Committee, board review and oversight of certain federal healthcare compliance matters, compliance programs, and disclosure programs; (ii) provide management certifications and compliance training and education; (iii) establish written compliance policies and procedures to meet federal health care program requirements; (iv) create procedures designed to ensure compliance with the Anti-Kickback Statute and/or Stark Law; (v) engage an independent review organization to conduct a thorough review of BioReference' s systems, policies, processes and procedures related to certain arrangements; (vi) implement a risk assessment and internal review process; (vii) establish a disclosure program for whistleblowers; and (viii) report or disclose certain events and physician payments. The Company's or BioReference's failure to comply with its obligations under the CIA could result in monetary penalties and the exclusion from participation in Federal Health Care Programs. The CIA does not apply to any of the Company's subsidiaries other than BioReference, and its scope is generally limited to "focus arrangements", which are those "arrangements" (as defined in the CIA) (i) between BioReference and any actual source or recipient of health care business or referrals and involves, directly or indirectly, the offer, payment, or provision of anything of value, or (ii) is between BioReference and any physician (or a physician's immediate family member). Most of these measures have already been implemented at BioReference. Following its acquisition of BioReference, the Company and BioReference implemented robust compliance measures that substantially align with those actions required under the CIA.   On March 1, 2019, the Company received a Civil Investigative Demand ("CID") from the U.S. Department of Justice ("DOJ"), Washington, DC. The CID sets forth document requests and interrogatories in connection with allegations that the Company and certain of its affiliates violated the False Claims Act and/or the Anti-Kickback Statute. On January 13, 2022, the Federal Government notified the U.S.D.C., Middle District Florida, Jacksonville Division, that it is declining to intervene in the matter but retains the right, via the Attorney General, to consent to any proposed dismissal of the action by the Court. On February 9, 2022, the States of Florida, Georgia, and Commonwealth of Massachusetts notified the U.S.D.C., Middle District Florida, Jacksonville Division, that they are declining to intervene in the matter. Notwithstanding the above declinations, on February 17, 2022, the Company was served with the Relator's Summons and Complaint ("Complaint"), which had been previously sealed. The Complaint alleges violations of the False Claims Act, the California Fraud Preventions Act, the Florida False Claims Act, the Massachusetts False Claims Act, the Georgia False Medicaid Claims Act, and illegal kickbacks. A motion to dismiss the Complaint was filed on April 25, 2022 and the case was dismissed in March 2023. However, the Relator filed an amended complaint in April 2023 and a second amended complaint, both of which were dismissed. Relator then filed an appeal in the U.S. Eleventh Circuit Court of Appeals which is pending before the court following a failed mediation in April 2024. While management cannot predict the outcome of these matters at this time, the ultimate outcome could be material to our business, financial condition, results of operations, and cash flows.   From time to time, we may receive inquiries, document requests, CIDs or subpoenas from the Department of Justice, OCR, CMS, various payors and fiscal intermediaries, and other state and federal regulators regarding investigations, audits

and reviews. In addition to the matters discussed in this note, we are currently responding to CIDs, subpoenas, payor audits, and document requests for various matters relating to our laboratory operations. Some pending or threatened proceedings against us may involve potentially substantial amounts as well as the possibility of civil, criminal, or administrative fines, penalties, or other sanctions, which could be material. Settlements of suits involving the types of issues that we routinely confront may require monetary payments as well as corporate integrity agreements. Additionally, qui tam or "whistleblower" actions initiated under the civil False Claims Act may be pending but placed under seal by the court to comply with the False Claims Act's requirements for filing such suits. Also, from time to time, we may detect issues of non-compliance with federal healthcare laws pertaining to claims submission and reimbursement practices and/or financial relationships with physicians, among other things. We may avail ourselves of various mechanisms to address these issues, including participation in voluntary disclosure protocols. Participating in voluntary disclosure protocols can have the potential for significant settlement obligations or even enforcement action. The Company generally has cooperated, and intends to continue to cooperate, with appropriate regulatory authorities as and when investigations, audits and inquiries arise.   We are a party to other litigation in the ordinary course of business. While we cannot predict the ultimate outcome of legal matters, we accrue a liability for legal contingencies when we believe that it is both probable that a liability has been incurred and that we can reasonably estimate the amount of the loss. It's reasonably possible the ultimate liability could exceed amounts currently estimated and we review established accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel and other relevant information. To the extent new information is obtained and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made. Because of the high degree of judgment involved in establishing loss estimates, the ultimate outcome of such matters will differ from our estimates and such differences may be material to our business, financial condition, results of operations, and cash flows.   At September 30, 2024, we were committed to make future purchases for inventory and other items in 2024 that occur in the ordinary course of business under various purchase arrangements with fixed purchase provisions aggregating approximately $44.0 million 246000000100000000.01598539581410415001440000000 NOTE 13 REVENUE RECOGNITION   We generate revenues from services, products and intellectual property as follows: Revenue from services   Revenue for laboratory services is recognized at the time test results are reported, which approximates when services are provided and the performance obligations are satisfied. Services are provided to patients covered by various third-party payor programs including various managed care organizations, as well as the Medicare and Medicaid programs. Billings for services are included in revenue net of allowances for contractual discounts, allowances for differences between the amounts billed and estimated program payment amounts, and implicit price concessions provided to uninsured patients which are all elements of variable consideration.   The following are descriptions of our payors for laboratory services: Healthcare Insurers. Reimbursements from healthcare insurers are based on negotiated fee-for-service schedules. Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements. Adjustments to the allowances, based on actual receipts from the third-party payors, are recorded upon settlement.   Government Payors. Reimbursements from government payors are based on fee-for-service schedules set by governmental authorities, including traditional Medicare and Medicaid. Revenues consist of amounts billed, net of contractual allowances for differences between amounts billed and the estimated consideration we expect to receive from such payors, which considers historical denial and collection experience and the terms of our contractual arrangements. Adjustments to the allowances, based on actual receipts from the government payors, are recorded upon settlement.   Client Payors. Client payors include physicians, hospitals, employers, and other institutions for which services are performed on a wholesale basis, and are billed and recognized as revenue based on negotiated fee schedules.   Patients. Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients. Insured patients (including amounts for coinsurance and deductible responsibilities) are billed based on fees negotiated with healthcare insurers. Collection of billings from patients is subject to credit risk and ability of the patients to pay. Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with our policies and implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration that we expect to receive from patients, which considers historical collection experience and other factors including current market conditions. Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement.   The complexities and ambiguities of billing, reimbursement regulations and claims processing, as well as considerations unique to Medicare and Medicaid programs, require us to estimate the potential for retroactive adjustments as an element of variable consideration in the recognition of revenue in the period the related services are rendered. Actual amounts are adjusted in the period those adjustments become known. For the nine months ended September 30, 2024 and 2023, we recorded $2.2 million and $19.8 million of negative revenue adjustments primarily due to the composition of patient pay mix.   Third-party payors, including government programs, may decide to deny payment or recoup payments for testing they contend were improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. Our revenues may be subject to retroactive adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payors in interpretations, requirements, and "conditions of participation" in various programs. We have processed requests for recoupment from third-party payors in the ordinary course of our business, and it is likely that we will continue to do so in the future. If a third-party payor denies payment for testing or recoups money from us in a later period, reimbursement for our testing could decline.   As an integral part of our billing compliance program, we periodically assess our billing and coding practices, respond to payor audits on a routine basis, and investigate reported failures or suspected failures to comply with federal and state healthcare reimbursement requirements, as well as overpayment claims which may arise from time to time without fault on the part of the Company. We may have an obligation to reimburse Medicare, Medicaid, and third-party payors for overpayments regardless of fault. We have periodically identified and reported overpayments, reimbursed payors for overpayments and taken appropriate corrective action.   Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are also considered variable consideration and are included in the determination of the estimated transaction price for providing services. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and our historical settlement activity, including an assessment of the probability a significant reversal of cumulative revenue recognized will occur when the uncertainty is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. As of September 30, 2024 and December 31, 2023, we had liabilities of approximately $4.9 million and $3.1 million, respectively, within Accrued expenses and Other long-term liabilities related to reimbursements for payor overpayments.   The composition of revenue from services by payor for the three and nine months ended September 30, 2024 and 2023 was as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> (In thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Healthcare insurers </td><td style="width: 1%; font-family: "Times New Roman", Times,

serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">76,184</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">81,469</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">229,600</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">238,934</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Government payers </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20,368</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19,909</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">63,561</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">61,250</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Client payers </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20,773</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25,906</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">71,521</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">77,973</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Patients </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,946</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,395</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,875</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,943</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">121,271</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">131,679</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">377,557</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">391,100</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>   Revenue from products   We recognize revenue from product sales when a customer obtains control of promised goods or services. The amount of revenue recorded reflects the consideration that we expect to receive in exchange for those goods or services. Our estimates for sales returns and allowances are based upon the historical patterns of product returns and allowances taken, matched against the sales from which they originated, and our evaluation of specific factors that may increase or decrease the risk of product returns. Product revenues are recorded net of estimated rebates, chargebacks, discounts, co-pay assistance and other deductions (collectively, “Sales Deductions”) as well as estimated product returns which are all elements of variable consideration. Allowances are recorded as a reduction of revenue at the time product revenues are recognized. The actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect revenue from products in the period such variances become known.   Rayaldee is distributed in the U.S. principally through the retail pharmacy channel, which initiates with the largest wholesalers in the U.S. (collectively, “Rayaldee Customers”). In addition to distribution agreements with Rayaldee Customers, we have entered into arrangements with many healthcare providers and payors that provide for government-mandated or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of Rayaldee.   We recognize revenue for shipments of Rayaldee at the time of delivery to customers after estimating Sales Deductions and product returns as elements of variable consideration utilizing historical information and market research projections. For the three and nine months ended September 30, 2024, we recognized $5.8 million and $19.9 million, respectively, in net product revenue from sales of Rayaldee. For the three and nine months ended September 30, 2023, we recognized $7.3 million and $21.7 million, respectively, in net product revenue from sales of <i>Rayaldee</i>.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The following table presents an analysis of <i>Rayaldee</i> product sales allowances and accruals for the <em style="font: inherit;">three and <em style="font: inherit;">nine months ended <em style="font: inherit;"> September 30, 2024 and <em style="font: inherit;">2023:</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Chargebacks, discounts, rebates and fees</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Governmental</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Returns</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at June 30, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,743</td><td

style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,991</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,928</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Provision related to current period sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,005</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,776</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">317</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,098</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Credits or payments made</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5,058</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(7,013</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(12,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at September 30, 2024</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,690</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,754</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,233</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,677</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Total gross Rayaldee sales</i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,865</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">64</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> (In thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Chargebacks, discounts, rebates and fees </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Governmental </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Returns </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,578</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,150</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,192</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,920</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Provision related to current period sales </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,224</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,325</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">989</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">29,538</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Credits or payments made </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(13,112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(17,721</td><td style="width: 1%; font-

family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(948</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(31,781</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,690</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,754</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,233</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,677</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total gross Rayaldee sales </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">49,447</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales</i></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;">60</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Chargebacks, discounts, rebates and fees</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Governmental</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Returns</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at June 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,330</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,954</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,634</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,918</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Provision related to current period sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,446</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,998</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">322</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,766</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Credits or payments made</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(8,347</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at September 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,651</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,745</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,941</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family:

Times New Roman; font-size: 10pt; margin-left: 0pt;">10,337</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total gross Rayaldee sales </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales</i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(In thousands)</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Chargebacks, discounts, rebates and fees</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Governmental</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Returns</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2022</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,532</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,063</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,683</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,278</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Provision related to current period sales</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,702</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,604</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">959</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26,265</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Credits or payments made</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(10,583</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(12,922</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(701</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(24,206</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at September 30, 2023</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,651</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,745</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,941</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,337</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total gross Rayaldee sales </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman",

Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">47,940</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">55</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table>   Taxes collected from customers related to revenues from services and revenues from products are excluded from revenues.   Revenue from intellectual property and other   We recognize revenues from the transfer of intellectual property generated through license, development, collaboration and/or commercialization agreements. The terms of these agreements typically include payment to us for one or more of the following: non-refundable, up-front license fees; development and commercialization milestone payments; funding of research and/or development activities; and royalties on sales of licensed products. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the customer.   For research, development and/or commercialization agreements that result in revenues, we identify all material performance obligations, which may include a license to intellectual property and know-how, and research and development activities. In order to determine the transaction price, in addition to any upfront payment, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. We constrain (reduce) our estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, we consider whether there are factors outside of our control that could result in a significant reversal of revenue. In making these assessments, we consider the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.   Upfront License Fees: If a license to our intellectual property is determined to be functional intellectual property distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront license fees based on the relative value prescribed to the license compared to the total value of the arrangement. The revenue is recognized when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are not distinct from other obligations identified in the arrangement, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If the combined performance obligation is satisfied over time, we apply an appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront license fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.   Research and Development Activities: If we are entitled to reimbursement from our customers for specified research and development expenses, we account for them as separate performance obligations if distinct. We also determine whether the research and development funding would result in revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The corresponding revenues or offset to research and development expenses are recognized as the related performance obligations are satisfied.   BARDA Contract: Revenue from the BARDA Contract is generated under terms that are cost plus fee. We recognize revenue using the incurred costs output method to measure progress. Revenue will only be recognized when research and development services are performed to the extent of actual costs incurred.   Sales-based Milestone and Royalty Payments: Our customers may be required to pay us sales-based milestone payments or royalties on future sales of commercial products. We recognize revenues related to sales-based milestone and royalty payments upon the later to occur of (i) achievement of the customer's underlying sales or (ii) satisfaction of any performance obligation(s) related to these sales, in each case assuming the license to our intellectual property is deemed to be the predominant item to which the sales-based milestones and/or royalties relate.   Other Potential Products and Services: Arrangements may include an option for license rights, future supply of drug substance or drug product for either clinical development or commercial supply at the licensee's election. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations at the inception of the contract and revenue is recognized only if the option is exercised and products or services are subsequently delivered or when the rights expire. If the promise is based on market terms and not considered a material right, the option is accounted for if and when exercised. If we are entitled to additional payments when the licensee exercises these options, any additional payments are generally recorded in license or other revenues when the licensee obtains control of the goods, which is upon delivery.   For the three months ended September 30, 2024, revenue from the transfer of intellectual property and other was $13.2 million, an increase from $6.2 million for the three months ended September 30, 2023. This increase was primarily attributable to $5.5 million from the BARDA Contract (as defined and described in Note 14). Gross profit share and royalty payments for NGENLA (Somatrogon) and Pfizer's Genotropin® (Somatropin) also increased to $7.0 million, compared with $4.9 million for the same period in 2023.   For the nine months ended September 30, 2024, revenue from the transfer of intellectual property and other decreased to $34.3 million from $165.9 million for the nine months ended September 30, 2023. This decrease was primarily due to one-time milestone payments received in 2023, including a $90.0 million payment related to NGENLA, a $50.0 million payment from Merck for rights granted under the Merck Agreement, a $7.0 million payment from VFMCRP triggered by the German price approval for Rayaldee, and a $2.5 million payment from Nicoya upon submission of an investigational new drug application to China's Center for Drug Evaluation. See Note 14 for a description of the arrangements pursuant to which such milestone payments were received. Revenue for the nine months ended September 30, 2024, included $18.9 million in gross profit share and royalty payments for NGENLA (Somatrogon) and Pfizer's Genotropin® (Somatropin), compared to $11.8 million in the same period in 2023, as well as $12.8 million from the BARDA Contract during the <em style="font: inherit;">2024 period.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> 22000001980000049000003100000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Three months ended September 30,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine months ended September 30,</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(In thousands)</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Healthcare insurers</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">76,184</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">81,469</td><td

style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">229,600</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">238,934</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Government payers </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20,368</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">19,909</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">63,561</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">61,250</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Client payers </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20,773</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25,906</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">71,521</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">77,973</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Patients </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,946</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,395</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,875</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,943</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">121,271</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">131,679</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">377,557</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">391,100</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>
7618400081469000229600000238934000203680001990900063561000612500002077300025906000715210007797300039460004395000128750001294300012127100013
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> (In thousands) </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Chargebacks, discounts, rebates and fees </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Governmental </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Returns </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Balance at June 30, 2024 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,743</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,991</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,928</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Provision related to current period sales </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,005</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,776</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">317</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,098</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Credits or payments made </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(5,058</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(7,013</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(278</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width:

9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(12,349</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Balance at September 30, 2024 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,690</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,754</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,233</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,677</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total gross Rayaldee sales </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,865</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales</i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(In thousands)</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Chargebacks, discounts, rebates and fees</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Governmental</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Returns</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2023</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,578</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,150</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,192</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,920</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Provision related to current period sales</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">12,224</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,325</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">989</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">29,538</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Credits or payments made</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(13,112</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(17,721</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(948</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(31,781</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,690</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,754</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,233</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,677</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman",

Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total gross Rayaldee sales </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">49,447</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales</i></p> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(In thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Chargebacks, discounts, rebates and fees</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Governmental</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Returns</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at June 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,330</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,954</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,634</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,918</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Provision related to current period sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,446</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,998</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">322</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,766</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Credits or payments made</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,125</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4,207</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(8,347</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at September 30, 2023</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,651</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,745</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,941</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,337</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Total gross Rayaldee sales</i></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,090</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt;">54</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> (In thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Chargebacks, discounts, rebates and fees </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td

style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Governmental </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Returns </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at December 31, 2022 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,532</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,063</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,683</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,278</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Provision related to current period sales </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,702</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">14,604</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">959</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">26,265</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Credits or payments made </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(10,583</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(12,922</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(701</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(24,206</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Balance at September 30, 2023 </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,651</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,745</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,941</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">10,337</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total gross Rayaldee sales </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">47,940</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Provision for Rayaldee sales allowances and accruals as a percentage of gross Rayaldee sales </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">55</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table>
2743000599100021940001092800040050005776000317000100980005058000701300027800012349000169000047540002233000867700015865000 0.64257800061500002
NOTE 14 STRATEGIC ALLIANCES   Biomedical Advanced Research and Development Authority   On September 28, 2023, ModeX was awarded a contract (as amended as decribed below, the “BARDA Contract”) by the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services. This contract aims to advance a platform and product candidates addressing various public health threats, specifically in viral infectious diseases. The funding enables the research, development, and clinical evaluation of multispecific antibodies based on ModeX's proprietary MSTAR technology. MSTAR is a flexible, plug-and-play platform capable of incorporating multiple independent antibody binding sites into a single molecule, expanding its therapeutic potential and enabling rapid responses to emerging infections, including viral variants like COVID-19, influenza, and other pathogens.   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin:

0pt; text-indent: 27pt;">In September 2024, ModeX entered into two amendments (the “BARDA Amendments”) to modify the scope and funding of the BARDA Contract. The BARDA Amendments structured the funding thereunder as cost-plus-fixed-fee, which includes a $26.9 million supplement to further advance the development of COVID-19 multispecific antibodies. This increased funding supports the ongoing development, manufacturing, and execution of a Phase 1 clinical trial for a next-generation MSTAR multispecific antibody with broad neutralizing activity against known SARS-CoV-2 variants. The BARDA Amendments also provided for BARDA's exercise of the option for the development of a multispecific protein antibody for influenza or another pathogen, with $24.1 million allocated to cover the expanded work under this exercised option. These modifications increased the total value of the BARDA Contract from $59.0 million to $110.0 million, with the potential value if BARDA exercises all options thereunder to expand ModeX's services, increasing from $168.6 million to $205 million.   As part of the research program, gene-based delivery methods for the multispecific antibodies will be developed using mRNA or DNA vectors to leverage the body's natural protein production processes. BARDA will make periodic progress assessments, and the continuation of the BARDA Contract depends on ModeX’s performance, the timeliness and quality of deliverables, and other factors. The BARDA Contract contains customary government contract provisions, including BARDA's right to terminate the contract in its discretion.   The Company evaluated the BARDA Contract under ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), and determined that the U.S. government meets the definition of a customer. The scope of the BARDA Contract includes preclinical, clinical, and manufacturing activities, as well as regulatory, quality assurance, management, and administrative activities. The research and development effort will progress in stages covering base and option segments, with ModeX completing specific tasks in each segment.   The Company identified three potential material promises under the BARDA Contract: (i) development of a tetravalent trispecific antibody for COVID-19; (ii) development of a multispecific protein antibody for influenza or another pathogen; and (iii) nucleic acid delivery of a multispecific antibody for influenza or another pathogen. The Company determined the promise to develop a tetravalent trispecific antibody for COVID-19 is a separate performance obligation, as it is distinct within the contract and provides standalone value. Similarly, the exercised option to develop a multispecific protein antibody for influenza or another pathogen is also a separate performance obligation. However, the Company determined that the nucleic acid delivery option does not offer incremental discounts beyond those typically provided for such goods and services, and therefore does not represent a material right. As such, the options in (iii) were not considered performance obligations at the outset of the BARDA Contract.   The Company concluded that research and development services performed under the BARDA Contract would be recognized as revenue when research and development services are performed to the extent of actual costs incurred including a fixed fee and will be reimbursed by BARDA. Costs incurred represent work performed, which corresponds with, and thereby best depicts, the transfer of control of the research and development to BARDA. Types of contract costs include labor, material, and third-party services. As such, the related BARDA revenue is recognized as revenue from transfer of intellectual property and other within the Company’s Consolidated Statements of Operations. For the three and nine months ended September 30, 2024, we recorded $5.5 million and $12.8 million in revenue under the BARDA Contract. As of September 30, 2024, the aggregate amount of transaction price allocated to remaining performance obligations, excluding unexercised contract options, was $96.0 million. We expect to recognize this amount as revenue through February 2028.   Merck   On March 8, 2023, ModeX, the Company (with respect to certain sections), and Merck Sharp & Dohme LLC (“Merck”) entered into a License and Research Collaboration Agreement (the “Merck Agreement”) pursuant to which ModeX granted to Merck a license to certain patent rights and know-how in connection with the development of ModeX’s preclinical nanoparticle vaccine candidate targeting the Epstein-Barr Virus.   Under the terms of the Merck Agreement, ModeX granted to Merck an exclusive, sublicensable, royalty-bearing license to certain intellectual property to develop, manufacture, use and commercialize (i) a multivalent or monovalent vaccine assembled using our platform for Epstein-Barr Virus (“Vaccine”), and (ii) any pharmaceutical or biological preparation in final form containing a Vaccine for sale or for administration to human patients in a clinical trial for all uses (“Product”). We received an initial payment of $50.0 million and are eligible to receive up to an additional $872.5 million upon the achievement of certain commercial and development milestones under several indications. We are also eligible to receive tiered royalty payments ranging from high single digits to low double digits upon achievement of certain sales targets of the Product. Certain of the rights subject to the license provided by us under the Merck Agreement were obtained by us from Sanofi pursuant to that certain License Agreement entered into as of July 1, 2021 (“Sanofi In-License Agreement”) between us and Sanofi, a French corporation (“Sanofi”), and a portion of the upfront payment, milestones and royalties received by us under the Merck Agreement may be payable to Sanofi under the terms of the Sanofi In-License Agreement. As a result of such obligations under the Sanofi In-License Agreement, we paid $12.5 million to Sanofi during the three months ended September 30, 2023.   As part of their strategic collaboration, ModeX and Merck have put in place a research plan to manage research and other development activities related to the development of a Vaccine or Product including a joint steering committee to facilitate the research program. As part of the research plan, they will use a third-party contract development and manufacturing organization to carry out such activities unless otherwise agreed. Development costs incurred by ModeX in furtherance of these development activities will be reimbursed by Merck. To date, we have spent $24.5 million of development costs related to the Epstein -Barr Virus, for which Merck has provided reimbursement.   The Merck Agreement will remain in effect until one or more Products receive marketing authorization, and, thereafter, until the expiration of all royalty obligations unless earlier terminated as permitted under the Merck Agreement. In addition to termination rights for material breach and bankruptcy, Merck is permitted to terminate the Merck Agreement in its entirety without cause after a specified notice period. If Merck terminates the Merck Agreement for convenience or by us for Merck’s uncured material breach, we may elect to receive a reversion license such that we can continue its work with Vaccines and Products which have not been terminated due to a material safety issue.   LeaderMed   On September 14, 2021, we and LeaderMed announced the formation of a joint venture to develop, manufacture and commercialize two of OPKO’s clinical stage, long-acting drug products in Greater China and eight other Asian territories.   Under the terms of the agreements, we have granted the joint venture exclusive rights to develop, manufacture and commercialize (a) OPK88003, an oxyntomodulin analog being developed for the treatment of obesity and diabetes, and (b) Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia, in exchange for a 47% ownership interest in the joint venture. In addition, during 2021 we received an upfront payment of $1 million and will be reimbursed for clinical trial material and technical support we provide the joint venture.   LeaderMed is responsible for funding the joint venture’s operations, development and commercialization efforts and, together with its syndicate partners, initially invested $11 million in exchange for a 53% ownership interest. We retain full rights to oxyntomodulin and Factor VIIa-CTP in all other geographies.   CAMP4 Therapeutics   On July 6, 2021, we entered into an exclusive license agreement (the “CAMP4 Agreement”) with CAMP4, pursuant to which we granted to CAMP4 an exclusive license to develop, manufacture, commercialize or improve therapeutics utilizing the AntagoNAT technology, an oligonucleotide platform developed under OPKO CURNA, which includes the molecule for the treatment of Dravet syndrome, together with any derivative or modification thereof (the “Licensed Compound”) and any pharmaceutical product that comprises or contains the Licensed Compound, alone or in combination with one or more other active ingredients (“Licensed Product”), worldwide. The CAMP4 Agreement grant covers human pharmaceutical, prophylactic, and therapeutic and certain diagnostic uses.   We received an initial upfront payment of $1.5 million and 3,373,008 shares of CAMP4’s Series A Prime Preferred Stock (“Preferred Stock”), which then equated to approximately 9% of the outstanding shares of CAMP4, and we are eligible to receive up to $3.5 million in development milestone payments for Dravet syndrome products, and $4 million for non-Dravet syndrome products, as well as sales milestones of up to $90 million for Dravet syndrome products and up to $90 million for non-Dravet syndrome products. We may also receive double digit royalty payments on the net sales of royalty bearing products, subject to adjustment. In addition, upon achievement of certain development milestones, we will be eligible to receive equity consideration of up to 5,782,299 shares of Preferred Stock in connection with Dravet syndrome products and up to 1,082,248 shares of Preferred Stock in connection with non-Dravet syndrome products. In connection with our acquisition of CURNA, we agreed to pay future consideration to the sellers upon the achievement of certain events. As a result of our execution of the CAMP4 Agreement, we will have to pay a percentage of any payments received under the CAMP4 Agreement to the former CURNA stockholders.   The Company was notified that the FDA placed the Dravet clinical trials on hold and CAMP4 subsequently ceased development efforts.   NICOYA Macau Limited   On June 18, 2021, EirGen, our wholly owned subsidiary, and NICOYA Macau Limited (“Nicoya”), a Macau corporation and an affiliate of NICOYA Therapeutics, entered into a Development and License Agreement (the “Nicoya Agreement”) granting Nicoya the exclusive rights for the development and commercialization of extended release calcifediol (the “Nicoya Product”) in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan (collectively, the “Nicoya Territory”). Extended release calcifediol is marketed in the U.S. by OPKO under the tradename Rayaldee. The license grant to Nicoya covers the therapeutic and preventative use of the Nicoya Product for SHPT in non-dialysis and hemodialysis chronic kidney disease patients (the “Nicoya Field”).   EirGen received an initial upfront payment of $5 million and was eligible to receive an additional $5 million tied to the first anniversary of the effective date of the Nicoya Agreement, as amended, of which EirGen has received $2.5 million plus accrued interest for the delayed payment. Furthermore, EirGen received the additional $2.5 million upon Nicoya’s submission of an investigational new drug (IND) application to the Center for Drug Evaluation of China in March 2023. EirGen is also eligible to receive up to an additional aggregate amount of $115 million upon the achievement of certain development, regulatory and sales-based milestones by Nicoya for the Nicoya Product in the Nicoya Territory. EirGen is eligible to receive tiered, double digit royalty payments at rates in the low double digits on net product sales within the Nicoya Territory and in the Nicoya Field.   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent:

27pt;">Nicoya is, at its sole cost and expense, responsible for performing all development activities necessary to obtain all regulatory approvals for the Nicoya Product in the Nicoya Territory and will be responsible for all commercial activities pertaining to the Nicoya Product in the Nicoya Territory.   Unless earlier terminated, the Nicoya Agreement will remain in effect until such time as all royalty payment terms and extended payment terms have expired, and Nicoya shall have no further payment obligations to EirGen under the terms of the Nicoya Agreement. Nicoya's royalty obligations expire on the later of (i) expiration of the last to expire valid patent claim covering the Nicoya Product sold in the Nicoya Territory, (ii) expiration of all regulatory and data exclusivity applicable to the Nicoya Product in the Nicoya Territory, and (iii) on a product-by-product basis, ten (10) years after such Nicoya Product's first commercial sale in the Nicoya Territory. In addition to termination rights for material breach and bankruptcy, Nicoya is permitted to terminate the Nicoya Agreement after a specified notice period.   VFMCRP   In May 2016, EirGen and Vifor Fresenius Medical Care Renal Pharma Ltd. ("VFMCRP ") entered into a Development and License Agreement (the "VFMCRP Agreement") for the development and commercialization of Rayaldee (the "Product") worldwide, except for (i) the United States and Canada, (ii) any country in Central America or South America (including Mexico), (iii) Russia, (iv) China, (v) South Korea, (vi) Ukraine, (vii) Belorussia, (viii) Azerbaijan, (ix) Kazakhstan, (x) Taiwan (xi) the Middle East, and (xii) all countries of Africa (the "VFMCRP Territory"), as amended. The license to VFMCRP potentially covers all therapeutic and prophylactic uses of the Product in human patients (the "VFMCRP Field"), provided that initially the license is for the use of the Product for the treatment or prevention of SHPT related to patients with CKD and vitamin D insufficiency/deficiency (the "VFMCRP Initial Indication").   In January 2023, the German Association of Statutory Health Insurance funds (GKV-SV) granted price approval for Rayaldee. This triggered a milestone payment of $7.0 million. In 2022, we recognized a separate milestone payment of $3.0 million in revenue from the transfer of intellectual property and other for the first sale of Rayaldee in Europe.   Effective May 23, 2021, we entered into an amendment to the VFMCRP Agreement pursuant to which the parties thereto agreed to include Japan as part of the VFMCRP Territory.   Effective May 5, 2020, we entered into an amendment to the VFMCRP Agreement pursuant to which the parties agreed to exclude Mexico, South Korea, the Middle East and all of the countries of Africa from the VFMCRP Territory. In addition, the parties agreed to certain amendments to the milestone structure and to reduce minimum royalties payable. As revised, the Company has received a $3 million payment triggered by the first marketing approval of Rayaldee in Europe, $7.0 million payment triggered by the Germany price approval by the local sick fund association, and is eligible to receive up to an additional $15 million in regulatory milestones and $200 million in milestone payments tied to launch, pricing and sales of Rayaldee, and tiered, double-digit royalties.   We plan to share responsibility with VFMCRP for the conduct of trials specified within an agreed-upon development plan, with each company leading certain activities within the plan. EirGen will lead the manufacturing activities within and outside the VFMCRP Territory and the commercialization activities outside the VFMCRP Territory and outside the VFMCRP Field in the VFMCRP Territory and VFMCRP will lead the commercialization activities in the VFMCRP Territory and the VFMCRP Field. For the initial development plan, the companies have agreed to certain cost sharing arrangements. VFMCRP will be responsible for all other development costs that VFMCRP considers necessary to develop the Product for the use of the Product for the VFMCRP Initial Indication in the VFMCRP Territory in the VFMCRP Field except as otherwise provided in the VFMCRP Agreement. The first of the clinical studies provided for in the development activities commenced in September 2018.   In connection with the VFMCRP Agreement, the parties entered into a letter agreement pursuant to which EirGen granted to VFMCRP an exclusive option (the "Option") to acquire an exclusive license under certain EirGen patents and technology to use, import, offer for sale, sell, distribute and commercialize the Product in the U.S. solely for the treatment of SHPT in dialysis patients with CKD and vitamin D insufficiency (the "Dialysis Indication"). Upon exercise of the Option, VFMCRP has agreed to reimburse EirGen for all of the development costs incurred by EirGen with respect to the Product for the Dialysis Indication in the U.S. VFMCRP would also pay EirGen up to an additional aggregate amount of $555 million of sales-based milestones upon the achievement of certain milestones and would be obligated to pay royalties at percentage rates that range from the mid-teens to the mid-twenties on sales of the Product in the U.S. for the Dialysis Indication. To date, VFMCRP has not exercised the Option.   Payments received for regulatory milestones and sales milestones are non-refundable. The regulatory milestones are payable if and when VFMCRP obtains approval from certain regulatory authorities and will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. We account for the sales milestones as royalties and sales milestones payments will be recognized as revenue in the period in which the associated milestone is achieved or sales occur, assuming all other revenue recognition criteria are met.   Pfizer Inc.   In December 2014, we entered into an exclusive worldwide agreement with Pfizer for the development and commercialization of our long-acting Somatrogon (hGH-CTP) for the treatment of growth hormone deficiency ("GHD") in adults and children, as well as for the treatment of growth failure in children born small for gestational age (the "Pfizer Transaction"). In May 2020, we entered into an amended and restated development and commercialization license with Pfizer, effective January 1, 2020 (the "Restated Pfizer Agreement"), pursuant to which the parties agreed, among other things, to share all costs for Manufacturing Activities, as defined in the Restated Pfizer Agreement, for developing a licensed product for the three indications included in the Restated Pfizer Agreement.   In June 2023, the FDA approved NGENLA (Somatrogon (hGH-CTP)) a once-weekly injection to treat pediatric growth hormone deficiency in the United States. In early 2022, the European Commission and Ministry of Health, Labour and Welfare in Japan approved NGENLA (Somatrogon). We have also received pricing approvals in Germany and Japan. NGENLA (Somatrogon (hGH-CTP)) is approved for the treatment of pediatric GHD in more than 50 markets, including Canada, Australia, Japan, and EU Member States. With the achievement of these milestones, in 2023 we recorded revenue of $90 million, and in 2022 we recorded $85.0 million, in each case under the Restated Pfizer Agreement.   On October 21, 2019, we and Pfizer announced that the global phase 3 trial evaluating Somatrogon dosed once-weekly in prepubertal children with GHD met its primary endpoint of non-inferiority to daily Genotropin® (somatropin) for injection, as measured by annual height velocity at 12 months.   Under the terms of the Restated Pfizer Agreement we received non-refundable and non-creditable upfront payments of $295.0 million and are eligible to receive up to an additional $275.0 million upon the achievement of certain regulatory milestones. Pfizer received the exclusive license to commercialize Somatrogon worldwide. In addition, we are eligible to receive regional, tiered gross profit sharing for both Somatrogon and Pfizer's Genotropin® (somatropin) in all global markets, with the U.S. region commencing gross profit sharing in August 2023.   The Restated Pfizer Agreement will remain in effect until the last sale of the licensed product, unless earlier terminated in accordance with its terms. In addition to termination rights for material breach and bankruptcy, Pfizer is permitted to terminate the Restated Pfizer Agreement in its entirety, or with respect to one or more world regions, without cause after a specified notice period. If the Restated Pfizer Agreement is terminated by us for Pfizer's uncured material breach, or by Pfizer without cause, provision has been made for transition of product and product responsibilities to us for the terminated regions, as well as continued supply of product by Pfizer or transfer of supply to us in order to support the terminated regions.   We recognized the non-refundable $295.0 million upfront payments as revenue as the research and development services were completed. As of September 30, 2024 and December 31, 2023, we had no contract liabilities related to the Pfizer Transaction.   The Restated Pfizer Agreement includes milestone payments of $275.0 million upon the achievement of certain milestones. The milestones range from $20.0 million to $90.0 million each and are based on achievement of regulatory approval in the U.S. and regulatory approval and price approval in other major markets. The milestone payments will be recognized as revenue in the period in which the associated milestone is achieved, assuming all other revenue recognition criteria are met. To date, $175.0 million of revenue has been recognized related to the achievement of the milestones.   Other   We have completed strategic deals with numerous institutions and commercial partners. In connection with these agreements, upon the achievement of certain milestones we are obligated to make certain payments and have royalty obligations upon sales of products developed under the license agreements. At this time, we are unable to estimate the timing and amounts of payments as the obligations are based on future development of the licensed products.
269000002410000059000000110000000168600000205000000550000012800000960000005000000087250000012500000245000000.471000000110000000.5315000003372
NOTE 15 SEGMENTS   We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations through BioReference. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.   Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For the three months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <em

style="font: inherit;">For the nine months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> (In thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenue from services: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

family: "Times New Roman", Times, serif; font-size: 10pt;"> Diagnostics </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">39,143</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,670</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">117,675</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">124,553</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Revenue from transfer of intellectual property and other: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Pharmaceutical </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">13,218</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,246</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">34,272</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">165,938</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Diagnostics </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,218</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,246</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34,272</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">165,938</td><td style="width: 1%;

font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Operating income (loss): </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Pharmaceutical </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(32,196</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(25,375</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(84,697</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">57,210</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Diagnostics </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">58,541</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(29,081</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,443</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(113,344</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12,129</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,951</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(31,786</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(31,841</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,216</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(64,407</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(118,926</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(87,975</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Depreciation and amortization: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Pharmaceutical </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,043</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,807</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">53,899</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">53,649</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Diagnostics </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,120</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,376</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">20,238</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">25,666</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New

Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New

<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">139,043</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">410,422</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">462,987</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Ireland</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11,514</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,654</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,579</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">121,249</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Chile</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,576</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,932</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">49,067</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">52,427</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Spain</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,297</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,349</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,828</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,427</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Israel</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">196</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,155</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">797</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,388</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Mexico</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,630</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,897</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,621</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,447</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Other</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">756</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">565</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,190</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,666</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">173,632</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">178,595</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">529,504</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">681,591</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-

variant:normal;text-align:center;margin:0pt;">December 31, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> (In thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Assets: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Pharmaceutical </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,271,781</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,331,764</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Diagnostics </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">517,871</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">630,753</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Corporate </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">466,451</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">49,181</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,256,103</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,011,698</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Goodwill: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Pharmaceutical </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">316,161</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">315,235</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Diagnostics </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">219,707</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">283,025</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">535,868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">598,260</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>   No customer represented more than 10% of our total consolidated revenue for the nine months ended September 30, 2024 and 2023. As of September 30, 2024 and December 31, 2023, no customer represented more than 10% of our accounts receivable balance.   00 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For the three months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For the nine months ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> (In thousands) </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Revenue from services: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Pharmaceutical </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Diagnostics </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Pharmaceutical </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif;

font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif;

size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40,670</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">117,675</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">124,553</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Revenue from transfer of intellectual property and other: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(2,443</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(113,344</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(12,129</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,951</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(31,786</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(31,841</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,216</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(64,407</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">) </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">(118,926</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(87,975</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Depreciation and amortization: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"

10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Pharmaceutical </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">(99</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Diagnostics </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Corporate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(20</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(99</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Revenues: </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> United States </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">132,663</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">139,043</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">410,422</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">462,987</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Ireland </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">11,514</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">8,654</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">30,579</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">121,249</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Chile </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,576</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,932</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">49,067</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td

style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">52,427</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Spain </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6,297</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,349</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,828</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16,427</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Israel </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">196</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,155</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">797</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9,388</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Mexico </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,630</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5,897</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">18,621</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">17,447</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">756</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">565</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,190</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,666</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">173,632</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">178,595</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">529,504</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">681,591</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table>
0000121271000131679000377557000391100000000012127100013167900037755700039110000039143000406700001176750001245530000000000039143000406700001
32196000-25375000-84697000572100005854100-29081000-2443000-113344000-12129000-9951000-31786000-3184100014216000-64407000-118926000-
879750001804300017807000538990005364900061200008376000202380002566600000002416300026183000741370007931500-3000-20000-7000-9900000000000-
3000-20000-7000-
990001326630001390430004104220004629870001151400086540003057900012124900016576000169320004906700052427000629700043490001782800016427000196000
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> (In thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Assets: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Pharmaceutical </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,271,781</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,331,764</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Diagnostics </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">517,871</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">630,753</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Corporate </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman;

font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">466,451</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">49,181</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,256,103</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,011,698</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Goodwill: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Pharmaceutical </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">316,161</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">315,235</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Diagnostics </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">219,707</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">283,025</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">535,868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">598,260</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>
127178100013317640005178710006307530004664510004918100022561030002011698000316161000315235002197070002830250005358680005982600000 NOTE 16 LEASES   We have operating leases for office space, laboratory operations, research and development facilities, manufacturing locations, warehouses and certain equipment. We determine if a contract contains a lease at inception or modification of a contract. Our leases generally do not provide an implicit interest rate, and we therefore use our incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate we would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease within a particular currency environment. We used the incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date. Many of our leases contain rental escalation, renewal options and/or termination options that are factored into our determination of lease payments as appropriate. Variable lease payment amounts that cannot be determined at the commencement of the lease are not included in the right-to-use assets or liabilities.   We elected the use of permitted practical expedients of not recording leases on our Condensed Consolidated Balance Sheet when the leases have terms of 12 months or less, and we elected not to separate nonlease components from lease components and instead account for each separate lease component and the nonlease components associated with that lease component as a single lease component.   On January 2, 2023, ModeX entered into a 10-year office lease agreement that commenced in October 2023. ModeX was previously located in Natick, Massachusetts and relocated to Weston, Massachusetts, upon lease commencement. The new location is approximately 33,056 square feet of office space. ModeX has two options to extend the lease term for an additional five years per extension, which would commence upon the expiration of the term in October 2033. Straight-line monthly expense for the lease is $243.5 thousand.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The following table presents the lease balances within the Condensed Consolidated Balance Sheet as of <em style="font: inherit;"> September 30, 2024 and <em style="font: inherit;"> December 31, 2023:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36.9%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 33.1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Classification on the Balance Sheet</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">September 30, 2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 31, 2023</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Operating lease right-of-use assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62,812</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">68,088</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Finance lease assets </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Property, plant and equipment, net </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,544</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Liabilities </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Current </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating lease liabilities </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Current maturities of operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,741</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,996</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Accrued expenses </td>

<td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Current maturities of finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,855</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,827</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Long-term </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating lease liabilities </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Operating lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">52,057</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">54,140</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other long-term liabilities </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Finance lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,689</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,274</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Weighted average remaining lease term </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> Operating leases (in years) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> Finance leases (in years) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Weighted average discount rate </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> Operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> Finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table>   The following table reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized on our Condensed Consolidated Balance Sheet as of September 30, 2024:   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Operating </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Finance </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> October 1, 2024 through December 31, 2024 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,043</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">673</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> 2025 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,772</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> 2026 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,937</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,334</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> 2027 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,775</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">806</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> 2028 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,785</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Thereafter </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,534</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,959</td><td style="width: 1%; font-family:

Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total undiscounted future minimum lease payments </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">73,846</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,788</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: Difference between lease payments and discounted lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,048</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">244</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">64,798</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,544</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>   Expense under operating leases and finance leases was $15.2 million and $2.5 million, respectively, for the nine months ended September 30, 2024, which included $1.5 million of variable lease costs. Expense under operating leases and finance leases was $12.0 million and $2.2 million, respectively, for the nine months ended September 30, 2023, which included $0.9 million of variable lease costs. Operating lease costs and finance lease costs are included within Operating loss in the Condensed Consolidated Statement of Operations. Short-term lease costs were <em style="font: inherit;">not material.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Supplemental cash flow information is as follows:</p> <p style="font-family:Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">For the nine months ended September 30,</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating cash out flows from operating leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,704</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating cash out flows from finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">354</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">327</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Financing cash out flows from finance leases</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,118</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,919</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,573</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,950</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> P10Y33056243500 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 36.9%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(in thousands)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 33.1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Classification on the Balance Sheet</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">September 30, 2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 31, 2023</p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating lease assets</p> </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;">Operating lease right-of-use assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">62,812</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">68,088</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Finance lease assets </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Property, plant and equipment, net </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,544</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Liabilities </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Current </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New

Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating lease liabilities </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Current maturities of operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,741</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,996</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Accrued expenses </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Current maturities of finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,855</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,827</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Long-term </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating lease liabilities </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Operating lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">52,057</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">54,140</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other long-term liabilities </td><td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> Finance lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,689</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,274</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Weighted average remaining lease term </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> Operating leases (in years) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> Finance leases (in years) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7.1</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6.2</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Weighted average discount rate </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> Operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="2" style="font-family: Times New Roman; font-size: 10pt;"> Finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table>
628120006808800065440001010100012741000129960001855000282700052057000541400004689000727400OP6Y3M18DP7Y1M6DP7Y1M6DP6Y2M12D0.0530.0540.0370
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Operating </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Finance </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> October 1, 2024 through December 31, 2024 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,043</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">673</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> 2025 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,772</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> 2026 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,937</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,334</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> 2027 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,775</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">806</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> 2028 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,785</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right;

font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">203</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Thereafter </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,534</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,959</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total undiscounted future minimum lease payments </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">73,846</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,788</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: Difference between lease payments and discounted lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,048</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">244</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total lease liabilities </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">64,798</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,544</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>
3043000673000117720001813000109370001334000107750008060001078500020300026534000195900073846000678800090480002440006479800065440001520000025
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> For the nine months ended September 30, </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> (in thousands) </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating cash out flows from operating leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11,704</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Operating cash out flows from finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">354</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">327</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Financing cash out flows from finance leases </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,118</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,919</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,573</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,950</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td></tr> </tbody></table>
151010001170400035400032700021180001919000175730001395000
Item 5. Other Information   During the quarter ended September 30, 2024, none of our officers or directors adopted or terminated any contract, instruction or written plan for the purchase or sale of securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement”, as defined in Item 408 of Regulation S-K.